ML17129A448: Difference between revisions
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
||
| Line 16: | Line 16: | ||
=Text= | =Text= | ||
{{#Wiki_filter:,BIWJ' Exelon Generatione LG-17-052 April 21, 2017 U. S. Nuclear Regulatory Commission Attn: Document Control Desk Washington, DC 20555-0001 Limerick Generating Station, Unit 1 and 2 Renewed Facility Operating License Nos. NPF-39 and NPF-85 NRC Docket Nos. 50-352 and 50-353 and 72-065 | {{#Wiki_filter:,BIWJ' | ||
~* Exelon Generatione TS 6.9.1.8 TS 6.14.1.c LG-17-052 April 21, 2017 U. S. Nuclear Regulatory Commission Attn: Document Control Desk Washington, DC 20555-0001 Limerick Generating Station, Unit 1 and 2 Renewed Facility Operating License Nos. NPF-39 and NPF-85 NRC Docket Nos. 50-352 and 50-353 and 72-065 | |||
==Subject:== | ==Subject:== | ||
Annual Radioactive Effluent Release Report No. 42 | Annual Radioactive Effluent Release Report No. 42 In accordance with Section 6.9.1.8 of the Limerick Generating Station (LGS) Technical Specifications (TS) and Section 6.2 of the Offsite Dose Calculation Manual (ODCM), | ||
There are no commitments contained in this letter. If you have any questions or require additional information, please contact Aaron Briggs at 610-718-2701. | Attachment 1 is the Annual Radioactive Effluent Release Report No. 42, 2016 Limerick Generating Station. | ||
Respectfully, Richard W. Libra Vice President-Limerick Generating Station Exelon Generation Company, LLC LG-17-052 Page 2 | During 2016 the ODCM was revised. Therefore, in accordance with Section 6.14.1.c of the LGS TS, Attachment 2 is the entire Limerick Generating Station Units 1 and 2 Offsite Dose Calculation Manual, Revision 29. | ||
Limerick has reviewed the Dosimeter of Legal Record (DLR) data for the nearest residence from the ISFSI modules currently loaded. During the period of January 1, 2016 to December 31, 2016, there were no liquid or gaseous effluent releases from the ISFSI at Limerick. | |||
EXELON GENERATION COMPANY, LLC ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT N0.42 January 1, 2016 through December 31, 2016 EXELON GENERATION COMPANY, LLC LIMERICK GENERATING STATION UNITS NO. 1 AND 2 DOCKET NO. 50-352 (Unit 1) DOCKET NO. 50-353 (Unit 2) DOCKET NO. 72-065 (ISFSI) Submitted to The United States Nuclear Regulatory Commission Pursuant to Renewed Facility Operating License: | There are no commitments contained in this letter. | ||
SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | If you have any questions or require additional information, please contact Aaron Briggs at 610-718-2701. | ||
EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | Respectfully, Richard W. Libra Vice President-Limerick Generating Station Exelon Generation Company, LLC | ||
SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | |||
EXELON GENERATION COMPANY, LLC Table of Contents *1. Introduction | LG-17-052 Page 2 : Annual Radioactive Effluent Release Report No. 42, 2016 Limerick Generating Station : Limerick Generating Station Units 1 and 2 Offsite Dose Calculation Manual Revision 29 cc: D. Dorman, Administrator, Region I, USNRC (w/attachments) | ||
........................................................................................................................................ | S. Rutenkroger, LGS USNRC Senior Resident Inspector (w/attachment 1 only) | ||
H. Anagnostopoulos, Inspector Region I, USNRC (w/attachments) | |||
.................................................................................................................. | Document Control Desk, (w/attachments) | ||
1 A. Regulatory Limits ............................................................................................................................ | Director, Division of Spent Fuel Management, Office of Nuclear Material Safety and Safeguards U.S. NRC, Washington, DC 20555-0001 E. Thorton-Jones (w/attachments) | ||
1 B. Effluent Concentration Limits ......................................................................................................... | U.S. Environmental Protection Agency, Center for Waste Management, Radiation Protection Division, Office of Radiation and Indoor Air, 1200 Pennsylvania Avenue, NW., Washington, DC 20460-0001; Mail Code: 6608J | ||
2 C. Average Energy (E) ........................................................................................................................ | |||
2 D. Measurements and Approximations of Total Radioactivity | Attachment 1 Annual Radioactive Effluent Release Report No. 42 2016 Limerick Generating Station | ||
............................................................ | |||
2 E. Batch Releases .............................................................................................................................. | ~ | ||
4 F. Abnormal Releases ........................................................................................................................ | Exelon Generation Annual Radioactive Effluent Release Report No. 42 2016 Limerick Generating Station | ||
4 G. Spills ............................................................................................................................................... | |||
5 H. Revisions to the ODCM .................................................................................................................. | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT N0.42 January 1, 2016 through December 31, 2016 EXELON GENERATION COMPANY, LLC LIMERICK GENERATING STATION UNITS NO. 1 AND 2 DOCKET NO. 50-352 (Unit 1) | ||
5 I. Radioactive Effluent Monitoring Instrumentation Out of Service for More Than 30 Days .............. | DOCKET NO. 50-353 (Unit 2) | ||
5 J. Independent Spent Fuel Storage Installation (ISFSI) ..................................................................... | DOCKET NO. 72-065 (ISFSI) | ||
6 K. Annual Land Use Census Changes ............................................................................................... | Submitted to The United States Nuclear Regulatory Commission Pursuant to Renewed Facility Operating License: | ||
6 A. Dose to Members of the Public at or Beyond Site Boundary ......................................................... | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | ||
6 B. Dose to Members of the Public Inside the Site Boundary .............................................................. | |||
7 Appendix A Effluent and Waste Disposal Summary ................................................................................ | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table of Contents | ||
9 Appendix B Solid Waste and Irradiated Fuel Shipments | *1. Introduction ........................................................................................................................................ 1 | ||
....................................................................... | : 2. Supplemental Information .................................................................................................................. 1 A. Regulatory Limits ............................................................................................................................ 1 B. Effluent Concentration Limits ......................................................................................................... 2 C. Average Energy (E) ........................................................................................................................ 2 D. Measurements and Approximations of Total Radioactivity ............................................................ 2 E. Batch Releases .............................................................................................................................. 4 F. Abnormal Releases ........................................................................................................................ 4 G. Spills ............................................................................................................................................... 5 H. Revisions to the ODCM .................................................................................................................. 5 I. Radioactive Effluent Monitoring Instrumentation Out of Service for More Than 30 Days .............. 5 J. Independent Spent Fuel Storage Installation (ISFSI) ..................................................................... 6 K. Annual Land Use Census Changes ............................................................................................... 6 | ||
19 Appendix C Meteorological Data ........................................................................................................... | : 3. Radiological Impact to Man and Compliance to 40 CFR 190 Limits ................................................. 6 A. Dose to Members of the Public at or Beyond Site Boundary ......................................................... 6 B. Dose to Members of the Public Inside the Site Boundary .............................................................. 7 Appendix A Effluent and Waste Disposal Summary ................................................................................ 9 Appendix B Solid Waste and Irradiated Fuel Shipments ....................................................................... 19 Appendix C Meteorological Data ........................................................................................................... 23 Appendix D Offsite Dose Calculation Manual Revision 29 Summary of Changes ................................. 92 Page i | ||
23 Appendix D Offsite Dose Calculation Manual Revision 29 Summary of Changes ................................. | |||
92 Page i SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | ||
EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page ii SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | Page ii | ||
EXELON GENERATION COMPANY, LLC 1. Introduction In accordance with the reporting requirements of Technical Specification 6.9.1.8 applicable during the reporting period, this report summarizes the effluent release data for Limerick Generating Station Units 1 and 2 for the period January 1, 2016 through December 31, 2016. This submittal complies with the format described in Regulatory Guide 1.21, "Measuring, Evaluating and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water Cooled Nuclear Power Plants", Revision 1, June, 1974. Meteorological data was reported in the format specified in Regulatory Guide 1.23, Revision 1, "Meteorological Monitoring Programs for Nuclear Power Plants". All vendor results were received and included in the report calculations. | |||
Therefore, the 2016 report is complete. | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC | ||
: 2. Supplemental Information A. Regulatory Limits Limit | : 1. Introduction In accordance with the reporting requirements of Technical Specification 6.9.1.8 applicable during the reporting period, this report summarizes the effluent release data for Limerick Generating Station Units 1 and 2 for the period January 1, 2016 through December 31, 2016. This submittal complies with the format described in Regulatory Guide 1.21, "Measuring, Evaluating and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water Cooled Nuclear Power Plants", Revision 1, June, 1974. | ||
: | Meteorological data was reported in the format specified in Regulatory Guide 1.23, Revision 1, "Meteorological Monitoring Programs for Nuclear Power Plants". | ||
: | All vendor results were received and included in the report calculations. Therefore, the 2016 report is complete. | ||
ODCM Control 3.2. | : 2. Supplemental Information A. Regulatory Limits Limit Units Receptor ODCM and 10 CFR 50, Appendix I Design Objective Limits | ||
: 1. Noble Gases: | |||
: a. ~500 mrem/Yr Total Body ODCM Control 3.2.2.1.a | |||
The Limerick radioactive effluent program employs the methodologies presented in U.S. NRG Regulatory Guide 1.109 "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, October 1977 and NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants, October 1978. Therefore, average energies are not applicable to Limerick. | ~3000 mrem/Yr Skin | ||
: b. ~10 mRad Air Gamma Quarterly air dose limits | |||
~20 mRad Air Beta ODCM Control 3.2.2.2.a | |||
: c. ~20 mRad Air Gamma Yearly air dose limits | |||
~40 mRad Air Beta ODCM Control 3.2.2.2.b | |||
: d. ~10 mrem Total Body 10 CFR 50, Appendix I, Section (Gamma) ll.B.2(b) (limits listed here are | |||
~30 mrem Skin (Beta) based on two unit operation) | |||
: 2. Iodines, Tritium, Particulates with Half Life > 8 days: | |||
: a. ~ 1500 mrem/Yr Any Organ ODCM Control 3.2.2.1.b | |||
: b. ~15 mrem Any Organ Quarterly dose limits ODCM Control 3.2.2.3.a | |||
: c. ~30 mrem Any Organ Yearly dose limits ODCM Control 3.2.2.3.b | |||
: 3. Liquid Effluents | |||
: a. 10 times the concentration limits in 10 CFR 20, ODCM Control 3.2.1.1 Appendix B, Table 2 Col. 2 | |||
: b. ~3 mrem Total Body Quarterly dose limits | |||
~10 mrem Any Organ ODCM Control 3.2.1.2.a | |||
: c. ~6 mrem Total Body Yearly dose limits | |||
~20 mrem Any Organ ODCM Control 3.2.1.2.b | |||
: 4. 40 CFR 190, 10 CFR 72.104 | |||
~25 mrem Total Body or Organ Yearly dose limits | |||
~ 75. mrem Thyroid ODCM Control 3.2.3 Page 1 | |||
I SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC I I | |||
: 8. Effluent Concentration Limits I | |||
Gaseous dose rates rather than effluent concentrations are used to calculate permissible release rates for I gaseous releases. The maximum permissible dose rates for gaseous releases are defined in Offsite Dose Calculation Manual (ODCM) Controls 3.2.2.1.a and 3.2.2.1.b as 500 mrem/yr (Total Body), 3000 mrem/yr (Skin), and 1500 mrem/yr (Organ). I The Effluent Concentration Limit (EGL) specified in 10 CFR 20, Appendix B, Table 2, Column 2 for I identified nuclides, were used to calculate permissible release rates and concentrations for liquid ! | |||
release per the Limerick ODCM Control 3.2.1.1. The total activity concentration for all dissolved or entrained gases was limited to < 2E-04 µCi/ml. I C. Average Energy (E) I The Limerick ODCM limits the instantaneous dose equivalent rates due to the release of noble gases to less than or equal to 500 mrem/year to the total body and less than or equal to 3000 mrem/year to the skin. The average beta and gamma energies (E) of the radionuclide mixture in releases of fission and activation gases as described in Regulatory Guide 1.21, "Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," may be used to calculate doses in lieu of more sophisticated software. The Limerick radioactive effluent program employs the methodologies presented in U.S. NRG Regulatory Guide 1.109 "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, October 1977 and NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants, October 1978. Therefore, average energies are not applicable to Limerick. | |||
D. Measurements and Approximations of Total Radioactivity | D. Measurements and Approximations of Total Radioactivity | ||
: 1. Fission and Activation Gases The method used for Gamma Isotopic Analysis is the Canberra Gamma Spectroscopy System with a gas Marinelli beaker. Airborne effluent gaseous activity was continuously monitored and recorded in accordance with ODCM Table 4.2-2. Additional vent grab samples were taken from the North Stack, Unit 1 South Stack, and Unit 2 South Stack and analyzed at least monthly to determine the isotopic mixture of noble gas activity released for the month. The data from the noble gas radiation monitors were analyzed to report net noble gas effluent activity. | : 1. Fission and Activation Gases The method used for Gamma Isotopic Analysis is the Canberra Gamma Spectroscopy System with a gas Marinelli beaker. Airborne effluent gaseous activity was continuously monitored and recorded in accordance with ODCM Table 4.2-2. Additional vent grab samples were taken from the North Stack, Unit 1 South Stack, and Unit 2 South Stack and analyzed at least monthly to determine the isotopic mixture of noble gas activity released for the month. The data from the noble gas radiation monitors were analyzed to report net noble gas effluent activity. When no activity was found in the grab isotopic analysis, the isotopic mixture was assumed to be that evaluated in the UFSAR (Section 11.5, Table 11.5-4). If activity was found in the grab isotopic analysis, the isotopic mixture for the Noble Gas Monitor was determined from that isotopic mixture. | ||
When no activity was found in the grab isotopic analysis, the isotopic mixture was assumed to be that evaluated in the UFSAR (Section 11.5, Table 11.5-4 ). If activity was found in the grab isotopic analysis, the isotopic mixture for the Noble Gas Monitor was determined from that isotopic mixture. Each month a monitor background was determined at the time of the noble gas grab sample and used to determine net radiation monitor activity. | Each month a monitor background was determined at the time of the noble gas grab sample and used to determine net radiation monitor activity. When no isotopic activity was identified in the grab noble gas sample, the noble gas radiation monitor 15-minute average data for one-hour prior to and one-hour post noble gas grab sampling were used to determine monitor background for the month. | ||
When no isotopic activity was identified in the grab noble gas sample, the noble gas radiation monitor 15-minute average data for one-hour prior to and one-hour post noble gas grab sampling were used to determine monitor background for the month. The mean plus two standard deviations was used as background for each Noble Gas Monitor. When activity was identified the background determination was made from the last month that no activity was found. 2. Particulates and Iodines The method used for Gamma Isotopic Analysis is the Canberra Gamma Spectroscopy System with a particulate filter (47 mm) or charcoal cartridge, respectively. | The mean plus two standard deviations was used as background for each Noble Gas Monitor. | ||
Particulate and iodine activity was continuously sampled and analyzed in accordance with ODCM Table 4.2-2. Charcoal and particulate samples are taken from the North Stack, Unit 1 South Stack, Unit 2 South Stack and Hot Maintenance Shop exhausts and analyzed at least weekly to determine the total activity released from the plant. Page2 | When activity was identified the background determination was made from the last month that no activity was found. | ||
EXELON GENERATION COMPANY, LLC 3. Carbon-14 in gaseous effluents Gaseous releases of Carbon-14 were estimated based upon a study by EPRI (EPRI 1021106, Estimation of Carbon-14 in Nuclear Power Plant Gaseous Effluents). | : 2. Particulates and Iodines The method used for Gamma Isotopic Analysis is the Canberra Gamma Spectroscopy System with a particulate filter (47 mm) or charcoal cartridge, respectively. Particulate and iodine activity was continuously sampled and analyzed in accordance with ODCM Table 4.2-2. Charcoal and particulate samples are taken from the North Stack, Unit 1 South Stack, Unit 2 South Stack and Hot Maintenance Shop exhausts and analyzed at least weekly to determine the total activity released from the plant. | ||
The principal production reaction leading to the release of C-14 during plant operation is the 0-17(n,a) | Page2 | ||
C-14 nuclear reaction in reactor coolant. Carbon-14 is also produced by neutron activation of N-14 in the BWR drywell and dissolved nitrogen in the reactor coolant, however these sources are a small fraction of that produced by the 0-17(n,a) | |||
C-14 reaction and can be neglected since reactor coolant normally contains less than 0.1 ppm by weight nitrogen and the neutron flux in the drywell is low. Most of the C-14 produced in a BWR is released in a gaseous form by the off-gas system, primarily in the form of 14 CO 2 An Exelon fleet-wide spreadsheet was developed using the production factors from the EPRI report. The spreadsheet requires site specific inputs of total reactor power ratings (7030) MWth and Equivalent Full Power Operation days. Using this method, total C-14 released was estimated at 34.47 Curies (Ci). Ninety-five percent or 32.75 Ci was in the form of | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC | ||
Using the total C-14 release value results in a conservative five percent overestimation of dose via the vegetation, meat and milk pathways. | : 3. Carbon-14 in gaseous effluents Gaseous releases of Carbon-14 were estimated based upon a study by EPRI (EPRI 1021106, Estimation of Carbon-14 in Nuclear Power Plant Gaseous Effluents). The principal production reaction leading to the release of C-14 during plant operation is the 0-17(n,a) C-14 nuclear reaction in reactor coolant. Carbon-14 is also produced by neutron activation of N-14 in the BWR drywell and dissolved nitrogen in the reactor coolant, however these sources are a small fraction of that produced by the 0-17(n,a) C-14 reaction and can be neglected since reactor coolant normally contains less than 0.1 ppm by weight nitrogen and the neutron flux in the drywell is low. Most of the C-14 produced in a BWR is released in a gaseous form by the off-gas system, primarily in the form of 14 CO 2 An Exelon fleet-wide spreadsheet was developed using the production factors from the EPRI report. The spreadsheet requires site specific inputs of total reactor power ratings (7030) MWth and Equivalent Full Power Operation days. Using this method, total C-14 released was estimated 14 at 34.47 Curies (Ci). Ninety-five percent or 32.75 Ci was in the form of C0 2 , which was the chemical form necessary to be incorporated in the dose pathways of vegetation, meat and milk. | ||
In addition, releases of C-14 were assumed to occur only through the North Vent, which is common to both units. The North Vent has the most conservative X/Q factors for calculating dose. 4. Liquid Effluents Each batch of liquid effluent was sampled and analyzed for gamma isotopic activity in accordance with ODCM Table 4.2-1 prior to release. The total activity of each released batch was determined by multiplying each nuclide's concentration by the total volume discharged and then summing. The total activity released during a quarter was then determined by summing the activity content of all batch releases discharged during the quarter. 5. Tritium in Liquid and Gaseous Effluents Liquid effluents are analyzed for tritium using a Liquid Scintillation Counter. Gaseous effluents are analyzed for tritium by passing air from stack effluents through two bubblers in series. An aliquot of the water from each bubbler was analyzed using a Liquid Scintillation Counter. The monthly liquid radwaste composite was analyzed for tritium using a Liquid Scintillation Counter. 6. Composite Samples Particulate air samples were composited monthly and analyzed for gross alpha, Sr-89, Sr-90, and Ni-63. Liquid radwaste samples were composited monthly and quarterly and analyzed for gross alpha (monthly) and Fe-55, Sr-89 and Sr-90 (quarterly). | Only inhalation pathway uses the full C-14 release value in estimating dose. | ||
These composites were submitted to an offsite vendor laboratory for analysis. | To simplify the dose calculations for C-14, the total release value was used in calculating dose via the offsite effluent pathways. Using the total C-14 release value results in a conservative five percent overestimation of dose via the vegetation, meat and milk pathways. In addition, releases of C-14 were assumed to occur only through the North Vent, which is common to both units. The North Vent has the most conservative X/Q factors for calculating dose. | ||
: 7. Lower Limit of Detection (LLD) The ODCM required lower limit of detection for airborne and liquid releases as follows: Airborne: | : 4. Liquid Effluents Each batch of liquid effluent was sampled and analyzed for gamma isotopic activity in accordance with ODCM Table 4.2-1 prior to release. The total activity of each released batch was determined by multiplying each nuclide's concentration by the total volume discharged and then summing. The total activity released during a quarter was then determined by summing the activity content of all batch releases discharged during the quarter. | ||
LLD Gross Aloha Sr-89 Sr-90 | : 5. Tritium in Liquid and Gaseous Effluents Liquid effluents are analyzed for tritium using a Liquid Scintillation Counter. | ||
EXELON GENERATION COMPANY, LLC Liquid: LLD Principal Gamma Emitters (Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 5E-07 uCi/ml Cs-134 Cs-137 Ce-141 Ce-144) 1-131 1E-06 uCi/ml Entrained Gases (Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, 1 E-05 uCi/ml Xe-138) H-3 1 E-05 uCi/ml Gross Alpha | Gaseous effluents are analyzed for tritium by passing air from stack effluents through two bubblers in series. An aliquot of the water from each bubbler was analyzed using a Liquid Scintillation Counter. | ||
The sum of errors used in this report was documented in IR 138895-02. | The monthly liquid radwaste composite was analyzed for tritium using a Liquid Scintillation Counter. | ||
E. Batch Releases Liquid Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Batch Releases 1.00E+OO 2.00E+01 1.00E+OO 3.00E+OO 2.50E+01 Total time period for batch releases (min) 1.44E+03 1.88E+03 1.20E+01 3.00E+02 3.63E+03 Maximum time period for batch release (min) 1.44E+03 1.15E+02 1.20E+01 2.00E+02 1.44E+03 Average time period for batch release (min) 1.44E+03 9.39E+01 1.20E+01 1.00E+02 1.45E+02 Minimum time period for batch release (min) 1.44E+03 7.40E+01 1.20E+01 5.00E+01 1.20E+01 Average stream flow (Schuylkill River) during periods of release of effluents into a flowing stream (LPM) | : 6. Composite Samples Particulate air samples were composited monthly and analyzed for gross alpha, Sr-89, Sr-90, and Ni-63. Liquid radwaste samples were composited monthly and quarterly and analyzed for gross alpha (monthly) and Fe-55, Sr-89 and Sr-90 (quarterly). These composites were submitted to an offsite vendor laboratory for analysis. | ||
* 1.70E+03 1.56E+07 1.61E+07 1.08E+06 8.20E+06 Average Slowdown Flowrate (LPM) 1.89E+04 2.22E+04 1.89E+04 1.89E+04 2.06E+04 Gaseous Qtr 1 Qtr2 Qtr 3 Qtr4 Total Number of Batch Releases O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Total time period for batch releases (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Maximum time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Average time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Minimum time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO F. Abnormal Releases 1. Liquid Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Releases 1.00E+OO O.OOE+OO 1.00E+OO 3.00E+OO 5.00E+OO Total Activity Released (Ci) 3.99E-05 O.OOE+OO 3.0SE-04 3.65E-04 7.10E-04 2. Gaseous Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Releases | : 7. Lower Limit of Detection (LLD) | ||
* 2.00E+OO 2.00E+OO 2.00E+OO 2.00E+OO 2.00E+OO* | The ODCM required lower limit of detection for airborne and liquid releases as follows: | ||
Total Activity Released (Ci) 1.20E-01 1.20E-01 1.20E-01 1.20E-01 4.SOE-01 *This represents one continuous release from each unit. Page4 SITE: | Airborne: LLD Gross Aloha Sr-89 Sr-90 1E-11 uCi/cc H-3 1E-06 uCi/cc 1-131 1E-12 uCi/cc Principal Gamma Emitters (Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 1E-11 uCi/cc 1-131 Cs-134 Cs-137 Ce-141 Ce-144) | ||
LIMERICK GENERATING STATION -UNITS 1 & 2 EXELON GENERATION COMPANY, LLC .. Tritiated water identified in the Unit 1 Underground Normal Waste Holding Tank was released via the Hold Pond during quarters 3 and 4. The concentrations released represent a small fraction of the Total Body and Organ Dose limits, and have been included as part of Appendix A in Table 2A. " In January of 2016 new pathways were identified and classified as an Insignificant Effluent Pathway. Gaseous effluents from the Main Turbine and Reactor Feed Pump Turbine lubrication oil vapor extractor exhaust vents to the Turbine Building roof. These pathways are not continuously monitored. | Noble Gas (Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, Xe-138) 1E-04 uCi/cc Page 3 | ||
Tritium analysis was performed in January and December 2016 of the water vapor exiting the vent and of nearby standing water. The tritium in the water is the result of condensation and direct deposition from the discharge of the entrained water vapor from the exhaust vents. This condensation does occur year-round, but increases during seasonally cold weather. The lube oil exhaust vents and associated systems were operating as designed to remove accumulated water from the lubricating and seal oil for the various turbine systems. The water was discharged as entrained vapor out the Turbine Building roof vent and a portion of it condensed on lower temperature surfaces. | |||
This water includes tritium, as the source is from the primary system. (IR 2606991) | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Liquid: LLD Principal Gamma Emitters (Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 5E-07 uCi/ml Cs-134 Cs-137 Ce-141 Ce-144) 1-131 1E-06 uCi/ml Entrained Gases (Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, 1 E-05 uCi/ml Xe-138) | ||
Tritium Site Gaseous Annual Percentage of Activity Relative to Concentration, Release of Tritium, Ci Total Release from the Site uCi/cc 2015 2016 2015 2016 U1 MTLO extractor 1.30E-08 6.4E-01% 1.0E-00% exhaust vent U2 MTLO extractor 1.03E-08 5.0E-01% 8.2E-01% exhaust vent 41.9 25.8 U1 and U2 RFPT extractor exhaust <LLD N/A N/A vent G. Spills In accordance with NEI 07-07 "Industry Ground Water Protection Initiative Final Guidance Document", on July 14, 2016 voluntary notification was made to the PA Department of Environmental Protection Bureau of Radiation Protection and the Nuclear Regulatory Commission due to leakage of tritiated water from a storm drain. A bounding dose calculation was performed using the maximum concentration at undiluted tritium source of 9,480 pCi/L. The calculated dose to the public was determined to be 1.90E-05 mrem to organ and total body, which is a fraction of a percent of the liquid effluent limits. (IR 2692113) H. Revisions to the ODCM Revision 29 of the ODCM was issued in December 2016. The summary of changes is included in Appendix D. The ODCM Revision 29 is being submitted, in its entirety, along with this Annual Report. I. Radioactive Effluent Monitoring Instrumentation Out of Service for More Than 30 Days The Service Water radiation monitor was inoperable from 7/25/16 -9/2/16. The extended inoperable time of the instrument was due to the revision of a technical document required for the radiation monitor calibration. | H-3 1 E-05 uCi/ml Gross Alpha 1E-07 uCi/ml Sr-89, Sr-90 5E-08 uCi/ml Fe-55 1E-06 uCi/ml | ||
During this period compensatory samples were collected and analyzed to meet the requirements of the ODCM. (IR 2680338 and 2410536) Page 5 SITE: | : 8. Estimated Total Error Present Procedure CY-AA-170-2100, Estimated Errors of Effluent Measurements, provides the methodology to obtain an overall estimate of the error associated with radioactive effluents. The sum of errors used in this report was documented in IR 138895-02. | ||
LIMERICK GENERATING STATION -UNITS 1 & 2 EXELON GENERATION COMPANY, LLC J. Independent Spent Fuel Storage Installation (ISFSI) An Independent Spent Fuel Storage Installation (ISFSI) was placed in service starting July 21, 2008. Direct radiation exposure was determined using dosimetry measurements (minus background levels) obtained from the Radiological Environmental Monitoring Program for the nearest residence to the Independent Spent Fuel Storage Installation (ISFSI). In 2016 the dose to the nearest resident from the ISFSI was 0.00 mrem. K. Annual Land Use Census Changes The 2016 Land Use Survey identified differences in locations for gardens only. The gardens identified in sectors NNE, NE, SSW, SW, W, and NNW are farther away than in 2015. A new garden was identified in the WNW sector. 3. Radiological Impact to Man and Compliance to 40 CFR 190 Limits A. Dose to Members of the Public at or Beyond Site Boundary Per ODCM Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of the radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases and other nearby uranium fuel cycle sources. The ODCM does not require population doses to be calculated. | E. Batch Releases Liquid Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Batch Releases 1.00E+OO 2.00E+01 1.00E+OO 3.00E+OO 2.50E+01 Total time period for batch releases (min) 1.44E+03 1.88E+03 1.20E+01 3.00E+02 3.63E+03 Maximum time period for batch release (min) 1.44E+03 1.15E+02 1.20E+01 2.00E+02 1.44E+03 Average time period for batch release (min) 1.44E+03 9.39E+01 1.20E+01 1.00E+02 1.45E+02 Minimum time period for batch release (min) 1.44E+03 7.40E+01 1.20E+01 5.00E+01 1.20E+01 Average stream flow (Schuylkill River) during periods of release of effluents into a flowing stream (LPM) | ||
For purposes of this calculation the following assumptions were made: Long term annual average meteorology XJQ and D/Q and actual gaseous effluent releases were used. Gamma air dose, Beta air dose, Total Body and Skin doses were attributed to noble gas releases. | * 1.70E+03 1.56E+07 1.61E+07 1.08E+06 8.20E+06 Average Slowdown Flowrate (LPM) 1.89E+04 2.22E+04 1.89E+04 1.89E+04 2.06E+04 Gaseous Qtr 1 Qtr2 Qtr 3 Qtr4 Total Number of Batch Releases O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Total time period for batch releases (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Maximum time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Average time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Minimum time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO F. Abnormal Releases | ||
: 1. Liquid Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Releases 1.00E+OO O.OOE+OO 1.00E+OO 3.00E+OO 5.00E+OO Total Activity Released (Ci) 3.99E-05 O.OOE+OO 3.0SE-04 3.65E-04 7.10E-04 | |||
: 2. Gaseous Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Releases | |||
* 2.00E+OO 2.00E+OO 2.00E+OO 2.00E+OO 2.00E+OO* | |||
Total Activity Released (Ci) 1.20E-01 1.20E-01 1.20E-01 1.20E-01 4.SOE-01 | |||
*This represents one continuous release from each unit. | |||
Page4 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC | |||
.. Tritiated water identified in the Unit 1 Underground Normal Waste Holding Tank was released via the Hold Pond during quarters 3 and 4. The concentrations released represent a small fraction of the Total Body and Organ Dose limits, and have been included as part of Appendix A in Table 2A. | |||
" In January of 2016 new pathways were identified and classified as an Insignificant Effluent Pathway. Gaseous effluents from the Main Turbine and Reactor Feed Pump Turbine lubrication oil vapor extractor exhaust vents to the Turbine Building roof. These pathways are not continuously monitored. Tritium analysis was performed in January and December 2016 of the water vapor exiting the vent and of nearby standing water. The tritium in the water is the result of condensation and direct deposition from the discharge of the entrained water vapor from the exhaust vents. This condensation does occur year-round, but increases during seasonally cold weather. | |||
The lube oil exhaust vents and associated systems were operating as designed to remove accumulated water from the lubricating and seal oil for the various turbine systems. The water was discharged as entrained vapor out the Turbine Building roof vent and a portion of it condensed on lower temperature surfaces. This water includes tritium, as the source is from the primary system. | |||
(IR 2606991) | |||
Based on Regulatory Guide 1.21, Rev 1, Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants these release pathways are considered insignificant. | |||
Tritium Site Gaseous Annual Percentage of Activity Relative to Vent Concentration, Release of Tritium, Ci Total Release from the Site uCi/cc 2015 2016 2015 2016 U1 MTLO extractor 1.30E-08 6.4E-01% 1.0E-00% | |||
exhaust vent U2 MTLO extractor 1.03E-08 5.0E-01% 8.2E-01% | |||
exhaust vent 41.9 25.8 U1 and U2 RFPT extractor exhaust <LLD N/A N/A vent G. Spills In accordance with NEI 07-07 "Industry Ground Water Protection Initiative Final Guidance Document", on July 14, 2016 voluntary notification was made to the PA Department of Environmental Protection Bureau of Radiation Protection and the Nuclear Regulatory Commission due to leakage of tritiated water from a storm drain. A bounding dose calculation was performed using the maximum concentration at undiluted tritium source of 9,480 pCi/L. The calculated dose to the public was determined to be 1.90E-05 mrem to organ and total body, which is a fraction of a percent of the liquid effluent limits. (IR 2692113) | |||
H. Revisions to the ODCM Revision 29 of the ODCM was issued in December 2016. The summary of changes is included in Appendix D. The ODCM Revision 29 is being submitted, in its entirety, along with this Annual Report. | |||
I. Radioactive Effluent Monitoring Instrumentation Out of Service for More Than 30 Days The Service Water radiation monitor was inoperable from 7/25/16 - 9/2/16. The extended inoperable time of the instrument was due to the revision of a technical document required for the radiation monitor calibration. During this period compensatory samples were collected and analyzed to meet the requirements of the ODCM. (IR 2680338 and 2410536) | |||
Page 5 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC J. Independent Spent Fuel Storage Installation (ISFSI) | |||
An Independent Spent Fuel Storage Installation (ISFSI) was placed in service starting July 21, 2008. | |||
Direct radiation exposure was determined using dosimetry measurements (minus background levels) obtained from the Radiological Environmental Monitoring Program for the nearest residence to the Independent Spent Fuel Storage Installation (ISFSI). In 2016 the dose to the nearest resident from the ISFSI was 0.00 mrem. | |||
K. Annual Land Use Census Changes The 2016 Land Use Survey identified differences in locations for gardens only. The gardens identified in sectors NNE, NE, SSW, SW, W, and NNW are farther away than in 2015. A new garden was identified in the WNW sector. | |||
: 3. Radiological Impact to Man and Compliance to 40 CFR 190 Limits A. Dose to Members of the Public at or Beyond Site Boundary Per ODCM Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of the radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases and other nearby uranium fuel cycle sources. The ODCM does not require population doses to be calculated. For purposes of this calculation the following assumptions were made: | |||
Long term annual average meteorology XJQ and D/Q and actual gaseous effluent releases were used. | |||
Gamma air dose, Beta air dose, Total Body and Skin doses were attributed to noble gas releases. | |||
Critical organ and age group dose attributed to iodine, particulate, carbon-14 and tritium releases. | Critical organ and age group dose attributed to iodine, particulate, carbon-14 and tritium releases. | ||
100 percent occupancy factor was assumed. Dosimetry measurements (minus background levels) obtained from the Radiological Environmental Monitoring Program for the nearest residence to the Independent Spent Fuel Storage Installation (ISFSI) was used to determine direct radiation exposure. | 100 percent occupancy factor was assumed. | ||
Dosimetry measurements (minus background levels) obtained from the Radiological Environmental Monitoring Program for the nearest residence to the Independent Spent Fuel Storage Installation (ISFSI) was used to determine direct radiation exposure. | |||
The highest doses from the critical organ and critical age group for each release pathway was summed and added to the net dosimetry measurement from nearest residence to the ISFSI for 40CFR 190 compliance. | The highest doses from the critical organ and critical age group for each release pathway was summed and added to the net dosimetry measurement from nearest residence to the ISFSI for 40CFR 190 compliance. | ||
Gaseous Releases (Table 1 ): The critical age-organ group was the child-bone. | Gaseous Releases (Table 1): | ||
Calculated dose was 1.05E+OO mrem, which represents 3.SOE+OO percent of the allowable limits. Carbon-14 represented 99.9% or 1.0SE+OO mrem of the total dose. Liquid Releases (Table 1 ): The critical age-organ was the adult-liver. | The critical age-organ group was the child-bone. Calculated dose was 1.05E+OO mrem, which represents 3.SOE+OO percent of the allowable limits. Carbon-14 represented 99.9% or 1.0SE+OO mrem of the total dose. | ||
Calculated total body dose was 3.80E-04 mrem and organ dose was 4.59E-04 mrem. 40 CFR 190 Compliance (Table 2): The maximum calculated dose to a real individual would not exceed 2.22E-01 mrem (total body), 1.07E+OO mrem (organ), or 2.22E-01 mrem (thyroid). | Liquid Releases (Table 1): | ||
The critical age-organ was the adult-liver. Calculated total body dose was 3.80E-04 mrem and organ dose was 4.59E-04 mrem. | |||
40 CFR 190 Compliance (Table 2): | |||
The maximum calculated dose to a real individual would not exceed 2.22E-01 mrem (total body), | |||
1.07E+OO mrem (organ), or 2.22E-01 mrem (thyroid). | |||
All doses calculated were well below all ODCM and 40 CFR Part 190 limits to a real individual. | All doses calculated were well below all ODCM and 40 CFR Part 190 limits to a real individual. | ||
Page 6 SITE: | Page 6 | ||
LIMERICK GENERATING STATION -UNITS 1 & 2 EXELON GENERATION COMPANY, LLC Table 1 Summary of Gaseous and Liquid Effluent Doses to Members of the Public at the Highest Dose Receptors Maximum Individual Applicable Estimated Age %of Limit Noble Gas Dose Dose Group Applicable limit Nearest Residence Gamma Air Dose 9.71 E-03 All 4.86E-02 20 Nearest Residence Beta Air Dose 8.58E-03 All 2.15E-02 40 Nearest Residence Total Body 9.21E-03 All 9.21 E-02 10 Nearest Residence Skin 1.79E-02 All 5.97E-02 30 Iodine, Particulate, C-14 & Tritium Vegetation Pathway Bone 1.05E+OO Child 3.50E+OO 30 Liquid LGS Outfall Total Body 3.80E-04 Adult 6.33E-03 6 LGS Outfall Liver 4.59E-04 Adult 2.30E-03 20 Table 2 Summary of Gaseous and Liquid Effluent Doses to Members of the Public for 40CFR190 Compliance 40 CFR 190 Compliance Gaseous Effluents | |||
% of Noble Particulate, Liquid Net Direct Total Applicable Gas Iodine, C-14 Effluents Radiation Limit & Tritium Total Body Dose 9.21 E-03 2.11 E-01 3.80E-04 O.OOE+OO 2.21 E-01 8.82E-01 Organ Dose 1.79E-02 1.05E+OO 4.59E-04 O.OOE+OO 1.07E+OO 4.27E+OO Thyroid Dose 9.21E-03 2.11E-01 3.00E-04 O.OOE+OO 2.21 E-01 2.94E-01 B. Dose to Members of the Public Inside the Site Boundary | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 1 Summary of Gaseous and Liquid Effluent Doses to Members of the Public at the Highest Dose Receptors Maximum Individual Applicable Estimated Age %of Limit Unit Noble Gas Dose Dose Group Applicable limit Nearest Residence Gamma Air Dose 9.71 E-03 All 4.86E-02 20 mRad Nearest Residence Beta Air Dose 8.58E-03 All 2.15E-02 40 mRad Nearest Residence Total Body 9.21E-03 All 9.21 E-02 10 mrem Nearest Residence Skin 1.79E-02 All 5.97E-02 30 mrem Iodine, Particulate, C-14 & | ||
Also excluded from this category are persons who enter the site to service equipment or to make deliveries. | Tritium Vegetation Pathway Bone 1.05E+OO Child 3.50E+OO 30 mrem Liquid LGS Outfall Total Body 3.80E-04 Adult 6.33E-03 6 mrem LGS Outfall Liver 4.59E-04 Adult 2.30E-03 20 mrem Table 2 Summary of Gaseous and Liquid Effluent Doses to Members of the Public for 40CFR190 Compliance 40 CFR 190 Compliance Gaseous Effluents | ||
This category does include persons who use portions of the site for recreational, occupational education, or other purposes not associated with the plant. A MEMBER OF THE PUBLIC may receive up to 100 mrem in a year (1 OCFR20.1301 | % of Noble Particulate, Liquid Net Direct Total Applicable Limit Unit Gas Iodine, C-14 Effluents Radiation Limit | ||
). Areas within the site boundary, where radiation dose of this type could occur include the Limerick Information Center on Longview Road, Frick's Lock on the south shore of the Schuylkill River, and the railroad track that runs along the north shore of the Schuylkill River. The radiation doses to Members of the Public have been estimated using methodology stated in the ODCM. The maximum gaseous dose to members of the public at these locations is based on the following assumptions: | & Tritium Total Body Dose 9.21 E-03 2.11 E-01 3.80E-04 O.OOE+OO 2.21 E-01 8.82E-01 25 mrem Organ Dose 1.79E-02 1.05E+OO 4.59E-04 O.OOE+OO 1.07E+OO 4.27E+OO 25 mrem Thyroid Dose 9.21E-03 2.11E-01 3.00E-04 O.OOE+OO 2.21 E-01 2.94E-01 75 mrem B. Dose to Members of the Public Inside the Site Boundary ODCM Control 6.2 also requires that the Annual Effluent Release Report shall include an assessment of the radiation doses from radioactive liquid and gaseous effluents to members of the public due to activities inside the Site Boundary during the report period. MEMBER OF THE PUBLIC shall include all persons not occupationally associated with the plant. This category does not include employees of the utility or contractors. Also excluded from this category are persons who enter the site to service equipment or to make deliveries. This category does include persons who use portions of the site for recreational, occupational education, or other purposes not associated with the plant. A MEMBER OF THE PUBLIC may receive up to 100 mrem in a year (1 OCFR20.1301 ). Areas within the site boundary, where radiation dose of this type could occur include the Limerick Information Center on Longview Road, Frick's Lock on the south shore of the Schuylkill River, and the railroad track that runs along the north shore of the Schuylkill River. The radiation doses to Members of the Public have been estimated using methodology stated in the ODCM. The maximum gaseous dose to members of the public at these locations is based on the following assumptions: | ||
Long term annual average meteorology and actual effluent releases for the sectors encompassing the Railroad Tracks 0N), Information Center, and Frick's Lock. Dose is from ground plane and inhalation only. No ingestion dose is included. | Long term annual average meteorology and actual effluent releases for the sectors encompassing the Railroad Tracks 0N), Information Center, and Frick's Lock. | ||
Dose is from ground plane and inhalation only. No ingestion dose is included. | |||
The maximum expected occupancy factor is 25% of a working year at all locations. | The maximum expected occupancy factor is 25% of a working year at all locations. | ||
The maximum calculated dose for activities on site was 3.59E-02 mrem at the Rail Road Tracks in the West sector (Table 3). All Doses calculated were a small fraction of the 10 CFR 20.1301 limits. Page 7 SITE: LIMERICK GENERATING STATION"""'" UNITS 1 & 2 LICENSEE: | The maximum calculated dose for activities on site was 3.59E-02 mrem at the Rail Road Tracks in the West sector (Table 3). All Doses calculated were a small fraction of the 10 CFR 20.1301 limits. | ||
EXELON GENERATION COMPANY, LLC Table 3 Summary of Gaseous Radiation Doses to Members of the Public for Activities on Site Total Body Dose, Organ Dose, Approx. mrem< | Page 7 | ||
EXELON GENERATION COMPANY, LLC Appendix A Effluent and Waste Disposal Summary Page 9 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | |||
EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 10 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | SITE: LIMERICK GENERATING STATION"""'" UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 3 Summary of Gaseous Radiation Doses to Members of the Public for Activities on Site Total Body Dose, Organ Dose, Approx. mrem< 1l mrem<1l XJQ D/Q Location Sector Distance Iodine, Iodine, Total s/m"3 1/m"2 (meters) Noble Gas Particulate, Particulate, C-14 & H-3 C-14 & H-3 R.R. Tracks w 225 2.66E-06 2.36E-08 1.09E-02 4.35E-03 2.13E-02 3.59E-02 Info. Center ESE 884 7.32E-07 9.27E-09 2.99E-03 1.20E-03 5.88E-03 1.01E-02 Frick's Lock WSW 450 5.58E-07 4.78E-09 2.81E-03 9.13E-04 4.48E-03 8.20E-03 (1) The limit for sum of the Total Body Dose and Organ Dose = 100 mrem (ref. 1O CFR 20.1301) | ||
EXELON GENERATION COMPANY, LLC LIST OF TABLES PAGE TABLE 1A GASEOUS EFFLUENTS | Page 8 | ||
-SUMMATION OF ALL RELEASES 13 TABLE 18-1 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE-BATCH MODE 14 TABLE 1B-:-2 GASEOUS EFFLUENTS | |||
-MIXED-LEVEL RELEASE-CONTINUOUS MODE 15 TABLE 2A LIQUID EFFLUENTS-SUMMATION OF ALL RELEASES 16 TABLE 2A-1 LIQUID EFFLUENTS-BATCH MODE 17 TABLE 2A-2 LIQUID EFFLUENTS-CONTINUOUS MODE 18 Page 11 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix A Effluent and Waste Disposal Summary Page 9 | ||
EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 12 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | |||
EXELON GENERATION COMPANY, LLC TABLE 1A GASEOUS EFFLUENTS | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | ||
-SUMMATION OF ALL RELEASES PERIOD 2016 A. Fission And Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | Page 10 | ||
(%} Total 1-131 Ci <LLD <LLD <LLD <LLD | |||
<LLD 20.4 Average Release Rate for uCi/sec <LLD <LLD <LLD | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC LIST OF TABLES PAGE TABLE 1A GASEOUS EFFLUENTS - SUMMATION OF ALL RELEASES 13 TABLE 18-1 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE- BATCH MODE 14 TABLE 1B-:-2 GASEOUS EFFLUENTS - MIXED-LEVEL RELEASE- CONTINUOUS MODE 15 TABLE 2A LIQUID EFFLUENTS- SUMMATION OF ALL RELEASES 16 TABLE 2A-1 LIQUID EFFLUENTS- BATCH MODE 17 TABLE 2A-2 LIQUID EFFLUENTS-CONTINUOUS MODE 18 Page 11 | ||
<LLD <LLD Period Percent of ODCM Limit % * * * * | |||
* C. Particulates Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | ||
(%} Total Release Ci <LLD <LLD <LLD <LLD <LLD 22.6 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD | Page 12 | ||
<LLD Period Percent of ODCM Limit % * * * * | |||
* D. Gross Alpha Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 1A GASEOUS EFFLUENTS - SUMMATION OF ALL RELEASES PERIOD 2016 A. Fission And Activation Uncertainty Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Gasses (%} | ||
(%} Total Release Ci <LLD <LLD <LLD <LLD <LLD 22.6 Average Release Rate for uCi/sec <LLD <LLD <LLD | Total Release Ci 1.28E+02 9.51E+OO 6.41E+OO 1.84E+OO 1.46E+02 36.6 Average Release Rate for uCi/sec 1.63E+01 1.21E+OO 8.06E-01 2.32E-01 4.62E+OO Period Dose - Gamma Air Dose mrad 8.64E-03 4.82E-04 5.21E-04 6.75E-05 9.71E-03 | ||
<LLD <LLD Period Percent of ODCM Limit % * * * * | - Beta Air Dose mrad 7.94E-03 2.97E-04 3.06E-04 4.14E-05 8.58E-03 Percent of ODCM Limit 8.64E-02 4.82E-03 5.21 E-03 6.75E-04 4.85E-02 | ||
* E. Tritium (H-3) Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total | - Gamma Air Dose % | ||
(%) Total Release Ci 2.76E+OO 5.91E+OO 9.19E+OO 7.95E+OO 2.58E+01 15.7 Average Release Rate for uCi/sec 3.52E-01 7.52E-01 1.16E+OO 1.00E+OO 8.17E-01 Period Percent of ODCM Limit % * * * * | - Beta Air Dose % 3.97E-02 1.49E-03 1.53E-03 2.0?E-04 2.15E-02 Uncertainty B. Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | ||
* F. Carbon-14 Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total Total Release Ci 7.08E+OO 9.77E+OO 1.06E+01 7.06E+OO 3.45E+01 Average Release Rate for uCi/sec 9.00E-01 1.24E+OO 1.33E+OO 8.88E-01 1.09E+OO Period Percent of ODCM Limit % * * * * | (%} | ||
* G. Iodine 131 & 133, Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Particulate, C-14 & H-3 Organ Dose mrem 2.64E-01 2.83E-01 3.94E-01 1.10E-01 1.05E+OO Percent of ODCM Limit % 1.76E+OO 1.89E+OO 2.63E+OO 7.32E-01 3.51E+OO | Total 1-131 Ci <LLD <LLD <LLD <LLD <LLD 20.4 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD <LLD Period Percent of ODCM Limit % * * * * | ||
* ODCM Limit for combined Iodine, Carbon-14, Tritium and particulate only, which is shown in Item G. Page 13 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | * Uncertainty C. Particulates Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total | ||
EXELON GENERATION COMPANY, LLC TABLE 1B-1 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE-BATCH MODE PERIOD 2016 Fission And Activation Gasses Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Ar-41 Ci NIA NIA NIA NIA NIA Kr-85 Ci NIA NIA NIA NIA NIA Kr-85m Ci NIA NIA NIA NIA NIA Kr-87 Ci NIA NIA NIA NIA NIA Kr-88 Ci NIA NIA NIA NIA NIA Xe-133 Ci NIA NIA NIA NIA NIA Xe-135 Ci NIA NIA NIA NIA NIA Xe-135m Ci NIA NIA NIA NIA NIA Xe-138 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total 1-131 Ci NIA NIA NIA NIA NIA 1-133 Ci NIA NIA NIA NIA NIA 1-135 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Particulates Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Cr-51 Ci NIA NIA NIA NIA NIA Mn-54 Ci NIA NIA NIA NIA NIA Co-58 Ci NIA NIA NIA NIA NIA Co-60 Ci NIA NIA NIA NIA NIA Zn-65 Ci NIA NIA NIA NIA NIA Sr-89 Ci NIA NIA NIA NIA NIA Sr-90 Ci NIA NIA NIA NIA NIA Mo-99 Ci NIA NIA NIA NIA NIA Ag-110m Ci NIA NIA NIA NIA NIA Cs-134 Ci NIA NIA NIA NIA NIA Cs-137 Ci NIA NIA NIA NIA NIA Ba-140 Ci NIA NIA NIA NIA NIA La-140 Ci NIA NIA NIA NIA NIA Ce-141 Ci NIA NIA NIA NIA NIA Ce-144 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA H-3 Ci NIA NIA NIA NIA NIA Gross Alpha Ci NIA NIA NIA NIA NIA C-14 Ci NIA NIA NIA NIA NIA Page 14 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | (%} | ||
EXELON GENERATION COMPANY, LLC TABLE 18-2 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE -CONTINUOUS MODE PERIOD 2016 Fission And Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Gasses Kr-85m Ci 1.84E+OO 1.65E-01 1.19E-01 3.22E-02 2.16E+OO Kr-85 Ci 1.17E+OO 4.05E-02 2.91 E-01 1.31 E-02 1.51E+OO Kr-87 Ci 2.49E+01 1.74E-01 1.77E-01 3.48E-02 2.53E+01 Kr-88 Ci 2.49E+OO 1.88E-01 2.81 E-01 3.94E-02 3.00E+OO Ar-41 Ci 6.45E+OO 6.46E-01 1.76E-01 1.20E-01 7.40E+OO xe-131m Ci 2.93E-02 1.01 E-03 7.29E-03 3.28E-04 3.80E-02 | Total Release Ci <LLD <LLD <LLD <LLD <LLD 22.6 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD <LLD Period Percent of ODCM Limit % * * * * | ||
EXELON GENERATION COMPANY, LLC TABLE 2A LIQUID EFFLUENTS-SUMMATION OF ALL RELEASES PERIOD 2016 Fission and Activation Products Excluding Uncertainty Tritium, Gasses & Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%} Alpha Total Release Ci <LLD 8.74E-04 <LLD <LLD 8.74E-04 21.1 Average Concentration uCi/ml <LLD 2.03E-08 <LLD <LLD 1.13E-08 Dose -Whole Body mrem NIA 1.04E-08 NIA NIA 1.0SE-08 -Organ mrem NIA 5.48E-06 NIA NIA 5.48E-06 % of ODCM Limit NIA 3.46E-07 NIA NIA 1.73E-07 -Whole Body Dose* % -Organ Dose* % NIA 5.48E-05 NIA NIA 2.74E-05 Tritium Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | * Uncertainty D. Gross Alpha Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | ||
(%) Total Release Ci 3.99E-05 4.91 E+OO 3.0SE-04 3.65E-04 4.91E+OO 6.4 V\verage Concentration uCilml 1.41 E-09 1.14E-04 1.24E-06 6.37E-08 6.34E-05 % of ODCM Limit -EGL % 1.41 E-05 1.14E+OO 1.24E-02 6.37E-04 6.34E-01 Dissolved and Entrained Uncertainty Gases Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total (%) Total Release Ci <LLD 4.74E-05 <LLD <LLD 4.74E-05 21.1 V\verage Concentration uCi/ml <LLD 1.10E-09 <LLD <LLD 6.13E-10 % of ODCM Limit -EGL % NIA 2.20E-02 NIA NIA 1.23E-02 Gross Alpha Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | (%} | ||
(%) Total Release Ci NIA <LLD NIA <LLD <LLD 23.0 V\verage Concentration uCi/ml NIA <LLD NIA <LLD <LLD Volume of Waste Uncertainty Released Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total (%) Total Liters 1.13E+06 1.35E+06 1.89E+04 5.68E+04 2.56E+06 5.0 Volume of Dilution Water used during Units Qtr 1 Qtr2 Qtr3 Qtr4 Total | Total Release Ci <LLD <LLD <LLD <LLD <LLD 22.6 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD <LLD Period Percent of ODCM Limit % * * * * | ||
* Percent of limit includes gases and tritium. Page 16 | * Uncertainty E. Tritium (H-3) Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total | ||
(%) | |||
Total Release Ci 2.76E+OO 5.91E+OO 9.19E+OO 7.95E+OO 2.58E+01 15.7 Average Release Rate for uCi/sec 3.52E-01 7.52E-01 1.16E+OO 1.00E+OO 8.17E-01 Period Percent of ODCM Limit % * * * * | |||
* F. Carbon-14 Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total Total Release Ci 7.08E+OO 9.77E+OO 1.06E+01 7.06E+OO 3.45E+01 Average Release Rate for uCi/sec 9.00E-01 1.24E+OO 1.33E+OO 8.88E-01 1.09E+OO Period Percent of ODCM Limit % * * * * | |||
* G. Iodine 131 & 133, Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Particulate, C-14 & H-3 Organ Dose mrem 2.64E-01 2.83E-01 3.94E-01 1.10E-01 1.05E+OO Percent of ODCM Limit % 1.76E+OO 1.89E+OO 2.63E+OO 7.32E-01 3.51E+OO | |||
* ODCM Limit for combined Iodine, Carbon-14, Tritium and particulate only, which is shown in Item G. | |||
Page 13 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 1B-1 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE-BATCH MODE PERIOD 2016 Fission And Activation Gasses Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Ar-41 Ci NIA NIA NIA NIA NIA Kr-85 Ci NIA NIA NIA NIA NIA Kr-85m Ci NIA NIA NIA NIA NIA Kr-87 Ci NIA NIA NIA NIA NIA Kr-88 Ci NIA NIA NIA NIA NIA Xe-133 Ci NIA NIA NIA NIA NIA Xe-135 Ci NIA NIA NIA NIA NIA Xe-135m Ci NIA NIA NIA NIA NIA Xe-138 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total 1-131 Ci NIA NIA NIA NIA NIA 1-133 Ci NIA NIA NIA NIA NIA 1-135 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Particulates Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Cr-51 Ci NIA NIA NIA NIA NIA Mn-54 Ci NIA NIA NIA NIA NIA Co-58 Ci NIA NIA NIA NIA NIA Co-60 Ci NIA NIA NIA NIA NIA Zn-65 Ci NIA NIA NIA NIA NIA Sr-89 Ci NIA NIA NIA NIA NIA Sr-90 Ci NIA NIA NIA NIA NIA Mo-99 Ci NIA NIA NIA NIA NIA Ag-110m Ci NIA NIA NIA NIA NIA Cs-134 Ci NIA NIA NIA NIA NIA Cs-137 Ci NIA NIA NIA NIA NIA Ba-140 Ci NIA NIA NIA NIA NIA La-140 Ci NIA NIA NIA NIA NIA Ce-141 Ci NIA NIA NIA NIA NIA Ce-144 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA H-3 Ci NIA NIA NIA NIA NIA Gross Alpha Ci NIA NIA NIA NIA NIA C-14 Ci NIA NIA NIA NIA NIA Page 14 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 18-2 GASEOUS EFFLUENTS- MIXED-LEVEL RELEASE - CONTINUOUS MODE PERIOD 2016 Fission And Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Gasses Kr-85m Ci 1.84E+OO 1.65E-01 1.19E-01 3.22E-02 2.16E+OO Kr-85 Ci 1.17E+OO 4.05E-02 2.91 E-01 1.31 E-02 1.51E+OO Kr-87 Ci 2.49E+01 1.74E-01 1.77E-01 3.48E-02 2.53E+01 Kr-88 Ci 2.49E+OO 1.88E-01 2.81 E-01 3.94E-02 3.00E+OO Ar-41 Ci 6.45E+OO 6.46E-01 1.76E-01 1.20E-01 7.40E+OO xe-131m Ci 2.93E-02 1.01 E-03 7.29E-03 3.28E-04 3.80E-02 | |||
~e-133m Ci O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO | |||
~e-133 Ci 3.36E+01 3.36E+OO 9.42E-01 6.24E-01 3.86E+01 D<e-135m Ci 2.65E+01 2.47E+OO 1.33E+OO 4.71 E-01 3.07E+01 Xe-135 Ci 2.18E+01 1.90E+OO 1.54E+OO 3.73E-01 2.56E+01 Xe-138 Ci 9.46E+OO 5.64E-01 1.55E+OO 1.32E-01 1.17E+01 Total Ci 1.28E+02 9.51E+OO 6.41 E+OO 1.84E+OO 1.46E+02 Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total 1-131 Ci <LLD <LLD <LLD <LLD <LLD 1-133 Ci <LLD <LLD <LLD <LLD <LLD 1-135 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD <LLD <LLD <LLD <LLD Particulates Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Cr-51 Ci <LLD <LLD <LLD <LLD <LLD Mn-54 Ci <LLD <LLD <LLD <LLD <LLD Co-58 Ci <LLD <LLD <LLD <LLD <LLD Co-60 Ci <LLD <LLD <LLD <LLD <LLD Ni-63 Ci <LLD <LLD <LLD <LLD <LLD Zn-65 Ci <LLD <LLD <LLD <LLD <LLD Sr-89 Ci <LLD <LLD <LLD <LLD <LLD Sr-90 Ci <LLD <LLD <LLD <LLD <LLD Mo-99 Ci <LLD <LLD <LLD <LLD <LLD Cs-134 Ci <LLD <LLD <LLD <LLD <LLD Cs-137 Ci <LLD <LLD <LLD <LLD <LLD Ba-140 Ci <LLD <LLD <LLD <LLD <LLD La-140 Ci <LLD <LLD <LLD <LLD <LLD Ce-141 Ci <LLD <LLD <LLD <LLD <LLD Ce-144 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD <LLD <LLD <LLD <LLD H-3 Ci 2.76E+OO 5.91 E+OO 9.19E+OO 7.95E+OO 2.58E+01 Gross Alpha Ci <LLD <LLD <LLD <LLD <LLD C-14 Ci 7.08E+OO 9.77E+OO 1.06E+01 7.06E+OO 3.45E+01 Page 15 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 2A LIQUID EFFLUENTS- SUMMATION OF ALL RELEASES PERIOD 2016 Fission and Activation Products Excluding Uncertainty Tritium, Gasses & Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%} | |||
Alpha Total Release Ci <LLD 8.74E-04 <LLD <LLD 8.74E-04 21.1 Average Concentration uCi/ml <LLD 2.03E-08 <LLD <LLD 1.13E-08 Dose -Whole Body mrem NIA 1.04E-08 NIA NIA 1.0SE-08 | |||
- Organ mrem NIA 5.48E-06 NIA NIA 5.48E-06 | |||
% of ODCM Limit NIA 3.46E-07 NIA NIA 1.73E-07 | |||
- Whole Body Dose* % | |||
- Organ Dose* % NIA 5.48E-05 NIA NIA 2.74E-05 Uncertainty Tritium Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%) | |||
Total Release Ci 3.99E-05 4.91 E+OO 3.0SE-04 3.65E-04 4.91E+OO 6.4 V\verage Concentration uCilml 1.41 E-09 1.14E-04 1.24E-06 6.37E-08 6.34E-05 | |||
% of ODCM Limit - EGL % 1.41 E-05 1.14E+OO 1.24E-02 6.37E-04 6.34E-01 Dissolved and Entrained Uncertainty Gases Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total (%) | |||
Total Release Ci <LLD 4.74E-05 <LLD <LLD 4.74E-05 21.1 V\verage Concentration uCi/ml <LLD 1.10E-09 <LLD <LLD 6.13E-10 | |||
% of ODCM Limit - EGL % NIA 2.20E-02 NIA NIA 1.23E-02 Uncertainty Gross Alpha Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%) | |||
Total Release Ci NIA <LLD NIA <LLD <LLD 23.0 V\verage Concentration uCi/ml NIA <LLD NIA <LLD <LLD Volume of Waste Uncertainty Released Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total (%) | |||
Total Liters 1.13E+06 1.35E+06 1.89E+04 5.68E+04 2.56E+06 5.0 Volume of Dilution Water used during Uncertainty Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%) | |||
period Total Liters 2.73E+07 4.17E+07 2.27E+05 5.68E+06 7.48E+07 5.0 | |||
* Percent of limit includes gases and tritium. | |||
Page 16 | |||
.,.-------- | .,.-------- | ||
SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GEf\IERATION COMPANY, LLC TABLE 2A-1 LIQUID EFFLUENTS - BATCH MODE PERIOD 2016 Fission and Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Products NA-24 Ci <LLD <LLD <LLD <LLD <LLD Cr-51 Ci <LLD 3.01E-04 <LLD <LLD 3.01E-04 Mn-54 Ci <LLD 5.80E-05 <LLD <LLD 5.80E-05 Fe-55 Ci <LLD <LLD <LLD I <LLD <LLD Co-58 Ci <LLD 5.81E-05 <LLD <LLD 5.81 E-05 Fe-59 Ci <LLD 3.40E-06 <LLD <LLD 3.40E-06 Co-60 Ci <LLD 3.62E-04 <LLD <LLD 3.62E-04 Zn-65 Ci <LLD 8.29E-05 <LLD <LLD 8.29E-05 Zn-69m Ci <LLD 5.75E-06 <LLD <LLD 5.75E-06 Sr-89 Ci <LLD <LLD <LLD <LLD <LLD Sr-90 Ci <LLD <LLD <LLD <LLD <LLD Zr-95 Ci <LLD <LLD <LLD <LLD <LLD Nb-95 Ci <LLD <LLD <LLD <LLD <LLD Nb-97 Ci <LLD <LLD <LLD <LLD <LLD Mo-99 Ci <LLD <LLD <LLD <LLD <LLD Tc-99m Ci <LLD <LLD <LLD <LLD <LLD Sb-122 Ci <LLD <LLD <LLD <LLD <LLD Sb-124 Ci <LLD <LLD <LLD <LLD <LLD Sb-125 Ci <LLD <LLD <LLD <LLD <LLD 1-131 Ci <LLD <LLD <LLD <LLD <LLD Cs-134 Ci <LLD <LLD <LLD <LLD <LLD Cs-137 Ci <LLD 1.88E-06 <LLD <LLD 1.88E-06 Ba-140 Ci <LLD <LLD <LLD <LLD <LLD La-140 Ci <LLD <LLD <LLD <LLD <LLD Ce-141 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD 8.74E-04 <LLD <LLD 8.74E-04 Dissolved and Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Entrained Gases Kr-87 Ci <LLD <LLD <LLD <LLD <LLD Kr-88 Ci <LLD <LLD <LLD <LLD <LLD Xe-133 Ci <LLD 1.05E-05 <LLD <LLD 1.0SE-05 Xe-133m Ci <LLD <LLD <LLD <LLD <LLD Xe-135 Ci <LLD 3.69E-05 <LLD <LLD 3.69E-05 Xe-135m Ci <LLD <LLD <LLD <LLD <LLD Xe-138 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD 4.74E-05 <LLD <LLD 4.74E-05 H-3 Ci 3.99E-05 4.91E+OO 3.05E-04 3.65E-04 4.91E+OO Gross Alpha Ci <LLD <LLD <LLD <LLD <LLD Page 17 | ||
EXELON GEf\IERATION COMPANY, LLC TABLE 2A-1 LIQUID EFFLUENTS | |||
-BATCH MODE PERIOD 2016 Fission and Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Products NA-24 Ci <LLD <LLD <LLD <LLD | *-,. | ||
<LLD Cr-51 Ci <LLD 3.01E-04 <LLD <LLD 3.01E-04 Mn-54 Ci <LLD 5.80E-05 <LLD <LLD 5.80E-05 Fe-55 Ci <LLD <LLD <LLD I <LLD <LLD Co-58 Ci <LLD 5.81E-05 <LLD <LLD 5.81 E-05 Fe-59 Ci <LLD 3.40E-06 <LLD <LLD 3.40E-06 Co-60 Ci <LLD 3.62E-04 <LLD <LLD 3.62E-04 Zn-65 Ci <LLD 8.29E-05 <LLD <LLD 8.29E-05 Zn-69m Ci <LLD 5.75E-06 <LLD <LLD 5.75E-06 Sr-89 Ci <LLD <LLD <LLD <LLD | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 2A-2 LIQUID EFFLUENTS - CONTINUOUS MODE PERIOD 2016 Fission and Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Products Cr-51 Ci NIA NIA NIA NIA NIA Mn-54 Ci NIA NIA NIA NIA NIA Fe-55 Ci NIA NIA NIA NIA NIA Co-58 Ci NIA NIA NIA NIA NIA Fe-59 Ci NIA NIA NIA NIA NIA Co-60 Ci NIA NIA NIA NIA NIA Zn-65 Ci NIA NIA NIA NIA NIA Sr-89 Ci NIA NIA NIA NIA NIA Sr-90 Ci NIA NIA NIA NIA NIA Zr-95 Ci NIA NIA NIA NIA NIA Nb-95 Ci NIA NIA NIA NIA NIA Mo-99 Ci NIA NIA NIA NIA NIA Tc-99m Ci NIA NIA NIA NIA NIA Ag-110m Ci NIA NIA NIA NIA NIA 1-131 Ci NIA NIA NIA NIA NIA Cs-134 Ci NIA NIA NIA NIA NIA Cs-137 Ci NIA NIA NIA NIA NIA Ba-140 Ci NIA NIA NIA NIA NIA La-140 Ci NIA NIA NIA NIA NIA Ce-141 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Dissolved and Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Entrained Gases Xe-131m Ci NIA NIA NIA NIA NIA Xe-133 Ci N/A NIA NIA NIA NIA Xe-135 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA H-3 Ci NIA NIA NIA NIA NIA Gross Alpha Ci NIA NIA NIA NIA NIA Page 18 | ||
<LLD Sr-90 Ci <LLD <LLD <LLD <LLD | |||
<LLD Zr-95 Ci <LLD <LLD <LLD <LLD <LLD Nb-95 Ci <LLD <LLD <LLD <LLD | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix B Solid Waste and Irradiated Fuel Shipments Page 19 | ||
<LLD Nb-97 Ci <LLD <LLD <LLD <LLD | |||
<LLD Mo-99 Ci <LLD <LLD <LLD <LLD | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | ||
<LLD Tc-99m Ci <LLD <LLD | Page 20 | ||
<LLD <LLD <LLD Sb-122 Ci <LLD <LLD <LLD <LLD | |||
<LLD Sb-124 Ci <LLD <LLD <LLD <LLD | SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC A. Solid waste shipped offsite for burial or disposal (not irradiated fuel) 1/1 /16 - 12/31 /16 | ||
<LLD Sb-125 Ci <LLD <LLD | : 1. Type of waste Tvpe of waste Unit 12 Month Period Estimated Error% I | ||
<LLD <LLD <LLD 1-131 Ci <LLD <LLD <LLD <LLD | : a. Spent resin, filters sludges, evaporator bottoms, m3 86.60 25% I etc Ci 1510.00 | ||
<LLD Cs-134 Ci <LLD <LLD <LLD <LLD | : b. Dry compressible waste, contaminated 155.04 25% | ||
<LLD Cs-137 Ci <LLD 1.88E-06 <LLD <LLD 1.88E-06 Ba-140 Ci <LLD <LLD <LLD <LLD | equipment, etc. 2.43 | ||
<LLD La-140 Ci <LLD <LLD <LLD <LLD <LLD Ce-141 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD 8.74E-04 <LLD <LLD 8.74E-04 Dissolved and Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Entrained Gases Kr-87 Ci <LLD <LLD <LLD <LLD | : c. Irradiated components, control rods, etc. m3 None N/A Ci None I~~ | ||
<LLD Kr-88 Ci <LLD <LLD <LLD <LLD | Id. Other (Describe) None N/A I None | ||
<LLD Xe-133 Ci <LLD 1.05E-05 <LLD <LLD 1.0SE-05 Xe-133m Ci <LLD <LLD <LLD <LLD <LLD Xe-135 Ci <LLD 3.69E-05 <LLD <LLD 3.69E-05 Xe-135m Ci <LLD <LLD <LLD <LLD | : 2. Estimate of Major Nuclide Composition (By Waste Type) | ||
<LLD Xe-138 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD 4.74E-05 <LLD <LLD 4.74E-05 H-3 Ci 3.99E-05 4.91E+OO 3.05E-04 3.65E-04 4.91E+OO Gross Alpha Ci <LLD <LLD <LLD <LLD <LLD Page 17 | Category A- Spent Resin, Filters, Sludges, Evaporator Bottoms, etc. | ||
*-,. SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | Waste Class Waste Class A Percent B Percent Isotope Curies* Abundance Curies* Abundance C-14 2.41E+OO 0.34% 2.83E-03 0.01% | ||
EXELON GENERATION COMPANY, LLC TABLE 2A-2 LIQUID EFFLUENTS | Mn-54 2.03E+01 2.87% 8.07E-01 0.10% | ||
-CONTINUOUS MODE PERIOD 2016 Fission and Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Products Cr-51 Ci NIA NIA NIA NIA NIA Mn-54 Ci NIA NIA NIA NIA NIA Fe-55 Ci NIA NIA NIA NIA NIA Co-58 Ci NIA NIA NIA NIA NIA Fe-59 Ci NIA NIA NIA NIA NIA Co-60 Ci NIA NIA NIA NIA NIA Zn-65 Ci NIA NIA NIA NIA NIA Sr-89 Ci NIA NIA NIA NIA NIA Sr-90 Ci NIA NIA NIA NIA NIA Zr-95 Ci NIA NIA NIA NIA NIA Nb-95 Ci NIA NIA NIA NIA NIA Mo-99 Ci NIA NIA NIA NIA NIA Tc-99m Ci NIA NIA NIA NIA NIA Ag-110m Ci NIA NIA NIA NIA NIA 1-131 Ci NIA NIA NIA NIA NIA Cs-134 Ci NIA NIA NIA NIA NIA Cs-137 Ci NIA NIA NIA NIA NIA Ba-140 Ci NIA NIA NIA NIA NIA La-140 Ci NIA NIA NIA NIA NIA Ce-141 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Dissolved and Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Entrained Gases Xe-131m Ci NIA NIA NIA NIA NIA Xe-133 Ci N/A NIA NIA NIA NIA Xe-135 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA H-3 Ci NIA NIA NIA NIA NIA Gross Alpha Ci NIA NIA NIA NIA NIA Page 18 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | Fe-55 2.71 E+02 38.18% 5.40E+02 67.17% | ||
EXELON GENERATION COMPANY, LLC Appendix B Solid Waste and Irradiated Fuel Shipments Page 19 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | Co-60 3.66E+02 51.56% 2.52E+02 31.35% | ||
EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 20 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | Ni-59 4.56E-02 0.01% 9.21 E-02 0.01% | ||
EXELON GENERATION COMPANY, LLC A. Solid waste shipped | Ni-63 1.10E+01 1.55% 9.44E+OO 1.17% | ||
* Activity is estimated Page 21 SITE: LIMERICK GENERATING STATION -UNITS 1 & 2 LICENSEE: | Zn-65 3.12E+01 4.40% 6.43E-05 0.01% | ||
EXELON GENERATION COMPANY, LLC Category B -Dry Compressible Waste, Contaminated Equipment, etc. Waste Class A Percent Isotope Curies* Abundance Co-60 1.28E+OO 52.76% Cs-137 4.99E-03 0.21% Fe-55 7.36E-01 30.34% Mn-54 1.02E-01 4.20% Ni-63 2.06E-01 8.49% Zn-65 7.60E-02 3.13% Cr-51 2.10E-02 0.87% TOTALS 2.43E+OO 100.00% | Sr-90 4.61 E-02 0.01% 6.80E-03 0.01% | ||
Cs-137 3.83E+OO 0.55% 9.86E-02 0.01% | |||
Ce-144 8.05E-01 0.12% 1.22E+OO 0.15% | |||
Cs-134 1.42E-01 0.02% O.OOE+OO 0.00% | |||
H-3 1.21 E-01 0.02% 2.49E-02 0.01% | |||
Co-58 2.61 E+OO 0.37% O.OOE+OO 0.00% | |||
TOTALS 7.10E+02 100.00% 8.04E+02 100.00% | |||
* Activity is estimated Page 21 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Category B - Dry Compressible Waste, Contaminated Equipment, etc. | |||
Waste Class A Percent Isotope Curies* Abundance Co-60 1.28E+OO 52.76% | |||
Cs-137 4.99E-03 0.21% | |||
Fe-55 7.36E-01 30.34% | |||
Mn-54 1.02E-01 4.20% | |||
Ni-63 2.06E-01 8.49% | |||
Zn-65 7.60E-02 3.13% | |||
Cr-51 2.10E-02 0.87% | |||
TOTALS 2.43E+OO 100.00% | |||
* Activity is estimated | * Activity is estimated | ||
: 3. Solid Waste (Disposition) | : 3. Solid Waste (Disposition) | ||
Number of Shipments Mode of Transportation Destination 23 Truck Energy Solutions Bear Creek Operations Facility to Enerav Solutions I Clive 18 Truck Limerick Gen. Sta. to Energy Solutions I Clive 1 Truck Limerick Gen. Sta. to Waste Control Spec./Texas Comments: | |||
41 Shipments were made from Limerick to Energy Solution Processing Facility for processing 1 Shipments were made from Limerick to TOXCO Processing Facility for processing No solidifications were performed Category A - 19 shipments Type A LSA Category A - 1 shipments > Type A LSA Category A - 4 shipments Type B Category B - 41 shipments Type A LSA Category C - No shipments made Category D - No shipments made B. Irradiated Fuel Shipments (disposition) | |||
Number of Shipments Mode of Transportation Destination 0 N/A N/A C. Changes to the Process Control Program There were no revisions to procedure RW-AA-100, "Process Control Program for Radioactive Wastes". | |||
Page 22 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix C Meteorological Data Page 23 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) | |||
Page 24 | |||
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC LIST OF TABLES PAGE Table D - 1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 27 Table D - 2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January - March, 2016 35 Table D - 3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 42 Table D - 4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the | |||
CY-LG-170-301 PART II - CALCULATION METHODOLOGIES 82 1.0 LIQUID EFFLUENTS 83 1.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS 83 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION 84 1.2.1 Radwaste Discharge Monitor and Discharge Flow Rate 84 1.2.2 Service Water and RHR Service Water Radiation Monitor 87 1.3 LIQUID EFFLUENT DOSE CALCULATIONS -10 CFR 50 88 1.3.1 Dose to Members of the Public 88 1.3.2 Liquid Effluent Dose Projection 91 2.0 GASEOUS EFFLUENTS 93 2.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS 93 2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION 93 2.2.1 North Vent Noble Gas Effluent Monitors 94 2.2.2 South Vent Noble Gas Effluent Monitors 96 2.2.3 Noble Gas Effluent Fractional Contribution 97 2.2.4 Noble Gas Effluent Default Setpoints 98 2.2.5 WRAM Noble Gas Effluent Monitor 100 2.3 GASEOUS EFFLUENT DOSE EVALUATIONS 102 2.3.1 Site Boundary Dose Rate - Noble Gases 102 2.3.2 Site Boundary Dose Rate - Radioiodine and Particulates 103 2.3.3 Noble Gas Air Dose 104 2.3.4 Radioiodine and Particulate Dose Calculations | |||
TABLE NOTATIONS | TABLE NOTATIONS | ||
: a. The LLD is defined as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. For a measurement system, which may include radiochemical separation: | : a. The LLD is defined as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95% | ||
(2. 71 + (A.L'.1t2) | probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. | ||
LLD E | For a measurement system, which may include radiochemical separation: | ||
(2. 71 + 4.66cr~) (A.L'.1t2) | |||
LLD ( C o m p o s i t e ) = - - - - - - - - - - - - - - - - - - - | |||
E | |||
* V | * V | ||
* 2.22E6 | * 2.22E6 | ||
* Y *[exp (-A.L1t1)] | * Y *[exp (-A.L1t1)] (1-exp(-A.L'.1t2)) | ||
(1-exp(-A.L'.1t2)) | (2.71 + 4.66 cr~) | ||
(2.71 + 4.66 LLD (Grab | LLD (Grab S a m p l e s ) = - - - - - - - - - - - - - | ||
E | |||
* V | * V | ||
* 2.22E6 | * 2.22E6 | ||
* Y (exp -A.L'.1t1) is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation. | * Y (exp - A.L'.1t1) | ||
is the a priori lower limit of detection as defined above ( as microcuries per unit mass or volume). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time {(A.L1t2) | Where: | ||
I [exp(-A.L'.1t1)](1-exp(-A.L'.1t2))}. | 2.71 is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation. | ||
is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute), is the counting efficiency, as counts per disintegration, is the sample size, in units of mass or volume, is the number of disintegrations per minute per microcurie, is the fractional radiochemical yield, when applicable, is the radioactive decay constant for the particular radionuclide, for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count. for the plant effluents is the elapsed time between the start and the end of sample collection. | LLD is the a priori lower limit of detection as defined above ( as microcuries per unit mass or volume). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time | ||
Rev.29 Page 33 of 329 12/2016 CY-LG-170-301 TABLE 4.2-1 (Continued) | {(A.L1t2) I [exp(-A.L'.1t1)](1-exp(-A.L'.1t2))}. | ||
is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute), | |||
E is the counting efficiency, as counts per disintegration, v is the sample size, in units of mass or volume, 2.22E6 is the number of disintegrations per minute per microcurie, y is the fractional radiochemical yield, when applicable, A. is the radioactive decay constant for the particular radionuclide, L1t1 for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count. | |||
for the plant effluents is the elapsed time between the start and the end of sample collection. | |||
Rev.29 Page 33 of 329 12/2016 | |||
CY-LG-170-301 TABLE 4.2-1 (Continued) | |||
TABLE NOTATIONS It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. | TABLE NOTATIONS It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. | ||
: b. A batch release is the discharge of liquid wastes of a discrete volume. Prior to sampling for analyses, each batch shall be isolated, and then thoroughly mixed to assure representative sampling. | : b. A batch release is the discharge of liquid wastes of a discrete volume. Prior to sampling for analyses, each batch shall be isolated, and then thoroughly mixed to assure representative sampling. | ||
: c. The principal gamma emitters for which the LLD specification applies include the following radionuclides: | : c. The principal gamma emitters for which the LLD specification applies include the following radionuclides: Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, Cs-134, Cs- | ||
Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, Cs-134, _137, Ce-141 and Ce-144. The dissolved and entrained noble gases (gamma emitters) for which the LLD specification applies include the following radionuclides: | _137, Ce-141 and Ce-144. The dissolved and entrained noble gases (gamma emitters) for which the LLD specification applies include the following radionuclides: | ||
Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, Xe-138. This list does not mean that only these nuclides are to be considered., Other gamma peaks that are identifiable, together with those of the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report pursuant to Administrative Control 6.2. d. The term "Composite Sample" means a combination of.individual samples obtained at regular intervals over a time period. Either the volume of each individual sample is proportional to discharge flow rates, or the sampling interval (for constant volume samples) is proportional to flow rates over the time period used to produce the composite. | Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, Xe-138. This list does not mean that only these nuclides are to be considered., Other gamma peaks that are identifiable, together with those of the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report pursuant to Administrative Control 6.2. | ||
: e. A continuous release is the discharge of liquid wastes of non-discrete volume, e.g. from a volume of a system that has an input flow during the continuous release. f. Whenever effluent releases are in excess of the monitor's setpoint. | : d. The term "Composite Sample" means a combination of.individual samples obtained at regular intervals over a time period. Either the volume of each individual sample is proportional to discharge flow rates, or the sampling interval (for constant volume samples) is proportional to flow rates over the time period used to produce the composite. | ||
Rev.29 Page 34 of 329 12/2016 CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.2 DOSE CONTROLS 3.2.1.2 ' The dose or dose commitment to a MEMBER OF THE PUBLIC from radioactive materials in liquid effluents released from the site to UNRESTRICTED AREAS (See Figure 1-1) shall be limited: a. During any calendar quarter to less than or equal to 3 mrem to the total body and to less than or equal to 10 mrem to any organ, and b. During any calendar year to less than or equal to 6 mrem to the total body and to less than or equal to 20 mrem to any organ. APPLICABILITY: | : e. A continuous release is the discharge of liquid wastes of non-discrete volume, e.g. | ||
At all times. ACTION: a. With the calculated dose from the release of radioactive materials in liquid effluents exceeding any of the above limits, Initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. This Special Report shall also include: (1) the results of the radiological analyses of the drinking water source, and (2) the radiological impact on finished drinking water supplies with regard to the requirements of 40 CFR Part 141, Safe Drinking Water Act.* b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | from a volume of a system that has an input flow during the continuous release. | ||
SURVEILLANCE REQUIREMENTS 4.2.1.2 | : f. Whenever effluent releases are in excess of the monitor's setpoint. | ||
Rev.29 Page 34 of 329 12/2016 | |||
In the case of river-sited plants this is 3 miles downstream only. Rev.29 Page 35 of 329 12/2016 CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM CONTROLS 3.2.1.3 The liquid radwaste treatment system shall be IN SERVICE and appropriate portions of the system shall be used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent, from the site, to UNRESTRICTED AREAS (See Figure 1-1) would exceed 0.12 mrem to the total body or 0.4 mrem to any organ in a 31-day period. APPLICABILITY: | |||
At all times. ACTION: a. With radioactive liquid waste being discharged without treatment and in excess of the above limits and any portion of the Liquid Radwaste Treatment System not in operation initiate a Special Report that includes the following information: 1 . Explanation of what liquid radwaste was being discharged without treatment, identification of any inoperable equipment or subsystems, and the reason for the inoperability. | CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.2 DOSE CONTROLS 3.2.1.2 ' The dose or dose commitment to a MEMBER OF THE PUBLIC from radioactive materials in liquid effluents released from the site to UNRESTRICTED AREAS (See Figure 1-1) shall be limited: | ||
: 2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and 3. Summary description of action(s) taken to prevent a recurrence. | : a. During any calendar quarter to less than or equal to 3 mrem to the total body and to less than or equal to 10 mrem to any organ, and | ||
: b. During any calendar year to less than or equal to 6 mrem to the total body and to less than or equal to 20 mrem to any organ. | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With the calculated dose from the release of radioactive materials in liquid effluents exceeding any of the above limits, Initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. This Special Report shall also include: (1) the results of the radiological analyses of the drinking water source, and (2) the radiological impact on finished drinking water supplies with regard to the requirements of 40 CFR Part 141, Safe Drinking Water Act.* | |||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | |||
SURVEILLANCE REQUIREMENTS 4.2.1.2 Cumulative dose contributions from liquid effluents for the current calendar quarter and the current calendar year shall.be determined at least once per 31 days. | |||
* The requirements of Action A. (1) and (2) are applicable only if drinking water supply is taken from the receiving water body within 3 miles of the plant discharge. In the case of river-sited plants this is 3 miles downstream only. | |||
Rev.29 Page 35 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM CONTROLS 3.2.1.3 The liquid radwaste treatment system shall be IN SERVICE and appropriate portions of the system shall be used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent, from the site, to UNRESTRICTED AREAS (See Figure 1-1) would exceed 0.12 mrem to the total body or 0.4 mrem to any organ in a 31-day period. | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With radioactive liquid waste being discharged without treatment and in excess of the above limits and any portion of the Liquid Radwaste Treatment System not in operation initiate a Special Report that includes the following information: | |||
: 1. Explanation of what liquid radwaste was being discharged without treatment, identification of any inoperable equipment or subsystems, and the reason for the inoperability. | |||
: 2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and | |||
: 3. Summary description of action(s) taken to prevent a recurrence. | |||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | |||
SURVEILLANCE REQUIREMENTS 4.2.1.3.1 Dose due to liquid releases from the site to UNRESTRICTED AREAS shall be projected at least once per 31 days, in accordance with the methodology and parameters in the ODCM when Liquid Radwaste Treatment Systems are not being fully utilized. | |||
4.2.1.3.2 The installed Liquid Radwaste Treatment System shall be considered OPERABLE by meeting Controls 3.2.1.1 and 3.2.1.2 Rev.29 Page 36 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.1 DOSE RATE CONTROLS 3.2.2.1 The dose rate due to radioactive materials released in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to: | |||
: a. For noble gases: less than or equal to 500 mrem/yr to the total body and less than or equal to 3000 mrem/yr to the skin, and | |||
: b. For iodine-131, iodine-133, tritium, and for all radionuclides in particulate form with half-lives greater than 8 days: less than or equal to 1500 mrem/yr to any organ (Inhalation pathway only). | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With the dose rate(s) exceeding the above limits, immediately restore the release rate to within the above limits. | |||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | : b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ||
SURVEILLANCE REQUIREMENTS 4.2.2.1.1 The dose rate due to noble gases in gaseous effluents shall be determined to be within the above limits in accordance with the methodology and parameters in the ODCM. | |||
4.2.2.1.2 The dose rate due to iodine-131, iodine-133, tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents shall be determined to be within the above limits in accordance with the methodology and parameters in the ODCM by obtaining representative samples and performing analyses in accordance with the sampling and analysis program specified in Table 4.2-2. | |||
Rev.29 Page 37 of 329 12/2016 | |||
SURVEILLANCE REQUIREMENTS 4.2.2.1.1 | |||
CY-LG-170-301 TABLE 4.2-2 RADIOACTIVE GASEOUS WASTE SAMPLING AND ANALYSIS PROGRAM Minimum Lower Limit of Gaseous Release Sampling Analysis Type of Activity Detection Point Frequency Frequency Analysis (LLD)a A. North Stack/ Mb Mb Noble Gas 1 E-4 uCi/cc South Stack Grab Sm~I. H-3 1 E-6 uCi/cc Continuousd we 1-131 1E-12 uCi/cc Char. Smpl. | |||
Part. Smpl. Principal 1E-11 uCi/cc Gamma Emitterse M Gross Alpha 1E-11 uCi/cc Comp. Part. | |||
Sr-89, Sr-90 1E-11 uCi/cc Sample Continuousd Continuous Noble Gas 1E-6 (Based Noble Gas Beta or Gamma on Xe-133) | |||
Monitor B. Hot Continuous a w 1-131 1 E-12 uCi/cc Mainten. Char. Smpl. | |||
Shop Vent Exhaustf Part. Smpl. Principal 1 E-11 uCi/cc Gamma Emitterse M Gross Alpha 1 E-11 uCi/cc Comp. Part. | |||
Sr-89, Sr-90 1E-11 uCi/cc Sample Rev.29 Page 38 of 329 12/2016 | |||
CY-LG-170-301 TABLE 4.2-2 (Continued) | |||
TABLE NOTATIONS | TABLE NOTATIONS | ||
: a. The LLD is defined, as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. It should be recognized that the LLD is defined as an ,a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. | : a. The LLD is defined, as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95% | ||
probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. It should be recognized that the LLD is defined as an ,a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. | |||
For a particular measurement system, (which may include radiochemical separation): | For a particular measurement system, (which may include radiochemical separation): | ||
(2.71 + 4.66crB) | (2.71 + 4.66crB) (/1.~h) | ||
LLD ( | LLD ( C o m p o s i t e ) = - - - - - - - - - - - - - - - - - | ||
E | E | ||
* V | * V | ||
* 2.22E6 | * 2.22E6 | ||
* Y *[exp (2. 71 + 4.66 O"B) LLD (Grab E | * Y *[exp (-A.~t1)](1-exp(-A.~h)) | ||
(2. 71 + 4.66 O"B) | |||
LLD (Grab S a m p l e s ) = - - - - - - - - - - - - - - | |||
E | |||
* V | * V | ||
* 2.22E6 | * 2.22E6 | ||
* Y (exp Where: 2.71 | * Y (exp -A.~t 1 ) | ||
is the a priori lower limit of detection as defined above (uCi/cc or uCi/ml). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time {{J .. | Where: | ||
2.71 is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation. | |||
LLD is the a priori lower limit of detection as defined above (uCi/cc or uCi/ml). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time {{J..~h)/[exp(-A.~t1)](1-exp(-A.~h))}, | |||
is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as cpm), shall be based on the actual observed variance of the background counting rate or of the counting rate of the blank samples (as appropriate) rather than on an unverified theoretically predicted variance. | is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as cpm), shall be based on the actual observed variance of the background counting rate or of the counting rate of the blank samples (as appropriate) rather than on an unverified theoretically predicted variance. | ||
is the counting efficiency, as counts per disintegration, is the sample size, in units of cc or ml, is the number of dpm/uCi is the fractional radiochemical yield, when applicable, is the radioactive decay constant for the particular radionuclide, and for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count. for the plant effluents is the elapsed time between the start and the end of sample collection. | E is the counting efficiency, as counts per disintegration, v is the sample size, in units of cc or ml, 2.22E6 is the number of dpm/uCi y is the fractional radiochemical yield, when applicable, A. is the radioactive decay constant for the particular radionuclide, and | ||
Rev.29 Page 39 of 329 12/2016 CY-LG-170-301 TABLE 4.2-2 (Continued) | ~t1 for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count. | ||
TABLE NOTATIONS . b. Sampling and analyses shall also be performed following shutdown, startup, or a THERMAL POWER change exceeding 15% of the RATED THERMAL POWER within a 1-hour period. This requirement does not apply if (1) analysis show that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the main condenser offgas pre-treatment radioactivity monitor shows that effluent activity has not increased more than a factor of 3. c. Samples shall be changed at least once per 7 days and analyses shall be completed within 48 hours after changing, or after removal from sampler. Sampling shall also be performed at least once per 24 hours for at least 7 days following each shutdown, startup or THERMAL POWER change exceeding 15% of RATED THERMAL POWER in 1 hour and analyses completed within 48 hours of changing. | for the plant effluents is the elapsed time between the start and the end of sample collection. | ||
When samples collected for 24 hours are analyzed, the corresponding LLDs may be increased by a factor of 10. This requirement does not apply if (1) analysis shows that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the noble gas monitor shows that effluent activity has not increased more than a factor of 3. d. The ratio of the sample flow rate to the sampled stream flow rate shall be known for the time period covered by each dose or dose rate calculation made in accordance with Controls 3.2.2.1, 3.2.2.2, and 3.2.2.3. e. The principal gamma emitters for which the LLD specification applies include the following radionuclides: | Rev.29 Page 39 of 329 12/2016 | ||
Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m and Xe-138 for gaseous emissions and Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 1-131, Cs-134, Cs-137, Ce-141 and Ce-144 for particulate emissions. | ' | ||
This list does not mean that only these nuclides are to be considered. | L | ||
Other gamma peaks which are identifiable, together with the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2. f. Required for the hot maintenance shop ventilation exhaust only during operation of the hot maintenance shop ventilation exhaust system. Rev.29 Page 40 of 329 12/2016 CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.2 DOSE -NOBLE GASES CONTROLS 3.2.2.2 The air dose due to noble gases released in gaseous effluents, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following: | |||
: a. During any calendar quarter: less than or equal to 10 mrad for gamma radiation and less than or equal to 20 mrad for beta radiation, and b. During any calendar year: less than or equal to 20 mrad for gamma radiation and less than or equal to 40 mrad for beta radiation. | CY-LG-170-301 TABLE 4.2-2 (Continued) | ||
APPLICABILITY: | TABLE NOTATIONS . | ||
At all times. ACTION: a. With the calculated air dose from radioactive noble gases in gaseous effluents exceeding any of the above limits, initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | : b. Sampling and analyses shall also be performed following shutdown, startup, or a THERMAL POWER change exceeding 15% of the RATED THERMAL POWER within a 1-hour period. This requirement does not apply if (1) analysis show that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the main condenser offgas pre-treatment radioactivity monitor shows that effluent activity has not increased more than a factor of 3. | ||
SURVEILLANCE REQUIREMENTS 4.2.2.2 Cumulative dose contributions for the current quarter and current calendar year for noble gases shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days. Rev.29 Page 41 of 329 12/2016 CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.3 DOSE-IODINE-131, IODINE-133, TRITIUM. AND RADIOACTIVE MATERIAL IN PARTICULATE FORM CONTROLS 3.2.2.3 The dose to a MEMBER OF THE PUBLIC from iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following: | : c. Samples shall be changed at least once per 7 days and analyses shall be completed within 48 hours after changing, or after removal from sampler. Sampling shall also be performed at least once per 24 hours for at least 7 days following each shutdown, startup or THERMAL POWER change exceeding 15% of RATED THERMAL POWER in 1 hour and analyses completed within 48 hours of changing. When samples collected for 24 hours are analyzed, the corresponding LLDs may be increased by a factor of 10. This requirement does not apply if (1) analysis shows that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the noble gas monitor shows that effluent activity has not increased more than a factor of 3. | ||
: a. During any calendar quarter: less than or equal to 15 mrem to any organ and, b. During any calendar year: less than or equal to 30 mrem to any organ. APPLICABILITY: | : d. The ratio of the sample flow rate to the sampled stream flow rate shall be known for the time period covered by each dose or dose rate calculation made in accordance with Controls 3.2.2.1, 3.2.2.2, and 3.2.2.3. | ||
At all times. ACTION: a. With the calculated dose from the release of iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents exceeding any of the above limits, initiate a Special Report that identifies the cause(s) for exceeding the limit and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. b. The provisions of Controls 3.0.3*and 3.0.4 are not applicable. | : e. The principal gamma emitters for which the LLD specification applies include the following radionuclides: Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m and Xe-138 for gaseous emissions and Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 1-131, Cs-134, Cs-137, Ce-141 and Ce-144 for particulate emissions. This list does not mean that only these nuclides are to be considered. Other gamma peaks which are identifiable, together with the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2. | ||
SURVEILLANCE REQUIREMENTS 4.2.2.3 Cumulative dose contributions for the current calendar quarter and current calendar year for iodine-131, iodine-133, tritium and radionuclides in particulate form with half-lives greater than 8 days shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days. Rev.29 Page 42 of 329 12/2016 | : f. Required for the hot maintenance shop ventilation exhaust only during operation of the hot maintenance shop ventilation exhaust system. | ||
See UFSAR Chapter 11.3. | Rev.29 Page 40 of 329 12/2016 | ||
At all times. ACTION: a. With gaseous waste being discharged without treatment, and in excess of the above limits, initiate a Special Report that includes the following information: | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.2 DOSE - NOBLE GASES CONTROLS 3.2.2.2 The air dose due to noble gases released in gaseous effluents, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following: | |||
: a. During any calendar quarter: less than or equal to 10 mrad for gamma radiation and less than or equal to 20 mrad for beta radiation, and | |||
: b. During any calendar year: less than or equal to 20 mrad for gamma radiation and less than or equal to 40 mrad for beta radiation. | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With the calculated air dose from radioactive noble gases in gaseous effluents exceeding any of the above limits, initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. | |||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | |||
SURVEILLANCE REQUIREMENTS 4.2.2.2 Cumulative dose contributions for the current quarter and current calendar year for noble gases shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days. | |||
Rev.29 Page 41 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.3 DOSE- IODINE-131, IODINE-133, TRITIUM. AND RADIOACTIVE MATERIAL IN PARTICULATE FORM CONTROLS 3.2.2.3 The dose to a MEMBER OF THE PUBLIC from iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following: | |||
: a. During any calendar quarter: less than or equal to 15 mrem to any organ and, | |||
: b. During any calendar year: less than or equal to 30 mrem to any organ. | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With the calculated dose from the release of iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents exceeding any of the above limits, initiate a Special Report that identifies the cause(s) for exceeding the limit and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. | |||
: b. The provisions of Controls 3.0.3*and 3.0.4 are not applicable. | |||
SURVEILLANCE REQUIREMENTS 4.2.2.3 Cumulative dose contributions for the current calendar quarter and current calendar year for iodine-131, iodine-133, tritium and radionuclides in particulate form with half-lives greater than 8 days shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days. | |||
Rev.29 Page 42 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS | |||
. 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.4 GASEOUS RADWASTE (OFFGAS) TREATMENT SYSTEM CONTROLS 3.2.2.4 Section is not applicable. See UFSAR Chapter 11.3. | |||
Rev.29 Page 43 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.5 VENTILATION EXHAUST TREATMENT SYSTEM CONTROLS 3.2.2.5 The VENTILATION EXHAUST TREATMENT SYSTEM shall be OPERABLE and appropriate portions of the system shall be used to reduce releases of radioactivity when the projected doses in 31 days due to gaseous effluent releases, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) would exceed | |||
: a. 0.4 mrad to air from gamma radiation, or | |||
: b. 0.8 mrad to air from beta radiation, or | |||
: c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC. | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With gaseous waste being discharged without treatment, and in excess of the above limits, initiate a Special Report that includes the following information: | |||
: 1. Identification of any inoperable equipment or subsystems, and the reason for the inoperability. | : 1. Identification of any inoperable equipment or subsystems, and the reason for the inoperability. | ||
: 2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and 3. Summary description of action(s) taken to prevent a recurrence. | : 2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and | ||
: 3. Summary description of action(s) taken to prevent a recurrence. | |||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | |||
SURVEILLANCE REQUIREMENTS 4.2.2.5.1 Doses due to gaseous releases from the site to areas at and beyond the SITE BOUNDARY shall be projected at least once per 31 days in accordance with the methodology and parameters in the ODCM, when the Ventilation Exhaust Treatment System is not being fully utilized. | |||
4.2.2.5.2 The installed VENTILATION EXHAUST TREATMENT SYSTEM shall be considered OPERABLE by meeting Controls 3.2.2.1, and either 3.2.2.2 or 3.2.2.3 Rev.29 Page 44 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.6 Not Used CONTROLS 3.2.2.6 Section is not applicable. | |||
Rev.29 Page 45 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.7 MARK II CONTAINMENT CONTROLS 3.2.2.7 The VENTING or PURGING of the Mark II containment drywell shall be through the Standby Gas Treatment System. | |||
APPLICABILITY: Whenever the drywell is vented or purged.* | |||
ACTION: | |||
: a. With the requirements of the above control not satisfied, suspend all VENTING and PURGING of the dryWell. | |||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | : b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ||
SURVEILLANCE REQUIREMENTS 4.2.2.7.1 The containment drywell shall be determined to be aligned for VENTING or PURGING through the Standby Gas Treatment System within 4 hours prior to start of and at least once per 12 hours during VENTING or PURGING of the containment. | |||
4.2.2.7.2 Prior to use of the purge system through the standby gas treatment system assure that: | |||
: a. Both standby gas treatment system trains are OPERABLE whenever the purge system is in use, and | |||
: b. Whenever the purge system is in use, only one of the standby gas treatment system trains shall be used to prevent damage to both trains should a LOCA occur (LCO 3.6.5.3 ACTION a applies during this configuration). | |||
SURVEILLANCE REQUIREMENTS 4.2.2.7.1 The containment drywell shall be determined to be aligned for VENTING or PURGING through the Standby Gas Treatment System within 4 hours prior to start of and at least once per 12 hours during VENTING or PURGING of the containment. | * Except after Containment is deinerted and purged OR for the one inch/two inch vent valves to the Reactor Enclosure Equipment Compartment Exhaust Filters when used for containment pressure control and nitrogen make-up operations. | ||
4.2.2.7.2 Prior to use of the purge system through the standby gas treatment system assure that: | Rev.29 Page 46 of 329 12/2016 | ||
Except after Containment is deinerted and purged OR for the one inch/two inch vent valves to the Reactor Enclosure Equipment Compartment Exhaust Filters when used for containment pressure control and nitrogen make-up operations. | CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.3 TOTAL DOSE CONTROLS 3.2.3 The annual (calendar year) dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from uranium fuel cycle sources shall be limited to less than or equal to 25 mrem to the total body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem. | ||
Rev.29 Page 46 of 329 12/2016 CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.3 TOTAL DOSE CONTROLS 3.2.3 The annual (calendar year) dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from uranium fuel cycle sources shall be limited to less than or equal to 25 mrem to the total body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem. APPLICABILITY: | APPLICABILITY: At all times. | ||
At all times. ACTION: a. With the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b., 3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., or 3.2.2.3.b calculations shall be made including direct radiation contributions from the reactor units (including outside storage tanks, etc.) to determine whether the above limits of Control 3.2.3 have been exceeded. | ACTION: | ||
If such is the case, initiate a Special Report that defines the corrective action to be taken to reduce subsequent releases to prevent recurrence of exceeding the above limits and includes the schedule for achieving conformance with the above limits. This Report, as defined in 10 CFR 20.2203, shall include an analysis that estimates the radiation exposure (dose) to a MEMBER OF THE PUBLIC from the uranium fuel cycle sources, including all effluent pathways and direct radiation, for the calendar year that includes the release(s) covered by this report. It shall also describe levels of radiation and concentration of radioactive material involved, and the cause of the exposure levels or concentrations. | : a. With the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b., | ||
If the estimated dose(s) exceeds the above limits, and if the release condition resulting in violation of 40 CFR Part 190 or 10 CFR 72.104 has not already been corrected, the Special Report shall include a request for a variance in accordance with the provisions of 40 CFR Part 190 or 10 CFR 72.104. Submittal of the report is considered a timely request, and a variance is granted until staff action on the request is complete. | 3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., or 3.2.2.3.b calculations shall be made including direct radiation contributions from the reactor units (including outside storage tanks, etc.) to determine whether the above limits of Control 3.2.3 have been exceeded. If such is the case, initiate a Special Report that defines the corrective action to be taken to reduce subsequent releases to prevent recurrence of exceeding the above limits and includes the schedule for achieving conformance with the above limits. This Report, as defined in 10 CFR 20.2203, shall include an analysis that estimates the radiation exposure (dose) to a MEMBER OF THE PUBLIC from the uranium fuel cycle sources, including all effluent pathways and direct radiation, for the calendar year that includes the release(s) covered by this report. It shall also describe levels of radiation and concentration of radioactive material involved, and the cause of the exposure levels or concentrations. If the estimated dose(s) exceeds the above limits, and if the release condition resulting in violation of 40 CFR Part 190 or 10 CFR 72.104 has not already been corrected, the Special Report shall include a request for a variance in accordance with the provisions of 40 CFR Part 190 or 10 CFR 72.104. Submittal of the report is considered a timely request, and a variance is granted until staff action on the request is complete. | ||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | : b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ||
SURVEILLANCE REQUIREMENTS 4.2.3.1 | SURVEILLANCE REQUIREMENTS 4.2.3.1 Cumulative dose contributions from liquid and gaseous effluents shall be determined in accordance with Surveillance Requirements 4.2.1.2, 4.2.2.2, and 4.2.2.3, and in accordance with the methodology and parameters in the ODCM. | ||
At all times. ACTION: a. With the Radiological Environmental Monitoring Program not being conducted as specified in Table 3.3-1, prepare and submit to the Commission, in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1, a description of the reasons for not conducting the program as required and the plans for preventing a recurrence. | 4.2.3.2 Cumulative dose contributions from direct radiation from the units (including outside storage tanks, ISFSI, etc.) shall be determined in accordance with the methodology and parameters in the ODCM. This requirement is applicable only under conditions set forth in Action a. of Control 3.2.3. | ||
Rev. 29 Page 4 7 of 329 12/2016 | |||
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.1 MONITORING PROGRAM CONTROLS 3.3.1 The Radiological Environmental Monitoring Program shall be conducted as specified in Table 3.3-1. | |||
APPLICABILITY: At all times. | |||
ACTION: | |||
: a. With the Radiological Environmental Monitoring Program not being conducted as specified in Table 3.3-1, prepare and submit to the Commission, in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1, a description of the reasons for not conducting the program as required and the plans for preventing a recurrence. | |||
: b. With the level of radioactivity as the result of plant effluents in an environmental sampling medium at a specified location exceeding the reporting levels of Table 3.3-2 when averaged over any calendar quarter, initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions to be taken to reduce radioactive effluents so that the potential annual dose to a MEMBER OF THE PUBLIC is less than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. When more than one of the radionuclides in Table 3.3-2 are detected in the sampling medium, this report shall be submitted if: | : b. With the level of radioactivity as the result of plant effluents in an environmental sampling medium at a specified location exceeding the reporting levels of Table 3.3-2 when averaged over any calendar quarter, initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions to be taken to reduce radioactive effluents so that the potential annual dose to a MEMBER OF THE PUBLIC is less than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. When more than one of the radionuclides in Table 3.3-2 are detected in the sampling medium, this report shall be submitted if: | ||
concentration (1) + concentration (2) + ... .:::_ 1.0 reporting level (1) reporting level (2) | |||
With milk or fresh leafy vegetable samples unavailable from one or more of the sample locations required by Table 3.3-1, identify locations for obtaining replacement samples and add them to the radiological environmental monitoring program within 30 days. The specific locations from which samples were unavailable may then be deleted from the monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the Annual Radioactive Effluent Release Report, a complete, legible copy of the entire ODCM, including a revised figure(s) and table for the ODCM reflecting the new location(s). | When radionuclides other than those in Table 3.3-2 are detected and are the result of plant effluents, a Special Report shall be initiated if the potential annual dose* to a MEMBER OF THE PUBLIC is equal to or greater than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. A Special Report is not required if the measured level of radioactivity was not the result of plant effluents; however; in such an event, the condition shall be reported and described in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1. | ||
The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | * The methodology and parameters used to estimate the potential annual dose to a MEMBER OF THE PUBLIC shall be indicated in this report. | ||
SURVEILLANCE REQUIREMENTS 4.3.1 The radiological environmental monitoring samples shall be collected pursuant to Table 3.3-1 from the specific locations given in the table and figure(s) in the ODCM and shall be analyzed pursuant to the requirements of Table 3.3-1, with the detection capabilities required by the Table 4.3-1. I **\ Rev.29 Page 49 of 329 12/2016 | Rev.29 Page 48 of 329 12/2016 | ||
The number, media, frequency, and location of samples may vary from site to site. This table presents an acceptable minimum program for a site at which each entry is applicable. | CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.1 MONITORING PROGRAM CONTROLS ACTION (Continued) | ||
Local site characteristics must be examined to determine if pathways not covered by this table may significantly contribute to an individual's dose and should be included in the sample program. Rev.29 Page 50 of 329 12/2016 | : c. With milk or fresh leafy vegetable samples unavailable from one or more of the sample locations required by Table 3.3-1, identify locations for obtaining replacement samples and add them to the radiological environmental monitoring program within 30 days. The specific locations from which samples were unavailable may then be deleted from the monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the Annual Radioactive Effluent Release Report, a complete, legible copy of the entire ODCM, including a revised figure(s) and table for the ODCM reflecting the new location(s). | ||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF REPRESENTATIVE SAMPLES AND SAMPLE LOCATION(a) | : d. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ||
Samples from 5 locations: | SURVEILLANCE REQUIREMENTS 4.3.1 The radiological environmental monitoring samples shall be collected pursuant to Table 3.3-1 from the specific locations given in the table and figure(s) in the ODCM and shall be analyzed pursuant to the requirements of Table 3.3-1, with the detection capabilities required by the Table 4.3-1. | ||
3 samples from close to the 3 SITE BOUNDARY locations (in different sectors) of the highest calculated annual average ground-level D/Q. 1 sample from the vicinity community having one of the highest calculated annual ground level D/Q. 1 sample from a control location, as for example 15-30 km distant and in the least prevalent wind direction. | I | ||
**\ | |||
Rev.29 Page 49 of 329 12/2016 | |||
,-------1 I TABLE 3.3-1 (Continued) | |||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. SAMPLE LOCATION(a) | CY-LG-170-301 TABLE 3.3-1 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM* | ||
NUMBER OF REPRESENTATIVE EXPOSURE PATHWAY SAMPLES AND SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLE LOCATION<al COLLECTION FREQ. OF ANALYSIS | |||
: 1. DIRECT RADIATIONb 40 routine monitoring stations either Quarterly Gamma dose quarterly. | |||
with two or more dosimeters or with one instrument for measuring and recording dose rate continuously placed as follows: | |||
( 1) An inner ring of stations, one in each meteorological sector, in the general area of the SITE BOUNDARY: | |||
( 2) An outer ring of stations, one in each meteorological sector, in the 3-9 mile range from the site; | |||
( 3 ) The balance of the stations placed in special interest areas such as population centers, nearby residences, schools and in 1 or 2 areas to serve as control stations. | |||
* The number, media, frequency, and location of samples may vary from site to site. This table presents an acceptable minimum program for a site at which each entry is applicable. Local site characteristics must be examined to determine if pathways not covered by this table may significantly contribute to an individual's dose and should be included in the sample program. | |||
Rev.29 Page 50 of 329 12/2016 | |||
CY-LG-170-301 TABLE 3.3-1 (Continued) | |||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a) | |||
: 2. AIRBORNE Samples from 5 locations: Continuous sampler operation Radioiodine canisters: | |||
Radioiodine and 3 samples from close to the 3 with sample collection weekly, 1-131 analysis weekly Particulates SITE BOUNDARY locations (in or more frequently if required different sectors) of the highest by dust loading. | |||
calculated annual average Particulate Sampler: | |||
ground-level D/Q. Gross beta radio activity analysis following filter 1 sample from the vicinity change:c community having one of the Gamma isotopic analysisd of highest calculated annual ground composite (by location) at level D/Q. least quarterly 1 sample from a control location, as for example 15-30 km distant and in the least prevalent wind direction. | |||
Rev. 29 Page 51 of 329 12/2016 | |||
,------- | |||
1 I | |||
CY-LG-170-301 TABLE 3.3-1 (Continued) | |||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a) | |||
: 3. WATERBORNE | : 3. WATERBORNE | ||
: a. Surfacee 1 sample upstream Composite sample over 1-1 sample downstream month periodt. b. Ground Samples from 1 or 2 sources only Quarterly. | : a. Surfacee 1 sample upstream Composite sample over 1- Gamma isotopic analysisd 1 sample downstream month periodt. monthly. Composite for tritium analysis quarterly. | ||
if likely to be affected 9 c. Drinking 1 sample of each on 1 to 3 of the Composite sample over 2-nearest water supplies that could week periodf when 1-131 be affected by its discharge. | : b. Ground Samples from 1 or 2 sources only Quarterly. Gamma isotopicd and tritium if likely to be affected 9 analysis | ||
analysis is performed; monthly composite otherwise. | : c. Drinking 1 sample of each on 1 to 3 of the Composite sample over 2- 1-131 analysis on each nearest water supplies that could week periodf when 1-131 composite when the dose be affected by its discharge. analysis is performed; calculated for the monthly composite otherwise. consumption of the water is greater than 1 mrem per 1 sample from a control location year.h Composite for gross beta and gamma isotopicd analysis monthly. Composite for tritium analysis quarterly. | ||
: d. Sediment from 1 sample from downstream area Semiannually. Gamma isotopic analysisd shoreline with existing or potential semiannually. | |||
recreational value. | |||
Rev.29 Page 52 of 329 12/2016 | |||
Gamma isotopic analysisd semiannually. | |||
Rev.29 Page 52 of 329 12/2016 | CY-LG-170-301 TABLE 3.3-1 (Continued) | ||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF REPRESENTATIVE EXPOSURE PATHWAY SAMPLES AND SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLE LOCATION(a) COLLECTION FREQ. OF ANALYSIS | |||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF REPRESENTATIVE SAMPLES AND SAMPLE LOCATION(a) | : 4. INGESTION Samples from milking animals in 3 Semimonthly when animals Gamma isotopica and | ||
Samples from milking animals in 3 locations within 5 km distance having the highest dose potential. | : a. Milk locations within 5 km distance are on pasture, monthly at 1-131 analysis semimonthly having the highest dose potential. other times. when animals are on pasture If there are none, then 1 sample (April 1 - Oct. 1): monthly at from milking animals in each of 3 other times. | ||
If there are none, then 1 sample from milking animals in each of 3 areas between 5 to 8 km distance where dose are calculated to be greater than 1 mrem per year. h 1 sample from milking animals at a control location (15-30 km distance) and in the least prevalent wind direction. | areas between 5 to 8 km distance where dose are calculated to be greater than 1 mrem per year. h 1 sample from milking animals at a control location (15-30 km distance) and in the least prevalent wind direction. | ||
: b. Fish and 1 sample of each commercially and Sample in season, or Gamma isotopicct analysis on Invertebrates recreationally important species in semiannually if they are not edible portions. | |||
vicinity of plant discharge area. seasonal. | |||
1 sample of same species in area not influenced by plant discharge. | |||
Rev.29 Page 53 of 329 12/2016 TABLE 3.3-1 (Continued) | Rev.29 Page 53 of 329 12/2016 | ||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. SAMPLE LOCATION(a) | |||
CY-LG-170-301 TABLE 3.3-1 (Continued) | |||
RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a) | |||
: 4. INGESTION (Continued) | : 4. INGESTION (Continued) | ||
: c. Food Products 1 sample of each principal class At time of harvesti of food products from any area that is irrigated by water in which liquid plant wastes have been discharged Samples of 3 different kinds of Monthly during the growing broad leaf vegetation grown season nearest each of 2 different offsite locations of highest predicted annual average ground level D/Q if milk sampling is not performed. | : c. Food Products 1 sample of each principal class At time of harvesti Gamma isotopicd and of food products from any area 1-131 analysis. | ||
1 sample of each of the similar Monthly during the growing broad leaf vegetation grown 15-30 season km distance in the least prevalent wind direction if milk sampling is not performed | that is irrigated by water in which liquid plant wastes have been discharged Samples of 3 different kinds of Monthly during the growing Gamma isotopicd and 1-131 broad leaf vegetation grown season analysis. | ||
nearest each of 2 different offsite locations of highest predicted annual average ground level D/Q if milk sampling is not performed. | |||
1 sample of each of the similar Monthly during the growing Gamma isotopicd and 1-131 broad leaf vegetation grown 15-30 season analysis. | |||
km distance in the least prevalent wind direction if milk sampling is not performed. | |||
Rev. 29 Page 54 of 329 12/2016 CY-LG-170-301 TABLE 3.3-1 (Continued) | Rev. 29 Page 54 of 329 12/2016 | ||
CY-LG-170-301 TABLE 3.3-1 (Continued) | |||
TABLE NOTATIONS | TABLE NOTATIONS | ||
: a. Specific parameters of distance and direction sector from the centerline of the two reactors and additional description where pertinent, shall be provided for each and every sample location in Table 3.3-1 in a table and figure(s) in the ODCM. Deviations are permitted from the required sampling schedule if specimens are unobtainable due to hazardous conditions, seasonal unavailability, malfunction of automatic sampling equipment and other legitimate reasons. If specimens are unobtainable due to sampling equipment malfunction, every effort shall be made to complete corrective action prior to the end of the next sampling period. All deviations from the sampling schedule shall be documented in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. It is recognized that, at times, it may not be possible or practicable to continue to obtain samples of the media of choice at the most desired location or time. In these instances suitable alternative media and locations may be chosen for the particular pathway in question and appropriate substitutions made within 30 days in the radiological environmental monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the next Annual Radioactive Effluent Release Report a complete legible copy of the ODCM including a revised figure(s) and table for the ODCM reflecting the new location(s). | : a. Specific parameters of distance and direction sector from the centerline of the two reactors and additional description where pertinent, shall be provided for each and every sample location in Table 3.3-1 in a table and figure(s) in the ODCM. | ||
: b. One or more instruments, such as a pressurized ion chamber, for measuring and recording dose rate continuously may be used in place of, or in addition to, integrating dosimeters. | Deviations are permitted from the required sampling schedule if specimens are unobtainable due to hazardous conditions, seasonal unavailability, malfunction of automatic sampling equipment and other legitimate reasons. If specimens are unobtainable due to sampling equipment malfunction, every effort shall be made to complete corrective action prior to the end of the next sampling period. All deviations from the sampling schedule shall be documented in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. It is recognized that, at times, it may not be possible or practicable to continue to obtain samples of the media of choice at the most desired location or time. In these instances suitable alternative media and locations may be chosen for the particular pathway in question and appropriate substitutions made within 30 days in the radiological environmental monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the next Annual Radioactive Effluent Release Report a complete legible copy of the ODCM including a revised figure(s) and table for the ODCM reflecting the new location(s). | ||
For the purpose of this table, a dosimeter (OSL, TLD, or similar) is considered to be one element; two or more elements in a packet are considered as two or more dosimeters. | : b. One or more instruments, such as a pressurized ion chamber, for measuring and recording dose rate continuously may be used in place of, or in addition to, integrating dosimeters. For the purpose of this table, a dosimeter (OSL, TLD, or similar) is considered to be one element; two or more elements in a packet are considered as two or more dosimeters. Film badges shall not be used as dosimeters for measuring direct radiation. | ||
Film badges shall not be used as dosimeters for measuring direct radiation. | : c. Airborne particulate sample filters shall be analyzed for gross beta radioactivity 24 hours or more after sampling to allow for radon and thoron daughter decay. If gross beta activity in air particulate samples is greater that 10 times the yearly mean of control samples, gamma isotopic analysis shall be performed on the individual samples. | ||
: c. Airborne particulate sample filters shall be analyzed for gross beta radioactivity 24 hours or more after sampling to allow for radon and thoron daughter decay. If gross beta activity in air particulate samples is greater that 10 times the yearly mean of control samples, gamma isotopic analysis shall be performed on the individual samples. d. Gamma isotopic analysis means the identification and quantification of emitting radionuclides that may be attributable to the effluents from the facility. | : d. Gamma isotopic analysis means the identification and quantification of gamma-emitting radionuclides that may be attributable to the effluents from the facility. | ||
: e. The "upstream sample" shall be taken at a distance beyond significant influence of the discharge. | : e. The "upstream sample" shall be taken at a distance beyond significant influence of the discharge. The "downstream sample" shall be taken in an area beyond but near the mixing zone. | ||
The "downstream sample" shall be taken in an area beyond but near the mixing zone. Rev.29 Page 55 of 329 12/2016 CY-LG-170-301 TABLE 3.3-1 (Continued) | Rev.29 Page 55 of 329 12/2016 | ||
CY-LG-170-301 TABLE 3.3-1 (Continued) | |||
TABLE NOTATIONS (Continued) | TABLE NOTATIONS (Continued) | ||
: f. A composite sample is one in which the quantity (aliquot) of liquid sampled is proportional to the quantity of flowing liquid and in which the method of sampling employed results in a specimen that is representative of the liquid flow. In this program composite sample aliquots shall be collected at time intervals that are very short (e.g., hourly) relative to the compositing period (e.g., monthly) in order to assure obtaining a representative sample. g. Groundwater samples shall be taken when this source is tapped for drinking or irrigation purposes in areas where the hydraulic gradient or recharge properties are suitable for contamination. | : f. A composite sample is one in which the quantity (aliquot) of liquid sampled is proportional to the quantity of flowing liquid and in which the method of sampling employed results in a specimen that is representative of the liquid flow. In this program composite sample aliquots shall be collected at time intervals that are very short (e.g., hourly) relative to the compositing period (e.g., monthly) in order to assure obtaining a representative sample. | ||
: h. The dose shall be calculated for the maximum organ and age group using the methodology and parameters in the ODCM. i. If harvest occurs more than once a year, sampling shall be performed during each discrete harvest. If harvest occurs continuously, sampling shall be monthly. Attention shall be paid to including samples of tuberous and root food produets. | : g. Groundwater samples shall be taken when this source is tapped for drinking or irrigation purposes in areas where the hydraulic gradient or recharge properties are suitable for contamination. | ||
Rev.29 Page 56 of 329 12/2016 CY-LG-170-301 TABLE 3.3-2 REPORTING LEVELS FOR RADIOACTIVITY CONCENTRATIONS IN ENVIRONMENTAL SAMPLES WATER ANALYSIS (pCi/I) H-3 20,000* Mn-54 1,000 Fe-59 400 Co-58 1,000 Co-60 300 Zn-65 300 Zr-Nb-95 400*** 1-131 2** Cs-134 30 Cs-137 50 Ba-La-140 200*** | : h. The dose shall be calculated for the maximum organ and age group using the methodology and parameters in the ODCM. | ||
: i. If harvest occurs more than once a year, sampling shall be performed during each discrete harvest. If harvest occurs continuously, sampling shall be monthly. | |||
* For drinking water samples. This is a 40 CFR Part 141 value. If no drinking pathway exists, a value of 30,000 pCi/I may be used. ** If no drinking water pathway exists, a value of 20 pCi/I may be used *** Total for parent and daughter. | Attention shall be paid to including samples of tuberous and root food produets. | ||
Rev.29 Page 57 of 329 12/2016 TABLE 4.3-1 DETECTION CAPABILITIES FOR ENVIRONMENTAL SAMPLE ANAL YS1s<a> (b) Lower limit of Detection (LLD)<c> AIRBORNE PARTICULATE or FISH WATER GASES (pCi/kg, ANALYSIS (pCi/I) (pCi/m 3) wet) Gross Beta 4 0.01 H-3 2,000* Mn-54 15 130 Fe-59 30 260 Co-58 15 130 Co-60 15 130 Zn-65 30 260 Zr-95 30 Nb-95 15 1-131 1** 0.07 Cs-134 15 0.05 130 Cs-137 18 0.06 150 Ba-140 60 La-140 15 | Rev.29 Page 56 of 329 12/2016 | ||
* If no drinking water pathway exists, a value of 3000 pCi/I may be used. ** If no drinking water pathway exists, a value of 15 pCi/I may be used. | |||
TABLE NOTATIONS (a) This list dose not mean that only these nuclides are to considered. | CY-LG-170-301 TABLE 3.3-2 REPORTING LEVELS FOR RADIOACTIVITY CONCENTRATIONS IN ENVIRONMENTAL SAMPLES | ||
Other peaks that are identifiable at 95% confidence level, together with those of the above nuclides, shall also be and reported in the Annual Radiological Environmental Operating report pursuant to Administrative Control 6.1. (b) Required detection capabilities for thermoluminescent dosimeters used for environmental measurements are given in Regulatory Guide 4.13. (c) The LLD is defined, for purposes of these controls, as the smallest concentration of radioactive material in a sample that will yield a net count (above system background) that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. | _Reporting Levels AIRBORNE FOOD WATER PARTICULATE or FISH MILK PRODUCTS ANALYSIS (pCi/I) GASES(pCi/m 3) (pCi/kg, wet) (pCi/I) (pCi/kg, wet) | ||
H-3 20,000* | |||
Mn-54 1,000 30,000 Fe-59 400 10,000 Co-58 1,000 30,000 Co-60 300 10,000 Zn-65 300 20,000 Zr-Nb-95 400*** | |||
1-131 2** 0.9 3 100 Cs-134 30 10 1,000 60 1,000 Cs-137 50 20 2,000 70 2,000 Ba-La-140 200*** 300 | |||
* For drinking water samples. This is a 40 CFR Part 141 value. If no drinking pathway exists, a value of 30,000 pCi/I may be used. | |||
** If no drinking water pathway exists, a value of 20 pCi/I may be used | |||
*** Total for parent and daughter. | |||
Rev.29 Page 57 of 329 12/2016 | |||
CY-LG-170-301 TABLE 4.3-1 DETECTION CAPABILITIES FOR ENVIRONMENTAL SAMPLE ANAL YS1s<a> (b) | |||
Lower limit of Detection (LLD)<c> | |||
AIRBORNE FOOD PARTICULATE or FISH PRODUCTS SEDIMENT WATER GASES (pCi/kg, MILK (pCi/kg, (pCi/kg, ANALYSIS (pCi/I) (pCi/m 3) wet) (pCi/I) wet) dry) | |||
Gross Beta 4 0.01 H-3 2,000* | |||
Mn-54 15 130 Fe-59 30 260 Co-58 15 130 Co-60 15 130 Zn-65 30 260 Zr-95 30 Nb-95 15 1-131 1** 0.07 1 60 Cs-134 15 0.05 130 15 60 150 Cs-137 18 0.06 150 18 80 180 Ba-140 60 60 La-140 15 15 | |||
* If no drinking water pathway exists, a value of 3000 pCi/I may be used. | |||
** If no drinking water pathway exists, a value of 15 pCi/I may be used. | |||
Rev.29 Page 58 of 329 12/2016 | |||
CY-LG-170-301 TABLE 4.3-1 (Continued) | |||
TABLE NOTATIONS (a) This list dose not mean that only these nuclides are to considered. Other peaks that are identifiable at 95% confidence level, together with those of the above nuclides, shall also be ~malyzed and reported in the Annual Radiological Environmental Operating report pursuant to Administrative Control 6.1. | |||
(b) Required detection capabilities for thermoluminescent dosimeters used for environmental measurements are given in Regulatory Guide 4.13. | |||
(c) The LLD is defined, for purposes of these controls, as the smallest concentration of radioactive material in a sample that will yield a net count (above system background) that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. | |||
For a particular measurement system (which may include radiochemical separation): | |||
LLD= 4.66sb E | |||
* V | * V | ||
* 2.22 | * 2.22 | ||
* Y | * Y | ||
* exp<-Mi) is the a priori lower limit of detection as defined above (as picocuries per unit mass or volume), is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute), is the counting efficiency (as counts per disintegration), is the sample size (in units of mass or volume), is the number of disintegrations per minute per picocurie, is the fractional radiochemical yield (when applicable), is the radioactive decay constant for the particular radionuclide, and for the environmental samples is the elapsed time between sample collection (or end of the sample collection period) and time of counting. | * exp<-Mi) | ||
Typical values of E, V, Y and At should be used in the calculation Rev.29 Page 59 of 329 12/2016 TABLE 4.3-1 (Continued) | Where: | ||
LLD is the a priori lower limit of detection as defined above (as picocuries per unit mass or volume), | |||
Sb is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute), | |||
E is the counting efficiency (as counts per disintegration), | |||
v is the sample size (in units of mass or volume), | |||
2.22 is the number of disintegrations per minute per picocurie, y is the fractional radiochemical yield (when applicable), | |||
A. is the radioactive decay constant for the particular radionuclide, and At for the environmental samples is the elapsed time between sample collection (or end of the sample collection period) and time of counting. | |||
Typical values of E, V, Y and At should be used in the calculation Rev.29 Page 59 of 329 12/2016 | |||
CY-LG-170-301 TABLE 4.3-1 (Continued) | |||
TABLE NOTATIONS (Continued) | TABLE NOTATIONS (Continued) | ||
It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. Analyses shall be performed in such a manner that the stated LLDs will be achieved under routine conditions. Occasionally background fluctuations, unavoidably small sample sizes, the presence of interfering nuclides, or other uncontrollable circumstances may render these LLDs unachievable. In such cases, the contributing factors shall be identified and described in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. | |||
Analyses shall be performed in such a manner that the stated LLDs will be achieved under routine conditions. | Rev.29 Page 60 of 329 12/2016 | ||
Occasionally background fluctuations, unavoidably small sample sizes, the presence of interfering nuclides, or other uncontrollable circumstances may render these LLDs unachievable. | |||
In such cases, the contributing factors shall be identified and described in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. Rev.29 Page 60 of 329 12/2016 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.2 LAND USE CENSUS CONTROLS | CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.2 LAND USE CENSUS CONTROLS 3.3.2 A land use census shall be conducted and shall identify within a distance of 8 km (5 miles) the location (in each of the 16 meteorological sectors) of the nearest . | ||
APPLICABILITY: | milk animal, the nearest residence and the nearest garden* of greater than 50 m2 (500 ft2) producing broad leaf vegetation. | ||
At all times. ACTION: a. With a land use census identifying a location(s) that yields a calculation dose or dose commitment greater than the values currently being calculated in Control 3.2.2.3, identify the new location(s) in the next Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2. b. With a land use census identifying a location(s) that yields a calculated dose or dose commitment (via the same exposure pathway) 20% greater than at a location from which samples are currently being obtained in accordance with Control 3.2.2.3, add the new location(s) to the radiological environmental monitoring program within 30 days. The sampling location(s), excluding the control station location, having the lowest calculated dose or dose commitment(s) (via the same exposure pathway) may be deleted from this monitoring program after October 31 of the year in which this land use census was conducted. | APPLICABILITY: At all times. | ||
Pursuant to Technical Specification 6.14, submit as a part of or concurrent with in the next Annual Radioactive Effluent Release Report a complete, legible copy of the entire ODCM including a revised figure(s) and table(s) for the ODCM reflecting the new location(s). | ACTION: | ||
: a. With a land use census identifying a location(s) that yields a calculation dose or dose commitment greater than the values currently being calculated in Control 3.2.2.3, identify the new location(s) in the next Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2. | |||
: b. With a land use census identifying a location(s) that yields a calculated dose or dose commitment (via the same exposure pathway) 20% greater than at a location from which samples are currently being obtained in accordance with Control 3.2.2.3, add the new location(s) to the radiological environmental monitoring program within 30 days. The sampling location(s), excluding the control station location, having the lowest calculated dose or dose commitment(s) (via the same exposure pathway) may be deleted from this monitoring program after October 31 of the year in which this land use census was conducted. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with in the next Annual Radioactive Effluent Release Report a complete, legible copy of the entire ODCM including a revised figure(s) and table(s) for the ODCM reflecting the new location(s). | |||
: c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | : c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ||
SURVEILLANCE REQUIREMENTS 4.3.2 The land use census shall be conducted during the growing season at least once per 12 months using that information that will provide the best results, such as by a door-to-door survey, aerial survey, or by consulting local agriculture authorities. | SURVEILLANCE REQUIREMENTS 4.3.2 The land use census shall be conducted during the growing season at least once per 12 months using that information that will provide the best results, such as by a door-to-door survey, aerial survey, or by consulting local agriculture authorities. The results of the land use census are included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. | ||
The results of the land use census are included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. | * Broad leaf vegetation sampling of at least 3 different kinds of vegetation may be performed at the SITE BOUNDARY in each of 2 different direction sectors with the highest predicted D/Qs in lieu of the garden census. Controls for broad leaf vegetation sampling in Table 3.3-1 item 4.c. shall be followed, including analysis of control samples. | ||
* Broad leaf vegetation sampling of at least 3 different kinds of vegetation may be performed at the SITE BOUNDARY in each of 2 different direction sectors with the highest predicted D/Qs in lieu of the garden census. Controls for broad leaf vegetation sampling in Table 3.3-1 item 4.c. shall be followed, including analysis of control samples. Rev.29 Page 61 of 329 12/2016 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.3 INTERLABORATORY COMPARISON PROGRAM CONTROLS | Rev.29 Page 61 of 329 12/2016 | ||
At all times. ACTION: a. With analyses not being performed as required above, report the corrective actions taken to prevent a recurrence to the Commission in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | |||
SURVEILLANCE REQUIREMENTS 4.3.3 The lnterlaboratory Comparison Program shall be described in the ODCM. A summary of the results shall be included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1 Rev.29 Page 62 of 329 12/2016 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION CONTROLS | CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.3 INTERLABORATORY COMPARISON PROGRAM CONTROLS 3.3.3 In accordance with LGS Technical Specification 6.8.4.f, analyses shall be performed on radioactive materials supplied as part of an lnterlaboratory Comparison Program traceable to NIST, that correspond to samples required by Table 3.3-1. | ||
APPLICABILITY: | APPLICABILITY: At all times. | ||
At all times. ACTION: a. With less than the minimum required instrumentation channels OPERABLE for more than 7 days, initiate an Issue Report outlining the cause of the malfunction and the plans for restoring the instrumentation to OPERABLE status. b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ACTION: | ||
SURVEILLANCE REQUIREMENTS 4.3.4 Each of the above required meteorological monitoring instrumentation channels shall be demonstrated OPERABLE by the performance of the CHANNEL CHECK and CHANNEL CALIBRATION operations at the frequencies shown in Table 4.3-2. Rev.29 Page 63 of 329 12/2016 CY-LG-170-301 TABLE 3.3-3 METEOROLOGICAL MONITORING INSTRUMENTATION INSTRUMENT TOWER 1 (PRIMARY) | : a. With analyses not being performed as required above, report the corrective actions taken to prevent a recurrence to the Commission in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. | ||
: 1. Wind Speed a. Elevation 1 30 feet b. Elevation 2 175 feet 2. Wind Direction | : b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | ||
: a. Elevation 1 30 feet b. Elevation 2 175 feet 3. Air Temperature Difference | SURVEILLANCE REQUIREMENTS 4.3.3 The lnterlaboratory Comparison Program shall be described in the ODCM. A summary of the results shall be included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1 Rev.29 Page 62 of 329 12/2016 | ||
: a. Elevations 266 feet 26 feet | |||
: 1. Wind Speed a. Elevation 1 (Tower 1 and Tower 2) D SA b. Elevation 2 (Tower 1 and Tower 2) D SA 2. Wind Direction | CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION CONTROLS 3.3.4 The meteorological monitoring instrumentation channels shown in Table 3.3-3 shall be OPERABLE. | ||
: a. Elevation 1 (Tower 1 and Tower 2) D SA b. Elevation 2 (Tower 1 and Tower 2) D SA 3. Air Temperature Difference T) a. Elevations 266 -26 ft (Tower 1) D SA b. Elevations 300 -26 ft (Tower 2) D SA NOTE: The meteorological towers shall be located as shown on Figure 3.3-1. Rev.29 Page 65 of 329 12/2016 ---_ __J Figure 3.3-1 METEOROLOGICAL TOWER LOCATIONS | APPLICABILITY: At all times. | ||
MAPS DEFINING UNRESTRICTED AREAS AND SITE BOUNDARY FOR RADIOACTIVE GASEOUS AND LIQUID EFFLUENTS Information regarding radioactive gaseous and liquid effluents, which will allow identification of structures and release points as well as definition of UNRESTRICTED AREAS within the SITE BOUNDARY that are accessible to MEMBER(S) | ACTION: | ||
OF THE PUBLIC, shall be as shown in Technical Specifications Figures 5.1.3-1 a and 5.1.3-1 b. The exclusion area and low population zone shall be as shown in Figures 1-1 and 1-2. 10 CFR 20 Per Technical Specification Section 6.8.4.d, the Radioactive Effluent Controls Program must conform with limitations specified in 10 CFR 50.36a, 10 CFR Part 50, Appendix I, 10 times the ECL limits of 10 CFR Part 20, Appendix B, Table 2, Column 2 and 40 CFR 190. (See Reference | : a. With less than the minimum required instrumentation channels OPERABLE for more than 7 days, initiate an Issue Report outlining the cause of the malfunction and the plans for restoring the instrumentation to OPERABLE status. | ||
: b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. | |||
* Non compliance with a Control shall exist when the requirements of the control and associated ACTION requirements are not performed within the specified time intervals. | SURVEILLANCE REQUIREMENTS 4.3.4 Each of the above required meteorological monitoring instrumentation channels shall be demonstrated OPERABLE by the performance of the CHANNEL CHECK and CHANNEL CALIBRATION operations at the frequencies shown in Table 4.3-2. | ||
If the control is restored prior to expiration of the specified time intervals, completion of the ACTION requirements is not required. | Rev.29 Page 63 of 329 12/2016 | ||
There are no actions in the ODCM which would require an operational condition change. There are no restrictions on changing operating conditions in any of the controls on the ODCM. Surveillance Requirements shall be met during the OPERATIONAL CONDITIONS or other conditions specified for individual controls unless otherwise stated in an individual Surveillance Each Surveillance Requirement shall be performed within the specified interval with a maximum allowable extension not to exceed 25% of the surveillance interval. | |||
Failure to perform a Surveillance Requirement within the allowed surveillance interval defined by Surveillance Requirement 4.0.2.a, shall constitute noncompliance with the OPERABILITY requirements for a control. The time limits of the ACTION requirements are applicable at the time it is identified that a Surveillance Requirement has not been performed. | CY-LG-170-301 TABLE 3.3-3 METEOROLOGICAL MONITORING INSTRUMENTATION INSTRUMENT TOWER 1 TOWER2 MINIMUM (PRIMARY) (BACKUP) INSTRUMENT OPERABLE | ||
The ACTION requirements may be delayed for up to 24 hours to permit the completion of the surveillance when the allowable outage time limits of the ACTION requirements are less than 24 hours. Surveillance requirements do not have to be performed on inoperable equipment. | : 1. Wind Speed | ||
* The associated bases from the LGS Technical Specifications apply to this section. Rev.29 Page 68 of 329 12/2016 3/4.1 INSTRUMENTATION BASES | : a. Elevation 1 30 feet 159 feet 1 | ||
The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50. 3/4.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION The radioactive gaseous effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in gaseous effluents during actual or potential releases of gaseous effluents. | : b. Elevation 2 175 feet 304 feet 1 | ||
The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and | : 2. Wind Direction | ||
* use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50. Rev.29 Page 69 of 329 12/2016 | : a. Elevation 1 30 feet 159 feet 1 | ||
3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.1 CONCENTRATION | : b. Elevation 2 175 feet 304 feet 1 | ||
The concentration limits for dissolved or entrained noble gases are based upon the assumption that Xe-135 is the controlling radioisotope and its ECL in air (submersion) was converted to an equivalent concentration in water using the methods described in the International Commission on Radiological Protection (ICRP) Publication | : 3. Air Temperature Difference (~T) | ||
: a. Elevations 266 feet 300 feet 26 feet 26 feet 1 Rev.29 Page 64 of 329 12/2016 | |||
Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination | |||
CY-LG-170-301 TABLE 4.3-2 METEOROLOGICAL MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS INSTRUMENT CHANNEL CHANNEL CHECK CALIBRATION | |||
Anal. Chem. 40, 586-93 (1968); and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). 3/4.2.1.2 DOSE This Control is provided to implement the requirements of Sections II.A, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.1.2 implements the guidance set forth in Section II.A of Appendix I and provides the required operating flexibility and at the same time implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in liquid effluents will be kept "as low as reasonably achievable". | : 1. Wind Speed | ||
Also, for fresh water sites with drinking water supplies which can be potentially affected by plant operations, there is reasonable assurance that the operation of the facility will not result in radionuclide concentrations in the finished drinking water that are in excess of the requirements of 40 CFR Part 141. The Surveillance Requirement 4.2.1.2 implement the requirements in Section Ill.A of Appendix I that conformance with the guidance of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. | : a. Elevation 1 (Tower 1 and Tower 2) D SA | ||
The equations specified in the ODCM for calculating the doses due to the actual release rates of radioactive materials in liquid effluents are Rev.29 Page 70 of 329 12/2016 3/4.2 RADIOACTIVE EFFLUENTS BASES | : b. Elevation 2 (Tower 1 and Tower 2) D SA | ||
Control 3.2.1.3 implements the requirements of 10 CFR 50.35a, General Design Criterion 60 of Appendix A to 10 CFR Part 50 and the design objective given in Section 11.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the liquid radwaste treatment system were specified as a suitable fraction of the dose design objectives set forth in Section II.A of Appendix I, 10 CFR Part 50, for liquid effluents. | : 2. Wind Direction | ||
3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.1 DOSE RATE This control is provided to ensure that the dose from radioactive materials in gaseous effluents at and beyond the SITE BOUNDARY will be within the annual dose limits of 10 CFR Part 20 to UNRESTRICTED AREAS. The annual dose limits are the doses associated with the concentrations of 10 CFR Part 20, Appendix B, Table 2, Column 1. These limits provide reasonable assurance that radioactive material discharged in gaseous effluents will not result in the exposure of a MEMBER OF THE PUBLIC, either within or outside the SITE BOUNDARY, to annual average concentrations exceeding the limits specified in Appendix B, Table 2 of 10 CFR Part 20. For MEMBERS OF THE PUBLIC who may at times be within the SITE BOUNDARY, the occupancy factor for that MEMBER OF THE PUBLIC will usually be sufficiently low to compensate for any increase in the atmospheric diffusion factor for above that for the SITE BOUNDARY. | : a. Elevation 1 (Tower 1 and Tower 2) D SA | ||
Examples of calculations for such MEMBERS OF THE PUBLIC, with the appropriate occupancy factors, are given in the ODCM. The specified release rate limits restrict, at all times, the corresponding gamma and beta dose rates above background to a MEMBER OF THE PUBLIC at or beyond the SITE BOUNDARY to less than or equal to 500 mrem/year to the total body or to less than or equal to 3000 mrem/year to the skin. These release rate limits also restrict, at all times, the corresponding thyroid dose rate above background to a child via the inhalation pathway to less than or equal to 1500 mrem/year. | : b. Elevation 2 (Tower 1 and Tower 2) D SA | ||
Rev.29 Page 71 of 329 12/2016 3/4.2 RADIOACTIVE EFFLUENTS BASES | : 3. Air Temperature Difference (~ T) | ||
Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination | : a. Elevations 266 - 26 ft (Tower 1) D SA | ||
: b. Elevations 300 - 26 ft (Tower 2) D SA NOTE: | |||
Anal. Chem. 40, 586-93 ( | The meteorological towers shall be located as shown on Figure 3.3-1. | ||
The Surveillance Requirement 4.2.2.2 implement the requirements in Section Ill.A of Appendix I that conformance with the guides of Appendix I be shown by calculational procedures based on appropriate pathways is unlikely to be substantially underestimated. | Rev.29 Page 65 of 329 12/2016 | ||
The dose calculation established in the ODCM for calculating the doses due to the actual release rates of radioactive noble gases in gaseous effluents are consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routing Releases from Light-Water Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. | - -- _ __J | ||
CY-LG-170-301 Figure 3.3-1 METEOROLOGICAL TOWER LOCATIONS Rev.29 Page 66 of 329 . | |||
12/2016 | |||
CY-LG-170-301 3/4.0 CONTROLS BASES GENERAL It is expected that releases of radioactive material in effluents will be kept at small fractions of the limits specified in Section 20.1302 of 10 CFR, Part 20. At the same time, the licensee is permitted the flexibility of operation, compatible with consideration of health and safety, to assure that the public is provided a dependable source of power even under unusual operating conditions which may temporarily result in releases higher than such small fractions, but still within the limits specified in Section 20.1302 of 10 CFR, Part 20. It is expected that in using this operational flexibility under unusual operating conditions the licensee will exert his best efforts to keep levels of radioactive material in effluents as low as practicable. | |||
MAPS DEFINING UNRESTRICTED AREAS AND SITE BOUNDARY FOR RADIOACTIVE GASEOUS AND LIQUID EFFLUENTS Information regarding radioactive gaseous and liquid effluents, which will allow identification of structures and release points as well as definition of UNRESTRICTED AREAS within the SITE BOUNDARY that are accessible to MEMBER(S) OF THE PUBLIC, shall be as shown in Technical Specifications Figures 5.1.3-1 a and 5.1.3-1 b. | |||
The exclusion area and low population zone shall be as shown in Figures 1-1 and 1-2. | |||
10 CFR 20 Per Technical Specification Section 6.8.4.d, the Radioactive Effluent Controls Program must conform with limitations specified in 10 CFR 50.36a, 10 CFR Part 50, Appendix I, 10 times the ECL limits of 10 CFR Part 20, Appendix B, Table 2, Column 2 and 40 CFR 190. (See Reference 14) | |||
Rev.29 Page 67 of 329 12/2016 | |||
CY-LG-170-301 3/4.0 CONTROLS BASES 3/4.0 APPLICABILITY Compliance with the controls is required during the OPERATIONAL CONDITIONS or other conditions specified therein; except that upon failure to meet the controls, the associated ACTION requirements shall be met. | |||
* Non compliance with a Control shall exist when the requirements of the control and associated ACTION requirements are not performed within the specified time intervals. If the control is restored prior to expiration of the specified time intervals, completion of the ACTION requirements is not required. | |||
There are no actions in the ODCM which would require an operational condition change. | |||
There are no restrictions on changing operating conditions in any of the controls on the ODCM. | |||
Surveillance Requirements shall be met during the OPERATIONAL CONDITIONS or other conditions specified for individual controls unless otherwise stated in an individual Surveillance R~quirement. | |||
Each Surveillance Requirement shall be performed within the specified interval with a maximum allowable extension not to exceed 25% of the surveillance interval. | |||
Failure to perform a Surveillance Requirement within the allowed surveillance interval defined by Surveillance Requirement 4.0.2.a, shall constitute noncompliance with the OPERABILITY requirements for a control. The time limits of the ACTION requirements are applicable at the time it is identified that a Surveillance Requirement has not been performed. The ACTION requirements may be delayed for up to 24 hours to permit the completion of the surveillance when the allowable outage time limits of the ACTION requirements are less than 24 hours. Surveillance requirements do not have to be performed on inoperable equipment. | |||
* The associated bases from the LGS Technical Specifications apply to this section. | |||
Rev.29 Page 68 of 329 12/2016 | |||
CY-LG-170-301 3/4.1 INSTRUMENTATION BASES 3/4.1.1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION The radioactive liquid effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in liquid effluents during actual or potential releases of liquid effluents. The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50. | |||
3/4.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION The radioactive gaseous effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in gaseous effluents during actual or potential releases of gaseous effluents. The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and | |||
* use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50. | |||
( | |||
Rev.29 Page 69 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.1 CONCENTRATION This control is provided to ensure that the concentration of radioactive materials released in liquid waste effluents to areas at and beyond the UNRESTRICTED AREAS will be less than 10 times the effluent concentration limits (ECL) specified in 10 CFR Part 20, Appendix B, Table 2, Column 2. This instantaneous limitation provides additional assurance that the levels of radioactive materials in bodies of water in areas at and beyond the SITE BOUNDARY will result in exposures within (1) the Section II.A design objectives of Appendix I, 10 CFR Part 50, to a MEMBER OF THE PUBLIC, and (2) the limits of 10 CFR 20.1302 to the population. The concentration limits for dissolved or entrained noble gases are based upon the assumption that Xe-135 is the controlling radioisotope and its ECL in air (submersion) was converted to an equivalent concentration in water using the methods described in the International Commission on Radiological Protection (ICRP) Publication 2. | |||
The required detection capabilities for radioactive materials in liquid waste samples are tabulated in terms of the lower limits of detection (LLDs). Detailed discussion of the LLD, and other detection limits can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination - | |||
Application to Radiochemistry"; Anal. Chem. 40, 586-93 (1968); and Hartwell, J.K., | |||
"Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). | |||
3/4.2.1.2 DOSE This Control is provided to implement the requirements of Sections II.A, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.1.2 implements the guidance set forth in Section II.A of Appendix I and provides the required operating flexibility and at the same time implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in liquid effluents will be kept "as low as reasonably achievable". Also, for fresh water sites with drinking water supplies which can be potentially affected by plant operations, there is reasonable assurance that the operation of the facility will not result in radionuclide concentrations in the finished drinking water that are in excess of the requirements of 40 CFR Part 141. The Surveillance Requirement 4.2.1.2 implement the requirements in Section Ill.A of Appendix I that conformance with the guidance of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. The equations specified in the ODCM for calculating the doses due to the actual release rates of radioactive materials in liquid effluents are Rev.29 Page 70 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," April, 1977. | |||
This control applies to the release of radioactive materials in liquid effluents from the site. | |||
3/4.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM The requirement that the appropriate portions of this system be used when specified provides assurance that the releases of radioactive materials in liquid effluents will be kept "as low as reasonably achievable". Control 3.2.1.3 implements the requirements of 10 CFR 50.35a, General Design Criterion 60 of Appendix A to 10 CFR Part 50 and the design objective given in Section 11.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the liquid radwaste treatment system were specified as a suitable fraction of the dose design objectives set forth in Section II.A of Appendix I, 10 CFR Part 50, for liquid effluents. | |||
3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.1 DOSE RATE This control is provided to ensure that the dose from radioactive materials in gaseous effluents at and beyond the SITE BOUNDARY will be within the annual dose limits of 10 CFR Part 20 to UNRESTRICTED AREAS. The annual dose limits are the doses associated with the concentrations of 10 CFR Part 20, Appendix B, Table 2, Column 1. | |||
These limits provide reasonable assurance that radioactive material discharged in gaseous effluents will not result in the exposure of a MEMBER OF THE PUBLIC, either within or outside the SITE BOUNDARY, to annual average concentrations exceeding the limits specified in Appendix B, Table 2 of 10 CFR Part 20. For MEMBERS OF THE PUBLIC who may at times be within the SITE BOUNDARY, the occupancy factor for that MEMBER OF THE PUBLIC will usually be sufficiently low to compensate for any increase in the atmospheric diffusion factor for above that for the SITE BOUNDARY. Examples of calculations for such MEMBERS OF THE PUBLIC, with the appropriate occupancy factors, are given in the ODCM. The specified release rate limits restrict, at all times, the corresponding gamma and beta dose rates above background to a MEMBER OF THE PUBLIC at or beyond the SITE BOUNDARY to less than or equal to 500 mrem/year to the total body or to less than or equal to 3000 mrem/year to the skin. These release rate limits also restrict, at all times, the corresponding thyroid dose rate above background to a child via the inhalation pathway to less than or equal to 1500 mrem/year. | |||
Rev.29 Page 71 of 329 12/2016 | |||
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES This Control applies to the release of radioactive materials in gaseous effluents from all reactors at the site. | |||
The required detection capability for radioactive materials in gaseous waste samples are tabulated in terms of the lower limits of detection (LLDs). Detailed discussion of the LLD, and other detection limits can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination - | |||
Application to Radiochemistry"; Anal. Chem. 40, 586-93 (1986); and Hartwell, J.K., | |||
"Detection Limits for Radioanalytical Counting Techniques." Atlantic Richfield Hanford Company Report ARH-SA-215 (June 1975). | |||
3/4.2.2.2 DOSE - NOBLE GASES This control is provided to implement the requirements of Sections 11.B, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.2.2 implements the guidance set forth in Section 11.B of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in gaseous effluents will be kept "as low as reasonably achievable". The Surveillance Requirement 4.2.2.2 implement the requirements in Section Ill.A of Appendix I that conformance with the guides of Appendix I be shown by calculational procedures based on appropriate pathways is unlikely to be substantially underestimated. The dose calculation established in the ODCM for calculating the doses due to the actual release rates of radioactive noble gases in gaseous effluents are consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routing Releases from Light-Water Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. | |||
The ODCM equations provided for determining the air doses at and beyond the SITE BOUNDARY are based upon the historical average atmospheric conditions. | The ODCM equations provided for determining the air doses at and beyond the SITE BOUNDARY are based upon the historical average atmospheric conditions. | ||
3/4.2.2.3 DOSE -IODINE-131. | 3/4.2.2.3 DOSE - IODINE-131. IODINE-133, TRITIUM. AND RADIONUCLIDES IN PARTICULATE FORM This control is provided to implement the requirements of Sections 11.C, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.2.3 implements the guidance set forth in Section 11.C of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." The ODCM calculational methods specified in the Surveillance Requirements 4.2.2.3 implement the Rev.29 Page 72 of 329 12/2016 | ||
IODINE-133, TRITIUM. AND RADIONUCLIDES IN PARTICULATE FORM This control is provided to implement the requirements of Sections 11.C, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.2.3 implements the guidance set forth in Section 11.C of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." The ODCM calculational methods specified in the Surveillance Requirements 4.2.2.3 implement the Rev.29 Page 72 of 329 12/2016 3/4.2 RADIOACTIVE EFFLUENTS BASES | |||
The ODCM calculational methods for calculating the doses due to the actual release rates of the subject materials are consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. | CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES requirements in Section Ill.A of Appendix I, that conformance with the guides of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. The ODCM calculational methods for calculating the doses due to the actual release rates of the subject materials are consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. These equations also provide for determining the actual doses based upon the historical average atmospheric conditions. The release rate specifications for iodine-131, iodine-133, tritium, and radionuclides in particulate form with half-lives greater than 8 days are dependent on the existing radionuclides pathways to man in areas at and beyond the SITE BOUNDARY. The pathways which were e~amined in the development of these calculations were: (1) individual inhalation of airborne radionuclides, (2) deposition of radionuclides onto green leafy vegetation with subsequent consumption by man, (3) deposition onto grassy areas where milk animals and meat-producing animals graze with consumption of the milk and meat by man, and (4) deposition on the ground with subsequent exposure of man. | ||
These equations also provide for determining the actual doses based upon the historical average atmospheric conditions. | 3/4.2.2.4 AND 3/4.2.2.5 GASEOUS RADWASTE TREATMENT SYSTEM AND VENTILATION EXHAUST TREATMENT SYSTEM The requirement that the appropriate portions of this system be used, when specified, provides reasonable assurance that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." Controls 3.2.2.4 and 3.2.2.5 implements the requirements of 10 CFR 50.36a, General Design Criteria 60 of Appendix A to 10 CFR Part 50, and the design objectives given in Section 11.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the systems were specified as a suitable fraction of the dose design objectives set forth in Section 11.B and 11.C of Appendix I, 10 CFR Part 50, for gaseous effluents. | ||
The release rate specifications for iodine-131, iodine-133, tritium, and radionuclides in particulate form with half-lives greater than 8 days are dependent on the existing radionuclides pathways to man in areas at and beyond the SITE BOUNDARY. | 3/4.2.2.7 MARK II CONTAINMENT This control provides reasonable assurance that releases from drywell venting or purging operations will not exceed the annual dose limits of 10 CFR Part 20 for areas at or beyond the UNRESTRICTED AREAS. | ||
The pathways which were in the development of these calculations were: (1) individual inhalation of airborne radionuclides, (2) deposition of radionuclides onto green leafy vegetation with subsequent consumption by man, (3) deposition onto grassy areas where milk animals and meat-producing animals graze with consumption of the milk and meat by man, and (4) deposition on the ground with subsequent exposure of man. 3/4.2.2.4 AND 3/4.2.2.5 GASEOUS RADWASTE TREATMENT SYSTEM AND VENTILATION EXHAUST TREATMENT SYSTEM The requirement that the appropriate portions of this system be used, when specified, provides reasonable assurance that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." Controls 3.2.2.4 and 3.2.2.5 implements the requirements of 10 CFR 50.36a, General Design Criteria 60 of Appendix A to 10 CFR Part 50, and the design objectives given in Section 11.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the systems were specified as a suitable fraction of the dose design objectives set forth in Section 11.B and 11.C of Appendix I, 10 CFR Part 50, for gaseous effluents. | Rev.29 Page 73 of 329 12/2016 | ||
3/4.2.2.7 MARK II CONTAINMENT This control provides reasonable assurance that releases from drywell venting or purging operations will not exceed the annual dose limits of 10 CFR Part 20 for areas at or beyond the UNRESTRICTED AREAS. Rev.29 Page 73 of 329 12/2016 3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4.2.3 TOTAL DOSE | |||
_9ry shielded canisters of spent fuel are placed on the ISFSI pad, it is expected that ISFSI operations will become the prominent contributor to the dose limits in this section. ISFSI dose contribution is in the form of direct radiation as no liquid or gas releases are expected to occur from the ISFSI canisters. | CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4.2.3 TOTAL DOSE This control is provided to meet the dose limitations of 40 CFR Part 190 that have been incorporated into 10 CFR Part 20 by 46 CFR 18525, as well as the dose limitations specific to Independent Spent Fuel Storage Installation (ISFSI) operations in accordance with 10 CFR 72.104. Over the long term, _as more storage modules containing _9ry shielded canisters of spent fuel are placed on the ISFSI pad, it is expected that ISFSI operations will become the prominent contributor to the dose limits in this section. ISFSI dose contribution is in the form of direct radiation as no liquid or gas releases are expected to occur from the ISFSI canisters. The LGS 10 CFR 72.212 Report prepared in accordance with 10 CFR 72 requirements assumes a certain array of storage modules exists on the pad. The dose contribution from this array of casks combination with historical uranium fuel cycle operations prior to ISFSI operations was analyzed to be within the 40 CFR 190 and 10 CFR 72.104 limits. Control 3.2.3 requires the preparation and submittal of a Special Report whenever the calculated doses due to releases of radioactivity and to radiation from uranium fuel cycle sources exceed 25 mrem to the whole body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem. For sites containing up to four reactors, it is highly unlikely that the resultant dose to a MEMBER OF THE PUBLIC will exceed the dose limits of 40 CFR Part 190 if the individual reactors remain within twice the dose design objectives of Appendix I, and if direct radiation does from the units (including outside storage tanks, etc.) are kept small. | ||
The LGS 10 CFR 72.212 Report prepared in accordance with 10 CFR 72 requirements assumes a certain array of storage modules exists on the pad. The dose contribution from this array of casks combination with historical uranium fuel cycle operations prior to ISFSI operations was analyzed to be within the 40 CFR 190 and 10 CFR 72.104 limits. Control 3.2.3 requires the preparation and submittal of a Special Report whenever the calculated doses due to releases of radioactivity and to radiation from uranium fuel cycle sources exceed 25 mrem to the whole body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem. For sites containing up to four reactors, it is highly unlikely that the resultant dose to a MEMBER OF THE PUBLIC will exceed the dose limits of 40 CFR Part 190 if the individual reactors remain within twice the dose design objectives of Appendix I, and if direct radiation does from the units (including outside storage tanks, etc.) are kept small. The Special Report will describe a course of action that should result in the limitation of the annual dose to a MEMBER .OF THE PUBLIC to within the 40 CFR Part 190 limits. For the purposes of the Special Report, it may be assumed that the dose commitment to the MEMBER OF THE PUBLIC from other uranium fuel cycle sources is negligible, with the exception that dose contributions from other nuclear fuel cycle facilities at the same site or within a radius of 5 miles must be considered. | The Special Report will describe a course of action that should result in the limitation of the annual dose to a MEMBER .OF THE PUBLIC to within the 40 CFR Part 190 limits. For the purposes of the Special Report, it may be assumed that the dose commitment to the MEMBER OF THE PUBLIC from other uranium fuel cycle sources is negligible, with the exception that dose contributions from other nuclear fuel cycle facilities at the same site or within a radius of 5 miles must be considered. If the dose to any MEMBER OF THE PUBLIC is estimated to exceed the requirements of 40 CFR Part 190 or 10 CFR 72.104, the Special Report with a request for a variance (provided the release condition resulting in violation of 40 CFR Part 190 or 10 CFR 72.104 have not already been corrected), in accordance with the provisions of 40 CFR 190.11, or 10 CFR 72.104 and 10 CFR 20.2203, is considered to be a timely request and fulfills the requirements of 40 CFR Part 190 or 10 CFR 72.104 until NRC staff action is completed. The variance only relates to the limits of 40 CFR Part 190 or 10 CFR 72.104, and does not apply in any way to the other requirements for dose limitation of 10 CFR Part 20, as addressed in Controls 3.2.1.1 and 3.2.2.1. An individual is not considered a MEMBER OF THE PUBLIC during any period in which he/she is engaged in carrying out any operation that is part of the nuclear fuel cycle. | ||
If the dose to any MEMBER OF THE PUBLIC is estimated to exceed the requirements of 40 CFR Part 190 or 10 CFR 72.104, the Special Report with a request for a variance (provided the release condition resulting in violation of 40 CFR Part 190 or 10 CFR 72.104 have not already been corrected), in accordance with the provisions of 40 CFR 190.11, or 10 CFR 72.104 and 10 CFR 20.2203, is considered to be a timely request and fulfills the requirements of 40 CFR Part 190 or 10 CFR 72.104 until NRC staff action is completed. | Rev.29 Page 74 of 329 12/2016 | ||
The variance only relates to the limits of 40 CFR Part 190 or 10 CFR 72.104, and does not apply in any way to the other requirements for dose limitation of 10 CFR Part 20, as addressed in Controls 3.2.1.1 and 3.2.2.1. An individual is not considered a MEMBER OF THE PUBLIC during any period in which he/she is engaged in carrying out any operation that is part of the nuclear fuel cycle. Rev.29 Page | |||
This monitoring program implements Section IV.B.2 of Appendix I to 10 CFR Part 50 and thereby supplements the radiological effluent monitoring program by verifying that the measurable concentrations of radioactive materials and levels of radiation are not higher than expected on the basis of the effluent measurements and modeling of the environmental exposure pathways. | CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING BASES 3/4.3.1 MONITORING PROGRAM The Radiological Environmental Monitoring Program (REMP) required by this control provides representative measurements of radiation and of radioactive materials in those exposure pathways and for those radionuclides that lead to the highest potential radiation exposures of MEMBER OF THE PUBLIC resulting from the station operation. This monitoring program implements Section IV.B.2 of Appendix I to 10 CFR Part 50 and thereby supplements the radiological effluent monitoring program by verifying that the measurable concentrations of radioactive materials and levels of radiation are not higher than expected on the basis of the effluent measurements and modeling of the environmental exposure pathways. | ||
The required detection capabilities for environmental sample analyses are tabulated in terms of the lower limits of detection (LLDs). The LLDs required by Table 4.3-1 are considered optimum for routine environmental measurements in industrial laboratories. | The required detection capabilities for environmental sample analyses are tabulated in terms of the lower limits of detection (LLDs). The LLDs required by Table 4.3-1 are considered optimum for routine environmental measurements in industrial laboratories. It should be recognized that the LLD is defined as an .§.priori (before the fact) limit representing the capability of a measurement system and not an after the fact limit for a particular measurement. | ||
It should be recognized that the LLD is defined as an .§.priori (before the fact) limit representing the capability of a measurement system and not an after the fact limit for a particular measurement. | Detailed discussion of the LLD, and other detection limits, can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry," Anal. Chem. 40, 586-93 (1968), and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). | ||
Detailed discussion of the LLD, and other detection limits, can be found in HASL Procedures Manual, HASL-300 (revised annually); | 3/4.3.2 LAND USE CENSUS This control is provided to ensure that changes in the use of areas at and beyond the SITE BOUNDARY are identified and that modifications to the monitoring program are made if required by the results of the census. The best information from the door-to-door survey, aerial survey or consulting with local agricultural authorities or any combination of these methods shall be used. This census satisfies the requirements of Section IV.B.3 of Appendix I to 10 CFR Part 50. Restricting the census to gardens of greaterthan 500 square feet provides assurance that significant exposure pathways via leafy vegetables will be identified and monitored since a garden of this size is the minimum required to produce the quantity (26 Kg/year) of leafy vegetables assumed in Regulatory Guide 1.109 for consumption by a child. To determine this minimum garden size, the following assumptions were used: (1) that 20% of the garden was used for growing broad leafy vegetation (i.e. | ||
Currie L.A., "Limits for Qualitative Detection and Quantitative Determination | similar to lettuce and cabbage), and (2) a vegetation yield of 2 kg/Square meter. | ||
-Application to Radiochemistry," Anal. Chem. 40, 586-93 (1968), and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). 3/4.3.2 LAND USE CENSUS This control is provided to ensure that changes in the use of areas at and beyond the SITE BOUNDARY are identified and that modifications to the monitoring program are made if required by the results of the census. The best information from the door-to-door survey, aerial survey or consulting with local agricultural authorities or any combination of these methods shall be used. This census satisfies the requirements of Section IV.B.3 of Appendix I to 10 CFR Part 50. Restricting the census to gardens of greaterthan 500 square feet provides assurance that significant exposure pathways via leafy vegetables will be identified and monitored since a garden of this size is the minimum required to produce the quantity (26 Kg/year) of leafy vegetables assumed in Regulatory Guide 1.109 for consumption by a child. To determine this minimum garden size, the following assumptions were used: (1) that 20% of the garden was used for growing broad leafy vegetation (i.e. similar to lettuce and cabbage), and (2) a vegetation yield of 2 kg/Square meter. Rev.29 Page 75 of 329 12/2016 | Rev.29 Page 75 of 329 12/2016 | ||
This capability is required to evaluate the need for initiating measures to protect the health and safety of the public. This instrumentation is consistent with the recommendations of Regulatory Guide 1.23 "Onsite Meteorological Programs," February, 1972. Site data compiled since January 1972 provide correlation between Elevation 1 (Tower 1) and Elevation 1 (Tower 2), and between Elevation 2 (Tower 1) and Elevation 2 (Tower 2). This correlation serves as justification for the use of the appropriate Tower 2 instrument as a back-up to the Tower 1 instrument as shown in Table 3.3-3. Rev.29 Page 76 of 329 12/2016 CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.1 ANNUAL RADIOLOGICAL ENVIRONMENTAL OPERATING REPORT 6.1 Routine Annual Radiological Environmental Operating Report covering the operation of Unit 1 and Unit 2 during the previous calendar year shall be submitted prior to May 1 for each year. The initial report was submitted prior to May 1 of the year following initial criticality (1984). A single report is submitted for a multiple unit station. The Annual Radiological Environmental Operating Report shall include summaries, interpretations, and an analysis of trends of the results report period, including a comparison (as appropriate), with preoperational studies, operational controls and previous environmental surveillance reports and an assessment of the observed impacts of the plant operation on the environment. | |||
The reports shall also include the results of land use census required by Control 3.3.2. The Annual Radiological Environmental Operating Report shall include the results of all radiological environmental samples and of all environmental radiation measurements taken during the report period pursuant to the locations specified in the tables and figures in the OFFSITE DOSE CALCULATION MANUAL, as well as summarized and tabulated results of these analyses and measurements in the format of the table in NU REG 1302. In the event that some individual results are not available for inclusion with the report, the report shall be submitted noting and explaining the reasons for the missing results. The missing data shall be submitted as soon as possible in a supplementary report. The report shall also include the following: | CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING BASES 3/4.3.3 INTERLABORATORY COMPARISON PROGRAM The requirement for participation in an lnterlaboratory Comparison Program ensures that independent checks on the precision and accuracy of the measurements of radioactive material in environmental sample matrices are performed as part of the quality assurance program for environmental monitoring in order to demonstrate that the results are reasonably valid for the purpose of Section IV.B.2 of Appendix I to 10 CFR Part .50. | ||
a summary description of the radiological environmental monitoring program and at least two legible maps. One map shall cover stations near the SITE BOUNDARY; a second shall include the more detailed distant stations. | 3/4.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION The OPERABILITY of the meteorological monitoring instrumentation ensures that sufficient meteorological data is available for estimating potential radiation doses to the public as a result of routine or accidental release of radioactive materials to the atmosphere. This capability is required to evaluate the need for initiating measures to protect the health and safety of the public. This instrumentation is consistent with the recommendations of Regulatory Guide 1.23 "Onsite Meteorological Programs," February, 1972. | ||
Covering all sampling locations keyed to a table giving distances and directions from the centerline of the reactor plant; the results of licensee participation in the lnterlaboratory Comparison Program, required by Control 3.3.3 discussion of all deviations from the Sampling Schedule of Table 3.3-1; and discussion of all analyses in which the LLD required by Table 4.3-1 was not achievable. | Site data compiled since January 1972 provide correlation between Elevation 1 (Tower 1) and Elevation 1 (Tower 2), and between Elevation 2 (Tower 1) and Elevation 2 (Tower 2). | ||
The Annual Radiological Environmental Monitoring Report shall include a summary of Special Reports detailing level of radioactivity as the result of plant effluents in an environmental sampling medium exceed the reporting levels of Table 3.3-2. Rev.29 Page 77 of 329 12/2016 CY-LG.:.170-301 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 6.2 A Routine Annual Radioactive Effluent Release Report covering the operation of Unit 1 and Unit 2 during the previous year shall be submitted in accordance with Tech Spec section 6.9.1.8. The period of the first report shall begin with the date of initial criticality. | This correlation serves as justification for the use of the appropriate Tower 2 instrument as a I. back-up to the Tower 1 instrument as shown in Table 3.3-3. | ||
A single unit submittal is made for the 2-unit station. The submittal combines those sections that are common to all units at the station. The Annual Radioactive Effluent Release Report shall include a summary of the quantities of radioactive liquid and gaseous effluents and solid waste released from the facility as outlined in Regulatory Guide 1.21, "Measuring, Evaluation, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, June 1974, with data summarized on a quarterly basis following the format of Appendix B with the following exception: | Rev.29 Page 76 of 329 12/2016 | ||
(1) Gaseous dose rates rather than effluent concentrations are used to calculate permissible release rates for gaseous releases. | |||
(2) ODCM Control 3.2.2.1 limits the dose equivalent rates due to the release of noble gases to less than or equal to 500 mrem per year to the total body and less than or equal to 3000 mrem per year to the skin. Therefore, the average beta and gamma energies (E) of the radionuclide mixture in releases of fission and activation gases are not applicable. | CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.1 ANNUAL RADIOLOGICAL ENVIRONMENTAL OPERATING REPORT 6.1 Routine Annual Radiological Environmental Operating Report covering the operation of Unit 1 and Unit 2 during the previous calendar year shall be submitted prior to May 1 for each year. The initial report was submitted prior to May 1 of the year following initial criticality (1984). A single report is submitted for a multiple unit station. The Annual Radiological Environmental Operating Report shall include summaries, interpretations, and an analysis of trends of the results report period, including a comparison (as appropriate), with preoperational studies, operational controls and previous environmental surveillance reports and an assessment of the observed impacts of the plant operation on the environment. The reports shall also include the results of land use census required by Control 3.3.2. The Annual Radiological Environmental Operating Report shall include the results of all radiological environmental samples and of all environmental radiation measurements taken during the report period pursuant to the locations specified in the tables and figures in the OFFSITE DOSE CALCULATION MANUAL, as well as summarized and tabulated results of these analyses and measurements in the format of the table in NU REG 1302. In the event that some individual results are not available for inclusion with the report, the report shall be submitted noting and explaining the reasons for the missing results. The missing data shall be submitted as soon as possible in a supplementary report. The report shall also include the following: a summary description of the radiological environmental monitoring program and at least two legible maps. One map shall cover stations near the SITE BOUNDARY; a second shall include the more detailed distant stations. Covering all sampling locations keyed to a table giving distances and directions from the centerline of the reactor plant; the results of licensee participation in the lnterlaboratory Comparison Program, required by Control 3.3.3 discussion of all deviations from the Sampling Schedule of Table 3.3-1; and discussion of all analyses in which the LLD required by Table 4.3-1 was not achievable. | ||
(3) Achieving doses of less than the limits of 10 CFR Part 50, Appendix I demonstrate.that Limerick's gaseous effluents are ALARA. Therefore, calculations of total body doses to the population out to 50 miles from gaseous effluents are not performed . . The Annual Radioactive Effluent Release Report shall include an annual summary of hourly meteorological data collected over the previous year. This annual summary may be either in the form of an hour-by-hour listing on magnetic tape of wind speed, wind direction and atmospheric stability, and precipitation (if measured), or in the form of joint frequency distributions of wind speed, wind direction, atmospheric stability. | The Annual Radiological Environmental Monitoring Report shall include a summary of Special Reports detailing level of radioactivity as the result of plant effluents in an environmental sampling medium exceed the reporting levels of Table 3.3-2. | ||
The licensee has the option of retaining this summary of required meteorological data on site in a file that shall be provided to the NRC upon request. This same report shall include an assessment of the radiation doses due to the radioactive liquid and gaseous effluents released from both units during the previous calendar year. This same report shall also include an assessment of the radiation doses from radioactive liquid and gaseous effluents to MEMBER OF THE PUBLIC due to their activities inside the SITE BOUNDARY (Figures 1-1 and 1-2) during the report period. All assumptions used in making these assessments shall be included in these reports. The assessment of radiation doses shall be performed in accordance with the methodology and parameters of the OFFSITE DOSE CALCULATION MANUAL (ODCM). The Annual Radioactive Effluent Release Report shall also include an assessment of radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases, ISFSI and other nearby uranium fuel cycle sources (including doses from primary effluent pathways and direct radiation) for the previous calendar Rev.29 Page 78 of 329 12/2016 CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT year to show conformance with 40 CFR Part 190, Environmental Radiation Protection Standards for Nuclear Power Operation. | Rev.29 Page 77 of 329 12/2016 | ||
Dose contribution from liquid and gaseous effluents is calculated based on NUREG-0133 methodology. | |||
The Annual Radioactive Effluent Release Reports includes the following information for each type of solid waste (as defined in 10 CFR Part 61) shipped offsite during the report period: 1. Total volume, activity and estimated total % error for each waste type: a. Spent resins filter sludges, evaporator bottoms, etc. b. Dry compressible waste, contaminated equipment, etc. c. Irradiated components, control rods, etc. d. Others (describe). | CY-LG.:.170-301 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 6.2 A Routine Annual Radioactive Effluent Release Report covering the operation of Unit 1 and Unit 2 during the previous year shall be submitted in accordance with Tech Spec section 6.9.1.8. The period of the first report shall begin with the date of initial criticality. A single unit submittal is made for the 2-unit station. The submittal combines those sections that are common to all units at the station. The Annual Radioactive Effluent Release Report shall include a summary of the quantities of radioactive liquid and gaseous effluents and solid waste released from the facility as outlined in Regulatory Guide 1.21, "Measuring, Evaluation, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, June 1974, with data summarized on a quarterly basis following the format of Appendix B with the following exception: (1) Gaseous dose rates rather than effluent concentrations are used to calculate permissible release rates for gaseous releases. | ||
: 2. Activity and percentage of each principle radionuclide | (2) ODCM Control 3.2.2.1 limits the dose equivalent rates due to the release of noble gases to less than or equal to 500 mrem per year to the total body and less than or equal to 3000 mrem per year to the skin. Therefore, the average beta and gamma energies (E) of the radionuclide mixture in releases of fission and activation gases are not applicable. (3) Achieving doses of less than the limits of 10 CFR Part 50, Appendix I demonstrate.that Limerick's gaseous effluents are ALARA. Therefore, calculations of total body doses to the population out to 50 miles from gaseous effluents are not performed . | ||
(>1 %), for each individual waste type as defined in 1. (a-d) above. 3. The disposition of solid waste shipments (identify the number of shipments, the mode of transport, and the destination). | . The Annual Radioactive Effluent Release Report shall include an annual summary of hourly meteorological data collected over the previous year. This annual summary may be either in the form of an hour-by-hour listing on magnetic tape of wind speed, wind direction and atmospheric stability, and precipitation (if measured), or in the form of joint frequency distributions of wind speed, wind direction, atmospheric stability. The licensee has the option of retaining this summary of required meteorological data on site in a file that shall be provided to the NRC upon request. | ||
This same report shall include an assessment of the radiation doses due to the radioactive liquid and gaseous effluents released from both units during the previous calendar year. This same report shall also include an assessment of the radiation doses from radioactive liquid and gaseous effluents to MEMBER OF THE PUBLIC due to their activities inside the SITE BOUNDARY (Figures 1-1 and 1-2) during the report period. All assumptions used in making these assessments shall be included in these reports. The assessment of radiation doses shall be performed in accordance with the methodology and parameters of the OFFSITE DOSE CALCULATION MANUAL (ODCM). | |||
The Annual Radioactive Effluent Release Report shall also include an assessment of radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases, ISFSI and other nearby uranium fuel cycle sources (including doses from primary effluent pathways and direct radiation) for the previous calendar Rev.29 Page 78 of 329 12/2016 | |||
CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT year to show conformance with 40 CFR Part 190, Environmental Radiation Protection Standards for Nuclear Power Operation. Dose contribution from liquid and gaseous effluents is calculated based on NUREG-0133 methodology. | |||
The Annual Radioactive Effluent Release Reports includes the following information for each type of solid waste (as defined in 10 CFR Part 61) shipped offsite during the report period: | |||
: 1. Total volume, activity and estimated total % error for each waste type: | |||
: a. Spent resins filter sludges, evaporator bottoms, etc. | |||
: b. Dry compressible waste, contaminated equipment, etc. | |||
: c. Irradiated components, control rods, etc. | |||
: d. Others (describe). | |||
: 2. Activity and percentage of each principle radionuclide (>1 %), for each individual waste type as defined in 1. (a-d) above. | |||
: 3. The disposition of solid waste shipments (identify the number of shipments, the mode of transport, and the destination). | |||
: 4. The disposition of irradiated fuel shipments (identify the number of shipments, the mode of transport, and the destination. | : 4. The disposition of irradiated fuel shipments (identify the number of shipments, the mode of transport, and the destination. | ||
The Annual Radioactive Effluent Release Report includes a list and description of unplanned releases from the site to UNRESTRICTED AREAS of radioactive material in gaseous and liquid effluents made during the reporting period. Changes made during the reporting period to procedure RW-AA-100 (formerly the PROCESS CONTROL PROGRAM) and to the ODCM, as well as a listing of new locations for dose calculations and/or environmental monitoring identified by the land. use census pursuant to Control 3.3.2. shall be submitted in the form of a complete, legible copy of the entire ODCM as part of or concurrent with the Annual Radiological Effluent Release Report for the period of the report in which any change to the ODCM was made. The Annual Radioactive Effluent Release Report shall include an explanation as to why the inoperability of liquid or gaseous effluent monitoring instrumentation was not corrected within the time specified in Controls 3.1.1 or 3.1.2, respectively; The Annual Radioactive Effluent Release Report shall include a summary of Special Reports detailing why discharge of liquid radwaste or gaseous radwaste without treatment exceeded the time specified in Controls 3.2.1.3 or 3.2.2.4, respectively. | The Annual Radioactive Effluent Release Report includes a list and description of unplanned releases from the site to UNRESTRICTED AREAS of radioactive material in gaseous and liquid effluents made during the reporting period. | ||
The Annual Radioactive Effluent Release Report shall include a summary of Special Reports for exceeding the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b., 3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., 3.2.2.3.b., 3.2.2.5.a., 3.2.2.5.b., 3.2.2.5.c., and 3.2.3. Rev.29 Page 79 of 329 12/2016 CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.3 MAJOR CHANGES TO RADIOACTIVE WASTE TREATMENT SYSTEMS 6.3 Licensee-initiated major changes to the radioactive waste systems (liquid, gaseous, and solid): a. Shall be reported to the Commission in the Annual Radioactive Effluent Release Report for the period in which the change was made effective. | Changes made during the reporting period to procedure RW-AA-100 (formerly the PROCESS CONTROL PROGRAM) and to the ODCM, as well as a listing of new locations for dose calculations and/or environmental monitoring identified by the land. | ||
The discussion of each change shall contain: 1. A summary of the evaluation that led to the determination that the change could be made in accordance with 10 CFR 50.59; 2. Sufficient detailed information to totally support the reason for the change without benefit of additional or supplemental information; | use census pursuant to Control 3.3.2. shall be submitted in the form of a complete, legible copy of the entire ODCM as part of or concurrent with the Annual Radiological Effluent Release Report for the period of the report in which any change to the ODCM was made. | ||
: 3. A detailed description of the equipment, components, and processes involved and the interface with other plant systems; 4. An evaluation of the change which shows the predicted releases of radioactive materials in liquid and gaseous effluents and/or quantity of solid waste that differ from those previously predicted in the license application and amendments thereto; 5. An evaluation of the change which shows the expected maximum exposures to individual in the UNRESTRICTED AREA and to the general population that differ from those previously estimated in the license application and amendments thereto; 6. A comparison .of the predicted releases of radioactive materials, in liquid and gaseous effluents and in solid waste, to the actual releases for the period prior to when the changes are to be made; and 7. An estimate of the exposure to plant operating personnel as a result of the change. Rev.29 Page 80 of 329 12/2016 CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.4 CHANGES TO THE ODCM 6.4 Licensee-initiated changes to the Offsite Dose Calculational Manual: a. Shall contain the program elements described in Technical Specifications 6.8.4.d, e and f. b. Shall be revised in accordance with the requirements described in Technical Specification 6.14. c. Shall be revised per applicable procedures detailing other requirements for making changes to the ODCM. d. Shall be reviewed and accepted by PORC and signed by the Plant Manager prior to implementation. | The Annual Radioactive Effluent Release Report shall include an explanation as to why the inoperability of liquid or gaseous effluent monitoring instrumentation was not corrected within the time specified in Controls 3.1.1 or 3.1.2, respectively; The Annual Radioactive Effluent Release Report shall include a summary of Special Reports detailing why discharge of liquid radwaste or gaseous radwaste without treatment exceeded the time specified in Controls 3.2.1.3 or 3.2.2.4, respectively. | ||
Rev.29 Page 81 of 329 12/2016 -------____ _J | The Annual Radioactive Effluent Release Report shall include a summary of Special Reports for exceeding the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b., | ||
In addition, the service water side of the fuel pool heat exchangers is kept at a higher pressure than the shell side to prevent potential radioactive contamination of the service water. 3) RHR Service Water System: The RHR Service Water Radiation (RHRSW) Monitors (RISH-12-0K619A, RISH-12-0K6198) provide alarm and automatic termination* | 3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., 3.2.2.3.b., 3.2.2.5.a., 3.2.2.5.b., 3.2.2.5.c., and 3.2.3. | ||
of radioactive material release from the RHRSW system, as required by ODCM Control 3.1.1. The Residual Heat Removal (RHR) Service Water System provides water from the Emergency Service Water (ESW) spray pond to the RHR heat exchangers. | Rev.29 Page 79 of 329 12/2016 | ||
In post accident conditions, RHR Service Water can supply water for vessel and containment flooding. | |||
While the RHRSW system is not a normal release pathway, the monitors provide indication of potential problems due to excessive leakage of the heat exchangers. | CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.3 MAJOR CHANGES TO RADIOACTIVE WASTE TREATMENT SYSTEMS 6.3 Licensee-initiated major changes to the radioactive waste systems (liquid, gaseous, and solid): | ||
*Termination of the release is accomplished by auto trip of the RHRSW pumps and remote manual closure of isolation valves. Rev.29 Page 83 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION Per the requirements of ODCM Control 3.1.1, alarm setpoints shall be established for the liquid effluent monitoring instrumentation to ensure that the _release concentration limits of ODCM Control 3.2.1.1 are met. The concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS shall be limited to 10 times the effluent concentration limits specified in 10 CFR 20, Appendix B, Table 2, Column 2, for radionuclides other than noble gases and 2.0E-04 µCi/ml for dissolved or entrained noble gases (NUREG 0133). 1.2.1 Radwaste Discharge Monitor and Discharge Flow Rate -RISH-63-0K604 The setpoint for the liquid radwaste discharge monitor is determined by equation 1-1. The radwaste discharge monitor high-high alarm/isolation setpoint is calculated with each tank release based on isotopes detected in the liquid radwaste sample tank to be released (LCiv), the default minimum cooling tower blowdown of 5,000 gallons per minute (CTBD), the radwaste discharge flow rate of 255 gpm and the maximum tank volume in gallons. The flow rate determination is calculated for each release and determined by equation 1-2. The ECL fraction calculated includes, in the concentration mix (dissolved and entrained noble gases), the most recent results the quarterly composite for SR-89, SR-90 and Fe-55, and the monthly composite for H-3 and gross alpha. If the calculated setpoint is less than the existing setpoint, the setpoint will be reduced to the new value or the tank will be returned for more processing. | : a. Shall be reported to the Commission in the Annual Radioactive Effluent Release Report for the period in which the change was made effective. The discussion of each change shall contain: | ||
If the calculated setpoint is greater than the existing setpoint, the setpoint may remain at the lower value or be increased to the higher calculated value. The actual setpoint may be reduced to a value less than the calculated setpoint at the discretion of supervision. | : 1. A summary of the evaluation that led to the determination that the change could be made in accordance with 10 CFR 50.59; | ||
Rev.29 Page 84 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES 1.2.1.1 Setpoint Determination | : 2. Sufficient detailed information to totally support the reason for the change without benefit of additional or supplemental information; | ||
-RISH-63-0K604 The setpoints for the liquid radwaste discharge monitor is determined by the following equations: . . . [ (S)(RR)[''E.(C113)! | : 3. A detailed description of the equipment, components, and processes involved and the interface with other plant systems; | ||
ECL;p)J][ | : 4. An evaluation of the change which shows the predicted releases of radioactive materials in liquid and gaseous effluents and/or quantity of solid waste that differ from those previously predicted in the license application and amendments thereto; | ||
('E.C;y) (RR+CTBD) | : 5. An evaluation of the change which shows the expected maximum exposures to individual in the UNRESTRICTED AREA and to the general population that differ from those previously estimated in the license application and amendments thereto; | ||
: 6. A comparison .of the predicted releases of radioactive materials, in liquid and gaseous effluents and in solid waste, to the actual releases for the period prior to when the changes are to be made; and | |||
: 7. An estimate of the exposure to plant operating personnel as a result of the change. | |||
('E.C1r/ECL1r) | Rev.29 Page 80 of 329 12/2016 | ||
+BKG(LRD) | |||
(1-1) Hi Setpoint = (F)(Hi-Hi Setpoint) | CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.4 CHANGES TO THE ODCM 6.4 Licensee-initiated changes to the Offsite Dose Calculational Manual: | ||
+ BKG(LRD) (1-1 a) where: CPM(LRD) | : a. Shall contain the program elements described in Technical Specifications 6.8.4.d, e and f. | ||
: b. Shall be revised in accordance with the requirements described in Technical Specification 6.14. | |||
: c. Shall be revised per applicable procedures detailing other requirements for making changes to the ODCM. | |||
: d. Shall be reviewed and accepted by PORC and signed by the Plant Manager prior to implementation. | |||
(µCi/ml) | Rev.29 Page 81 of 329 12/2016 | ||
'LCif31 ECLif3 = the effective nongamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless) where: C;f3 | -- - - - -- ____ _J | ||
(µCi/ml) * (See note below) = the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20, Appendix B, Table 2, Column 2 *NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55 and ross al ha. EXAMPLE: Given the following information: | |||
Tank Discharge Rate: 255 gpm Cooling Tower Slowdown: | CY-LG-170-301 PARTll CALCULATION METHODOLOGIES Rev.29 Page 82 of 329 12/2016 | ||
5000 gpm Monitor Efficiency: | |||
3.66E-09 Radwaste sample activity: | CY-LG-170-301 CALCULATION METHODOLOGIES 1.0 LIQUID EFFLUENTS 1.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS The liquid effluent monitoring instrumentation and controls at Limerick for controlling and monitoring normal radioactive material releases in accordance with the Limerick ODCM Controls are summarized as follows: | ||
Nuclide Activity uCi/ml H-3 3.19E-03 Mn-54 9.00E-08 Co-60 7 .OOE-08 Cs-137 1.1 | : 1) Liquid Radwaste System: The liquid radwaste discharge monitor (RISH 0K604) provides an alarm and automatic termination of radioactive material releases from the liquid radwaste system as required by ODCM Control 3.1.1. Additional design features of the liquid radwaste system which prevent inadvertent releases to the environment include 1) redundant discharge valves, 2) single discharge line with loop seal and siphon breaker to eliminate probability of inadvertent discharges, 3) Low Cooling Tower , | ||
Slowdown flow interlock which isolates the radwaste discharge line. | |||
: 2) Service Water System: The Service Water discharge monitor (RISH-10-1 K605 AND RISH-10-2K605) provides an alarm upon indication of activity in the service water system as required by ODCM Control 3.1 .1. | |||
While the service water system is not a normal release pathway, the monitor provides an indication of potential problems due to excessive leakage of the heat exchangers. In addition, the service water side of the fuel pool heat exchangers is kept at a higher pressure than the shell side to prevent potential radioactive contamination of the service water. | |||
: 3) RHR Service Water System: The RHR Service Water Radiation (RHRSW) | |||
Monitors (RISH-12-0K619A, RISH-12-0K6198) provide alarm and automatic termination* of radioactive material release from the RHRSW system, as required by ODCM Control 3.1.1. The Residual Heat Removal (RHR) Service Water System provides water from the Emergency Service Water (ESW) spray pond to the RHR heat exchangers. In post accident conditions, RHR Service Water can supply water for vessel and containment flooding. While the RHRSW system is not a normal release pathway, the monitors provide indication of potential problems due to excessive leakage of the heat exchangers. | |||
*Termination of the release is accomplished by auto trip of the RHRSW pumps and remote manual closure of isolation valves. | |||
Rev.29 Page 83 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION Per the requirements of ODCM Control 3.1.1, alarm setpoints shall be established for the liquid effluent monitoring instrumentation to ensure that the _release concentration limits of ODCM Control 3.2.1.1 are met. The concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS shall be limited to 10 times the effluent concentration limits specified in 10 CFR 20, Appendix B, Table 2, Column 2, for radionuclides other than noble gases and 2.0E-04 µCi/ml for dissolved or entrained noble gases (NUREG 0133). | |||
1.2.1 Radwaste Discharge Monitor and Discharge Flow Rate - RISH-63-0K604 The setpoint for the liquid radwaste discharge monitor is determined by equation 1-1. The radwaste discharge monitor high-high alarm/isolation setpoint is calculated with each tank release based on isotopes detected in the liquid radwaste sample tank to be released (LCiv), the default minimum cooling tower blowdown of 5,000 gallons per minute (CTBD), the radwaste discharge flow rate of 255 gpm and the maximum tank volume in gallons. | |||
The flow rate determination is calculated for each release and determined by equation 1-2. | |||
The ECL fraction calculated includes, in the concentration mix (dissolved and entrained noble gases), the most recent results the quarterly composite for SR-89, SR-90 and Fe-55, and the monthly composite for H-3 and gross alpha. | |||
If the calculated setpoint is less than the existing setpoint, the setpoint will be reduced to the new value or the tank will be returned for more processing. If the calculated setpoint is greater than the existing setpoint, the setpoint may remain at the lower value or be increased to the higher calculated value. | |||
The actual setpoint may be reduced to a value less than the calculated setpoint at the discretion of supervision. | |||
Rev.29 Page 84 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 1.2.1.1 Setpoint Determination - RISH-63-0K604 The setpoints for the liquid radwaste discharge monitor is determined by the following equations: | |||
. . . | |||
H1-H1 Setpomt = CPM(LRDJ.5. [1- (S)(RR)[''E.(C113)! | |||
(RR+CTBD) | |||
ECL;p)J][ ('E.C;y) (RR+CTBD) ] | |||
(S)(E)(RR) ('E.C1r/ECL1r) +BKG(LRD) (1-1) | |||
Hi Setpoint =(F)(Hi-Hi Setpoint) + BKG(LRD) (1-1 a) where: | |||
CPM(LRD) = calculated liquid radwaste discharge monitor (RISH-63-0K604) count rate attributable to the gamma emitting radionuclide, cpm LCiy = the sum of the concentration of the identified gamma emitting nuclides (µCi/ml), | |||
CTBD = the required minimum cooling tower blowdown rate during discharge (gpm), | |||
RR = average liquid radwaste discharge flow (gpm), | |||
BKG(LRD) = background count rate of liquid radwaste discharge monitor (CPM), | |||
E = the gross detection efficiency of the liquid radwaste discharge monitor (µCi/ml/cpm), and s = 2; margin of safety factor to assure that the release is terminated prior to 10 CFR 20 limits being exceeded. Included in this factor are errors associated with monitor uncertainty, sampling uncertainty, flow rate uncertainty, and the contribution of other release paths (Service Water and RHRSW) which are not normally contaminated. | |||
F = 0.75 (a factor less than 1 that is used to calculate the Hi-Setpoint) | |||
L.Ciyl EC.Ljy = the effective gamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless). | |||
where: | |||
C;y = the concentration of each identified gamma emitting radionuclide | |||
' i ' in the liquid effluent (undiluted) (µCi/ml) | |||
ECL;y = the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20 Appendix B, Table 2, Column 2 (dissolved and entrained noble gases ECL 2.0E-4 µCi/ml) = | |||
Rev.29 Page 85 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES | |||
'LCif31 ECLif3 = the effective nongamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless) where: | |||
C;f3 = the concentration of each identified nongamma radionuclide ' i ' in the liquid effluent (undiluted) (µCi/ml) | |||
* (See note below) | |||
ECL;f3 = the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20, Appendix B, Table 2, Column 2 | |||
*NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55 and ross al ha. | |||
EXAMPLE: | |||
Given the following information: | |||
Tank Discharge Rate: 255 gpm Cooling Tower Slowdown: 5000 gpm Monitor Efficiency: 3.66E-09 Radwaste sample activity: | |||
Nuclide Activity uCi/ml 10 x ECL Pre Dilution ECL Fraction H-3 3.19E-03 1.00E-02 3.19E-01 Mn-54 9.00E-08 3.00E-04 3.00E-04 Co-60 7 .OOE-08 3.00E-05 2.33E-03 Cs-137 1.1 OE-07 1.00E-05 1.10E-02 Total Beta 3.19E-03 3.19E~01 Total Gamma 2.70E-07 1.36E-02 5.402E + 04 ~ [J (2)(255)[(3.l9E-Ol)]] | |||
(255+-500Q) | (255+-500Q) | ||
[ (2.70E-07) (255+-500Q) | |||
(2)(3.66E-09)(255) (l.36E-02) 1.2.1.2 Flow Rate Determination The maximum liquid radwaste tank flow rate discharge to the river is determined by the following equation: | (2)(3.66E-09)(255) (l.36E-02) | ||
Rev.29 Page 86 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES FLOW(LRD) | J+o.OO 1.2.1.2 Flow Rate Determination The maximum liquid radwaste tank flow rate discharge to the river is determined by the following equation: | ||
Rev.29 Page 86 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES | |||
where: Ci = the concentration of each identified radionuclide ' i ' in the liquid effluent (undiluted) | *crnn FLOW(LRD) < 1~( | ||
(µCi/ml)* (See note below) = the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20 Appendix 8, Table 2, Column 2, (dissolved and entrained noble gases ECL = 2E-4 µCi/ml. The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55, gross alpha and dissolved and entrained nob.le gases. 1.2.2 Service Water Radiation Monitor -RISH-010-1 K605, -2K605 RHR Service Water Monitor -RISH-012-0K619A. -OK6198 The High-High radiation setpoints for the Service Water and the RHR Service Water monitors are set at 10 times the Cs 137 Effluent Concentration Limits (ECL) of 1.0E-06 uCi/mL. Considering the radionuclides predominant in the Limerick reactors (e.g., Co-58, Co-60, Fe-59, Mn-54, Zn-65 and Cr-51 ), the use of a setpoint based on the Cs-137 Effluent Concentration Limit (ECL) is reasonable due to the following parameters: | S L.J Ci I ECLi | ||
: 1) High photon abundance (85%), 2) Spectrum midrange photon energy (0.662 MeV) 3) Conservative magnitude of the applicable ECL limit (1.0E-05 µCi/ml) Rev.29 Page 87 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES The Service Water and the RHR Service Water maximum Radiation Monitor High) setpoint is determined by the following equation to meet the requirements of ODCM Control 3.2.1.1. The High Setpoint shall be administratively controlled to a value that is less than the.High-High setpoint. | )- 1I (1-2) where: | ||
FLOW(LRD) = flow limit for radwaste discharge line (gpm). | |||
CTBD = required minimum cooling tower blowdown flow during discharge (gpm). | |||
s = 2; margin of safety factor to assure that the release does not* | |||
exceed 10 CFR 20 limits. | |||
~(C/ECLi) = the effective ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless) for ~(C/ECLi)>1. If | |||
~(C/ECLi)<1, then no flow rate determination is necessary. | |||
where: | |||
Ci = the concentration of each identified radionuclide ' i | |||
' in the liquid effluent (undiluted) (µCi/ml)* (See note below) | |||
= the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20 Appendix 8, Table 2, Column 2, (dissolved and entrained noble gases ECL =2E-4 µCi/ml. | |||
*NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55, gross alpha and dissolved and entrained nob.le gases. | |||
1.2.2 Service Water Radiation Monitor - RISH-010-1 K605, -2K605 RHR Service Water Monitor - RISH-012-0K619A. -OK6198 The High-High radiation setpoints for the Service Water and the RHR Service Water monitors are set at 10 times the Cs 137 Effluent Concentration Limits (ECL) of 1.0E-06 uCi/mL. Considering the radionuclides predominant in the Limerick reactors (e.g., Co-58, Co-60, Fe-59, Mn-54, Zn-65 and Cr-51 ), the use of a setpoint based on the Cs-137 Effluent Concentration Limit (ECL) is reasonable due to the following parameters: | |||
: 1) High photon abundance (85%), | |||
: 2) Spectrum midrange photon energy (0.662 MeV) | |||
: 3) Conservative magnitude of the applicable ECL limit (1.0E-05 µCi/ml) | |||
Rev.29 Page 87 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES The Service Water and the RHR Service Water maximum Radiation Monitor (High-High) setpoint is determined by the following equation to meet the requirements of ODCM Control 3.2.1.1. | |||
The High Setpoint shall be administratively controlled to a value that is less than the.High-High setpoint. | |||
1.2.2.1 Setpoint Determination The setpoints for the Service Water and RHR Service Water Radiation Monitors are determined by the following equations: | 1.2.2.1 Setpoint Determination The setpoints for the Service Water and RHR Service Water Radiation Monitors are determined by the following equations: | ||
Hi-HiSetpoint | Hi-HiSetpoint = CPM = (10* ECLcs-137 )(CF) +(0.5)B (1-3) | ||
= CPM = (10* ECLcs-137)(CF) +(0.5)B (1-3) Hi Setpoint | = | ||
(1-4) where: CPM | Hi Setpoint (F)(Hi-Hi Setpoint) (1-4) where: | ||
* Column 2 to maintain the 500 mrem/yr instantaneous release limits ECLcs-137 | CPM = calculated maximum radiation monitor (RISH-010-1 K605, -2K605, RISH-012-0K619A, -OK619B) count rate, cpm 10 = 10 times the ECL limit from 10 CFR 20 Appendix B, Table 2, | ||
= ECL limit for Cs-137 (1.0E-06 µCi/ml) monitor calibration factor -in cpm/µCi/ml Background count rate (cpm) | * Column 2 to maintain the 500 mrem/yr instantaneous release limits ECLcs-137 = ECL limit for Cs-137 (1.0E-06 µCi/ml) | ||
FserviceWater | CF = monitor calibration factor - in cpm/µCi/ml B = Background count rate (cpm) | ||
= 0.75 FRHRServiceWater | F = a factor less than 1 that is used to calculate the Hi-Setpoint. | ||
= 0.50 1.3 LIQUID EFFLUENT DOSE CALCULATION | FserviceWater = 0.75 FRHRServiceWater = 0.50 1.3 LIQUID EFFLUENT DOSE CALCULATION - 10 CFR 50 1.3.1 Dose to Members of the Public Control 3.2.1.2 limits the dose or dose commitment to MEMBERS OF THE PUBLIC from radioactive materials in liquid effluents from Limerick Generating Station to: | ||
-10 CFR 50 1.3.1 Dose to Members of the Public Control 3.2.1.2 limits the dose or dose commitment to MEMBERS OF THE PUBLIC from radioactive materials in liquid effluents from Limerick Generating Station to: During any Calendar Quarter During any Calendar Year 3 mrem to total body mrem to any organ. | During any Calendar Quarter During any Calendar Year | ||
The NUREG-0133 methodology is based upon that presented in Reg. Guide 1.109, but has been simplified. | ~ 3 mrem to total body ~ 6 mrem to total body | ||
Comparisons between the two methodologies indicate the doses calculated by NUREG-0133 are approximately 3 to 5% higher than those calculated using Reg. Guide 1.109 methodology. | ~10 mrem to any organ. ~20 mrem to any organ Rev.29 Page 88 of 329 12/2016 | ||
1.3.1.1 Aquatic Pathway -NUREG-0133 D = | |||
(1-6) (tank volumer.,,..,,)+ (Cooling Tower Dilution The dilution factor at point of exposure or at point of withdrawal of drinking water (dimensionless). | CY-LG-170-301 CALCULATION METHODOLOGIES Per Surveillance Requirement 4.2.1.2 the cumulative dose contribution from liquid effluents for the current calendar quarter and calendar year shall be determined at least once per 31 days in accordance with the following calculation methods. The results are accumulated to give the quarterly doses and the quarterly results are accumulated to give the annual doses. | ||
Values are based on average daily river flow. Dw factors are calculated in equations 1-7 through 1-11. LGS Outfall 0.685 + 0.026 | Pathways Receptor Location Dist. Potable Fish Shoreline (mi) Water LGS Outfall 0 x x PA. American Water 2.5 x x x Phoenixville Water 9.0 x x x Aqua America 13.6 x x Crew Course 37.8 x Software currently used at the Limerick Generating Station calculates doses from liquid releases based upon the methodology presented in NUREG-0133. | ||
* rflow (1-7) American Water 0.237 | The NUREG-0133 methodology is based upon that presented in Reg. Guide 1.109, but has been simplified. Comparisons between the two methodologies indicate the doses calculated by NUREG-0133 are approximately 3 to 5% higher than those calculated using Reg. Guide 1.109 methodology. | ||
* rflow 1*17 (1-8) Phoenixville Water 0. 121 | 1.3.1.1 Aquatic Pathway - NUREG-0133 D = t[A,,~At,Ci,F,] | ||
* rflow 0*973 (1-9) Aqua America 0.089 | (1-5) | ||
* rflow 0*993 (1-10) Phil. Crew Course 0.076 | -r D w | ||
* rflow 0*996 (1-11) where: rflow is river flow in | where: | ||
Drinking Water A.= k | D, = The cumulative dose commitment to the total body or any organ, r , from liquid effluents for the total time period f&l , in mrem. | ||
* U *D .. | £=! | ||
* | = The length of the eth time period over which Cl and Fl are averaged for the liquid release, in hours. | ||
* U *BF *D | = The average concentration of radionuclide, i, in undiluted liquid effluent during time period !it l , from any | ||
* Us* W *Ti* Daipi *RC | . | ||
)(1-e -!.;Tb) | liquid release, Rev.29 Page 89 of 329 12/2016 | ||
* 1000 ml/LI 8760 hr/yr). Note for fish units are g/kg. Rev.29 Page 90 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES kos = | |||
* 1.0E6 pCi/uCi/8760 hr/yr). usage factor per'pathway | CY-LG-170-301 CALCULATION METHODOLOGIES (determined by the effluent sampling analysis program, ODCM Part I, Table 4.2-1, in uCi/ml). | ||
-Table 111-8. dose conversion factor for nuclide, i, for total body or any organ, r, in mrem/pCi, from Tables 111-3 th rough 111-7. bioaccumulation factor for nuclide, i, in fresh water fish, pCi/kg per pCi/L, from Table 111-2. reconcentration factor as indicated in Table 111-21. shoreline width factor (dimensionless) as indicated in Table 111-21. radioactive half-life of nuclide' i '(days) from Table 111-1. radioactive decay constant of nuclide ' i ' (hr-1) from Table 111-1. delay time for water pathway in hours to allow for nuclide decay during transport through the water purification plant and the water distribution system as indicated in Table 111-21. tpF = delay time for fish pathway to allow for nuclide decay during transport through the food chain, as well as during food preparation as indicated in Table 111-21. tp | ~ = The near field average dilution factor for Ct during any liquid effluent release. Defined as the ratio of the maximum undiluted liquid waste flow during the release to the average flow through the discharge pathway (minimum factor is 0.04853) defined by the following: | ||
Dtbp = | (tank volume111-*i) (1-6) | ||
days (1-15) Dmaxp = (Dmaxfd) | Ft (tank volumer.,,..,,)+ (Cooling Tower Dilution r*-~) | ||
* 31 days ( 1-16) Rev.29 Page 91 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES | Ow = The dilution factor at point of exposure or at point of withdrawal of drinking water (dimensionless). Values are based on average daily river flow. Dw factors are calculated in equations 1-7 through 1-11. | ||
*where: Dtbp = | LGS Outfall 0.685 + 0.026 | ||
The plant gaseous discharges via this vent are monitored by two Particulate, Iodine and Gas (PIG) monitors (RY26-075A and RY26-0758) in parallel and by the Wide Range Accident Monitor . (WRAM) (RY26-076). | * rflow (1-7) | ||
The PIGS have separate Particulate, Iodine, and Gas sampling and monitoring channels but the Controls require only particulate and iodine sampling and noble gas monitoring. | American Water 0.237 | ||
The WRAM has extended range (via three channels) noble gas monitoring and particulate and iodine sampling capability. | * rflow 1 *17 (1-8) | ||
In addition, the WRAM provides an isolation (Group 6A) of the large Drywell Purge and Vent valves. 2) South Vent (one per unit): The plant gaseous discharges via each South Vent are monitored by two redundant PIG monitors (RY26-285A,B). | Phoenixville Water 0. 121 | ||
As is the case of the North Vent, each PIG has separate particulate, iodine, and gas sampling and monitoring channels but the Controls require only particulate and iodine sampling with gas monitoring. | * rflow 0 *973 (1-9) | ||
: 3) Hot Maintenance Shop (Common): | Aqua America 0.089 | ||
Due to the composition of the radioactive materials in the effluent steam (i.e., very low potential for noble gas), this release point is sampled by a particulate and iodine (P&I) monitor (RY26-025). | * rflow 0 *993 (1-10) | ||
The P&I monitor has a separate particulate and iodine sampling and monitoring channels but Controls require only particulate and iodine sampling. | Phil. Crew Course 0.076 | ||
2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION Control 3.1.2 requires that an alarm setpoint be established for the noble gas effluent monitoring channels (RY26-075A(B), RY26-185A(B), RY26-285A(B), and RY26-076) to ensure that the release rate of radioactive materials does not exceed the limits of Control 3.2.2.1.a, which corresponds to a dose rate at the SITE BOUNDARY of 500 mrem/yr to the total body or 3000 mrem/yr to the skin. Control limits are expressed in terms of dose rate, while the instruments that monitor effluents produce data in units of concentration or release rate. It is therefore necessary to identify the isotopes and calculate the corresponding release rate that will result in the dose rate limit being reached at the site Rev.29 Page 93 of 329 12/2016 | * rflow 0 *996 (1-11) where: | ||
This calculation is made more complex by the use of multiple release points at LGS. Calculation Bases The alarm setpoint calculation is performed whenever the default Hi-Hi setpoint alarms based on analytical results of grab samples from the appropriate release point. The concentration of each identified radionuclide in the grab samples is determined, and the data is used to perform a setpoint calculation for that nuclide mix and release point. The highest calculated annual average concentration (x/Q) for an area at or beyond the site boundary (Table 112-31) is used in the setpoint calculation. | rflow is river flow in ft3/sec. | ||
Maximum flow rates through the North and South vents are used in alarm setpoint calculations. | Ai" = The site specific ingestion dose commitment factor to the total body or organ, r, for each radionuclide and pathway listed in Table 111-10 through Table 111-17 in mrem-mL per uCi-hr. A.l't' for each pathway and age group are calculated using the following equations: | ||
This is necessary since flow can vary. By using maximum values, any flow less than the maximum will assure that the monitor will alarm before release rate limits are exceeded. | Drinking Water A.= k 0 | ||
The fractional contribution of noble gas is calculated for each release point. The fractional contribution to the whole body and skin dose rates due to noble gases for the north stack and south stack vents are calculated by taking the product of this fraction and the limiting release rate. A comparison of the release rate for whole body and skin dose rates due to noble gas release is made to determine if the whole body or skin dose limit will be most restrictive. | * U w *D atpj l't | ||
It is expected that the whole body limit will always be most restrictive, but the comparison is necessary to assure compliance with Control 3.2.2.1. The sum of the contributions from each release point, independently calculated for noble gases, will equal the maximum instantaneous release rate allowed from the site. 2.2.1 North Vent Noble Gas Effluent Monitors (RY26-075A-3, RY26-075B-3. | .. | ||
and RY26-076-2) | * RC*e(-A.it~) (1-12) | ||
The North Vent Noble Gas Effluent monitor high-high setpoint is calculated whenever the default Hi-Hi setpoint alarms based on the grab sample results performed in accordance with Table 4.2-2. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value or be increased to the new value. 2.2.1.1 Setpoint Determination The High-High setpoint is calculated per equation 2-1 or 2-2. The High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the lesser of the NVSP(Hi-Hi)NGWB OR NVSP(Hi-Hi)NGSK value (equations 2-1 or 2-2). Rev.29 Page 94 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES NSVP(Hl-Hl)NGWB [3 .4 ?lE + g] L[(CiNv )(K;)] (2-1) NVSP(Hi-Hi)NasK< | Freshwater Fish A.= k 0 | ||
[3.47IE+9] | * U F *BF *D a!pJ l't I | ||
.. *RC *e(-1-it~) (1-13) | |||
Hi Setpoint = (F)(Hi-Hi Setpoint) | Shoreline Ait=kos | ||
(2-2a) where: . NVSP (Hi-Hi)NGSK | * Us* W *Ti* Daipi *RC (e-1.;t~ )(1-e -!.;Tb) (1-14) where: | ||
= north vent high-high setpoint -noble gas skin (µCi/cc). | ko = 114155, units conversion factor (1.0 E6 pCi/uCi | ||
NVSP (Hi-Hi)NGWB | * 1000 ml/LI 8760 hr/yr). Note for fish units are g/kg. | ||
= north vent high-high setpoint -noble gas whole body (µCi/cc). | Rev.29 Page 90 of 329 12/2016 | ||
VFNVNG = fractional contribution to site boundary noble gas dose rate from the North Vent. (unitless). | |||
500 = total body dose rate limit (mrem/yr) 3000 = skin dose rate limit (mrem/yr) | CY-LG-170-301 CALCULATION METHODOLOGIES kos = 11416000, units conversion factor to account for the proportionality constant used in the sediment radioactivity model. (100 L/kg-hr kg/m 2 hr/day* 1000 ml/L | ||
LCiNV = total noble gas activity from North Vent grab sample (µCi/cc) F = 0.289855 (a factor less than 1 that is used to calculate the Hi-Setpoint) 3.471 E+9 = conversion factor, units are | * 1.0E6 pCi/uCi/8760 hr/yr). | ||
(µCi)(m ) | u = usage factor per'pathway - Table 111-8. | ||
1min y2.a3a:+4cc'J ( | Daipi = dose conversion factor for nuclide, i, for total body or any organ, r, in mrem/pCi, from Tables 111-3 th rough 111-7. | ||
= concentration of noble gas nuclide ' i ' as determined by radioanalysis of North Vent grab sample (µCi/cc). | BFi = bioaccumulation factor for nuclide, i, in fresh water fish, pCi/kg per pCi/L, from Table 111-2. | ||
= total body dose conversion factor for noble gas nuclide ' i ' (mrem/yr per pCi/m 3 , from ODCM Table 112-1 ). = beta skin dose conversion factor noble gas nuclide' i' (mrem/yr per pCim 3 , from ODCM Table 112-1 ). = gamma air dose conversion factor for noble gas nuclide ' i ' (mrad/yr per pCi/m | RC = reconcentration factor as indicated in Table 111-21. | ||
RY26-185B-3. | w = shoreline width factor (dimensionless) as indicated in Table 111-21. | ||
Ti = radioactive half-life of nuclide' i '(days) from Table 111-1. | |||
A.1 = radioactive decay constant of nuclide ' i ' (hr-1) from Table 111-1. | |||
tpD = delay time for water pathway in hours to allow for nuclide decay during transport through the water purification plant and the water distribution system as indicated in Table 111-21. | |||
tpF = delay time for fish pathway to allow for nuclide decay during transport through the food chain, as well as during food preparation as indicated in Table 111-21. | |||
8 tp = delay time in hours for shoreline pathway as indicated in Table 111-21. Zero hours are assumed as shoreline activities can occur at the outfall. | |||
Tb = time period during which sediment is exposed to contaminated water as indicated in Table 111-21. | |||
1.3.2 Liquid Effluent Dose Projections Control 3.2.1.3 requires that the liquid radwaste treatment system shall be operable and appropriate portions of the systems used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent to UNRESTRICTED AREAS would exceed: | |||
0.12 mrem to the total body or 0.4 mrem to any organ. | |||
Dose projections are made at least once per 31-days when liquid radwaste treatment systems are not being fully utilized using the following equations: | |||
Dtbp = (Dt~d)*31 days (1-15) | |||
Dmaxp = (Dmaxfd) | |||
* 31 days (1-16) | |||
Rev.29 Page 91 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES | |||
*where: | |||
Dtbp = the total body dose projection for the current 31-day period (mrem). | |||
Dtb = the total body dose to date for the current calendar quarter as determined by equation 1-5 (mrem). | |||
Dmaxp = the maximum organ dose projection for the current 31-day period (mrem). | |||
Dmax = the maximum organ dose to date for the current calendar quarter as determined by equations 1-5 (mrem). | |||
d = the actual number of days in the current calendar quarter at the end of the release (days). | |||
31 days = the number of days of concern Rev.29 Page *92 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 2.0 GASEOUS EFFLUENTS 2.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS The gaseous effluent monitoring instrumentation and controls at Limerick for controlling and monitoring radioactive material releases in accordance with the ODCM Part I are summarized as follows: | |||
: 1) North Vent (Common): The plant gaseous discharges via this vent are monitored by two Particulate, Iodine and Gas (PIG) monitors (RY26-075A and RY26-0758) in parallel and by the Wide Range Accident Monitor | |||
. (WRAM) (RY26-076). The PIGS have separate Particulate, Iodine, and Gas sampling and monitoring channels but the Controls require only particulate and iodine sampling and noble gas monitoring. The WRAM has extended range (via three channels) noble gas monitoring and particulate and iodine sampling capability. In addition, the WRAM provides an isolation (Group 6A) of the large Drywell Purge and Vent valves. | |||
: 2) South Vent (one per unit): The plant gaseous discharges via each South Vent are monitored by two redundant PIG monitors (RY26-285A,B). As is the case of the North Vent, each PIG has separate particulate, iodine, and gas sampling and monitoring channels but the Controls require only particulate and iodine sampling with gas monitoring. | |||
: 3) Hot Maintenance Shop (Common): Due to the composition of the radioactive materials in the effluent steam (i.e., very low potential for noble gas), this release point is sampled by a particulate and iodine (P&I) monitor (RY26-025). The P&I monitor has a separate particulate and iodine sampling and monitoring channels but Controls require only particulate and iodine sampling. | |||
2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION Control 3.1.2 requires that an alarm setpoint be established for the noble gas effluent monitoring channels (RY26-075A(B), RY26-185A(B), RY26-285A(B), | |||
and RY26-076) to ensure that the release rate of radioactive materials does not exceed the limits of Control 3.2.2.1.a, which corresponds to a dose rate at the SITE BOUNDARY of 500 mrem/yr to the total body or 3000 mrem/yr to the skin. | |||
Control limits are expressed in terms of dose rate, while the instruments that monitor effluents produce data in units of concentration or release rate. It is therefore necessary to identify the isotopes and calculate the corresponding release rate that will result in the dose rate limit being reached at the site Rev.29 Page 93 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES boundary. This calculation is made more complex by the use of multiple release points at LGS. | |||
Calculation Bases The alarm setpoint calculation is performed whenever the default Hi-Hi setpoint alarms based on analytical results of grab samples from the appropriate release point. The concentration of each identified radionuclide in the grab samples is determined, and the data is used to perform a setpoint calculation for that nuclide mix and release point. | |||
The highest calculated annual average concentration (x/Q) for an area at or beyond the site boundary (Table 112-31) is used in the setpoint calculation. | |||
Maximum flow rates through the North and South vents are used in alarm setpoint calculations. This is necessary since flow can vary. By using maximum values, any flow less than the maximum will assure that the monitor will alarm before release rate limits are exceeded. | |||
The fractional contribution of noble gas is calculated for each release point. The fractional contribution to the whole body and skin dose rates due to noble gases for the north stack and south stack vents are calculated by taking the product of this fraction and the limiting release rate. A comparison of the release rate for whole body and skin dose rates due to noble gas release is made to determine if the whole body or skin dose limit will be most restrictive. It is expected that the whole body limit will always be most restrictive, but the comparison is necessary to assure compliance with Control 3.2.2.1. The sum of the contributions from each release point, independently calculated for noble gases, will equal the maximum instantaneous release rate allowed from the site. | |||
2.2.1 North Vent Noble Gas Effluent Monitors (RY26-075A-3, RY26-075B-3. and RY26-076-2) | |||
The North Vent Noble Gas Effluent monitor high-high setpoint is calculated whenever the default Hi-Hi setpoint alarms based on the grab sample results performed in accordance with Table 4.2-2. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value or be increased to the new value. | |||
2.2.1.1 Setpoint Determination The High-High setpoint is calculated per equation 2-1 or 2-2. The High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the lesser of the NVSP(Hi-Hi)NGWB OR NVSP(Hi-Hi)NGSK value (equations 2-1 or 2-2). | |||
Rev.29 Page 94 of 329 12/2016 l_ | |||
CY-LG-170-301 CALCULATION METHODOLOGIES NSVP(Hl-Hl)NGWB ~ [ 3 .4?lE + g] L[(CiNv )(K;)] (2-1) | |||
NVSP(Hi-Hi)NasK< [VFm'Nal[300Ql[~CiNv] (2-2) | |||
[3.47IE+9] ~[(CiNv)(L;+ 1.1 lM;)] | |||
The High Setpoint shall be administratively controlled to a value that is less than the High-High Setpoint. | |||
Hi Setpoint =(F)(Hi-Hi Setpoint) (2-2a) where: | |||
. NVSP (Hi-Hi)NGSK = north vent high-high setpoint - noble gas skin (µCi/cc). | |||
NVSP (Hi-Hi)NGWB = north vent high-high setpoint - noble gas whole body | |||
(µCi/cc). | |||
VFNVNG = fractional contribution to site boundary noble gas dose rate from the North Vent. (unitless). | |||
500 = total body dose rate limit (mrem/yr) 3000 = skin dose rate limit (mrem/yr) | |||
LCiNV = total noble gas activity from North Vent grab sample | |||
(µCi/cc) | |||
F = 0.289855 (a factor less than 1 that is used to calculate the Hi-Setpoint) 3.471 E+9 = conversion factor, units are (pCi)(c~) | |||
(µCi)(m ) | |||
1.1E-ssecy1.0E+6.pct( 66f#~ott.3x 1min y2.a3a:+4cc'J (2 _3 ) | |||
( rri3 A uCt A_ mm 60secJ. tt3 ) | |||
where: | |||
1.1 E-5 sec/m 3 = highest annual average x/Q (NE Sector) 1E+6 pCi/µCi = units conversion 668 ,450 cfm = maximum North Vent flow rate for two unit operation 1 min/60 sec = units conversion Rev.29 Page 95 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 2.832E+4 cc/ft3 = units conversion | |||
= concentration of noble gas nuclide ' i ' as determined by radioanalysis of North Vent grab sample (µCi/cc). | |||
= total body dose conversion factor for noble gas nuclide ' i ' | |||
(mrem/yr per pCi/m 3 , from ODCM Table 112-1 ). | |||
= beta skin dose conversion factor noble gas nuclide' i' (mrem/yr per pCim 3 , from ODCM Table 112-1 ). | |||
= gamma air dose conversion 3 | |||
factor for noble gas nuclide ' i ' | |||
(mrad/yr per pCi/m , From ODCM Table 112-1). | |||
1.11 = the average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0). | |||
2.2.2 South Vent Noble Gas Effluent Monitors (RY26-185A-3. RY26-185B-3. | |||
RY26-285A-3, and RY26-2858-3) | RY26-285A-3, and RY26-2858-3) | ||
Each unit's South Vent Noble Gas Effluent monitor High-High setpoint is calculated whenever the default Hi-Hi setpoint alarms based on the grab sample results performed in accordance with ODCM Part I, Table 4.2-2. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value. 2.2.2.1 Setpoint determination The High-High setpoint for the South Vent Noble Gas Effluent Monitor is set at the lesser of the SVSP(Hi-Hi)NGws and SVSP(Hi-Hi)NGSK value. SVSP(Hi-Hi)NGWB and SVSP(Hi-Hi)NGSK are calculated for each unit's South Vent. The High-High setpoint is calculated per equation 2-4 or 2-5. [VF SVNG ][500][ L C isv] SVSP(Hl-Hl)NGWB [1.2149E + 9]L[(Cisv | Each unit's South Vent Noble Gas Effluent monitor High-High setpoint is calculated whenever the default Hi-Hi setpoint alarms based on the grab sample results performed in accordance with ODCM Part I, Table 4.2-2. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value. | ||
)(Ki)] [VF SVNG][3000][L Cisv1 SVSP(Hl-Hl)NGSK [1.2149E + 9]L[(Cisv | 2.2.2.1 Setpoint determination The High-High setpoint for the South Vent Noble Gas Effluent Monitor is set at the lesser of the SVSP(Hi-Hi)NGws and SVSP(Hi-Hi)NGSK value. SVSP(Hi-Hi)NGWB and SVSP(Hi-Hi)NGSK are calculated for each unit's South Vent. | ||
)(Li+ 1.11 Mi)] | The High-High setpoint is calculated per equation 2-4 or 2-5. | ||
Rev.29 Page 96 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES Hi Setpoint | [VF SVNG ][500][ L C isv] | ||
= south vent high-high setpoint -noble gas whole body (µCi/cc) SVSP(Hi-Hi)NGSK | SVSP(Hl-Hl)NGWB ~ [1.2149E + 9]L[(Cisv )(Ki)] (2-4) | ||
= south vent high-high setpoint -noble gas skin (µCi/cc) = fractional contribution to site boundary noble gas dose rate from the Unit's South Vent. (unitless) | [VF SVNG][3000][L Cisv1 SVSP(Hl-Hl)NGSK ~ [1.2149E + 9]L[(Cisv )(Li+ 1.11 Mi)] (2-5) | ||
= total body dose rate limit (mrem/yr) | The High Setpoint shall be administratively controlled to a value that is less than the High-High Setpoint. | ||
= skin dose rate limit (mrem/yr) | Rev.29 Page 96 of 329 12/2016 | ||
= 0.5 (a factor less than 1 that is used to calculate the Setpoint) | |||
= total noble gas activity from each unit South Vent grab sample (µCi/cc). | CY-LG-170-301 CALCULATION METHODOLOGIES | ||
= concentration of noble gas nuclide ' i ' determined by radioanalysis of South Vent grab sample (µCi/cc) = total body dose conversion factor for noble gas nuclide ' i ' (mrem/yr per pCi/m3, from ODCM Table 112-1). = beta skin dose conversion factor noble gas nuclide ' i ' (mrem/yr per pCi/m3, From ODCM Table 112-1 ). = gamma air dose conversion factor for noble gas nuclide ' i ' (mrad/yr per pCi/m3, From ODCM Table 112-1 ). = the average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0) = conversion factor units are in | = | ||
Hi Setpoint (F)(Hi-Hi Setpoint) (2-5a) where: | |||
SVSP(Hi-Hi)NGWB = south vent high-high setpoint - noble gas whole body | |||
(µCi/cc) | |||
SVSP(Hi-Hi)NGSK = south vent high-high setpoint - noble gas skin (µCi/cc) | |||
VFsvNG = fractional contribution to site boundary noble gas dose rate from the Unit's South Vent. (unitless) 500 = total body dose rate limit (mrem/yr) 3000 = skin dose rate limit (mrem/yr) | |||
F = 0.5 (a factor less than 1 that is used to calculate the Hi-Setpoint) | |||
= total noble gas activity from each unit South Vent grab sample (µCi/cc). | |||
= concentration of noble gas nuclide ' i ' determined by radioanalysis of South Vent grab sample (µCi/cc) | |||
= total body dose conversion factor for noble gas nuclide ' i ' | |||
(mrem/yr per pCi/m3, from ODCM Table 112-1). | |||
= beta skin dose conversion factor noble gas nuclide ' i ' | |||
(mrem/yr per pCi/m3, From ODCM Table 112-1 ). | |||
= gamma air dose conversion factor for noble gas nuclide ' i ' | |||
(mrad/yr per pCi/m3, From ODCM Table 112-1 ). | |||
1.11 = the average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0) 1.2149E+9 = conversion factor units are in (pCi)(c~) | |||
(µCi)(m ) | (µCi)(m ) | ||
1.0E 2.34E : | 1.1E-5se~Y 1.0E +~pelf 2.34E :5tt3 Y1min Y2.83:E +4ccJ | ||
tt3 (2-6) where: 1 .1 E-5 sec/m 3 = highest annual average x/Q (NE Sector) | ( m3 A uC1 A_ mm }_60secA_ tt3 (2-6) where: | ||
= maximum South Vent flow rate 1/60 min/sec = units conversion 2.832E+4 cc/ | 1 .1 E-5 sec/m 3 = highest annual average x/Q (NE Sector) 1E+6 pCi/µCi = units conversion 2.34E+5 ft3/m = maximum South Vent flow rate 1/60 min/sec = units conversion 2.832E+4 cc/ft3 = units conversion 2.2.3 Noble Gas Effluent Fractional Contribution The three release points will be partitioned such that the sum does not exceed 100 percent of the limit (500 mrem/yr whole body noble gas, 3000 mrem/yr skin noble Rev.29 Page 97 of 329 12/2016 | ||
= fractional contribution to site boundary noble gas total body dose rate from the Unit 1 South Vent (unitless) | |||
.. = fractional contribution to site boundary noble gas total body dose rate from the Unit 2 South Vent (unitless). | CY-LG-170-301 CALCULATION METHODOLOGIES gas.) The default fraction will be set at 80 percent for the North Vent, 10 percent for the Unit-1 South Vent and 10 percent for the Unit-2 South Vent. | ||
2.2.4 Noble Gas Effluent Default Setpoint This methodology may be used when grab sample results from either the North Vent or the South Vent do not identify any radionuclides. | These percentages can vary should operational concentrations warrant such change. However, the sum of the percentages shall be equal to or less than 100%. | ||
This methodology is based on expected release concentration ratios as outlined in Section 11.3 of the Limerick U FSAR. 2.2.4.1 North Vent Noble Gas Monitors (RY26-075A-3 and RY26-075B-3). | The following relationship shall be met: | ||
The default High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the NVSP(Hi-Hi)NGD value. NVSP(Hi-Hi)NGD [8.00E-1][500 | VFNvNG + VF1svNG + VF2svNG ~ 1 (2-7) where: | ||
][1.31E -6] | VFNVNG = fractional contribution to site boundary noble gas total body dose rate from the North Vent (unitless). | ||
][4.37E-9] | VF1SvNG = fractional contribution to site boundary noble gas total body dose rate from the Unit 1 South Vent (unitless) .. | ||
VF2svNG = fractional contribution to site boundary noble gas total body dose rate from the Unit 2 South Vent (unitless). | |||
:s. 3.45E-5 µCi/cc where: NVSP(Hi-Hi)NGD | 2.2.4 Noble Gas Effluent Default Setpoint This methodology may be used when grab sample results from either the North Vent or the South Vent do not identify any radionuclides. This methodology is based on expected release concentration ratios as outlined in Section 11.3 of the Limerick U FSAR. | ||
= total noble gas concentration from North Vent (µCi/cc). | 2.2.4.1 North Vent Noble Gas Monitors (RY26-075A-3 and RY26-075B-3). The default High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the NVSP(Hi-Hi)NGD value. | ||
Ref: a) based on UFSAR Table 11.3-1. b) based on maximum North Vent flow of 668,450 cfm. Rev.29 Page 98 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES 3.471E+9 | NVSP(Hi-Hi)NGD ~ [8.00E-1][500 ][1.31E -6] (2-8) | ||
[3.471E+9 ][4.37E-9] | |||
The default High-High setpoint for each Unit's South Vent Noble Gas Effluent Monitor is set at or below the SVSP(Hi-Hi)NGD value. SVSP(Hi-[1.00E-l][soo][l.02E-7] [1.2149E + 9 ][2.71E -10] | NVSP(Hi-Hi)NGD :s. 3.45E-5 µCi/cc where: | ||
= default fractional contribution to site boundary noble gas total body dose rate from the South Vent (unitless). | NVSP(Hi-Hi)NGD = default north vent high-high setpoint - noble gas whole body | ||
= total body dose rate limit (mrem/yr). | (µCi/cc) 8.00E-1 = default fractional contribution to site boundary noble gas total body dose rate from the North Vent (unitless) . | ||
500 = total body dose rate limit (mrem/yr). | |||
Ref: a) | 1.31 E-6 = total noble gas concentration from North Vent (µCi/cc). | ||
Ref: a) based on UFSAR Table 11.3-1. | |||
The Wide Range Accident Monitor (WRAM) noble gas total effluent channel displays the North Vent noble gas release rate. This monitor has Main Control Room Annunciation as well as a group 6A isolation function on the primary containment purge and vent valves. The isolation setpoint value of | b) based on maximum North Vent flow of 668,450 cfm. | ||
µCi/cc specified in Technical Specification Table 3.3.2-2 is based on the accident dose limits for containment purge during an accident (Ref: UFSAR Section 1.13). For routine operations the total effluent high and high-high setpoints are based upon the methodology of Sections II 2.2.5.1 and II 2.2.5.2. The setpoint units are in microcuries per second using the two-unit maximum North Vent flow rate of 668,450 scfm. The total effluent channel High-High setpoint is set at a value less than or equal to ten times the High setpoint (not to exceed the 2.1 µCi/cc equivalent using the two-unit maximum North Vent flow rate). These values are always more conservative than the Technical Specification Table 3.3.2-2 required value 2.1 . If the calculated setpoint value is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value. 2.2.5.1 Routine Operations High Setpoint Determination For routine operations, the High setpoint for the WRAM Noble Gas Total Effluent Channel is set at or below the lesser of the NVSP(Hi-Hi)NGWB or NVSP(Hi-Hi)NGSK value when activity is detected. | Rev.29 Page 98 of 329 12/2016 | ||
When no activity is detected, the High setpoint is set at or below the NVSP(Hi-Hi)NGD* | |||
This setpoint is calculated to ensure compliance with Control 3.2.2.1.a. | CY-LG-170-301 CALCULATION METHODOLOGIES 3.471E+9 = conversion factor, units are in (pCi)(c~) . See Equation | ||
The setpoint values are converted from µCi/cc to µCi/sec using the maximum unit North Vent flow rate: WRAM(Hi)ws | . (µCi)(m ) | ||
= [NVSP(Hi-Hi)NGWB or NGD] [3.155E+8] | 2-3. | ||
(2-10) Rev.29 Page 100 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES WRAM(Hi)sK | 4.37E-9 = summation of the north vent concentration of noble gas nuclide ' i ' multiplied by the corresponding whole body dose 3 | ||
= [NVSP(Hi-Hi)NGSK] | factor. Units are in (µCi)(mrem)(m ) | ||
[3.155E+8] | (cc )(yr )(pCi) | ||
Ref: a) based on UFSAR Table 11.3-1. | |||
= WRAM total effluent channel north vent high setpoint -noble gas whole body (µCi/sec). | b) based on maximum North Vent flow of 668,450 cfm. | ||
* WRAM(Hi)sK | c) ODCM Table 112-1. | ||
= WRAM total effluent channel north vent high setpoint -noble gas skin (µCi/sec). | 2.2.4.2 South Vent Noble Gas Monitors (RY26-185A-3, RY26-285A-3, RY26-185B-3, and RY26-285B-3). The default High-High setpoint for each Unit's South Vent Noble Gas Effluent Monitor is set at or below the SVSP(Hi-Hi)NGD value. | ||
NVSP(Hi-Hi)NGWB | SVSP(Hi- Hi~GD ~ [1.00E- l][soo][l.02E- 7] | ||
= North Vent high-high setpoint -noble gas whole body or NGD (µCi/cc) from equation 2-1 or 2-8. NVSP(Hi-Hi)NGSK | (2-9) | ||
= North Vent high-high setpoint -noble gas skin (µCi/cc) from equation 2-2. 3.155E+8 = conversion factor (cc/sec). 1min J(2.832E+4ccJ (2-12) mm 60sec tt 3 2.2.5.2 Routine Operations High-High Setpoint Determination For routine operations, the High-High setpoint for the WRAM Noble Gas total effluent channel is set at or below ten .times the lesser of. the routine operations WRAM(Hi)ws or WRAM(Hi)sK value. WRAM(Hi-Hi)ws | [1.2149E + 9][2.71E -10] | ||
= [WRAM(Hi)ws] | SVSP(Hi-Hi)NGD ~ 1.54E-5 µCi/cc where: | ||
[1 O] WRAM(Hi-Hi)sK | SVSP(Hi-Hi)NGD = default south vent setpoint - noble gas (µCl/cc). | ||
= [WRAM(Hi)sK] | 1.00E-1 = default fractional contribution to site boundary noble gas total body dose rate from the South Vent (unitless). | ||
[1 O] where: WRAM(Hi-Hi)ws | 500 = total body dose rate limit (mrem/yr). | ||
= WRAM total effluent channel north vent high-high setpoint noble gas whole body (µCi/sec). | 1.02E-7 = total noble gas concentration from South Vent | ||
WRAM(Hi-Hi)sK | (µCi/cc). | ||
= WRAM total effluent channel north vent high-high setpoint noble gas skin (µCi/sec). | Ref: a) Based on UFSAR Table 11.3-1. | ||
( | b) Based on maximum South Vent flow of 234,000 cfm. | ||
= WRAM total effluent channel north vent high setpoint -noble gas whole body (µCi/sec) from equation 2-10. WRAM(Hi)sK | 1.2149E+9 = conversion factor, units are in (pCi)(c~) . See | ||
= WRAM total effluent channel north vent setpoint -noble gas skin (µCi/sec) from equation 2-11. 10 = multiplication factor to calculate high-high value (unitless) | (µCi)(m ) | ||
Rev.29 Page | Equation 2-6. | ||
For the noble gas dose calculation, effluent release data are based on grab sample analysis for radionuclide composition and weekly stack effluent radiation monitor readings. | 2.71E-10 = summation of the south vent concentration of noble gas nuclide' i 'multiplied by the corresponding whole body dose factor. | ||
For the iodine and particulate dose calculations, the effluent release radionuclide composition and release activity are based on weekly continuous samples. The quarterly and annual dose calculations are a summation of the applicable dose results for the period of interest. | Rev.29 Page 99 of 329 12/2016 | ||
2.3.1 Site Boundary Dose Rate -Noble Gases (1 OCFR20 Limits) Control 3.2.2.1.a limits the dose rate in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY due to noble gas releases to mrem/yr total body and mrem/yr skin. Radiation monitor alarm setpoints are established to ensure that these release limits are not exceeded. | |||
Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.a. | CY-LG-170-301 CALCULATION METHODOLOGIES 3 | ||
following any releases exceeding the alarm setpoints. | "t . (µCi)(mrem)(m ) | ||
Monitor indications (readings) are averaged over time periods not to exceed 60 minutes. NOTE: For administrative purposes, more conservative alarm setpoints than those required to meet 10 CFR 20 Dose Rate limits are imposed. However, conditions exceeding these more limiting alarm setpoints do not necessarily indicate radioactive material release rates exceeding the | U ni s are m - - - - - - | ||
* dose limits of Control 3.2.2.1.a. | (cc )(yr )(pCi) | ||
Provided actual releases do not result in radiation monitor indications exceeding values based on the dose rate limits of Control 3.2.2.1.a., no further analyses are required for demonstrating compliance with the limits of Control 3.2.2.1.a. | Ref: a) Based on UFSAR Table 11.3-1. | ||
In the event of a noble gas effluent release exceeding the setpoint value specified in ODCM Part II, Sections 2.2.1 or 2.2.2, the site boundary dose rate from the release is calculated using the methodology stated below. This methodology is based on worst sector annual average meteorological dispersion but, if further refinement is required to meet the requirements of Control 3.2.2.1.a, actual meteorological data from the time period of concern may be used to calculate actual meteorological dispersion. | b) Based on maximum South Vent flow of 234,000 cfm. | ||
Rev.29 Page 102 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES | c) ODCM Table 112-1. | ||
(2-16) Drn | 2.2.5 Wide Range Accident Monitor Noble Gas Effluent Monitor (RIX-26-076-4) | ||
The Wide Range Accident Monitor (WRAM) noble gas total effluent channel displays the North Vent noble gas release rate. This monitor has Main Control Room Annunciation as well as a group 6A isolation function on the primary containment purge and vent valves. The isolation setpoint value of ~2.1 µCi/cc specified in Technical Specification Table 3.3.2-2 is based on the accident dose limits for containment purge during an accident (Ref: UFSAR Section 1.13). For routine operations the total effluent high and high-high setpoints are based upon the methodology of Sections II 2.2.5.1 and II 2.2.5.2. The setpoint units are in microcuries per second using the two-unit maximum North Vent flow rate of 668,450 scfm. The total effluent channel High-High setpoint is set at a value less than or equal to ten times the High setpoint (not to exceed the 2.1 µCi/cc equivalent using the two-unit maximum North Vent flow rate). These values are always more conservative than the Technical Specification Table 3.3.2-2 required value of~ 2.1 | |||
= skin plume dose rate (mrem/yr). | ~~- . | ||
= | If the calculated setpoint value is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value. | ||
= total body dose factor for noble gas nuclide ' i ' in units of mrem/yr per pCi/m 3. Values are listed in ODCM Table 112-1. = skin dose factor for the beta contribution for noble gas nuclide' i 'in units of mrem/yr per pCi/m 3. Values are listed in ODCM Table 112-1. = the ratio of tissue to air absorption coefficients over the range of photons of interest. | 2.2.5.1 Routine Operations High Setpoint Determination For routine operations, the High setpoint for the WRAM Noble Gas Total Effluent Channel is set at or below the lesser of the NVSP(Hi-Hi)NGWB or NVSP(Hi-Hi)NGSK value when activity is detected. When no activity is detected, the High setpoint is set at or below the NVSP(Hi-Hi)NGD* This setpoint is calculated to ensure compliance with Control 3.2.2.1.a. | ||
This ratio converts dose (mrad) to dose equivalent (mrem). = gamma air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3. Values are listed in ODCM Table 112-1. = units conversion pCi/µCi. 2.3.2 Site Boundary Dose Rate -Radioiodine and Particulates (1 OCFR20 Limits) Control 3.2.2.1.b limits the dose rate to mrem/yr to any organ (inhalation pathways only) for 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents. | The setpoint values are converted from µCi/cc to µCi/sec using the maximum two-unit North Vent flow rate: | ||
Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.b. | WRAM(Hi)ws = [NVSP(Hi-Hi)NGWB or NGD] [3.155E+8] (2-10) | ||
Release* activity is based upon the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. Rev.29 Page 103 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES n | Rev.29 Page 100 of 329 12/2016 | ||
* n/H = x/Q L PiQi (2-17) | |||
CY-LG-170-301 CALCULATION METHODOLOGIES WRAM(Hi)sK = [NVSP(Hi-Hi)NGSK] [3.155E+8] (2-11) where: | |||
= highest average annual x/Q (sec/m3) (see Table 112-31 ). = dose factor' for radionuclides other than noble gases for the inhalation pathway only (mrem/yr per µCi/m3). Values are listed in ODCM Table 112-2 through Table 112-5. Pi= k | WRAM(Hi)ws = WRAM total effluent channel north vent high setpoint | ||
The dose calculations are performed in accordance with the methodology below. Rev.29 Page 104 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES 0')(1/R = (3.17E -ax1.00E + 6)x/ | - noble gas whole body (µCi/sec). | ||
(2-18) Of3AIR = (3.17E -BX1.00E + 6)x/ | * WRAM(Hi)sK = WRAM total effluent channel north vent high setpoint | ||
(2-19) where: | - noble gas skin (µCi/sec). | ||
[year/sec]. | NVSP(Hi-Hi)NGWB = North Vent high-high setpoint - noble gas whole body or NGD (µCi/cc) from equation 2-1 or 2-8. | ||
= units conversion pCi/uCi. = | NVSP(Hi-Hi)NGSK = North Vent high-high setpoint - noble gas skin | ||
= gamma air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3. Values are listed in ODCM Table 112-1. = beta air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3. Values are listed in ODCM Table 112-1. 2.3.4 Radio iodine and Particulate Dose Calculations (1 OCFR50. Appendix I Limits) Control 3.2.2.3 limits the dose (from both reactor units) to a MEMBER OF THE PUBLIC from 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released to areas at or beyond the SITE BOUNDARY to: 15 mrem to any organ during any calendar quarter 30 mrem to any organ during any calendar year As required by Surveillance Requirement 4.2.2.3, these doses are calculated at least once per 31 days using the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. The dose calculation is performed using the most limiting average annual meteorological dispersion values for the appropriate dose receptor pathway (e.g. milk pathway SSE sector 2.5' miles, etc.). The quarterly and annual doses are based on the summation of Rev.29 Page 105 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES the applicable dose results determined the period of interest. | (µCi/cc) from equation 2-2. | ||
The dose calculations are performed in accordance with the methodology below. Total organ dose is the maximum organ dose obtained by the summation of the organ dose from each pathway. 2.3.4.1 Ground Pathway DaPAR = 3.17E-8 | 3.155E+8 = conversion factor (cc/sec). | ||
= highest average annual deposition (1/m | =(668,4~0sft J( | ||
= dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. -Values of Ri are provided in ODCM Table 112-6 through Table 112-9 and calculated per the following equation: (k') (k'') (SF)* Daw [(I - | 3 1min J(2.832E+4ccJ (2-12) mm 60sec tt 3 2.2.5.2 Routine Operations High-High Setpoint Determination For routine operations, the High-High setpoint for the WRAM Noble Gas total effluent channel is set at or below ten .times the lesser of. the routine operations WRAM(Hi)ws or WRAM(Hi)sK value. | ||
WRAM(Hi-Hi)ws = [WRAM(Hi)ws] [1 O] (2-13) | |||
highest average annual x/Q (sec/m3) (see Table 112-31). highest average annual deposition rate (1/m 2) (see Table 112-31 ). dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. -Values of Ri are provided in ODCM Table 112-10 through Table 112-25 and calculated per the following equations. | WRAM(Hi-Hi)sK = [WRAM(Hi)sK] [1 O] (2-14) where: | ||
m 2-mrem/yr per uCi/sec 1.0 E+6 pCi/uCi | WRAM(Hi-Hi)ws = WRAM total effluent channel north vent high-high setpoint noble gas whole body (µCi/sec). | ||
Therefore, the Ri is based on [x/Q] as follows: RY-3 = (k')* (k' ") * [uL*(fL) +US*(f ) | WRAM(Hi-Hi)sK = WRAM total effluent channel north vent high-high setpoint noble gas skin (µCi/sec). | ||
* D .. * [ 0.75 * (0.5/H)] | WRAM(Hi)ws = WRAM total effluent channel north vent high setpoint | ||
* | - noble gas whole body (µCi/sec) from equation 2-10. | ||
WRAM(Hi)sK = WRAM total effluent channel north vent setpoint - | |||
noble gas skin (µCi/sec) from equation 2-11. | |||
10 = multiplication factor to calculate high-high value (unitless) | |||
Rev.29 Page 1Ol of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 2.3 GASEOUS EFFLUENT DOSE EVALUATION Dose calculations are performed ,based on limiting sector average annual meteorological dispersion parameters. For the noble gas dose calculation, effluent release data are based on grab sample analysis for radionuclide composition and weekly stack effluent radiation monitor readings. For the iodine and particulate dose calculations, the effluent release radionuclide composition and release activity are based on weekly continuous samples. | |||
The quarterly and annual dose calculations are a summation of the applicable dose results for the period of interest. | |||
2.3.1 Site Boundary Dose Rate - Noble Gases (1 OCFR20 Limits) | |||
Control 3.2.2.1.a limits the dose rate in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY due to noble gas releases to ~500 mrem/yr total body and ~3000 mrem/yr skin. Radiation monitor alarm setpoints are established to ensure that these release limits are not exceeded. | |||
Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.a. following any releases exceeding the alarm setpoints. Monitor indications (readings) are averaged over time periods not to exceed 60 minutes. | |||
NOTE: For administrative purposes, more conservative alarm setpoints than those required to meet 10 CFR 20 Dose Rate limits are imposed. | |||
However, conditions exceeding these more limiting alarm setpoints do not necessarily indicate radioactive material release rates exceeding the | |||
* dose limits of Control 3.2.2.1.a. Provided actual releases do not result in radiation monitor indications exceeding values based on the dose rate limits of Control 3.2.2.1.a., no further analyses are required for demonstrating compliance with the limits of Control 3.2.2.1.a. | |||
In the event of a noble gas effluent release exceeding the setpoint value specified in ODCM Part II, Sections 2.2.1 or 2.2.2, the site boundary dose rate from the release is calculated using the methodology stated below. | |||
This methodology is based on worst sector annual average meteorological dispersion but, if further refinement is required to meet the requirements of Control 3.2.2.1.a, actual meteorological data from the time period of concern may be used to calculate actual meteorological dispersion. | |||
Rev.29 Page 102 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES Dw ~ x/Q (IE +6)[t.({NV)] (2-15) | |||
Dr= z/Q (1E+6{~ (L+l.lMi)Q;] (2-16) where: | |||
Drn = total body plume dose rate (mrem/yr). | |||
Dy = skin plume dose rate (mrem/yr). | |||
x/Q = highest3 annual average relative concentration (sec/m ) at site boundary (see Table 112-31) . | |||
* q = The release rate of noble gas nuclide ' i ' from all vent releases averaged over one hour (uCi/sec). | |||
= total body dose factor for noble gas nuclide ' i ' in units of mrem/yr per pCi/m 3 . Values are listed in ODCM Table 112-1. | |||
= skin dose factor for the beta contribution for noble gas nuclide' i 'in units of mrem/yr per pCi/m 3 . Values are listed in ODCM Table 112-1. | |||
1.1 = the ratio of tissue to air absorption coefficients over the range of photons of interest. This ratio converts dose (mrad) to dose equivalent (mrem). | |||
= gamma air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1. | |||
1E+6 = units conversion pCi/µCi. | |||
2.3.2 Site Boundary Dose Rate - Radioiodine and Particulates (1 OCFR20 Limits) | |||
Control 3.2.2.1.b limits the dose rate to ~1500 mrem/yr to any organ (inhalation pathways only) for 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents. | |||
Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.b. Release* | |||
activity is based upon the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. | |||
Rev.29 Page 103 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES n | |||
* n/H = x/Q L PiQi i=l (2-17) where: | |||
D1H = inhalation dose rate (mrem/yr). | |||
xto = highest average annual x/Q (sec/m3) (see Table 112-31 ). | |||
= dose factor' for radionuclides other than noble gases for the inhalation pathway only (mrem/yr per µCi/m3). | |||
Values are listed in ODCM Table 112-2 through Table 112-5.0 Pi= k (BR) (Daipj) (2-17a) where: | |||
k' = 1.0E+6 unit conversion pCi/uCi. | |||
BR = breathing rate from Table 112-31. | |||
Daipj = Inhalation Dose Factor Table 112-27 through Table 112-30 . | |||
* q = The release rate of radionuclide ' i ' other than noble gases from all vent releases (µCi/s). | |||
2.3.3 Noble Gas Air Doses (1 OCFRSO. Appendix I Limits) | |||
Control 3.2.2.2 limits the air dose due to noble gases released in gaseous effluents (from both reactor units) to areas at or beyond the SITE BOUNDARY to: | |||
~ 10 mrad gamma for any quarter | |||
~ 20 mrad beta for any quarter | |||
~ 20 mrad gamma during any calendar year | |||
~ 40 mrad beta during any calendar year As required by Surveillance Requirement 4.2.2.2, these doses are calculated at least once per 31 days using the results of the most recent grab samples for isotopic composition performed in accordance with ODCM Part I, Table 4.2-2. The dose calculation is performed using the most limiting average annual meteorological dispersion values. The quarterly and annual doses are based on the summation of the applicable dose results for the period of interest. The dose calculations are performed in accordance with the methodology below. | |||
Rev.29 Page 104 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 0')(1/R = (3.17E -ax1.00E + 6)x/Q~M;Q; (2-18) | |||
Of3AIR = (3.17E -BX1.00E + 6)x/Q~N;Q; (2-19) where: | |||
DyAIR = gamma air dose from noble gas releases in mrad. | |||
DpAIR = beta air dose from noble gas release in mrad. | |||
3.17E-8 = units conversion [year/sec]. | |||
1.00E+6 = units conversion pCi/uCi. | |||
xtO = highest3 average annual relative concentration in sec/m (see Table 112-31 ). | |||
= release of noble gas radionuclides ' i 'from all vents in uCi. Releases shall be cumulative over the period of interest. | |||
= gamma air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1. | |||
= beta air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1. | |||
2.3.4 Radio iodine and Particulate Dose Calculations (1 OCFR50. Appendix I Limits) | |||
Control 3.2.2.3 limits the dose (from both reactor units) to a MEMBER OF THE PUBLIC from 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released to areas at or beyond the SITE BOUNDARY to: | |||
~ 15 mrem to any organ during any calendar quarter | |||
~ 30 mrem to any organ during any calendar year As required by Surveillance Requirement 4.2.2.3, these doses are calculated at least once per 31 days using the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. The dose calculation is performed using the most limiting average annual meteorological dispersion values for the appropriate dose receptor pathway (e.g. milk pathway SSE sector 2.5' miles, etc.). The quarterly and annual doses are based on the summation of Rev.29 Page 105 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES the applicable dose results determined d~ring the period of interest. The dose calculations are performed in accordance with the methodology below. Total organ dose is the maximum organ dose obtained by the summation of the organ dose from each pathway. | |||
2.3.4.1 Ground Pathway DaPAR = 3.17E-8 [n/Q~R;QJ (2-20) where: | |||
= dose from ground pathway due to release of particulates and iodines (mrem). | |||
3.17E-8 = units conversion (year/sec). | |||
2 D/Q = highest average annual deposition (1/m ) (see Table 112-31 ). | |||
= release of nuclide ' i ' from all vents in uCi. Releases shall be cumulative over the time period of interest. | |||
= dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - Values of Ri are provided in ODCM Table 112-6 through Table 112-9 and calculated per the following equation: | |||
(k') (k'') (SF)* Daw [(I - -A/) I A, J e (2-20a) where: | |||
Rf [DIQ] = 2 m -mrem/yr per uCi/sec. | |||
k' = 1E+06 pCi/uCi. | |||
k" = 8760 hr/yr. | |||
SF = shielding factor (see Table 112-31). | |||
Daipi = dose factor for standing on contaminated ground (see Table 111-7). | |||
/l; = decay constant for nuclide i in seconds (see Table 111-1). | |||
= period of buildup in soil in seconds (see Table 112-31). | |||
Rev.29 Page 106 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 2.3.4.2 Vegetation, Meat and Cow Milk or Goat Milk Pathway Dw~ ~ 3.17£-8 [ z/Q tl/,Q, + D/Q t,R*Q*] (2-21) where: | |||
DvPAR = dose from vegetation, meat, cow milk, and goat milk, pathways due to releases of particulates, iodines, and tritium (mrem). | |||
3.17E-8 = units conversion (year/sec). | |||
= | |||
i 1, 2 = 3H, 14C. | |||
= | |||
i 3 thru n = all other isotopes (particulate and iodine). | |||
Qi = the release of nuclide ' i ' from all vents in uCi. Releases shall be cumulative over the time period of interest. | |||
x/O = highest average annual x/Q (sec/m3) (see Table 112-31). | |||
D/Q = highest average annual deposition rate (1/m 2 ) (see Table 112-31 ). | |||
Ri = dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - Values of Ri are provided in ODCM Table 112-10 through Table 112-25 and calculated per the following equations. | |||
(2-21 a) where: | |||
RVI = m 2-mrem/yr per uCi/sec k' = 1.0 E+6 pCi/uCi r = fraction of deposited particulates retained on vegetation (Table 112-31). | |||
2 Yv = vegetation area density kg/m (Table 112-31 ). | |||
A, i = decay constant for the ith radionuclide, in sec-1 (Table 111-1 ). | |||
A,w = decay constant for removal of activity on leaf and plant surfaces by 1 | |||
weathering, in sec- (Table 112-31 ). | |||
Daipi = ingestion dose factor, in mrem/pCi (Table 111-3 through Table 111-6). | |||
Rev. 29 Page 107 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES LJLa = consumption rate of fresh leafy vegetation by the receptor in age group (a), | |||
in kg/yr (Table 112-31). | |||
fl = fraction of the annual intake of fresh leafy vegetation grown locally (dimensionless) (Table 112-31). | |||
tL = average time between harvest of leafy vegetation and its consumption, in seconds (Table 112-31). | |||
us a = consumption rate of stored vegetation by the receptor in age group (a), in kg/yr (Table 112-31). | |||
fg = fraction of the annual intake of stored vegetation grown locally (dimensionless) (Table 112-31). | |||
th = average time between harvest of stored vegetation and its consumption, in seconds (Table 112-31 ). | |||
The concentrations of tritium and carbon-14 in vegetation are based on their airborne concentrations rather than their deposition. Therefore, the Ri is based on [x/Q] as follows: | |||
a a g J | |||
RY-3 = (k')* (k' ") * [uL*(fL) +US*(f ) | |||
* D .. * [0.75 * (0.5/H)] | |||
aipJ (2-21 b) v Rc.1* = (k')* (k' ") * [uL*(t: ) +lP*(f) a L a g J* DaipJ.. | |||
* p [ 0.11 | * p [ 0.11 | ||
* 0.16] | * 0.16] (2-21 c) where: | ||
R~-3 3 | |||
0.16 = the concentration of natural carbon in the atmosphere, in g/m 3 Rev.29 Page 108 of 329 12/2016 | = mrem/yr per uCi/m | ||
* R~-14 3 | |||
* liters/yr or kg/yr (Table 112-31 ). decay constant for the ith radionuclide, in sec-1 (Table 111-1). decay constant for removal of activity on leaf and plant surfaces by weathering, in sec-1 (Table 112-31). stable element transfer coefficients in days/liter or days/kg (Table 112-26). fraction of deposited particulates retained on vegetation (Table 112-31). ingestion dose factor, in mrem/pCi (Table 111-3 through Table 111-6). fraction of the year that the cow/goat is on pasture (dimensionless) (Table 112-31). fraction of the cow/goat feed that is pasture grass while the animal is on pasture (dimensionless) (Table 112-31). | = mrem/yr per uCi/m | ||
Therefore, the Riis based on [x/Q] as follows: = (k')* (k'")*Fm*QF*Uap*Daipj | * k' II | ||
* [0.75*(0.5/H)] | = 1E+3, constant of unit conversion (gm/kg). | ||
3 H = absolute humidity of the atmosphere, in gm/m (Table 112-31 ). | |||
*p*(0.11/0.16] | 0.75 = fraction of total feed that is water. | ||
where: R1;/_3 | 0.5 = ratio of the specific activity of the feed grass water to the atmospheric water. | ||
= mrem/yr per uCi/m3 = mrern/yr per uCi/m3 | p = fractional equilibrium ratio (4400 hrs/8760 hrs). The ratio of the total annual release time (for C-14) atmospheric releases) to the total annual time during photosynthesis occurs (taken to be 4400 hrs), under the condition that the value of p should never exceed unity. For continuous C-14 releases, pis taken to be unity. | ||
the release of nuclide ' i 'from all vents in uCi. Releases shall be cumulative over the time period of interest. | 0.11 = the fraction of total plant mass that is natural carbon, dimensionless. | ||
highest average annual x!Q (sec/m3) (see Table 112-31). dose factor for organ type, age group, and pathway (for radionu,clides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. -values of Ri are provided in ODCM Table 112-2 through Table 112-5 and calculated from the following equation. | 0.16 = the concentration of natural carbon in the atmosphere, in g/m 3 | ||
R/ = k' (BR) (Daipj) (2-22a) where: R/ = mrem/yr per uCi/m3. k' = 1.0E+6 unit conversion pCi/uCi. BR = breathing rate from Table 112-31. Daipj = Inhalation Dose Factor Table 112-27 through Table 112-30. 2.3.5 Intentionally left blank. Rev.29 Page 110 of 329 12/2016 CY-LG-170-301 CALCULATION METHODOLOGIES 2.3.6 Gaseous Effluent Dose Projection Control 3.2.2.5 requires the VENTILATION EXHAUST TREATMENT SYSTEM be used to reduce radioactive material levels prior to discharge when projected doses from both units to areas at and beyond the SITE BOUNDARY would exceed in a 31 day period: a. 0.4 mrad to air from gamma radiation, or b. 0.8 mrad to air from beta radiation, or c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC A dose projection is performed at least once per 31-days by the following equations: | Rev.29 Page 108 of 329 12/2016 | ||
Dmaxgamma | |||
The direct radiation contribution shall be determined by the methodology described below. This methodology calculates the direct radiation contribution, which then must be added to the dose or dose commitment determined in accordance with ODCM Part II, Sections 1.3.1, 2.3.3, and 2.3.4 to determine total dose from all pathways. | CY-LG-170-301 CALCULATION METHODOLOGIES All other values as previously defined above. | ||
This evaluation* | Cow Milk I Goat Milk I Meat Pathway RIM (k') ( (Q,*UAP) * (rm 17 ) *( )*D * [fPfs + (1-fPfs)e-Mh]-Mi (2-21d) | ||
of direct radiation contribution is in accordance with ANSI/ANS 6.6.1-1979 Section 7. The error using this method is estimated to be approximately 8%. The following evaluation is performed for each receptor of concern. Dws = D1EFFL-WB | '] ) r alp} e | ||
+ (Dm -Dx BKG) * (4-1) Do= D1EFFL-o + (Dro -Dx BKG) Dr= D1EFFL-T + (Dm -Dx BKG) (4- | /l,i + Aw Yp Ys where: | ||
= effluent contribution to total body dose (as evaluated in ODCM Part II, Sections1 | RMI | ||
.3.1, 2.3.3, and 2.3.4). D1EFFL-o = effluent contribution to organ dose (as evaluated in ODCM Part II, Sections1 | = 'm 2-mrem/yr per uCi/sec. | ||
.3.1, 2.3.3, and 2.3.4). D1EFFL-r = effluent contribution to thyroid dose (as evaluated in ODCM Part II, Sections1 | k' = 1.0E+6 pCi/uCi. | ||
.3.1, 2.3.3, and 2.3.4). | QF = cow/goat consumption rate kg/day (wet weight) (Table 112-31). | ||
* 4.2 DOSES DUE TO ACTIVITIES INSIDE THE SITE BOUNDARY In accordance with Administrative Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of radiation dose from radioactive liquid and gaseous effluents to MEMBERS OF THE PUBLIC due to their activities inside the SITE BOUNDARY. | UAP = receptor's milk consumption rate or meat consumption rate for age (a), in | ||
There are three locations within the SITE BOUNDARY that are accessible to MEMBERS OF THE PUBLIC for activities unrelated to the operation of Limerick Station. These locations are: 1) the railroad tracks which run along the river within the SITE BOUNDARY; | * liters/yr or kg/yr (Table 112-31 ). | ||
A.i = decay constant for the ith radionuclide, in sec-1 (Table 111-1). | |||
Sectors and distances of these locations are provided below: Rev. 29 1** Page 113 of 329 1212016 I CALCULATION METHODOLOGIES Sector Railroad Tracks: s SSW SW WSW w WNW NW Information Center: ESE Fricks Lock: WSW | = decay constant for removal of activity on leaf and plant surfaces by | ||
"-w weathering, in sec- 1 (Table 112-31). | |||
Fm = stable element transfer coefficients in days/liter or days/kg (Table 112-26). | |||
r = fraction of deposited particulates retained on vegetation (Table 112-31). | |||
Daipi = ingestion dose factor, in mrem/pCi (Table 111-3 through Table 111-6). | |||
fp = fraction of the year that the cow/goat is on pasture (dimensionless) | |||
(Table 112-31). | |||
fs = fraction of the cow/goat feed that is pasture grass while the animal is on I | |||
I pasture (dimensionless) (Table 112-31). | |||
Yµ = agricultural productivity by unit area of pasture feed grass, in kg/m 2 11 * | |||
(Table 112-31). | |||
Ys = agricultural productivity by unit area of stored feed, in kg/m 2 (Table 112-31 ). | |||
Th(milkl = transport time from pasture to harvest, to milk animal, to milk, to receptor, in sec (Table 112-31). . | |||
Tf(milkJ = transport time from pasture to milk animal, to milk, to receptor, in sec (Table 112-31). | |||
Th(meal) = transport time from crop field to ingestion receptor, in sec (Table 112-31). | |||
Tf(meal) = transport time from pasture to ingestion receptor, in sec (Table 112-31). | |||
The concentrations of tritium and carbon-14 in milk and meat are based on their airborne concentration rather than their deposition. Therefore, the Riis based on [x/Q] as follows: | |||
R~_3 = (k')* (k'")*Fm*QF*Uap*Daipj * [0.75*(0.5/H)] (2-21e) | |||
R11t_14 = (k')*(k"')*Fm*QF*Uap*Daipj *p*(0.11/0.16] (2-21f) where: | |||
R1;/_3 = mrem/yr per uCi/m3 R~14 = mrern/yr per uCi/m3 Rev.29 Page 109 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES All other values as previously defined above. | |||
2.3.4.3 Inhalation Pathway D,,AR = 3.11 E-s [ x/Q LR1Q1] (2-22) where: | |||
D1PAR = dose from inhalation pathway due to release of particulates, iodines, and tritium (mrem). | |||
3.17E-8 = units conversion (year/sec). | |||
Qi = the release of nuclide ' i 'from all vents in uCi. Releases shall be cumulative over the time period of interest. | |||
xta = highest average annual x!Q (sec/m3) (see Table 112-31). | |||
Ri = dose factor for organ type, age group, and pathway (for radionu,clides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - values of Ri are provided in ODCM Table 112-2 through Table 112-5 and calculated from the following equation. | |||
R/ = k' (BR) (Daipj) (2-22a) where: | |||
R/ = mrem/yr per uCi/m3. | |||
k' = 1.0E+6 unit conversion pCi/uCi. | |||
BR = breathing rate from Table 112-31. | |||
Daipj = Inhalation Dose Factor Table 112-27 through Table 112-30. | |||
2.3.5 Intentionally left blank. | |||
Rev.29 Page 110 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 2.3.6 Gaseous Effluent Dose Projection Control 3.2.2.5 requires the VENTILATION EXHAUST TREATMENT SYSTEM be used to reduce radioactive material levels prior to discharge when projected doses from both units to areas at and beyond the SITE BOUNDARY would exceed in a 31 day period: | |||
: a. 0.4 mrad to air from gamma radiation, or | |||
: b. 0.8 mrad to air from beta radiation, or | |||
: c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC A dose projection is performed at least once per 31-days by the following equations: | |||
Dmaxgamma (Dmaxg Id)* 31 (2-23) | |||
Dmaxbeta (Dmaxb Id)* 31. (2-24) | |||
Om ax organ . (Dmaxo Id)* 31 (2-25) where: | |||
DmaXgamma = maximum gamma air dose projection for current 31-day period (mrad) | |||
DmaXbeta = maximum beta air dose projection for current 31-day period (mrad) | |||
DmaXorgan = maximum organ dose projection for current 31-day period (mrem) | |||
Dmaxg = maximum gamma air dose to date for current calendar quarter as obtained by equation (2-18). | |||
Dmaxb = maximum beta air dose to date for current calendar quarter as obtained by equation (2-19). | |||
Dmaxo = maximum organ dose to date for current calendar quarter as determined by summing the organ dose obtained from equations (2-20), (2-21) and (2-22) (mrem). | |||
d = number of days in current calendar quarter at the end of the release. | |||
31 = the number.of days of concern. | |||
Rev.29 Page 111 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES 3.0 ANNUAL DOSE EVALUATION The assessment of radiation doses for the Annual Radoactive Effluent Release Report (ARERR) shall be performed utilizing the methodology provided in NUREG-0133, Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants, October 1978. Any deviations from the methodology provided NUREG-0133 shall be documented in the Annual Radioactive Effluent Release Report. | |||
The meteorological conditions concurrent with the time of release of radioactive materials (as determined by sampling frequency of measurement) or approximate methods shall be used as input to the dose model. | |||
4.0 SPECIAL DOSE ANALYSIS 4.1 TOTAL DOSE TO MEMBERS OF THE PUBLIC Control 3.2.3 requires that the annual dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from the uranium fuel cycle shall be limited to: | |||
~ 25 mrem whole body or any organ except thyroid | |||
~ 75 mrem thyroid Surveillance Requirement 4.2.3.2 requires that cumulative dose contributions from direct radiation from operations be evaluated when the calculated dose from the release of radioactive materials in liquid or gaseous effluents exceed the limits of Controls 3.2.1.2.a, 3.2.1.2.b, 3.2.2.2.a, 3.2.2.2.b, 3.2.2.3.a, or 3.2.2.3.b. The direct radiation contribution shall be determined by the methodology described below. | |||
This methodology calculates the direct radiation contribution, which then must be added to the dose or dose commitment determined in accordance with ODCM Part II, Sections 1.3.1, 2.3.3, and 2.3.4 to determine total dose from all pathways. This evaluation* of direct radiation contribution is in accordance with ANSI/ANS 6.6.1-1979 Section 7. The error using this method is estimated to be approximately 8%. | |||
The following evaluation is performed for each receptor of concern. | |||
Dws = D1EFFL-WB + (Dm - Dx BKG) * (4-1) | |||
Do= D1EFFL-o + (Dro - Dx BKG) (4-2) | |||
Dr= D1EFFL-T + (Dm - Dx BKG) (4-3) | |||
Rev.29 Page 112 of 329 12/2016 | |||
CY-LG-170-301 CALCULATION METHODOLOGIES where: | |||
Dws = cumulative total body dose contribution from direct radiation, liquid and gaseous effluents at the appropriate receptors (mrem). | |||
Do = cumulative_organ dose contribution from direct radiation, liquid and gaseous effluents at the appropriate receptors (mrem). | |||
Dr = cumulative thyroid dose contribution from direct radiation, liquid and gaseous effluents at the appropriate receptors (mrem). | |||
Oro = total dose at receptor of interest as evaluated by dosimetry measurement (mrem). | |||
NOTE: If there is not a dosimetry location at the actual receptor location, a more conservative location will be used to evaluate Total Dose. | |||
NOTE: Due to the statistics of radiation measurements and to the conservative nature of effluent calculations it is plausible the Oro - Dx BKG may yield a negative value. In this situation the value for Oro_ Dx BKG shall be reported as zero (0). | |||
Dx BKG = Background dose as evaluated by dosimetry at background sites (mrem). | |||
D1EFFL-rs = effluent contribution to total body dose (as evaluated in ODCM Part II, Sections1 .3.1, 2.3.3, and 2.3.4). | |||
D1EFFL-o = effluent contribution to organ dose (as evaluated in ODCM Part II, Sections1 .3.1, 2.3.3, and 2.3.4). | |||
D1EFFL-r = effluent contribution to thyroid dose (as evaluated in ODCM Part II, Sections1 .3.1, 2.3.3, and 2.3.4). | |||
* 4.2 DOSES DUE TO ACTIVITIES INSIDE THE SITE BOUNDARY In accordance with Administrative Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of radiation dose from radioactive liquid and gaseous effluents to MEMBERS OF THE PUBLIC due to their activities inside the SITE BOUNDARY. | |||
There are three locations within the SITE BOUNDARY that are accessible to MEMBERS OF THE PUBLIC for activities unrelated to the operation of Limerick Station. These locations are: 1) the railroad tracks which run along the river within the SITE BOUNDARY; 2) the Limerick Information Center, on Longview Road next to the 500kv substation; and 3) Fricks Lock. Of these three locations, the railroad tracks are the closest to the plant confines. Sectors and distances of these locations are provided below: | |||
Rev. 29 1** | |||
Page 113 of 329 1212016 I | |||
CY-LG-170-301 CALCULATION METHODOLOGIES Sector Distance to Location (m) | |||
Railroad Tracks: | |||
s 300 SSW 225 SW 225 WSW 225 w 225 WNW 345 NW 450 Information Center: | |||
ESE 884 Fricks Lock: | |||
WSW 450 Annual doses will be calculated in accordance with NUREG-0133 methodology, as appropriate and assume an occupancy factor of 0.25. The maximum dose calculated will be reported in the Annual Radioactive Effluent Release Report. | |||
5.0 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM 5.1 SAMPLING PROGRAM The operational phase of the Radiological Environmental Monitoring Program (REMP) is conducted in accordance with the requirements of Control 3.3.1. The objectives of the program are: | |||
To provide data on measurable levels of radiation and radioactive materials in the site environs. | |||
To evaluate the relationship between quantities of radioactive materials released from LGS and resultant radiation doses to individuals from principal pathways of exposure. | To evaluate the relationship between quantities of radioactive materials released from LGS and resultant radiation doses to individuals from principal pathways of exposure. | ||
The sampling requirements (type of samples, collection frequency, and analysis) and sample locations are presented in Appendix A. | |||
5.2 INTERLABORATORY COMPARISON PROGRAM Control 3.3.3 requires analyses be performed on radioactive material supplied as part of an lnterlaboratory Comparison. | |||
Participation in an NIST traceable lnterlaboratory Comparison Program provides a check on the preciseness of measurements of radioactive material in environmental samples. A summary of the lnterlaboratory Comparison Program results is provided in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. | |||
Rev.29 Page 114 of 329 12/2016 | |||
CY-LG-170-301 TABLES Rev.29 Page 115 of 329 12/2016 | |||
CY-LG-170-301 TABLE 111-1 DECAY CONSTANTS FOR NUCLIDES OF INTEREST 1 DECAY DECAY DECAY KOCHER T112 CONSTANT T112 CONSTANT T112 CONSTANT NUCLIDE T112 HOURS HR"1 SECONDS sEc-1 DAYS DAYs-1 H-3 1.228E+01 y 1.076E+05 6.439E-06 3.875E+08 1.789E-09 4.485E+03 1.545E-04 C-14 5.730E+03 y 5.023E+07 1.380E-08 1.808E+11 3.833E-12 2.093E+06 3.312E-07 NA-22 2.602E+OO y 2.281E+04 3.039E-05 8.211E+07 8.441E-09 9.504E+02 7.293E-04 NA-24 1.500E+01 H 1.500E+01 4.621E-02 5.400E+04 1.284E-05 6.250E-01 1.109E+OO P-32 1.429E+01 D 3.430E+02 2.021E-03 1.235E+06 5.614E-07 1.429E+01 4.851E-02 CA-41 1.030E+05 y 9.029E+08, 7.677E-10 3.250E+12 2.132E-13 3.762E+07 1.842E-08 SC-46 8.383E+01 D 2.012E+03 3.445E-04 7.243E+06 9.570E-08 8.383E+01 8.268E-03 CR-51 2.770E+01 D 6.649E+02 1.042E-03 2.394E+06 2.896E-07 2.770E+01 2.502E-02 MN-54 3.127E+02 D 7.505E+03 9.236E-05 2.702E+07 2.566E | |||
: 2) The References refer to tables contained in Regulatory Guide 1.109 unless otherwise specified. | : 2) The References refer to tables contained in Regulatory Guide 1.109 unless otherwise specified. | ||
: 3) From Reg. Guide 1.109, Appendix C, Equation C-2 4) From NUREG-0133, Section 5.3.1.3 5) Site specific value from the Limerick Generating Station Final Environmental Statement (NUREG-0974) 6) 2010 -2014 Five year average of site meteorology data Rev. 29 Page 309 of 329 12/2016 CY-LG-170-301 TABLE 112-32 NEAREST GASEOUS EFFLUENT DOSE RECEPTOR DISTANCES (Meters) Plume Ground Inhalation Pathways Vegetation Meat Cow Goat Direction (Nearest Pathway(1> Pathway(1> Pathway<1> Pathway(1> Residence)< | : 3) From Reg. Guide 1.109, Appendix C, Equation C-2 | ||
1> N 948 1016 7551 7551 0 NNE 825 2929 8015 0 0 NE 1057 4358 4287 0 0 ENE 985 4331 2271 0 0 E 873 3573 0 0 0 ESE 1047 1371 (2) 3775 0 0 SE 1202 7113(2) 7695 0 0 SSE 1647 2107 0 0 0 s 1325 1860 3722 6740 0 SSW 1543 1622 2323 3167 0 SW 991 1389 7055 0 0 WSW 1158 1374 4321 4321 0 w 1105 1317 5223 0 0 WNW 1123 0 0 0 0 NW 1104 2499 0 0 0 NNW 1540 1703 6379 0 0 (1) Based upon Control 3.3.2, Land Use Census (2015) (2) REMP garden located in the ESE sector at 555 meters and in the SE sector at 390 meters. Rev.29 Page 310 of 329 12/2016 | : 4) From NUREG-0133, Section 5.3.1.3 | ||
: 5) Site specific value from the Limerick Generating Station Final Environmental Statement (NUREG-0974) | |||
__ __ .....,..._... | : 6) 2010 - 2014 Five year average of site meteorology data Rev. 29 Page 309 of 329 12/2016 | ||
...,.... __ . I ; ! i 1 | CY-LG-170-301 TABLE 112-32 NEAREST GASEOUS EFFLUENT DOSE RECEPTOR DISTANCES (Meters) | ||
......... | Plume Ground Inhalation Pathways Vegetation Meat Cow Goat Direction (Nearest Pathway(1> Pathway(1> Pathway<1> Pathway(1> | ||
......... | Residence)< 1> | ||
o...+-__ ________ ........,_,_....._, 'LE+01 1 E+02 FLOW (cfs) Figure 111.3.1-1 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW STATION OUTFALL | N 948 1016 7551 7551 0 NNE 825 2929 8015 0 0 NE 1057 4358 4287 0 0 ENE 985 4331 2271 0 0 E 873 3573 0 0 0 ESE 1047 1371 (2) 3775 0 0 SE 1202 7113(2) 7695 0 0 SSE 1647 2107 0 0 0 s 1325 1860 3722 6740 0 SSW 1543 1622 2323 3167 0 SW 991 1389 7055 0 0 WSW 1158 1374 4321 4321 0 w 1105 1317 5223 0 0 WNW 1123 0 0 0 0 NW 1104 2499 0 0 0 NNW 1540 1703 6379 0 0 (1) Based upon Control 3.3.2, Land Use Census (2015) | ||
: .*.** .. " Figure 111.3.1-2 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PENNSYLVANIA AMERICA WATER | (2) REMP garden located in the ESE sector at 555 meters and in the SE sector at 390 meters. | ||
. | Rev.29 Page 310 of 329 12/2016 | ||
1.E+ | |||
CY-LG-170-301 FIGURES Rev.29 Page 311 of 329 12/2016 | |||
CY-LG-170-301 100 --~--....,._--....,.. __ ~ __.....,..._...________,..____________...,....__ | |||
*-* -- - w - -*--- | |||
~~~~~----~--.....,..-- | |||
. I | |||
; | |||
! i 1 -~,~~--------.........--~;--~--~-------...._.........o...+-__~________........,_,_....._, | |||
'LE+01 1 E+02 1.E+b4 FLOW (cfs) | |||
Figure 111.3.1-1 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW STATION OUTFALL Rev.29 Page 312 of 329 12/2016 | |||
CY-LG-170-301 I* *. | |||
100 1.E+02 1.Ei-03 1;E+04 FLOW(cfs) | |||
: .*.** .. " | |||
. " ~ . ,, | |||
Figure 111.3.1-2 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PENNSYLVANIA AMERICA WATER Rev.29 Page 313 of 329 12/2016 | |||
CY-LG-170-301 I | |||
I | |||
=. -~. I:. | |||
.. | |||
I tI"-~*==-l-~l-£1~ | |||
1 | |||
*****1 .11****** | |||
i i . . I | |||
. ' 1 1 E+.01 1;E+04 1.E+03 1.E+04 FLOW (Cf$) | |||
Figure 111.3.1-3 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PHOENIXVILLE Rev.29 Page 314 of 329 12/2016 | |||
CY-LG-170-301 1 **+-------~~-- | |||
1.E+01 | |||
. . . . ----.. . . . | |||
1.E+02 1:E+03 1.E+04 fLOW(cf~) | |||
. .* ' | |||
Figure 111.3.1-4 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW AQUA AMERICA Rev.29 Page 315 of 329 12/2016 | |||
CY-LG-170-301 i | |||
- | - | ||
I 1.E+02 FLOW (cfs) Figure 111.3.1-5 | a:: | ||
----! frillllt*Cflil!IR. | 0 l-100 - - - - - - | ||
w11*1! Y.iJ.nk | o | ||
<( | |||
u.. | |||
*.* ** .. ' ... Ta* C'ohdoiliac&I* | z 0 | ||
@1aita9111 TanJt' . 'W..nt.rl6N G<<i.aii1!11lnQ | E | ||
'!l'l*lktn. | :J 10 5 | ||
u .. 11 .. *ti;.,{* uqu1.:a *emumf . | ---c-1********---*-*** - | ||
Rev.29 Page 317 of 329 12/2016 e-.ul*1*. | -f-~l----+--+-+-+---.~*---~****-*********-*----... | ||
1"41n* | I 1 | ||
* Daa fliilJQit | 1.E+01 1.E+02 1.E+03 1 E+Q4 FLOW (cfs) | ||
*lh>11iro.11. | Figure 111.3.1-5 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW CREW COURSE Rev.29 Page 316 of 329 12/2016 | ||
CY-LG-170-301 Lauridrv | |||
()l{klM fl.D) | |||
: 8.Utiltf*lcm | |||
----! | |||
frillllt*Cflil!IR. | |||
w11*1! Y.iJ.nk FD S,t\MPl.E "fJU.n( M:.i * . * ** . . ' ... ~* | |||
Ta* C'ohdoiliac&I* | |||
'"' w..,.,. @1aita9111 TanJt' . | |||
> :3tu.dl~.,. T*n' Egulpmmt | |||
.Orcll' Ulf>J | |||
. e)~h,,:::..*:.::l*::::fll:...._--1 EO | |||
,.~u1:;~1t. | |||
Tl\J:fj< | |||
~ FE-ll3.'..<<i3 'W..nt.rl6N G<<i.aii1!11lnQ '!l'l*lktn. | |||
""~1stj~:,-0.1:i o~~o~ u.. 11.. *ti;.,{* | |||
uqu1.:a *emumf . | |||
Fi~~?1*it.t""1. | |||
Figure 111-1 Rev.29 Page 317 of 329 12/2016 | |||
CY-LG-170-301 "No.rill *v*n*** | |||
1t)fl4w* ~ .z, ~ Wfde | |||
'!'*"";' **1 ii~~ ~ang~ | |||
Accident, Mi::i:ntt()r** | |||
IC~r,!4J1l'.D\t* | |||
e-.ul*1*. 1"41n* * 'A..,.... ~.,. | |||
~c-111*' Daa N~r~~ | |||
fliilJQit *lh>11iro.11. | |||
twbrin. mnalD'Im* | twbrin. mnalD'Im* | ||
Equlj..' | Equlj..' c6~.t,P ..1t E~~AllMI t | ||
.. 1t t , | , ~IH~ r.*c~~ t!~h,µJ*lli>' s* . .Qf\V *~LSr.a* | ||
s* . | ~t_z}_,,.~~---::---i-~+-~....... | ||
+-* | |||
+- | O<Q*:i). | ||
....... O<Q*:i). iz! | iz! . | ||
** | |||
*. | U1n*1d"'k.>O*n"""""!iJ' .tim1loi'O Unllll I &*':!" | ||
Ga11i.ou11 Emuontil | |||
:froi-t or..11ram * | |||
'Ui;ir1fr:S111ok * | |||
*-,Uni~ _1-Ch*.rcanl *.ay..,ttuns | |||
GAi) | .. iint,iz.ci.1.Mt~i\A.e~t~m: | ||
.. , cil | Figure 112-1 Rev.29 Page 318 of 329 12/2016 | ||
* | |||
* | CY-LG-170-301 | ||
* Soult* Vant 1>0'.ulh \itiM S>anti:iuh~U* | |||
P lillioul"1" UnH 1 'Ulitl :(:!' | |||
.1odim* | |||
,loolna t>i'l4 t-l<it>l* GAi) | |||
Elc 411' | |||
. C-i>nll;.~Y<)aJ ii-El; 4.11' | |||
~ntinuo'llii | |||
:,,,.,t;;,,. mnd | |||
~ .... | |||
*u"'**. i .111 ;i. <)a11nrmua. | ,.;.,.,,11.., cil Mor:iU~ ~:i!l | ||
emuenl Flow. Dlagnsm * . Rev.29 Page 319 of 329 12/2016 UNTT'2 * . | *~ | ||
* R$3Ctor: | 2-lJ<l.ll!1>Q. | ||
Bi it E1f1au 1t a:4 rt ; 7000 C1111 ParticulaWbdln$ | CfllM'. | ||
Mo.ri1tor | Miint: | ||
* | .~f1.ualln9 .fli::iw. | ||
f\*1\urtUna fl<><11t El\ti ..Y*' | |||
<l*n*r.atmg .m .. u.o:" ' "* '' lh.1 <* ' ' ' | £)tlliau&l * ~~~~~~~~~~~~~-1-i il1!'ft&c;lqt . EMl'2ti.lfill | ||
* R11~tor E.n.ito11w;~ | |||
(3) Controls and Special Interest | 1----4--*~ | ||
Slihau~ *~~~~~~~~~~~~~-+ii"* 45 1 64.000 E:1d1au*l | |||
* CFM Min;* | |||
. J&i:jfJfj:i!l'UU'll IEqulp~*nl c~~p.utm.an1. .~fl:fllP.**nttt*tt1 ERhl'IU'l.Ji . . ---""9k;>;: Ei,hllUlll | |||
~::....C:;;;;...,;:;;:....J Umilllf!ck: °'"'""''*h*ttnd SI.ll!IRm | |||
*u"'**. i .111 ;i. | |||
<)a11nrmua. emuenl Flow. Dlagnsm | |||
* S-ciUitl~ ~l'i!!r/;k . | |||
Figure 112-2 Rev.29 Page 319 of 329 12/2016 | |||
CY-LG-170-301 UNTT'2 * | |||
.*R$3Ctor: Bl~t Bi it E1f1au 1t | |||
$fac~. a:4 i~ rt | |||
; 7000 C1111 ParticulaWbdln$ | |||
Radlatq~ Mo.ri1tor | |||
~. *. l. | |||
., dJ | |||
. . .. | |||
.l,.lt>ll>r1,.;1t <l*n*r.atmg .m.. u.o:" | |||
' "* '' lh.1 <* ' ' ' | |||
* EXHAU$A 'FAN. ~**FILTER Figure 112-3 Rev. 29 Page 320 of 329 12/2016 | |||
CY-LG-170-301 APPENDIX A RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM - | |||
SAMPLE TYPE, LOCATION, AND ANALYSIS Rev.29 Page 321 of 329 12/2016 | |||
CY-LG-170-301 TABLE A-1 Page 1of3 ODCM - Limerick Generating Station Radiological Environmental Monitoring Program Pathway Station Code Location Collection Method Analyses Direct 36S2 3, 183 feet N of site 1 set of four (4) dosimeters from Gamma dose quarterly (1) Inner Ring 3S1 2,301 feet NNE of site each location at least quarterly 5S1 2,350 feet NE of site 7S1 3,099 feet ENE of site 10S3 2,648 feet E of site 11S1 2,017 feet ESE of site 13S2 2, 149 feet SE of site 14S1 3,319 feet SSE of site 18S2 1,390 feet S of site 21S2 977 feet SSW of site 23S2 2,793 feet SW of site 25S2 2,445 feet WSW of site 26S3 2,088 feet W of site 29S1 2,886 feet WNW of site 31S1 1,395 feet NW of site 34S2 3,071 feet NNW of site (2) Outer Ring 3601 18,527 feet N of site 2E1 25,112 feet NNE of site 4E1 25,221 feet NE of site 7E1 22,489 feet ENE of site 10E1 20,826 feet E of site 10F3 29,442 feet ESE of site 13E1 22,772 feet SE of site 16F1 26,608 feet SSE of site 1901 18,439 feet S of site 20F1 27,648 feet SSW of site 2401 20,972 feet SW of site 2501 21,044 feet WSW of site 2802 20,231 feet W of site 29E1 26, 11 o feet WNW of site 3102 20,446 feet NW of site 34E1 24,243 feet NNW of site Rev.29 Page 322 of 329 12/2016 | |||
CY-LG-170-301 TABLE A-1 (Continued) Page 2 of 3 Pathway Station Code Location Collection Method Analyses Direct (Continued) 5H1 C 130,742 feet NE of site (3) Controls and 6C1 11,305 feet NE of site Special Interest 9C1 11,377 feet E of site 13C1 14,980 feet SE of site 1501 16,877 feet SE of site 1781 8,462 feet S of site 2001 16, 157 feet SSW of site 3101 15,853 feet WNW of site II. Airborne 10S3 2,648 feet E of site Approximately 1 cfm continuous flow Gross beta analysis on each weekly Particulates 11S1 2,017 feet ESE of site through glass fiber filter which is collected sample. Gamma spectrometry shall be 14S1 3,319 feet SSE of site weekly. done when gross beta exceeds ten times 13S4 1, 186 feet SE of site the yearly mean of control station value. | |||
1501 16,877 feet SE of site 22G1 C 93,619 feet SW of site Gross beta analysis done 24 hr after sampling to allow for Radon and Thoran daughter decay. | |||
Gamma Spec on quarterly composite. | |||
Iodine 10S3 2,648 feet E of site A TEDA impregnated flow-through Iodine 131 analysis on each weekly 11S1 2,017 feet ESE of site cartridge is connected to air sampler and sample. | |||
14S1 3,319 feet SSE of site is collected weekly at site filter change. | |||
13S4 1, 186 feet SE of site 1501 16,877 feet SE of site 22G1 C 93,619 feet SW of site Ill. Water 24SI c 1,058 feet SW of site Sample collected from a continuous water Gamma isotopic analysis monthly. | |||
: a. Surface 1381 9,225 feet SE of site sampler, monthly. In event sampler is inoperable, weekly grab samples will be H-3 on quarterly composite collected until sampler returned to service. | |||
: b. Ground No Ground water is sampled and analyzed, because ground water flow is to the river per UFSAR Section 2.4.13 | |||
: c. Drinking 15F7 33,400 feet SSE of site Sample collected froru. a continuous water lodine-131 LL, Gross beta and 15F4 45,514 feet SE of site sampler monthly. In event sampler is gamma isotopic monthly, 16C2 14,034 feet SSE of site inoperable, weekly grab samples will be 28F3 C 30,811 feet WNW of site collected until sampler returned to service. H-3 on quarterly composite | |||
: d. Sediment from 16C4 11,51 O feet SSE of site A sediment sample is taken down stream Gamma isotopic analysis each shoreline of discharge semi-annually sample Rev. 29 Page 323 of 329 12/2016 | |||
CY-LG-170-301 TABLE A-1 (Continued) Page 3 of 3 Pathway Station Code Location Collection Method Analyses IV. Ingestion 18E1 22,704 feet S of site Sample of fresh milk is collected from Gamma isotopic and 1-131 analyses a.Milk 1981 10,317 feet SSW of site each farm biweekly when cows are on on each sample 25C1 14,224 feet WSW of site pasture (April) through October), monthly 23F1 C 26,505 feet SW of site at other times. | |||
: b. Fish and 16C5 9,251 feet SE of site Two species of recreationally Gamma isotopic analyses on edible Invertebrates 29C1 C 13, 725 feet WNW of site important fish (Predator and bottom portions. | |||
feeder) sampled in season or semiannual! if not seasonal. | |||
Seasons are Spring and Fall There are no commercially or recreationally important species of invertebrates. Therefore no invertebrates are sampld. | |||
: c. Food Products There are no downstream food products that are irrigated by water in which liquid plant wastes have been discharged. | |||
No broad leaf vegetation sampling is performed, because milk sampling is performed. | No broad leaf vegetation sampling is performed, because milk sampling is performed. | ||
C = Control Location Rev.29 Page 324 of 329 12/2016 | |||
Rev.29 Page 324 of 329 12/2016 Environmental SaFigu.re A-1 Near the | |||
* re . .. Figure A-2 Environmental Sampling Locations at Distances Less Than Five Miles from the Limerick Generating Station. Rev.29 Page 326 of 329 12/2016 | CY-LG-170-301 Environmental SaFigu.re A-1 Near the Lime~~~n~enerating LocationsStOn . s*t at1onI e or P Rev.29 age 325 of 329 1212016 I | ||
: 1. Regulatory Guide 1.109, "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of"Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, October 1977. 2. Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, July 1977. 3. Regulatory Guide 1.112, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Light-Water-Cooled Power Reactors," U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1976. 4. Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1977. 5. U.S. Nuclear Regulatory Commission, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Boiling Water Reactors (BWR-GALE Code)," USNRC Report NUREG-0016, Washington, D.C. 20555, April 1976. 6. U.S. Nuclear Regulatory Commission, "XOQDOQ, Program for the Methodological Evaluation of Routine Effluent Releases at Nuclear Power Stations," USNRC Report NUREG-0324, Washington, D.C. 20555, September, 1977. 7. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 20, Appendix B, U.S. Government Printing Office, Washington, D.C. 20402, January 1, 1977. 8. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 100, U.S. Government Printing Office, Washington, D.C. 20404, January 1, 1977. 9. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 141, U.S. Government Printing Office, Washington, D.C. 20402, January 1, 1977. 10. Regulatory Guide 1.21, "Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, June 1974. 11. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 190, Federal Register, Vol. 42, No. 9, Washington, D.C. 20402, January 13, 1977. 12. U.S. Nuclear Regulatory Commission, "Short Term Diffusion Estimates," Section 2.3.4, Standard Review Plan for the Review of Safety Analysis Reports for Nuclear Power Plants -LWR Edition, USNRC Report NUREG-75/087, Washington, D.C. 20555, November 1975. 13. U.S. Nuclear Regulatory Commission, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants," USNRC Report NUREG-0133, Washington, D.C. 20555, October 1978. Rev.29 Page 328 of 329 12/2016 CY-LG-170-301 | CY-LG-170-301 E | ||
: 14. Letter From Thomas E. Marley, Director Office of Nuclear Reactor Regulations, To Thomas E. Tipton Vice President and Director Operations, Nuclear Management and Resources Council, 6/30/93. 15. ANSI N42.14-1991 (Revision of ANSI N42.14-1978) "Calibration and Use of Germanium Spectrometers For the Measurement of Gamma-Ray Emission Rates of Radionuclides", Sect. 6.2.2 16. EML Procedures Manual, H.L. Volchok and G. dePlangue, Editors, U.S. Dept. Of Energy (Revised Annually) | UJ | ||
: 17. L.A. Currie, "Limits For Qualitative Detection and Quantitative Determination | * re | ||
. | |||
Definition and Elaboration of a Proposed Position for Radiological Effluent and Environmental Measurements", prepared by NRC by L.A. Currie (Chapter II, Sect. D.2; Chapter Ill, Sect. C.1 ), September 1984 19. Tech. Spec. Section 1.24 (Definitions) | ~. | ||
: 20. USNRC Generic Letter, 89-01 21. Tech. Spec. Section 6.14. 22. Tech. Spec. Section 6.5.1.6m. | .. ~ | ||
: 23. Tech. Spec. Section 6.5.3. 24. Tech. Spec. Section 6.8.4d, e and f. 25. Tech. Spec. Section 6.9.1.8/0DCM Control 1.3.6. 26. Tech. Spec. Section 6.10.3m and n. 27. UFSAR, Section 11.5.6. 28. Bechtel, Inc., "Dilution Studies for Routine and Accidental Releases from Limerick Nuclear Plant into the Schuylkill River", March, 1996. 29. ANSl/ANS-6.6.1-1979 "calculation and measurement of direct and scattered gamma radiation from LWR nuclear power plants, Section 7. 30. Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques," Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). 31. NUREG/CR-4653 GASPAR II, Technical Reference and User Guide 32. NUREG/CR-4013, LADTAP II Technical Reference and User Guide. 33. Kocher, David C., "Radioactive Decay Data Tables," DOE/TIC-11026,138 (1981). 34. NUREG 1302, "Offsite Dose Calculation Manual Guidance: | Figure A-2 Environmental Sampling Locations at Distances Less Than Five Miles from the Limerick Generating Station. | ||
Standard Radiological Effluent Controls for Boiling Water Reactors." 35. NUREG-0974, Final Environmental Statement related to the operation of Limerick Generating Station, Units 1 and 2 (April 1984) Rev.29 Page 329 of 329 12/2016}} | Rev.29 Page 326 of 329 12/2016 | ||
CY-LG-170-301 | |||
.- | |||
*22G1 Figure A-3 Environmental Sampling Locations at Distances Greater Than Five Miles from the Limerick Generating Station. | |||
Rev. 29 Page 327 of 329 12/2016 | |||
CY-LG-170-301 REFERENCES | |||
: 1. Regulatory Guide 1.109, "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of"Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. | |||
20555, October 1977. | |||
: 2. Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, July 1977. | |||
: 3. Regulatory Guide 1.112, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Light-Water-Cooled Power Reactors," U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1976. | |||
: 4. Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1977. | |||
: 5. U.S. Nuclear Regulatory Commission, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Boiling Water Reactors (BWR-GALE Code)," | |||
USNRC Report NUREG-0016, Washington, D.C. 20555, April 1976. | |||
: 6. U.S. Nuclear Regulatory Commission, "XOQDOQ, Program for the Methodological Evaluation of Routine Effluent Releases at Nuclear Power Stations," USNRC Report NUREG-0324, Washington, D.C. 20555, September, 1977. | |||
: 7. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 20, Appendix B, U.S. | |||
Government Printing Office, Washington, D.C. 20402, January 1, 1977. | |||
: 8. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 100, U.S. Government Printing Office, Washington, D.C. 20404, January 1, 1977. | |||
: 9. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 141, U.S. Government Printing Office, Washington, D.C. 20402, January 1, 1977. | |||
: 10. Regulatory Guide 1.21, "Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, June 1974. | |||
: 11. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 190, Federal Register, Vol. 42, No. 9, Washington, D.C. 20402, January 13, 1977. | |||
: 12. U.S. Nuclear Regulatory Commission, "Short Term Diffusion Estimates," Section 2.3.4, Standard Review Plan for the Review of Safety Analysis Reports for Nuclear Power Plants - LWR Edition, USNRC Report NUREG-75/087, Washington, D.C. 20555, November 1975. | |||
: 13. U.S. Nuclear Regulatory Commission, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants," USNRC Report NUREG-0133, Washington, D.C. 20555, October 1978. | |||
Rev.29 Page 328 of 329 12/2016 | |||
CY-LG-170-301 | |||
: 14. Letter From Thomas E. Marley, Director Office of Nuclear Reactor Regulations, To Thomas E. Tipton Vice President and Director Operations, Nuclear Management and Resources Council, 6/30/93. | |||
: 15. ANSI N42.14-1991 (Revision of ANSI N42.14-1978) "Calibration and Use of Germanium Spectrometers For the Measurement of Gamma-Ray Emission Rates of Radionuclides", | |||
Sect. 6.2.2 | |||
: 16. EML Procedures Manual, H.L. Volchok and G. dePlangue, Editors, U.S. Dept. Of Energy (Revised Annually) | |||
: 17. L.A. Currie, "Limits For Qualitative Detection and Quantitative Determination - | |||
Application to Radiochemistry", Analytical Chemistry, Vol. 40, pp. 586-593 (TABLE II), | |||
1968 | |||
: 18. NUREG/CR-4007, "Lower Limit of Detection: Definition and Elaboration of a Proposed Position for Radiological Effluent and Environmental Measurements", prepared by NRC by L.A. Currie (Chapter II, Sect. D.2; Chapter Ill, Sect. C.1 ), September 1984 | |||
: 19. Tech. Spec. Section 1.24 (Definitions) | |||
: 20. USNRC Generic Letter, 89-01 | |||
: 21. Tech. Spec. Section 6.14. | |||
: 22. Tech. Spec. Section 6.5.1.6m. | |||
: 23. Tech. Spec. Section 6.5.3. | |||
: 24. Tech. Spec. Section 6.8.4d, e and f. | |||
: 25. Tech. Spec. Section 6.9.1.8/0DCM Control 1.3.6. | |||
: 26. Tech. Spec. Section 6.10.3m and n. | |||
: 27. UFSAR, Section 11.5.6. | |||
: 28. Bechtel, Inc., "Dilution Studies for Routine and Accidental Releases from Limerick Nuclear Plant into the Schuylkill River", March, 1996. | |||
: 29. ANSl/ANS-6.6.1-1979 "calculation and measurement of direct and scattered gamma radiation from LWR nuclear power plants, Section 7. | |||
: 30. Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques," Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). | |||
: 31. NUREG/CR-4653 GASPAR II, Technical Reference and User Guide | |||
: 32. NUREG/CR-4013, LADTAP II Technical Reference and User Guide. | |||
: 33. Kocher, David C., "Radioactive Decay Data Tables," DOE/TIC-11026,138 (1981). | |||
: 34. NUREG 1302, "Offsite Dose Calculation Manual Guidance: Standard Radiological Effluent Controls for Boiling Water Reactors." | |||
: 35. NUREG-0974, Final Environmental Statement related to the operation of Limerick Generating Station, Units 1 and 2 (April 1984) | |||
Rev.29 Page 329 of 329 12/2016}} | |||
Revision as of 03:44, 30 October 2019
| ML17129A448 | |
| Person / Time | |
|---|---|
| Site: | Limerick  |
| Issue date: | 04/21/2017 |
| From: | Libra R Exelon Generation Co |
| To: | Document Control Desk, Office of Nuclear Material Safety and Safeguards, Office of Nuclear Reactor Regulation |
| References | |
| LG-17-052 | |
| Download: ML17129A448 (432) | |
Text
{{#Wiki_filter:,BIWJ' ~* Exelon Generatione TS 6.9.1.8 TS 6.14.1.c LG-17-052 April 21, 2017 U. S. Nuclear Regulatory Commission Attn: Document Control Desk Washington, DC 20555-0001 Limerick Generating Station, Unit 1 and 2 Renewed Facility Operating License Nos. NPF-39 and NPF-85 NRC Docket Nos. 50-352 and 50-353 and 72-065
Subject:
Annual Radioactive Effluent Release Report No. 42 In accordance with Section 6.9.1.8 of the Limerick Generating Station (LGS) Technical Specifications (TS) and Section 6.2 of the Offsite Dose Calculation Manual (ODCM), Attachment 1 is the Annual Radioactive Effluent Release Report No. 42, 2016 Limerick Generating Station. During 2016 the ODCM was revised. Therefore, in accordance with Section 6.14.1.c of the LGS TS, Attachment 2 is the entire Limerick Generating Station Units 1 and 2 Offsite Dose Calculation Manual, Revision 29. Limerick has reviewed the Dosimeter of Legal Record (DLR) data for the nearest residence from the ISFSI modules currently loaded. During the period of January 1, 2016 to December 31, 2016, there were no liquid or gaseous effluent releases from the ISFSI at Limerick. There are no commitments contained in this letter. If you have any questions or require additional information, please contact Aaron Briggs at 610-718-2701. Respectfully, Richard W. Libra Vice President-Limerick Generating Station Exelon Generation Company, LLC
LG-17-052 Page 2 : Annual Radioactive Effluent Release Report No. 42, 2016 Limerick Generating Station : Limerick Generating Station Units 1 and 2 Offsite Dose Calculation Manual Revision 29 cc: D. Dorman, Administrator, Region I, USNRC (w/attachments) S. Rutenkroger, LGS USNRC Senior Resident Inspector (w/attachment 1 only) H. Anagnostopoulos, Inspector Region I, USNRC (w/attachments) Document Control Desk, (w/attachments) Director, Division of Spent Fuel Management, Office of Nuclear Material Safety and Safeguards U.S. NRC, Washington, DC 20555-0001 E. Thorton-Jones (w/attachments) U.S. Environmental Protection Agency, Center for Waste Management, Radiation Protection Division, Office of Radiation and Indoor Air, 1200 Pennsylvania Avenue, NW., Washington, DC 20460-0001; Mail Code: 6608J
Attachment 1 Annual Radioactive Effluent Release Report No. 42 2016 Limerick Generating Station
~ Exelon Generation Annual Radioactive Effluent Release Report No. 42 2016 Limerick Generating Station
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT N0.42 January 1, 2016 through December 31, 2016 EXELON GENERATION COMPANY, LLC LIMERICK GENERATING STATION UNITS NO. 1 AND 2 DOCKET NO. 50-352 (Unit 1) DOCKET NO. 50-353 (Unit 2) DOCKET NO. 72-065 (ISFSI) Submitted to The United States Nuclear Regulatory Commission Pursuant to Renewed Facility Operating License:
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank)
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table of Contents
- 1. Introduction ........................................................................................................................................ 1
- 2. Supplemental Information .................................................................................................................. 1 A. Regulatory Limits ............................................................................................................................ 1 B. Effluent Concentration Limits ......................................................................................................... 2 C. Average Energy (E) ........................................................................................................................ 2 D. Measurements and Approximations of Total Radioactivity ............................................................ 2 E. Batch Releases .............................................................................................................................. 4 F. Abnormal Releases ........................................................................................................................ 4 G. Spills ............................................................................................................................................... 5 H. Revisions to the ODCM .................................................................................................................. 5 I. Radioactive Effluent Monitoring Instrumentation Out of Service for More Than 30 Days .............. 5 J. Independent Spent Fuel Storage Installation (ISFSI) ..................................................................... 6 K. Annual Land Use Census Changes ............................................................................................... 6
- 3. Radiological Impact to Man and Compliance to 40 CFR 190 Limits ................................................. 6 A. Dose to Members of the Public at or Beyond Site Boundary ......................................................... 6 B. Dose to Members of the Public Inside the Site Boundary .............................................................. 7 Appendix A Effluent and Waste Disposal Summary ................................................................................ 9 Appendix B Solid Waste and Irradiated Fuel Shipments ....................................................................... 19 Appendix C Meteorological Data ........................................................................................................... 23 Appendix D Offsite Dose Calculation Manual Revision 29 Summary of Changes ................................. 92 Page i
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page ii
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC
- 1. Introduction In accordance with the reporting requirements of Technical Specification 6.9.1.8 applicable during the reporting period, this report summarizes the effluent release data for Limerick Generating Station Units 1 and 2 for the period January 1, 2016 through December 31, 2016. This submittal complies with the format described in Regulatory Guide 1.21, "Measuring, Evaluating and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water Cooled Nuclear Power Plants", Revision 1, June, 1974.
Meteorological data was reported in the format specified in Regulatory Guide 1.23, Revision 1, "Meteorological Monitoring Programs for Nuclear Power Plants". All vendor results were received and included in the report calculations. Therefore, the 2016 report is complete.
- 2. Supplemental Information A. Regulatory Limits Limit Units Receptor ODCM and 10 CFR 50, Appendix I Design Objective Limits
- 1. Noble Gases:
- a. ~500 mrem/Yr Total Body ODCM Control 3.2.2.1.a
~3000 mrem/Yr Skin
- b. ~10 mRad Air Gamma Quarterly air dose limits
~20 mRad Air Beta ODCM Control 3.2.2.2.a
- c. ~20 mRad Air Gamma Yearly air dose limits
~40 mRad Air Beta ODCM Control 3.2.2.2.b
- d. ~10 mrem Total Body 10 CFR 50, Appendix I, Section (Gamma) ll.B.2(b) (limits listed here are
~30 mrem Skin (Beta) based on two unit operation)
- 2. Iodines, Tritium, Particulates with Half Life > 8 days:
- a. ~ 1500 mrem/Yr Any Organ ODCM Control 3.2.2.1.b
- b. ~15 mrem Any Organ Quarterly dose limits ODCM Control 3.2.2.3.a
- c. ~30 mrem Any Organ Yearly dose limits ODCM Control 3.2.2.3.b
- 3. Liquid Effluents
- a. 10 times the concentration limits in 10 CFR 20, ODCM Control 3.2.1.1 Appendix B, Table 2 Col. 2
- b. ~3 mrem Total Body Quarterly dose limits
~10 mrem Any Organ ODCM Control 3.2.1.2.a
- c. ~6 mrem Total Body Yearly dose limits
~20 mrem Any Organ ODCM Control 3.2.1.2.b
- 4. 40 CFR 190, 10 CFR 72.104
~25 mrem Total Body or Organ Yearly dose limits
~ 75. mrem Thyroid ODCM Control 3.2.3 Page 1
I SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC I I
- 8. Effluent Concentration Limits I
Gaseous dose rates rather than effluent concentrations are used to calculate permissible release rates for I gaseous releases. The maximum permissible dose rates for gaseous releases are defined in Offsite Dose Calculation Manual (ODCM) Controls 3.2.2.1.a and 3.2.2.1.b as 500 mrem/yr (Total Body), 3000 mrem/yr (Skin), and 1500 mrem/yr (Organ). I The Effluent Concentration Limit (EGL) specified in 10 CFR 20, Appendix B, Table 2, Column 2 for I identified nuclides, were used to calculate permissible release rates and concentrations for liquid ! release per the Limerick ODCM Control 3.2.1.1. The total activity concentration for all dissolved or entrained gases was limited to < 2E-04 µCi/ml. I C. Average Energy (E) I The Limerick ODCM limits the instantaneous dose equivalent rates due to the release of noble gases to less than or equal to 500 mrem/year to the total body and less than or equal to 3000 mrem/year to the skin. The average beta and gamma energies (E) of the radionuclide mixture in releases of fission and activation gases as described in Regulatory Guide 1.21, "Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," may be used to calculate doses in lieu of more sophisticated software. The Limerick radioactive effluent program employs the methodologies presented in U.S. NRG Regulatory Guide 1.109 "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, October 1977 and NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants, October 1978. Therefore, average energies are not applicable to Limerick. D. Measurements and Approximations of Total Radioactivity
- 1. Fission and Activation Gases The method used for Gamma Isotopic Analysis is the Canberra Gamma Spectroscopy System with a gas Marinelli beaker. Airborne effluent gaseous activity was continuously monitored and recorded in accordance with ODCM Table 4.2-2. Additional vent grab samples were taken from the North Stack, Unit 1 South Stack, and Unit 2 South Stack and analyzed at least monthly to determine the isotopic mixture of noble gas activity released for the month. The data from the noble gas radiation monitors were analyzed to report net noble gas effluent activity. When no activity was found in the grab isotopic analysis, the isotopic mixture was assumed to be that evaluated in the UFSAR (Section 11.5, Table 11.5-4). If activity was found in the grab isotopic analysis, the isotopic mixture for the Noble Gas Monitor was determined from that isotopic mixture.
Each month a monitor background was determined at the time of the noble gas grab sample and used to determine net radiation monitor activity. When no isotopic activity was identified in the grab noble gas sample, the noble gas radiation monitor 15-minute average data for one-hour prior to and one-hour post noble gas grab sampling were used to determine monitor background for the month. The mean plus two standard deviations was used as background for each Noble Gas Monitor. When activity was identified the background determination was made from the last month that no activity was found.
- 2. Particulates and Iodines The method used for Gamma Isotopic Analysis is the Canberra Gamma Spectroscopy System with a particulate filter (47 mm) or charcoal cartridge, respectively. Particulate and iodine activity was continuously sampled and analyzed in accordance with ODCM Table 4.2-2. Charcoal and particulate samples are taken from the North Stack, Unit 1 South Stack, Unit 2 South Stack and Hot Maintenance Shop exhausts and analyzed at least weekly to determine the total activity released from the plant.
Page2
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC
- 3. Carbon-14 in gaseous effluents Gaseous releases of Carbon-14 were estimated based upon a study by EPRI (EPRI 1021106, Estimation of Carbon-14 in Nuclear Power Plant Gaseous Effluents). The principal production reaction leading to the release of C-14 during plant operation is the 0-17(n,a) C-14 nuclear reaction in reactor coolant. Carbon-14 is also produced by neutron activation of N-14 in the BWR drywell and dissolved nitrogen in the reactor coolant, however these sources are a small fraction of that produced by the 0-17(n,a) C-14 reaction and can be neglected since reactor coolant normally contains less than 0.1 ppm by weight nitrogen and the neutron flux in the drywell is low. Most of the C-14 produced in a BWR is released in a gaseous form by the off-gas system, primarily in the form of 14 CO 2 An Exelon fleet-wide spreadsheet was developed using the production factors from the EPRI report. The spreadsheet requires site specific inputs of total reactor power ratings (7030) MWth and Equivalent Full Power Operation days. Using this method, total C-14 released was estimated 14 at 34.47 Curies (Ci). Ninety-five percent or 32.75 Ci was in the form of C0 2 , which was the chemical form necessary to be incorporated in the dose pathways of vegetation, meat and milk.
Only inhalation pathway uses the full C-14 release value in estimating dose. To simplify the dose calculations for C-14, the total release value was used in calculating dose via the offsite effluent pathways. Using the total C-14 release value results in a conservative five percent overestimation of dose via the vegetation, meat and milk pathways. In addition, releases of C-14 were assumed to occur only through the North Vent, which is common to both units. The North Vent has the most conservative X/Q factors for calculating dose.
- 4. Liquid Effluents Each batch of liquid effluent was sampled and analyzed for gamma isotopic activity in accordance with ODCM Table 4.2-1 prior to release. The total activity of each released batch was determined by multiplying each nuclide's concentration by the total volume discharged and then summing. The total activity released during a quarter was then determined by summing the activity content of all batch releases discharged during the quarter.
- 5. Tritium in Liquid and Gaseous Effluents Liquid effluents are analyzed for tritium using a Liquid Scintillation Counter.
Gaseous effluents are analyzed for tritium by passing air from stack effluents through two bubblers in series. An aliquot of the water from each bubbler was analyzed using a Liquid Scintillation Counter. The monthly liquid radwaste composite was analyzed for tritium using a Liquid Scintillation Counter.
- 6. Composite Samples Particulate air samples were composited monthly and analyzed for gross alpha, Sr-89, Sr-90, and Ni-63. Liquid radwaste samples were composited monthly and quarterly and analyzed for gross alpha (monthly) and Fe-55, Sr-89 and Sr-90 (quarterly). These composites were submitted to an offsite vendor laboratory for analysis.
- 7. Lower Limit of Detection (LLD)
The ODCM required lower limit of detection for airborne and liquid releases as follows: Airborne: LLD Gross Aloha Sr-89 Sr-90 1E-11 uCi/cc H-3 1E-06 uCi/cc 1-131 1E-12 uCi/cc Principal Gamma Emitters (Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 1E-11 uCi/cc 1-131 Cs-134 Cs-137 Ce-141 Ce-144) Noble Gas (Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, Xe-138) 1E-04 uCi/cc Page 3
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Liquid: LLD Principal Gamma Emitters (Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 5E-07 uCi/ml Cs-134 Cs-137 Ce-141 Ce-144) 1-131 1E-06 uCi/ml Entrained Gases (Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, 1 E-05 uCi/ml Xe-138) H-3 1 E-05 uCi/ml Gross Alpha 1E-07 uCi/ml Sr-89, Sr-90 5E-08 uCi/ml Fe-55 1E-06 uCi/ml
- 8. Estimated Total Error Present Procedure CY-AA-170-2100, Estimated Errors of Effluent Measurements, provides the methodology to obtain an overall estimate of the error associated with radioactive effluents. The sum of errors used in this report was documented in IR 138895-02.
E. Batch Releases Liquid Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Batch Releases 1.00E+OO 2.00E+01 1.00E+OO 3.00E+OO 2.50E+01 Total time period for batch releases (min) 1.44E+03 1.88E+03 1.20E+01 3.00E+02 3.63E+03 Maximum time period for batch release (min) 1.44E+03 1.15E+02 1.20E+01 2.00E+02 1.44E+03 Average time period for batch release (min) 1.44E+03 9.39E+01 1.20E+01 1.00E+02 1.45E+02 Minimum time period for batch release (min) 1.44E+03 7.40E+01 1.20E+01 5.00E+01 1.20E+01 Average stream flow (Schuylkill River) during periods of release of effluents into a flowing stream (LPM)
- 1.70E+03 1.56E+07 1.61E+07 1.08E+06 8.20E+06 Average Slowdown Flowrate (LPM) 1.89E+04 2.22E+04 1.89E+04 1.89E+04 2.06E+04 Gaseous Qtr 1 Qtr2 Qtr 3 Qtr4 Total Number of Batch Releases O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Total time period for batch releases (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Maximum time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Average time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Minimum time period for batch release (min) O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO F. Abnormal Releases
- 1. Liquid Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Releases 1.00E+OO O.OOE+OO 1.00E+OO 3.00E+OO 5.00E+OO Total Activity Released (Ci) 3.99E-05 O.OOE+OO 3.0SE-04 3.65E-04 7.10E-04
- 2. Gaseous Qtr 1 Qtr2 Qtr3 Qtr4 Total Number of Releases
- 2.00E+OO 2.00E+OO 2.00E+OO 2.00E+OO 2.00E+OO*
Total Activity Released (Ci) 1.20E-01 1.20E-01 1.20E-01 1.20E-01 4.SOE-01
*This represents one continuous release from each unit.
Page4
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC
.. Tritiated water identified in the Unit 1 Underground Normal Waste Holding Tank was released via the Hold Pond during quarters 3 and 4. The concentrations released represent a small fraction of the Total Body and Organ Dose limits, and have been included as part of Appendix A in Table 2A.
" In January of 2016 new pathways were identified and classified as an Insignificant Effluent Pathway. Gaseous effluents from the Main Turbine and Reactor Feed Pump Turbine lubrication oil vapor extractor exhaust vents to the Turbine Building roof. These pathways are not continuously monitored. Tritium analysis was performed in January and December 2016 of the water vapor exiting the vent and of nearby standing water. The tritium in the water is the result of condensation and direct deposition from the discharge of the entrained water vapor from the exhaust vents. This condensation does occur year-round, but increases during seasonally cold weather.
The lube oil exhaust vents and associated systems were operating as designed to remove accumulated water from the lubricating and seal oil for the various turbine systems. The water was discharged as entrained vapor out the Turbine Building roof vent and a portion of it condensed on lower temperature surfaces. This water includes tritium, as the source is from the primary system. (IR 2606991) Based on Regulatory Guide 1.21, Rev 1, Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants these release pathways are considered insignificant. Tritium Site Gaseous Annual Percentage of Activity Relative to Vent Concentration, Release of Tritium, Ci Total Release from the Site uCi/cc 2015 2016 2015 2016 U1 MTLO extractor 1.30E-08 6.4E-01% 1.0E-00% exhaust vent U2 MTLO extractor 1.03E-08 5.0E-01% 8.2E-01% exhaust vent 41.9 25.8 U1 and U2 RFPT extractor exhaust <LLD N/A N/A vent G. Spills In accordance with NEI 07-07 "Industry Ground Water Protection Initiative Final Guidance Document", on July 14, 2016 voluntary notification was made to the PA Department of Environmental Protection Bureau of Radiation Protection and the Nuclear Regulatory Commission due to leakage of tritiated water from a storm drain. A bounding dose calculation was performed using the maximum concentration at undiluted tritium source of 9,480 pCi/L. The calculated dose to the public was determined to be 1.90E-05 mrem to organ and total body, which is a fraction of a percent of the liquid effluent limits. (IR 2692113) H. Revisions to the ODCM Revision 29 of the ODCM was issued in December 2016. The summary of changes is included in Appendix D. The ODCM Revision 29 is being submitted, in its entirety, along with this Annual Report. I. Radioactive Effluent Monitoring Instrumentation Out of Service for More Than 30 Days The Service Water radiation monitor was inoperable from 7/25/16 - 9/2/16. The extended inoperable time of the instrument was due to the revision of a technical document required for the radiation monitor calibration. During this period compensatory samples were collected and analyzed to meet the requirements of the ODCM. (IR 2680338 and 2410536) Page 5
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC J. Independent Spent Fuel Storage Installation (ISFSI) An Independent Spent Fuel Storage Installation (ISFSI) was placed in service starting July 21, 2008. Direct radiation exposure was determined using dosimetry measurements (minus background levels) obtained from the Radiological Environmental Monitoring Program for the nearest residence to the Independent Spent Fuel Storage Installation (ISFSI). In 2016 the dose to the nearest resident from the ISFSI was 0.00 mrem. K. Annual Land Use Census Changes The 2016 Land Use Survey identified differences in locations for gardens only. The gardens identified in sectors NNE, NE, SSW, SW, W, and NNW are farther away than in 2015. A new garden was identified in the WNW sector.
- 3. Radiological Impact to Man and Compliance to 40 CFR 190 Limits A. Dose to Members of the Public at or Beyond Site Boundary Per ODCM Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of the radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases and other nearby uranium fuel cycle sources. The ODCM does not require population doses to be calculated. For purposes of this calculation the following assumptions were made:
Long term annual average meteorology XJQ and D/Q and actual gaseous effluent releases were used. Gamma air dose, Beta air dose, Total Body and Skin doses were attributed to noble gas releases. Critical organ and age group dose attributed to iodine, particulate, carbon-14 and tritium releases. 100 percent occupancy factor was assumed. Dosimetry measurements (minus background levels) obtained from the Radiological Environmental Monitoring Program for the nearest residence to the Independent Spent Fuel Storage Installation (ISFSI) was used to determine direct radiation exposure. The highest doses from the critical organ and critical age group for each release pathway was summed and added to the net dosimetry measurement from nearest residence to the ISFSI for 40CFR 190 compliance. Gaseous Releases (Table 1): The critical age-organ group was the child-bone. Calculated dose was 1.05E+OO mrem, which represents 3.SOE+OO percent of the allowable limits. Carbon-14 represented 99.9% or 1.0SE+OO mrem of the total dose. Liquid Releases (Table 1): The critical age-organ was the adult-liver. Calculated total body dose was 3.80E-04 mrem and organ dose was 4.59E-04 mrem. 40 CFR 190 Compliance (Table 2): The maximum calculated dose to a real individual would not exceed 2.22E-01 mrem (total body), 1.07E+OO mrem (organ), or 2.22E-01 mrem (thyroid). All doses calculated were well below all ODCM and 40 CFR Part 190 limits to a real individual. Page 6
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 1 Summary of Gaseous and Liquid Effluent Doses to Members of the Public at the Highest Dose Receptors Maximum Individual Applicable Estimated Age %of Limit Unit Noble Gas Dose Dose Group Applicable limit Nearest Residence Gamma Air Dose 9.71 E-03 All 4.86E-02 20 mRad Nearest Residence Beta Air Dose 8.58E-03 All 2.15E-02 40 mRad Nearest Residence Total Body 9.21E-03 All 9.21 E-02 10 mrem Nearest Residence Skin 1.79E-02 All 5.97E-02 30 mrem Iodine, Particulate, C-14 & Tritium Vegetation Pathway Bone 1.05E+OO Child 3.50E+OO 30 mrem Liquid LGS Outfall Total Body 3.80E-04 Adult 6.33E-03 6 mrem LGS Outfall Liver 4.59E-04 Adult 2.30E-03 20 mrem Table 2 Summary of Gaseous and Liquid Effluent Doses to Members of the Public for 40CFR190 Compliance 40 CFR 190 Compliance Gaseous Effluents
% of Noble Particulate, Liquid Net Direct Total Applicable Limit Unit Gas Iodine, C-14 Effluents Radiation Limit
& Tritium Total Body Dose 9.21 E-03 2.11 E-01 3.80E-04 O.OOE+OO 2.21 E-01 8.82E-01 25 mrem Organ Dose 1.79E-02 1.05E+OO 4.59E-04 O.OOE+OO 1.07E+OO 4.27E+OO 25 mrem Thyroid Dose 9.21E-03 2.11E-01 3.00E-04 O.OOE+OO 2.21 E-01 2.94E-01 75 mrem B. Dose to Members of the Public Inside the Site Boundary ODCM Control 6.2 also requires that the Annual Effluent Release Report shall include an assessment of the radiation doses from radioactive liquid and gaseous effluents to members of the public due to activities inside the Site Boundary during the report period. MEMBER OF THE PUBLIC shall include all persons not occupationally associated with the plant. This category does not include employees of the utility or contractors. Also excluded from this category are persons who enter the site to service equipment or to make deliveries. This category does include persons who use portions of the site for recreational, occupational education, or other purposes not associated with the plant. A MEMBER OF THE PUBLIC may receive up to 100 mrem in a year (1 OCFR20.1301 ). Areas within the site boundary, where radiation dose of this type could occur include the Limerick Information Center on Longview Road, Frick's Lock on the south shore of the Schuylkill River, and the railroad track that runs along the north shore of the Schuylkill River. The radiation doses to Members of the Public have been estimated using methodology stated in the ODCM. The maximum gaseous dose to members of the public at these locations is based on the following assumptions:
Long term annual average meteorology and actual effluent releases for the sectors encompassing the Railroad Tracks 0N), Information Center, and Frick's Lock. Dose is from ground plane and inhalation only. No ingestion dose is included. The maximum expected occupancy factor is 25% of a working year at all locations. The maximum calculated dose for activities on site was 3.59E-02 mrem at the Rail Road Tracks in the West sector (Table 3). All Doses calculated were a small fraction of the 10 CFR 20.1301 limits. Page 7
SITE: LIMERICK GENERATING STATION"""'" UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 3 Summary of Gaseous Radiation Doses to Members of the Public for Activities on Site Total Body Dose, Organ Dose, Approx. mrem< 1l mrem<1l XJQ D/Q Location Sector Distance Iodine, Iodine, Total s/m"3 1/m"2 (meters) Noble Gas Particulate, Particulate, C-14 & H-3 C-14 & H-3 R.R. Tracks w 225 2.66E-06 2.36E-08 1.09E-02 4.35E-03 2.13E-02 3.59E-02 Info. Center ESE 884 7.32E-07 9.27E-09 2.99E-03 1.20E-03 5.88E-03 1.01E-02 Frick's Lock WSW 450 5.58E-07 4.78E-09 2.81E-03 9.13E-04 4.48E-03 8.20E-03 (1) The limit for sum of the Total Body Dose and Organ Dose = 100 mrem (ref. 1O CFR 20.1301) Page 8
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix A Effluent and Waste Disposal Summary Page 9
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 10
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC LIST OF TABLES PAGE TABLE 1A GASEOUS EFFLUENTS - SUMMATION OF ALL RELEASES 13 TABLE 18-1 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE- BATCH MODE 14 TABLE 1B-:-2 GASEOUS EFFLUENTS - MIXED-LEVEL RELEASE- CONTINUOUS MODE 15 TABLE 2A LIQUID EFFLUENTS- SUMMATION OF ALL RELEASES 16 TABLE 2A-1 LIQUID EFFLUENTS- BATCH MODE 17 TABLE 2A-2 LIQUID EFFLUENTS-CONTINUOUS MODE 18 Page 11
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 12
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 1A GASEOUS EFFLUENTS - SUMMATION OF ALL RELEASES PERIOD 2016 A. Fission And Activation Uncertainty Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Gasses (%} Total Release Ci 1.28E+02 9.51E+OO 6.41E+OO 1.84E+OO 1.46E+02 36.6 Average Release Rate for uCi/sec 1.63E+01 1.21E+OO 8.06E-01 2.32E-01 4.62E+OO Period Dose - Gamma Air Dose mrad 8.64E-03 4.82E-04 5.21E-04 6.75E-05 9.71E-03
- Beta Air Dose mrad 7.94E-03 2.97E-04 3.06E-04 4.14E-05 8.58E-03 Percent of ODCM Limit 8.64E-02 4.82E-03 5.21 E-03 6.75E-04 4.85E-02
- Gamma Air Dose %
- Beta Air Dose % 3.97E-02 1.49E-03 1.53E-03 2.0?E-04 2.15E-02 Uncertainty B. Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total
(%} Total 1-131 Ci <LLD <LLD <LLD <LLD <LLD 20.4 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD <LLD Period Percent of ODCM Limit % * * * *
- Uncertainty C. Particulates Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total
(%} Total Release Ci <LLD <LLD <LLD <LLD <LLD 22.6 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD <LLD Period Percent of ODCM Limit % * * * *
- Uncertainty D. Gross Alpha Units Qtr 1 Qtr2 Qtr3 Qtr4 Total
(%} Total Release Ci <LLD <LLD <LLD <LLD <LLD 22.6 Average Release Rate for uCi/sec <LLD <LLD <LLD <LLD <LLD Period Percent of ODCM Limit % * * * *
- Uncertainty E. Tritium (H-3) Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total
(%) Total Release Ci 2.76E+OO 5.91E+OO 9.19E+OO 7.95E+OO 2.58E+01 15.7 Average Release Rate for uCi/sec 3.52E-01 7.52E-01 1.16E+OO 1.00E+OO 8.17E-01 Period Percent of ODCM Limit % * * * *
- F. Carbon-14 Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total Total Release Ci 7.08E+OO 9.77E+OO 1.06E+01 7.06E+OO 3.45E+01 Average Release Rate for uCi/sec 9.00E-01 1.24E+OO 1.33E+OO 8.88E-01 1.09E+OO Period Percent of ODCM Limit % * * * *
- G. Iodine 131 & 133, Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Particulate, C-14 & H-3 Organ Dose mrem 2.64E-01 2.83E-01 3.94E-01 1.10E-01 1.05E+OO Percent of ODCM Limit % 1.76E+OO 1.89E+OO 2.63E+OO 7.32E-01 3.51E+OO
- ODCM Limit for combined Iodine, Carbon-14, Tritium and particulate only, which is shown in Item G.
Page 13
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 1B-1 GASEOUS EFFLUENTS-MIXED-LEVEL RELEASE-BATCH MODE PERIOD 2016 Fission And Activation Gasses Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Ar-41 Ci NIA NIA NIA NIA NIA Kr-85 Ci NIA NIA NIA NIA NIA Kr-85m Ci NIA NIA NIA NIA NIA Kr-87 Ci NIA NIA NIA NIA NIA Kr-88 Ci NIA NIA NIA NIA NIA Xe-133 Ci NIA NIA NIA NIA NIA Xe-135 Ci NIA NIA NIA NIA NIA Xe-135m Ci NIA NIA NIA NIA NIA Xe-138 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total 1-131 Ci NIA NIA NIA NIA NIA 1-133 Ci NIA NIA NIA NIA NIA 1-135 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Particulates Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Cr-51 Ci NIA NIA NIA NIA NIA Mn-54 Ci NIA NIA NIA NIA NIA Co-58 Ci NIA NIA NIA NIA NIA Co-60 Ci NIA NIA NIA NIA NIA Zn-65 Ci NIA NIA NIA NIA NIA Sr-89 Ci NIA NIA NIA NIA NIA Sr-90 Ci NIA NIA NIA NIA NIA Mo-99 Ci NIA NIA NIA NIA NIA Ag-110m Ci NIA NIA NIA NIA NIA Cs-134 Ci NIA NIA NIA NIA NIA Cs-137 Ci NIA NIA NIA NIA NIA Ba-140 Ci NIA NIA NIA NIA NIA La-140 Ci NIA NIA NIA NIA NIA Ce-141 Ci NIA NIA NIA NIA NIA Ce-144 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA H-3 Ci NIA NIA NIA NIA NIA Gross Alpha Ci NIA NIA NIA NIA NIA C-14 Ci NIA NIA NIA NIA NIA Page 14
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 18-2 GASEOUS EFFLUENTS- MIXED-LEVEL RELEASE - CONTINUOUS MODE PERIOD 2016 Fission And Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Gasses Kr-85m Ci 1.84E+OO 1.65E-01 1.19E-01 3.22E-02 2.16E+OO Kr-85 Ci 1.17E+OO 4.05E-02 2.91 E-01 1.31 E-02 1.51E+OO Kr-87 Ci 2.49E+01 1.74E-01 1.77E-01 3.48E-02 2.53E+01 Kr-88 Ci 2.49E+OO 1.88E-01 2.81 E-01 3.94E-02 3.00E+OO Ar-41 Ci 6.45E+OO 6.46E-01 1.76E-01 1.20E-01 7.40E+OO xe-131m Ci 2.93E-02 1.01 E-03 7.29E-03 3.28E-04 3.80E-02 ~e-133m Ci O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ~e-133 Ci 3.36E+01 3.36E+OO 9.42E-01 6.24E-01 3.86E+01 D<e-135m Ci 2.65E+01 2.47E+OO 1.33E+OO 4.71 E-01 3.07E+01 Xe-135 Ci 2.18E+01 1.90E+OO 1.54E+OO 3.73E-01 2.56E+01 Xe-138 Ci 9.46E+OO 5.64E-01 1.55E+OO 1.32E-01 1.17E+01 Total Ci 1.28E+02 9.51E+OO 6.41 E+OO 1.84E+OO 1.46E+02 Radioiodines Units Qtr 1 Qtr2 Qtr3 Qtr4 Total 1-131 Ci <LLD <LLD <LLD <LLD <LLD 1-133 Ci <LLD <LLD <LLD <LLD <LLD 1-135 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD <LLD <LLD <LLD <LLD Particulates Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Cr-51 Ci <LLD <LLD <LLD <LLD <LLD Mn-54 Ci <LLD <LLD <LLD <LLD <LLD Co-58 Ci <LLD <LLD <LLD <LLD <LLD Co-60 Ci <LLD <LLD <LLD <LLD <LLD Ni-63 Ci <LLD <LLD <LLD <LLD <LLD Zn-65 Ci <LLD <LLD <LLD <LLD <LLD Sr-89 Ci <LLD <LLD <LLD <LLD <LLD Sr-90 Ci <LLD <LLD <LLD <LLD <LLD Mo-99 Ci <LLD <LLD <LLD <LLD <LLD Cs-134 Ci <LLD <LLD <LLD <LLD <LLD Cs-137 Ci <LLD <LLD <LLD <LLD <LLD Ba-140 Ci <LLD <LLD <LLD <LLD <LLD La-140 Ci <LLD <LLD <LLD <LLD <LLD Ce-141 Ci <LLD <LLD <LLD <LLD <LLD Ce-144 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD <LLD <LLD <LLD <LLD H-3 Ci 2.76E+OO 5.91 E+OO 9.19E+OO 7.95E+OO 2.58E+01 Gross Alpha Ci <LLD <LLD <LLD <LLD <LLD C-14 Ci 7.08E+OO 9.77E+OO 1.06E+01 7.06E+OO 3.45E+01 Page 15
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 2A LIQUID EFFLUENTS- SUMMATION OF ALL RELEASES PERIOD 2016 Fission and Activation Products Excluding Uncertainty Tritium, Gasses & Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%} Alpha Total Release Ci <LLD 8.74E-04 <LLD <LLD 8.74E-04 21.1 Average Concentration uCi/ml <LLD 2.03E-08 <LLD <LLD 1.13E-08 Dose -Whole Body mrem NIA 1.04E-08 NIA NIA 1.0SE-08
- Organ mrem NIA 5.48E-06 NIA NIA 5.48E-06
% of ODCM Limit NIA 3.46E-07 NIA NIA 1.73E-07
- Whole Body Dose* %
- Organ Dose* % NIA 5.48E-05 NIA NIA 2.74E-05 Uncertainty Tritium Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%)
Total Release Ci 3.99E-05 4.91 E+OO 3.0SE-04 3.65E-04 4.91E+OO 6.4 V\verage Concentration uCilml 1.41 E-09 1.14E-04 1.24E-06 6.37E-08 6.34E-05 % of ODCM Limit - EGL % 1.41 E-05 1.14E+OO 1.24E-02 6.37E-04 6.34E-01 Dissolved and Entrained Uncertainty Gases Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total (%) Total Release Ci <LLD 4.74E-05 <LLD <LLD 4.74E-05 21.1 V\verage Concentration uCi/ml <LLD 1.10E-09 <LLD <LLD 6.13E-10 % of ODCM Limit - EGL % NIA 2.20E-02 NIA NIA 1.23E-02 Uncertainty Gross Alpha Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%) Total Release Ci NIA <LLD NIA <LLD <LLD 23.0 V\verage Concentration uCi/ml NIA <LLD NIA <LLD <LLD Volume of Waste Uncertainty Released Units Qtr 1 Qtr 2 Qtr3 Qtr4 Total (%) Total Liters 1.13E+06 1.35E+06 1.89E+04 5.68E+04 2.56E+06 5.0 Volume of Dilution Water used during Uncertainty Units Qtr 1 Qtr2 Qtr3 Qtr4 Total (%) period Total Liters 2.73E+07 4.17E+07 2.27E+05 5.68E+06 7.48E+07 5.0
- Percent of limit includes gases and tritium.
Page 16
.,.-------- SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GEf\IERATION COMPANY, LLC TABLE 2A-1 LIQUID EFFLUENTS - BATCH MODE PERIOD 2016 Fission and Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Products NA-24 Ci <LLD <LLD <LLD <LLD <LLD Cr-51 Ci <LLD 3.01E-04 <LLD <LLD 3.01E-04 Mn-54 Ci <LLD 5.80E-05 <LLD <LLD 5.80E-05 Fe-55 Ci <LLD <LLD <LLD I <LLD <LLD Co-58 Ci <LLD 5.81E-05 <LLD <LLD 5.81 E-05 Fe-59 Ci <LLD 3.40E-06 <LLD <LLD 3.40E-06 Co-60 Ci <LLD 3.62E-04 <LLD <LLD 3.62E-04 Zn-65 Ci <LLD 8.29E-05 <LLD <LLD 8.29E-05 Zn-69m Ci <LLD 5.75E-06 <LLD <LLD 5.75E-06 Sr-89 Ci <LLD <LLD <LLD <LLD <LLD Sr-90 Ci <LLD <LLD <LLD <LLD <LLD Zr-95 Ci <LLD <LLD <LLD <LLD <LLD Nb-95 Ci <LLD <LLD <LLD <LLD <LLD Nb-97 Ci <LLD <LLD <LLD <LLD <LLD Mo-99 Ci <LLD <LLD <LLD <LLD <LLD Tc-99m Ci <LLD <LLD <LLD <LLD <LLD Sb-122 Ci <LLD <LLD <LLD <LLD <LLD Sb-124 Ci <LLD <LLD <LLD <LLD <LLD Sb-125 Ci <LLD <LLD <LLD <LLD <LLD 1-131 Ci <LLD <LLD <LLD <LLD <LLD Cs-134 Ci <LLD <LLD <LLD <LLD <LLD Cs-137 Ci <LLD 1.88E-06 <LLD <LLD 1.88E-06 Ba-140 Ci <LLD <LLD <LLD <LLD <LLD La-140 Ci <LLD <LLD <LLD <LLD <LLD Ce-141 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD 8.74E-04 <LLD <LLD 8.74E-04 Dissolved and Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Entrained Gases Kr-87 Ci <LLD <LLD <LLD <LLD <LLD Kr-88 Ci <LLD <LLD <LLD <LLD <LLD Xe-133 Ci <LLD 1.05E-05 <LLD <LLD 1.0SE-05 Xe-133m Ci <LLD <LLD <LLD <LLD <LLD Xe-135 Ci <LLD 3.69E-05 <LLD <LLD 3.69E-05 Xe-135m Ci <LLD <LLD <LLD <LLD <LLD Xe-138 Ci <LLD <LLD <LLD <LLD <LLD Total Ci <LLD 4.74E-05 <LLD <LLD 4.74E-05 H-3 Ci 3.99E-05 4.91E+OO 3.05E-04 3.65E-04 4.91E+OO Gross Alpha Ci <LLD <LLD <LLD <LLD <LLD Page 17
*-,.
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TABLE 2A-2 LIQUID EFFLUENTS - CONTINUOUS MODE PERIOD 2016 Fission and Activation Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Products Cr-51 Ci NIA NIA NIA NIA NIA Mn-54 Ci NIA NIA NIA NIA NIA Fe-55 Ci NIA NIA NIA NIA NIA Co-58 Ci NIA NIA NIA NIA NIA Fe-59 Ci NIA NIA NIA NIA NIA Co-60 Ci NIA NIA NIA NIA NIA Zn-65 Ci NIA NIA NIA NIA NIA Sr-89 Ci NIA NIA NIA NIA NIA Sr-90 Ci NIA NIA NIA NIA NIA Zr-95 Ci NIA NIA NIA NIA NIA Nb-95 Ci NIA NIA NIA NIA NIA Mo-99 Ci NIA NIA NIA NIA NIA Tc-99m Ci NIA NIA NIA NIA NIA Ag-110m Ci NIA NIA NIA NIA NIA 1-131 Ci NIA NIA NIA NIA NIA Cs-134 Ci NIA NIA NIA NIA NIA Cs-137 Ci NIA NIA NIA NIA NIA Ba-140 Ci NIA NIA NIA NIA NIA La-140 Ci NIA NIA NIA NIA NIA Ce-141 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA Dissolved and Units Qtr 1 Qtr2 Qtr3 Qtr4 Total Entrained Gases Xe-131m Ci NIA NIA NIA NIA NIA Xe-133 Ci N/A NIA NIA NIA NIA Xe-135 Ci NIA NIA NIA NIA NIA Total Ci NIA NIA NIA NIA NIA H-3 Ci NIA NIA NIA NIA NIA Gross Alpha Ci NIA NIA NIA NIA NIA Page 18
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix B Solid Waste and Irradiated Fuel Shipments Page 19
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 20
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC A. Solid waste shipped offsite for burial or disposal (not irradiated fuel) 1/1 /16 - 12/31 /16
- 1. Type of waste Tvpe of waste Unit 12 Month Period Estimated Error% I
- a. Spent resin, filters sludges, evaporator bottoms, m3 86.60 25% I etc Ci 1510.00
- b. Dry compressible waste, contaminated 155.04 25%
equipment, etc. 2.43
- c. Irradiated components, control rods, etc. m3 None N/A Ci None I~~
Id. Other (Describe) None N/A I None
- 2. Estimate of Major Nuclide Composition (By Waste Type)
Category A- Spent Resin, Filters, Sludges, Evaporator Bottoms, etc. Waste Class Waste Class A Percent B Percent Isotope Curies* Abundance Curies* Abundance C-14 2.41E+OO 0.34% 2.83E-03 0.01% Mn-54 2.03E+01 2.87% 8.07E-01 0.10% Fe-55 2.71 E+02 38.18% 5.40E+02 67.17% Co-60 3.66E+02 51.56% 2.52E+02 31.35% Ni-59 4.56E-02 0.01% 9.21 E-02 0.01% Ni-63 1.10E+01 1.55% 9.44E+OO 1.17% Zn-65 3.12E+01 4.40% 6.43E-05 0.01% Sr-90 4.61 E-02 0.01% 6.80E-03 0.01% Cs-137 3.83E+OO 0.55% 9.86E-02 0.01% Ce-144 8.05E-01 0.12% 1.22E+OO 0.15% Cs-134 1.42E-01 0.02% O.OOE+OO 0.00% H-3 1.21 E-01 0.02% 2.49E-02 0.01% Co-58 2.61 E+OO 0.37% O.OOE+OO 0.00% TOTALS 7.10E+02 100.00% 8.04E+02 100.00%
- Activity is estimated Page 21
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Category B - Dry Compressible Waste, Contaminated Equipment, etc. Waste Class A Percent Isotope Curies* Abundance Co-60 1.28E+OO 52.76% Cs-137 4.99E-03 0.21% Fe-55 7.36E-01 30.34% Mn-54 1.02E-01 4.20% Ni-63 2.06E-01 8.49% Zn-65 7.60E-02 3.13% Cr-51 2.10E-02 0.87% TOTALS 2.43E+OO 100.00%
- Activity is estimated
- 3. Solid Waste (Disposition)
Number of Shipments Mode of Transportation Destination 23 Truck Energy Solutions Bear Creek Operations Facility to Enerav Solutions I Clive 18 Truck Limerick Gen. Sta. to Energy Solutions I Clive 1 Truck Limerick Gen. Sta. to Waste Control Spec./Texas Comments: 41 Shipments were made from Limerick to Energy Solution Processing Facility for processing 1 Shipments were made from Limerick to TOXCO Processing Facility for processing No solidifications were performed Category A - 19 shipments Type A LSA Category A - 1 shipments > Type A LSA Category A - 4 shipments Type B Category B - 41 shipments Type A LSA Category C - No shipments made Category D - No shipments made B. Irradiated Fuel Shipments (disposition) Number of Shipments Mode of Transportation Destination 0 N/A N/A C. Changes to the Process Control Program There were no revisions to procedure RW-AA-100, "Process Control Program for Radioactive Wastes". Page 22
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix C Meteorological Data Page 23
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 24
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC LIST OF TABLES PAGE Table D - 1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 27 Table D - 2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January - March, 2016 35 Table D - 3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 42 Table D - 4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 49 Table D - 5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July - September, 2016 56 Table D - 6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July - September, 2016 63 Table D - 7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 70 Table D - 8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 77 Table D - 9 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January - December, 2016 83 Table D - 1O Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January - December, 2016 85 Table D - 11 Annual x/Q undepleted and D/Q values for the North Stack, Limerick Generating Station, 2016 87 Table D - 12 Annual x/Q undepleted and D/Q values for the South Stack, Limerick Generating Station, 2016 89 Page 25
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 26
SITE: LIMERICK GENERATING STATION - UNITS 1 &2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January - March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-I (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 0 0 0 0 0 0 0 ENE 0 0 0 0 0 0 0 E 0 0 0 0 0 0 0 ESE 0 0 0 0 0 0 0 SE 0 0 0 0 0 0 0 SSE 0 0 0 0 0 0 0 s 0 1 2 0 0 0 3 SSW 0 3 0 0 0 0 3 SW 0 2 0 0 0 0 2 WSW 0 0 1 0 0 0 1 w 0 0 1 1 0 0 2 WNW 0 0 0 0 0 0 0 NW 0 0 0 1 0 0 1 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0 Total 0 6 4 2 0 0 12 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 54 Page 27
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Extremely Unstable - l 71Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 0 0 0 0 0 0 0 ENE 0 2 0 0 0 0 2 E 0 0 2 0 0 0 2 ESE 0 0 3 1 0 0 4 SE 0 0 0 0 0 0 0 SSE 0 1 0 1 0 0 2 s 0 3 2 0 0 0 5 SSW 0 2 3 0 0 0 5 SW 0 6 6 0 0 0 12 WSW 0 1 15 0 0 0 16 w 0 1 7 0 0 0 8 WNW 0 2 1 1 0 0 4 NW 0 0 0 1 0 0 1 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0
- Total 0 18 39 4 0 0 61 Hours of calm in this stability class: 1 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 13 Page 28
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January - March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 1 2 1 0 0 0 4 NNE 0 1 0 0 0 0 1 NE 1 0 0 0 0 0 1 ENE 0 1 1 0 0 0 2 E 0 0 1 0 0 0 1 ESE 1 1 1 1 0 0 4 SE 0 1 1 0 0 0 2 SSE 0 0 1 0 0 0 1 s 0 0 1 0 0 0 1 SSW 0 2 1 0 0 0 3 SW 0 7 2 0 0 0 9 WSW 0 3 1 0 0 0 4 w 1 3 7 0 0 0 11 WNW 0 6 5 8 0 0 19 NW 0 4 2 10 2 0 18 NNW 0 0 4 0 0 0 4 Variable 0 0 0 0 0 0 0 Total 4 31 29 19 2 0 85 Hours of calm in this stability class: 2 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 13 Page 29
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D -1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 2 3 3 2 0 0 10 NNE 0 5 1 0 0 0 6 NE 1 4 0 0 0 0 5 ENE 3 2 1 0 0 0 6 E 0 2 3 0 0 0 5 ESE 0 0 2 1 0 0 3 SE 1 0 1 0 0 0 2 SSE 0 0 0 1 0 0 1 s '1 1 3 0 0 0 5 SSW 1 3 4 0 0 0 8 SW 0 6 1 0 0 0 7 WSW 1 3 0 0 0 0 4 w 1 4 6 3 2 0 16 WNW 0 3 5 16 1 0 25 NW 1 5 6 20 3 0 35 NNW 1 2 11 2 0 0 16 Variable 0 0 0 0 0 0 0 Total 13 43 47 45 6 0 154 Hours of calm in this stability class: 3 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 30
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 19 25 8 4 0 0 56 NNE 14 19 16 3 0 0 52 NE 16 31 16 0 0 0 63 ENE 17 54 15 0 0 0 86 E 16 34 24 0 0 0 74 ESE 4 8 13 1 0 0 26 SE 5 4 2 1 0 0 12 SSE 5 7 5 1 0 0 18 s 5 12 6 0 0 0 23 SSW 9 14 7 1 0 0 31 SW 11 8 8 0 0 0 27 WSW 8 13 8 2 0 0 31 w 11 30 26 25 5 0 97 WNW 6 50 81 69 4 0 210 NW 8 41 86 48 0 0 183 NNW 7 20 27 9 0 0 63 Variable 0 0 0 0 0 0 0 Total 161 370 348 164 9 0 1052 Hours of calm in this stability class: 11 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 31
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Slightly Stable - 171Ft-26Ft Delta-I (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 12 5 0 0 0 0 17 NNE 10 13 0 0 0 0 23 NE 12 1 0 0 0 0 13 ENE 6 7 0 0 0 0 13 E 11 10 0 0 0 0 21 ESE 2 6 4 0 0 0 12 SE 5 4 4 2 0 0 15 SSE 2 11 2 7 0 0 22 s 13 18 8 0 0 0 39 SSW 14 17 8 0 0 0 39 SW 12 22 6 0 0 0 40 WSW 18 10 3 1 0 0 32 w 18 27 4 0 0 0 49 WNW 12 27 6 1 0 0 46 NW 19 26 7 0 0 0 52 NNW 9 17 1 0 0 0 27 Variable 0 0 0 0 0 0 0 Total 175 221 53 11 0 0 460 Hours of calm in this stability class: 2 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 13 Page 32
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D -1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January - March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 2 0 0 0 0 0 2 NNE 4 2 0 0 0 0 6 NE 9 2 0 0 0 0 11 ENE 5 1 0 0 0 0 6 E 8 3 0 0 0 0 11 ESE 6 3 1 0 0 0 10 SE 4 0 0 0 0 0 4 SSE 3 2 0 0 0 0 5 s 1 0 0 0 0 0 1 SSW 3 2 0 0 0 0 5 SW 16 2 0 0 0 0 18 WSW 17 1 0 0 0 0 18 w 16 3 0 0 0 0 19 WNW 13 5 1 0 0 0 19 NW 7 3 0 0 0 0 10 NNW 5 0 0 0 0 0 5 Variable 0 0 0 0 0 0 0 Total 119 29 2 0 0 0 150 Hours of calm in this stability class: 2 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 33
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-1 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 13 0 0 0 0 0 13 NNE 11 0 0 0 0 0 11 NE 15 0 0 0 0 0 15 ENE 5 0 0 0 0 0 5 E 6 1 0 0 0 0 7 ESE 5 0 0 0 0 0 5 SE 6 1 0 0 0 0 7 SSE 0 0 0 0 0 0 0 s 2 0 0 0 0 0 2 SSW 2 0 0 0 0 0 2 SW 2 0 0 0 0 0 2 WSW 8 1 0 0 0 0 9 w 22 1 0 0 0 0 23 WNW 30 1 0 0 0 0 31 NW 21 1 0 0 0 0 22 NNW 19 0 0 0 0 0 19 Variable 0 0 0 0 0 0 0 Total 167 6 0 0 0 0 173 Hours of calm in this stability class: 12 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 34
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 0 0 0 0 0 0 0 ENE 0 1 1 0 0 0 2 E 0 1 2 0 0 0 3 ESE 0 0 2 2 0 0 4 SE 0 0 0 0 0 0 0 SSE 0 1 0 1 0 0 2 s 0 2 2 2 0 0 6 SSW 0 1 4 4 1 0 10 SW 0 0 5 6 0 0 11 WSW 0 0 4 11 1 0 16 w 0 0 3 3 0 0 6 WNW 0 1 0 0 2 0 3 NW 0 0 0 0 0 0 0 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0 Total 0 7 23 29 4 0 63 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 35
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 1 1 0 1 0 0 3 NNE 0 1 0 0 0 0 1 NE 0 2 0 0 0 0 2 ENE 0 0 2 0 0 0 2 E 1 0 1 0 0 0 2 ESE 0 0 1 1 0 0 2 SE 0 2 2 0 0 0 4 SSE 0 0 1 0 0 0 1 s 0 0 0 1 0 0 1 SSW 0 0 4 2 0 0 6 SW 0 2 4 3 0 0 9 WSW 0 0 2 4 0 0 6 w 1 4 2 6 2 0 15 WNW 0 5 2 1 7 1 16 NW 0 2 0 2 8 1 13 NNW 0 1 1 3 0 0 5 Variable 0 0 0 0 0 0 0 Total 3 20 22 24 17 2 88 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 36
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January - March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 4 2 2 0 0 8 NNE 3 5 1 0 0 0 9 NE 2 3 3 0 0 0 8 ENE 0 1 3 0 0 0 4 E 0 2 2 1 0 0 5 ESE 1 0 1 0 0 0 2 SE 0 2 2 0 0 0 4 SSE 0 0 0 1 0 0 1 s 0 2 3 1 0 0 6 SSW 0 2 4 3 1 0 10 SW 0 1 2 1 0 0 4 WSW 1 1 4 0 0 0 6 w 1 5 0 7 4 2 19 WNW 0 1 2 7 20 6 36 NW 1 2 6 2 10 1 22 NNW 0 0 1 12 0 0 13 Variable 0 0 0 0 0 0 0 Total 9 31 36 37 35 9 157 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 37
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC . Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 7 16 24 7 1 0 55 NNE 4 22 15 7 3 0 51 NE 5 26 28 9 0 0 68 ENE 9 32 45 4 0 0 90 E 8 17 34 12 0 0 71 ESE 4 6 9 8 0 0 27 SE 5 1 4 1 0 0 11 SSE 2 2 7 3 1 0 15 s 4 8 12 8 0 0 32 SSW 3 9 14 7 3 0 36 SW 3 10 4 4 0 0 21 WSW 3 9 13 8 9 0 42 w 3 17 18 30 19 6 93 WNW 7 14 61 100 69 6 257 NW 6 13 35 55 15 3 127 NNW 6 9 13 24 7 0 59 Variable 0 0 0 0 0 0 0 Total 79 211 336 287 127 15 1055 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 8 Hours of missing stability measurements in all stability classes: 13 Page 38
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Slightly Stable - 1 71Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 1 14 5 0 0 0 20 NNE 3 5 13 0 0 0 21 NE 5 7 1 0 0 0 13 ENE 3 10 4 0 0 0 17 E 3 4 9 0 0 0 16 ESE 1 5 3 4 0 0 13 SE 3 2 4 1 2 0 12 SSE 0 6 9 3 5 1 24 s 3 7 19 8 1 0 38 SSW 2 13 20 22 1 0 58 SW 0 17 12 3 2 0 34 WSW 1 7 7 4 0 0 19 w 4 18 23 3 0 0 48 WNW 2 14 36 6 1 0 59 NW 2 11 15 7 0 0 35 NNW 1 9 21 1 0 0 32 Variable 0 0 0 0 0 0 0 Total 34 149 201 62 12 1 459 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 4 Hours of missing stability measurements in all stability classes: 13 Page 39
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 1 2 1 0 0 0 4 NNE 3 4 2 0 0 0 9 NE 2 3 1 O* 0 0 6 ENE 1 3 0 0 0 0 4 E 1 2 0 0 0 0 3 ESE 0 1 1 0 0 0 2 SE 2 2 4 0 1 0 9 SSE 1 1 0 0 0 0 2 s 2 4 2 0 0 0 8 SSW 3 3 1 0 0 0 7 SW 1 7 6 0 0 0 14 WSW 2 5 6 0 0 0 13 w 3 12 3 1 0 0 19 WNW 2 14 6 1 0 0 23 NW 4 10 3 0 0 0 17 NNW 5 4 1 0 0 0 10 Variable 0 0 0 0 0 0 0 Total 33 77 37 2 1 0 150 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 2 Hours of missing stability measurements in all stability classes: 13 Page 40
SITE: LIMERICK GENERATING.STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-2 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January- March, 2016 Limerick Tower 1 Period of Record: January - March 2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 3 1 3 0 0 0 7 NNE 4 2 1 0 0 0 7 NE 3 0 0 0 0 0 3 ENE 4 1 0 0 0 0 5 E 3 1 1 0 0 0 5 ESE 1 3 1 0 0 0 5 SE 0 4 1 0 0 0 5 SSE 5 8 1 0 0 0 14 s 3 9 0 0 0 0 12 SSW 5 8 3 0 0 0 16 SW 6 6 2 0 0 0 14 WSW 4 2 5 2 0 0 13 w 5 9 1 0 0 0 15 WNW 5 16 4 0 0 0 25 NW 12 11 1 0 0 0 24 NNW 6 9 0 0 0 0 15 Variable 0 0 0 0 0 0 0 Total 69 90 24 2 0 0 185 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 13 Page 41
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D- 3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 2 0 0 0 0 2 NNE 1 2 0 0 0 0 3 NE 0 3 0 0 0 0 3 ENE 1 8 0 0 0 0 9 E 0 8 4 0 0 0 12 ESE 0 5 0 1 0 0 6 SE 0 4 1 0 0 0 5 SSE 0 0 0 0 0 0 0 s 2 7 3 2 0 0 14 SSW 0 28 12 0 0 0 40 SW 0 17 3 0 0 0 20 WSW 0 13 3 0 0 0 16 w 0 13 1 2 0 0 16 WNW 0 7 7 6 0 0 20 NW 0 8 9 0 0 0 17 NNW 0 3 1 0 0 0 4 Variable 0 0 0 0 0 0 0 Total 4 128 44 11 0 0 187 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 42
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 4 2 0 0 0 6 NNE 0 7 2 0 0 0 9 NE. 0 4 0 0 0 0 4 ENE 0 3 1 0 0 0 4 E 1 3 2 0 0 0 6 ESE 0 6 1 0 0 0 7 SE 1 2 0 0 0 0 3 SSE 0 2 0 0 0 0 2 s 4 0 0 1 0 0 5 SSW 4 10 1 0 0 0 15 SW 4 9 1 0 0 0 14 WSW 0 8 4 0 0 0 12 w 2 7 9 1 0 0 19 WNW 2 10 3 6 0 0 21 NW 1 8 6 4 3 0 22 NNW 0 3 7 1 0 0 11 Variable 0 0 0 0 0 0 0 Total 19 86 39 13 3 0 160 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 43
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC I Table D-3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-I (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 1 5 4 3 0 0 13 NNE 1 12 0 0 0 0 13 NE 1 3 0 0 0 0 4 ENE 2 2 1 0 0 0 5 E 3 3 2 0 0 0 8 ESE 2 4 1 0 0 0 7 SE 2 0 0 0 0 0 2 SSE 0 2 0 0 0 0 2 s 2 l 0 0 0 0 3 SSW 4 8 3 0 0 0 15 SW 4 7 1 0 0 0 12 WSW 3 12 6 0 0 0 21 w 3 5 6 1 0 0 15 WNW 1 11 6 6 0 0 24 NW 0 9 8 17 2 0 36 NNW 1 5 7 10 0 0 23 Variable 0 0 0 0 0 0 0 Total 30 89 45 37 2 0 203 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 44
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 0-3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 10 16 17 5 0 0 48 NNE 12 20 6 0 0 0 38 NE 17 27 3 0 0 0 47 ENE 24 64 8 0 0 0 96 E 23 68 11 0 0 0 102 ESE 12 20 8 0 0 0 40 SE 7 12 5 0 0 0 24 SSE 8 18 11 0 0 0 37 s 15 28 6 0 0 0 49 SSW 17 21 8 0 0 0 46 SW 20 9 2 0 0 0 31 WSW 15 22 7 0 0 0 44 w 13 17 18 3 1 0 52 WNW 24 13 13 8 3 0 61 NW 15 32 29 17 3 0 96 NNW 8 13 32 7 1 0 61 Variable 0 0 0 0 0 0 0 Total 240 400 184 40 8 0 872 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 7 Page 45
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Slightly Stable - 1 71Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 10 1 0 0 0 0 11 NNE 9 5 1 0 0 0 15 NE 13 5 0 0 0 0 18 ENE 11 6 0 0 0 0 17 E 7 13 3 0 0 0 23 ESE 4 6 1 0 0 0 11 SE 4 6 2 0 0 0 12 SSE 4 18 5 0 0 0 27 s 20 30 0 0 0 0 50 SSW 23 29 0 0 0 0 52 SW 23 10 0 0 0 0 33 WSW 21 18 1 0 0 0 40 w 33 20 2 0 0 0 55 WNW 19 26 4 0 0 0 49 NW 21 15 2 0 0 0 38 NNW 10 4 0 0 0 0 14 Variable 0 0 0 0 0 0 0 Total 232 212 21 0 0 0 4 65 Hours of calm in this stability class: 1 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 46
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 10 0 0 0 0 0 10 NNE 7 0 0 0 0 0 7 NE 8 0 0 0 0 0 8 ENE 12 0 0 0 0 0 12 E 9 1 0 0 0 0 10 ESE 2 0 0 0 0 0 2 SE 4 0 0 0 0 0 4 SSE 4 0 0 0 0 0 4 s 1 0 0 0 0 0 1 SSW 3 1 0 0 0 0 4 SW 4 0 0 0 0 0 4 WSW 6 0 0 0 0 0 6 w 18 4 0 0 0 0 22 WNW 14 3 0 0 0 0 17 NW 19 3 0 0 0 0 22 NNW 8 0 0 0 0 0 8 Variable 0 0 0 0 0 0 0 Total 129 12 0 0 0 0 141 Hours of calm in this stability class: 4 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 7 Page 47
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-3 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 15 0 0 0 0 0 15 NNE 11 0 0 0 0 0 11 NE 11 0 0 0 0 0 11 ENE 9 0 0 0 0 0 9 E 2 1 0 0 0 0 3 ESE 1 0 0 0 0 0 1 SE 0 0 0 0 0 0 0 SSE 0 0 0 0 0 0 0 s 2 0 0 0 0 0 2 SSW 1 0 0 0 0 0 1 SW 1 0 0 0 0 0 1 WSW 5 0 0 0 0 0 5 w 15 0 0 0 0 0 15 WNW 19 6 0 0 0 0 25 NW 16 2 0 0 0 0 18 NNW 14 0 0 0 0 0 14 Variable 0 0 0 0 0 0 0 Total 122 9 0 0 0 0 131 Hours of calm in this stability class: 11 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 48
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TableD-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 2 0 0 0 0 2 NNE 0 1 2 0 0 0 3 NE 0 1 1 0 0 0 2 ENE 0 7 0 0 0 0 7 E 0 9 5 1 0 0 15 ESE 0 5 0 0 0 0 5 SE 0 3 2 0 0 0 5 SSE 0 0 1 1 0 0 2 s 0 3 8 4 1 0 16 SSW 0 5 27 11 0 0 43 SW 0 7 7 3 0 0 17 WSW 0 6 10 1 2 0 19 w 0 8 2 2 1 0 13 WNW 0 3 9 5 5 0 22 NW 0 4 7 2 0 0 13 NNW 0 3 0 0 0 0 3 Variable 0 0 0 0 0 0 0 Total 0 67 81 30 9 0 187 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 49
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TableD-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-I (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 3 2 2 0 0 7 NNE 0 3 5 0 0 0 8 NE 0 6 0 0 0 0 6 ENE 0 1 2 0 0 0 3 E 0 4 1 1 0 0 6 ESE 0 2 0 0 0 0 2 SE 0 3 3 0 0 0 6 SSE 1 1 0 0 0 0 2 s 2 4 1 0 1 0 8 SSW 2 4 9 2 0 0 17 SW 0 4 7 2 1 0 14 WSW 0 5 5 3 0 0 13 w 1 8 7 4 1 0 21 WNW 0 7 5 4 7 5 28 NW 1 3 1 4 0 0 9 NNW 0 1 4 4 1 0 10 Variable 0 0 0 0 0 0 0 Total 7 59 52 26 11 5 160 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 50
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TableD-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 6 3 5 0 0 14 NNE 1 5 8 0 0 0 14 NE 2 0 1 0 0 0 3 ENE 1 4 1 0 0 0 6 E 3 1 2 1 0 0 7 ESE 1 3 1 0 0 0 5 SE 2 0 0 0 0 0 2 SSE 1 2 0 0 0 0 3 s 3 0 1 0 0 0 4 SSW 1 9 5 3 0 0 18 SW 2 5 4 2 0 0 13 WSW 1 5 8 3 1 0 18 w 0 5 6 5 2 0 18 WNW 2 6 5 7 8 3 31 NW 0 7 3 10 8 2 30 NNW 1 2 3 10 1 0 17 Variable 0 0 0 0 0 0 0 Total 21 60 51 46 20 5 203 Hours of calm in this stability class: O Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 51
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 4 10 16 17 0 0 47 NNE 4 11 17 1 0 0 33 NE 8 28 18 1 0 0 55 ENE 7 55 25 5 0 0 92 E 5 41 45 3 0 0 94 ESE 7 19 14 2 0 0 42 SE 3 14 7 0 0 0 24 SSE 6 13 23 7 0 0 49 s 8 17 29 6 1 0 61 SSW 8 14 22 9 3 0 56 SW 7 10 8 4 0 0 29 WSW 8 12 12 8 0 0 40 w 7 14 12 18 2 2 55 WNW 6 23 12 18 11 6 76 NW 7 10 22 23 4 1 67 NNW 5 4 21 20 2 0 52 Variable 0 0 0 0 0 0 0 Total 100 295 303 142 23 9 872 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 7 Page 52
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Slightly Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 3 3 0 0 0 6 NNE 4 5 3 1 0 0 13 NE 2 16 1 0 0 0 19 ENE 2 7 2 0 0 0 11 E 3 7 10 4 0 0 24 ESE 1 1 9 1 0 0 12 SE 0 1 4 0 0 0 5 SSE 2 9 15 3 0 0 29 s 1 16 38 2 0 0 57 SSW 2 21 29 4 0 0 56 SW 6 23 14 1 0 0 44 WSW 1 18 22 3 0 0 44 w 3 16 18 4 0 0 41 WNW 1 30 20 5 0 0 56 NW 3 20 11 1 0 0 35 NNW 1 8 5 0 0 0 14 Variable 0 0 0 0 0 0 0 Total 32 201 204 29 0 0 466 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 53
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 2 7 0 0 0 0 9 NNE 2 2 2 0 0 0 6 NE 4 3 1 0 0 0 8 ENE 0 1 0 0 0 0 1 E 3 2 1 0 0 0 6 ESE 1 2 1 0 0 0 4 SE 3 3 0 0 0 0 6 SSE 1 0 0 0 0 0 1 s 5 3 1 0 0 0 9 SSW 3 4 1 0 0 0 8 SW 1 2 2 0 0 0 5 WSW 2 12 4 0 0 0 18 w 3 8 4 1 0 0 16 WNW 3 14 13 1 0 0 31 NW 5 4 4 0 0 0 13 NNW 1 3 1 0 0 0 5 Variable 0 0 0 0 0 0 0 Total 39 70 35 2 0 0 146 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 54
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-4 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, April - June, 2016 Limerick Tower 1 Period of Record: April - June 2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 1 3 0 0 0 0 4 NNE 1 0 0 0 0 0 1 NE 5 0 0 0 0 0 5 ENE 2 2 1 0 0 0 5 E 3 1 0 0 0 0 4 ESE 0 0 1 0 0 0 1 SE 2 1 0 0 0 0 3 SSE 2 2 0 0 0 0 4 s 7 0 0 0 0 0 7 SSW 3 0 0 0 0 0 3 SW 1 1 2 0 0 0 4 WSW 3 5 1 0 0 0 9 w 0 15 2 0 0 0 17 WNW 10 17 17 4 0 0 48 NW 2 13 3 1 0 0 19 NNW 2 6 0 0 0 0 8 Variable 0 0 0 0 0 0 0 Total 44 66 27 5 0 0 142 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 7 Page 55
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 9 3 0 0 0 12 NNE 0 2 2 0 0 0 4 NE 0 4 4 0 0 0 8 ENE 2 9 3 0 0 0 14 E 1 13 0 0 0 0 14 ESE 0 4 0 0 0 0 4 SE 1 6 0 0 0 0 7 SSE 0 3 0 0 0 0 3 s 0 8 3 0 0 0 11 SSW 2 29 2 0 0 0 33 SW 0 27 3 0 0 0 30 WSW 0 26 2 0 0 0 28 w 1 26 13 0 0 0 40 WNW 2 23 4 0 0 0 29 NW 0 7 6 0 0 0 13 NNW 0 6 6 2 0 0 14 Variable 0 0 0 0 0 0 0 Total 9 202 51 2 0 0 264 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 56
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 1 10 1 0 0 0 12 NNE 0 6 0 0 0 0 6 NE 3 2 1 0 0 0 6 ENE 0 5 2 0 0 0 7 E 1 2 0 0 0 0 3 ESE 1 2 1 0 0 0 4 SE 0 2 0 0 0 0 2 SSE 1 2 0 0 0 0 3 s 0 4 0 0 0 0 4 SSW 1 7 1 0 0 0 9 SW 2 10 0 0 0 0 12 WSW 4 8 6 0 0 0 18 w 1 13 5 0 0 0 19 WNW 2 13 2 0 0 0 17 NW 3 16 23 1 0 0 43 NNW 1 7 8 1 0 0 17 Variable 0 0 0 0 0 0 0 Total 21 109 50 2 0 0 182 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 57
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 2 4 0 0 0 0 6 NNE 1 6 0 0 0 0 7 NE 0 1 1 0 0 0 2 ENE 2 1 1 0 0 0 4 E 1 3 1 0 0 0 5 ESE 1 2 0 0 0 0 3 SE 1 2 0 0 0 0 3 SSE 0 4 0 0 0 0 4 s 1 2 2 0 0 0 5 SSW 10 4 0 0 0 0 14 SW 5 7 0 0 0 0 12 WSW 5 7 1 0 0 0 13 w 9 5 1 0 0 0 15 WNW 6 3 2 0 0 0 11 NW 4 9 21 0 0 0 34 NNW 0 2 10 0 0 0 12 Variable 0 0 0 0 0 0 0 Total 48 62 40 0 0 0 150 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 58
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 9 14 6 1 0 0 30 NNE 17 14 2 0 0 0 33 NE 15 11 3 0 0 0 29 ENE 13 27 20 0 0 0 60 E 8 18 20 6 0 0 52 ESE 2 5 2 0 0 0 9 SE 4 8 2 0 0 0 14 SSE 4 13 2 0 0 0 19 s 9 28 5 0 0 0 42 SSW 14 28 0 0 0 0 42 SW 13 14 0 0 0 0 27 WSW 16 24 0 0 0 0 40 w 19 14 2 0 0 0 35 WNW 15 18 4 0 0 0 37 NW 23 33 11 2 0 0 69 NNW 11 10 7 0 0 0 28 Variable 0 0 0 0 0 0 0 Total 192 279 86 9 0 0 566 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 59
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Slightly Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 8 7 0 0 0 0 15 NNE 9 7 0 0 0 0 16 NE 11 5 0 0 0 0 16 ENE 5 5 0 0 0 0 10 E 5 5 1 0 0 0 11 ESE 4 1 0 0 0 0 5 SE 5 2 0 0 0 0 7 SSE 6 5 0 0 0 0 11 s 19 11 0 0 0 0 30 SSW 34 13 0 0 0 0 47 SW 36 7 0 0 0 0 43 WSW 35 5 0 0 0 0 40 w 36 10 0 0 0 0 46 WNW 28 19 1 0 0 0 48 NW 17 13 2 0 0 0 32 NNW 22 3 0 0 0 0 25 Variable 0 0 0 0 0 0 0 Total 280 118 4 0 0 0 402 Hours of calm in this stability class: 6 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 60
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July - September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 17 0 0 0 0 0 17 NNE 13 1 0 0 0 0 14 NE 12 0 0 0 0 0 12 ENE 12 1 0 0 0 0 13 E 5 2 0 0 0 0 7 ESE 1 0 0 0 0 0 1 SE 3 0 0 0 0 0 3 SSE 1 0 0 0 0 0 1 s 3 0 0 0 0 0 3 SSW 4 2 0 0 0 0 6 SW 13 0 0 0 0 0 13 WSW 13 0 0 0 0 0 13 w 19 3 0 0 0 0 22 WNW 47 8 0 0 0 0 55 NW 32 1 0 0 0 0 33 NNW 21 0 0 0 0 0 21 Variable 0 0 0 0 0 0 0 Total 216 18 0 0 0 0 234 Hours of calm in this stability class: 14 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 61
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-5 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 24 0 0 0 0 0 24 NNE 16 0 0 0 0 0 16 NE 13 0 0 0 0 0 13 ENE 2 0 0 0 0 0 2 E 0 0 0 0 0 0 0 ESE 1 0 0 0 0 0 1 SE 0 0 0 0 0 0 0 SSE 1 0 0 0 0 0 1 s 1 0 0 0 0 0 1 SSW 0 0 1 0 0 0 1 SW 0 0 0 0 0 0 0 WSW 3 0 0 0 0 0 3 w 8 1 0 0 0 0 9 WNW 16 1 0 0 0 0 17 NW 11 0 0 0 0 0 11 NNW 26 0 0 0 0 0 26 Variable 0 0 0 0 0 0 0 Total 122 2 1 0 0 0 125 Hours of calm in this stability class: 22 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 62
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D- 6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July - September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 6 3 2 0 0 11 NNE 0 2 2 0 0 0 4 NE 0 3 6 1 0 0 10 ENE 0 9 3 1 0 0 13 E 0 12 1 0 0 0 13 ESE 0 6 0 0 0 0 6 SE 0 2 2 0 0 0 4 SSE 0 1 3 1 0 0 5 s 0 10 7 4 0 0 21 SSW 0 7 25 5 0 0 37 SW 0 5 19 3 0 0 27 WSW 0 15 14 5 0 0 34 w 0 11 20 5 0 0 36 WNW 0 7 11 0 0 0 18 NW 1 2 6 5 0 0 14 NNW 1 3 5 2 0 0 11 Variable 0 0 0 0 0 0 0 Total 2 101 127 34 0 0 264 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 63
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 1 5 7 1 0 0 14 NNE 0 3 2 0 0 0 5 NE 0 3 2 0 0 0 5 ENE 0 3 1 1 0 0 5 E 0 3 1 0 0 0 4 ESE 1 1 0 0 0 0 2 SE 0 1 2 0 0 0 3 SSE 0 1 1 0 0 0 2 s 0 3 4 0 0 0 7 SSW 0 2 7 2 0 0 11 SW 1 3 7 2 1 0 14 WSW 2 5 6 5 1 0 19 w 0 8 9 3 0 0 20 WNW 3 7 6 5 0 0 21 NW 1 13 16 9 1 0 40 NNW 1 1 4 4 0 0 10 Variable 0 0 0 0 0 0 0 Total 10 62 75 32 3 0 182 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 64
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 1 3 1 0 0 0 5 NNE 0 1 4 0 0 0 5 NE 0 3 1 0 0 0 4 ENE 1 1 2 0 0 0 4 E 1 1 3 1 0 0 6 ESE 0 1 1 0 0 0 2 SE 0 1 1 0 0 0 2 SSE 2 2 4 0 0 0 8 s 1 2 1 2 0 0 6 SSW 4 3 4 2 0 0 13 SW 2 5 9 0 0 0 16 WSW 3 2 1 2 0 0 8 w 4 12 3 0 0 0 19 WNW 4 4 6 2 0 0 16 NW 0 2 10 13 0 0 25 NNW 2 1 5 3 0 0 11 Variable 0 0 0 0 0 0 0 Total 25 44 56 25 0 0 150 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 65
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 5 7 10 3 1 0 26 NNE 6 11 11 1 0 0 29 NE 6 15 16 2 0 0 39 ENE 4 19 18 15 3 0 59 E 5 14 17 10 2 0 48 ESE 3 4 4 0 0 0 11 SE 1 5 9 1 0 0 16 SSE 1 7 16 0 0 0 24 s 2 13 22 9 0 0 46 SSW 2 17 23 4 0 0 46 SW 7 12 12 4 0 0 35 WSW 3 15 11 1 0 0 30 w 9 12 6 1 0 0 28 WNW 8 33 19 5 0 0 65 NW 4 9 22 3 1 0 39 NNW 3 5 11 5 0 0 24 Variable 0 0 0 0 0 0 0 Total 69 198 227 64 7 0 565 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 1 Hours of missing stability measurements in all stability classes: 243 Page 66
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - Septembe.r 2016 Stability Class - Slightly Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 5 8 10 0 0 0 23 NNE 5 5 3 0 0 0 13 NE 6 13 5 0 0 0 24 ENE 2 7 2 0 0 0 11 E 1 5 3 0 0 0 9 ESE 4 0 2 1 0 0 7 SE 1 1 1 0 0 0 3 SSE 2 5 1 0 0 0 8 s 1 21 20 0 0 0 42 SSW 7 28 20 0 0 0 55 SW 1 34 19 0 0 0 54 WSW 0 20 11 1 0 0 32 w 3 23 6 2 0 0 34 WNW 4 26 26 0 0 0 56 NW 4 9 7 2 0 0 22 NNW 5 3 7 0 0 0 15 Variable 0 0 0 0 0 0 0 Total 51 208 143 6 0 0 408 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 67
--
I I SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July- September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 4 7 3 0 0 0 14 NNE 1 5 4 0 0 0 10 NE 2 8 2 0 0 0 12 ENE 7 5 0 0 0 0 12 E 6 3 6 0 0 0 15 ESE 2 0 1 0 0 0 3 SE 3 1 0 0 0 0 4 SSE 0 0 0 0 0 0 0 s 1 0 0 0 0 0 1 SSW 2 3 7 0 0 0 12 SW 2 10 1 0 0 0 13 WSW 3 12 1 0 0 0 16 w 5 12 1 0 0 0 18 WNW 6 26 24 0 0 0 56 NW 5 26 2 1 0 0 34 NNW 4 18 4 0 0 0 26 Variable 0 0 0 0 0 0 0 Total 53 136 56 1 0 0 246 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 2 Hours of missing stability measurements in all stability classes: 243 Page 68
SITE: LIMERICK GENERATING STATION - UNITS 1 &2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-6 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, July - September, 2016 Limerick Tower 1 Period of Record: July - September 2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 5 9 0 0 0 0 14 NNE 4 5 1 0 0 0 10 NE 5 0 2 0 0 0 7 ENE 7 4 0 0 0 0 11 E 3 1 0 0 0 0 4 ESE 2 0 1 0 0 0 3 SE 2 1 0 0 0 0 3 SSE 1 1 0 0 0 0 2 s 2 1 0 0 0 0 3 SSW 0 3 1 1 0 0 5 SW 2 2 0 0 0 0 4 WSW 2 3 0 0 0 0 5 I w 4 5 0 0 0 0 9 WNW 8 9 4 0 0 0 21 NW 8 14 2 0 0 0 24 NNW 9 11 2 0 0 0 22 Variable 0 0 0 0 0 0 0 Total 64 69 13 1 0 0 147 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 243 Page 69
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 0 0 0 0 0 0 0 ENE 0 0 0 0 0 0 0 E 0 0 0 0 0 0 0 ESE 0 0 0 0 0 0 0 SE 0 0 0 0 0 0 0 SSE 0 0 0 0 0 0 0 s 0 0 0 0 0 0 0 SSW 0 3 1 0 0 0 4 SW 0 3 0 0 0 0 3 WSW 0 1 0 0 0 0 1 w 0 0 0 0 0 0 0 WNW 0 0 0 0 0 0 0 NW 0 0 0 0 0 0 0 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0 Total 0 7 1 0 0 0 8 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 70
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D- 7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 1 0 0 0 0 0 1 ENE 0 4 0 0 0 0 4 E 0 2 0 0 0 0 2 ESE 0 0 0 0 0 0 0 SE 0 0 0 0 0 0 0 SSE 0 0 0 0 0 0 0 s 0 0 0 0 0 0 0 SSW 0 1 3 0 0 0 4 SW 0 1 0 0 0 0 1 WSW 0 0 1 0 0 0 1 w 0 2 1 0 0 0 3 WNW 0 0 2 0 0 0 2 NW 0 2 1 0 0 0 3 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0 Total 1 12 8 0 0 0 21 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 71
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 0- 7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 2 0 1 0 0 3 NNE 1 0 0 0 0 0 1 NE 0 1 0 0 0 0 1 ENE 0 2 1 0 0 0 3
,E 0 1 0 0 0 0 1 ESE 1 0 1 0 0 0 2 SE 0 0 0 0 0 0 0 SSE 0 0 1 0 0 0 1 s 1 0 0 0 0 0 1 SSW 1 5 0 0 0 0 6 SW 0 1 0 0 0 0 1 WSW 1 1 1 0 0 0 3 w 0 2 4 1 1 0 8 WNW 1 14 9 3 3 0 30 NW 0 6 3 0 0 0 9 NNW 0 1 2 1 0 0 4 Variable 0 0 0 0 0 0 0 Total 6 36 22 6 4 0 74 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability meas.urements in all stability classes: 370 Page 72
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 0- 7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 12 14 26 6 0 0 58 NNE 4 10 3 0 0 0 17 NE 12 13 0 0 0 0 25 ENE 10 35 1 0 0 0 46 E 17 26 3 0 0 0 46 ESE 11 11 1 0 0 0 23 SE 6 7 1 0 0 0 14 SSE 5 8 3 0 0 0 16 s 3 11 1 0 0 0 15 SSW 6 14 3 0 0 0 23 SW 3 11 2 0 0 0 16 WSW 8 11 1 0 0 0 20 w 6 11 24 17 2 0 60 WNW 13 38 66 63 16 0 196 NW 9 32 72 43 5 0 161 NNW 16 14 40 15 0 0 85 Variable 0 0 0 0 0 0 0 Total 141 266 247 144 23 0 821 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 73
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Slightly Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 12 7 1 0 0 0 20 NNE 11 9 0 0 0 0 20 NE 8 11 0 0 0 0 19 ENE 8 5 0 0 0 0 13 E 8 8 0 0 0 0 16 ESE 3 8 0 0 0 0 11 SE 6 3 0 0 0 0 9 SSE 6 5 0 0 0 0 11 s 9 3 0 0 0 0 12 SSW 15 11 0 0 0 0 26 SW 15 6 0 0 0 0 21 WSW 19 13 1 0 0 0 33 w 25 41 15 0 0 0 81 WNW 22 66 16 0 0 0 104 NW 24 30 12 1 0 0 67 NNW 20 8 2 0 0 0 30 Variable 0 0 0 0 0 0 0 J.; Total 211 234 47 1 0 0 493 Hours of calm in this stability class: 3 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 74
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table 0-,- 7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 7 0 0 0 0 0 7 NNE 8 0 0 0 0 0 8 NE 4 1 0 0 0 0 5 ENE 3 0 0 0 0 0 3 E 3 0 0 0 0 0 3 ESE 3 3 0 0 0 0 6 SE 1 0 0 0 0 0 1 SSE 1 1 0 0 0 0 2 s 2 0 0 0 0 0 2 SSW 3 1 0 0 0 0 4 SW 4 0 0 0 0 0 4 WSW 16 6 0 0 0 0 22 w 28 9 1 0 0 0 38 WNW 27 10 0 0 0 0 37 NW 16 8 1 0 0 0 25 NNW 13 4 0 0 0 0 17 Variable 0 0 0 0 0 0 0 Total 139 43 2 0 0 0 184 Hours of calm in this stability class: 4 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 75
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-7 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 30 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 15 0 0 0 0 0 15 NNE 15 0 0 0 0 0 15 NE 7 0 0 0 0 0 7 ENE 6 0 0 0 0 0 6 E 2 0 0 0 0 0 2 ESE 2 1 0 0 0 0 3 SE 1 0 0 0 0 0 1 SSE 1 0 0 0 0 0 1 s 0 0 0 0 0 0 0 SSW 2 0 0 0 0 0 2 SW 5 0 0 0 0 0 5 WSW 11 1 0 0 0 0 12 w 33 4 0 0 0 0 37 WNW 48 9 0 0 0 0 57 NW 26 2 0 0 0 0 28 NNW 17 0 0 0 0 0 17 Variable 0 0 0 0 0 0 0 Total 191 17 0 0 0 0 208 Hours of calm in this stability class: 22 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 76
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Extremely Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 0 0 0 0 0 0 0 ENE 0 0 0 0 0 0 0 E 0 0 0 0 0 0 0 ESE 0 0 0 0 0 0 0 SE 0 0 0 0 0 0 0 SSE 0 0 0 0 0 0 0 s 0 0 1 1 0 0 2 SSW 0 0 3 0 0 0 3 SW 0 0 3 0 0 0 3 WSW 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 WNW 0 0 0 0 0 0 0 NW 0 0 0 0 0 0 0 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0 Total 0 0 7 1 0 0 8 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 77
SITE: LIMERICK GENERATING STATION - UNITS 1 &2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October- December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Moderately Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 0 0 0 0 0 0 0 NNE 0 0 0 0 0 0 0 NE 1 0 1 0 0 0 2 ENE 0 2 1 0 0 0 3 E 0 1 1 0 0 0 2 ESE 0 0 0 0 0 0 0 SE 0 0 0 0 0 0 0 SSE 0 0 0 0 0 0 0 s 0 0 1 1 1 0 3 SSW 0 1 0 0 1 0 2 SW 0 0 0 0 0 0 0 WSW 0 0 0 1 0 0 1 w 0 0 3 1 0 0 4 WNW 0 0 3 0 0 0 3 NW 0 0 1 0 0 0 1 NNW 0 0 0 0 0 0 0 Variable 0 0 0 0 0 0 0 Total 1 4 11 3 2 0 21 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 78
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Slightly Unstable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 0 1 0 0 1 0 2 NNE 0 1 0 0 0 0 1 NE 0 0 1 0 0 0 1 ENE 0 1 2 0 0 0 3 E 0 2 0 0 0 0 2 ESE 0 0 1 0 0 0 1 SE 0 0 0 0 0 0 0 SSE 0 0 0 1 0 0 1 s 0 1 2 0 0 0 3 SSW 0 3 1 0 0 0 4 SW 1 1 1 0 0 0 3 WSW 0 1 0 1 0 0 2 w 1 3 14 2 2 2 24 WNW 0 3 7 7 2 2 21 NW 0 1 1 0 0 0 2 NNW 0 0 1 3 0 0 4 Variable 0 0 0 0 0 0 0 Total 2 18 31 14 5 4 74 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 79
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC TableD-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Neutral - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 5 6 27 7 2 0 47 NNE 6 7 4 1 0 0 18 NE 7 11 10 0 0 0 28 ENE 6 23 26 0 0 0 55 E 9 13 18 1 0 0 41 ESE 3 10 6 0 0 0 19 SE 3 7 5 0 0 0 15 SSE 0 3 7 2 0 0 12 s 5 8 14 6 1 0 34 SSW 2 4 6 7 1 0 20 SW 4 5 9 0 0 0 18 WSW 2 2 4 1 0 0 9 w 6 8 21 39 33 20 127 WNW 4 25 45 68 38 20 200 NW 3 9 29 44 10 2 97 NNW 9 7 21 33 10 0 80 Variable 0 0 0 0 0 0 0 Total 74 148 252 209 95 42 820 Hours of calm in this stability class: 1 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 80
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Slightly Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total
---------
N 2 9 6 1 0 0 18 NNE 1 5 7 1 0 0 14 NE 5 8 4 0 0 0 17 ENE 2 13 5 1 0 0 21 E 2 7 3 0 0 0 12 ESE 3 6 6 0 0 0 15 SE 1 4 6 0 0 0 11 SSE 1 5 2 0 0 0 8 s 2 9 7 0 0 0 18 SSW 1 16 12 0 0 0 29 SW 4 13 14 1 1 0 33 WSW 1 8 6 0 0 0 15 w 7 11 28 21 0 0 67 WNW 2 43 70 17 2 0 134 NW 4 13 22 10 0 0 49 NNW 6 13 14 0 0 0 33 Variable 0 0 0 0 0 0 0 Total 44 183 212 52 3 0 494 Hours of calm in this stability class: 2 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 81
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October- December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stability Class - Moderately Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 8-12 13-18 19-24 > 24 Total N 6 7 2 0 0 0 15 NNE 1 3 0 0 0 0 4 NE 3 1 0 0 0 0 4 ENE 2 6 0 0 0 0 8 E 3 5 2 0 0 0 10 ESE 2 3 1 0 0 0 6 SE 0 3 1 0 0 0 4 SSE 0 2 0 0 0 0 2 s 2 2 1 0 0 0 5 SSW 0 6 0 0 0 0 6 SW 0 9 2 0 0 0 11 WSW 0 10 5 0 0 0 15 0 7 14 0 0 0 21 WNW 1 10 24 5 0 0 40 NW 1 13 13 0 0 0 27 NNW 4 2 4 0 0 0 10 Variable 0 0 0 0 0 0 0 Total 25 89 69 5 0 0 188 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 82
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D-8 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, October - December, 2016 Limerick Tower 1 Period of Record: October - December2016 Stabilit~ Class - Extremely Stable - 171Ft-26Ft Delta-T (F) Winds Measured at 175 Feet Wind Speed (in mph) Wind Direction 1-3 4-7 *8-12 13-18 19-24 > 24 Total
---------
N 4 3 1 0 0 0 8 NNE 1 3 1 0 0 0 5 NE 5 3 1 0 0 0 9 ENE 2 4 1 0 0 0 7 E 5 4 0 0 0 0 9 ESE 1 2 1 0 0 0 4 SE 0 1 0 0 0 0 1 SSE 1 2 0 0 0 0 3 s 2 1 1 0 0 0 4 SSW 3 5 1 0 0 0 9 SW 3 3 1 0 0 0 7 WSW 4 9 3 0 0 0 16 w 5 25 7 0 0 0 37 WNW 3 35 35 2 0 0 75 NW 6 10 8 0 0 0 24 NNW 3 8 1 0 0 0 12 Variable 0 0 0 0 0 0 0 Total 48 118 62 2 0 0 230 Hours of calm in this stability class: 0 Hours of missing wind measurements in this stability class: 0 Hours of missing stability measurements in all stability classes: 370 Page 83
SITE: LIMERICK GENERATING STATION- UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 9 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January - December, 2016 Limerick Tower 1 January-December, 2016 30 ft. Wind Speed and Direction 171Ft-26Ft Delta-T (F) Number of Observations = 8028 Values are Percent Occurrence SPEED WIND DIRECTION CLASSES ---------------------------------- STABILITY CLASSES CLASS N NNE NE ENE E ESE SE SSE S SSW SW WSW w WNW NW NNW TOTAL EU MU SU N SS MS ES TOTAL EU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 CSU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 A N 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 L SS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 M MS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 EU 0.00 0.01 0.00 0.04 0.01 0.00. 0.01 0.00 0.02 0.02 0.00 0.00 0.01 0.02 0.00 0.00 0.16 0.16 MU 0.02 0.00 0.06 0.00 0.02 0.02 0.01 0.01 0.05 0.06 0.07 0.05 0.05 0.05 0.05 0.01 0.56 0.56 1 SU 0.06 0.04 0.02 0.09 0.05 0.05 0.05 0.00 0.06 0.20 0.11 0.12 0.16 0.10 0.06 0.02 1.21 1.21 N 0.62 0.59 0.75 0.80 0.80 0.36 0.27 0.27 0.40 0.57 0.59 0.59 0.61 0.72 0.69 0.52 9.14 9.14 3 SS 0.52 0.49 0.55 0.37 0.39 0.16 0.25 0.22 0.76 1.07 1.07 1.16 1.40 1.01 1.01 0. 76 11.19 11.19 MS 0.45 0.40 0.41 0.40 0.31 0.15 0.15 0.11 0.09 0.16 0.46 0.65 1.01 1.26 0.92 0.59 7.51 7.51 ES 0.83 0.66 0.57 0.27 0.12 0.11 0.09 0.02 0.06 0.06 0.10 0.34 0.97 1.41 0.92 0.95 7.50 7.50 37.27 EU 0.14 0.05 0.09 0.24 0.26 0.11 0.12 0.05 0.22 0.77 0.66 0.51 0.50 0.40 0.19 0 .11 4.42 4.42 MU 0.20 0.17 0.07 0.16 0.09 0.11 0.06 0.05 0.05 0.25 0.34 0.24 0.31 0.36 0.37 0.12 2. 96 2.96 4 SU 0.17 0.29 0.11 0.09 0.11 0.07 0.02 0.07 0.05 0.25 0.26 0.29 0.20 0.39 0.36 0.12 2.86 2.86
- N 0.86 0.78 1.02 2.24 1. 82 0.55 0.39 0.57 0.98 0.96 0.52 0.87 0.90 1.48 1.72 0. 71 16.38 16.38 7 SS ~.25 0.42 0.27 0.29 0.45 0.26 0.19 0.49 0.77 0.87 0.56 0.57 1.22 1.72 1.05 0.40 9.78 '"9. 78 MS 0.00 0.04 0.04 0.02 0.07 0.07 0.00 0.04 0.00 0.07 0.02 0.09 0.24 0.32 0.19 0.05 1.27 1. 27 ES 0.00 0.00 0.00 0.00 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.02 0.07 0.21 0.06 0.00 0.42 0.42 38.10 EU 0.04 0.02 0.05 0.04 0.07 0.04 0.01 0.00 0.10 0.22 0.15 0.25 0.26 0.15 0.19 0.09 1.68 1.68 MU 0.05 0.02 0.01 0.05 0.04 0.04 0.01 0.01 0.01 0.07 0.04 0.15 0.27 0.15 0.40 0.24 1.57* 1.57 SU 0.09 0.01 0.01 0.05 0.07 0.05 0.01 0.01 0.06 0.09 0.02 0.10 0.21 0.27 0.47 0.37 1.92 1. 92
- N 0.71 0.34 0.27 0.55 0.72 0.30 0.12 0.26 0.22 0.22 0.15 0.20 0.87 2.04 2.47 1.32 10.77 10.77 1 SS O.Dl 0.01 0.00 0.00 0.05 0.06 0.07 0.09 0.10 0.10 0.07 0.06 0.26 0.34 0.29 0.04 1. 56 1. 56 2 MS 0.00 0.00 O:OO 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.05 0.05 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 17.56 EU 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.01 0.02 0.00 0.00 0.00 0.02 0.09 0.01 0.02 0.21 0.21 1 MU 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.17 0.19 0.02 0.42 0.42 3 SU 0.07 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.06 0.31 0.46 0.16 1.10 1.10
- N 0.20 0.04 0.00 0.00 0.07 0.01 0.01 0.01 0.00 0.01 0.00 0.02 0.56 1.74 1.37 0.39 4.45 4.45 1 SS 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.09 0.00 0.00 0.00 0.01 0.00 0.01 0.01 o. oo* 0.15 0.15 8 MS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.33 Page 83
*-------- ~~~~~~-~~~~~~~.~~~~~~~~~~~~~~~~~~~~~~-!
SITE: LIMERICK GENERATING STATION- UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 9 Wind Speed by Direction Measured at 30 Feet for Various Stability Classes for the Limerick Generating Station, January- December, 2016 Limerick Tower 1 January-December, 2016 30 ft. Wind Speed and Direction 171Ft-26Ft Delta-T (F) STABILITY CLASSES SPEED ---------------------------------- WIND DIRECTION CLASSES SW .WSW w WNW NW NNW TOTAL EU MU SU N SS MS ES TOTAL CLASS N NNE NE ENE E ESE SE SSE S SSW 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 EU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 o.oo 0.06 0.06 1 MU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.04 0.05 0.06 0.00 0.15 0.15 9 SU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.10 0.29 0.10 0.01 0.50 0.50 - N 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.00 0.00 0.00 2 SS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo. 0.00 0.00 0.00 0.00 0.00 0.00 4 MS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00
- 0. 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.00 0.00 0.00 EU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 G MU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.00 0.00 0.00 TSU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 N 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.00 0.00 0.00 2 SS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.00 4 MS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.00 0.00 0.00 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 TOT 5.31 4.38 4.32 5.69 5.57 2.62 1.91 2.42 4.06 6.07 5.21 6.29 10.34 15.10 13.68 7.04 99.99 6.48 5.58 7.24 41.24 22.67 8.83 7.95 99.99 Wind Direction by Stability ENE ESE SE SSE s SSW SW WSW w WNW NW NNW TOTAL -STABILITY CLASSES-N NNE NE E 0.31 0.35 0.17 0.15 0.06 0.37 1. 02 0.81 0.76 0.80 0.66 0.39 0.22 6.48 Extremely Unstable 0.17 0.09 0.14 0.21 0.15 0.19 0.09 0.07 0.12 0.39 0.45 0.44 0.65 0.73 1. 07 0.40 5.58 Moderately Unstable 0.27 0.20 0.15 0.24 0.19 0.09 0.10 0.17 0.54 0.40 0.51 0.67 1.12 1. 42 0.69 7.24 Slightly Unstable 0.40 0.34 0.15 0.22 2.04 3.59 3.41 1.22 0.80 1.12 1. 61 1. 77 1.26 1. 68 3.04 6.28 6.34 2.95 41. 24 Neutral 2.39 1.74 0.82 0.66 o.88 'o.49 0.54 0.88 1.63 2.04 1. 71 1. 81 2.88 3.08 2.35 1.20 22.67 Slightly Stable 0.78 0.92 0.42 0.39 0.24 0.15 0.15 0.09 0.24 0.49 o. 73 1.26 1.59 1.12 0.64 8.83 Moderately Stable 0.45 0.44 0.45 0.27 0.15 0.12 0.10 0.02 0.06 0.07 0.10 0.36 1.05 1.63 0.98 0.95 7.95 Extremely Stable 0.83 0.66 0.57 Wind Direction by Wind Speed N NNE NE ENE E ESE SE SSE s SSW SW WSW w WNW NW NNW TOTAL -WIND SPEED CLASSES-0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 C A L M 0.00 0.00 0.86 0.83 0.65 1.44 2.15 2.40 2.90 4.21 4.57 3.65 2.85 37.27 < 3.5 mph 2.52 2.18 2.37 1. 97 1. 71 3.04 2.83 1. 20 0.80 1. 27 2.08 3.18 2.37 2.59 3.44 4.88 3.94 1. 52 38.10 3.6 - 7.5 mph
- 1. 62 1. 76 1. 61 0.69 0.96 0.50 0.24 0.37 0.50 0. 72 0. 44 0.76 1. 89 2. 96 3.82 2.06 17.56 7.6 - 12.5 mph 0.90 0.41 0.35 0.00 0.07 0.06 0.04 0.12 0.04 0.01 0.00 0.04 0.66 2.33 2.04 0.60 6.33 12.6 - 18.5 mph 0.27 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14 0.34 0.22 0.01 0. 71 18.6 - 24.5 mph 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 > 24.5 mph 0.00 0.00 0.00 Page 84
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 1OWind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January - December, 2016 Limerick Tower 1 January-December, 2016 175 ft. liind Speed and Direction 171Ft-26Ft Delta-T (F) Number of Observations = 8130 Values are Percent Occurrence SPEED ---------------------------------- WIND DIRECTION CLASSES STABILITY CLASSES CLASS N NNE NE ENE E ESE SE SSE S SSW SW WSW w WNW NW NNW TOTAL EU MU SU N SS MS ES TOTAL EU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 C SU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 A N 0.00 0.00 0.00 0.00 0.00 0~00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 L SS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 M MS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0:00 0.00 0.00 EU 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 MU 0.02 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.02 0.02 0.04 0.02 0.01 0.26 0.26 1 SU 0.01 0.05 0.05 0.02 0.05 0.02 0.02 0.04 0.05 0.06 0.06 0.06 0.07 0.07 0.01 0.04 0.70 0.70 - N 0.26 0.25 0.32 0.32 0.33 0.21 0.15 0.11 0.23 0.18 0.26 0.20 0.31 0.31 0.25 0.28 3.96 3.96 3 SS 0.10 0.16 0.22 0.11 0.11 0.11 0.06 0.06 0.09 0.15 0.14 0.04 0.21 0.11 0.16 0.16 1. 98 1. 98 MS 0.16 0.09 0.14 0.12 0.16 0.06 0.10 0.02 0.12 0.10 0.05 0.09 0.14 0.15 0.18 0.17 1. 85 1. 85 ES 0.16 0.12 0.22 0.18 0.17 0.05 0.05 0.11 0.17 0.14 0.15 0.16 0.17 0.32 0.34 0.25 2.77 2.77 11.54 EU 0.10 0.04 0.05 0.21 0.27 0.14 0.06 0.02 0.18 0.16 0.15 0.26 0.23 0.14 0.07 0;07 2 .15 2.15 MU 0 .11 0.09 0.14 0.07 0.10 0.04 0.07 0.02 0.09 0.09 0.11 0.12 0.25 0.23 0.22 0.04 1.-78 1. 78 4 SU 0.17 0.15 0.07 0.09 0.07 0.05 0.04 0.05 0.06 0.21 0.15 0.11 0.31 0.17 0.15 0.04 1. 88 1. 88 - N 0.48 0.63 0.98 1.59 1.05 0.48 0.33 0.31 0.57 0.54 0.46 0.47 0.63 1.17 0.50 0.31 10 .48 10.48 7 SS 0.42 0.25 0.54 0.46 0.28 0.15 0.10 0.31 0.65 0.96 1.07 0.65 0.84 1.39 0.65 0.41 9.11 9.11 MS 0.28 0.17 0.18 0.18 0.15 0.07 0.11 0.04 0.11 0.20 0.34 0.48 0.48 0.79 0.65 0.33 4.58 4.58 ES 0.20 0.12 0.04 0.14 0.09 0.06 0.09 0.16 0.14 0.20 0.15 0.23 0.66 0.95 0.59 0.42 4.22 4.22 34.21 EU 0.04 0.05 0.0~ 0.05 0.10 0.02 0.05 0.05 0.22 0.73 0.42 0.34 0.31 0.25 0.16 0.06 2.93 2.93 MU 0.11 0.09 0.04 0.07. 0.05 0.01 . 0.09 0.02 0.07 0.25 0.22 0.16 0.26 0.20 0.22 0.11 1.97 1.97 8 SU 0.07 0.16 0.07 0.10 0.09 0.05 0.04 0.05 0.09 0.17 0.20 0.16 0.28 0.25 0.25 0.12 2.14 2.14 - N 0.95 0.58 0.89 1. 40 1. 40 0.41 0.31 0.65 0.95 0.80 0.41 0.49 0.70 1. 69 1. 33 0.81 13.75 13.75 1 SS 0.30 0.32 0.14 0.16 0.31 0.25 0.18 0.33 1.03 1.00 0. 73 0.57 0.92 1.87 0.68 0.58 9.35 9.35 2 MS 0.07 0.10 0.05 0.00 0.11 0.05 0.06 0.00 0.05 0.11 0.14 0.20 0.27 0.82 0.27 0.12 2.42 2.42 ES 0.05 0.04 0.04 0.02 0.01 0.05 0.01 0.01 0.01 0.06 0.06 0 .11 0 .12 0.74 0.17 0.04 1.55 1.55 34 .11 EU 0.02 0.00 0.01 0.01 0.01 0.02 0.00 0.04 0.14 0.25 0.15 0.21 0.12 0.06 0.09 0.02 1.16 1.16 1 MU 0.05 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.02 0.07 0.09 0.16 0.17 0.12 0.18 0.14 1. 05 1. 05 3 SU 0.09 0.00 0.00 0.00 0.04 0.00 0.00 0.02 0.04 0.10 0.04 0.07 0.17 0.28 0.31 0.34 1. 50 1. 50 - N 0.42 0.12 0.15 0.30 0.32 0.12 0.02 0.15 0.36 0.33 0.15 0.22 1.08 2.35 1.54 1. 01 8.63 8.63 1 SS 0.01 0.02 0.00 0.01 0.05 0.07 0.01 0.07 0.12 0.32 0.06 0.10 0.37 0.34 0.25 0.01 1.83 1. 83 8 MS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.09 0.01 0.00 0.12 0.12 ES 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.00 0.07 0.01 0.00 0.12 0.12 14.42 Page 85
SITE: LIMERICK GENERATING STATION- UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 10 Wind Speed by Direction Measured at 175 Feet for Various Stability Classes for the Limerick Generating Station, January - December, 2016 Limerick Tower 1 January-December, 2a16 175 ft. Wind Speed and Direction 171Ft-26Ft Delta-T (F) SPEED ---------------------------------- WIND DIRECTION CLASSES STABILITY CLASSES CLASS N NNE NE ENE .E ESE SE SSE S SSW SW WSW w WNW NW NNW TOTAL EU MU SU N SS MS ES TOTAL EU a.aO a.aa a.aO a.aa a.oa a.ao a.ao a.aa a.al a.al a.oa a.a4 a.al o.a9 o.oa a.ao a.16 a.16 1 MU a.aa a.oa a.aa a.aa a.aa a.ao a.aa a.aa a.a2 a.01 a.a2 o.al o.a4 0.17 0.11 a.al a.41 a.41 9 SU a.al a.aa a.aa o.aa a.aa o.aa a.aa o.aa a.aa 0.01 a.oo 0.01 a.1a 0.37 a.22 a.al a.74 a.74 - N 0.05 0.04 0.00 a.04 o.a2 a.oa a.oo a.01 a.a2 o.a9 a.ao 0.11 a.66 1. 45 a.37 0.23 3.10 3.10 2 SS O.aa O.ao O.Oa 0.00 o.aa o.oa a.a2 a.a6 a.al a.al 0.04 o.oa 0.00 0.04 o.ao a.aa a.18 a.18 4 MS a.aa a.aa a.aa O.aa o.ao a.oa a.al a.oo a.oo o.aa o.ao o.aa 0.00 o.ao a.oa a.oo a.al 0.01 ES a.aa O.aa O.aa a.Oa o.aa 0.00 o.oa 0.00 a.oo a.aa 0.00 o.oa 0.00 o.ao 0.00 o.ao o.aa a.aa 4.6a EU O.aa O.ao O.Oa O.aa O.aO O.aa 0.0a a.aa a.ao O.aa O.aa a.aa 0.00 a.aa O.Oa a.aa a.aa a.aa G MU a.aa o.aa a.aa a.aa a.aa a.aa o.ao o.ao o.aa a.ao a.oo a.oo a.oa 0.07 a.al a.oo 0.09 a.a9 T SU a.ao o.aa a.aa o.ao a.oa a.ao o.ao a.ao o.aa o.oa a.oa a.ao a.as 0.14 a.a4 0.00 a.22 0.22 N a. ao a.aa a.aa a.ao a.oa a.aa a.ao a.aa a.oa o.oa o.aa a.aa a.34 0.39 a.a7 o.oa 0.81 a.81 2.ss a.oo a.aa a.ao a.aa a.aa a.aa a.aa a.al a.aa o.ao a.ao a.ao a.aa o.oa a.aa 0.00 o.al a.al 4 MS a.aa a.aa a.oa a.aa o.aa o.oa a.aa a.oa a.ao a.aa o.aa o.aa a.ao a.aa a.aa a.aa a.aa o.aa ES a.oa a.oa a.aa o.oa a.ao a.aa a.aa a.aa o.aa a.oo a.oa a.ao a.oa a.oa o.ao a.aa a.oa 0.00 1.13 TOT 4.71 3.62 4.43 5.67 5.36 2.52 1.99 2.76 5.66 7.33 5.79 5.88 10.33 17.68 la.11 6.16 laa.aa 6.42 5.55 7.18 40.74 22.47 8.98 *8.66 1aa.OO Wind.Direction by Stability N NNE NE ENE E ESE SE SSE S SSW SW WSW W WNW NW NNW TOTAL -STABILITY CLASSES-a.16 a.a9 0.15 0.27 a.38 a.18 a.11 a.11 0.55 1.14 a.71 a.85 a.68 a.53 a.33 0.17 6.42 Extremely Unstable a.3a a.17 0.18 0.16 0.17 0.07 0.16 0.06 0.23 0.44 0.46 0.48 0.74 0.84 0.77 0.31 5.55 Moderately Unstable 0.36 a.36 a.20 0.21 0.25 0.12 0.10 0.16 a.23 0.55 0.44 0.42 0.98 1.28 0.97 0.55 7.18 Slightly Unstable 2.15 1.61 2.34 3.64 3.12 1. 22 a.81 1.23 2.13 1. 94 1.27 1.49 3.73 7.36 4.06 2.64 40.74 Neutral a.82 0.75 0.90 a.74 0.75 0.58 0.38 0.85 1.91 2.44 2.03 1. 35 2.34 3.75 1. 73 1.16 22.47 Slightly Stable 0.52. a.36 a.37 0.31 0.42 0.18 0.28 0.06 0.28 0.41 0.53 a.76 0.91 1.85 1.12 0.63 8.98 Moderately Stable 0.41 a.28 0.30 a.34 0.27 0.16 0.15 0.28 0.32 0.41 0.36 0.53 0.96 2.08 1.12 0.70 8.66 Extremely Stable Wind Direction by Wind Speed N NN_E NE ENE E ESE SE SSE s SSW SW WSW W WNW NW NNW. TOTAL -WIND SPEED CLASSES-o.aa a.oo *a.ao 0.00 0.00 o.oa 0.00 0.00 0.00 0.00 0.00 0.00 a.oo a.oo o.oa 0.00 o.oo C A L M
- 0. 71 a.66 0.96 0. 76 0.84 0.47 0.38 0.36 0.69 0.65 0.66 0.57 0. 92 1. 00 0.98 0,92 11.54 < 3.5 mph
- 1. 76 1.44 2.aa 2.73 2.00 0.98 0.80 0.91 1.80 2.35 2.42 2.32 3.39 4.83 2.84 1. 61 34.21 3.6 - 7.5 mph 1.59 1. 33 1. 3a 1. 81 2.07 0.84 0.74 1.12 2.42 3.11 2.16 2.03 2.87 5.81 3.08 1. 85 34 .11 7.6 - 12.5 mph 0.59 a.15 a.16 0.33 0.43 0.23 0.04 0.28 0.68 1. 08 0.48 0.79 1. 94 3.32 2.39 1. 53 14.42 12.6 - 18.5 mph 0.06 0.04 a.oo 0.04 0.02 0.00 0.04 0.07 0.07 0.14 0.06 0.17 0.81 2.12 0.70 0.26 4.60 18.6 - 24.5 mph o.aa a.ao o.oa 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.39 0.60 0.12 0.00 1.13 > 24.5 mph Page 86
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 11 Annual x/Q and D/Q values for the North Stack, Limerick Generating Station, 2016 Limerick Generating Station x!Q and D/Q values North Stack - Flow =316000 cfm Stack ID Location Direction Ranqe (m) X/Q (s/m"3) Undeoleted D/Q (1/m"2) N Site Boundary s 762 1.33E-07 1.67E-09 N Site Boundary SSW 762 9.11 E-08 8.34E-10 N Site Boundary SW 884 6.57E-08 6.58E-10 N Site Boundary WSW 854 1.28E-07 1.27E-09 N Site Boundary w 854 1.45E-07 1.54E-09 N Site Boundary WNW 793 7.31E-08 8.24E-10 N Site Boundary NW 762 5.03E-08 5.28E-10 N Site Boundary NNW 884 7.40E-08 7.43E-10 N Site Boundary N 884 1.00E-07 1.10E-09 N Site Boundary NNE 793 1.72E-07 2.26E-09 N Site Boundary NE 793 1.25E-07 1.65E-09 N Site Boundary ENE 793 1.53E-07 2.01E-09 N Site Boundary E 762 3.37E-07 4.55E-09 N Site Boundary ESE 762 6.22E-07 8.85E-09 N Site Boundary SE 762 5.88E-07 8.50E-09 N Site Boundary SSE 1006 1.55E-07 2.10E-09 N RR-Inf-Lek-NG s 300 5.55E-07 6.12E-09 N RR-Inf-Lek-NG SSW 225 6.71 E-07 4.47E-09 N RR-Inf-Lek-NG SW 225 5.64E-07 3.81 E-09 N RR-Inf-Lek-NG WSW 345 4.86E-07 3.90E-09 N RR-Inf-Lek-NG w 225 1.20E-06 8.66E-09 N RR-Inf-Lek-NG WNW 345 2.52E-07 2.38E-09 N RR-Inf-Lek-NG NW 450 1.04E-07 1.02E-09 N RR-Inf-Lek-NG ESE 884 5.12E-07 7.12E-09 N RR-Inf-Lek-NG WSW 450 3.06E-07 2.79E-09 N RR-Inf-Lek-NG NNE 682 1.99E-07 2.68E-09 N Inhalation N 948 9.42E-08 1.01 E-09 N Inhalation NNE 825 1.66E-07 2.16E-09 N Inhalation NE 1057 1.01 E-07 1.20E-09 N Inhalation ENE 985 1.35E-07 1.57E-09 N Inhalation E 873 2.95E-07 3.82E-09 N Inhalation ESE 1047 4.17E-07 5.85E-09 N Inhalation SE 1202 3.33E-07 4.47E-09 N Inhalation SSE 1647 9.56E-08 1.16E-09 N Inhalation s 1325 7.07E-08 8.89E-10 N Inhalation SSW 1543 4.50E-08 4.47E-10 N Inhalation SW 991 5.71 E-08 5.90E-10 N Inhalation WSW 1158 9.17E-08 9.60E-10 N Inhalation w 1105 1.08E-07 1.16E-09 Page 87
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 11 Annual x/Q and D/Q values for the North Stack, Limerick Generating Station, 2016 Limerick Generating Station x/Q and D/Q values North Stack - Flow =316000 cfm Stack ID Location Direction Ranoe (m) X/Q (s/m"3) Undeoleted D/Q (1/m"2) N Inhalation WNW 1123 4.91 E-08 5.60E-10 N Inhalation NW 1104 3.45E-08 3.48E-10 N Inhalation NNW 1540 5.59E-08 3.94E-10 N Vegetation N 1016 8.91 E-08 9.38E-10 N Vegetation NNE 3779 1.73E-07 3.46E-10 N Vegetation NE 5096 1.95E-07 2.01E-10 N Vegetation ENE 4331 2.03E-07 2.67E-10 N Vegetation E 3573 2.16E-07 5.89E-10 N Vegetation ESE 1371 3.33E-07 4.23E-09 N Vegetation SE 7113 9.93E-08 3.41E-10 N Vegetation SSE 2107 8.72E-08 8.46E-10 N Vegetation s 1860 5.77E-08 6.26E-10 N Vegetation SSW 1747 4.40E-08 3.96E-10 N Vegetation SW 1995 4.53E-08 3.49E-10 N Vegetation WSW 1374 7.98E-08 8.66E-10 N Vegetation w 2708 7.79E-08 4.54E-10 N Vegetation WNW 6529 2.15E-08 6.89E-11 N Vegetation NW 2499 2.70E-08 1.43E-10 N Vegetation NNW 1973 5.50E-08 2.89E-10 N Meat N 7551 6.73E-08 9.15E-11 N Meat NNE 8015 7.98E-08 1.06E-10 N Meat NE 4287 1.76E-07 2.39E-10 N Meat ENE 2271 1.45E-07 5.91E-10 N Meat ESE 3775 2.09E-07 9.46E-10 N Meat SE 7695 9.77E-08 2.98E-10 N Meat s 3722 6.59E-08 2.80E-10 N Meat SSW 2323 4.78E-08 2.97E-10 N Meat SW 7055 2.05E-07 1.79E-10 N Meat WSW 4321 9.54E-08 2.83E-10 N Meat w 5223 8.28E-08 2.05E-10 N Meat NNW 6379 5.99E-08 1.54E-10 N Cow N 7551 6.73E-08 9.15E-11 N Cow s 6740 1.18E-07 1.34E-10 N Cow SSW 3167 7.18E-08 2.32E-10 N Cow WSW 4321 9.54E-08 2.83E-10
- Page 88
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 12 Annual x/Q and D/Q values for the South Stack, Limerick Generating Station, 2016 Limerick Generating Station x!Q and D/Q values South Stack - Flow =187000 cfm Stack ID Location Direction Rani::ie (m) XIQ (s/m/\3) Undeoleted D/Q (1/m/\2) s Site Boundary s 762 7.17E-08 1.08E-09 s Site Boundary SSW 762 4.48E-08 5.19E-10 s Site Boundary SW 884 3.19E-08 4.45E-10 s Site Boundary WSW 854 6.68E-08 8.88E-10 s Site Boundary w 854 8.32E-08 1.10E-09 s Site Boundary WNW 793 3.66E-08 6.21E-10 s Site Boundary NW 762 2.99E-08 4.20E-10 s Site Boundary NNW 884 4.22E-08 4.81E-10 s Site Boundary N 884 6.29E-08 8.46E-10 s Site Boundary NNE 793 1.11 E-07 1.84E-09 s Site Boundary NE 793 8.44E-08 1.37E-09 s Site Boundary ENE 793 9.93E-08 1.96E-09 s Site Boundary E 762 2.05E-07 3.68E-09 s Site Boundary ESE 762 3.18E-07 5.89E-09 s Site Boundary SE 762 3.12E-07 5.34E-09 s Site Boundary SSE 1006 9.05E-08 1.46E-09 s RR-Inf-Lek-NG s 300 2.83E-07 3.25E-09 s RR-Inf-Lek-NG SSW 225 3.17E-07 2.35E-09 s RR-Inf-Lek-NG SW 225 2.40E-07 1.92E-09 s RR-Inf-Lek-NG WSW 345 2.27E-07 2.27E-09 s RR-Inf-Lek-NG w 225 6.18E-07 4.92E-09 s RR-Inf-Lek-NG WNW 345 1.09E-07 1.34E-09 s RR-Inf-Lek-NG NW 450 5.49E-08 6.55E-10 s RR-Inf-Lek-NG ESE 884 2.74E-07 4.98E-09 s RR-Inf-Lek-NG WSW 450 1.44E-07 1.71E-09 s RR-Inf-Lek-NG NNE 682 1.17E-07 2.14E-09 s Inhalation N 948 6.16E-08 7.90E-10 s Inhalation NNE 825 1.09E-07 2.19E-09 s Inhalation NE 1057 8.09E-08 1.03E-09 s Inhalation ENE 985 1.04E-07 1.58E-09 s Inhalation E 873 1.95E-07 3.19E-09 s Inhalation ESE 1047 2.44E-07 4.15E-09 s Inhalation SE 1202 2.10E-07 3.59E-09 s Inhalation SSE 1647 7.24E-08 9.55E-10 s Inhalation s 1325 4.84E-08 6.99E-10 s Inhalation SSW 1543 3.24E-08 3.66E-10 s Inhalation SW 991 2.89E-08 4.17E-10 s Inhalation WSW 1158 5.52E-08 7.41E-10 s Inhalation w 1105 6.82E-08 8.86E-10 Page 89
-- ____J
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Table D - 12 Annual x/Q and D/Q values for the South Stack, Limerick Generating Station, 2016 Limerick Generating Station x!Q and D/Q values South Stack - Flow =187000 cfm Stack ID Location Direction RanQe (m) XJQ (slm"3) Undepleted D/Q (1/m"2) s Inhalation WNW 1123 2.89E-08 4.28E-10 s Inhalation NW 1104 2.40E-08 3.08E-10 s Inhalation NNW 1540 4.77E-08 2.98E-10 s Vegetation N 1016 6.07E-08 7.41E-10 s Vegetation NNE 2929 1.49E-07 4.69E-10 s Vegetation NE 4358 1.92E-07 2.30E-10 s Vegetation ENE 4331 2.18E-07 2.67E-10 s Vegetation E 3573 2.29E-07 5.42E-10 s Vegetation ESE 1371 2.43E-07 3.30E-09 s Vegetation SE 7113 1.02E-07 3.21E-10 s Vegetation SSE 2107 7.67E-08 7.32E-10 s Vegetation s 1860 4.89E-08 5.39E-10 s Vegetation SSW 1622 3.33E-08 3.52E-10 s Vegetation SW 1389 2.69E-08 3.85E-10 s Vegetation WSW 1374 5.42E-08 7.10E-10 s Vegetation w 1317 6.32E-08 7.95E-10 s Vegetation WNW 8888 2.16E-08 4.09E-11 s Vegetation NW 2499 2.69E-08 1.26E-10 s Vegetation NNW 1703 4.98E-08 2.68E-10 s Meat N 7551 6.97E-08 8.95E-11 s Meat NNE 8015 8.26E-08 1.04E-10 s Meat NE 4287 1.88E-07 2.35E-10 s Meat ENE 2271 1.55E-07 6.21E-10 s Meat ESE 3775 2.12E-07 8.55E-10 s Meat SE 7695 1.01 E-07 2.88E-10 s Meat s 3722 6.98E-08 2.81E-10 s Meat SSW 2323 4.60E-08 2.71E-10 s Meat SW 7055 2.15E-07 2.01 E-10 s Meat WSW 4321 1.01 E-07 2.97E-10 s Meat w 5223 8.70E-08 2.09E-10 s Meat NNW 6379 6.06E-08 1.56E-10 s Cow N 7551 6.97E-08 8.95E-11 s Cow s 6740 1.28E-07 1.35E-10 s Cow SSW 3167 7.65E-08 2.14E-10 s Cow WSW 4321 1.01 E-07 2.97E-10 Page 90
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC
. I I
(Page Intentionally Left Blank) Page 91 i
--
I ! __ _J _ _I
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC Appendix D Offsite Dose Calculation Manual Revision 29 Summary of Changes Page 92
SITE: LIMERICK GENERATING STATION - UNITS 1 & 2 LICENSEE: EXELON GENERATION COMPANY, LLC (Page Intentionally Left Blank) Page 93
Attachment 2 Limerick Generating Station Units 1 and 2 Offsite Dose Calculation Manual Revision 29
CY-LG-170-301 LIMERICK GENERATING STATION UNITS 1AND2 OFFSITE DOSE CALCULATION MANUAL Revision 29 EXELON NUCLEAR DOCKET NOS. 50-352 AND 50-353 (This Manual cannot be changed without PORC and Plant Manager Approval) Rev.29 Page 1of329 12/2016
CY-LG-170-301 Limerick Generating Station Offsite Dose Calculation Manual PURPOSE: The OFFSITE DOSE CALCULATION MANUAL (ODCM) shall contain the methodology and parameters used in the calculation of offsite doses resulting from radioactive gaseous and liquid effluent, in the calculation of gaseous and liquid effluent monitoring alarm/trip setpoints, and in the conduct of the Radiological Environmental Monitoring Program. SCOPE: The ODCM shall also contain the Radioactive Effluent Controls Programs, the Meteorological Monitoring Program, the Radiological Environmental Monitoring Program required by Tech. Spec. Section 6.8.4 and the descriptions of the information that should be included in the Annual Radiological Environmental Operating and Annual Radioactive Effluent Release Reports required by Tech Spec. Sections 6.9.1.7 and 6.9.1.8, respectively. Rev.29 Page 2 of 329 12/2016
CY-LG-170-301 Change Matrix The following details the linkage between the Revision 21 of the ODCM and the current revision of the ODCM regarding the renumbering of the various sections. The purpose of this section is to permit a cross-reference from the old to new revision of the ODCM for procedures and surveillance tests. Changes to procedures to address the new numbering will occur as the procedures are revised on their normal revision process cycle. Revision 21 - Old Current Revision Part I 1.0 Definitions 1.0 Definitions Table 11-1 Table 1-1 Figure 12.2-1a Figure 1-1 Figure 12.2-1 b Figure 1-2 2.0 Bases Bases 3.0 Applicability 3.0.1 3.0.2 3.0.3 3.0.4 4.0 Surveillance Requirement 4.0.1 4.0.2 4.0.3 4.0.4 3.1 Meteorology 3.3.4 Meteorology 3.1-1 4.3.4 Table 13.1-1 Table 3.3-3 Table 13.1-2 Table 4.3-2 Table 13.1-3 Figure 13.1-1 Figure 3.3-1 3.2.1 Radioactive Liquid Effluent 3.1.1 Radioactive Liquid Effluent Monitoring Instrumentation Monitoring Instrumentation 3.2.1-1 4.1.1 Table 13.2-1 Table 3.1-1 Table 13.2-2 Table 4.1-1 3.2.2 Concentration in Liquid Effluents 3.2.1.1 Concentration Liquid Effluents 3.2.2-1 4.2.1.1.1 3.2.2-2 4.2.1.1.2 Table 13.2-3 Table 4.2-1 3.2.3 Dose due to Liquid Effluents 3.2.1.2 Dose Liquid Effluents 3.2.3-1 4.2.1.2 Rev. 29 Page 3 of 329 12/2016
CY-LG-170-301 Revision 21 - Old Current Revision
- Part I 3.2.4 Liquid Radwaste Treatment System 3.2.1.3 Liquid Radwaste Treatment System 3.2.4-1 4.2.1.3.1 4.2.1.3.2 3.3.1 Radioactive Gaseous Effluent 3.1.2 Radioactive Gaseous Effluent Monitoring Instrumentation Monitoring Instrumentation 3.3.1-1 4.1.2 Table 13.3-1 Table 3.1-2 Table 13.3-2 Table 4.1-2 3.3.2 Site Boundary Dose Rate 3.2.2.1 Dose Rate 3.3.2-1 4.2.2.1.1 3.3.2-2 4.2.2.1.2 Table 13.3-3 Table 4.2-2 3.3.3 Dose - Noble Gas 3.2.2.2 Dose - Noble Gas 3.3.3-1 4.2.2.2 3.3.4 Dose - lodine-133, tritium and c3.2.2.3 Dose - lodine-131, lodine-133, radionuclides in particulate forms tritium and radionuclides in particulate forms 3.3.4-1 4.2.2.3 None 3.2.2.4 Gaseous Radwaste Treatment Svstem 3.3.5 Ventilation Exhaust Treatment System 3.2.2.5 Ventilation Exhaust Treatment System 3.3.5-1 4.2.2.5.1
- 4.2.2.5.2 3.3.6 Venting or Purging 3.2.2.7 Venting or Purging 3.3.6-1 4.2.2.7.1 3.3.6-2 4.2.2.7.2 3;3.7 Total Dose 3.2.3 Total Dose 3.3.7-1 4.2.3.1 3.3.7-2 4.2.3.2 3.3.8 Dose - Incineration of Radioactive 3.2.2.6 Incineration of Radioactive Waste Waste Oil Oil 3.3.8-1 4.2.2.6.1 3.3.8-2 4.2.2.6.2 3.4.1 Radiological Environmental Monitoring 3.3.1 Radiological Environmental Monitoring Program Program 3.4.1-1 4.3.1 Table 13.4-1 REMP Table 3.3-1 REMP Table 13.4-2 Reporting Levels Table 3.3-2 Reporting Levels Table 13.4-3 Lower Limit of Detection Table 4.3-1 Lower Limit of Detection 3.4.2 Land Use Census 3.3.2 Land Use Census 3.4.2-1 4.3.2 Rev.29 Page 4 of 329 12/2016
CY-LG-170-301 Revision 21 - Old Current Revision Part I 3.4.3 lnterlaboratory Comparison Program 3.3.3 lnterlaboratory Comparison Program 3.4.3-1 4.3.3 - 6.0 Administrative Controls 3.5 Annual Radiological Environmental 6.1 Annual Radiological Environmental Operating Report Operating Report 3.6 Annual Radioactive Effluent Release 6.2 Annual Radioactive Effluent Release Report Report 3.7 Major Changes to Radioactive Waste 6.3 Major Changes to Radioactive Waste Treatment Systems Treatment Systems Part II 1.4 Liquid Effluent Dose Projection 1.3.2 Liquid Effluent Dose Projection Appendix A Technical Specification/ODCM Deleted Matrix Appendix B - Radiological Environmental Appendix A - Radiological Environmental Monitoring Program - Sample Type, Monitoring Program - Sample Type, Location and Analysis Location and Analysis Appendix C - ODCM Revision Process Part I, Section 6.4 Changes to the ODCM Rev.29 Page 5 of 329 12/2016
- ------
CY-LG-170-301 TABLE OF CONTENTS PART I - RADIOLOGICAL EFFLUENT CONTROLS 11 1.0 DEFINITIONS 12 3.0 APPLICABILITY 18 3.1 INSTRUMENTATION 20 3.1.1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION 20 3.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION 25 3.2 RADIOACTIVE EFFLUENTS 31 3.2.1 LIQUID EFFLUENTS 31 3.2.1.1 CONCENTRATION 31 3.2.1.2 DOSE 35 3.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM 36 3.2.2 GASEOUS EFFLUENTS 37 3.2.2.1 DOSE RATE 37 3.2.2.2 DOSE - NOBLE GASES 41 3.2.2.3 DOSE - IODINE-131, IODINE-133, TRITIUM, AND RADIONUCLIDES IN PARTICULATE FORM 42 3.2.2.4 GASEOUS RADWASTE (OFFGAS) TREATMENT SYSTEM 43 3.2.2.5 VENTILATION EXHAUST TREATMENT SYSTEM 44 3.2.2.7 MARK II CONTAINMENT 46 3.2.3 TOTAL DOSE 47 3.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 48 3.3.1 MONITORING PROGRAM 48 3.3.2 LAND USE CENSUS 61 3.3.3 INTERLABORATORY COMPARISON PROGRAM 62 3.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION 63 BASES 67 6.0 ADMINISTRATIVE CONTROLS 77 6.1 ANNUAL RADIOLOGICAL ENVIRONMENTAL OPERATING REPORT 77 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 78 6.3 MAJOR CHANGES TO RADIOACTIVE WASTE TREATMENT SYSTEMS 80 6.4 CHANGES TO THE ODCM 81 Rev.29 Page 6 of 329 12/2016
CY-LG-170-301 PART II - CALCULATION METHODOLOGIES 82 1.0 LIQUID EFFLUENTS 83 1.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS 83 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION 84 1.2.1 Radwaste Discharge Monitor and Discharge Flow Rate 84 1.2.2 Service Water and RHR Service Water Radiation Monitor 87 1.3 LIQUID EFFLUENT DOSE CALCULATIONS -10 CFR 50 88 1.3.1 Dose to Members of the Public 88 1.3.2 Liquid Effluent Dose Projection 91 2.0 GASEOUS EFFLUENTS 93 2.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS 93 2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION 93 2.2.1 North Vent Noble Gas Effluent Monitors 94 2.2.2 South Vent Noble Gas Effluent Monitors 96 2.2.3 Noble Gas Effluent Fractional Contribution 97 2.2.4 Noble Gas Effluent Default Setpoints 98 2.2.5 WRAM Noble Gas Effluent Monitor 100 2.3 GASEOUS EFFLUENT DOSE EVALUATIONS 102 2.3.1 Site Boundary Dose Rate - Noble Gases 102 2.3.2 Site Boundary Dose Rate - Radioiodine and Particulates 103 2.3.3 Noble Gas Air Dose 104 2.3.4 Radioiodine and Particulate Dose Calculations 105 2.3.6 Gaseous Effluent Dose Projection 111 3.0 ANNUAL DOSE EVALUATION 112 4.0 SPECIAL DOSE ANALYSIS 112 4.1 TOTAL DOSES TO MEMBERS OF THE PUBLIC 112 4.2 DOSES DUE TO ACTIVITIES INSIDE THE SITE BOUNDARY 113 5.0 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM 114 5.1 SAMPLING PROGRAM 114 5.2 INTERLABORATORY COMPARISON PROGRAM 114 REFERENCES 328 Rev.29 Page 7 of 329 12/2016
CY-LG-170-301 LIST OF TABLES PARTI 1-1 Surveillance Frequency Notation 15 3.1-1 Radioactive Liquid Effluent Monitoring Instrumentation 21 4.1-1 Radioactive Liquid Effluent Monitoring Instrumentation Surveillance Requirements 23 3.1-2 Radioactive Gaseous Effluent Monitoring Instrumentation 26 4.1-2 Radioactive Gaseous Effluent Monitoring Instrumentation Surveillance Requirements 29 4.2-1 Radioactive Liquid Waste Sampling and Analysis Program 32 4.2-2 Radioactive Gaseous Waste Sampling and Analysis Program 38 3.3-1 Radiological Environmental Monitoring Program 50 3.3-2 Reporting Levels for Radioactivity Concentrations In Environmental Samples 57 4.3-1 Detection Capabilities For Environmental Sample Analysis 58 3.3-3 Meteorological Monitoring Instrumentation 64 4.3-2 Meteorological Monitoring Instrumentation Surveillance Requirements 65 PARTll 111-1 Decay Constants For Nuclides Of Interest 116 111-2 Bioaccumulation Factors For Freshwater Fish 120 111-3 Ingestion Dose Factors for Adult (Daipj) 121 111-4 Ingestion Dose Factors for Teen (Daipi) 125 111-5 Ingestion Dose Factors for Child (Daipj) 129 111-6 Ingestion Dose Factors for Infant (Daipj) 133 111-7 Dose Factors for Standing on Contaminated Ground (Daipj) 137 111-8 Aquatic Pathway Usage Factors (Uap) 141 111-9 Adult Drinking Water Air Factors 142 111-10 Adult Freshwater Fish Air Factors 146 111-11 Adult Shoreline Air Factors 150 111-12 Teen Drinking Water Air Factors 154 111-13 Teen Freshwater Fish Air Factors 158 111-14 Teen Shoreline Air Factors 162 111-15 Child Drinking Water Air Factors 166 111-16 Child Freshwater Fish Air Factors 170 111-17 Child Shoreline Air Factors 174 111-18 Infant Drinking Water Air Factors 178 Rev.29 Page 8 of 329 12/2016
CY-LG-170-301 111-19 Infant Freshwater Fish Air Factors 182 111-20 Infant Shoreline Air Factors 186 111-21 Assumptions Used In Limerick Liquid Effluent Dose Evaluations 190 112-1 Dose Factors for Noble Gases 191 112-2 Ri Dose Factors Age: Adult Pathway: Inhalation 192 112-3 Ri Dose Factors Age: Teen Pathway: Inhalation 196 112-4 Ri Dose Factors Age: Child Pathway: Inhalation 200 112-5 Ri Dose Factors Age: Infant Pathway: Inhalation 204 112-6 Ri Dose Factors Age: Adult Pathway: Ground 208 112-7 Ri Dose Factors Age: Teen Pathway: Ground 212 112-8 Ri Dose Factors Age: Child Pathway: Ground 216 112-9 Ri Dose Factors Age: Infant Pathway: Ground 220 112-10 Ri Dose Factors Age: Adult Pathway: Vegetation 224 112-11 Ri Dose Factors Age: Teen Pathway: Vegetation 228 112-12 Ri Dose Factors Age: Child Pathway: Vegetation 232 112-13 Ri Dose Factors Age: Infant Pathway: Vegetation 236 112-14 Ri Dose Factors Age: Adult Pathway: Meat 240 112-15 Ri Dose Factors Age: Teen Pathway: Meat 244 112-16 Ri Dose Factors Age: Child Pathway: Meat 248 112-17 Ri Dose Factors Age: Infant Pathway: Meat 252 112-18 Ri Dose Factors Age: Adult Pathway: Cow Milk 256 112-19 Ri Dose Factors Age: Teen Pathway: Cow Milk 260 112-20 Ri Dose Factors Age: Child Pathway: Cow Milk 264 112-21 Ri Dose Factors Age: Infant Pathway: Cow Milk 268 112-22 Ri Dose Factors Age: Adult Pathway: Goat Milk 272 112-23 Ri Dose Factors Age: Teen Pathway: Goat Milk 276 112-24 Ri Dose Factors Age: Child Pathway: Goat Milk 280 112-25 Ri Dose Factors Age: Infant Pathway: Goat Milk 284 112-26 Stable Element Transfer Data 288 112-27 Inhalation Dose Factors For Adult (Daipj) 292 Rev.29 Page 9 of 329 . 12/2016
CY-LG-170-301 112-28 Inhalation Dose Factors For Teenager (Daipj) 296 112-29 Inhalation Dose Factors For Child (Daipj) 300 112-30 Inhalation Dose Factors For Infant (Daipj) 304 112-31 Assumptions Used In Limerick Gaseous Effluent Ri Evaluation 308 112-32 Nearest Gaseous Effluent Dose Receptor Distances 310 A-1 ODCM - Limerick Generating Station Radiological *Environmental Monitoring Program 322 LIST OF FIGURES PARTI 1-1 Map Detailing the Restricted Area Boundary for Radioactive Gaseous And Liquid Effluents 16 1-2 Map Detailing Low Population Areas for Radioactive Gaseous and Liquid Effluents 17 3.3-1 Meteorological Tower Locations 66 PARTll 111.3.1-1 LGS Dilution Vs River Flow (Station Outfall) 312 111.3.1-2 LGS Dilution Vs River Flow (Pennsylvania American Water Company) 313 . 111.3.1-3 LGS Dilution Vs River Flow (Phoenixville) 314 111.3.1-4 LGS Dilution Vs River Flow (Aqua America) 315 111.3.1-5 LGS Dilution Vs River Flow (Crew Course) 316 111-1 Liquid Effluent Flow Diagram 317 112-1 Gaseous Effluent Flow Diagram - North Stack 318 112-2 Gaseous Effluent Flow Diagram - South Stack 319 112-3 Gaseous Effluent Flow Diagram - Hot Maintenance Shop 320 A-1 Environmental Sampling Location on Site or Near the Limerick Generating Station 325 A-2 Environmental Sampling Locations at Distances Less Than Five Miles from the Limerick Generating Station 326 A-3 Environmental Sampling Locations at Distances Greater Than Five Miles from the Limerick Generating Station 327 Rev.29 Page 10 of 329 12/2016
CY-LG-170-301 PART! RADIOLOGICAL EFFLUENT CONTROLS Rev.29 Page 11 of 329 12/2016
CY-LG-170-301 1.0 DEFINITIONS The following terms are taken from LGS Unit 1/Unit 2 Tech Specs, unless otherwise noted: 1.1 ACTION ACTION shall be that part of a specification, which prescribes remedial measures, required under designated conditions. 1.2 . CHANNEL CALIBRATION A CHANNEL CALIBRATION shall be the adjustment, as necessary, of the channel output such that it responds with the necessary range and accuracy to known values of the parameter which the channel monitors. The CHANNEL CALIBRATION shall encompass the entire channel including the sensor and alarm and/or trip functions, and shall include the CHANNEL FUNCTION TEST. The CHANNEL CALIBRATION may be performed by any series of sequential, overlapping or total channel steps such that the entire channel is calibrated. 1.3 CHANNEL CHECK A CHANNEL CHECK shall be the qualitative assessment of channel behavior during operation by observation. This determination shall include, where possible, comparison of the channel indication and/or status with other indications and/or status derived from independent instrument channels measuring the same parameter.
- 1.4 CHANNEL FUNCTIONAL TEST A CHANNEL FUNCTIONAL TEST shall be:
- a. Analog channels - the injection of a simulated signal into the channel as close to the sensor as practicable to verify OPERABILITY including alarm and/or trip functions and channel failure trips.
- b. Bistable channels - the injection of a simulated signal into the sensor to verify OPERABILITY including alarm and/or trip functions.
- The CHANNEL FUNCTIONAL TEST may be performed by any series of sequential, overlapping or total channel steps such that the entire channel is tested.
Rev.29 Page 12 of 329 12/2016
CY-LG-170-301 1.0 DEFINITIONS 1.5 CONTROLLED AREA CONTROLLED AREA means an area, outside of a restricted area but inside the site boundary, access to which can be limited by the licensee for any reason. The CONTROLLED AREA equals the RESTRICTED AREA. By definition Limerick does not have a CONTROLLED AREA. 1.6 DOSE EQUIVALENT 1-131 DOSE EQUIVALENT 1-131 shall be that concentration of 1-131, microcuries per gram, which alone would produce the same inhalation committed effective dose equivalent (CEDE) as the quantity and isotopic mixture of 1-131, 1-132, 1-133, 1-134, and 1-135 actually present. The inhalation committed effective dose equivalent (CEDE) conversion factors used for this calculation shall be those listed in Table 2.1 of Federal Guidance Report 11, Limiting Values of Radionuclide Intake and Air Concentration and Dose Conversion Factors for Inhalation, Submersion, and Ingestion," ORNL, 1989, as described in Regulatory Guide 1.183. The factors in the column headed "effective" yield doses corresponding to the CEDE. 1.7 FREQUENCY NOTATION The FREQUENCY NOTATION specified for the performance of Surveillance Requirements shall correspond to the intervals defined in Table 1-1. 1.8 MEMBER(S) OF THE PUBLIC MEMBER(S) OF THE PUBLIC means any individual except when that individual is receiving an occupational dose. 1.9 OPERABLE - OPERABILITY A system, subsystem, train, component or device shall be OPERABLE or have OPERABILITY when it is capable of performing its specified functions(s) and when all necessary attendant instrumentation, controls, electrical power, cooling or seal water, lubrication or other auxiliary equipment that are required for the system, subsystem, train, component or device to perform its function(s) are also capable of performing their related support function(s). 1.10 OPERATIONAL CONDITION - CONDITION An OPERATIONAL CONDITION, i.e., CONDITION, shall be any one inclusive combination of mode switch position and average reactor coolant temperature as defined in the Technical Specifications. Rev.29 Page 13 of 329 12/2016
CY-LG-170-301 1.0 DEFINITIONS 1.11 P.URGE - PURGING PURGE or PURGING shall be the controlled process of discharging air or gas from a confinement to maintain temperature, pressure, humidity, concentration or other operating condition, in such a manner that replacement air or gas is required to purify the confinement. 1.12 RATED THERMAL POWER See current LGS Tech Spec definition. 1.13 REPORTABLE EVENT A REPORTABLE EVENT shall be any of those conditions specified in Section 50.73of10 CFR Part 50or10 CFR 72.75. 1.14 RESTRICTED AREA The RESTRICTED AREA means an area, access to which is limited by the licensee for the purpose of protecting individuals against undue risks from exposure to radiation and radioactive materials (Figure 1-1 ). Per UFSAR 2.1.1.3 the RESTRICTED AREA extends to the SITE BOUNDARY. 1.15 SITE BOUNDARY The SITE BOUNDARY shall be that line beyond which the land or property is not owned, leased, or otherwise controlled by the licensee (Figure 1-1 ) . . 1.16 SOURCE CHECK A SOURCE CHECK shall be the qualitative assessment of channel response when the channel sensor is exposed to a radioactive source. 1.17 THERMAL POWER THERMAL POWER shall be the total reactor core heat transfer rate to the reactor coolant. 1.18 UNRESTRICTED AREA UNRESTRICTED AREA means an area, access to which is neither limited nor controlled by the licensee. 1.19 VENTILATION EXHAUST TREATMENT SYSTEM A VENTILATION EXHAUST TREATMENT SYSTEM shall be any system designed and installed to reduce gaseous radioiodine or radioactive material in particulate form in effluents by passing ventilation or vent exhaust gases through charcoal absorbers and/or HEPA filters. for the purpose of removing iodines or particulates from the gaseous exhaust stream prior to the release to the environment (such a system is not considered to have any effect on noble gas effluents). Engineered Safety Feature (ESF) atmospheric cleanup systems are Rev.29 Page 14 of 329 12/2016
CY-LG-170-301 1.0 DEFINITIONS not considered to be VENTILATION, EXHAUST TREATMENT SYSTEM components. 1.20 VENTING VENTING shall be the controlled process of discharging air or gas from a confinement to maintain temperature, pressure, humidity, concentration or other operating condition, in such a manner that replacement air or gas is not provided or required during VENTING. Vent, used in system names, does not imply a VENTING process. TABLE 1-1
- SURVEILLANCE FREQUENCY NOTATION NOTATION FREQUENCY S (Shift) At least once per 12 hours.
D (Daily) At least once per 24 hours. W (Weekly) At least once per 7 days. M (Monthly) At least once per 31 days. Q (Quarterly) At least once per 92 days. SA (Semi-annual) At least once per 184 days. A (Annual) At least once per 366 days. E At least once per 18 months (550 days). R At least once per 24 months (731 days). S/U Prior to each reactor startup. p Prior to each radioactive release. N.A. Not applicable Rev.29 Page 15 of 329 12/2016
CY-LG-170-301 1.0 DEFINITIONS FIGURE 1-1 MAP DETAILING THE RESTRICTED AREA BOUNDARY FOR RADIOACTIVE GASEOUS AND LIQUID EFFLUENTS Rev.29 Page 16 of 329 12/2016
CY-LG-170-301 1.0 DEFINITIONS FIGURE 1-2 MAP DETAILING LOW POPULATION AREAS FOR RADIOACTIVE GASEOUS AND LIQUID EFFLUENTS Rev.29 Page 17 of 329 12/2016
CY-LG-170-301 3/4 CONTROLS AND SURVEILLANCE REQUIREMENTS 3/4.0 APPLICABILITY CONTROLS 3.0.1 Compliance with the Controls contained in the succeeding controls is required during the OPERATIONAL CONDITIONS or other conditions specified therein; except that upon failure to meet the Control, the associated ACTION requirements shall be met. 3.0.2 Noncompliance with a Control shall exist when the reqL,Jirements of the Control and associated ACTION requirements are not met within the specified time intervals. If the Control is restored prior to expiration of the specified time intervals, completion of the ACTION requirements is not required. 3.0.3 When a Control is not met, except as provide in the associated ACTION requirements, within 1 hour action shall be initiated to place the unit in an
- a. At least STARTUP within the next 6 hours
- b. At least HOT SHUTDOWN within the following 6 hours, and
- c. At least COLD SHUTDOWN within the subsequent 24 hours.
Where corrective measures are completed that permit operation under the ACTION requirements, the ACTION may be taken in accordance with the specified time limits as measured from the time of failure to meet the Control. Exceptions to these requirements are stated in the individual controls. This control is not applicable in OPERATIONAL CONDITIONS 4 or 5. 3.0.4 When a Limiting Condition for Operation is not met, entry into an OPERATIONAL CONDITION or other specified condition in the Applicability shall only be made:
- a. When the associated ACTION requirements to be entered permit continued operation in the OPERATIONAL CONDITION or other specified condition in the Applicability for an unlimited period of time; or
- b. After performance of a risk assessment addressing inoperable systems and components, consideration of the results, determination of the acceptability of entering the OPERATIONAL CONDITION or other specified condition in the Applicability, and establishment of risk management actions, if appropriate; exceptions to this Control are stated in the individual Controls; or
- c. When an allowance is stated in the individual value, parameter, or other Control.
Rev.29 Page 18 of 329 12/2016
CY-LG-170-301 3/4 CONTROLS AND SURVEILLANCE REQUIREMENTS 3/4.0 APPLICABILITY SURVEILLANCE REQUIREMENTS 4.0.1 Surveillance Requirements shall be met during the OPERATIONAL CONDITIONS or other specified conditions in the Applicability for individual Controls, unless othe..Wise stated in the Surveillance Requirement. Failure to meet a Surveillance, whether such failure is experienced during the performance of the Surveillance or between performances of the Surveillance, shall be failure to meet the Control. Failure to perform a Surveillance within the specified Surveillance time interval and allowed extension per Surveillance Requirement 4.0.2, shall be failure to meet the Control except as provided in Surveillance Requirement 4.0.3. Surveillances do not have to be performed on inoperable equipment or variables outside specified limits. 4.0.2 Each Surveillance Requirement shall be performed within the specified surveillance time interval with a maximum allowable extension not to exceed 25% of the surveillance interval. 4.0.3 If it is discovered that a Surveillance was not performed within its specified Surveillance time interval and allowed extension per Surveillance Requirement 4.0.2, then compliance with the requirement to declare the Control not met may be delayed, from the time of discovery, up to 24 hours or up to the limit of the specified Surveillance time interval, whichever is greater. This delay period is permitted to allow performance of the Surveillance. A risk evaluation shall be performed for any Surveillance delayed greater than 24 hours and the risk impact shall be managed. If the Surveillance is not performed within the delay period, the Control must immediately be declared not met, and the applicable ACTION requirements must be entered. When the Surveillance is performed within the delay period and the Surveillance is not met, the Control must immediately be declared not met, and the applicable ACTION requirements must be entered. 4.0.4 Entry into an OPERATIONAL CONDITION or other specified condition in the Applicability of a Control shall only be made when the Control's Surveillance Requirements have been met within their Surveillance time interval, except as provided in Surveillance Requirement 4.0.3. When a Control is not met due to its Surveillance Requirements not having been met, entry into an OPERATIONAL CONDITION or other specified condition in the Applicability shall only be made in accordance with Control 3.0.4. Rev. 29 Page 19 of 329 12/2016
CY-LG-170-301 3/4.1 INSTRUMENTATION 3/4.1.1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION CONTROLS 3.1.1 The radioactive liquid effluent monitoring instrumentation channels shown in Table 3.1-1 shall be OPERABLE with their Alarm/Trip Setpoints set to ensure that the limits of Control 3.2.1.1 are not exceeded. The Alarm/Trip Setpoints* of these channels shall be determined and adjusted in accordance with the methodology and parameters in ODCM Part II, Section 1.2. APPLICABILITY: As shown in Table 3.1-1 ACTION:
- a. With a radioactive liquid effluent monitoring instrumentation channel Alarm/Trip Setpoint less conservative than required by the above control, immediately suspend the release of radioactive liquid effluents monitored by the affected channel, or declare the channel inoperable, or change the setpoint so it is acceptably conservative.
- b. With less than the minimum number of radioactive liquid effluent monitoring instrumentation channels OPERABLE, take the ACTION shown in Table 3.1-1.
Restore the inoperable instrumentation to OPERABLE status within 30 days and, if unsuccessful explain in the next Annual Radioactive Effluent Release Report pursuant to CONTROL 6.2 why this inoperability was not corrected in a timely manner.
- c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. Report all deviations in the Annual Radioactive Effluent Release Report.
SURVEILLANCE REQUIREMENTS 4.1.1 Each radioactive liquid effluent monitoring instrumentation channel shall be demonstrated OPERABLE by performance of the CHANNEL CHECK, SOURCE CHECK, CHANNEL CALIBRATION and CHANNEL FUNCTIONAL TEST operations at the frequencies shown in Table 4.1-1.
- Excluding the flow rate measuring devices which are not determined and adjusted in accordance with the ODCM.
Rev.29 Page 20 of 329 12/2016
CY-LG-170-301 TABLE 3.1-1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION MINIMUM CHANNELS INSTRUMENT OPERABLE APPLICABILITY ACTION
- 1. Gross Radioactivity Monitors Providing Automatic Termination of Release ***
1 100
- a. Liquid Radwaste Effluent Line
- b. A/B RHR Service Water Effluent Line
- 1/loop ** 101
- 2. Gross Radioactivity Monitors Not Providing Automatic Termination of Release
- a. Service Water Effluent Line 1 ** 101 3 Flow Rate Measurement Devices
- a. Liquid Radwaste Effluent Line 1 *** 102
- b. Discharge Line 1 *** 102
- Termination of the release is accomplished by auto trip of the RHRSW pumps and remote manual closure of isolation valves.
- While system pumps are in operation.
- During a liquid effluent release.
- While system pumps are in operation.
Rev.29 Page 21 of 329 12/2016
CY-LG-170-301 TABLE 3.1-1 (Continued) ACTION STATEMENTS Action 100 - With the number of channels OPERABLE less than required by the Minimum Channels requirement, effluent releases via this pathway may continue provided that prior to initiating a release:
- a. At least two independent samples are analyzed in accordance with SURVEILLANCE REQUIREMENT 4.2.1.1.1, and
- b. At least two technically qualified members of the facility staff independently verify the release rate calculations and discharge line valving.
Otherwise, suspend release of radioactive effluents via this pathway. Action 101 - With the number of channels OPERABLE less than required by the Minimum Channels OPERABLE requirement, effluent releases via this pathway may continue provided that, at least once per 12 hours, grab samples are collected and analyzed for radioactivity at a lower limit of detection (LLD) of no more than 1E-7 uCi/ml. If the A or B RHRSW Process Rad Monitor should become inoperable, sampling is required at least once every twelve (12) hours at a sample point common with the inoperable A and/or B RHRSW Process Rad Monitor(s). If a monitor is inoperable but will still continuously sample and annunciate on high activity, i.e. rad monitor bypass switch placed in "Bypass", Chemistry sampling is not required as the continuous monitor sampling complies with the periodic sampling requirement. Action 102 - With the number of channels OPERABLE less than required by the Minimum Channels requirement, effluent releases via this pathway may continue provided the flow rate is estimated at least once per 4 hours during actual releases. Pump performance curves generated in place may be used to estimate flow. Rev.29 Page 22 of 329 12/2016
CY-LG-170-301 TABLE 4.1-1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS CHANNEL CHANNEL SOURCE CHANNEL FUNCTIONAL INSTRUMENT CHECK CHECK CALIBRATION TEST
- 1. Gross Radioactivity Monitors Providing Automatic Termination of Release
- a. Liquid Radwaste Effluent Line D* D* R(3) Q(1)
- b. RHR Service Water System Effluent Line D M R(3) Q(1)
- 2. Gross Radioactivity Monitored Not Providing Automatic Termination of Release
- a. Service Water System Effluent Line D M R(3) Q(2)
- 3. Flow Rate Measurement Devices
- a. Liquid Radwaste Effluent Line D(4) N.A. R Q
- b. Discharge Line D(4) N.A. R Q
- Daily when in use Rev. 29 Page 23 of 329 12/2016
CY-LG-170-301 TABLE 4.1-1 (Continued) TABLE NOTATIONS (1) The CHANNEL FUNCTIONAL TEST shall also demonstrate that automatic isolation of this pathway and control room alarm annunciation will occur if any of the following conditions exists:
- 1. Instrument indicates measured levels above the alarm/trip setpoint.
- 2. Circuit failure.
- 3. Instrument indicates a downscale failure.
(2) The CHANNEL FUNCTIONAL TEST shall also demonstrate that control room alarm annunciation occurs if any of the following conditions exists:
- 1. Instrument indicates measured levels above the alarm setpoint.
- 2. Circuit failure.
- 3. Instrument indicates a downscale failure.
(3) The initial CHANNEL CALIBRATION shall be performed using reference standards certified by the National Institute of Standards and Technology (NIST) obtained from suppliers that participate in measurement assurance activities with NIST. These standards shall permit calibrating the system over its intended range of energy and measurements range. For subsequent CHANNEL CALIBRATION, sources that have been related to the initial calibration shall be used. (4) CHANNEL CHECK shall consist of verifying indication of flow during periods of release. CHANNEL CHECK shall be made at least once per 24 hours on days on which batch releases are made. Rev.29 Page 24 of 329 12/2016
CY-LG-170-301 3/4.1 INSTRUMENTATION 3/4.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION CONTROLS 3.1.2 The radioactive gaseous effluents monitoring instrumentation channels in Table 3.1-2 shall be OPERABLE with their Alarm/Trip Setpoints set to ensure that the limits of Control 3.2.2.1 are not exceeded. The alarm/trip setpoints of the applicable channels shall be determined in accordance with the methodology and parameters in ODCM Part II, Section 2.2. APPLICABILITY: As shown in Table 3.1-2. ACTION:
- a. With a radioactive gaseous effluent monitoring instrumentation channel Alarm/Trip Setpoints less conservative than required by the above control, immediately suspend the release of radioactive gaseous effluents monitored by the affected channel, or declare the channel inoperable, or change the setpoint so it is acceptably conservative.
- b. With less than the minimum number of radioactive gaseous effluent monitoring instrumentation channels OPERABLE, take the ACTION shown in Table 3.1-2.
Restore the inoperable instrumentation to OPERABLE status within 30 days and, if unsuccessful, explain in the next Annual Radioactive Effluent Release Report pursuant to Control 6.2 why this inoperability was not corrected in a timely manner.
- c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. Report all deviations in the Annual Radioactive Effluent Release Report.
SURVEILLANCE REQUIREMENTS 4.1.2 Each radioactive gaseous effluent monitoring instrumentation channel shall be demonstrated OPERABLE by performance of the CHANNEL CHECK, SOURCE CHECK, CHANNEL CALIBRATION AND CHANNEL FUNCTIONAL TEST operations at the frequencies shown in Table 4.1-2. Rev. 29 Page 25 of 329 12/2016
CY-LG-170-301 TABLE 3.1-2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION INSTRUMENT MINIMUM CHANNELS OPERABLE APPLICABILITY ACTION
- 1. SOUTH STACK EFFLUENT MONITORING SYSTEM
- a. Noble Gas Activity Monitor 1
- 111
- b. Iodine Sampler 1
- 112
- c. Particulate Sampler 1
- 112
- d. Effluent System Flow Rate Monitor 1
- 113
- e. Sampler Flow Rate Monitor 1
- 116
- 2. NORTH STACK EFFLUENT MONITORING SYSTEM+
- a. Noble Gas Activity Monitor 1
- 114
- b. Iodine Sampler 1
- 112
- c. Particulate Sampler 1
- 112
- d. Effluent System Flow Rate Monitor 1
- 113
- e. Sampler Flow Rate Monitor 1
- 116
- 3. HOT MAINTENANCE SHOP VENTILATION EXHAUST RADIATION MONITOR
- a. Iodine Sampler 1 ** 115
- b. Particulate Sampler 1 ** 115
- c. Effluent System Flow Rate Monitor 1 ** 113
- d. Sampler Flow Rate Monitor 1 ** 116 TABLE NOTATIONS
+ The (A or B) North Stack Normal Range Radiation Monitors OR the Wide Range Accident Monitor (Low Range) may be used to satisfy requirements for the North Stack Effluent Monitoring System.
- At all times.
- During operation of the hot maintenance shop ventilation system.
Rev.29 Page 26 of 329 12/2016
CY-LG-170-301 TABLE 3.1-2 (Continued) TABLE NOTATIONS ACTION STATEMENTS ACTION 111 - (SS Noble Gas) With the number of channels OPERABLE less than required by the Minimum Channels OPERABLE requirement, effluent releases via this pathway may continue provided grab samples are taken at least once per 12 hours and these samples are analyzed for radioactivity within 24 hours. IF monitor readings are available from local computer output, THEN GRAB SAMPLES ARE NOT REQUIRED. Obtain monitor readings at least once per 12 hours. ACTION 112- With the number of channels OPERABLE less than required by (NS and SS Iodine & the Minimum Channels OPERABLE requirement, effluent releases Part.) via the affected pathway may continue provided samples are continuously collected with auxiliary sampling equipment as required in Table 4.2-2. IF replacing particulate and iodine filter media for weekly analysis as required by Table 4.2-2, THEN auxiliary sampling equipment is not required if the interruption of sample collection will not exceed one (1) hour. ACTION 113- With the number of channels OPERABLE less than required by (Effluent Flow Rate) the Minimum Channels OPERABLE requirement, effluent releases via NS, SS or HMS may continue provided the Effluent System flow rate is estimated by adding the nominal flow rates indicated in P&ID M-26 for each in-service fan. This shall be documented in the MCR operations Shift Log at least once per 4 hours. ACTION 114- With the number of channels OPERABLE less than required by (NS Noble Gas) the Minimum Channels OPERABLE requirement, effluent releases via this pathway may continue provided grab samples are taken at least once per 12 hours and these samples are analyzed for radioactivity within 24 hours. The Mechanical Vacuum Pumps may not be operated while in this action statement. IF monitor readings are available from local computer output, THEN GRAB SAMPLES ARE NOT REQUIRED. Obtain monitor readings at least once per 12 hours. Rev.29 Page 27 of 329 12/2016
CY-LG-170-301 ACTION 115- With the number of channels OPERABLE less than required by (HMS) the Minimum Channels OPERABLE requirement, then secure Hot Maintenance Shop Ventilation. IF replacing particulate and iodine filter media for weekly analysis as required by Table 4.2-2, THEN Hot Maintenance Shop Ventilation may remain in service if the interruption of sample collection will not exceed one (1) hour. ACTION 116- With the number of channels OPERABLE less than required by (Sample Flow Rate) the Minimum Channels OPERABLE requirement, the sample pump shall be documented in service by recording the air pump local flow indicator value in the MCR operations Shift Log at least once per 8 hours. Rev.29 Page 28 of 329 12/2016
CY-LG-170-301 TABLE 4.1-2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS MODES IN WHICH CHANNEL SOURCE CHANNEL CHANNEL SURVEILLANCE IS INSTRUMENT CHECK CHECK CALIBR. FUNCT. TEST REQUIRED
- 1. SOUTH STACK EFFLUENT MONITORING SYSTEM
- a. Noble Gas Activity Monitor D M R(2) Q(1) *
- b. Iodine Sampler W(3) N.A. N.A. N.A. *
- c. Particulate Sampler . W(3) N.A. N.A. N.A. *
- d. Effluent System Flow Rate Monitor D N.A. R Q *
- e. Sampler Flow Rate Monitor D N.A. R Q *
- 2. NORTH STACK EFFLUENT MONITORING SYSTEM+
- a. Noble Gas Activity Monitor D M R(2) Q(1) *
- b. Iodine Sampler W(3) N.A. N.A. N.A. *
- c. Particulate Sampler W(3) N.A. N.A. N.A. *
- d. Effluent System Flow Rate Monitor D N.A. R Q *
- e. Sampler Flow Rate Monitor D N.A. R Q *
- 3. HOT MAINTENANCE SHOP VENTILATION EXHAUST RADIATION MONITOR
- a. Iodine Sampler W(3) N.A. N.A. N.A. **
- b. Particulate Sampler W(3) N.A. N.A. N.A. **
- c. Effluent System Flow Rate Monitor D N.A. R Q **
- d. Sampler Flow Rate Monitor D N.A. R Q **
TABLE NOTATIONS + The (A or 8) Wide Range Accident Monitor (WRAM) surveillance is specified in Technical Specification 3.3. 7.5.
- At all times.
- During operation of the hot maintenance shop ventilation exhaust system.
Rev.29 Page 29 of 329 12/2016
CY-LG-170-301 TABLE 4.1-2 (Continued) TABLE NOTATIONS (1) The CHANNEL FUNCTIONAL TEST shall also demonstrate that control room alarm annunciation occurs if any of the following conditions exists:
- 1. Instruments indicate measured levels above the alarm/trip setpoint.
- 2. Circuit failure.
- 3. Instrument indicates a downscale failure.
- 4. Instrument controls not set in operate mode.
(2) The initial CHANNEL CALIBRATION shall be performed using one or more of the reference standards certified by the National Institute of Standards and Testing (NIST) or using standards that have been obtained from suppliers that participate in measurement assurance activities with NIST. These standards shall permit calibrating the system over its intended range of energy and measurement range. For subsequent CHANNEL CALIBRATION, sources that are traceable to the initial calibration shall be used. (3) The iodine cartridges and particulate filters will be changed and analyzed at least once per 7 days. Rev.29 Page 30 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.1 CONCENTRATION CONTROLS 3.2.1.1 The concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS (see Figures 1-1 and 1-2) shall be limited to 10 times the effluent concentration limits (ECL) specified in 10 CFR Part 20, Appendix B, Table 2, Column 2 for radionuclides other than dissolved or entrained nobles gases. For dissolved or entrained noble gases, the concentration shall be limited to 2E-4 microcuries/ml total activity (NUREG 0133, Section 2). APPLICABILITY: At all times. ACTION:
- a. With the concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS exceeding the above limits, immediately restore the concentration to within the above limits or terminate the release.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.1.1.1 Radioactive liquid wastes shall be sampled and analyzed according to the sampling and analysis program of Table 4.2-1. 4.2.1.1.2 The results of the radioactivity analyses shall be used in accordance with the methodology and parameters in ODCM Part II, Section 1.2 to assure that the concentrations at the point of release are maintained within the limits of Control 3.2.1.1. Rev.29 Page 31 of 329 12/2016
CY-LG-170-301 TABLE 4.2-1 RADIOACTIVE LIQUID WASTE SAMPLING AND ANALYSIS PROGRAM Lower Limit of Minimum Analysis Type of Activity Detection Liquid Release Type Sampling Frequency Frequency Analysis (LLD)a (uCi/ml) p p Principal Gamma 5E-7 A. Batch Waste Release Tanks b Each Batch Each Batch Emittersc
- 1. Floor Drain Sample 1-131 1E-6 Tank Dissolved and Entrained 1E-5 Gases (Gamma Emitters)c
- 2. Equip. Drain Sample M H-3 1E-5 Tanks Composited Gross Alpha 1E-7
- 3. Laundry Drain Sample Q Sr-89, Sr-90 5E-8 Tank Composited Fe-55 1E-6 B. Continuous Release e w w Principal Gamma Emittersc 5E-7 Grab Sample 1-131 1E-6
- 1. RHR Service Water Dissolved and Entrained 1E-5 System Effluent Gases (Gamma Emitters)c Linet M H-3 1E-5
- 2. Service Water System Composited Gross Alpha 1E-7 Effluent Line t Q Sr-89, Sr-90 5E-8 Composited Fe-55 1E-6 Rev.29 Page 32 of 329 12/2016
CY-LG-170-301 TABLE 4.2-1 (Continued) TABLE NOTATIONS
- a. The LLD is defined as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95%
probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. For a measurement system, which may include radiochemical separation: (2. 71 + 4.66cr~) (A.L'.1t2) LLD ( C o m p o s i t e ) = - - - - - - - - - - - - - - - - - - - E
- V
- 2.22E6
- Y *[exp (-A.L1t1)] (1-exp(-A.L'.1t2))
(2.71 + 4.66 cr~) LLD (Grab S a m p l e s ) = - - - - - - - - - - - - - E
- V
- 2.22E6
- Y (exp - A.L'.1t1)
Where: 2.71 is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation. LLD is the a priori lower limit of detection as defined above ( as microcuries per unit mass or volume). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time {(A.L1t2) I [exp(-A.L'.1t1)](1-exp(-A.L'.1t2))}. is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute), E is the counting efficiency, as counts per disintegration, v is the sample size, in units of mass or volume, 2.22E6 is the number of disintegrations per minute per microcurie, y is the fractional radiochemical yield, when applicable, A. is the radioactive decay constant for the particular radionuclide, L1t1 for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count. for the plant effluents is the elapsed time between the start and the end of sample collection. Rev.29 Page 33 of 329 12/2016
CY-LG-170-301 TABLE 4.2-1 (Continued) TABLE NOTATIONS It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement.
- b. A batch release is the discharge of liquid wastes of a discrete volume. Prior to sampling for analyses, each batch shall be isolated, and then thoroughly mixed to assure representative sampling.
- c. The principal gamma emitters for which the LLD specification applies include the following radionuclides: Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, Cs-134, Cs-
_137, Ce-141 and Ce-144. The dissolved and entrained noble gases (gamma emitters) for which the LLD specification applies include the following radionuclides: Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, Xe-138. This list does not mean that only these nuclides are to be considered., Other gamma peaks that are identifiable, together with those of the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report pursuant to Administrative Control 6.2.
- d. The term "Composite Sample" means a combination of.individual samples obtained at regular intervals over a time period. Either the volume of each individual sample is proportional to discharge flow rates, or the sampling interval (for constant volume samples) is proportional to flow rates over the time period used to produce the composite.
- e. A continuous release is the discharge of liquid wastes of non-discrete volume, e.g.
from a volume of a system that has an input flow during the continuous release.
- f. Whenever effluent releases are in excess of the monitor's setpoint.
Rev.29 Page 34 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.2 DOSE CONTROLS 3.2.1.2 ' The dose or dose commitment to a MEMBER OF THE PUBLIC from radioactive materials in liquid effluents released from the site to UNRESTRICTED AREAS (See Figure 1-1) shall be limited:
- a. During any calendar quarter to less than or equal to 3 mrem to the total body and to less than or equal to 10 mrem to any organ, and
- b. During any calendar year to less than or equal to 6 mrem to the total body and to less than or equal to 20 mrem to any organ.
APPLICABILITY: At all times. ACTION:
- a. With the calculated dose from the release of radioactive materials in liquid effluents exceeding any of the above limits, Initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. This Special Report shall also include: (1) the results of the radiological analyses of the drinking water source, and (2) the radiological impact on finished drinking water supplies with regard to the requirements of 40 CFR Part 141, Safe Drinking Water Act.*
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.1.2 Cumulative dose contributions from liquid effluents for the current calendar quarter and the current calendar year shall.be determined at least once per 31 days.
- The requirements of Action A. (1) and (2) are applicable only if drinking water supply is taken from the receiving water body within 3 miles of the plant discharge. In the case of river-sited plants this is 3 miles downstream only.
Rev.29 Page 35 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM CONTROLS 3.2.1.3 The liquid radwaste treatment system shall be IN SERVICE and appropriate portions of the system shall be used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent, from the site, to UNRESTRICTED AREAS (See Figure 1-1) would exceed 0.12 mrem to the total body or 0.4 mrem to any organ in a 31-day period. APPLICABILITY: At all times. ACTION:
- a. With radioactive liquid waste being discharged without treatment and in excess of the above limits and any portion of the Liquid Radwaste Treatment System not in operation initiate a Special Report that includes the following information:
- 1. Explanation of what liquid radwaste was being discharged without treatment, identification of any inoperable equipment or subsystems, and the reason for the inoperability.
- 2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and
- 3. Summary description of action(s) taken to prevent a recurrence.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.1.3.1 Dose due to liquid releases from the site to UNRESTRICTED AREAS shall be projected at least once per 31 days, in accordance with the methodology and parameters in the ODCM when Liquid Radwaste Treatment Systems are not being fully utilized. 4.2.1.3.2 The installed Liquid Radwaste Treatment System shall be considered OPERABLE by meeting Controls 3.2.1.1 and 3.2.1.2 Rev.29 Page 36 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.1 DOSE RATE CONTROLS 3.2.2.1 The dose rate due to radioactive materials released in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to:
- a. For noble gases: less than or equal to 500 mrem/yr to the total body and less than or equal to 3000 mrem/yr to the skin, and
- b. For iodine-131, iodine-133, tritium, and for all radionuclides in particulate form with half-lives greater than 8 days: less than or equal to 1500 mrem/yr to any organ (Inhalation pathway only).
APPLICABILITY: At all times. ACTION:
- a. With the dose rate(s) exceeding the above limits, immediately restore the release rate to within the above limits.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.2.1.1 The dose rate due to noble gases in gaseous effluents shall be determined to be within the above limits in accordance with the methodology and parameters in the ODCM. 4.2.2.1.2 The dose rate due to iodine-131, iodine-133, tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents shall be determined to be within the above limits in accordance with the methodology and parameters in the ODCM by obtaining representative samples and performing analyses in accordance with the sampling and analysis program specified in Table 4.2-2. Rev.29 Page 37 of 329 12/2016
CY-LG-170-301 TABLE 4.2-2 RADIOACTIVE GASEOUS WASTE SAMPLING AND ANALYSIS PROGRAM Minimum Lower Limit of Gaseous Release Sampling Analysis Type of Activity Detection Point Frequency Frequency Analysis (LLD)a A. North Stack/ Mb Mb Noble Gas 1 E-4 uCi/cc South Stack Grab Sm~I. H-3 1 E-6 uCi/cc Continuousd we 1-131 1E-12 uCi/cc Char. Smpl. Part. Smpl. Principal 1E-11 uCi/cc Gamma Emitterse M Gross Alpha 1E-11 uCi/cc Comp. Part. Sr-89, Sr-90 1E-11 uCi/cc Sample Continuousd Continuous Noble Gas 1E-6 (Based Noble Gas Beta or Gamma on Xe-133) Monitor B. Hot Continuous a w 1-131 1 E-12 uCi/cc Mainten. Char. Smpl. Shop Vent Exhaustf Part. Smpl. Principal 1 E-11 uCi/cc Gamma Emitterse M Gross Alpha 1 E-11 uCi/cc Comp. Part. Sr-89, Sr-90 1E-11 uCi/cc Sample Rev.29 Page 38 of 329 12/2016
CY-LG-170-301 TABLE 4.2-2 (Continued) TABLE NOTATIONS
- a. The LLD is defined, as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95%
probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. It should be recognized that the LLD is defined as an ,a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. For a particular measurement system, (which may include radiochemical separation): (2.71 + 4.66crB) (/1.~h) LLD ( C o m p o s i t e ) = - - - - - - - - - - - - - - - - - E
- V
- 2.22E6
- Y *[exp (-A.~t1)](1-exp(-A.~h))
(2. 71 + 4.66 O"B) LLD (Grab S a m p l e s ) = - - - - - - - - - - - - - - E
- V
- 2.22E6
- Y (exp -A.~t 1 )
Where: 2.71 is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation. LLD is the a priori lower limit of detection as defined above (uCi/cc or uCi/ml). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time {{J..~h)/[exp(-A.~t1)](1-exp(-A.~h))}, is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as cpm), shall be based on the actual observed variance of the background counting rate or of the counting rate of the blank samples (as appropriate) rather than on an unverified theoretically predicted variance. E is the counting efficiency, as counts per disintegration, v is the sample size, in units of cc or ml, 2.22E6 is the number of dpm/uCi y is the fractional radiochemical yield, when applicable, A. is the radioactive decay constant for the particular radionuclide, and
~t1 for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count.
for the plant effluents is the elapsed time between the start and the end of sample collection. Rev.29 Page 39 of 329 12/2016 ' L
CY-LG-170-301 TABLE 4.2-2 (Continued) TABLE NOTATIONS .
- b. Sampling and analyses shall also be performed following shutdown, startup, or a THERMAL POWER change exceeding 15% of the RATED THERMAL POWER within a 1-hour period. This requirement does not apply if (1) analysis show that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the main condenser offgas pre-treatment radioactivity monitor shows that effluent activity has not increased more than a factor of 3.
- c. Samples shall be changed at least once per 7 days and analyses shall be completed within 48 hours after changing, or after removal from sampler. Sampling shall also be performed at least once per 24 hours for at least 7 days following each shutdown, startup or THERMAL POWER change exceeding 15% of RATED THERMAL POWER in 1 hour and analyses completed within 48 hours of changing. When samples collected for 24 hours are analyzed, the corresponding LLDs may be increased by a factor of 10. This requirement does not apply if (1) analysis shows that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the noble gas monitor shows that effluent activity has not increased more than a factor of 3.
- d. The ratio of the sample flow rate to the sampled stream flow rate shall be known for the time period covered by each dose or dose rate calculation made in accordance with Controls 3.2.2.1, 3.2.2.2, and 3.2.2.3.
- e. The principal gamma emitters for which the LLD specification applies include the following radionuclides: Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m and Xe-138 for gaseous emissions and Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, 1-131, Cs-134, Cs-137, Ce-141 and Ce-144 for particulate emissions. This list does not mean that only these nuclides are to be considered. Other gamma peaks which are identifiable, together with the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2.
- f. Required for the hot maintenance shop ventilation exhaust only during operation of the hot maintenance shop ventilation exhaust system.
Rev.29 Page 40 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.2 DOSE - NOBLE GASES CONTROLS 3.2.2.2 The air dose due to noble gases released in gaseous effluents, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following:
- a. During any calendar quarter: less than or equal to 10 mrad for gamma radiation and less than or equal to 20 mrad for beta radiation, and
- b. During any calendar year: less than or equal to 20 mrad for gamma radiation and less than or equal to 40 mrad for beta radiation.
APPLICABILITY: At all times. ACTION:
- a. With the calculated air dose from radioactive noble gases in gaseous effluents exceeding any of the above limits, initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.2.2 Cumulative dose contributions for the current quarter and current calendar year for noble gases shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days. Rev.29 Page 41 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.3 DOSE- IODINE-131, IODINE-133, TRITIUM. AND RADIOACTIVE MATERIAL IN PARTICULATE FORM CONTROLS 3.2.2.3 The dose to a MEMBER OF THE PUBLIC from iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following:
- a. During any calendar quarter: less than or equal to 15 mrem to any organ and,
- b. During any calendar year: less than or equal to 30 mrem to any organ.
APPLICABILITY: At all times. ACTION:
- a. With the calculated dose from the release of iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents exceeding any of the above limits, initiate a Special Report that identifies the cause(s) for exceeding the limit and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits.
- b. The provisions of Controls 3.0.3*and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.2.3 Cumulative dose contributions for the current calendar quarter and current calendar year for iodine-131, iodine-133, tritium and radionuclides in particulate form with half-lives greater than 8 days shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days. Rev.29 Page 42 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS . 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.4 GASEOUS RADWASTE (OFFGAS) TREATMENT SYSTEM CONTROLS 3.2.2.4 Section is not applicable. See UFSAR Chapter 11.3. Rev.29 Page 43 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.5 VENTILATION EXHAUST TREATMENT SYSTEM CONTROLS 3.2.2.5 The VENTILATION EXHAUST TREATMENT SYSTEM shall be OPERABLE and appropriate portions of the system shall be used to reduce releases of radioactivity when the projected doses in 31 days due to gaseous effluent releases, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) would exceed
- a. 0.4 mrad to air from gamma radiation, or
- b. 0.8 mrad to air from beta radiation, or
- c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC.
APPLICABILITY: At all times. ACTION:
- a. With gaseous waste being discharged without treatment, and in excess of the above limits, initiate a Special Report that includes the following information:
- 1. Identification of any inoperable equipment or subsystems, and the reason for the inoperability.
- 2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and
- 3. Summary description of action(s) taken to prevent a recurrence.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.2.5.1 Doses due to gaseous releases from the site to areas at and beyond the SITE BOUNDARY shall be projected at least once per 31 days in accordance with the methodology and parameters in the ODCM, when the Ventilation Exhaust Treatment System is not being fully utilized. 4.2.2.5.2 The installed VENTILATION EXHAUST TREATMENT SYSTEM shall be considered OPERABLE by meeting Controls 3.2.2.1, and either 3.2.2.2 or 3.2.2.3 Rev.29 Page 44 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.6 Not Used CONTROLS 3.2.2.6 Section is not applicable. Rev.29 Page 45 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.7 MARK II CONTAINMENT CONTROLS 3.2.2.7 The VENTING or PURGING of the Mark II containment drywell shall be through the Standby Gas Treatment System. APPLICABILITY: Whenever the drywell is vented or purged.* ACTION:
- a. With the requirements of the above control not satisfied, suspend all VENTING and PURGING of the dryWell.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.2.7.1 The containment drywell shall be determined to be aligned for VENTING or PURGING through the Standby Gas Treatment System within 4 hours prior to start of and at least once per 12 hours during VENTING or PURGING of the containment. 4.2.2.7.2 Prior to use of the purge system through the standby gas treatment system assure that:
- a. Both standby gas treatment system trains are OPERABLE whenever the purge system is in use, and
- b. Whenever the purge system is in use, only one of the standby gas treatment system trains shall be used to prevent damage to both trains should a LOCA occur (LCO 3.6.5.3 ACTION a applies during this configuration).
- Except after Containment is deinerted and purged OR for the one inch/two inch vent valves to the Reactor Enclosure Equipment Compartment Exhaust Filters when used for containment pressure control and nitrogen make-up operations.
Rev.29 Page 46 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.3 TOTAL DOSE CONTROLS 3.2.3 The annual (calendar year) dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from uranium fuel cycle sources shall be limited to less than or equal to 25 mrem to the total body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem. APPLICABILITY: At all times. ACTION:
- a. With the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b.,
3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., or 3.2.2.3.b calculations shall be made including direct radiation contributions from the reactor units (including outside storage tanks, etc.) to determine whether the above limits of Control 3.2.3 have been exceeded. If such is the case, initiate a Special Report that defines the corrective action to be taken to reduce subsequent releases to prevent recurrence of exceeding the above limits and includes the schedule for achieving conformance with the above limits. This Report, as defined in 10 CFR 20.2203, shall include an analysis that estimates the radiation exposure (dose) to a MEMBER OF THE PUBLIC from the uranium fuel cycle sources, including all effluent pathways and direct radiation, for the calendar year that includes the release(s) covered by this report. It shall also describe levels of radiation and concentration of radioactive material involved, and the cause of the exposure levels or concentrations. If the estimated dose(s) exceeds the above limits, and if the release condition resulting in violation of 40 CFR Part 190 or 10 CFR 72.104 has not already been corrected, the Special Report shall include a request for a variance in accordance with the provisions of 40 CFR Part 190 or 10 CFR 72.104. Submittal of the report is considered a timely request, and a variance is granted until staff action on the request is complete.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.2.3.1 Cumulative dose contributions from liquid and gaseous effluents shall be determined in accordance with Surveillance Requirements 4.2.1.2, 4.2.2.2, and 4.2.2.3, and in accordance with the methodology and parameters in the ODCM. 4.2.3.2 Cumulative dose contributions from direct radiation from the units (including outside storage tanks, ISFSI, etc.) shall be determined in accordance with the methodology and parameters in the ODCM. This requirement is applicable only under conditions set forth in Action a. of Control 3.2.3. Rev. 29 Page 4 7 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.1 MONITORING PROGRAM CONTROLS 3.3.1 The Radiological Environmental Monitoring Program shall be conducted as specified in Table 3.3-1. APPLICABILITY: At all times. ACTION:
- a. With the Radiological Environmental Monitoring Program not being conducted as specified in Table 3.3-1, prepare and submit to the Commission, in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1, a description of the reasons for not conducting the program as required and the plans for preventing a recurrence.
- b. With the level of radioactivity as the result of plant effluents in an environmental sampling medium at a specified location exceeding the reporting levels of Table 3.3-2 when averaged over any calendar quarter, initiate a Special Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions to be taken to reduce radioactive effluents so that the potential annual dose to a MEMBER OF THE PUBLIC is less than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. When more than one of the radionuclides in Table 3.3-2 are detected in the sampling medium, this report shall be submitted if:
concentration (1) + concentration (2) + ... .:::_ 1.0 reporting level (1) reporting level (2) When radionuclides other than those in Table 3.3-2 are detected and are the result of plant effluents, a Special Report shall be initiated if the potential annual dose* to a MEMBER OF THE PUBLIC is equal to or greater than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. A Special Report is not required if the measured level of radioactivity was not the result of plant effluents; however; in such an event, the condition shall be reported and described in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1.
- The methodology and parameters used to estimate the potential annual dose to a MEMBER OF THE PUBLIC shall be indicated in this report.
Rev.29 Page 48 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.1 MONITORING PROGRAM CONTROLS ACTION (Continued)
- c. With milk or fresh leafy vegetable samples unavailable from one or more of the sample locations required by Table 3.3-1, identify locations for obtaining replacement samples and add them to the radiological environmental monitoring program within 30 days. The specific locations from which samples were unavailable may then be deleted from the monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the Annual Radioactive Effluent Release Report, a complete, legible copy of the entire ODCM, including a revised figure(s) and table for the ODCM reflecting the new location(s).
- d. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.3.1 The radiological environmental monitoring samples shall be collected pursuant to Table 3.3-1 from the specific locations given in the table and figure(s) in the ODCM and shall be analyzed pursuant to the requirements of Table 3.3-1, with the detection capabilities required by the Table 4.3-1. I
**\
Rev.29 Page 49 of 329 12/2016
CY-LG-170-301 TABLE 3.3-1 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM* NUMBER OF REPRESENTATIVE EXPOSURE PATHWAY SAMPLES AND SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLE LOCATION<al COLLECTION FREQ. OF ANALYSIS
- 1. DIRECT RADIATIONb 40 routine monitoring stations either Quarterly Gamma dose quarterly.
with two or more dosimeters or with one instrument for measuring and recording dose rate continuously placed as follows: ( 1) An inner ring of stations, one in each meteorological sector, in the general area of the SITE BOUNDARY: ( 2) An outer ring of stations, one in each meteorological sector, in the 3-9 mile range from the site; ( 3 ) The balance of the stations placed in special interest areas such as population centers, nearby residences, schools and in 1 or 2 areas to serve as control stations.
- The number, media, frequency, and location of samples may vary from site to site. This table presents an acceptable minimum program for a site at which each entry is applicable. Local site characteristics must be examined to determine if pathways not covered by this table may significantly contribute to an individual's dose and should be included in the sample program.
Rev.29 Page 50 of 329 12/2016
CY-LG-170-301 TABLE 3.3-1 (Continued) RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a)
- 2. AIRBORNE Samples from 5 locations: Continuous sampler operation Radioiodine canisters:
Radioiodine and 3 samples from close to the 3 with sample collection weekly, 1-131 analysis weekly Particulates SITE BOUNDARY locations (in or more frequently if required different sectors) of the highest by dust loading. calculated annual average Particulate Sampler: ground-level D/Q. Gross beta radio activity analysis following filter 1 sample from the vicinity change:c community having one of the Gamma isotopic analysisd of highest calculated annual ground composite (by location) at level D/Q. least quarterly 1 sample from a control location, as for example 15-30 km distant and in the least prevalent wind direction. Rev. 29 Page 51 of 329 12/2016
,------- 1 I CY-LG-170-301 TABLE 3.3-1 (Continued) RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a)
- 3. WATERBORNE
- a. Surfacee 1 sample upstream Composite sample over 1- Gamma isotopic analysisd 1 sample downstream month periodt. monthly. Composite for tritium analysis quarterly.
- b. Ground Samples from 1 or 2 sources only Quarterly. Gamma isotopicd and tritium if likely to be affected 9 analysis
- c. Drinking 1 sample of each on 1 to 3 of the Composite sample over 2- 1-131 analysis on each nearest water supplies that could week periodf when 1-131 composite when the dose be affected by its discharge. analysis is performed; calculated for the monthly composite otherwise. consumption of the water is greater than 1 mrem per 1 sample from a control location year.h Composite for gross beta and gamma isotopicd analysis monthly. Composite for tritium analysis quarterly.
- d. Sediment from 1 sample from downstream area Semiannually. Gamma isotopic analysisd shoreline with existing or potential semiannually.
recreational value. Rev.29 Page 52 of 329 12/2016
CY-LG-170-301 TABLE 3.3-1 (Continued) RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF REPRESENTATIVE EXPOSURE PATHWAY SAMPLES AND SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLE LOCATION(a) COLLECTION FREQ. OF ANALYSIS
- 4. INGESTION Samples from milking animals in 3 Semimonthly when animals Gamma isotopica and
- a. Milk locations within 5 km distance are on pasture, monthly at 1-131 analysis semimonthly having the highest dose potential. other times. when animals are on pasture If there are none, then 1 sample (April 1 - Oct. 1): monthly at from milking animals in each of 3 other times.
areas between 5 to 8 km distance where dose are calculated to be greater than 1 mrem per year. h 1 sample from milking animals at a control location (15-30 km distance) and in the least prevalent wind direction.
- b. Fish and 1 sample of each commercially and Sample in season, or Gamma isotopicct analysis on Invertebrates recreationally important species in semiannually if they are not edible portions.
vicinity of plant discharge area. seasonal. 1 sample of same species in area not influenced by plant discharge. Rev.29 Page 53 of 329 12/2016
CY-LG-170-301 TABLE 3.3-1 (Continued) RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a)
- 4. INGESTION (Continued)
- c. Food Products 1 sample of each principal class At time of harvesti Gamma isotopicd and of food products from any area 1-131 analysis.
that is irrigated by water in which liquid plant wastes have been discharged Samples of 3 different kinds of Monthly during the growing Gamma isotopicd and 1-131 broad leaf vegetation grown season analysis. nearest each of 2 different offsite locations of highest predicted annual average ground level D/Q if milk sampling is not performed. 1 sample of each of the similar Monthly during the growing Gamma isotopicd and 1-131 broad leaf vegetation grown 15-30 season analysis. km distance in the least prevalent wind direction if milk sampling is not performed. Rev. 29 Page 54 of 329 12/2016
CY-LG-170-301 TABLE 3.3-1 (Continued) TABLE NOTATIONS
- a. Specific parameters of distance and direction sector from the centerline of the two reactors and additional description where pertinent, shall be provided for each and every sample location in Table 3.3-1 in a table and figure(s) in the ODCM.
Deviations are permitted from the required sampling schedule if specimens are unobtainable due to hazardous conditions, seasonal unavailability, malfunction of automatic sampling equipment and other legitimate reasons. If specimens are unobtainable due to sampling equipment malfunction, every effort shall be made to complete corrective action prior to the end of the next sampling period. All deviations from the sampling schedule shall be documented in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. It is recognized that, at times, it may not be possible or practicable to continue to obtain samples of the media of choice at the most desired location or time. In these instances suitable alternative media and locations may be chosen for the particular pathway in question and appropriate substitutions made within 30 days in the radiological environmental monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the next Annual Radioactive Effluent Release Report a complete legible copy of the ODCM including a revised figure(s) and table for the ODCM reflecting the new location(s).
- b. One or more instruments, such as a pressurized ion chamber, for measuring and recording dose rate continuously may be used in place of, or in addition to, integrating dosimeters. For the purpose of this table, a dosimeter (OSL, TLD, or similar) is considered to be one element; two or more elements in a packet are considered as two or more dosimeters. Film badges shall not be used as dosimeters for measuring direct radiation.
- c. Airborne particulate sample filters shall be analyzed for gross beta radioactivity 24 hours or more after sampling to allow for radon and thoron daughter decay. If gross beta activity in air particulate samples is greater that 10 times the yearly mean of control samples, gamma isotopic analysis shall be performed on the individual samples.
- d. Gamma isotopic analysis means the identification and quantification of gamma-emitting radionuclides that may be attributable to the effluents from the facility.
- e. The "upstream sample" shall be taken at a distance beyond significant influence of the discharge. The "downstream sample" shall be taken in an area beyond but near the mixing zone.
Rev.29 Page 55 of 329 12/2016
CY-LG-170-301 TABLE 3.3-1 (Continued) TABLE NOTATIONS (Continued)
- f. A composite sample is one in which the quantity (aliquot) of liquid sampled is proportional to the quantity of flowing liquid and in which the method of sampling employed results in a specimen that is representative of the liquid flow. In this program composite sample aliquots shall be collected at time intervals that are very short (e.g., hourly) relative to the compositing period (e.g., monthly) in order to assure obtaining a representative sample.
- g. Groundwater samples shall be taken when this source is tapped for drinking or irrigation purposes in areas where the hydraulic gradient or recharge properties are suitable for contamination.
- h. The dose shall be calculated for the maximum organ and age group using the methodology and parameters in the ODCM.
- i. If harvest occurs more than once a year, sampling shall be performed during each discrete harvest. If harvest occurs continuously, sampling shall be monthly.
Attention shall be paid to including samples of tuberous and root food produets. Rev.29 Page 56 of 329 12/2016
CY-LG-170-301 TABLE 3.3-2 REPORTING LEVELS FOR RADIOACTIVITY CONCENTRATIONS IN ENVIRONMENTAL SAMPLES _Reporting Levels AIRBORNE FOOD WATER PARTICULATE or FISH MILK PRODUCTS ANALYSIS (pCi/I) GASES(pCi/m 3) (pCi/kg, wet) (pCi/I) (pCi/kg, wet) H-3 20,000* Mn-54 1,000 30,000 Fe-59 400 10,000 Co-58 1,000 30,000 Co-60 300 10,000 Zn-65 300 20,000 Zr-Nb-95 400*** 1-131 2** 0.9 3 100 Cs-134 30 10 1,000 60 1,000 Cs-137 50 20 2,000 70 2,000 Ba-La-140 200*** 300
- For drinking water samples. This is a 40 CFR Part 141 value. If no drinking pathway exists, a value of 30,000 pCi/I may be used.
- If no drinking water pathway exists, a value of 20 pCi/I may be used
- Total for parent and daughter.
- If no drinking water pathway exists, a value of 20 pCi/I may be used
Rev.29 Page 57 of 329 12/2016
CY-LG-170-301 TABLE 4.3-1 DETECTION CAPABILITIES FOR ENVIRONMENTAL SAMPLE ANAL YS1s<a> (b) Lower limit of Detection (LLD)<c> AIRBORNE FOOD PARTICULATE or FISH PRODUCTS SEDIMENT WATER GASES (pCi/kg, MILK (pCi/kg, (pCi/kg, ANALYSIS (pCi/I) (pCi/m 3) wet) (pCi/I) wet) dry) Gross Beta 4 0.01 H-3 2,000* Mn-54 15 130 Fe-59 30 260 Co-58 15 130 Co-60 15 130 Zn-65 30 260 Zr-95 30 Nb-95 15 1-131 1** 0.07 1 60 Cs-134 15 0.05 130 15 60 150 Cs-137 18 0.06 150 18 80 180 Ba-140 60 60 La-140 15 15
- If no drinking water pathway exists, a value of 3000 pCi/I may be used.
- If no drinking water pathway exists, a value of 15 pCi/I may be used.
Rev.29 Page 58 of 329 12/2016
CY-LG-170-301 TABLE 4.3-1 (Continued) TABLE NOTATIONS (a) This list dose not mean that only these nuclides are to considered. Other peaks that are identifiable at 95% confidence level, together with those of the above nuclides, shall also be ~malyzed and reported in the Annual Radiological Environmental Operating report pursuant to Administrative Control 6.1. (b) Required detection capabilities for thermoluminescent dosimeters used for environmental measurements are given in Regulatory Guide 4.13. (c) The LLD is defined, for purposes of these controls, as the smallest concentration of radioactive material in a sample that will yield a net count (above system background) that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. For a particular measurement system (which may include radiochemical separation): LLD= 4.66sb E
- V
- 2.22
- Y
- exp<-Mi)
Where: LLD is the a priori lower limit of detection as defined above (as picocuries per unit mass or volume), Sb is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute), E is the counting efficiency (as counts per disintegration), v is the sample size (in units of mass or volume), 2.22 is the number of disintegrations per minute per picocurie, y is the fractional radiochemical yield (when applicable), A. is the radioactive decay constant for the particular radionuclide, and At for the environmental samples is the elapsed time between sample collection (or end of the sample collection period) and time of counting. Typical values of E, V, Y and At should be used in the calculation Rev.29 Page 59 of 329 12/2016
CY-LG-170-301 TABLE 4.3-1 (Continued) TABLE NOTATIONS (Continued) It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. Analyses shall be performed in such a manner that the stated LLDs will be achieved under routine conditions. Occasionally background fluctuations, unavoidably small sample sizes, the presence of interfering nuclides, or other uncontrollable circumstances may render these LLDs unachievable. In such cases, the contributing factors shall be identified and described in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. Rev.29 Page 60 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.2 LAND USE CENSUS CONTROLS 3.3.2 A land use census shall be conducted and shall identify within a distance of 8 km (5 miles) the location (in each of the 16 meteorological sectors) of the nearest . milk animal, the nearest residence and the nearest garden* of greater than 50 m2 (500 ft2) producing broad leaf vegetation. APPLICABILITY: At all times. ACTION:
- a. With a land use census identifying a location(s) that yields a calculation dose or dose commitment greater than the values currently being calculated in Control 3.2.2.3, identify the new location(s) in the next Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2.
- b. With a land use census identifying a location(s) that yields a calculated dose or dose commitment (via the same exposure pathway) 20% greater than at a location from which samples are currently being obtained in accordance with Control 3.2.2.3, add the new location(s) to the radiological environmental monitoring program within 30 days. The sampling location(s), excluding the control station location, having the lowest calculated dose or dose commitment(s) (via the same exposure pathway) may be deleted from this monitoring program after October 31 of the year in which this land use census was conducted. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with in the next Annual Radioactive Effluent Release Report a complete, legible copy of the entire ODCM including a revised figure(s) and table(s) for the ODCM reflecting the new location(s).
- c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.3.2 The land use census shall be conducted during the growing season at least once per 12 months using that information that will provide the best results, such as by a door-to-door survey, aerial survey, or by consulting local agriculture authorities. The results of the land use census are included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1.
- Broad leaf vegetation sampling of at least 3 different kinds of vegetation may be performed at the SITE BOUNDARY in each of 2 different direction sectors with the highest predicted D/Qs in lieu of the garden census. Controls for broad leaf vegetation sampling in Table 3.3-1 item 4.c. shall be followed, including analysis of control samples.
Rev.29 Page 61 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.3 INTERLABORATORY COMPARISON PROGRAM CONTROLS 3.3.3 In accordance with LGS Technical Specification 6.8.4.f, analyses shall be performed on radioactive materials supplied as part of an lnterlaboratory Comparison Program traceable to NIST, that correspond to samples required by Table 3.3-1. APPLICABILITY: At all times. ACTION:
- a. With analyses not being performed as required above, report the corrective actions taken to prevent a recurrence to the Commission in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.3.3 The lnterlaboratory Comparison Program shall be described in the ODCM. A summary of the results shall be included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1 Rev.29 Page 62 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION CONTROLS 3.3.4 The meteorological monitoring instrumentation channels shown in Table 3.3-3 shall be OPERABLE. APPLICABILITY: At all times. ACTION:
- a. With less than the minimum required instrumentation channels OPERABLE for more than 7 days, initiate an Issue Report outlining the cause of the malfunction and the plans for restoring the instrumentation to OPERABLE status.
- b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.
SURVEILLANCE REQUIREMENTS 4.3.4 Each of the above required meteorological monitoring instrumentation channels shall be demonstrated OPERABLE by the performance of the CHANNEL CHECK and CHANNEL CALIBRATION operations at the frequencies shown in Table 4.3-2. Rev.29 Page 63 of 329 12/2016
CY-LG-170-301 TABLE 3.3-3 METEOROLOGICAL MONITORING INSTRUMENTATION INSTRUMENT TOWER 1 TOWER2 MINIMUM (PRIMARY) (BACKUP) INSTRUMENT OPERABLE
- 1. Wind Speed
- a. Elevation 1 30 feet 159 feet 1
- b. Elevation 2 175 feet 304 feet 1
- 2. Wind Direction
- a. Elevation 1 30 feet 159 feet 1
- b. Elevation 2 175 feet 304 feet 1
- 3. Air Temperature Difference (~T)
- a. Elevations 266 feet 300 feet 26 feet 26 feet 1 Rev.29 Page 64 of 329 12/2016
CY-LG-170-301 TABLE 4.3-2 METEOROLOGICAL MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS INSTRUMENT CHANNEL CHANNEL CHECK CALIBRATION
- 1. Wind Speed
- a. Elevation 1 (Tower 1 and Tower 2) D SA
- b. Elevation 2 (Tower 1 and Tower 2) D SA
- 2. Wind Direction
- a. Elevation 1 (Tower 1 and Tower 2) D SA
- b. Elevation 2 (Tower 1 and Tower 2) D SA
- 3. Air Temperature Difference (~ T)
- a. Elevations 266 - 26 ft (Tower 1) D SA
- b. Elevations 300 - 26 ft (Tower 2) D SA NOTE:
The meteorological towers shall be located as shown on Figure 3.3-1. Rev.29 Page 65 of 329 12/2016
- -- _ __J
CY-LG-170-301 Figure 3.3-1 METEOROLOGICAL TOWER LOCATIONS Rev.29 Page 66 of 329 . 12/2016
CY-LG-170-301 3/4.0 CONTROLS BASES GENERAL It is expected that releases of radioactive material in effluents will be kept at small fractions of the limits specified in Section 20.1302 of 10 CFR, Part 20. At the same time, the licensee is permitted the flexibility of operation, compatible with consideration of health and safety, to assure that the public is provided a dependable source of power even under unusual operating conditions which may temporarily result in releases higher than such small fractions, but still within the limits specified in Section 20.1302 of 10 CFR, Part 20. It is expected that in using this operational flexibility under unusual operating conditions the licensee will exert his best efforts to keep levels of radioactive material in effluents as low as practicable. MAPS DEFINING UNRESTRICTED AREAS AND SITE BOUNDARY FOR RADIOACTIVE GASEOUS AND LIQUID EFFLUENTS Information regarding radioactive gaseous and liquid effluents, which will allow identification of structures and release points as well as definition of UNRESTRICTED AREAS within the SITE BOUNDARY that are accessible to MEMBER(S) OF THE PUBLIC, shall be as shown in Technical Specifications Figures 5.1.3-1 a and 5.1.3-1 b. The exclusion area and low population zone shall be as shown in Figures 1-1 and 1-2. 10 CFR 20 Per Technical Specification Section 6.8.4.d, the Radioactive Effluent Controls Program must conform with limitations specified in 10 CFR 50.36a, 10 CFR Part 50, Appendix I, 10 times the ECL limits of 10 CFR Part 20, Appendix B, Table 2, Column 2 and 40 CFR 190. (See Reference 14) Rev.29 Page 67 of 329 12/2016
CY-LG-170-301 3/4.0 CONTROLS BASES 3/4.0 APPLICABILITY Compliance with the controls is required during the OPERATIONAL CONDITIONS or other conditions specified therein; except that upon failure to meet the controls, the associated ACTION requirements shall be met.
- Non compliance with a Control shall exist when the requirements of the control and associated ACTION requirements are not performed within the specified time intervals. If the control is restored prior to expiration of the specified time intervals, completion of the ACTION requirements is not required.
There are no actions in the ODCM which would require an operational condition change. There are no restrictions on changing operating conditions in any of the controls on the ODCM. Surveillance Requirements shall be met during the OPERATIONAL CONDITIONS or other conditions specified for individual controls unless otherwise stated in an individual Surveillance R~quirement. Each Surveillance Requirement shall be performed within the specified interval with a maximum allowable extension not to exceed 25% of the surveillance interval. Failure to perform a Surveillance Requirement within the allowed surveillance interval defined by Surveillance Requirement 4.0.2.a, shall constitute noncompliance with the OPERABILITY requirements for a control. The time limits of the ACTION requirements are applicable at the time it is identified that a Surveillance Requirement has not been performed. The ACTION requirements may be delayed for up to 24 hours to permit the completion of the surveillance when the allowable outage time limits of the ACTION requirements are less than 24 hours. Surveillance requirements do not have to be performed on inoperable equipment.
- The associated bases from the LGS Technical Specifications apply to this section.
Rev.29 Page 68 of 329 12/2016
CY-LG-170-301 3/4.1 INSTRUMENTATION BASES 3/4.1.1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION The radioactive liquid effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in liquid effluents during actual or potential releases of liquid effluents. The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50. 3/4.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION The radioactive gaseous effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in gaseous effluents during actual or potential releases of gaseous effluents. The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and
- use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50.
( Rev.29 Page 69 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.1 CONCENTRATION This control is provided to ensure that the concentration of radioactive materials released in liquid waste effluents to areas at and beyond the UNRESTRICTED AREAS will be less than 10 times the effluent concentration limits (ECL) specified in 10 CFR Part 20, Appendix B, Table 2, Column 2. This instantaneous limitation provides additional assurance that the levels of radioactive materials in bodies of water in areas at and beyond the SITE BOUNDARY will result in exposures within (1) the Section II.A design objectives of Appendix I, 10 CFR Part 50, to a MEMBER OF THE PUBLIC, and (2) the limits of 10 CFR 20.1302 to the population. The concentration limits for dissolved or entrained noble gases are based upon the assumption that Xe-135 is the controlling radioisotope and its ECL in air (submersion) was converted to an equivalent concentration in water using the methods described in the International Commission on Radiological Protection (ICRP) Publication 2. The required detection capabilities for radioactive materials in liquid waste samples are tabulated in terms of the lower limits of detection (LLDs). Detailed discussion of the LLD, and other detection limits can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry"; Anal. Chem. 40, 586-93 (1968); and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). 3/4.2.1.2 DOSE This Control is provided to implement the requirements of Sections II.A, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.1.2 implements the guidance set forth in Section II.A of Appendix I and provides the required operating flexibility and at the same time implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in liquid effluents will be kept "as low as reasonably achievable". Also, for fresh water sites with drinking water supplies which can be potentially affected by plant operations, there is reasonable assurance that the operation of the facility will not result in radionuclide concentrations in the finished drinking water that are in excess of the requirements of 40 CFR Part 141. The Surveillance Requirement 4.2.1.2 implement the requirements in Section Ill.A of Appendix I that conformance with the guidance of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. The equations specified in the ODCM for calculating the doses due to the actual release rates of radioactive materials in liquid effluents are Rev.29 Page 70 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," April, 1977. This control applies to the release of radioactive materials in liquid effluents from the site. 3/4.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM The requirement that the appropriate portions of this system be used when specified provides assurance that the releases of radioactive materials in liquid effluents will be kept "as low as reasonably achievable". Control 3.2.1.3 implements the requirements of 10 CFR 50.35a, General Design Criterion 60 of Appendix A to 10 CFR Part 50 and the design objective given in Section 11.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the liquid radwaste treatment system were specified as a suitable fraction of the dose design objectives set forth in Section II.A of Appendix I, 10 CFR Part 50, for liquid effluents. 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.1 DOSE RATE This control is provided to ensure that the dose from radioactive materials in gaseous effluents at and beyond the SITE BOUNDARY will be within the annual dose limits of 10 CFR Part 20 to UNRESTRICTED AREAS. The annual dose limits are the doses associated with the concentrations of 10 CFR Part 20, Appendix B, Table 2, Column 1. These limits provide reasonable assurance that radioactive material discharged in gaseous effluents will not result in the exposure of a MEMBER OF THE PUBLIC, either within or outside the SITE BOUNDARY, to annual average concentrations exceeding the limits specified in Appendix B, Table 2 of 10 CFR Part 20. For MEMBERS OF THE PUBLIC who may at times be within the SITE BOUNDARY, the occupancy factor for that MEMBER OF THE PUBLIC will usually be sufficiently low to compensate for any increase in the atmospheric diffusion factor for above that for the SITE BOUNDARY. Examples of calculations for such MEMBERS OF THE PUBLIC, with the appropriate occupancy factors, are given in the ODCM. The specified release rate limits restrict, at all times, the corresponding gamma and beta dose rates above background to a MEMBER OF THE PUBLIC at or beyond the SITE BOUNDARY to less than or equal to 500 mrem/year to the total body or to less than or equal to 3000 mrem/year to the skin. These release rate limits also restrict, at all times, the corresponding thyroid dose rate above background to a child via the inhalation pathway to less than or equal to 1500 mrem/year. Rev.29 Page 71 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES This Control applies to the release of radioactive materials in gaseous effluents from all reactors at the site. The required detection capability for radioactive materials in gaseous waste samples are tabulated in terms of the lower limits of detection (LLDs). Detailed discussion of the LLD, and other detection limits can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry"; Anal. Chem. 40, 586-93 (1986); and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques." Atlantic Richfield Hanford Company Report ARH-SA-215 (June 1975). 3/4.2.2.2 DOSE - NOBLE GASES This control is provided to implement the requirements of Sections 11.B, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.2.2 implements the guidance set forth in Section 11.B of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in gaseous effluents will be kept "as low as reasonably achievable". The Surveillance Requirement 4.2.2.2 implement the requirements in Section Ill.A of Appendix I that conformance with the guides of Appendix I be shown by calculational procedures based on appropriate pathways is unlikely to be substantially underestimated. The dose calculation established in the ODCM for calculating the doses due to the actual release rates of radioactive noble gases in gaseous effluents are consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routing Releases from Light-Water Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. The ODCM equations provided for determining the air doses at and beyond the SITE BOUNDARY are based upon the historical average atmospheric conditions. 3/4.2.2.3 DOSE - IODINE-131. IODINE-133, TRITIUM. AND RADIONUCLIDES IN PARTICULATE FORM This control is provided to implement the requirements of Sections 11.C, Ill.A, and IV.A of Appendix I, 10 CFR Part 50. Control 3.2.2.3 implements the guidance set forth in Section 11.C of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." The ODCM calculational methods specified in the Surveillance Requirements 4.2.2.3 implement the Rev.29 Page 72 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES requirements in Section Ill.A of Appendix I, that conformance with the guides of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. The ODCM calculational methods for calculating the doses due to the actual release rates of the subject materials are consistent with the methodology provided in NUREG-0133, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants" and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. These equations also provide for determining the actual doses based upon the historical average atmospheric conditions. The release rate specifications for iodine-131, iodine-133, tritium, and radionuclides in particulate form with half-lives greater than 8 days are dependent on the existing radionuclides pathways to man in areas at and beyond the SITE BOUNDARY. The pathways which were e~amined in the development of these calculations were: (1) individual inhalation of airborne radionuclides, (2) deposition of radionuclides onto green leafy vegetation with subsequent consumption by man, (3) deposition onto grassy areas where milk animals and meat-producing animals graze with consumption of the milk and meat by man, and (4) deposition on the ground with subsequent exposure of man. 3/4.2.2.4 AND 3/4.2.2.5 GASEOUS RADWASTE TREATMENT SYSTEM AND VENTILATION EXHAUST TREATMENT SYSTEM The requirement that the appropriate portions of this system be used, when specified, provides reasonable assurance that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." Controls 3.2.2.4 and 3.2.2.5 implements the requirements of 10 CFR 50.36a, General Design Criteria 60 of Appendix A to 10 CFR Part 50, and the design objectives given in Section 11.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the systems were specified as a suitable fraction of the dose design objectives set forth in Section 11.B and 11.C of Appendix I, 10 CFR Part 50, for gaseous effluents. 3/4.2.2.7 MARK II CONTAINMENT This control provides reasonable assurance that releases from drywell venting or purging operations will not exceed the annual dose limits of 10 CFR Part 20 for areas at or beyond the UNRESTRICTED AREAS. Rev.29 Page 73 of 329 12/2016
CY-LG-170-301 3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4.2.3 TOTAL DOSE This control is provided to meet the dose limitations of 40 CFR Part 190 that have been incorporated into 10 CFR Part 20 by 46 CFR 18525, as well as the dose limitations specific to Independent Spent Fuel Storage Installation (ISFSI) operations in accordance with 10 CFR 72.104. Over the long term, _as more storage modules containing _9ry shielded canisters of spent fuel are placed on the ISFSI pad, it is expected that ISFSI operations will become the prominent contributor to the dose limits in this section. ISFSI dose contribution is in the form of direct radiation as no liquid or gas releases are expected to occur from the ISFSI canisters. The LGS 10 CFR 72.212 Report prepared in accordance with 10 CFR 72 requirements assumes a certain array of storage modules exists on the pad. The dose contribution from this array of casks combination with historical uranium fuel cycle operations prior to ISFSI operations was analyzed to be within the 40 CFR 190 and 10 CFR 72.104 limits. Control 3.2.3 requires the preparation and submittal of a Special Report whenever the calculated doses due to releases of radioactivity and to radiation from uranium fuel cycle sources exceed 25 mrem to the whole body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem. For sites containing up to four reactors, it is highly unlikely that the resultant dose to a MEMBER OF THE PUBLIC will exceed the dose limits of 40 CFR Part 190 if the individual reactors remain within twice the dose design objectives of Appendix I, and if direct radiation does from the units (including outside storage tanks, etc.) are kept small. The Special Report will describe a course of action that should result in the limitation of the annual dose to a MEMBER .OF THE PUBLIC to within the 40 CFR Part 190 limits. For the purposes of the Special Report, it may be assumed that the dose commitment to the MEMBER OF THE PUBLIC from other uranium fuel cycle sources is negligible, with the exception that dose contributions from other nuclear fuel cycle facilities at the same site or within a radius of 5 miles must be considered. If the dose to any MEMBER OF THE PUBLIC is estimated to exceed the requirements of 40 CFR Part 190 or 10 CFR 72.104, the Special Report with a request for a variance (provided the release condition resulting in violation of 40 CFR Part 190 or 10 CFR 72.104 have not already been corrected), in accordance with the provisions of 40 CFR 190.11, or 10 CFR 72.104 and 10 CFR 20.2203, is considered to be a timely request and fulfills the requirements of 40 CFR Part 190 or 10 CFR 72.104 until NRC staff action is completed. The variance only relates to the limits of 40 CFR Part 190 or 10 CFR 72.104, and does not apply in any way to the other requirements for dose limitation of 10 CFR Part 20, as addressed in Controls 3.2.1.1 and 3.2.2.1. An individual is not considered a MEMBER OF THE PUBLIC during any period in which he/she is engaged in carrying out any operation that is part of the nuclear fuel cycle. Rev.29 Page 74 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING BASES 3/4.3.1 MONITORING PROGRAM The Radiological Environmental Monitoring Program (REMP) required by this control provides representative measurements of radiation and of radioactive materials in those exposure pathways and for those radionuclides that lead to the highest potential radiation exposures of MEMBER OF THE PUBLIC resulting from the station operation. This monitoring program implements Section IV.B.2 of Appendix I to 10 CFR Part 50 and thereby supplements the radiological effluent monitoring program by verifying that the measurable concentrations of radioactive materials and levels of radiation are not higher than expected on the basis of the effluent measurements and modeling of the environmental exposure pathways. The required detection capabilities for environmental sample analyses are tabulated in terms of the lower limits of detection (LLDs). The LLDs required by Table 4.3-1 are considered optimum for routine environmental measurements in industrial laboratories. It should be recognized that the LLD is defined as an .§.priori (before the fact) limit representing the capability of a measurement system and not an after the fact limit for a particular measurement. Detailed discussion of the LLD, and other detection limits, can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry," Anal. Chem. 40, 586-93 (1968), and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975). 3/4.3.2 LAND USE CENSUS This control is provided to ensure that changes in the use of areas at and beyond the SITE BOUNDARY are identified and that modifications to the monitoring program are made if required by the results of the census. The best information from the door-to-door survey, aerial survey or consulting with local agricultural authorities or any combination of these methods shall be used. This census satisfies the requirements of Section IV.B.3 of Appendix I to 10 CFR Part 50. Restricting the census to gardens of greaterthan 500 square feet provides assurance that significant exposure pathways via leafy vegetables will be identified and monitored since a garden of this size is the minimum required to produce the quantity (26 Kg/year) of leafy vegetables assumed in Regulatory Guide 1.109 for consumption by a child. To determine this minimum garden size, the following assumptions were used: (1) that 20% of the garden was used for growing broad leafy vegetation (i.e. similar to lettuce and cabbage), and (2) a vegetation yield of 2 kg/Square meter. Rev.29 Page 75 of 329 12/2016
CY-LG-170-301 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING BASES 3/4.3.3 INTERLABORATORY COMPARISON PROGRAM The requirement for participation in an lnterlaboratory Comparison Program ensures that independent checks on the precision and accuracy of the measurements of radioactive material in environmental sample matrices are performed as part of the quality assurance program for environmental monitoring in order to demonstrate that the results are reasonably valid for the purpose of Section IV.B.2 of Appendix I to 10 CFR Part .50. 3/4.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION The OPERABILITY of the meteorological monitoring instrumentation ensures that sufficient meteorological data is available for estimating potential radiation doses to the public as a result of routine or accidental release of radioactive materials to the atmosphere. This capability is required to evaluate the need for initiating measures to protect the health and safety of the public. This instrumentation is consistent with the recommendations of Regulatory Guide 1.23 "Onsite Meteorological Programs," February, 1972. Site data compiled since January 1972 provide correlation between Elevation 1 (Tower 1) and Elevation 1 (Tower 2), and between Elevation 2 (Tower 1) and Elevation 2 (Tower 2). This correlation serves as justification for the use of the appropriate Tower 2 instrument as a I. back-up to the Tower 1 instrument as shown in Table 3.3-3. Rev.29 Page 76 of 329 12/2016
CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.1 ANNUAL RADIOLOGICAL ENVIRONMENTAL OPERATING REPORT 6.1 Routine Annual Radiological Environmental Operating Report covering the operation of Unit 1 and Unit 2 during the previous calendar year shall be submitted prior to May 1 for each year. The initial report was submitted prior to May 1 of the year following initial criticality (1984). A single report is submitted for a multiple unit station. The Annual Radiological Environmental Operating Report shall include summaries, interpretations, and an analysis of trends of the results report period, including a comparison (as appropriate), with preoperational studies, operational controls and previous environmental surveillance reports and an assessment of the observed impacts of the plant operation on the environment. The reports shall also include the results of land use census required by Control 3.3.2. The Annual Radiological Environmental Operating Report shall include the results of all radiological environmental samples and of all environmental radiation measurements taken during the report period pursuant to the locations specified in the tables and figures in the OFFSITE DOSE CALCULATION MANUAL, as well as summarized and tabulated results of these analyses and measurements in the format of the table in NU REG 1302. In the event that some individual results are not available for inclusion with the report, the report shall be submitted noting and explaining the reasons for the missing results. The missing data shall be submitted as soon as possible in a supplementary report. The report shall also include the following: a summary description of the radiological environmental monitoring program and at least two legible maps. One map shall cover stations near the SITE BOUNDARY; a second shall include the more detailed distant stations. Covering all sampling locations keyed to a table giving distances and directions from the centerline of the reactor plant; the results of licensee participation in the lnterlaboratory Comparison Program, required by Control 3.3.3 discussion of all deviations from the Sampling Schedule of Table 3.3-1; and discussion of all analyses in which the LLD required by Table 4.3-1 was not achievable. The Annual Radiological Environmental Monitoring Report shall include a summary of Special Reports detailing level of radioactivity as the result of plant effluents in an environmental sampling medium exceed the reporting levels of Table 3.3-2. Rev.29 Page 77 of 329 12/2016
CY-LG.:.170-301 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 6.2 A Routine Annual Radioactive Effluent Release Report covering the operation of Unit 1 and Unit 2 during the previous year shall be submitted in accordance with Tech Spec section 6.9.1.8. The period of the first report shall begin with the date of initial criticality. A single unit submittal is made for the 2-unit station. The submittal combines those sections that are common to all units at the station. The Annual Radioactive Effluent Release Report shall include a summary of the quantities of radioactive liquid and gaseous effluents and solid waste released from the facility as outlined in Regulatory Guide 1.21, "Measuring, Evaluation, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, June 1974, with data summarized on a quarterly basis following the format of Appendix B with the following exception: (1) Gaseous dose rates rather than effluent concentrations are used to calculate permissible release rates for gaseous releases. (2) ODCM Control 3.2.2.1 limits the dose equivalent rates due to the release of noble gases to less than or equal to 500 mrem per year to the total body and less than or equal to 3000 mrem per year to the skin. Therefore, the average beta and gamma energies (E) of the radionuclide mixture in releases of fission and activation gases are not applicable. (3) Achieving doses of less than the limits of 10 CFR Part 50, Appendix I demonstrate.that Limerick's gaseous effluents are ALARA. Therefore, calculations of total body doses to the population out to 50 miles from gaseous effluents are not performed .
. The Annual Radioactive Effluent Release Report shall include an annual summary of hourly meteorological data collected over the previous year. This annual summary may be either in the form of an hour-by-hour listing on magnetic tape of wind speed, wind direction and atmospheric stability, and precipitation (if measured), or in the form of joint frequency distributions of wind speed, wind direction, atmospheric stability. The licensee has the option of retaining this summary of required meteorological data on site in a file that shall be provided to the NRC upon request.
This same report shall include an assessment of the radiation doses due to the radioactive liquid and gaseous effluents released from both units during the previous calendar year. This same report shall also include an assessment of the radiation doses from radioactive liquid and gaseous effluents to MEMBER OF THE PUBLIC due to their activities inside the SITE BOUNDARY (Figures 1-1 and 1-2) during the report period. All assumptions used in making these assessments shall be included in these reports. The assessment of radiation doses shall be performed in accordance with the methodology and parameters of the OFFSITE DOSE CALCULATION MANUAL (ODCM). The Annual Radioactive Effluent Release Report shall also include an assessment of radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases, ISFSI and other nearby uranium fuel cycle sources (including doses from primary effluent pathways and direct radiation) for the previous calendar Rev.29 Page 78 of 329 12/2016
CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT year to show conformance with 40 CFR Part 190, Environmental Radiation Protection Standards for Nuclear Power Operation. Dose contribution from liquid and gaseous effluents is calculated based on NUREG-0133 methodology. The Annual Radioactive Effluent Release Reports includes the following information for each type of solid waste (as defined in 10 CFR Part 61) shipped offsite during the report period:
- 1. Total volume, activity and estimated total % error for each waste type:
- a. Spent resins filter sludges, evaporator bottoms, etc.
- b. Dry compressible waste, contaminated equipment, etc.
- c. Irradiated components, control rods, etc.
- d. Others (describe).
- 2. Activity and percentage of each principle radionuclide (>1 %), for each individual waste type as defined in 1. (a-d) above.
- 3. The disposition of solid waste shipments (identify the number of shipments, the mode of transport, and the destination).
- 4. The disposition of irradiated fuel shipments (identify the number of shipments, the mode of transport, and the destination.
The Annual Radioactive Effluent Release Report includes a list and description of unplanned releases from the site to UNRESTRICTED AREAS of radioactive material in gaseous and liquid effluents made during the reporting period. Changes made during the reporting period to procedure RW-AA-100 (formerly the PROCESS CONTROL PROGRAM) and to the ODCM, as well as a listing of new locations for dose calculations and/or environmental monitoring identified by the land. use census pursuant to Control 3.3.2. shall be submitted in the form of a complete, legible copy of the entire ODCM as part of or concurrent with the Annual Radiological Effluent Release Report for the period of the report in which any change to the ODCM was made. The Annual Radioactive Effluent Release Report shall include an explanation as to why the inoperability of liquid or gaseous effluent monitoring instrumentation was not corrected within the time specified in Controls 3.1.1 or 3.1.2, respectively; The Annual Radioactive Effluent Release Report shall include a summary of Special Reports detailing why discharge of liquid radwaste or gaseous radwaste without treatment exceeded the time specified in Controls 3.2.1.3 or 3.2.2.4, respectively. The Annual Radioactive Effluent Release Report shall include a summary of Special Reports for exceeding the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b., 3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., 3.2.2.3.b., 3.2.2.5.a., 3.2.2.5.b., 3.2.2.5.c., and 3.2.3. Rev.29 Page 79 of 329 12/2016
CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.3 MAJOR CHANGES TO RADIOACTIVE WASTE TREATMENT SYSTEMS 6.3 Licensee-initiated major changes to the radioactive waste systems (liquid, gaseous, and solid):
- a. Shall be reported to the Commission in the Annual Radioactive Effluent Release Report for the period in which the change was made effective. The discussion of each change shall contain:
- 1. A summary of the evaluation that led to the determination that the change could be made in accordance with 10 CFR 50.59;
- 2. Sufficient detailed information to totally support the reason for the change without benefit of additional or supplemental information;
- 3. A detailed description of the equipment, components, and processes involved and the interface with other plant systems;
- 4. An evaluation of the change which shows the predicted releases of radioactive materials in liquid and gaseous effluents and/or quantity of solid waste that differ from those previously predicted in the license application and amendments thereto;
- 5. An evaluation of the change which shows the expected maximum exposures to individual in the UNRESTRICTED AREA and to the general population that differ from those previously estimated in the license application and amendments thereto;
- 6. A comparison .of the predicted releases of radioactive materials, in liquid and gaseous effluents and in solid waste, to the actual releases for the period prior to when the changes are to be made; and
- 7. An estimate of the exposure to plant operating personnel as a result of the change.
Rev.29 Page 80 of 329 12/2016
CY-LG-170-301 6.0 ADMINISTRATIVE CONTROLS 6.4 CHANGES TO THE ODCM 6.4 Licensee-initiated changes to the Offsite Dose Calculational Manual:
- a. Shall contain the program elements described in Technical Specifications 6.8.4.d, e and f.
- b. Shall be revised in accordance with the requirements described in Technical Specification 6.14.
- c. Shall be revised per applicable procedures detailing other requirements for making changes to the ODCM.
- d. Shall be reviewed and accepted by PORC and signed by the Plant Manager prior to implementation.
Rev.29 Page 81 of 329 12/2016
-- - - - -- ____ _J
CY-LG-170-301 PARTll CALCULATION METHODOLOGIES Rev.29 Page 82 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 1.0 LIQUID EFFLUENTS 1.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS The liquid effluent monitoring instrumentation and controls at Limerick for controlling and monitoring normal radioactive material releases in accordance with the Limerick ODCM Controls are summarized as follows:
- 1) Liquid Radwaste System: The liquid radwaste discharge monitor (RISH 0K604) provides an alarm and automatic termination of radioactive material releases from the liquid radwaste system as required by ODCM Control 3.1.1. Additional design features of the liquid radwaste system which prevent inadvertent releases to the environment include 1) redundant discharge valves, 2) single discharge line with loop seal and siphon breaker to eliminate probability of inadvertent discharges, 3) Low Cooling Tower ,
Slowdown flow interlock which isolates the radwaste discharge line.
- 2) Service Water System: The Service Water discharge monitor (RISH-10-1 K605 AND RISH-10-2K605) provides an alarm upon indication of activity in the service water system as required by ODCM Control 3.1 .1.
While the service water system is not a normal release pathway, the monitor provides an indication of potential problems due to excessive leakage of the heat exchangers. In addition, the service water side of the fuel pool heat exchangers is kept at a higher pressure than the shell side to prevent potential radioactive contamination of the service water.
- 3) RHR Service Water System: The RHR Service Water Radiation (RHRSW)
Monitors (RISH-12-0K619A, RISH-12-0K6198) provide alarm and automatic termination* of radioactive material release from the RHRSW system, as required by ODCM Control 3.1.1. The Residual Heat Removal (RHR) Service Water System provides water from the Emergency Service Water (ESW) spray pond to the RHR heat exchangers. In post accident conditions, RHR Service Water can supply water for vessel and containment flooding. While the RHRSW system is not a normal release pathway, the monitors provide indication of potential problems due to excessive leakage of the heat exchangers.
*Termination of the release is accomplished by auto trip of the RHRSW pumps and remote manual closure of isolation valves.
Rev.29 Page 83 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION Per the requirements of ODCM Control 3.1.1, alarm setpoints shall be established for the liquid effluent monitoring instrumentation to ensure that the _release concentration limits of ODCM Control 3.2.1.1 are met. The concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS shall be limited to 10 times the effluent concentration limits specified in 10 CFR 20, Appendix B, Table 2, Column 2, for radionuclides other than noble gases and 2.0E-04 µCi/ml for dissolved or entrained noble gases (NUREG 0133). 1.2.1 Radwaste Discharge Monitor and Discharge Flow Rate - RISH-63-0K604 The setpoint for the liquid radwaste discharge monitor is determined by equation 1-1. The radwaste discharge monitor high-high alarm/isolation setpoint is calculated with each tank release based on isotopes detected in the liquid radwaste sample tank to be released (LCiv), the default minimum cooling tower blowdown of 5,000 gallons per minute (CTBD), the radwaste discharge flow rate of 255 gpm and the maximum tank volume in gallons. The flow rate determination is calculated for each release and determined by equation 1-2. The ECL fraction calculated includes, in the concentration mix (dissolved and entrained noble gases), the most recent results the quarterly composite for SR-89, SR-90 and Fe-55, and the monthly composite for H-3 and gross alpha. If the calculated setpoint is less than the existing setpoint, the setpoint will be reduced to the new value or the tank will be returned for more processing. If the calculated setpoint is greater than the existing setpoint, the setpoint may remain at the lower value or be increased to the higher calculated value. The actual setpoint may be reduced to a value less than the calculated setpoint at the discretion of supervision. Rev.29 Page 84 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 1.2.1.1 Setpoint Determination - RISH-63-0K604 The setpoints for the liquid radwaste discharge monitor is determined by the following equations:
. . .
H1-H1 Setpomt = CPM(LRDJ.5. [1- (S)(RR)[E.(C113)! (RR+CTBD) ECL;p)J][ ('E.C;y) (RR+CTBD) ] (S)(E)(RR) ('E.C1r/ECL1r) +BKG(LRD) (1-1) Hi Setpoint =(F)(Hi-Hi Setpoint) + BKG(LRD) (1-1 a) where: CPM(LRD) = calculated liquid radwaste discharge monitor (RISH-63-0K604) count rate attributable to the gamma emitting radionuclide, cpm LCiy = the sum of the concentration of the identified gamma emitting nuclides (µCi/ml), CTBD = the required minimum cooling tower blowdown rate during discharge (gpm), RR = average liquid radwaste discharge flow (gpm), BKG(LRD) = background count rate of liquid radwaste discharge monitor (CPM), E = the gross detection efficiency of the liquid radwaste discharge monitor (µCi/ml/cpm), and s = 2; margin of safety factor to assure that the release is terminated prior to 10 CFR 20 limits being exceeded. Included in this factor are errors associated with monitor uncertainty, sampling uncertainty, flow rate uncertainty, and the contribution of other release paths (Service Water and RHRSW) which are not normally contaminated. F = 0.75 (a factor less than 1 that is used to calculate the Hi-Setpoint) L.Ciyl EC.Ljy = the effective gamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless). where: C;y = the concentration of each identified gamma emitting radionuclide
' i ' in the liquid effluent (undiluted) (µCi/ml)
ECL;y = the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20 Appendix B, Table 2, Column 2 (dissolved and entrained noble gases ECL 2.0E-4 µCi/ml) = Rev.29 Page 85 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES
'LCif31 ECLif3 = the effective nongamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless) where:
C;f3 = the concentration of each identified nongamma radionuclide ' i ' in the liquid effluent (undiluted) (µCi/ml)
* (See note below)
ECL;f3 = the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20, Appendix B, Table 2, Column 2
*NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55 and ross al ha.
EXAMPLE: Given the following information: Tank Discharge Rate: 255 gpm Cooling Tower Slowdown: 5000 gpm Monitor Efficiency: 3.66E-09 Radwaste sample activity: Nuclide Activity uCi/ml 10 x ECL Pre Dilution ECL Fraction H-3 3.19E-03 1.00E-02 3.19E-01 Mn-54 9.00E-08 3.00E-04 3.00E-04 Co-60 7 .OOE-08 3.00E-05 2.33E-03 Cs-137 1.1 OE-07 1.00E-05 1.10E-02 Total Beta 3.19E-03 3.19E~01 Total Gamma 2.70E-07 1.36E-02 5.402E + 04 ~ [J (2)(255)[(3.l9E-Ol)]] (255+-500Q) [ (2.70E-07) (255+-500Q) (2)(3.66E-09)(255) (l.36E-02) J+o.OO 1.2.1.2 Flow Rate Determination The maximum liquid radwaste tank flow rate discharge to the river is determined by the following equation: Rev.29 Page 86 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES
*crnn FLOW(LRD) < 1~(
S L.J Ci I ECLi
)- 1I (1-2) where:
FLOW(LRD) = flow limit for radwaste discharge line (gpm). CTBD = required minimum cooling tower blowdown flow during discharge (gpm). s = 2; margin of safety factor to assure that the release does not* exceed 10 CFR 20 limits.
~(C/ECLi) = the effective ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless) for ~(C/ECLi)>1. If
~(C/ECLi)<1, then no flow rate determination is necessary.
where: Ci = the concentration of each identified radionuclide ' i
' in the liquid effluent (undiluted) (µCi/ml)* (See note below)
= the ECL value for radionuclide ' i ' corresponding to 10 times the ECL limit from 10 CFR 20 Appendix 8, Table 2, Column 2, (dissolved and entrained noble gases ECL =2E-4 µCi/ml.
*NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55, gross alpha and dissolved and entrained nob.le gases.
1.2.2 Service Water Radiation Monitor - RISH-010-1 K605, -2K605 RHR Service Water Monitor - RISH-012-0K619A. -OK6198 The High-High radiation setpoints for the Service Water and the RHR Service Water monitors are set at 10 times the Cs 137 Effluent Concentration Limits (ECL) of 1.0E-06 uCi/mL. Considering the radionuclides predominant in the Limerick reactors (e.g., Co-58, Co-60, Fe-59, Mn-54, Zn-65 and Cr-51 ), the use of a setpoint based on the Cs-137 Effluent Concentration Limit (ECL) is reasonable due to the following parameters:
- 1) High photon abundance (85%),
- 2) Spectrum midrange photon energy (0.662 MeV)
- 3) Conservative magnitude of the applicable ECL limit (1.0E-05 µCi/ml)
Rev.29 Page 87 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES The Service Water and the RHR Service Water maximum Radiation Monitor (High-High) setpoint is determined by the following equation to meet the requirements of ODCM Control 3.2.1.1. The High Setpoint shall be administratively controlled to a value that is less than the.High-High setpoint. 1.2.2.1 Setpoint Determination The setpoints for the Service Water and RHR Service Water Radiation Monitors are determined by the following equations: Hi-HiSetpoint = CPM = (10* ECLcs-137 )(CF) +(0.5)B (1-3)
=
Hi Setpoint (F)(Hi-Hi Setpoint) (1-4) where: CPM = calculated maximum radiation monitor (RISH-010-1 K605, -2K605, RISH-012-0K619A, -OK619B) count rate, cpm 10 = 10 times the ECL limit from 10 CFR 20 Appendix B, Table 2,
- Column 2 to maintain the 500 mrem/yr instantaneous release limits ECLcs-137 = ECL limit for Cs-137 (1.0E-06 µCi/ml)
CF = monitor calibration factor - in cpm/µCi/ml B = Background count rate (cpm) F = a factor less than 1 that is used to calculate the Hi-Setpoint. FserviceWater = 0.75 FRHRServiceWater = 0.50 1.3 LIQUID EFFLUENT DOSE CALCULATION - 10 CFR 50 1.3.1 Dose to Members of the Public Control 3.2.1.2 limits the dose or dose commitment to MEMBERS OF THE PUBLIC from radioactive materials in liquid effluents from Limerick Generating Station to: During any Calendar Quarter During any Calendar Year
~ 3 mrem to total body ~ 6 mrem to total body
~10 mrem to any organ. ~20 mrem to any organ Rev.29 Page 88 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES Per Surveillance Requirement 4.2.1.2 the cumulative dose contribution from liquid effluents for the current calendar quarter and calendar year shall be determined at least once per 31 days in accordance with the following calculation methods. The results are accumulated to give the quarterly doses and the quarterly results are accumulated to give the annual doses. Pathways Receptor Location Dist. Potable Fish Shoreline (mi) Water LGS Outfall 0 x x PA. American Water 2.5 x x x Phoenixville Water 9.0 x x x Aqua America 13.6 x x Crew Course 37.8 x Software currently used at the Limerick Generating Station calculates doses from liquid releases based upon the methodology presented in NUREG-0133. The NUREG-0133 methodology is based upon that presented in Reg. Guide 1.109, but has been simplified. Comparisons between the two methodologies indicate the doses calculated by NUREG-0133 are approximately 3 to 5% higher than those calculated using Reg. Guide 1.109 methodology. 1.3.1.1 Aquatic Pathway - NUREG-0133 D = t[A,,~At,Ci,F,] (1-5)
-r D w
where: D, = The cumulative dose commitment to the total body or any organ, r , from liquid effluents for the total time period f&l , in mrem.
£=!
= The length of the eth time period over which Cl and Fl are averaged for the liquid release, in hours.
= The average concentration of radionuclide, i, in undiluted liquid effluent during time period !it l , from any
.
liquid release, Rev.29 Page 89 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES (determined by the effluent sampling analysis program, ODCM Part I, Table 4.2-1, in uCi/ml).
~ = The near field average dilution factor for Ct during any liquid effluent release. Defined as the ratio of the maximum undiluted liquid waste flow during the release to the average flow through the discharge pathway (minimum factor is 0.04853) defined by the following:
(tank volume111-*i) (1-6) Ft (tank volumer.,,..,,)+ (Cooling Tower Dilution r*-~) Ow = The dilution factor at point of exposure or at point of withdrawal of drinking water (dimensionless). Values are based on average daily river flow. Dw factors are calculated in equations 1-7 through 1-11. LGS Outfall 0.685 + 0.026
- rflow (1-7)
American Water 0.237
- rflow 1 *17 (1-8)
Phoenixville Water 0. 121
- rflow 0 *973 (1-9)
Aqua America 0.089
- rflow 0 *993 (1-10)
Phil. Crew Course 0.076
- rflow 0 *996 (1-11) where:
rflow is river flow in ft3/sec. Ai" = The site specific ingestion dose commitment factor to the total body or organ, r, for each radionuclide and pathway listed in Table 111-10 through Table 111-17 in mrem-mL per uCi-hr. A.l't' for each pathway and age group are calculated using the following equations: Drinking Water A.= k 0
- U w *D atpj l't
..
- RC*e(-A.it~) (1-12)
Freshwater Fish A.= k 0
- U F *BF *D a!pJ l't I
.. *RC *e(-1-it~) (1-13)
Shoreline Ait=kos
- Us* W *Ti* Daipi *RC (e-1.;t~ )(1-e -!.;Tb) (1-14) where:
ko = 114155, units conversion factor (1.0 E6 pCi/uCi
- 1000 ml/LI 8760 hr/yr). Note for fish units are g/kg.
Rev.29 Page 90 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES kos = 11416000, units conversion factor to account for the proportionality constant used in the sediment radioactivity model. (100 L/kg-hr kg/m 2 hr/day* 1000 ml/L
- 1.0E6 pCi/uCi/8760 hr/yr).
u = usage factor per'pathway - Table 111-8. Daipi = dose conversion factor for nuclide, i, for total body or any organ, r, in mrem/pCi, from Tables 111-3 th rough 111-7. BFi = bioaccumulation factor for nuclide, i, in fresh water fish, pCi/kg per pCi/L, from Table 111-2. RC = reconcentration factor as indicated in Table 111-21. w = shoreline width factor (dimensionless) as indicated in Table 111-21. Ti = radioactive half-life of nuclide' i '(days) from Table 111-1. A.1 = radioactive decay constant of nuclide ' i ' (hr-1) from Table 111-1. tpD = delay time for water pathway in hours to allow for nuclide decay during transport through the water purification plant and the water distribution system as indicated in Table 111-21. tpF = delay time for fish pathway to allow for nuclide decay during transport through the food chain, as well as during food preparation as indicated in Table 111-21. 8 tp = delay time in hours for shoreline pathway as indicated in Table 111-21. Zero hours are assumed as shoreline activities can occur at the outfall. Tb = time period during which sediment is exposed to contaminated water as indicated in Table 111-21. 1.3.2 Liquid Effluent Dose Projections Control 3.2.1.3 requires that the liquid radwaste treatment system shall be operable and appropriate portions of the systems used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent to UNRESTRICTED AREAS would exceed: 0.12 mrem to the total body or 0.4 mrem to any organ. Dose projections are made at least once per 31-days when liquid radwaste treatment systems are not being fully utilized using the following equations: Dtbp = (Dt~d)*31 days (1-15) Dmaxp = (Dmaxfd)
- 31 days (1-16)
Rev.29 Page 91 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES
*where:
Dtbp = the total body dose projection for the current 31-day period (mrem). Dtb = the total body dose to date for the current calendar quarter as determined by equation 1-5 (mrem). Dmaxp = the maximum organ dose projection for the current 31-day period (mrem). Dmax = the maximum organ dose to date for the current calendar quarter as determined by equations 1-5 (mrem). d = the actual number of days in the current calendar quarter at the end of the release (days). 31 days = the number of days of concern Rev.29 Page *92 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 2.0 GASEOUS EFFLUENTS 2.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS The gaseous effluent monitoring instrumentation and controls at Limerick for controlling and monitoring radioactive material releases in accordance with the ODCM Part I are summarized as follows:
- 1) North Vent (Common): The plant gaseous discharges via this vent are monitored by two Particulate, Iodine and Gas (PIG) monitors (RY26-075A and RY26-0758) in parallel and by the Wide Range Accident Monitor
. (WRAM) (RY26-076). The PIGS have separate Particulate, Iodine, and Gas sampling and monitoring channels but the Controls require only particulate and iodine sampling and noble gas monitoring. The WRAM has extended range (via three channels) noble gas monitoring and particulate and iodine sampling capability. In addition, the WRAM provides an isolation (Group 6A) of the large Drywell Purge and Vent valves.
- 2) South Vent (one per unit): The plant gaseous discharges via each South Vent are monitored by two redundant PIG monitors (RY26-285A,B). As is the case of the North Vent, each PIG has separate particulate, iodine, and gas sampling and monitoring channels but the Controls require only particulate and iodine sampling with gas monitoring.
- 3) Hot Maintenance Shop (Common): Due to the composition of the radioactive materials in the effluent steam (i.e., very low potential for noble gas), this release point is sampled by a particulate and iodine (P&I) monitor (RY26-025). The P&I monitor has a separate particulate and iodine sampling and monitoring channels but Controls require only particulate and iodine sampling.
2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION Control 3.1.2 requires that an alarm setpoint be established for the noble gas effluent monitoring channels (RY26-075A(B), RY26-185A(B), RY26-285A(B), and RY26-076) to ensure that the release rate of radioactive materials does not exceed the limits of Control 3.2.2.1.a, which corresponds to a dose rate at the SITE BOUNDARY of 500 mrem/yr to the total body or 3000 mrem/yr to the skin. Control limits are expressed in terms of dose rate, while the instruments that monitor effluents produce data in units of concentration or release rate. It is therefore necessary to identify the isotopes and calculate the corresponding release rate that will result in the dose rate limit being reached at the site Rev.29 Page 93 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES boundary. This calculation is made more complex by the use of multiple release points at LGS. Calculation Bases The alarm setpoint calculation is performed whenever the default Hi-Hi setpoint alarms based on analytical results of grab samples from the appropriate release point. The concentration of each identified radionuclide in the grab samples is determined, and the data is used to perform a setpoint calculation for that nuclide mix and release point. The highest calculated annual average concentration (x/Q) for an area at or beyond the site boundary (Table 112-31) is used in the setpoint calculation. Maximum flow rates through the North and South vents are used in alarm setpoint calculations. This is necessary since flow can vary. By using maximum values, any flow less than the maximum will assure that the monitor will alarm before release rate limits are exceeded. The fractional contribution of noble gas is calculated for each release point. The fractional contribution to the whole body and skin dose rates due to noble gases for the north stack and south stack vents are calculated by taking the product of this fraction and the limiting release rate. A comparison of the release rate for whole body and skin dose rates due to noble gas release is made to determine if the whole body or skin dose limit will be most restrictive. It is expected that the whole body limit will always be most restrictive, but the comparison is necessary to assure compliance with Control 3.2.2.1. The sum of the contributions from each release point, independently calculated for noble gases, will equal the maximum instantaneous release rate allowed from the site. 2.2.1 North Vent Noble Gas Effluent Monitors (RY26-075A-3, RY26-075B-3. and RY26-076-2) The North Vent Noble Gas Effluent monitor high-high setpoint is calculated whenever the default Hi-Hi setpoint alarms based on the grab sample results performed in accordance with Table 4.2-2. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value or be increased to the new value. 2.2.1.1 Setpoint Determination The High-High setpoint is calculated per equation 2-1 or 2-2. The High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the lesser of the NVSP(Hi-Hi)NGWB OR NVSP(Hi-Hi)NGSK value (equations 2-1 or 2-2). Rev.29 Page 94 of 329 12/2016 l_
CY-LG-170-301 CALCULATION METHODOLOGIES NSVP(Hl-Hl)NGWB ~ [ 3 .4?lE + g] L[(CiNv )(K;)] (2-1) NVSP(Hi-Hi)NasK< [VFm'Nal[300Ql[~CiNv] (2-2) [3.47IE+9] ~[(CiNv)(L;+ 1.1 lM;)] The High Setpoint shall be administratively controlled to a value that is less than the High-High Setpoint. Hi Setpoint =(F)(Hi-Hi Setpoint) (2-2a) where:
. NVSP (Hi-Hi)NGSK = north vent high-high setpoint - noble gas skin (µCi/cc).
NVSP (Hi-Hi)NGWB = north vent high-high setpoint - noble gas whole body (µCi/cc). VFNVNG = fractional contribution to site boundary noble gas dose rate from the North Vent. (unitless). 500 = total body dose rate limit (mrem/yr) 3000 = skin dose rate limit (mrem/yr) LCiNV = total noble gas activity from North Vent grab sample (µCi/cc) F = 0.289855 (a factor less than 1 that is used to calculate the Hi-Setpoint) 3.471 E+9 = conversion factor, units are (pCi)(c~) (µCi)(m ) 1.1E-ssecy1.0E+6.pct( 66f#~ott.3x 1min y2.a3a:+4cc'J (2 _3 ) ( rri3 A uCt A_ mm 60secJ. tt3 ) where: 1.1 E-5 sec/m 3 = highest annual average x/Q (NE Sector) 1E+6 pCi/µCi = units conversion 668 ,450 cfm = maximum North Vent flow rate for two unit operation 1 min/60 sec = units conversion Rev.29 Page 95 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 2.832E+4 cc/ft3 = units conversion
= concentration of noble gas nuclide ' i ' as determined by radioanalysis of North Vent grab sample (µCi/cc).
= total body dose conversion factor for noble gas nuclide ' i '
(mrem/yr per pCi/m 3 , from ODCM Table 112-1 ).
= beta skin dose conversion factor noble gas nuclide' i' (mrem/yr per pCim 3 , from ODCM Table 112-1 ).
= gamma air dose conversion 3
factor for noble gas nuclide ' i ' (mrad/yr per pCi/m , From ODCM Table 112-1). 1.11 = the average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0). 2.2.2 South Vent Noble Gas Effluent Monitors (RY26-185A-3. RY26-185B-3. RY26-285A-3, and RY26-2858-3) Each unit's South Vent Noble Gas Effluent monitor High-High setpoint is calculated whenever the default Hi-Hi setpoint alarms based on the grab sample results performed in accordance with ODCM Part I, Table 4.2-2. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value. 2.2.2.1 Setpoint determination The High-High setpoint for the South Vent Noble Gas Effluent Monitor is set at the lesser of the SVSP(Hi-Hi)NGws and SVSP(Hi-Hi)NGSK value. SVSP(Hi-Hi)NGWB and SVSP(Hi-Hi)NGSK are calculated for each unit's South Vent. The High-High setpoint is calculated per equation 2-4 or 2-5. [VF SVNG ][500][ L C isv] SVSP(Hl-Hl)NGWB ~ [1.2149E + 9]L[(Cisv )(Ki)] (2-4) [VF SVNG][3000][L Cisv1 SVSP(Hl-Hl)NGSK ~ [1.2149E + 9]L[(Cisv )(Li+ 1.11 Mi)] (2-5) The High Setpoint shall be administratively controlled to a value that is less than the High-High Setpoint. Rev.29 Page 96 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES
=
Hi Setpoint (F)(Hi-Hi Setpoint) (2-5a) where: SVSP(Hi-Hi)NGWB = south vent high-high setpoint - noble gas whole body (µCi/cc) SVSP(Hi-Hi)NGSK = south vent high-high setpoint - noble gas skin (µCi/cc) VFsvNG = fractional contribution to site boundary noble gas dose rate from the Unit's South Vent. (unitless) 500 = total body dose rate limit (mrem/yr) 3000 = skin dose rate limit (mrem/yr) F = 0.5 (a factor less than 1 that is used to calculate the Hi-Setpoint)
= total noble gas activity from each unit South Vent grab sample (µCi/cc).
= concentration of noble gas nuclide ' i ' determined by radioanalysis of South Vent grab sample (µCi/cc)
= total body dose conversion factor for noble gas nuclide ' i '
(mrem/yr per pCi/m3, from ODCM Table 112-1).
= beta skin dose conversion factor noble gas nuclide ' i '
(mrem/yr per pCi/m3, From ODCM Table 112-1 ).
= gamma air dose conversion factor for noble gas nuclide ' i '
(mrad/yr per pCi/m3, From ODCM Table 112-1 ). 1.11 = the average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0) 1.2149E+9 = conversion factor units are in (pCi)(c~) (µCi)(m ) 1.1E-5se~Y 1.0E +~pelf 2.34E :5tt3 Y1min Y2.83:E +4ccJ ( m3 A uC1 A_ mm }_60secA_ tt3 (2-6) where: 1 .1 E-5 sec/m 3 = highest annual average x/Q (NE Sector) 1E+6 pCi/µCi = units conversion 2.34E+5 ft3/m = maximum South Vent flow rate 1/60 min/sec = units conversion 2.832E+4 cc/ft3 = units conversion 2.2.3 Noble Gas Effluent Fractional Contribution The three release points will be partitioned such that the sum does not exceed 100 percent of the limit (500 mrem/yr whole body noble gas, 3000 mrem/yr skin noble Rev.29 Page 97 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES gas.) The default fraction will be set at 80 percent for the North Vent, 10 percent for the Unit-1 South Vent and 10 percent for the Unit-2 South Vent. These percentages can vary should operational concentrations warrant such change. However, the sum of the percentages shall be equal to or less than 100%. The following relationship shall be met: VFNvNG + VF1svNG + VF2svNG ~ 1 (2-7) where: VFNVNG = fractional contribution to site boundary noble gas total body dose rate from the North Vent (unitless). VF1SvNG = fractional contribution to site boundary noble gas total body dose rate from the Unit 1 South Vent (unitless) .. VF2svNG = fractional contribution to site boundary noble gas total body dose rate from the Unit 2 South Vent (unitless). 2.2.4 Noble Gas Effluent Default Setpoint This methodology may be used when grab sample results from either the North Vent or the South Vent do not identify any radionuclides. This methodology is based on expected release concentration ratios as outlined in Section 11.3 of the Limerick U FSAR. 2.2.4.1 North Vent Noble Gas Monitors (RY26-075A-3 and RY26-075B-3). The default High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the NVSP(Hi-Hi)NGD value. NVSP(Hi-Hi)NGD ~ [8.00E-1][500 ][1.31E -6] (2-8) [3.471E+9 ][4.37E-9] NVSP(Hi-Hi)NGD :s. 3.45E-5 µCi/cc where: NVSP(Hi-Hi)NGD = default north vent high-high setpoint - noble gas whole body (µCi/cc) 8.00E-1 = default fractional contribution to site boundary noble gas total body dose rate from the North Vent (unitless) . 500 = total body dose rate limit (mrem/yr). 1.31 E-6 = total noble gas concentration from North Vent (µCi/cc). Ref: a) based on UFSAR Table 11.3-1. b) based on maximum North Vent flow of 668,450 cfm. Rev.29 Page 98 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 3.471E+9 = conversion factor, units are in (pCi)(c~) . See Equation
. (µCi)(m )
2-3. 4.37E-9 = summation of the north vent concentration of noble gas nuclide ' i ' multiplied by the corresponding whole body dose 3 factor. Units are in (µCi)(mrem)(m ) (cc )(yr )(pCi) Ref: a) based on UFSAR Table 11.3-1. b) based on maximum North Vent flow of 668,450 cfm. c) ODCM Table 112-1. 2.2.4.2 South Vent Noble Gas Monitors (RY26-185A-3, RY26-285A-3, RY26-185B-3, and RY26-285B-3). The default High-High setpoint for each Unit's South Vent Noble Gas Effluent Monitor is set at or below the SVSP(Hi-Hi)NGD value. SVSP(Hi- Hi~GD ~ [1.00E- l][soo][l.02E- 7] (2-9) [1.2149E + 9][2.71E -10] SVSP(Hi-Hi)NGD ~ 1.54E-5 µCi/cc where: SVSP(Hi-Hi)NGD = default south vent setpoint - noble gas (µCl/cc). 1.00E-1 = default fractional contribution to site boundary noble gas total body dose rate from the South Vent (unitless). 500 = total body dose rate limit (mrem/yr). 1.02E-7 = total noble gas concentration from South Vent (µCi/cc). Ref: a) Based on UFSAR Table 11.3-1. b) Based on maximum South Vent flow of 234,000 cfm. 1.2149E+9 = conversion factor, units are in (pCi)(c~) . See (µCi)(m ) Equation 2-6. 2.71E-10 = summation of the south vent concentration of noble gas nuclide' i 'multiplied by the corresponding whole body dose factor. Rev.29 Page 99 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 3
"t . (µCi)(mrem)(m )
U ni s are m - - - - - - (cc )(yr )(pCi) Ref: a) Based on UFSAR Table 11.3-1. b) Based on maximum South Vent flow of 234,000 cfm. c) ODCM Table 112-1. 2.2.5 Wide Range Accident Monitor Noble Gas Effluent Monitor (RIX-26-076-4) The Wide Range Accident Monitor (WRAM) noble gas total effluent channel displays the North Vent noble gas release rate. This monitor has Main Control Room Annunciation as well as a group 6A isolation function on the primary containment purge and vent valves. The isolation setpoint value of ~2.1 µCi/cc specified in Technical Specification Table 3.3.2-2 is based on the accident dose limits for containment purge during an accident (Ref: UFSAR Section 1.13). For routine operations the total effluent high and high-high setpoints are based upon the methodology of Sections II 2.2.5.1 and II 2.2.5.2. The setpoint units are in microcuries per second using the two-unit maximum North Vent flow rate of 668,450 scfm. The total effluent channel High-High setpoint is set at a value less than or equal to ten times the High setpoint (not to exceed the 2.1 µCi/cc equivalent using the two-unit maximum North Vent flow rate). These values are always more conservative than the Technical Specification Table 3.3.2-2 required value of~ 2.1
~~- .
If the calculated setpoint value is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value. 2.2.5.1 Routine Operations High Setpoint Determination For routine operations, the High setpoint for the WRAM Noble Gas Total Effluent Channel is set at or below the lesser of the NVSP(Hi-Hi)NGWB or NVSP(Hi-Hi)NGSK value when activity is detected. When no activity is detected, the High setpoint is set at or below the NVSP(Hi-Hi)NGD* This setpoint is calculated to ensure compliance with Control 3.2.2.1.a. The setpoint values are converted from µCi/cc to µCi/sec using the maximum two-unit North Vent flow rate: WRAM(Hi)ws = [NVSP(Hi-Hi)NGWB or NGD] [3.155E+8] (2-10) Rev.29 Page 100 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES WRAM(Hi)sK = [NVSP(Hi-Hi)NGSK] [3.155E+8] (2-11) where: WRAM(Hi)ws = WRAM total effluent channel north vent high setpoint
- noble gas whole body (µCi/sec).
- WRAM(Hi)sK = WRAM total effluent channel north vent high setpoint
- noble gas skin (µCi/sec).
NVSP(Hi-Hi)NGWB = North Vent high-high setpoint - noble gas whole body or NGD (µCi/cc) from equation 2-1 or 2-8. NVSP(Hi-Hi)NGSK = North Vent high-high setpoint - noble gas skin (µCi/cc) from equation 2-2. 3.155E+8 = conversion factor (cc/sec).
=(668,4~0sft J(
3 1min J(2.832E+4ccJ (2-12) mm 60sec tt 3 2.2.5.2 Routine Operations High-High Setpoint Determination For routine operations, the High-High setpoint for the WRAM Noble Gas total effluent channel is set at or below ten .times the lesser of. the routine operations WRAM(Hi)ws or WRAM(Hi)sK value. WRAM(Hi-Hi)ws = [WRAM(Hi)ws] [1 O] (2-13) WRAM(Hi-Hi)sK = [WRAM(Hi)sK] [1 O] (2-14) where: WRAM(Hi-Hi)ws = WRAM total effluent channel north vent high-high setpoint noble gas whole body (µCi/sec). WRAM(Hi-Hi)sK = WRAM total effluent channel north vent high-high setpoint noble gas skin (µCi/sec). WRAM(Hi)ws = WRAM total effluent channel north vent high setpoint
- noble gas whole body (µCi/sec) from equation 2-10.
WRAM(Hi)sK = WRAM total effluent channel north vent setpoint - noble gas skin (µCi/sec) from equation 2-11. 10 = multiplication factor to calculate high-high value (unitless) Rev.29 Page 1Ol of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 2.3 GASEOUS EFFLUENT DOSE EVALUATION Dose calculations are performed ,based on limiting sector average annual meteorological dispersion parameters. For the noble gas dose calculation, effluent release data are based on grab sample analysis for radionuclide composition and weekly stack effluent radiation monitor readings. For the iodine and particulate dose calculations, the effluent release radionuclide composition and release activity are based on weekly continuous samples. The quarterly and annual dose calculations are a summation of the applicable dose results for the period of interest. 2.3.1 Site Boundary Dose Rate - Noble Gases (1 OCFR20 Limits) Control 3.2.2.1.a limits the dose rate in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY due to noble gas releases to ~500 mrem/yr total body and ~3000 mrem/yr skin. Radiation monitor alarm setpoints are established to ensure that these release limits are not exceeded. Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.a. following any releases exceeding the alarm setpoints. Monitor indications (readings) are averaged over time periods not to exceed 60 minutes. NOTE: For administrative purposes, more conservative alarm setpoints than those required to meet 10 CFR 20 Dose Rate limits are imposed. However, conditions exceeding these more limiting alarm setpoints do not necessarily indicate radioactive material release rates exceeding the
- dose limits of Control 3.2.2.1.a. Provided actual releases do not result in radiation monitor indications exceeding values based on the dose rate limits of Control 3.2.2.1.a., no further analyses are required for demonstrating compliance with the limits of Control 3.2.2.1.a.
In the event of a noble gas effluent release exceeding the setpoint value specified in ODCM Part II, Sections 2.2.1 or 2.2.2, the site boundary dose rate from the release is calculated using the methodology stated below. This methodology is based on worst sector annual average meteorological dispersion but, if further refinement is required to meet the requirements of Control 3.2.2.1.a, actual meteorological data from the time period of concern may be used to calculate actual meteorological dispersion. Rev.29 Page 102 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES Dw ~ x/Q (IE +6)[t.({NV)] (2-15) Dr= z/Q (1E+6{~ (L+l.lMi)Q;] (2-16) where: Drn = total body plume dose rate (mrem/yr). Dy = skin plume dose rate (mrem/yr). x/Q = highest3 annual average relative concentration (sec/m ) at site boundary (see Table 112-31) .
- q = The release rate of noble gas nuclide ' i ' from all vent releases averaged over one hour (uCi/sec).
= total body dose factor for noble gas nuclide ' i ' in units of mrem/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.
= skin dose factor for the beta contribution for noble gas nuclide' i 'in units of mrem/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.
1.1 = the ratio of tissue to air absorption coefficients over the range of photons of interest. This ratio converts dose (mrad) to dose equivalent (mrem).
= gamma air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.
1E+6 = units conversion pCi/µCi. 2.3.2 Site Boundary Dose Rate - Radioiodine and Particulates (1 OCFR20 Limits) Control 3.2.2.1.b limits the dose rate to ~1500 mrem/yr to any organ (inhalation pathways only) for 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents. Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.b. Release* activity is based upon the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. Rev.29 Page 103 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES n
- n/H = x/Q L PiQi i=l (2-17) where:
D1H = inhalation dose rate (mrem/yr). xto = highest average annual x/Q (sec/m3) (see Table 112-31 ).
= dose factor' for radionuclides other than noble gases for the inhalation pathway only (mrem/yr per µCi/m3).
Values are listed in ODCM Table 112-2 through Table 112-5.0 Pi= k (BR) (Daipj) (2-17a) where: k' = 1.0E+6 unit conversion pCi/uCi. BR = breathing rate from Table 112-31. Daipj = Inhalation Dose Factor Table 112-27 through Table 112-30 .
- q = The release rate of radionuclide ' i ' other than noble gases from all vent releases (µCi/s).
2.3.3 Noble Gas Air Doses (1 OCFRSO. Appendix I Limits) Control 3.2.2.2 limits the air dose due to noble gases released in gaseous effluents (from both reactor units) to areas at or beyond the SITE BOUNDARY to:
~ 10 mrad gamma for any quarter
~ 20 mrad beta for any quarter
~ 20 mrad gamma during any calendar year
~ 40 mrad beta during any calendar year As required by Surveillance Requirement 4.2.2.2, these doses are calculated at least once per 31 days using the results of the most recent grab samples for isotopic composition performed in accordance with ODCM Part I, Table 4.2-2. The dose calculation is performed using the most limiting average annual meteorological dispersion values. The quarterly and annual doses are based on the summation of the applicable dose results for the period of interest. The dose calculations are performed in accordance with the methodology below.
Rev.29 Page 104 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 0')(1/R = (3.17E -ax1.00E + 6)x/Q~M;Q; (2-18) Of3AIR = (3.17E -BX1.00E + 6)x/Q~N;Q; (2-19) where: DyAIR = gamma air dose from noble gas releases in mrad. DpAIR = beta air dose from noble gas release in mrad. 3.17E-8 = units conversion [year/sec]. 1.00E+6 = units conversion pCi/uCi. xtO = highest3 average annual relative concentration in sec/m (see Table 112-31 ).
= release of noble gas radionuclides ' i 'from all vents in uCi. Releases shall be cumulative over the period of interest.
= gamma air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.
= beta air dose factor for noble gas nuclide ' i ' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.
2.3.4 Radio iodine and Particulate Dose Calculations (1 OCFR50. Appendix I Limits) Control 3.2.2.3 limits the dose (from both reactor units) to a MEMBER OF THE PUBLIC from 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released to areas at or beyond the SITE BOUNDARY to:
~ 15 mrem to any organ during any calendar quarter
~ 30 mrem to any organ during any calendar year As required by Surveillance Requirement 4.2.2.3, these doses are calculated at least once per 31 days using the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. The dose calculation is performed using the most limiting average annual meteorological dispersion values for the appropriate dose receptor pathway (e.g. milk pathway SSE sector 2.5' miles, etc.). The quarterly and annual doses are based on the summation of Rev.29 Page 105 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES the applicable dose results determined d~ring the period of interest. The dose calculations are performed in accordance with the methodology below. Total organ dose is the maximum organ dose obtained by the summation of the organ dose from each pathway. 2.3.4.1 Ground Pathway DaPAR = 3.17E-8 [n/Q~R;QJ (2-20) where:
= dose from ground pathway due to release of particulates and iodines (mrem).
3.17E-8 = units conversion (year/sec). 2 D/Q = highest average annual deposition (1/m ) (see Table 112-31 ).
= release of nuclide ' i ' from all vents in uCi. Releases shall be cumulative over the time period of interest.
= dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - Values of Ri are provided in ODCM Table 112-6 through Table 112-9 and calculated per the following equation:
(k') (k) (SF)* Daw [(I - -A/) I A, J e (2-20a) where: Rf [DIQ] = 2 m -mrem/yr per uCi/sec. k' = 1E+06 pCi/uCi. k" = 8760 hr/yr. SF = shielding factor (see Table 112-31). Daipi = dose factor for standing on contaminated ground (see Table 111-7).
/l; = decay constant for nuclide i in seconds (see Table 111-1).
= period of buildup in soil in seconds (see Table 112-31).
Rev.29 Page 106 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 2.3.4.2 Vegetation, Meat and Cow Milk or Goat Milk Pathway Dw~ ~ 3.17£-8 [ z/Q tl/,Q, + D/Q t,R*Q*] (2-21) where: DvPAR = dose from vegetation, meat, cow milk, and goat milk, pathways due to releases of particulates, iodines, and tritium (mrem). 3.17E-8 = units conversion (year/sec).
=
i 1, 2 = 3H, 14C.
=
i 3 thru n = all other isotopes (particulate and iodine). Qi = the release of nuclide ' i ' from all vents in uCi. Releases shall be cumulative over the time period of interest. x/O = highest average annual x/Q (sec/m3) (see Table 112-31). D/Q = highest average annual deposition rate (1/m 2 ) (see Table 112-31 ). Ri = dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - Values of Ri are provided in ODCM Table 112-10 through Table 112-25 and calculated per the following equations. (2-21 a) where: RVI = m 2-mrem/yr per uCi/sec k' = 1.0 E+6 pCi/uCi r = fraction of deposited particulates retained on vegetation (Table 112-31). 2 Yv = vegetation area density kg/m (Table 112-31 ). A, i = decay constant for the ith radionuclide, in sec-1 (Table 111-1 ). A,w = decay constant for removal of activity on leaf and plant surfaces by 1 weathering, in sec- (Table 112-31 ). Daipi = ingestion dose factor, in mrem/pCi (Table 111-3 through Table 111-6). Rev. 29 Page 107 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES LJLa = consumption rate of fresh leafy vegetation by the receptor in age group (a), in kg/yr (Table 112-31). fl = fraction of the annual intake of fresh leafy vegetation grown locally (dimensionless) (Table 112-31). tL = average time between harvest of leafy vegetation and its consumption, in seconds (Table 112-31). us a = consumption rate of stored vegetation by the receptor in age group (a), in kg/yr (Table 112-31). fg = fraction of the annual intake of stored vegetation grown locally (dimensionless) (Table 112-31). th = average time between harvest of stored vegetation and its consumption, in seconds (Table 112-31 ). The concentrations of tritium and carbon-14 in vegetation are based on their airborne concentrations rather than their deposition. Therefore, the Ri is based on [x/Q] as follows: a a g J RY-3 = (k')* (k' ") * [uL*(fL) +US*(f )
- D .. * [0.75 * (0.5/H)]
aipJ (2-21 b) v Rc.1* = (k')* (k' ") * [uL*(t: ) +lP*(f) a L a g J* DaipJ..
- p [ 0.11
- 0.16] (2-21 c) where:
R~-3 3
= mrem/yr per uCi/m
- R~-14 3
= mrem/yr per uCi/m
- k' II
= 1E+3, constant of unit conversion (gm/kg).
3 H = absolute humidity of the atmosphere, in gm/m (Table 112-31 ). 0.75 = fraction of total feed that is water. 0.5 = ratio of the specific activity of the feed grass water to the atmospheric water. p = fractional equilibrium ratio (4400 hrs/8760 hrs). The ratio of the total annual release time (for C-14) atmospheric releases) to the total annual time during photosynthesis occurs (taken to be 4400 hrs), under the condition that the value of p should never exceed unity. For continuous C-14 releases, pis taken to be unity. 0.11 = the fraction of total plant mass that is natural carbon, dimensionless. 0.16 = the concentration of natural carbon in the atmosphere, in g/m 3 Rev.29 Page 108 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES All other values as previously defined above. Cow Milk I Goat Milk I Meat Pathway RIM (k') ( (Q,*UAP) * (rm 17 ) *( )*D * [fPfs + (1-fPfs)e-Mh]-Mi (2-21d)
'] ) r alp} e
/l,i + Aw Yp Ys where:
RMI
= 'm 2-mrem/yr per uCi/sec.
k' = 1.0E+6 pCi/uCi. QF = cow/goat consumption rate kg/day (wet weight) (Table 112-31). UAP = receptor's milk consumption rate or meat consumption rate for age (a), in
- liters/yr or kg/yr (Table 112-31 ).
A.i = decay constant for the ith radionuclide, in sec-1 (Table 111-1).
= decay constant for removal of activity on leaf and plant surfaces by
"-w weathering, in sec- 1 (Table 112-31).
Fm = stable element transfer coefficients in days/liter or days/kg (Table 112-26). r = fraction of deposited particulates retained on vegetation (Table 112-31). Daipi = ingestion dose factor, in mrem/pCi (Table 111-3 through Table 111-6). fp = fraction of the year that the cow/goat is on pasture (dimensionless) (Table 112-31). fs = fraction of the cow/goat feed that is pasture grass while the animal is on I I pasture (dimensionless) (Table 112-31). Yµ = agricultural productivity by unit area of pasture feed grass, in kg/m 2 11 * (Table 112-31). Ys = agricultural productivity by unit area of stored feed, in kg/m 2 (Table 112-31 ). Th(milkl = transport time from pasture to harvest, to milk animal, to milk, to receptor, in sec (Table 112-31). . Tf(milkJ = transport time from pasture to milk animal, to milk, to receptor, in sec (Table 112-31). Th(meal) = transport time from crop field to ingestion receptor, in sec (Table 112-31). Tf(meal) = transport time from pasture to ingestion receptor, in sec (Table 112-31). The concentrations of tritium and carbon-14 in milk and meat are based on their airborne concentration rather than their deposition. Therefore, the Riis based on [x/Q] as follows: R~_3 = (k')* (k'")*Fm*QF*Uap*Daipj * [0.75*(0.5/H)] (2-21e) R11t_14 = (k')*(k"')*Fm*QF*Uap*Daipj *p*(0.11/0.16] (2-21f) where: R1;/_3 = mrem/yr per uCi/m3 R~14 = mrern/yr per uCi/m3 Rev.29 Page 109 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES All other values as previously defined above. 2.3.4.3 Inhalation Pathway D,,AR = 3.11 E-s [ x/Q LR1Q1] (2-22) where: D1PAR = dose from inhalation pathway due to release of particulates, iodines, and tritium (mrem). 3.17E-8 = units conversion (year/sec). Qi = the release of nuclide ' i 'from all vents in uCi. Releases shall be cumulative over the time period of interest. xta = highest average annual x!Q (sec/m3) (see Table 112-31). Ri = dose factor for organ type, age group, and pathway (for radionu,clides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - values of Ri are provided in ODCM Table 112-2 through Table 112-5 and calculated from the following equation. R/ = k' (BR) (Daipj) (2-22a) where: R/ = mrem/yr per uCi/m3. k' = 1.0E+6 unit conversion pCi/uCi. BR = breathing rate from Table 112-31. Daipj = Inhalation Dose Factor Table 112-27 through Table 112-30. 2.3.5 Intentionally left blank. Rev.29 Page 110 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 2.3.6 Gaseous Effluent Dose Projection Control 3.2.2.5 requires the VENTILATION EXHAUST TREATMENT SYSTEM be used to reduce radioactive material levels prior to discharge when projected doses from both units to areas at and beyond the SITE BOUNDARY would exceed in a 31 day period:
- a. 0.4 mrad to air from gamma radiation, or
- b. 0.8 mrad to air from beta radiation, or
- c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC A dose projection is performed at least once per 31-days by the following equations:
Dmaxgamma (Dmaxg Id)* 31 (2-23) Dmaxbeta (Dmaxb Id)* 31. (2-24) Om ax organ . (Dmaxo Id)* 31 (2-25) where: DmaXgamma = maximum gamma air dose projection for current 31-day period (mrad) DmaXbeta = maximum beta air dose projection for current 31-day period (mrad) DmaXorgan = maximum organ dose projection for current 31-day period (mrem) Dmaxg = maximum gamma air dose to date for current calendar quarter as obtained by equation (2-18). Dmaxb = maximum beta air dose to date for current calendar quarter as obtained by equation (2-19). Dmaxo = maximum organ dose to date for current calendar quarter as determined by summing the organ dose obtained from equations (2-20), (2-21) and (2-22) (mrem). d = number of days in current calendar quarter at the end of the release. 31 = the number.of days of concern. Rev.29 Page 111 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES 3.0 ANNUAL DOSE EVALUATION The assessment of radiation doses for the Annual Radoactive Effluent Release Report (ARERR) shall be performed utilizing the methodology provided in NUREG-0133, Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants, October 1978. Any deviations from the methodology provided NUREG-0133 shall be documented in the Annual Radioactive Effluent Release Report. The meteorological conditions concurrent with the time of release of radioactive materials (as determined by sampling frequency of measurement) or approximate methods shall be used as input to the dose model. 4.0 SPECIAL DOSE ANALYSIS 4.1 TOTAL DOSE TO MEMBERS OF THE PUBLIC Control 3.2.3 requires that the annual dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from the uranium fuel cycle shall be limited to:
~ 25 mrem whole body or any organ except thyroid
~ 75 mrem thyroid Surveillance Requirement 4.2.3.2 requires that cumulative dose contributions from direct radiation from operations be evaluated when the calculated dose from the release of radioactive materials in liquid or gaseous effluents exceed the limits of Controls 3.2.1.2.a, 3.2.1.2.b, 3.2.2.2.a, 3.2.2.2.b, 3.2.2.3.a, or 3.2.2.3.b. The direct radiation contribution shall be determined by the methodology described below.
This methodology calculates the direct radiation contribution, which then must be added to the dose or dose commitment determined in accordance with ODCM Part II, Sections 1.3.1, 2.3.3, and 2.3.4 to determine total dose from all pathways. This evaluation* of direct radiation contribution is in accordance with ANSI/ANS 6.6.1-1979 Section 7. The error using this method is estimated to be approximately 8%. The following evaluation is performed for each receptor of concern. Dws = D1EFFL-WB + (Dm - Dx BKG) * (4-1) Do= D1EFFL-o + (Dro - Dx BKG) (4-2) Dr= D1EFFL-T + (Dm - Dx BKG) (4-3) Rev.29 Page 112 of 329 12/2016
CY-LG-170-301 CALCULATION METHODOLOGIES where: Dws = cumulative total body dose contribution from direct radiation, liquid and gaseous effluents at the appropriate receptors (mrem). Do = cumulative_organ dose contribution from direct radiation, liquid and gaseous effluents at the appropriate receptors (mrem). Dr = cumulative thyroid dose contribution from direct radiation, liquid and gaseous effluents at the appropriate receptors (mrem). Oro = total dose at receptor of interest as evaluated by dosimetry measurement (mrem). NOTE: If there is not a dosimetry location at the actual receptor location, a more conservative location will be used to evaluate Total Dose. NOTE: Due to the statistics of radiation measurements and to the conservative nature of effluent calculations it is plausible the Oro - Dx BKG may yield a negative value. In this situation the value for Oro_ Dx BKG shall be reported as zero (0). Dx BKG = Background dose as evaluated by dosimetry at background sites (mrem). D1EFFL-rs = effluent contribution to total body dose (as evaluated in ODCM Part II, Sections1 .3.1, 2.3.3, and 2.3.4). D1EFFL-o = effluent contribution to organ dose (as evaluated in ODCM Part II, Sections1 .3.1, 2.3.3, and 2.3.4). D1EFFL-r = effluent contribution to thyroid dose (as evaluated in ODCM Part II, Sections1 .3.1, 2.3.3, and 2.3.4).
- 4.2 DOSES DUE TO ACTIVITIES INSIDE THE SITE BOUNDARY In accordance with Administrative Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of radiation dose from radioactive liquid and gaseous effluents to MEMBERS OF THE PUBLIC due to their activities inside the SITE BOUNDARY.
There are three locations within the SITE BOUNDARY that are accessible to MEMBERS OF THE PUBLIC for activities unrelated to the operation of Limerick Station. These locations are: 1) the railroad tracks which run along the river within the SITE BOUNDARY; 2) the Limerick Information Center, on Longview Road next to the 500kv substation; and 3) Fricks Lock. Of these three locations, the railroad tracks are the closest to the plant confines. Sectors and distances of these locations are provided below: Rev. 29 1** Page 113 of 329 1212016 I
CY-LG-170-301 CALCULATION METHODOLOGIES Sector Distance to Location (m) Railroad Tracks: s 300 SSW 225 SW 225 WSW 225 w 225 WNW 345 NW 450 Information Center: ESE 884 Fricks Lock: WSW 450 Annual doses will be calculated in accordance with NUREG-0133 methodology, as appropriate and assume an occupancy factor of 0.25. The maximum dose calculated will be reported in the Annual Radioactive Effluent Release Report. 5.0 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM 5.1 SAMPLING PROGRAM The operational phase of the Radiological Environmental Monitoring Program (REMP) is conducted in accordance with the requirements of Control 3.3.1. The objectives of the program are: To provide data on measurable levels of radiation and radioactive materials in the site environs. To evaluate the relationship between quantities of radioactive materials released from LGS and resultant radiation doses to individuals from principal pathways of exposure. The sampling requirements (type of samples, collection frequency, and analysis) and sample locations are presented in Appendix A. 5.2 INTERLABORATORY COMPARISON PROGRAM Control 3.3.3 requires analyses be performed on radioactive material supplied as part of an lnterlaboratory Comparison. Participation in an NIST traceable lnterlaboratory Comparison Program provides a check on the preciseness of measurements of radioactive material in environmental samples. A summary of the lnterlaboratory Comparison Program results is provided in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. Rev.29 Page 114 of 329 12/2016
CY-LG-170-301 TABLES Rev.29 Page 115 of 329 12/2016
CY-LG-170-301 TABLE 111-1 DECAY CONSTANTS FOR NUCLIDES OF INTEREST 1 DECAY DECAY DECAY KOCHER T112 CONSTANT T112 CONSTANT T112 CONSTANT NUCLIDE T112 HOURS HR"1 SECONDS sEc-1 DAYS DAYs-1 H-3 1.228E+01 y 1.076E+05 6.439E-06 3.875E+08 1.789E-09 4.485E+03 1.545E-04 C-14 5.730E+03 y 5.023E+07 1.380E-08 1.808E+11 3.833E-12 2.093E+06 3.312E-07 NA-22 2.602E+OO y 2.281E+04 3.039E-05 8.211E+07 8.441E-09 9.504E+02 7.293E-04 NA-24 1.500E+01 H 1.500E+01 4.621E-02 5.400E+04 1.284E-05 6.250E-01 1.109E+OO P-32 1.429E+01 D 3.430E+02 2.021E-03 1.235E+06 5.614E-07 1.429E+01 4.851E-02 CA-41 1.030E+05 y 9.029E+08, 7.677E-10 3.250E+12 2.132E-13 3.762E+07 1.842E-08 SC-46 8.383E+01 D 2.012E+03 3.445E-04 7.243E+06 9.570E-08 8.383E+01 8.268E-03 CR-51 2.770E+01 D 6.649E+02 1.042E-03 2.394E+06 2.896E-07 2.770E+01 2.502E-02 MN-54 3.127E+02 D 7.505E+03 9.236E-05 2.702E+07 2.566E-08 3.127E+02 2.217E-03 FE-55 2.700E+OO y 2.367E+04 2.929E-05 8.521E+07 8.135E-09 9.862E+02 7.029E-04 MN-56 2.579E+OO H 2.579E+OO 2.688E-01 9.283E+03 7.467E-05 1.074E-01 6.452E+OO C0-57 2.709E+02 D 6.502E+03 1.066E-04 2.341E+07 2.961E-08 2.709E+02 2.559E-03 C0-58 7.080E+01 D 1.699E+03 4.079E-04 6.117E+06 1.133E-07 7.080E+01 9.790E-03 FE-59 4.463E+01 D 1.071E+03 6.471E-04 3.856E+06 1.798E-07 4.463E+01 1.553E-02 C0-60 5.271E+OO y 4.621E+04 1.500E-05 1.663E+08 4.167E-09 1:925E+03 3.600E-04 Nl-59 7.500E+04 y 6.575E+08 1.054E-09 2.367E+12 2.929E-13 2.739E+07 2.530E-08 Nl-63 1.001E+02 y 8.775E+05 7.899E-07 3.159E+09 2.194E-10 3.656E+04 1.896E-05 CU-64 1.270E+01 H 1.270E+01 5.457E-02 4.572E+04 1.516E-05 5.292E-01 1.310E+OO Nl-65 2.520E+OO H 2.520E+OO 2.751E-01 9.072E+03 7.641E-05 1.050E-01 6.601E+OO ZN-65 2.444E+02 D 5.866E+03 1.182E-04 2.112E+07 3.283E-08 2.444E+02 2.836E-03 ZN-69M 1.376E+01 H 1.376E+01 5.039E-02 4.952E+04 1.400E-05 5.732E-01 1.209E+OO ZN-69 9.267E-01 H 9.267E-01 7.480E-01 3.336E+03 2.078E-04 3.861E-02 1.795E+01 SE-79 6.500E+04 y 5.698E+08 1.216E-09 2.051E+12 3.379E-13 2.374E+07 2.920E-08 BR-82 3.530E+01 H 3.530E+01 1.964E-02 1.271E+05 5.454E-06 1.471E+OO 4.713E-01 BR-83 2.390E+OO H 2.390E+OO 2.900E-01 8.604E+03 8.056E-05 9.958E-02 6.960E+OO BR-84 5.300E-01 H 5.300E-01 1.308E+OO 1.908E+03 3.633E-04 2.208E-02 3.139E+01 BR-85 4.778E-02 H 4.778E-02 1.451 E+01 1.720E+02 4.030E-03 1.991E-03 3.482E+02 RB-86 1.866E+01 D 4.478E+02 1.548E-03 1.612E+06 4.299E-'07 1.866E+01 3.715E-02 RB-87 4.730E+10 y 4.146E+14 1.672E-15 1.493E+18 4.644E-19 1.728E+13 4.012E-14 RB-88 2.967E-01 H 2.967E-01 2.336E+OO 1.068E+03 6.490E-04 1.236E-02 5.607E+01 RB-89 2.573E-01 H 2.573E-01 2.694E+OO 9.264E+02 7.482E-04 1.072E-02 6.465E+01 SR-89 5.055E+01 D 1.213E+03 5.713E-04 4.368E+06 1.587E-07 5.055E+01 1.371E-02 SR-90 2.860E+01 y 2.507E+05 2.765E-06 9.025E+08 7.680E-10 1.045E+04 6.635E-05 Y-90 6.410E+01 H 6.410E+01 1.081E-02 2.308E+05 3.004E-06 2.671E+OO 2.595E-01 SR~91 9.500E+OO H 9.500E+OO 7.296E-02 3.420E+04 2.027E-05 3.958E-01 1.751E+OO Y-91M 8.285E-01 H 8.285E-01 8.366E-01 2.983E+03 2.324E-04 3.452E-02 2.008E+01 Y-91 5.851E+01 D 1.404E+03 4.936E-04 5.055E+06 1.371E-07 5.851E+01 1.185E-02 SR-92 2.710E+OO H 2.710E+OO 2.558E-01 9.756E+03 7.105E-05 1.129E-01 6.139E+OO Y-92 3.540E+OO H 3.540E+OO 1.958E-01 1.274E+04 5.439E-05 1.475E-01 4.699E+OO Y-93 1.010E+01 H 1.010E+01 6.863E-02 3.636E+04 1.906E-05 4.208E-01 1.647E+OO NB-93M 1.460E+01 y 1.280E+05 5.416E-06 4.607E+08 1.504E-09 5.333E+03 1.300E-04 NB-95 3.506E+01 D 8.414E+02 8.238E-04 3.029E+06 2.288E-07 3.506E+01 1.977E-02 Rev.29 Page 116 of 329 12/2016
CY-LG-170-301 TABLE 111-1 DECAY CONSTANTS FOR NUCLIDES OF INTEREST 1 DECAY DECAY DECAY KOCHER T112 CONSTANT T112 CONSTANT T112 CONSTANT NUCLIDE T112 HOURS HR"1 SECONDS SEC-1 DAYS DAYs-1 NB-97 1.202E+OO H 1.202E+OO 5.768E-01 4.326E+03 1.602E-04 5.007E-02 1.384E+01 ZR-93 1.530E+06 y 1.341E+10 5.168E-11 4.828E+13 1.436E-14 5.588E+08 1.240E-09 ZR-95 6.402E+01 D 1.536E+03 4.511E-04 5.531E+06 1.253E-07 6.402E+01 1.083E-02 ZR-97 1.690E+01 H 1.690E+01 4.101E-02 6.084E+04 1.139E-05 7.042E-01 9.844E-01 M0-93 3.500E+03 y 3.068E+07 2.259E-08. 1.105E+11 6.276E-12 1.278E+06 5.422E-07 M0-99 6.602E+01 H 6.602E+01 1.050E-02 2.377E+05 2.916E-06 2.751E+OO 2.520E-01 TC-99 2.130E+05 y 1.867E+09 3.712E-10 6.722E+12 1.031E-13 7.780E+07 8.910E-09 TC-99M 6.020E+OO H 6.020E+OO 1.151E-01 2.167E+04 3.198E-05 2.508E-01 2.763E+OO TC-101 2.367E-01 H 2.367E-01 2.929E+OO 8.520E+02 8.136E-04 9.861E-03 7.029E+01 RU-103 3.935E+01 D 9.444E+02 7.340E-04 3.400E+06 2.039E-07 3.935E+01 1.761E-02 RU-105 4.440E+OO H 4.440E+OO 1.561 E-01 1.598E+04 4.337E-05 1.850E-01 3.747E+OO RU-106 3.682E+02 D 8.837E+03 7.844E-05 3.181E+07 2.179E-08 3.682E+02 1.883E-03 RH-105 3.536E+01 H 3.536E+01 1.960E-02 1.273E+05 5.445E-06 1.473E+OO 4.705E-01 PD-107 6.500E+06 y 5.698E+10 1.216E-11 2.051E+14 3.379E-15 2.374E+09 2.920E-10 PD-109 1.345E+01 H 1.345E+01 5.152E-02 4.843E+04 1.431 E-05 5.605E-01 1.237E+OO AG-110M 2.499E+02 D 5.996E+03 1.156E-04 2.159E+07 3.211 E-08 2.499E+02 2.774E-03 AG-111 7.460E+OO D 1.790E+02 3.871E-03 6.445E+05 1.075E-06 7.460E+OO 9.292E-02 CD-113M 1.370E+_01 y 1.201E+05 5.772E-06 4.323E+08 1.603E-09 5.004E+03 1.385E-04 CD-115M 4.460E+01 D 1.070E+03 6.476E-04 3.853E+06 1.799E-07 4.460E+01 1.554E-02 SN-123 1.292E+02 D 3.101E+03 2.235E-04 1.116E+07 6.209E-08 1.292E+02 5.365E-03 SN-125 9.640E+OO D 2.314E+02 2.996E-03 8.329E+05 8.322E-07 9.640E+OO 7.190E-02 SN-126 1.000E+05 y 8.766E+08 7.907E-10 3.156E+12 2.196E-13 3.653E+07 1.898E-08 SB-124 6.020E+01 D 1.445E+03 4.798E-04 5.201E+06 1.333E-07 6.020E+01 1.151E-02 SB-125 2.770E+OO y 2.428E+04 2.855E-05 8.741E+07 7.929E-09 1.012E+03 6.851E-04 SB-126 1.240E+01 D 2.976E+02 2.329E-03 1.071E+06 6.470E-07 1.240E+01 5.590E-02 SB-127 3.850E+OO D 9.240E+01 7.502E-03 3.326E+05 2.084E-06 3.850E+OO 1.800E-01 TE-125M 5.800E+01 D 1.392E+03 4.980E-04 5.011E+06 1.383E-07 5.800E+01 1.195E-02 TE-127M 1.090E+02 D 2.616E+03 2.650E-04 9.418E+06 7.360E-08 1.090E+02 6.359E-03 TE-127 9.350E+OO H 9.350E+OO 7.413E-02 3.366E+04 2.059E-05 3.896E-01 1.779E+OO TE-129M
- 3.360E+01 D 8.064E+02 8.596E-04 2.903E+06 2.388E-07 3.360E+01 2.063E-02 TE-129 1.160E+OO H 1.160E+OO 5.975E-01 4.176E+03 1.660E-04 4.833E-02 1.434E+01 TE-133M 9.233E-01 H 9.233E-01 7.507E-01 3.324E+03 2.085E-04 3.847E-02 1.802E+01 TE-134 6.967E-01 H 6.967E-01 9.949E-01 2.508E+03 2.764E-04 2.903E-02 2.388E+01 1-129 1.570E+07 y 1.376E+11 5.036E-12 4.955E+14 1.399E-15 5.734E+09 1.209E-10 1-130 1.236E+01 H 1.236E+01 5.608E-02 4.450E+04 1.558E-05 5.150E-01 1.346E+OO 1-131 8.040E+OO D 1.930E+02 3.592E-03 6.947E+05
- 9.978E-07 8.040E+OO 8.621E-02 TE-131M 3.000E+01 H 3.000E+01 2.310E-02 1.080E+05 6.418E-06 1.250E+OO 5.545E-01 TE-131 4.167E-01 H 4.167E-01 1.664E+OO 1.500E+03 4.621E-04 1.736E-02 3.993E+01 1-132 2.300E+OO H 2.300E+OO 3.014E-01 8.280E+03 8.371E-05 9.583E-02 7.233E+OO TE-132 7.820E+01 H 7.820E+01 8.864E-03 2.815E+05 2.462E-06 3.258E+OO 2.127E-01 1-133 2.080E+01 H 2.080E+01 3.332E-02 7.488E+04 9.257E-06 8.667E-01 7.998E-01 CS-134M 2.900E+OO H 2.900E+OO 2.390E-01 1.044E+04 6.639E-05 1.208E-01 5.736E+OO CS-134 2.062E+OO y 1.808E+04 3.835E-05 6.507E+07 1.065E-08 7.531E+02 9.203E-04 Rev.29 Page 117 of 329 12/2016
CY-LG-170-301 TABLE 111-1 DECAY CONSTANTS FOR NUCLIDES OF INTEREST 1 DECAY DECAY DECAY KOCHER T112 CONSTANT T112 CONSTANT T112 CONSTANT NUCLIDE T112 HOURS HR"1 SECONDS SEC-1 DAYS DAYs-1 1-134 8.767E-01 H 8.767E-01 7.907E-01 3.156E+03 2.196E-04 3.653E-02 1.898E+01 1-135 6.610E+OO H 6.610E+OO 1.049E-01 2.380E+04 2.913E-05 2.754E-01 2.517E+OO CS-135 2.300E+06 y 2.016E+10 3.438E-11 7.258E+13 9.550E-15 8.401E+08 8.251E-10 CS-136 1.316E+01 D 3.158E+02 2.195E-03 1.137E+06 6.096E-07 1.316E+01 5.267E-02 CS-137 3.017E+01 y 2.645E+05 2.621E-06 9.521E+08 7.280E-10 1.102E+04 6.290E-05 CS-138 5.367E-01 H 5.367E-01 1.292E+OO 1.932E+03 3.588E-04 2.236E-02 3.100E+01 CS-139 1.567E-01 H 1.567E-01 4.424E+OO 5.640E+02 1.229E-03 6.528E-03 1.062E+02 BA-139 1.385E+OO H 1.385E+OO 5.005E-01 4.986E+03 1.390E-04 5.771E-02 1.201E+01 BA-140 1.279E+01 D 3.069E+02 2.258E-03 1.105E+06 6.273E-07 1.279E+01 5.420E-02 LA-140 4.022E+01 H 4.022E+01 1.723E-02 1.448E+05 4.787E-06 1.676E+OO 4.136E-01 BA-141 3.045E-01 H 3.045E-01 2.276E+OO 1.096E+03 6.323E-04 1.269E-02 5.463E+01 LA-141 3.940E+OO H 3.940E+OO 1.759E-01 1.418E+04 4.887E-05 1.642E-01 4.222E+OO CE-141 3.250E+01 D 7.800E+02 8.887E-04 2.808E+06 2.468E-07 3.250E+01 2.133E-02 BA-142 1.783E-01 H 1.783E-01 3.887E+OO 6.420E+02 1.080E-03 7.431E-03 9.328E+01 LA-142 1.590E+OO H 1.590E+OO 4.359E-01 5.724E+03 1.211E-04 6.625E-02 1.046E+01 CE-143 3.300E+01 H 3.300E+01 2.100E-02 1.188E+05 5.835E-06 1.375E+OO 5.041E-01 PR-143 1.356E+01 D 3.254E+02 2.130E-03 1.172E+06 5.916E-07 1.356E+01 5.112E-02 CE-144 2.843E+02 D 6.823E+03 1.016E-04 2.456E+07 2.822E-08 2.843E+02 2.438E-03 PR-144 2.880E-01 H 2.880E-01 2.407E+OO 1.037E+03 6.685E-04 1.200E-02 5.776E+01 ND-147 1.098E+01 D 2.635E+02 2.630E-03 9.487E+05 7.306E-07 1.098E+01 6.313E-02 PM-147 2.623E+OO y 2.300E+04 3.014E-05 8.279E+07 8.373E-09 9.582E+02 7.234E-04 PM-148M 4.130E+01 D 9.912E+02 6.993E-04 3.568E+06 1.943E-07 4.130E+01 1.678E-02 PM-148 5.370E+OO D 1.289E+02 5.378E-03 4.640E+05 1.494E-06 5.370E+OO 1.291E-01 PM-149 5.308E+01 H 5.308E+01 1.306E-02 1.911E+05 3.627E-06 2.212E+OO 3.134E-01 PM-151 2.840E+01 H 2.840E+01 2.441E-02 1.022E+05 6.780E-06 1.183E+OO 5.858E-01 SM-151 9.000E+01 y 7.889E+05 8.786E-07 2.840E+09 2.441E-10 3.287E+04 2.109E-05 SM-153 4.670E+01 H 4.670E+01 1.484E-02 1.681E+05 4.123E-06 1.946E+OO 3.562E-01 EU-152 1.360E+01 y 1.192E+05 5.814E-06 4.292E+08 1.615E-09 4.967E+03 1.395E-04 EU-154 8.800E+OO y 7.714E+04 8.985E-06 2.777E+08 2.496E-09 3.214E+03 2.157E-04 EU-155 4.960E+OO y 4.348E+04 1.594E-05 1.565E+08 4.428E-09 1.812E+03 3.826E-04 EU-156 1.519E+01 D 3.646E+02 1.901E-03 1.312E+06 5.281E-07 1.519E+01 4.563E-02 TB-160 7.230E+01 D 1.735E+03 3.995E-04 6.247E+06 1.110E-07 7.230E+01 9.587E-03 H0-166M 1.200E+03 y 1.052E+07 6.589E-08 3.787E+10 1.830E-11 4.383E+05 1.581E-06 W-181 1.210E+02 D 2.903E+03 2.388E-04 1.045E+07 6.633E-08 1.210E+02 5.731E-03 W-185 7.510E+01 D 1.802E+03 3.846E-04 6.489E+06 1.068E-07 7.510E+01 9.230E-03 W-187 2.383E+01 H 2.383E+01 2.909E-02 8.579E+04 8.0BOE-06 9.929E-01 6.9&1E-01 NP-239 2.355E+OO D 5.652E+01 1.226E-02 2.035E+05 3.407E-06 2.355E+OO 2.943E-01 U-232 7.200E+01 y 6.312E+05 1.098E-06 2.272E+09 3.051E-10 2.630E+04 2.636E-05 U-233 1.592E+05 y 1.396E+09 4.967E-10 5.024E+12 1.380E-13 5.815E+07 1.192E-08 U-234 2.445E+05 y 2.143E+09 3.234E-10 7.716E+12 8.983E-14 8.930E+07 7.762E-09 U-235 7.038E+08 y 6.170E+12 1.124E-13 2.221E+16 3.121E-17 2.571E+11 2.696E-12 U-236 2.342E+07 y 2.053E+11 3.377E-12 7.389E+14 9.381E-16 8.552E+09 8.105E-11 U-237 6.750E+OO D 1.620E+02 4.279E-03 5.832E+05 1.189E-06 6.750E+OO 1.027E-01 Rev.29 Page 118 of 329 12/2016
CY-LG-170-301 TABLE 111-1 DECAY CONSTANTS FOR NUCLIDES OF INTEREST1 DECAY DECAY DECAY KOCHER T112 CONSTANT T112 CONSTANT T112 CONSTANT NUCLIDE T112 HOURS HR"1 SECONDS SEC"1 DAYS DAYs*1 U-238 4.468E+09 y 3.917E+13 1.770E-14 1.410E+17 4.916E-18 1.632E+12 4.247E-13 NP-237 2.140E+06 y 1.876E+10 3.695E-11 6.753E+13 1.026E-14 7.816E+08 8.868E-10 NP-238 2.117E+OO D 5.081E+01 1.364E-02 1.829E+05 3.790E-06 2.117E+OO 3.274E-01 PU-238 8.775E+01 y 7.692E+05 9.011E-07 2.769E+09 2.503E-10 3.205E+04 2.163E-05 PU-239 2.413E+04 y 2.115E+08 3.277E-09 7.615E+11 9.102E-13 8.814E+06 7.864E-08 PU-240 6.569E+03 y 5.758E+07 1.204E-08 2.073E+11 3.344E-12 2.399E+06 2.889E-07 PU-241 1.440E+01 y 1.262E+05 5.491E-06 4.544E+08 1.525E-09 5.260E+03 1.318E-04 PU-242 3.758E+05 y 3.294E+09 2.104E-10 1.186E+13 5.845E-14 1.373E+08 5.050E-09 PU-244 8.260E+07 y 7.241E+11 9.573E-13 2.607E+15 2.659E-16 3.017E+10 2.297E-11 AM-241 4.322E+02 y 3.789E+06 1.830E-07 1.364E+10 5.082E-11 1.579E+05 4.391E-06 AM-242M 1.520E+02 y 1.332E+06 5.202E-07 4.797E+09 1.445E-10 5.552E+04 1.249E-05 AM-243 7.380E+03 y 6.469E+07 1.071E-08 2.329E+11 2.976E-12 2.696E+06 2.571E-07 CM-242 1.632E+02 D 3.917E+03 1.770E-04 1.41 OE+07 4.916E-08 *1.632E+02 4.247E-03 CM-243 2.850E+01 y 2.498E+05 2.774E-06 8.994E+08 7.707E-10 1.041E+04 6.659E-05 CM-244 1.811 E+01 y 1.588E+05 4.366E-06 5.715E+08 1.213E-09 6.615E+03 1.048E-04 CM-245 8.500E+03 y 7.451E+07 9.303E-09 2.682E+11 2.584E-12 3.105E+06 2.233E-07 CM-246 4.750E+03 y 4.164E+07 1.665E-08 1.499E+11 4.624E-12 1.735E+06 3.995E-07 CM-247 1.560E+07 y 1.367E+11 5.069E-12 4.923E+14 1.408E-15 5.698E+09 1.216E-10 CM-248 3.390E+05 y 2.972E+09 2.333E-10 1.070E+13 6.479E-14 1.238E+08
- 5.598E-09 CF-252 2.639E+OO y 2.313E+04 2.9~6E-05 8.328E+07 8.323E-09 9.639E+02 7.191E-04
- 1. Kocher, David C., "Radioactive Decay Data Tables," DOE/TIC-11026,138 (1981)._
Rev. 29 Page 119 of 329 12/2016
CY-LG-170-301 TABLE 111-2 1 BIOACCUMULATION FACTORS FOR FRESHWATER FISH (pCi/kg per pCi/liter) NUCLIDE FISH NUCLIDE FISH NUCLIDE FISH NUCLIDE FISH H-3 9.0E-01 ZR-93 3.3E+OO 1-131 1.5E+01 W-187 1.2E+03 C-14 4.6E+03 ZR-95 3.3E+OO 1-132 1.5E+01 U-232 2.0E+OO NA-22 1.0E+02 ZR-97 3.3E+OO 1-133 1.5E+01 U-233 2.0E+OO NA-24 1.0E+02 NB-93M 3.0E+04 1-134 1.5E+01 U-234 2.0E+OO P-32 2
- 3.0E+03 2 NB-95 3.0E+04 1-135 1.5E+01 U-235 2.0E+OO CA-41 4.0E+01 NB-97 3.0E+04 CS-134M 2.0E+03 U-236 2.0E+OO SC-46 2.0E+OO M0-93 1.0E+01 CS-134 2.0E+03 U-237 2.0E+OO CR-51 2.0E+02 M0-99 1.0E+01 CS-135 2.0E+03 U-238 2.0E+OO MN-54 4.0E+02 TC-99M 1.5E+01 CS-136 2.0E+03 NP-237 1.0E+01 MN-56 4.0E+02 TC-99 1.5E+01 CS-137 2.0E+03 NP-238 1.0E+01 FE-55 1.0E+02 TC-101 1.5E+01 CS-138 2.0E+03 NP-239 1.0E+01 FE-59 1.0E+02 RU-103 1.0E+01 CS-139 2.0E+03 PU-238 3.5E+OO C0-57 5.0E+01 RU-105 1.0E+01 BA-139 4.0E+OO PU-239 3.5E+OO C0-58 5.0E+01 RU-106 1.0E+01 BA-140 4.0E+OO PU-240 3.5E+OO C0-60 5.0E+01 RH-105 1.0E+01 BA-141 4.0E+OO PU-241 3.5E+OO Nl-59 1.0E+02 PD-107 1.0E+01 BA-142 4.0E+OO PU-242 3.5E+OO Nl-63 1.0E+02 PD-109 1.0E+01 LA-140 2.5E+01 PU-244 3.5E+OO Nl-65 1.0E+02 AG-110M 2.5E+OO LA-141 2.5E+01 AM-241 2.5E+01 CU-64 5.0E+01 AG-111 2.5E+OO LA-142 2.5E+01 AM-242M 2.5E+01 ZN-65 2.0E+03 CD-113M 2.0E+02 CE-141 1.0E+OO AM-243 2.5E+01 ZN-69M 2.0E+03 CD-115M 2.0E+02 CE-143 1.0E+OO CM-242 2.5E+01 ZN-69 2.0E+03 SN-123 3.0E+03 CE-144 1.0E+OO CM-243 2.5E+01 SE-79 \
1.7E+02 SN-125 3.0E+03 PR-143 2.5E+01 CM-244 2.5E+01 BR-82 4.2E+02 SN-126 3.0E+03 PR-144 2.5E+01 CM-245 2.5E+01 BR-83 4.2E+02 SB-124 1.0E+OO ND-147 2.5E+01 CM-246 2.5E+01 BR-84 4.2E+02 SB-125 1.0E+OO PM-147 2.5E+01 CM-247 2.5E+01 BR-85 4.2E+02 SB-126 1.0E+OO PM-148M 2.5E+01 CM-248 2.5E+01 RB-86 2.0E+03 SB-127 1.0E+OO PM-148 2.5E+01 CF-252 2.5E+01 RB-87 2.0E+03 TE-125M 4.0E+02 PM-149 2.5E+01 RB-88 2.0E+03 TE-127M 4.0E+02 PM-151 2.5E+01 RB-89 2.0E+03 TE-127 4.0E+02 SM-151 2.5E+01 SR-89 3.0E+01 TE-129M 4.0E+02 SM-153 2.5E+01 SR-90 3.0E+01 TE-129 4.0E+02 EU-152 2.5E+01 SR-91 3.0E+01 TE-131M 4.0E+02 EU-154 2.5E+01 SR-92 3.0E+01 TE-131 4.0E+02 EU-155 2.5E+01 Y-90 2.5E+01 TE-132 4.0E+02 EU-156 2.5E+01 Y-91M 2.5E+01 TE-133M 4.0E+02 TB-160 2.5E+01 Y-91 2.5E+01 TE-134 4.0E+02 H0-166M 2.5E+01 Y-92 2.5E+01 1-129 1.5E+01 W-181 1.2E+03 Y-93 2.5E+01 1-130 1.5E+01 W-185 1.2E+03 1 NUREG/CR-4013, LADTAP II, Technical Reference and User Guide, Table 3.1 2 Letter LTR 881209L001, from R.J. Clark, U.S.N.R.C., to G.A. Hunger, Philadelphia Electric Co., December 9, 1988, transmitting evaluation of Limerick ODCM. Rev.29 Page 120 of 329 12/2016
CY-LG-170-301 TABLE 111-3 INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 5.99E-08 5.99E-08 5.99E-08 5.99E-08 5.99E-08 5.99E-08 O.OOE+OO C-14 2.84E-06 5.68E-07 5.68E-07 5.68E-07 5.68E-07 5.68E-07 5.68E-07 O.OOE+OO NA-22 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 O.OOE+OO NA-24 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 O.OOE+OO P-32 1.93E-04 1.20E-05 7.46E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.17E-05 O.OOE+OO CA-41 . 1.85E-04 O.OOE+OO 2.00E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.84E-07 O.OOE+OO SC-46 5.51E-09 1.07E-08 3.11 E-09 O.OOE+OO 9.99E-09 O.OOE+OO 5.21E-05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 2.66E-09 1.59E-09 5.86E-10 3.53E-09 6.69E-07 O.OOE+OO MN-54 O.OOE+OO 4.57E-06 8.72E-07 O.OOE+OO 1.36E-06 O.OOE+OO 1.40E-05 O.OOE+OO MN-56 O.OOE+OO 1.15E-07 2.04E-08 O.OOE+OO 1.46E-07 O.OOE+OO 3.67E-06 O.OOE+OO FE-55 2.75E-06 1.90E-06 4.43E-07 O.OOE+OO O.OOE+OO 1.06E-06 1.09E-06 O.OOE+OO FE-59 4.34E-06 1.02E-05 3.91E-06 O.OOE+OO O.OOE+OO 2.85E-06 3.40E-05 O.OOE+OO C0-57 O.OOE+OO 1.75E-07 2.91E-07 O.OOE+OO O.OOE+OO O.OOE+OO 4.44E-06 O.OOE+OO C0-58 O.OOE+OO 7.45E-07 1.67E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.51 E-05 O.OOE+OO C0-60 O.OOE+OO 2.14E-06 4.72E-06 O.OOE+OO O.OOE+OO O.OOE+OO 4.02E-05 O.OOE+OO Nl-59 9.76E-06 3.35E-06 1.63E-06 O.OOE+OO O.OOE+OO O.OOE+OO 6.90E-07 O.OOE+OO Nl-63 1.30E-04 9.01E-06 4.36E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.88E-06 O.OOE+OO Nl-65 5.28E-07 6.86E-08 3.13E-08 O.OOE+OO I O.OOE+OO O.OOE+OO 1.74E-06 O.OOE+OO CU-64 O.OOE+OO 8.33E-08 3.91E-08 O.OOE+OO 2.10E-07 O.OOE+OO 7.10E-06 O.OOE+OO ZN-65 4.84E-06 1.54E-05 6.96E-06 O.OOE+OO 1.03E-05 O.OOE+OO 9.70E-06 O.OOE+OO ZN-69M 1.70E-07 4.08E-07 3.73E-08 O.OOE+OO 2.47E-07 O.OOE+OO 2.49E-05 O.OOE+OO ZN-69 1.03E-08 1.97E-08 1.37E-09 O.OOE+OO 1.28E-08 O.OOE+OO 2.96E-09 O.OOE+OO SE-79 O.OOE+OO 2.63E-06 4.39E-07 O.OOE+OO 4.55E-06 O.OOE+OO 5.38E-07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 2.26E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.59E-06 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 4.02E-08 O.OOE+OO O.OOE+OO O.OOE+OO 5.79E-08 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 5.21E-08 O.OOE+OO O.OOE+OO O.OOE+OO 4.09E-13 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 2'.14E-09 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 2.11E-05 9.83E-06 O.OOE+OO O.OOE+OO O.OOE+OO 4.16E-06 O.OOE+OO RB-87 O.OOE+OO 1.23E-05 4.28E-06 O.OOE+OO O.OOE+OO O.OOE+OO 5.76E-07 O.OOE+OO RB-88 O.OOE+OO 6.05E-08 3.21E-08 O.OOE+OO O.OOE+OO O.OOE+OO 8.36E-19 O.OOE+OO RB-89 O.OOE+OO 4.01E-08 2.82E-08 O.OOE+OO O.OOE+OO O.OOE+OO 2.33E-21 O.OOE+OO SR-89 3.08E-04 O.OOE+OO 8.84E-06 O.OOE+OO O.OOE+OO O.OOE+OO 4.94E-05 O.OOE+OO SR-90 8.71E-03 O.OOE+OO 1.75E-04 O.OOE+OO O.OOE+OO O.OOE+OO 2.19E-04 O.OOE+OO SR-91 5.67E-06 O.OOE+OO 2.29E-07 O.OOE+OO O.OOE+OO O.OOE+OO 2.70E-05 O.OOE+OO SR-92 2.15E-06 O.OOE+OO 9.30E-08 O.OOE+OO O.OOE+OO O.OOE+OO 4.26E-05 O.OOE+OO Y-90 9.62E-09 O.OOE+OO 2.58E-10 O.OOE+OO O.OOE+OO O.OOE+OO 1.02E-04 O.OOE+OO Y-91M 9.09E-11 O.OOE+OO 3.52E-12 O.OOE+OO O.OOE+OO O.OOE+OO 2.67E-10 O.OOE+OO Y-91 1.41 E-07 O.OOE+OO 3.77E-09 O.OOE+OO O.OOE+OO O.OOE+OO 7.76E-05 O.OOE+OO Y-92 8.45E-10 O.OOE+OO 2.47E-11 O.OOE+OO O.OOE+OO O.OOE+OO 1.48E-05 O.OOE+OO Y-93 2.68E-09 O.OOE+OO 7.40E-11 O.OOE+OO O.OOE+OO O.OOE+OO 8.50E-05 O.OOE+OO ZR-93 4.18E-08 2.34E-09 1.09E-09 O.OOE+OO 8.87E-09 O.OOE+OO 2.43E-06 O.OOE+OO ZR-95 3.04E-08 9.75E-09 6.60E-09 O.OOE+OO 1.53E-08 O.OOE+OO 3.09E-05 O.OOE+OO ZR-97 1.68E-09 3.39E-10 1.55E-10 O.OOE+OO 5.12E-10 O.OOE+OO 1.05E-04 O.OOE+OO NB-93M 2.55E-08 8.32E-09 2.05E-09 O.OOE+OO 9.57E-09 O.OOE+OO 3.84E-06 O.OOE+OO NB-95 6.22E-09 3.46E-09 1.86E-09 O.OOE+OO ,3.42E-09 O.OOE+OO 2.10E-05 O.OOE+OO NB-97 5.22E-11 1.32E-11 4.82E-12 O.OOE+OO 1.54E-11 O.OOE+OO 4.87E-08 O.OOE+OO Rev.29 Page 121 of 329 12/2016
CY-LG-170-301 TABLE 111-3 INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN M0-93 O.OOE+OO 7.51E-06 2.03E-07 O.OOE+OO 2.13E-06 O.OOE+OO 1.22E-06 O.OOE+OO M0-99 O.OOE+OO 4.31E-06 8.20E-07 O.OOE+OO 9.76E-06 O.OOE+OO 9.99E-06 O.OOE+OO TC-99M 2.47E-10 6.98E-10 8.89E-09 O.OOE+OO 1.06E-08 3.42E-10 4.13E-07 O.OOE+OO TC-99 1.25E-07 1.86E-07 5.02E-08 O.OOE+OO 2.34E-06 1.58E-08 6.08E-06 O.OOE+OO TC-101 2.54E-10 3.66E-10 3.59E-09 O.OOE+OO 6.59E-09 1.87E-10 1.10E-21 O.OOE+OO RU-103 1.85E-07 O.OOE+OO 7.97E-08 O.OOE+OO 7.06E-07 O.OOE+OO 2.16E-05 O.OOE+OO RU-105 1.54E-08 O.OOE+OO 6.08E-09 O.OOE+OO 1.99E-07 O.OOE+OO 9.42E-06 O.OOE+OO RU-106 2.75E-06 O.OOE+OO 3.48E-07 O.OOE+OO 5.31E-06 O.OOE+OO 1.78E-04 O.OOE+OO RH-105 1.21E-07 8.85E-08 5.83E-08 O.OOE+OO 3.76E-07 O.OOE+OO 1.41 E-05 O.OOE+OO PD-107 O.OOE+OO 1.47E-07 9.40E-09 O.OOE+OO 1.32E-06 O.OOE+OO 9.11E-07 O.OOE+OO PD-109 O.OOE+OO 1.77E-07 3.99E-08 O.OOE+OO 1.01E-06 O.OOE+OO 1.96E-05 O.OOE+OO AG-110M 1.60E-07 1.48E-07 8.79E-08 O.OOE+OO 2.91 E-07 O.OOE+OO 6.04E-05 O.OOE+OO AG-111 5.81E-08 2.43E-08 1.21 E-08 O.OOE+OO 7.84E-08 O.OOE+OO 4.46E-05 O.OOE+OO CD-113M O.OOE+OO 3.18E-06 1.02E-07 O.OOE+OO 3.50E-06 O.OOE+OO 2.56E-05 O.OOE+OO CD-115M O.OOE+OO 1.84E-06 5.87E-08 O.OOE+OO 1.46E-06 O.OOE+OO 7.74E-05 O.OOE+OO SN-123 3.11E-05 5.15E-07 7.59E-07 4.38E-07 O.OOE+OO O.OOE+OO 6.33E-05 O.OOE+OO SN-125 8.33E-06 1.68E-07 3.78E-07 1.39E-07 O.OOE+OO O.OOE+OO 1.04E-04 O.OOE+OO SN-126 8.45E-05 1.67E-06 2.40E-06 4.92E-07 O.OOE+OO O.OOE+OO 2.43E-05 O.OOE+OO SB-124 2.80E-06 5.29E-08 1.11 E-06 6.79E-09 O.OOE+OO 2.18E-06 7.95E-05 O.OOE+OO SB-125 1.79E-06 2.00E-08 4.26E-07 1.82E-09 O.OOE+OO 1.38E-06 1.97E-05 O.OOE+OO SB-126 1.15E~06 2.34E-08 4.15E-07 7.04E-09 O.OOE+OO 7.05E-07 9.40E-05 O.OOE+OO SB-127 2.58E-07 5.65E-09 9.90E-08 3.10E-09 O.OOE+OO 1.53E-07 5.90E-05 O.OOE+OO TE-125M 2.68E-06 9.71E-07 3.59E-07 8.06E-07 1.09E-05 O.OOE+OO 1.07E-05 O.OOE+OO TE-127M 6.77E-06 2.42E-06 8.25E-07 1.73E-06 2.75E-05 O.OOE+OO 2.27E-05 O.OOE+OO TE-127 1.10E-07 3.95E-08 2.38E-08 8.15E-08 4.48E-07 O.OOE+OO 8.68E-06 O.OOE+OO TE-129M 1.15E-05 4.29E-06 1.82E-06 3.95E-06 4.80E-05 O.OOE+OO 5.79E-05 O.OOE+OO TE-129 3.14E-08 1.18E-08 7.65E-09 2.41 E-08 1.32E-07 O.OOE+OO 2.37E-08 O.OOE+OO TE-131M 1.73E-06 8.46E-07 7.05E-07 1.34E-06 8.57E-06 O.OOE+OO 8.40E-05 O.OOE+OO TE-131 1.97E-08 8.23E-09 6.22E-09 1.62E-08 8.63E-08 O.OOE+OO 2.79E-09 O.OOE+OO TE-133M 4.62E-08 2.70E-08 2.60E-08 3.91E-08 2.67E-07 O.OOE+OO 9.26E-09 O.OOE+OO TE-134 3.24E-08 2.12E-08 1.30E-08 2.83E-08 2.05E-07 O.OOE+OO 3.59E-11 O.OOE+OO TE-132 2.52E-06 1.63E-06 1.53E-06 1.80E-06 1.57E-05 O.OOE+OO 7.71E-05 O.OOE+OO 1-129 3.27E-06 2.81E-06 9.21E-06 7.23E-03 6.04E-06 O.OOE+OO 4.44E-07 O.OOE+OO 1-130 7.56E-07 2.23E-06 8.80E-07 1.89E-04 3.48E-06 O.OOE+OO 1.92E-06 O.OOE+OO 1-131 4.16E-06 5.95E-06 3.41E-06 1.95E-03 1.02E-05 O.OOE+OO 1.57E-06 O.OOE+OO 1-132 2.03E-07 5.43E-07 1.90E-07 1.90E-05 8.65E-07 O.OOE+OO 1.02E-07 O.OOE+OO 1-133 1.42E-06 2.47E-06 7.53E-07 3.63E-04 4.31 E-06 O.OOE+OO 2.22E-06 O.OOE+OO 1-134 1.06E-07 2.88E-07 1.03E-07 4.99E-06 4.58E-07 O.OOE+OO 2.51E-10 O.OOE+QO 1-135 4.43E-07 1.16E-06 4.28E-07 7.65E-05 1.86E-06 O.OOE+OO 1.31 E-06 O.OOE+OO CS-134M 2.13E-08 4.48E-08 2.29E-08 O.OOE+OO 2.43E-08 3.83E-09 1.58E-08 O.OOE+OO CS-134 6.22E-05 1.48E-04 1.21E-04 O.OOE+OO 4.79E-05 1.59E-05 2.59E-06 O.OOE+OO CS-135 1.95E-05 1.80E-05 7.99E-06 O.OOE+OO 6.81E-06
- 2.04E-06 4.21 E-07 O.OOE+OO CS-136 6.51E-06 2.57E-05 1.85E-05 O.OOE+OO 1.43E-05 1.96E-06 2.92E-06 O.OOE+OO CS-137 7.97E-05 1.09E-04 7.14E-05 O.OOE+OO 3.70E-05 1.23E-05 2.11 E-06 O.OOE+OO CS-138 5.52E-08 1.09E-07 5.40E-08 O.OOE+OO 8.01E-08 7.91E-09 4.65E-13 O.OOE+OO CS-139 3.41E-08 5.08E-08 1.85E-08 O.OOE+OO 4.07E-08 3.70E-09 1.10E-30 O.OOE+OO BA-139 9.70E-08 6.91 E-11 2.84E-09 O.OOE+OO 6.46E-11 3.92E-11 1.72E-07 O.OOE+OO Rev.29 Page 122 of 329 12/2016
CY-LG-170-301 TABLE 111-3 INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN BA-140 2.03E-05 2.55E-08 1.33E-06 O.OOE+OO 8.67E-09 1.46E-08 4.18E-05 O.OOE+OO BA-141 4.71E-08 3.56E-11 1.59E~09 O.OOE+OO 3.31 E-11 2.02E-11 2.22E-17 O.OOE+OO BA-142 2.13E-08 2.19E-11 1.34E-09 O.OOE+OO 1.85E-11 1.24E-11 3.00E-26 O.OOE+OO LA-140 2.50E-09 1.26E-09 3.33E-10 O.OOE+OO O.OOE+OO O.OOE+OO 9.25E-05 O.OOE+OO LA-141 3.19E-10 9.90E-11 1.62E-11 O.OOE+OO O.OOE+OO O.OOE+OO 1.18E-05 O.OOE+OO LA-142 1.28E-10 5.82E-11 1.45E-11 O.OOE+OO O.OOE+OO O.OOE+OO 4.25E-07 O.OOE+OO CE-141 9.36E-09 6.33E-09 7.18E-10 O.OOE+OO 2.94E-09 O.OOE+OO 2.42E-05 O.OOE+OO CE-143 1.65E-09 1.22E-06 1.35E-10 0.00.E+OO 5.37E-10 O.OOE+OO 4.56E-05 O.OOE+OO CE-144 4.88E-07 2.04E-07 2.62E-08 O.OOE+OO 1.21 E-07 O.OOE+OO 1.65E-04 O.OOE+OO PR-143 9.20E-09 3.69E-09 4.56E-10 O.OOE+OO 2.13E-09 O.OOE+OO 4.03E-05 O.OOE+OO PR-144 3.01E-11 1.25E-11 1.53E-12 O.OOE+OO 7.05E-12 O.OOE+OO 4.33E-18 O.OOE+OO ND-147 6.29E-09 7.27E-09 4.35E-10 O.OOE+OO 4.25E-09 O.OOE+OO 3.49E-05 O.OOE+OO PM-147 7.54E-08 7.09E-09 2.8E-09 O.OOE+OO 1.34E-08 O.OOE+OO 8.93E-06 O.OOE+OO PM-148M 3.07E-08 7.95E-09 6.08E-09 O.OOE+OO 1.20E-08 O.OOE+OO 6.74E-05 O.OOE+OO PM-148 7.17E-09 1.19E-09 5.99E-10 O.OOE+OO 2.25E-09 O.OOE+OO 9.35E-05 O.OOE+OO PM-149 1.52E-09 2.15E-10 8.78E-11 O.OOE+OO 4.06E-10 O.OOE+OO 4.03E-05 O.OOE+OO PM-151 6.97E-10 1.17E-10 5.91 E-11 O.OOE+OO 2.09E-10 O.OOE+OO 3.22E-05 O.OOE+OO SM-151 6.90E-08 1.19E-08 2.85E-09 O.OOE+OO 1.33E-08 O.OOE+OO 5.25E-06 O.OOE+OO SM-153 8.57E-10 7.15E-10 5.22E-11 O.OOE+OO 2.31E-10 O.OOE+OO 2.55E-05 O.OOE+OO EU-152 1.95E-07 4.44E-08 3.90E-08 O.OOE+OO 2.75E-07 O.OOE+OO 2.56E-05 O.OOE+OO EU-154 6.15E-07
- 7.56E-08 5.38E-08 O.OOE+OO 3.62E-07 O.OOE+OO 5.48E-05 O.OOE+OO EU-155 8.60E-08 1.22E-08 7.87E-09 O.OOE+OO 5.63E-08 O.OOE+OO 9.60E-06 O.OOE+OO EU-156 1.37E-08 1.06E-08 1.71 E-09 O.OOE+OO 7.08E-09 O.OOE+OO 7.26E-05 O.OOE+OO TB-160 4.70E-08 O.OOE+OO 5.86E-09 O.OOE+OO 1.94E-08 O.OOE+OO 4.33E-05 O.OOE+OO H0-166M 2.70E-07 8.43E-08 6.40E-08 O.OOE+OO 1.26E-07 O.OOE+OO 2.56E-05 O.OOE+OO W-181 9.91E-09 3.23E-09 3.46E-10 O.OOE+OO O.OOE+OO O.OOE+OO 3.68E-07 O.OOE+OO W-185 4.05E-07 1.35E-07 1.42E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.56E-05 O.OOE+OO W-187 1.03E-07 8.61E-08 3.01E-08 O.OOE+OO O.OOE+OO O.OOE+OO 2.82E-05 O.OOE+OO U-232 4.13E-03 O.OOE+OO 2.95E-04 O.OOE+OO 4.47E-04 O.OOE+OO 6.78E-05 O.OOE+OO U-233 8.71E-04 O.OOE+OO 5.28E-05 O.OOE+OO 2.03E-04 O.OOE+OO 6.27E-05 O.OOE+OO U-234 8.36E-04 O.OOE+OO 5.17E-05 O.OOE+OO 1.99E-04 O.OOE+OO 6.14E-05 O.OOE+OO U-235 8.01E-04 O.OOE+OO 4.86E-05 O.OOE+OO 1.87E-04 O.OOE+OO 7.81E-05 O.OOE+OO U-236 8.01E-04 O.OOE+OO 4.96E-05 O.OOE+OO 1.91 E-04 O.OOE+OO 5.76E-05 O.OOE+OO U-237 5.52E-08 O.OOE+OO 1.47E-08 O.OOE+OO 2.27E-07 O.OOE+OO 1.94E-05 O.OOE+OO U-238 7.67E-04 O.OOE+OO 4.54E-05 O.OOE+OO 1.75E-04 O.OOE+OO 5.50E-05 O.OOE+OO NP-237 1.26E-03 8.96E-05 5.54E-05 O.OOE+OO 4.12E-04 O.OOE+OO 7.94E-05 O.OOE+OO NP-238 1.37E-08 3.69E-10 2.13E-10 O.OOE+OO 1.25E-09 O.OOE+OO 3.43E-05 O.OOE+OO NP-239 1.19E-09 1.17E-10 6.45E-11 O.OOE+OO 3.65E-10 O.OOE+OO 2.40E-05 O.OOE+OO PU-238 6.30E-04 7.98E-05 1.71E-05 O.OOE+OO 7.32E-05 O.OOE+OO 7.30E-05 O.OOE+OO PU-239 7.25E-04 8.71E-05 1.91 E-05 O.OOE+OO 8.11 E-05 O.OOE+OO 6.66E-05 O.OOE+OO PU-240 7.24E-04 8.70E-05 1.91 E-05 O.OOE+OO 8.10E-05 O.OOE+OO 6.78E-05 O.OOE+OO PU-241 1.57E-05 7.45E-07 3.32E-07 O.OOE+OO 1.53E-06 O.OOE+OO 1.40E-06 O.OOE+OO PU-242 6.72E-04 8.39E-05 1.84E-05 O.OOE+OO 7.81E-05 O.OOE+OO 6.53E~o5 O.OOE+OO PU-244 7.84E-04 9.61E-05 2.11 E-05 O.OOE+OO 8.95E-05 O.OOE+OO 9.73E-05 O.OOE+OO AM-241 7.55E-04 7.05E-04 5.41 E-05 O.OOE+OO 4.07E-04 O.OOE+OO 7.42E-05 O.OOE+OO AM-242M 7.61E-04 6.63E-04 5.43E-05 O.OOE+OO 4.05E-04 O.OOE+OO 9.34E-05 O.OOE+OO AM-243 7.54E-04 6.90E-04 5.30E-05 O.OOE+OO 3.99E-04 O.OOE+OO 8.70E-05 O.OOE+OO Rev.29 Page 123 of 329 12/2016
CY-LG-170-301 TABLE 111-3 INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CM-242 2.06E-05 2.19E-05 1.37E-06 O.OOE+OO 6.22E-06 O.OOE+OO 7.92E-05 O.OOE+OO CM-243 5.99E-04 5.49E-04 3.75E-05 O.OOE+OO 1.75E-04 O.OOE+OO 7.81 E-05 O.OOE+OO CM-244 4.56E-04 4.27E-04 2.87E-05 O.OOE+OO 1.34E-04 O.OOE+OO 7.55E-05 O.OOE+OO CM-245 9.38E-04 8.17E-04 5.76E-05 O.OOE+OO 2.69E-04 O.OOE+OO 7.04E-05 O.OOE+OO CM-246 9.30E-04 8.16E-04 5.75E-05 O.OOE+OO 2.68E-04 O.OOE+OO 6.91 E-05 O.OOE+OO CM-247 9.07E-04 8.04E-04 5.67E-05 O.OOE+OO 2.64E-04 O.OOE+OO 9.09E-05 O.OOE+OO CM-248 7.54E-03 6.63E-03 4.67E-04 O.OOE+OO 2.18E-03 O.OOE+OO 1.47E-03 O.OOE+OO CF-252 2.61 E-04 O.OOE+OO 6.29E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.88E-04 O.OOE+OO NUREG/CR-4653, GASPAR II, Technical Reference and User Guide Rev.29 Page 124 of 329 12/2016
CY-LG-170-301 TABLE 111-4 INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 6.04E-08 6.04E-08 6.04E-08 6.04E-08 6.04E-08 6.04E-08 O.OOE+OO C-14 4.06E-06 8.12E-07 8.12E-07 8.12E-07 8.12E-07 8.12E-07 8.12E-07 O.OOE+OO NA-22 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 O.OOE+OO NA-24 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 O.OOE+OO P-32 2.76E-04 1.71E-05 1.07E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.32E-05 O.OOE+OO CA-41 1.97E-04 O.OOE+OO 2.13E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.95E-07 O.OOE+OO SC-46 7.24E-09 1.41E-08 4.18E-09 O.OOE+OO 1.35E-08 O.OOE+OO 4.80E-05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 3.60E-09 2.00E-09 7.89E-10 5.14E-09 6.05E-07 O.OOE+OO MN-54 O.OOE+OO 5.90E-06 1.17E-06 O.OOE+OO 1.76E-06 O.OOE+OO 1.21 E-05 O.OOE+OO MN-56 O.OOE+OO 1.58E-07 2.81E-08 O.OOE+OO 2.00E-07 O.OOE+OO 1.04E-05 O.OOE+OO FE-55 3.78E-06 2.68E-06 6.25E-07 O.OOE+OO O.OOE+OO 1.70E-06 1.16E-06 O.OOE+OO FE-59 5.87E-06 1.37E-05 5.29E-06 O.OOE+OO O.OOE+OO 4.32E-06 3.24E-05 O.OOE+OO C0-57 O.OOE+OO 2.38E-07 3.99E-07 O.OOE+OO O.OOE+OO O.OOE+OO 4.44E-06 O.OOE+OO C0-58 O.OOE+OO 9.72E-07 2.24E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.34E~05 O.OOE+OO C0-60 O.OOE+OO 2.81E-06 6.33E-06 O.OOE+OO O.OOE+OO O.OOE+OO 3.66E-05 O.OOE+OO Nl-59 1.32E-05 4.66E-06 2.24E-06 O.OOE+OO O.OOE+OO O.OOE+OO 7.31E-07 O.OOE+OO Nl-63 1.77E-04 1.25E-05 6.00E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.99E-06 O.OOE+OO Nl-65 7.49E-07 9.57E-08 4.36E-08 O.OOE+OO O.OOE+OO O.OOE+OO 5.19E-06 O.OOE+OO CU-64 0,00E+OO 1.15E-07 5.41E-08 O.OOE+OO 2.91E-07 O.OOE+OO 8.92E-06 O.OOE+OO ZN-65 5.76E-06 2.00E-05 9.33E-06 O.OOE+OO 1.28E-05 O.OOE+OO 8.47E-06 O.OOE+OO ZN-69M 2.40E-07 5.66E-07 5.19E-08 O.OOE+OO 3.44E-07 O.OOE+OO 3.11E-05 O.OOE+OO ZN-69 1.47E-08 2.80E-08 1.96E-09 O.OOE+OO 1.83E-08 O.OOE+OO 5.16E-08 O.OOE+OO SE-79 O.OOE+OO 3.73E-06 6.27E-07 O.OOE+OO 6.50E-06 O.OOE+OO 5.70E-07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 3.04E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 5.74E-08 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 7.22E-08 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 3.05E-09 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 2.98E-05 1.40E-05 O.OOE+OO O.OOE+OO O.OOE+OO 4.41E-06 O.OOE+OO RB-87 O.OOE+OO 1.75E-05 6.11E-06 O.OOE+OO O.OOE+OO O.OOE+OO 6.11E-07 O.OOE+OO RB-88 O.OOE+OO 8.52E-08 4.54E-08 O.OOE+OO O.OOE+OO O.OOE+OO 7.30E-15 O.OOE+OO RB-89 O.OOE+OO 5.50E-08 3.89E-08 O.OOE+OO O.OOE+OO O.OOE+OO 8.43E-17 O.OOE+OO SR-89 4.40E-04 O.OOE+OO 1.26E-05 O.OOE+OO O.OOE+OO O.OOE+OO 5.24E-05 O.OOE+OO SR-90 1.02E-02 O.OOE+OO 2.04E-04 O.OOE+OO O.OOE+OO O.OOE+OO 2.33E-04 O.OOE+OO SR-91 8.07E-06 O.OOE+OO 3.21E-07 O.OOE+OO O.OOE+OO O.OOE+OO 3.66E-05 O.OOE+OO SR-92 3.05E-06 O.OOE+OO 1.30E-07 O.OOE+OO O.OOE+OO O.OOE+OO 7.77E-05 O.OOE+OO Y-90 1.37E-08 O.OOE+OO 3.69E-10 O.OOE+OO O.OOE+OO O.OOE+OO 1.13E-04 O.OOE+OO Y-91M 1.29E-10 O.OOE+OO 4.93E-12 O.OOE+OO O.OOE+OO O.OOE+OO 6.09E-09 O.OOE+OO Y-91 2.01E-07 O.OOE+OO 5.39E-09 O.OOE+OO O.OOE+OO O.OOE+OO 8.24E-05 O.OOE+OO Y-92 1.21 E-09 O.OOE+OO 3.50E-11 O.OOE+OO O.OOE+OO O.OOE+OO ' 3.32E-05 O.OOE+OO Y-93 3.83E-09 O.OOE+OO 1.05E-10 O.OOE+OO O.OOE+OO O.OOE+OO 1.17E-04 O.OOE+OO ZR-93 5.53E-08 2.73E-09 1.49E-09 O.OOE+OO 9.65E-09 O.OOE+OO 2.58E-09 O.OOE+OO ZR-95 4.12E-08 1.30E-08 8.94E-09 O.OOE+OO 1.91E-08 O.OOE+OO 3.00E-05 O.OOE+OO ZR-97 2.37E-09 4.69E-10 2.16E-10 O.OOE+OO 7.11E-10 O.OOE+OO 1.27E-04 O.OOE+OO NB-93M 3.44E-08 1.13E-08 2.83E-09 O.OOE+OO 1.32E-08 O.OOE+OO 4.07E-06 O.OOE+OO NB-95 8.22E-09 4.56E-09 2.51E-09 O.OOE+OO 4.42E-09 O.OOE+OO 1.95E-05 O.OOE+OO Rev. 29 Page 125 of 329 12/2016
CY-LG-170-301 TABLE 111-4 INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi NUCLIDE' BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN NB-97 7.37E-11 1.83E-11 6.68E-12 O.OOE+OO 2.14E-11 O.OOE+OO 4.37E-07 O.OOE+OO M0-93 O.OOE+OO 1.06E-05 2.90E-07 O.OOE+OO 3.04E-06 O.OOE+OO 1.29E-06 O.OOE+OO M0-99 O.OOE+OO 6.03E-06 1.15E-06 O.OOE+OO 1.38E-05 O.OOE+OO 1.0SE-05 O.OOE+OO TC-99M 3.32E-10 9.26E-10 1.20E-08 O.OOE+OO 1.38E-08 5.14E-10 6.0SE-07 O.OOE+OO TC-99 1.79E-07 2.63E-07 7.17E-08 O.OOE+OO 3.34E-06 2.72E-08 6.44E-06 O.OOE+OO TC-101 3.60E-10 5.12E-10 5.03E-09 O.OOE+OO 9.26E-09 3.12E-10 8.75E-17 O.OOE+OO RU-103 2.55E-07 O.OOE+OO 1.09E-07 O.OOE+OO 8.99E-07 O.OOE+OO 2.13E-05 O.OOE+OO RU-105 2:18E-08 O.OOE+OO 8.46E-09 O.OOE+OO 2.75E-07 O.OOE+OO 1.76E-05 O.OOE+OO RU-106 3.92E-06 O.OOE+OO 4.94E-07 O.OOE+OO 7.56E-06 O.OOE+OO 1.88E-04 O.OOE+OO RH-105 1.73E-07 1.25E-07 8.20E-08 O.OOE+OO 5.31E-07 O.OOE+OO 1.59E-05 O.OOE+OO PD-107 O.OOE+OO 2.0SE-07 1.34E-08 O.OOE+OO 1.88E-06 O.OOE+OO 9.66E-07 O.OOE+OO PD-109 O.OOE+OO 2.51E-07 5.70E-08 O.OOE+OO 1.45E-06 O.OOE+OO 2.53E-05 O.OOE+OO AG-110M 2.05E-07 1.94E-07 1.18E-07 O.OOE+OO 3.70E-07 O.OOE+OO 5.45E-05 O.OOE+OO AG-111 8.29E-08 3.44E-08 1.73E-08 O.OOE+OO 1.12E-07 O.OOE+OO 4.80E-05 O.OOE+OO CD-113M O.OOE+OO 4.51E-06 1.45E-07 O.OOE+OO 4.99E-06 O.OOE+OO 2.71E-05 O.OOE+OO CD-115M O.OOE+OO 2.60E-06 8.39E-08 O.OOE+OO 2.0SE-06 O.OOE+OO 8.23E-05 O.OOE+OO SN-123 4.44E-05 7.29E-07 1.0SE-06 5.84E-07 O.OOE+OO O.OOE+OO 6.71E-05 O.OOE+OO SN-125 1.19E-05 2.37E-07 5.37E-07 1.86E-07 O.OOE+OO O.OOE+OO 1.12E-04 O.OOE+OO SN-126 1.16E-04 2.16E-06 3.30E-06 5.69E-07 O.OOE+OO O.OOE+OO 2.58E-05 O.OOE+OO SB-124 3.87E-06 7.13E-08 1.51 E-06 8.78E-09 O.OOE+OO 3.38E-06 7.SOE-05 O.OOE+OO SB-125 2.48E-06 2.71E-08 5.SOE-07 2.37E-09 O.OOE+OO 2.18E-06 1.93E-05 O.OOE+OO SB-126 1.59E-06 3.25E-08 5.71E-07 8.99E-09 O.OOE+OO 1.14E-06 9.41 E-05 O.OOE+OO SB-127 3.63E-07 7.76E-09 1.37E-07 4.0SE-09 O.OOE+OO 2.47E-07 6.16E-05 O.OOE+OO TE-125M 3.83E-06 1.38E-06 5.12E-07 1.07E-06 O.OOE+OO O.OOE+OO 1.13E-05 O.OOE+OO TE-127M 9.67E-06 3.43E-06 1.15E-06 2.30E-06 3.92E-05 O.OOE+OO 2.41E-05 O.OOE+OO TE-127 1.58E-07 5.60E-08 3.40E-08 1.09E-07 6.40E-07 O.OOE+OO 1.22E-05 O.OOE+OO TE-129M 1.63E-05 6.05E-06 2.58E-06 5.26E-06 6.82E-05 O.OOE+OO 6.12E-05 O.OOE+OO TE-129 4.48E-08 1.67E-08 1.09E-08 3.20E-08 1.88E-07 O.OOE+OO 2.45E-07 O.OOE+OO TE-131M 2.44E-06 1.17E-06 9.76E-07 1.76E-06 1.22E-05 O.OOE+OO 9.39E-05 O.OOE+OO TE-131 2.79E-08 1.15E-08 8.72E-09 2.15E-08 1.22E-07 O.OOE+OO 2.29E-09 O.OOE+OO TE-132 3.49E-06 2.21E-06 2.0BE-06 2.33E-06 2.12E-05 O.OOE+OO 7.00E-05 O.OOE+OO TE-133M 6.44E-08 3.66E-08 3.56E-08 5.11 E-08 3.62E-07 O.OOE+OO 1.48E-07 O.OOE+OO TE-134 4.47E-08 2.87E-08 3.00E-08 3.67E-08 2.74E-07 O.OOE+OO 1.66E-09 O.OOE+OO 1-129 4.66E-06 3.92E-06 6.54E-06 4.77E-03 7.01E-06 O.OOE+OO 4.57E-07 O.OOE+OO 1-130 1.03E-06 2.98E-06 1.19E-06 2.43E-04 4.59E-06 O.OOE+OO 2.29E-06 O.OOE+OO 1-131 5.85E-06 8.19E-06 4.40E-06 2.39E-03 1.41 E-05 O.OOE+OO 1.62E-06 O.OOE+OO 1-132 2.79E-07 7.30E-07 2.62E-07 2.46E-05 1.15E-06 O.OOE+OO 3.18E-07 O.OOE+OO 1-133 2.01 E-06 3.41E-06 1.04E-06 4.76E-04 5.98E-06 O.OOE+OO 2.58E-06 O.OOE+OO 1-134 1.46E-07 3.87E-07 1.39E-07 6.45E-06 6.10E-07 O.OOE+OO 5.10E-09 O.OOE+OO 1-135 6.10E-07 1.57E-06 5.82E-07 1.01 E-04 2.48E-06 O.OOE+OO 1.74E-06 O.OOE+OO CS-134M 2.94E-08 6.09E-08 3.13E-08 O.OOE+OO 3.39E-08 5.95E-09 4.05E-08 O.OOE+OO CS-134 8.37E-05 1.97E-04 9.14E-05 O.OOE+OO 6.26E-05 2.39E-05 2.45E-06 O.OOE+OO CS-135 2.78E-05 2.55E-05 5.96E-06 O.OOE+OO 9.73E-06 3.52E-06 4.46E-07 O.OOE+OO CS-136 8.59E-06 3.38E-05 2.27E-05 O.OOE+OO 1.84E-05 2.90E-06 2.72E-06 O.OOE+OO CS-137 1.12E-04 1.49E-04 5.19E-05 O.OOE+OO 5.07E-05 1.97E-05 2.12E-06 O.OOE+OO CS-138 7.76E-08 1.49E-07 7.45E-08 O.OOE+OO 1.10E-07 1.28E-08 6.76E-11 O.OOE+OO CS-139 4.87E-08 7.17E-08 2.63E-08 O.OOE+OO 5.79E-08 6.34E-09 3.33E-23 O.OOE+OO Rev.29 Page 126 of 329 12/2016
CY-LG-170-301 TABLE 111-4 INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN BA-139 1.39E-07 9.78E-11 4.05E-09 O.OOE+OO 9.22E-11 6.74E-11 1.24E-06 O.OOE+OO BA-140 2.84E-05 3.48E-08 1.83E-06 O.OOE+OO 1.18E-08 2.34E-08 4.38E-05 O.OOE+OO BA-141 6.71E-08 5.01 E-11 2.24E-09 O.OOE+OO 4.65E-11 3.43E-11 1.43E-13 O.OOE+OO BA-142 2.99E-08 2.99E-11 1.84E-09 O.OOE+OO 2.53E-11 1.99E-11 9.18E-20 O.OOE+OO LA-140 3.48E-09 1.71E-09 4.55E-10 O.OOE+OO O.OOE+OO O.OOE+OO 9.82E-05 O.OOE+OO LA-141 4.55E-10 1.40E-10 2.31E-11 O.OOE+OO O.OOE+OO O.OOE+OO 2.48E-05 O.OOE+OO LA-142 1.79E-10 7.95E-11 1.98E-11 O.OOE+OO O.OOE+OO O.OOE+OO 2.42E-06 O.OOE+OO CE-141 1.33E-08 8.88E-09 1.02E-09 O.OOE+OO 4.18E-09 O.OOE+OO 2.54E-05 O.OOE+OO CE-143 2.35E-09 1.71E-06 1.91E-10 O.OOE+OO 7.67E-10 O.OOE+OO 5.14E-05 O.OOE+OO CE-144 6.96E-07 2.88E-07 3.74E-08 O.OOE+OO 1.72E-07 O.OOE+OO 1.75E-04 O.OOE+OO PR-143 1.31 E-08 5.23E-09 6.52E-10 O.OOE+OO 3.04E-09 O.OOE+OO 4.31 E-05 O.OOE+OO r* PR-144 4.30E-11 1.76E-11 2.18E-12 O.OOE+OO 1.01E-11 O.OOE+OO 4.74E-14 O.OOE+OO ND-147 9.38E-09 1.02E-08 6.11E-10 O.OOE+OO 5.99E-09 O.OOE+OO 3.68E-05 O.OOE+OO PM-147 1.05E-07 9.~6E-09 4.06E-09 O.OOE+OO 1.90E-08 O.OOE+OO 9.47E-06 O.OOE+OO PM-148M 4.14E-08 1.05E-08 8.21E-09 O.OOE+OO 1.59E-08 O.OOE+OO 6.61E-05
- O.OOE+OO PM-148 1.02E-08 1.66E-09 8.36E-10 O.OOE+OO 3.00E-09 O.OOE+OO 9.90E-05 O.OOE+OO PM-149 2.17E-09 3.05E-10 1.25E-10 O.OOE+OO 5.81E-10 O.OOE+OO 4.49E-05 O.OOE+OO PM-151 9.87E-10 1.63E-10 8.25E-11 O.OOE+OO 2.93E-10 O.OOE+OO 3.66E-05 O.OOE+OO SM-151 8.73E-08 1.68E-08 3.94E-09 O.OOE+OO 1.84E-08 O.OOE+OO 5.70E-06 O.OOE+OO SM-153 1.22E-09 1.01 E-09 7.43E-11 O.OOE+OO 3.30E-10 O.OOE+OO 2.85E-05 O.OOE+OO EU-152 2.45E-07 5.90E-08 5.20E-08 O.OOE+OO 2.74E-07 O.OOE+OO 2.17E-05 O.OOE+OO EU-154 7.91E-07 1.02E-07 7.19E-08 O.OOE+OO 4.56E-07 O.OOE+OO 5.39E-05 O.OOE+OO EU-155 1.74E-07 1.68E-08 1.04E-08 O.OOE+OO 6.57E-08 O.OOE+OO 9.63E-05 O.OOE+OO EU-156 1.92E-08 1.44E-08 2.35E-09 O.OOE+OO 9.69E-09 O.OOE+OO 7.36E-05 O.OOE+OO TB-160 6.47E-08 O.OOE+OO 8.07E-09 O.OOE+OO 2.56E-08 O.OOE+OO 4.19E-05 O.OOE+OO H0-166M 3.57E-07 1.10E-07 7.96E-08 O.OOE+OO 1.61E-07 O.OOE+OO 2.71E-05 O.OOE+OO W-181 1.42E-08 4.58E-09 4.79E-10 O.OOE+OO O.OOE+OO O.OOE+OO 3.90E-07 O.OOE+OO W-185 5.79E-07 1.91 E-07 2.02E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.65E-05 O.OOE+OO W-187 1.46E-07 1.19E-07 4.17E-08 O.OOE+OO O.OOE+OO O.OOE+OO 3.22E-05 O.OOE+OO U-232 5.89E-03 O.OOE+OO 4.21E-04 O.OOE+OO 6.38E-04 O.OOE+OO 7.19E-05 O.OOE+OO U-233 1.24E-03 O.OOE+OO 7.54E-05 O.OOE+OO 2.90E-04 O.OOE+OO 6.65E-05 O.OOE+OO U-234 1.19E-03 O.OOE+OO 7.39E-05 O.OOE+OO 2.85E-04 O.OOE+OO 6.51E-05 O.OOE+OO U-235 1.14E-03 O.OOE+OO 6.94E-05 O.OOE+OO 2.67E-04 O.OOE+OO 8.28E-05 O.OOE+OO U-236 1.14E-03 O.OOE+OO 7.09E-05 O.OOE+OO 2.73E-04 O.OOE+OO 6.11E-05 O.OOE+OO U-237 7.89E-08 O.OOE+OO 2.10E-08 O.OOE+OO 3.24E-07 O.OOE+OO 2.09E-05 O.OOE+OO U-238 1.09E-03 O.OOE+OO 6.49E-05 O.OOE+OO 2.50E-04 O.OOE+OO 5.83E-05 O.OOE+OO NP-237 1.33E-03 9.55E-05 5.85E-05 O.OOE+OO 4.33E-04 O.OOE+OO 8.41E-05 O.OOE+OO NP-238 1.95E-08 5.22E-10 3.04E-10 O.OOE+OO 1.79E-09 O.OOE+OO 3.83E-05 O.OOE+OO NP-239 1.76E-09 1.66E-10 9.22E-11 O.OOE+OO 5.21E-10 O.OOE+OO 2.67E-05 O.OOE+OO PU-238 6.70E-04 8.58E-05 1.82E-05 O.OOE+OO 7.80E-05 O.OOE+OO 7.73E-05 O.OOE+OO PU-239 7.65E-04 9.29E-05 2.01E-05 O.OOE+OO 8.57E-05* O.OOE+OO 7.06E-05 O.OOE+OO PU-240 7.64E-04 9.27E-05 2.01E-05 O.OOE+OO 8.56E-05 O.OOE+OO
- 7.19E-05 O.OOE+OO PU-241 1.75E-05 8.40E-07 3.69E-07 O.OOE+OO 1.71E-06 O.OOE+OO 1.48E-06 O.OOE+OO PU-242 7.09E-04 8.94E-05 1.94E-05 O.OOE+OO 8.25E-05 O.OOE+OO 6.92E-05 O.OOE+OO PU-244 8.28E-04 1.02E-04 2.22E-05 O.OOE+OO 9.45E-05 O.OOE+OO 1.03E-04 O.OOE+OO AM-241 7.98E-04 7.53E-04 5.75E-05 O.OOE+OO 4.31E-04 O.OOE+OO 7.87E-05 O.OOE+OO AM-242M 8.07E-04 7.11E-04 5.80E-05 O.OOE+OO 4.30E-04 O.OOE+OO 9.90E-05 O.OOE+OO Rev.29 Page 127 of 329 12/2016
CY-LG-170-301 TABLE 111-4 INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN AM-243 7.96E-04 7.35E-04 5.62E-05 O.OOE+OO 4.22E-04 O.OOE+OO 9.23E-05 O.OOE+OO CM-242 2.94E-05 3.10E-05 1.95E-06 O.OOE+OO 8.89E-06 O.OOE+OO 8.40E-05 O.OOE+OO CM-243 6.50E-04 6.03E-04 4.09E-05 O.OOE+OO 1.91 E-04 O.OOE+OO 8.28E-05 O.OOE+OO CM-244 5.04E-04 4.77E-04 3.19E-05 O.OOE+OO 1.49E-04 O.OOE+OO 8.00E-05 O.OOE+OO CM-245 9.90E-04 8.71 E-04 6.10E-05 O.OOE+OO 2.85E-04 *o.OOE+OO 7.46E-05 O.OOE+OO CM-246 9.82E-04 8.70E-04 6.09E-05 O.OOE+OO 2.84E-04 O.OOE+OO 7.33E-05 O.OOE+OO CM-247 9.57E-04 8.57E-04 6.00E-05 O.OOE+OO 2.80E-04 O.OOE+OO 9.63E-05 O.OOE+OO CM-248 7.95E-03 7.06E-03 4.95E-04 O.OOE+OO 2.31E-03 O.OOE+OO 1.55E-03 O.OOE+OO CF-252 3.47E-04 O.OOE+OO 8.37E-06, O.OOE+OO O.OOE+OO O.OOE+OO 3.05E-04 O.OOE+OO NUREG/CR-4653, GASPAR II, Technical Reference and User Guide Rev. 29 Page 128 of 329 12/2016
CY-LG-170-301 TABLE 111-5 INGESTION DOSE FACTORS FOR CHILD (Daipi) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.16E-07 1.16E-07 1.16E-07 1.16E-07 1.16E-07 1.16E-07 O.OOE+OO C-14 1.21E-05 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 O.OOE+OO NA-22 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 O.OOE+OO NA-24 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 O.OOE+OO P-32 8.25E-04 3.86E-05 3.18E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.28E-05 O.OOE+OO CA-41 3.47E-04 O.OOE+OO 3.79E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.90E-07 O.OOE+OO SC-46 1.97E-08 2.70E-08 1.04E-08 O.OOE+OO 2.39E-08 O.OOE+OO 3.95E-05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 8.90E-09 4.94E-09 1.35E-09 9.02E-09 4.72E-07 O.OOE+OO MN-54 O.OOE+OO 1.07E-05 2.85E-06 O.OOE+OO 3.00E-06 O.OOE+OO 8.98E-06 O.OOE+OO MN-56 O.OOE+OO 3.34E-07 7.54E-08 O.OOE+OO 4.04E-07 O.OOE+OO 4.84E-05 O.OOE+OO FE-55 1.15E-05 6.10E-06 1.89E-06 O.OOE+OO O.OOE+OO 3.45E-06 1.13E-06 O.OOE+OO FE-59 1.65E-05 2.67E-05 1.33E-05 O.OOE+OO O.OOE+OO 7.74E-06 2.78E-05 O.OOE+OO C0-57 O.OOE+OO 4.93E-07 9.98E-07 O.OOE+OO O.OOE+OO O.OOE+OO 4.04E-06 O.OOE+OO C0-58 O.OOE+OO 1.80E-06 5.51E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.05E-05 O.OOE+OO C0-60 O.OOE+OO 5.29E-06 1.56E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.93E-05 O.OOE+OO Nl-59 4.02E-05 1.07E-05 6.82E-06 O.OOE+OO O.OOE+OO O.OOE+OO 7.10E-07 O.OOE+OO Nl-63 5.38E-04 2.88E-05 1.83E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.94E-06 O.OOE+OO Nl-65 2.22E-06 2.09E-07 1.22E-07 O.OOE+OO O.OOE+OO O.OOE+OO 2.56E-05 O.OOE+OO CU-64 O.OOE+OO 2.45E-07 1.48E-07 O.OOE+OO 5.92E-07 O.OOE+OO 1.15E-05 O.OOE+OO ZN-65 1.37E-05 3.65E-05 2.27E-05 O.OOE+OO 2.30E-05 O.OOE+OO 6.41E-06 O.OOE+OO ZN-69M 7.10E-07 1.21E-06 1.43E-07 O.OOE+OO 7.03E-07 O.OOE+OO 3.94E-05 O.OOE+OO ZN-69 4.38E-08 6.33E-08 5.85E-09 O.OOE+OO 3.84E-08 O.OOE+OO 3.99E-06 O.OOE+OO SE-79 O.OOE+OO 8.43E-06 1.87E-06 O.OOE+OO 1.37E-05 O.OOE+OO 5.53E-07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 7.55E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.71 E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 0.00E+OO BR-84 O.OOE+OO O.OOE+OO 1.98E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 9.12E-09 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 6.70E-05 4.12E-05 O.OOE+OO O.OOE+OO O.OOE+OO 4.31E-06 O.OOE+OO RB-87 O.OOE+OO 3.95E-05 1.83E-05 O.OOE+OO O.OOE+OO O.OOE+OO 5.92E-07 O.OOE+OO RB-88 O.OOE+OO 1.90E-07 1.32E-07 O.OOE+OO O.OOE+OO O.OOE+OO 9.32E-09 O.OOE+OO RB-89 O.OOE+OO 1.17E-07 1.04E-07 O.OOE+OO O.OOE+OO O.OOE+OO 1.02E-09 O.OOE+OO SR-89 1.32E-03 O.OOE+OO 3.77E-05 O.OOE+OO O.OOE+OO O.OOE+OO 5.11E-05 O.OOE+OO SR-90 2.56E-02 O.OOE+OO 5.15E-04 O.OOE+OO O.OOE+OO O.OOE+OO 2.29E-04 O.OOE+OO SR-91 2.40E-05 O.OOE+OO 9.06E-07 O.OOE+OO O.OOE+OO O.OOE+OO 5.30E-05 O.OOE+OO SR-92 9.03E-06 O.OOE+OO 3.62E-07 O.OOE+OO O.OOE+OO O.OOE+OO 1.71E-04 O.OOE+OO Y-90 4.11E-08 O.OOE+OO 1.10E-09 O.OOE+OO O.OOE+OO O.OOE+OO 1.17E-04 O.OOE+OO Y-91M 3.82E-10 O.OOE+OO 1.39E-11 O.OOE+OO O.OOE+OO O.OOE+OO 7.48E-07 O.OOE+OO Y-91 6.02E-07 O.OOE+OO 1.61 E-08 O.OOE+OO O.OOE+OO O.OOE+OO 8.02E-05 O.OOE+OO Y-92 3.60E-09 O.OOE+OO 1.03E-10 O.OOE+OO O.OOE+OO O.OOE+OO 1.04E-04 O.OOE+OO Y-93 1.14E-08 O.OOE+OO 3.13E-10 O.OOE+OO O.OOE+OO O.OOE+OO 1.70E-04 O.OOE+OO ZR-93 1.67E-07 6.25E-09 4.45E-09 O.OOE+OO 2.42E-08 O.OOE+OO 2.37E-06 O.OOE+OO ZR-95 1.16E-07 2.55E-08 2.27E-08 O.OOE+OO 3.65E-08 O.OOE+OO 2.66E-05 O.OOE+OO ZR-97 6.99E-09 1.01 E-09 5.96E-10 O.OOE+OO 1.45E-09 O.OOE+OO 1.53E-04 O.OOE+OO NB-93M 1.05E-07 2.62E-08 8.61E-09 O.OOE+OO 2.83E-08 O.OOE+OO 3.95E-06 O.OOE+OO NB-95 2.25E-08 8.76E-09 6.26E-09 O.OOE+OO 8.23E-09 O.OOE+OO 1.62E-05 O.OOE+OO Rev.29 Page 129 of 329 12/2016
CY-LG-170-301 TABLE 111-5
/
INGESTION DOSE FACTORS FOR CHILD (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 2.17E-10 3.92E-11 1.83E-11 O.OOE+OO 4.35E-11 O.OOE+OO 1.21E-05 O.OOE+OO M0-93 O.OOE+OO 2.41E-05 8.65E-07 O.OOE+OO 6.35E-06 O.OOE+OO 1.22E-06 O.OOE+OO M0-99 O.OOE+OO 1.33E-05 3.29E-06 O.OOE+OO 2.84E-05 O.OOE+OO 1.10E-05 O.OOE+OO TC-99M 9.23E-10 1.81 E-09 3.00E-08 O.OOE+OO 2.63E-08 9.19E-10 1.03E-06 O.OOE+OO TC-99 5.35E-07 5.96E-07 2.14E-07 O.OOE+OO 7.02E-06 5.27E-08 6.25E-06 O.OOE+OO TC-101 1.07E-09 1.12E-09 1.42E-08 O.OOE+OO 1.91 E-08 5.92E-10 3.56E-09 O.OOE+OO RU-103 7.31E-07 O.OOE+OO 2.81E-07 O.OOE+OO 1.84E-06 O.OOE+OO 1.89E-05 O.OOE+OO RU-105 6.45E-08 O.OOE+OO 2.34E-08 O.OOE+OO 5.67E-07 O.OOE+OO 4.21E-05 O.OOE+OO RU-106 1.17E-05 O.OOE+OO 1.46E-06 O.OOE+OO 1.58E-05 O.OOE+OO 1.82E-04 O.OOE+OO RH-105 5.14E-07 2.76E-07 2.36E-07 O.OOE+OO 1.10E-06 O.OOE+OO 1.71E-05 O.OOE+OO PD-107 O.OOE+OO 4.72E-07 4.01 E-08 O.OOE+OO 3.95E-06 O.OOE+OO 9.37E-07 O.OOE+OO PD-109 O.OOE+OO 5.67E-07 1.70E-07 O.OOE+OO 3.04E-06 . O.OOE+OO 3.35E-05 O.OOE+OO 'AG-110M 5.39E-07 3.64E-07 2.91E-07 O.OOE+OO 6.78E-07 O.OOE+OO 4.33E-05 O.OOE+OO AG-111 2.48E-07 7.76E-08 5.12E-08 O.OOE+OO 2.34E-07 O.OOE+OO 4.75E-05 O.OOE+OO CD-113M O.OOE+OO 1.02E-05 4.34E-07 O.OOE+OO 1.05E-05 O.OOE+OO 2.63E-05 O.OOE+OO CD-115M O.OOE+OO 5.89E-06 2.51 E-07 O.OOE+OO 4.38E-06 O.OOE+OO 8.01E-05 O.OOE+OO SN-123 1.33E-04 1.65E-06 3.24E-06 1.75E-06 O.OOE+OO O.OOE+OO 6.52E-05 O.OOE+OO SN-125 3.55E-05 5.35E-07 1.59E-06 5.55E-07 O.OOE+OO O.OOE+OO 1.10E-04 O.OOE+OO SN-126 3.33E-04 4.15E-06 9.46E-06 1.14E-06 O.OOE+OO O.OOE+OO 2.50E-05 O.OOE+OO SB-124 1.11 E-05 1.44E-07 3.89E-06 2.45E-08 O.OOE+OO 6.16E-06 6.94E-05 O.OOE+OO SB-125 7.16E-06 5.52E-08 1.50E-06 6.63E-09 O.OOE+OO 3.99E-06 1.71E-05 O.OOE+OO SB-126 4.40E-06 6.73E-08 1.58E-06 2.58E-08 O.OOE+OO 2.10E-06 8.87E-05 O.OOE+OO SB-127 1.06E-06 1.64E-08 3.68E-07 1.18E-08 O.OOE+OO 4.60E-07 5.97E-05 O.OOE+OO TE-125M 1.14E-05 3.09E-06 1.52E-06 3.20E-06 O.OOE+OO O.OOE+OO 1.10E-05 O.OOE+OO TE-127M 2.89E-05 7.78E-06 3.43E-06 6.91E-06 8.24E-05 O.OOE+OO 2.34E-05 O.OOE+OO TE-127 4.71E-07 1.27E-07 1.01 E-07 3.26E-07 1.34E-06 O.OOE+OO 1.84E-05 O.OOE+OO TE-129M 4.87E-05 1.36E-05 7.56E-06 1.57E-05 1.43E-04 O.OOE+OO 5.94E-05 O.OOE+OO TE-129 1.34E-07 3.74E-08 3.18E-08 9.56E-08 3.92E-07 O.OOE+OO 8.34E-06 O.OOE+OO TE-131M 7.20E-06 2.49E-06 2.65E-06 5.12E-06 2.41E-05 O.OOE+OO 1.01 E-04 O.OOE+OO TE-131 8.30E-08 2.53E-08 2.47E-08 6.35E-08 2.51E-07 O.OOE+OO 4.36E-07 O.OOE+OO TE-132 1.01 E-05 4.47E-06 5.40E-06 6.51 E-06 4.15E-05 O.OOE+OO 4.50E-05 O.OOE+OO TE-133M 1.87E-07 7.56E-08 9.37E-08 1.45E-07 7.18E-07 O.OOE+OO 5.77E-06 O.OOE+OO TE-134 1.29E-07 5.80E-08 7.74E-08 1.02E-07 5.37E-07 O.OOE+OO 5.89E-07 O.OOE+OO 1-129 1.39E-05 8.53E-06 7.62E-06 5.58E-03 1.44E-05 O.OOE+OO 4.29E-07 O.OOE+OO 1-130 2.92E-06 5.90E-06 3.04E-06 6.50E-04 8.82E-06 O.OOE+OO 2.76E-06 O.OOE+OO 1-131 1.72E-05 1.73E-05 9.83E-06 5.72E-03 2.84E-05 O.OOE+OO 1.54E-06 O.OOE+OO 1-132 8.00E-07 1.47E-06 6.76E-07 6.82E-05 2.25E-06 O.OOE+OO 1.73E-06 O.OOE+OO 1-133 5.92E-06 7.32E-06 2.77E-06 1.36E-03 1.22E-05 O.OOE+OO 2.95E-06 O.OOE+OO 1-134 4.19E-07 7.78E-07 3.58E-07 1.79E-05 1.19E-06 O.OOE+OO 5.16E-07 O.OOE+OO 1-135 1.75E-06 3.15E-06 1.49E-06 2.79E-04 4.83E-06 O.OOE+OO 2.40E-06 O.OOE+OO CS-134M 8.44E-08 1.25E-07 8.16E-08 O.OOE+OO 6.59E-08 1.09E-08 1.58E-07 O.OOE+OO CS-134 2.34E-04 3.84E-04 8.10E-05 O.OOE+OO 1.19E-04 4.27E-05 2.07E-06 O.OOE+OO CS-135 8.30E-05 5.78E-05 5.93E-06 O.OOE+OO 2.04E-05 6.81E-06 4.33E-07 O.OOE+OO CS-136 2.35E-05 6.46E-05 4.18E-05 O.OOE+OO 3.44E-05 5.13E-06 2.27E-06 O.OOE+OO CS-137 3.27E-04 3.13E-04 4.62E-05 O.OOE+OO 1.02E-04 3.67E-05 1.96E-06 O.OOE+OO CS-138 2.28E-07 3.17E-07 2.01E-07 O.OOE+OO 2.23E-07 2.40E-08 1.46E-07 O.OOE+OO CS-139 1.45E-07 1.61 E-07 7.74E-08 O.OOE+OO 1.21E-07 1.22E-08 1.45E-11 O.OOE+OO Rev.29 Page 130 of 329 12/2016
CY-LG-170-301 TABLE 111-5 INGESTION DOSE FACTORS FOR CHILD (Daipi) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN BA-139 4.14E-07 2.21E-10 1.20E-08 O.OOE+OO 1.93E-10 1.30E-10 2.39E-05 O.OOE+OO BA-140 8.31E-05 7.28E-08 4.85E-06 O.OOE+OO 2.37E-08 4.34E-08 4.21E-05 O.OOE+OO BA-141 2.00E-07 1.12E-10 6.51E-09 O.OOE+OO 9.69E-11 6.58E-10 1.14E-07 O.OOE+OO BA-142 8.74E-08 6.29E-11 4.88E-09 O.OOE+OO 5.09E-11 3.70E-11 1.14E-09 O.OOE+OO LA-140 1.01 E-08 3.53E-09 1.19E-09 O.OOE+OO O.OOE+OO O.OOE+OO 9.84E-05 O.OOE+OO LA-141 1.36E-09 3.17E-10 6.88E-11 O.OOE+OO O.OOE+OO O.OOE+OO 7.05E-05 O.OOE+OO LA-142 5.24E-10 1.67E-10 5.23E-11 O.OOE+OO O.OOE+OO O.OOE+OO 3.31E-05 O.OOE+OO CE-141 3.97E-08 1.98E-08 2.94E-09 O.OOE+OO 8.68E-09 O.OOE+OO 2.47E-05 O.OOE+OO CE-143 6.99E-09 3.79E-06 5.49E-10 O.OOE+OO 1.59E-09 O.OOE+OO 5.55E-05 O.OOE+OO CE-144 2.08E-06 6.52E-07 1.11E-07 O.OOE+OO 3.61 E-07 O.OOE+OO 1.70E-04 O.OOE+OO PR-143 3.93E-08 1.18E-08 1.95E-09 O.OOE+OO 6.39E-09 O.OOE+OO 4.24E-05 O.OOE+OO PR-144 1.29E-10 3.99E-11 6.49E-12 O.OOE+OO 2.11 E-11 O.OOE+OO 8.59E-08 O.OOE+OO ND-147 2.79E-08 2.26E-08 1.75E-09 O.OOE+OO 1.24E-08 O.OOE+OO 3.58E-05 O.OOE+OO PM-147 3.18E-07 2.27E-08 1.22E-08 O.OOE+OO 4.01E-08 O.OOE+OO 9.19E-06 O.OOE+OO PM-148M 1.03E-07 2.05E-08 2.05E-08 O.OOE+OO 3.04E-08 O.OOE+OO 5.78E-05 O.OOE+OO PM-148 3.02E-08 3.63E-09 2.35E-09 O.OOE+OO 6.17E-09 O.OOE+OO 9.70E-05 O.OOE+OO PM-149 6.49E-09 6.90E-10 3.74E-10 O.OOE+OO 1.22E-09 O.OOE+OO 4.71E-05 O.OOE+OO PM-151 2.92E-09 3.55E-10 2.31E-10 O.OOE+OO 6.02E-10 O.OOE+OO 4.03E-05 O.OOE+OO SM-151 2.56E-07 3.81E-08 1.20E-08 O.OOE+OO 3.94E-08 O.OOE+OO 5.53E-06 O.OOE+OO SM-153 3.65E-09 2.27E-09 2.19E-10 O.OOE+OO 6.91E-10 O.OOE+OO 3.02E-05 O.OOE+OO EU-152 6.15E-07 1.12E-07 1.33E-07 O.OOE+OO 4.73E-07 O.OOE+OO 1.84E-05 O.OOE+OO EU-154 2.30E-06 2.07E-07 1.89E-07 O.OOE+OO 9.09E-07 O.OOE+OO 4.81 E-05 O.OOE+OO EU-155 4.82E-07 3.47E-08 2.72E-08 O.OOE+OO 1.30E-07 O.OOE+OO 8.69E-05 O.OOE+OO EU-156 5.62E-08 3.01E-08 6.23E-09 O.OOE+OO 1.94E-08 O.OOE+OO 6.83E-05 O.OOE+OO TB-160 1.66E-07 O.OOE+OO 2.06E-08 O.OOE+OO 4.94E-08 O.OOE+OO 3.68E-05 O.OOE+OO H0-166M 1.08E-06 2.26E-07 1.91 E-07 O.OOE+OO 3.22E-07 O.OOE+OO 2.63E-05 O.OOE+OO W-181 4.23E-08 1.04E-08 1.43E-09 O.OOE+OO O.OOE+OO O.OOE+OO 3.79E-07 O.OOE+OO W-185 1.73E-06 4.32E-07 . 6.05E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.61 E-05 O.OOE+OO W-187 4.29E-07 2.54E-07 1.14E-07 O.OOE+OO O.OOE+OO O.OOE+OO 3.57E-05 O.OOE+OO U-232 1.76E-02 O.OOE+OO 1.26E-03 O.OOE+OO 1.34E-03 O.OOE+OO 6.98E-05 O.OOE+OO U-233 3.72E-03 O.OOE+OO 2.25E-04 O.OOE+OO 6.10E-04 O.OOE+OO 6.45E-05 O.OOE+OO U-234 3.57E-03 O.OOE+OO 2.21 E-04 O.OOE+OO 5.98E-04 . O.OOE+OO 6.32E-05 O.OOE+OO U-235 3.42E-03 O.OOE+OO 2.07E-04 O.OOE+OO 5.61E-04 O.OOE+OO 8.03E-05 O.OOE+OO U-236 3.42E-03 O.OOE+OO 2.12E-04 O.OOE+OO 5.73E-04 O.OOE+OO 5.92E-05 O.OOE+OO U-237 2.36E-07 O.OOE+OO 6.27E-08 O.OOE+OO 6.81E-07 O.OOE+OO 2.08E-05 O.OOE+OO U-238 3.27E-03 O.OOE+OO 1.94E-04 O.OOE+OO 5.24E-04 O.OOE+OO 5.66E-05 O.OOE+OO NP-237 2.23E-03 1.47E-04 9.79E-05 O.OOE+OO 6.05E-04 O.OOE+OO 8.16E-05 O.OOE+OO NP-238 p.83E-08 1.18E-09 9.08E-10 O.OOE+OO 3.76E-09 O.OOE+OO 4.04E-05 O.OOE+OO NP-239 5.25E-09 3.77E-10 2.65E-10 O.OOE+OO 1.09E-09 O.OOE+OO 2.79E-05 O.OOE+OO PU-238 1.19E-03 1.38E-04 3.16E-05 O.OOE+OO 1.15E-04 O.OOE+OO 7.50E-05 O.OOE+OO PU-239 1.29E-03 1.38E-04 3.31E-05 O.OOE+OO 1.22E-04 O.OOE+OO 6.85E-05 O.OOE+OO PU-240 1.28E-03 1.43E-04 3.31E-05 O.OOE+OO 1.22E-04 O.OOE+OO 6.98E-05 O.OOE+OO PU-241 3.87E-05 1.58E-06 8.04E-07 O.OOE+OO 2.96E-06 O.OOE+OO 1.44E-06 O.OOE+OO PU-242 1.19E-03 1.38E-04 3.19E-05 O.OOE+OO 1.17E-04 O.OOE+OO 6.71E-05 O.OOE+OO PU-244 1.39E-03 1.58E-03 3.65E-05 O.OOE+OO 1.35E-04 O.OOE+OO 1.00E-04 O.OOE+OO AM-241 1.36E-03 1.17E-03 1.02E-04 O.OOE+OO 6.23E-04 O.OOE+OO 7.64E-05 O.OOE+OO AM-242M 1.40E-03 1.12E-03 1.04E-04 O.OOE+OO 6.30E-04 O.OOE+OO 9.61E-05 O.OOE+OO Rev.29 Page 131 of 329 12/2016
CY-LG-170-301 TABLE 111-5 INGESTION DOSE FACTORS FOR CHILD (Daipi) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN AM-243 1.34E-03 1.13E-03 9.83E-05 O.OOE+OO 6.06E-04 O.OOE+OO 8.95E-05 O.OOE+OO CM-242 8.78E-05 7.01 E-05 5.84E-06 O.OOE+OO 1.87E-05 O.OOE+OO 8.16E-05 O.OOE+OO CM-243 1.28E-03 1.04E-03 8.24E-05 O.OOE+OO 3.08E-04 O.OOE+OO 8.03E-05 O.OOE+OO CM-244 1.08E-03 8.74E-04 6.93E-05 O.OOE+OO 2.54E-04 O.OOE+OO 7.77E-05 O.OOE+OO CM-245 1.67E-03 1.34E-03 1.05E-04 O.OOE+OO 4.11 E-04 O.OOE+OO 7.24E-05 O.OOE+OO CM-246 1.65E-03 1.34E-03 1.05E-04 O.OOE+OO 4.10E-04 O.OOE+OO 7.11E-05 O.OOE+OO CM-247 1.61E-03 1.32E-03 1.03E-04 O.OOE+OO 4.04E-04 O.OOE+OO 9.35E-05 O.OOE+OO CM-248 1.34E-02 1.09E-02 8.52E-04 O.OOE+OO 3.33E-03 O.OOE+OO 1.51 E-03 O.OOE+OO CF-252 1.05E-03 O.OOE+OO 2.54E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.96E-04 O.OOE+OO NUREG/CR-4653, GASPAR II, Technical Reference and User Guide Rev.29 Page 132 of 329 12/2016
CY-LG-170-301 TABLE 111-6 INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO 1.76E-07 1.76E-07 1.76E-07 1.76E-07 1.76E-07 1.76E-07 O.OOE+OO C-14 2.37E-05 5.06E-06 5.06E-06 5.06E-06 5.06E-06 5.06E-06 5.06E-06 O.OOE+OO NA-22 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 O.OOE+OO NA-24 1.01 E-05 1.01E-05 1.01 E-05 1.01 E-05 1.01 E-05 1.01 E-05 1.01 E-05 O.OOE+OO P-32 1.70E-03 1.00E-04 6.59E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.30E-05 O.OOE+OO CA-41 3.74E-04 O.OOE+OO 4.08E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.91 E-07 O.OOE+OO SC-46 3.75E-08 5.41E-08 1.69E-08 O.OOE+OO 3.56E-08 O.OOE+OO 3.53E-05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.41 E-08 9.20E-09 2.01E-09 1.79E-08 4.11 E-07 O.OOE+OO . MN-54 O.OOE+OO 1.99E-05 4.51E-06 O.OOE+OO 4.41E-06 O.OOE+OO 7.31E-06 O.OOE+OO MN-56 O.OOE+OO 8.18E-07 1.41 E-07 O.OOE+OO 7.03E-07 O.OOE+OO 7.43E-05 O.OOE+OO FE-55 1.39E-05 8.98E-06 2.40E-06 O.OOE+OO O.OOE+OO 4.39E-06 1.14E-06 O.OOE+OO FE-59 3.08E-05 5.38E-05 2.12E-05 O.OOE+OO O.OOE+OO 1.59E-05 2.57E-05 O.OOE+OO C0-57 O.OOE+OO 1.15E-06 1.87E-06 O.OOE+OO O.OOE+OO O.OOE+OO 3.92E-06 O.OOE+OO C0-58 O.OOE+OO 3.60E-06 8.98E-06 O.OOE+OO O.OOE+OO O.OOE+OO 8.97E-06 O.OOE+OO C0-60 O.OOE+OO 1.08E-05 2.55E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.57E-05 O.OOE+OO Nl-59 4.73E-05 1.45E-05 8.17E-06 O.OOE+OO O.OOE+OO O.OOE+OO 7.16E-07 O.OOE+OO Nl-63 6.34E-04 3.92E-05 2.20E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.95E-06 O.OOE+OO Nl-65 4.70E-06 5.32E-07 2.42E-07 O.OOE+OO O.OOE+OO O.OOE+OO 4.05E-05 O.OOE+OO CU-64 O.OOE+OO 6.09E-07 2.82E-07 O.OOE+OO 1.03E-06 O.OOE+OO 1.25E-05 O.OOE+OO ZN-65 1.84E-05 6.31E-05 2.91E-05 O.OOE+OO 3.06E-05 O.OOE+OO 5.33E-05 O.OOE+OO ZN-69M 1.50E-06 3.06E-06 2.79E-07 O.OOE+OO 1.24E-06 O.OOE+OO 4.24E-05 O.OOE+OO ZN-69 9.33E-08 1.68E-07 1.25E-08 O.OOE+OO 6.98E-08 O.OOE+OO 1.37E-05 O.OOE+OO SE-79 O.OOE+OO 2.10E-05 3.90E-06 O.OOE+OO 2.43E-05 O.OOE+OO 5.58E-07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.27E-05 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.63E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 3.82E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.94E-08 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.70E-04 8.40E-05 O.OOE+OO O.OOE+OO O.OOE+OO 4.35E-06 O.OOE+OO RB-87 O.OOE+OO 8.88E-05 3.52E-05 O.OOE+OO O.OOE+OO O.OOE+OO 5.98E-07 O.OOE+OO RB-88 O.OOE+OO 4.98E-07 2.73E-07 O.OOE+OO O.OOE+OO O.OOE+OO 4.85E-07 O.OOE+OO RB-89 O.OOE+OO 2.86E-07 1.97E-07 O.OOE+OO O.OOE+OO O.OOE+OO 9.74E-08 O.OOE+OO SR-89 2.51E-03 O.OOE+OO 7.20E-05 O.OOE+OO O.OOE+OO O.OOE+OO 5.16E-05 O.OOE+OO SR-90 2.83E-02 O.OOE+OO 5.74E-04 O.OOE+OO O.OOE+OO O.OOE+OO 2.31 E-04 .O.OOE+OO SR-91 5.00E-05 O.OOE+OO 1.81 E-06 O.OOE+OO O.OOE+OO O.OOE+OO 5.92E-05 O.OOE+OO SR-92 1.92E-05 O.OOE+OO 7.13E-07 O.OOE+OO O.OOE+OO O.OOE+OO 2.07E-04 O.OOE+OO Y-90 8.69E-08 O.OOE+OO 2.33E-09 O.OOE+OO O.OOE+OO O.OOE+OO 1.20E-04 O.OOE+OO Y-91M 8.1 OE-10 O.OOE+OO 2.76E-11 O.OOE+OO O.OOE+OO O.OOE+OO 2.70E-06 O.OOE+OO Y-91 1.13E-06 O.OOE+OO 3.01E-08 O.OOE+OO O.OOE+OO O.OOE+OO 8.10E-05 O.OOE+OO Y-92 7.65E-09 O.OOE+OO 2.15E-10 O.OOE+OO O.OOE+OO O.OOE+OO 1.46E-04 O.OOE+OO Y-93 2.43E-08 O.OOE+OO 6.62E-10 O.OOE+OO O.OOE+OO O.OOE+OO
- 1.92E-04 O.OOE+OO ZR-93 1.93E-07 9.19E-09 5.54E-09 O.OOE+OO 2.71E-08 O.OOE+OO 2.39E-06 O.OOE+OO ZR-95 2.06E-67 5.02E-08 3.56E-08 O.OOE+OO 5.41 E-08 O.OOE+OO 2.50E-05 O.OOE+OO ZR-97 1.48E-08 2.54E-09 1.16E-09 O.OOE+OO 2.56E-09 O.OOE+OO 1.62E-04 O.OOE+OO NB-93M 1.23E-07 3.33E-08 1.04E-08 O.OOE+OO 3.25E-08 O.OOE+OO 3.98E-06 O.OOE+OO NB-95 4.20E-08 1.73E-08 1.00E-08 O.OOE+OO 1.24E-08 O.OOE+OO 1.46E-05 O.OOE+OO Rev.29 Page 133 of 329 12/2016
CY-LG-170-301 TABLE 111-6 INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 4.59E-10 9.79E-11 3.53E-11 O.OOE+OO 7.65E-11 O.OOE+OO 3.09E-05 O.OOE+OO M0-93 O.OOE+OO 5.65E-05 1.82E-06 O.OOE+OO 1.13E-05 O.OOE+OO 1.21E-06 O.OOE+OO M0-99 O.OOE+OO 3.40E-05 6.63E-06 O.OOE+OO 5.08E-05 O.OOE+OO 1.12E-05 O.OOE+OO TC-99M 1.92E-09 3.96E-09 5.10E-08 O.OOE+OO 4.26E-08 2.07E-09 1.15E-06 O.OOE+OO TC-99 1.08E-06 1.46E-06 4.55E-07 O.OOE+OO 1.23E-05 1.42E-07 6.31E-06 O.OOE+OO TC-101 2.27E-09 2.86E-09 2.83E-08 O.OOE+OO 3.40E-08 1.56E-09 4.86E-07 O.OOE+OO RU-103 1.48E-06 O.OOE+OO 4.95E-07 O.OOE+OO 3.08E-06 O.OOE+OO 1.80E-05 O.OOE+OO RU-105 1.36E-07 O.OOE+OO 4.58E-08 O.OOE+OO 1.00E-06 O.OOE+OO 5.41E-05 O.OOE+OO RU-106 2.41E-05 O.OOE+OO 3.01E-06 O.OOE+OO 2.85E-05 O.OOE+OO 1.83E-04 O.OOE+OO RH-105 1.09E-06 7.13E-07 4.79E-07 O.OOE+OO 1.98E-06 O.OOE+OO 1.77E-05 O.OOE+OO PD-107 O.OOE+OO 1.19E-06 8.45E-08 O.OOE+OO 6.79E-06 O.OOE+OO 9.46E-07 O.OOE+OO PD-109 O.OOE+OO 1.50E-06 3.62E-07 O.OOE+OO 5.51E-06 O.OOE+OO 3.68E-05 O.OOE+OO AG-110M 9.96E-07 7.27E-07 4.81E-07 O.OOE+OO 1.04E-06 O.OOE+OO 3.77E-05 O.OOE+OO AG-111 5.20E-07 2.02E-07 1.07E-07 O.OOE+OO 4.22E-07 O.OOE+OO 4.82E-05 O.OOE+OO CD-113M O.OOE+OO 1.77E-05 6.52E-07 O.OOE+OO 1.34E-05 O.OOE+OO 2.66E-05 O.OOE+OO CD-115M O.OOE+OO 1.42E-05 4.93E-07 O.OOE+OO
- 7.41E-06 O.OOE+OO 8.09E-05 O.OOE+OO SN-123 2.49E-04 3.89E-06 6.50E-06 3.91E-06 O.OOE+OO O.dOE+OO 6.58E-05 O.OOE+OO SN-125 7.41 E-05 1.38E-06 3.29E-06 1.36E-06 O.OOE+OO O.OOE+OO 1.11 E-04 O.OOE+OO SN-126 5.53E-04 7.26E-06 1.80E-05 1.91E-06 O.OOE+OO O.OOE+OO 2.52E-05 O.OOE+OO SB-124 2.14E-05 3.15E-07 6.63E-06 5.68E-08 O.OOE+OO 1.34E-05 6.60E-05 O.OOE+OO SB-125 1.23E-05 1.19E-07 2.53E-06 1.54E-08 O.OOE+OO 7.12E-06 1.64E-05 O.OOE+OO SB-126 8.06E-06 1.58E-07 2.91E-06 6.19E-08 O.OOE+OO 5.07E-06 8.35E-05 O.OOE+OO SB-127 2.23E-06 3.98E:.o8 6.90E-07 2.84E-08 O.OOE+OO 1.15E-06 5.91E-05 O.OOE+OO TE-125M 2.33E-05 7.79E-06 3.15E-06 7.84E-06 O.OOE+OO O.OOE+OO 1.11 E-05 O.OOE+OO TE-127M 5.85E-05 1.94E-05 7.08E-06 1.69E-05 1.44E-04 O.OOE+OO 2.36E-05 O.OOE+OO TE-127 1.00E-06 3.35E-07 2.15E-07 8.14E-07 2.44E-06 O.OOE+OO 2.10E-05 O.OOE+OO TE-129M 1.00E-04 3.43E-05 1.54E-05 3.84E-05 2.50E-04 O.OOE+OO 5.97E-05 O.OOE+OO TE-129 2.84E-07 9.79E-08 6.63E-08 2.38E-07 7.07E-07 O.OOE+OO 2.27E-05 O.OOE+OO TE-131M 1.52E-05 6.12E-06 5.05E-06 1.24E-05 4.21 E-05 O.OOE+OO 1.03E-04 O.OOE+OO TE-131 1.76E-07 6.50E-08 4.94E-08 1.57E-07 4.50E-07 O.OOE+OO 7.11E-06 O.OOE+OO TE-132 2.08E-05 1.03E-05 9.61E-06 1.52E-05 6.44E-05 O.OOE+OO 3.81E-05 O.OOE+OO TE-133M 3.91E-07 1.79E-07 1.71E-07 3.45E-07 1.22E-06 O.OOE+OO 1.93E-05 O.OOE+OO TE-134 2.67E-07 1.34E-07 1.38E-07 2.39E-07 9.03E-07 O.OOE+OO 3.06E-06 O.OOE+OO 1-129 2.86E-05 2.12E-05 1.55E-05 1.36E-02 2.51E-05 O.OOE+OO 4.24E-07 O.OOE+OO 1-130 6.00E-06 1.32E-05 5.30E-06 1.48E-03 1.45E-05 O.OOE+OO 2.83E-06 O.OOE+OO 1-131 3.59E-05 4.23E-05 1.86E-05 1.39E-02 4.94E-05 O.OOE+OO 1.51 E-06 O.OOE+OO 1-132 1.S6E-06 3.37E-06 1.20E-06 1.58E-04 3.76E-06 O.OOE+OO 2.73E-06 O.OOE+OO 1-133 1.25E-05 1.82E-05 5.33E-06 3.31E-03 2.14E-05 O.OOE+OO 3.08E-06 O.OOE+OO 1-134 8.69E-07 1.78E-06 6.33E-07 4.15E-05 1.99E-06 O.OOE+OO 1.84E-06 O.OOE+OO 1-135 3.64E-06 7.24E-06 2.64E-06 6.49E-04 8.07E-06 O.OOE+OO 2.62E-06 O.OOE+OO CS-134M 1.76E-07 2.93E-07 1.48E-07 O.OOE+OO 1.13E-07 2.60E-08 2.32E-07 O.OOE+OO CS-134 3.77E-04 7.03E-04 7.10E-05 O.OOE+OO 1.81 E-04 7.42E-05 1.91 E-06 O.OOE+OO CS-135 1.33E-04 1.21E-04 6.30E-06 O.OOE+OO 3.44E-05 1.31E-05 4.37E-07 O.OOE+OO CS-136 4.59E-05 1.35E-04 5.04E-05 O.OOE+OO 5.38E-05 1.10E-05 2.05E-06 O.OOE+OO CS-137 5.22E-04 6.11E-04 4.33E-05 O.OOE+OO 1.64E-04 6.64E-05 1.91 E-06 O.OOE+OO CS-138 4.81E-07 7.82E-07 3.79E-07 O.OOE+OO 3.90E-07 6.09E-08 1.25E-06 O.OOE+OO Rev.29 Page 134 of 329 12/2016
CY-LG-170-301 TABLE 111-6 INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-139 3.10E-07 4.24E-07 1.62E-07 O.OOE+OO 2.19E-07 3.30E-08 2.66E-08 O.OOE+OO BA-139 8.81 E-07 5.84E-10 2.55E-08 O.OOE+OO 3.51E-10 3.54E-10 5.58E-05 O.OOE+OO BA-140 1.71E-04 1.71E-07 8.81E-06 O.OOE+OO 4.06E-08 1.05E-07 4.20E-05 O.OOE+OO BA-141 4.25E-07 2.91 E-10 1.34E-08 O.OOE+OO 1.75E-10 1.77E-10 5.19E-06 O.OOE+OO BA-142 1.84E-07 1.53E-10 9.06E-09 O.OOE+OO 8.81 E-11 9.26E-11 7.59E-07 O.OOE+OO LA-140 2.11E-08 8.32E-09 2.14E-09 O.OOE+OO O.OOE+OO O.OOE+OO 9.77E-05 O.OOE+OO LA-141 2.89E-09 8.38E-10 1.46E-10 O.OOE+OO O.OOE+OO O.OOE+OO 9.61 E-05 O.OOE+OO LA-142 1.10E-09 4.04E.,10 9.67E-11 O.OOE+OO O.OOE+OO O.OOE+OO 6.86E-05 O.OOE+OO CE-141 7.87E-08 4.80E-08 5.65E-09 O.OOE+OO 1.48E-08 O.OOE+OO 2.48E-05 O.OOE+OO CE-143 1.48E-08 9.82E-06 1.12E-09 O.OOE+OO 2.86E-09 O.OOE+OO 5.73E-05 O.OOE+OO CE-144 2.98E-06 1.22E-06 1.67E-07 O.OOE+OO 4.93E-07 O.OOE+OO 1.71E-04 O.OOE+OO PR-143 8.13E-08 3.04E-08 4.03E-09 O.OOE+OO 1.13E-08 O.OOE+OO 4.29E-05 O.OOE+OO PR-144 2.74E-10 1.06E-10 1.38E-11 O.OOE+OO 3.84E-11 O.OOE+OO 4.93E-06 O.OOE+OO ND-147 5.53E-08 5.68E-08 3.48E-09 O.OOE+OO 2.19E-08 O.OOE+OO 3.60E-05 O.OOE+OO PM-147 3.88E-07 3.27E-08 1.59E-08 O.OOE+OO 4.88E-08 O.OOE+OO 9.27E-06 O.OOE+OO PM-148M 1.65E-07 4.18E-08 3.28E-08 O.OOE+OO 4.80E-08 O.OOE+OO 5.44E-05 O.OOE+OO PM-148 6.32E-08 9.13E-09 4.60E-09 O.OOE+OO 1.09E-08 O.OOE+OO 9.74E-05 O.OOE+OO PM-149 1.38E-08 1.81E-09 7.90E-10 O.OOE+OO 2.20E-09 O.OOE+OO 4.86E-05 O.OOE+OO PM-151 6.18E-09 9.01E-10 4.56E-10 O.OOE+OO 1.07E-09 O.OOE+OO 4.17E-05 O.OOE+OO SM-151 2.90E-07 6.67E-08 1.44E-08 O.OOE+OO 4.53E-08 O.OOE+OO 5.58E-06 O.OOE+OO SM-153 7.72E-09 5.97E-09 4.58E-10 O.OOE+OO 1.25E-09 O.OOE+OO 3.12E-05 O.OOE+OO EU-152 6.74E-07 1.79E-07 1.51 E-07 O.OOE+OO 5.02E-07 O.OOE+OO 1.59E-05 O.OOE+OO EU-154 2.64E-06 3.67E-07 2.20E-07 O.OOE+OO 9.95E-07 O.OOE+OO 4.58E-05 O.OOE+OO EU-155 5.42E-07 6.25E-08 3.23E-08 O.OOE+OO 1.40E-07 O.OOE+OO 8.37E-05 O.OOE+OO EU-156 1.14E-07 7.06E-08 1.12E-08 O.OOE+OO 3.26E-08 O.OOE+OO 6.67E-05 O.OOE+OO TB-160 2.59E-07 O.OOE+OO 3.24E-08 O.OOE+OO 7.37E-08 O.OOE+OO 3.45E-05 O.OOE+OO H0-166M 1.25E-06 2.69E-07 2.13E-07 O.OOE+OO 3.57E-07 O.OOE+OO 2.66E-05 O.OOE+OO W-181 8.85E-08 2.72E-08 3.04E-09 O.OOE+OO O.OOE+OO O.OOE+OO 3.82E-07 O.OOE+OO W-185 3.62E-06 1.13E-06 1.29E-07 O.OOE+OO O.OOE+OO O.OOE+OO 1.62E-05 O.OOE+OO W-187 9.03E-07 6.28E-07 2.17E-07 O.OOE+OO O.OOE+OO O.OOE+OO 3.69E-05 O.OOE+OO U-232 2.42E-02 O.OOE+OO 2.16E-03 O.OOE+OO 2.37E-03 O.OOE+OO 7.04E-05 O.OOE+OO U-233 5.08E-03 O.OOE+OO 3.87E-04 O.OOE+OO 1.08E-03 O.OOE+OO 6.51 E-05 O.OOE+OO U-234 4.88E-03 O.OOE+OO 3.80E-04 O.OOE+OO 1.06E-03 O.OOE+OO 6.37E-05 O.OOE+OO U-235 4.67E-03 O.OOE+OO 3.56E-04 O.OOE+OO 9.93E-04 O.OOE+OO 8.10E-05 O.OOE+OO U-236 4.67E-03 O.OOE+OO 3.64E-04 O.OOE+OO 1.01 E-03 O.OOE+OO 5.98E-05 O.OOE+OO U-237 4.95E-07 O.OOE+OO 1.32E-07 O.OOE+OO 1.23E-06 O.OOE+OO 2.11E-05 O.OOE+OO U-238 4.47E-03 O.OOE+OO 3.33E-04 O.OOE+OO 9.28E-04 O.OOE+OO 5.71E-05 O.OOE+OO NP-237 2.40E-03 1.59E-04 1.05E-04 O.OOE+OO 6.34E-04 O.OOE+OO 8.23E-05 O.OOE+OO NP-238 1.24E-07 3.12E-09 1.92E-09 O.OOE+OO 6.81E-09 O.OOE+OO 4.17E-05 O.OOE+OO NP-239 1.11 E-08 9.93E-10 5.61E-10 O.OOE+OO 1.98E-09 O.OOE+OO 2.87E-05 O.OOE+OO PU-238 1.28E-03 1.50E-04 3.40E-05 ,-0.00E+OO 1.21E-04 O.OOE+OO 7.57E-05 O.OOE+OO PU-239 1.38E-03 1.55E-04 3.54E-05 O.OOE+OO 1.28E-04 O.OOE+OO 6.91E-05 O.OOE+OO PU-240 1.38E-03 1.55E-04 3.54E-05 O.OOE+OO 1.28E-04 O.OOE+OO 7.04E-05 O.OOE+OO PU-241 4.25E-05 1.76E-06 8.82E-07 O.OOE+OO 3.17E-06 O.OOE+OO 1.45E-06 O.OOE+OO PU-242 1.28E-03 1.49E-04 3.41E-05 O.OOE+OO 1.23E-04 O.OOE+OO 6.77E-05 O.OOE+OO PU-244 1.49E-03 1.71E-04 3.91E-05 O.OOE+OO 1.41E-04 O.OOE+OO 1.01E-04 O.OOE+OO Rev.29 Page 135 of 329 12/2016
CY-LG-170-301 TABLE 111-6 INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN AM-241 1.46E-03 1.27E-03 1.09E-04 O.OOE+OO 6.55E-04 O.OOE+OO 7.70E-05 O.OOE+OO AM-242M 1.51 E-03 1.22E-03 1.13E-04 O.OOE+OO 6.64E-04 O.OOE+OO 9.69E-05 O.OOE+OO AM-243 1.44E-03 1.23E-03 1.06E-04 O.OOE+OO 6.36E-04 O.OOE+OO 9.03E-05 O.OOE+OO CM-242 1.37E-04 1.27E-04 9.10E-06 O.OOE+OO 2.62E-05 O.OOE+OO 8.23E-05 O.OOE+OO CM-243 1.40E-03 1.15E-03 8.98E-05 O.OOE+OO 3.27E-04 O.OOE+OO 8.10E-05 O.OOE+OO CM-244 1.18E-03 9.70E-04 7.59E-05 O.OOE+OO 2.71 E-04 O.OOE+OO 7.84E-05 O.OOE+OO CM-245 1.79E-03 1.45E-03 1.13E-04 O.OOE+OO 4.32E-04 O.OOE+OO 7.30E-05 O.OOE+OO CM-246 1.77E-03 1.45E-03 1.13E-04 O.OOE+OO 4.31 E-04 O.OOE+OO 7.17E-05 O.OOE+OO CM-247 1.73E-03 1.43E-03 1.11 E-04 O.OOE+OO 4.24E-04 O.OOE+OO 9.43E-05 O.OOE+OO CM-248 1.43E-02 1.18E-02 9.16E-04 O.OOE+OO 3.50E-03 O.OOE+OO 1.52E-03 O.OOE+OO CF-252 1.22E-03 O.OOE+OO 2.95E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.99E-04 O.OOE+OO NUREG/CR-4653, GASPAR II, Technical Reference and User Guide Rev.29 Page 136 of 329 12/2016
CY-LG-170-301
..
TABLE 111-7 DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (Daipj) (mrem/hr per pCi/m2) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.80E-08 NA-24 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.90E-08 P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 3.41E-09 3.41E-09 3.41 E-09 3.41 E-09 3.41E-09 3.41 E-09 3.41E-09 4.01E-09 SC-46 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.50E-08 CR-51 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.60E-10 MN-54 5.80E-09 5.80E-09 5.80E-09 5.80E-09 5.80E-09 5.80E-09 5.80E-09 6.80E-09 MN-56 1.10E-08 1.10E-08 1.10E-08 1.10E-08 1.10E-08 1.10E-08 1.10E-08 1.30E-08 FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 8.00E-09 8.00E-09 8.00E-09 8.00E-09 8.00E-09 8.00E-09 8.00E-09 9.40E-09 C0-57 9.10E-10 9.10E-10 9.10E-10 9.10E-10 9.1 OE-10 9.10E-10 9.10E-10 1.00E-09 C0-58 7.00E-09 7.00E-09 7.00E-09 7.00E-09 7.00E-09 7.00E-09 7.00E-09 8.20E-09 C0-60 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 2.00E-08 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 4.30E-09 CU-64 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.70E-09 ZN-65 4.00E-09 4.00E-09 4.00E-09 4.00E-09 4.00E-09 4.00E-09 4.00E-09 4.60E-09 ZN-69M 2.90E-09 2.90E-09 2.90E-09 2.90E-09 2.90E-09 2.90E-09 2.90E-09 3.40E-09 ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 1.90E-08 1.90E-08 1.90E-08 1.90E-08 1.90E-08 1.90E-08 1.90E-08 2.20E-08 BR-83 6.40E-11 6.40E-11 6.40E-11 6.40E-11 6.40E-11 6.40E-11 6.40E-11 9.30E-11 BR-84 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.40E-08 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 6.30E-10 6.30E-10 6.30E-10 6.30E-10 6.30E-10 6.30E-10 6.30E-10 7.20E-10 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 3.50E-09 3.50E-09 3.50E-09 3.50E-09 3.50E-09 3.50E-09 3.50E-09 4.00E-09 RB-89 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.80E-08 SR-89 5.60E-13 5.60E-13 5.60E-13 5.60E-13 5.60E-13 5.60E-13 5.60E-13 6.50E-13 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 7.10E-09 7.10E-09 7.10E-09 7.10E-09 7.10E-09 7.10E-09 7.10E-09 8.30E-09 SR-92 9.00E-09 9.00E-09 9.00E-09 9.00E-09 9.00E-09 9.00E-09 9.00E-09 1.00E-08 Y-90 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.60E-12 Y-91M 3.80E-09 3.80E-09 3.80E-09 3.80E-09 3.80E-09 3.80E-09 3.80E-09 4.40E-09 Y-91 2.40E-11 2.40E-11 2.40E-11 2.40E-11 2.40E-11 2.40E-11 2.40E-11 2.70E-11 Y-92 1.60E-09 1.60E-09 1.60E-09 1.60E-09 1.60E-09 1.60E-09 t.60E-09 1.90E-09 Y-93 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 7.80E-10 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 5.00E-09 5.00E-09 5.00E-09 5.00E-09 5.00E-09 5.00E-09 5.00E-09 5.80E-09 ZR-97 5.50E-09 5.50E-09 5.50E-09 5.50E-09 5.50E-09 5.50E-09 5.50E-09 6.40E-09 NB-93M 8.20E-13 8.20E-13 8.20E-13 8.20E-13 8.20E-13 8.20E-13 8.20E-13 1.00E-10 Rev.29 Page 137 of 329 12/2016
CY-LG-170-301 TABLE 111-7 DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (Daipj) (mrem/hr per pCi/m2 ) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-95 5.10E-09 5.10E-09 5.10E-09 5.10E-09 5.10E-09 5.10E-09 5.10E-09 6.00E-09 NB-97 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 5.40E-09 M0-93 2.29E-11 2.29E-11 2.29E-11 2.29E-11 2.29E-11 2.29E-11 2.29E-11 9.32E-10 M0-99 1.90E-09 1.90E-09 1.90E-09 1.90E-09 1.90E-09 1.90E-09 1.90E-09 2.20E-09 TC-99M 9.60E-10 9.60E-10 9.60E-10 9.60E-10 9.60E-10 9.60E-10 9.60E-10 1.10E-09 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 2.70E-09 2.70E-09 2.70E-09 2.70E-09 2.70E-09 2.70E-09 2.70E-09 3.00E-09 RU-103 3.60E-09 3.60E-09 3.60E-09 3.60E-09 3.60E-09 3.60E-09 3.60E-09 4.20E-09 RU-105 4.50E-09 4.50E-09 4.50E-09 4.50E-09 4.50E-09 4.50E-09 4.50E-09 5.10E-09 RU-106 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.80E-09 RH-105 6.60E-10 6.60E-10 6.60E-10 6.60E-10 6.60E-10 6.60E-10 6.60E-10 7.70E-10 PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 4.00E-11 AG-110M 1.80E-08 1.80E-08 1.80E-08 1.80E-08 1.80E-08 1.80E-08 1.80E-08 2.10E-08 AG-111 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 2.10E-10 CD-113M 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.60E-12 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 6.46E-08 SN-125 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 6.60E-10 SN-126 9.00E-09 9.00E-09 9.00E-09 9.00E-09 9.00E-09 9.00E-09 9.00E-09 1.00E-08 SB-124 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.50E-08 SB-125 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.50E-09 SB-126 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 1.00E-08 SB-127 5.70E-09 5.70E-09 5.70E-09 5.70E-09 5.70E-09 5.70E-09 5.70E-09 6.60E-09 TE-125M 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 4.80E-11 TE-127M 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.30E-12 TE-127 1.00E-11 1.00E-11 1.00E-11 1.00E-11. 1.00E-11 1.00E-11 1.00E-11 1.10E-11 TE-129M 7.70E-10 7.70E-10 7.70E-10 7.70E-10 7.70E-10 7.70E-10 7.70E-10 9.00E-10 TE-129 7.10E-10 7.10E-10 7.10E-10 7.10E-10 7.10E-10 7.10E-10 7.10E-10 8.40E-10 TE-131M 8.40E-09 8.40E-09 8.40E-09 8.40E-09 8.40E-09 8.40E-09 8.40E-09 9.90E-09 TE-131 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.60E-06 TE-132 1.70E-09 1.70E-09 1.70E-09 1.70E-09 1.70E-09 1.70E-09 1.70E-09 2.00E-09 TE-133M 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 TE-134 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.20E-09 1-129 4.50E-10 4.50E-10 4.50E-10 4.50E-10 4.50E-10 4.50E-10 4.50E-10 7.50E-10 1-130 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.70E-08 1-131 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 3.40E-09 1-132 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 2.00E-08 1-133 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 4.50E-09 1-134 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.90E-08 1-135 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.40E-08 CS-134M 6.20E-10 6.20E-10 6.20E-10 6.20E-10 6.20E-10 6.20E-10 6.20E-10 7.30E-10 CS-134 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.40E-08 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 138 of 329 12/2016
CY-LG-170-301 TABLE 111-7 DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (Daipj) (mrem/hr per pCi/m2) ' NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-136 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 CS-137 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.90E-09 CS-138 2.10E-08 2.10E-08 2.10E-08 2.10E-08 2.10E-08 2.10E-08 2.10E-08 2.40E-08 CS-139 6.30E-09 6.30E-09 6.30E-09 6.30E-09 6.30E-09 6.30E-09 6.30E-09 7.20E-09 BA-139 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.70E-09 BA-140 2.10E-09 2.10E-09 2.10E-09 2.10E-09 2.10E-09 2.10E-09 2.10E-09 2.40E-09 BA-141 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.90E-09 BA-142 7.90E-09 7.90E-09 7.90E-09 7.90E-09 7.90E-09 7.90E-09 7.90E-09 9.00E-09 LA-140 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 LA-141 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.80E-10 LA-142 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.80E-08 CE-141 5.50E-10 5.50E-10 5.50E-10 5.50E-10 5.50E-10 5.50E-10 5.50E-10 6.20E-10 CE-143 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.50E-09 CE-144 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.70E-10 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.30E-10 ND-147 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.20E-09 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 1.41 E-08 1.41 E-08 1.41 E-08 1.41 E-08 1.41E-08 1.41E-08 1.41 E-08 8.16E-08 PM-148 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 5.30E-09 PM-149 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.90E-11 PM-151 2.20E-09 2.20E-09 .2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.30E-09 SM-151 4.80E-11 4.80E-11 4.80E-11 4.80E'-11 4.80E-11 4.80E-11 4.80E-11 2.10E-10 SM-153 2.70E-10 2.70E-10 2.70E-10 2.70E-10 2.70E-10 2.70E-10 2.70E-10 3.00E-10 EU-152 7.37E-09 7.37E-09 7.37E-09 7.37E-09 7.37E-09 7.37E-09 7.37E-09 8.53E-09 EU-154 7.80E-09 7.80E-09 7.80E-09 7.80E-09 7.80E-09 7.80E-09 7.80E-09 9.00E-09 EU-155 3.81E-10 3.81E-10 3.81E-10 3.81 E-10 3.81E-10 3.81E-10 3.81E-10 4.33E-10 EU-156 7.60E-09 7.60E-09 7.60E-09 7.60E-09 7.60E-09 7.60E-09 7.60E-09 8.70E-09 TB-160 8.60E-09 8.60E-09 8.60E-09 8.60E-09 8.60E-09 8.60E-09 8.60E-09 1.00E-08 H0-166M 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 1.00E-08 W-181 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.80E-12 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.10E-09 3.60E-09 U-232 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.69E-11 U-233 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.80E-09 U-234 6.32E-13 6.32E-13 6.32E-13 6.32E-13 6.32E-13 6.32E-13 6.32E-13 1.59E-10 U-235 3.20E-09 3.20E-09 3.20E-09 3.20E-09 3.20E-09 3.20E-09 3.20E-09 4.00E-09 U-236 2.10E-14 2.10E-14 2.10E-14 2.10E-14 2.10E-14 2.10E-14 2.10E-14 1.80E-11 U-237 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.00E-09 1.30E-09 U-238 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.50E-10 NP-237 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.60E-09 NP-238 2.80E-09 2.80E-09 2.80E-09 2.80E~09 2.80E-09 2.80E-09 2.80E-09 3.20E-09 NP-239 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 1.10E-09 PU-238 1.30E-12 1.30E-12 1.30E-12 1~30E-12 1.30E-12 1.30E-12 1.30E-12 1.80E-11 Rev.29 Page 139 of 329 12/2016
CY-LG-170-301 TABLE 111-7 DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (Daipj) (mrem/hr per pCi/m2) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-239 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.70E-12 PU-240 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.BOE-11 PU-241 4.60E-12 4.60E-12 4.60E-12 4.60E-12 4.60E-12 4.60E-12 4.60E-12 6.BOE-12 PU-242 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.60E-11 PU-244 8.95E-10 8.95E-10 8.95E-10 8.95E-10 8.95E-10 8.95E-10 8.95E-10 9.62E-10 AM-241 1.BOE-10 1.BOE-10 1.BOE-10 1.BOE-10 1.BOE-10 1.BOE-10 1.BOE-10 2.60E-10 AM-242M 2.60E-11 2.60E-11 2.60E-11 2.60E-11 2.60E-11 2.60E-11 2.60E-11 1.BOE-10 AM-243 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.50E-09 CM-242 5.50E-12 5.50E-12 5.50E-12 5.50E-12 5.50E-12 5.50E-12 5.50E-12 2.30E-11 CM-243 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.90E-09 CM-244 2.90E-12 2.90E-12 2.90E-12 2.90E-12 2.90E-12 2.90E-12 2.90E-12 1.BOE-11 CM-245 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 1.20E-09 CM-246 1.00E-12 1.00E-12 1.00E-12 1.00E-12 1.00E-12 1.00E-12 1.00E-12 1.50E-11 CM-247 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.60E-09 CM-248 5.23E-09 5.23E-09 5.23E-09 5.23E-09 5.23E-09 5.23E-09 5.23E-09 6.81E-09 CF-252 6.60E-08 6.60E-08 6.60E-08 6.60E-08 6.60E-08 6.60E-08 6.60E-08 7.20E-08 NUREG/CR-4653, GASPAR II, Technical Reference and User Guide Rev.29 Page 140 of 329 12/2016
CY-LG-170-301 TABLE 111-8 AQUATIC PATHWAY USAGE FACTORS (Uap) Pathwav Infant Child Teen Adult Fish (kg/yr) - 6.9 8 168 21 8 Potable Water (I/yr) 330 8 510 8 510 8 730 8 Shoreline Recreation (hr/yr) - goo 600° 600° Ref: a Regulatory Guide 1.109, Rev 1, Table E-5 b EROL Table 5.2.A-3 Rev.29 Page 141 of 329 12/2016
CY-LG-170-301 TABLE 111-9 ADULT DRINKING WATER A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 4.99E+OO 4.99E+OO 4.99E+OO 4.99E+OO 4.99E+OO 4.99E+OO O.OOE+OO C-14 2.37E+02 4.73E+01 4.73E+01 4.73E+01 4.73E+01 4.73E+01 4.73E+01 O.OOE+OO NA-22 1.45E+03 1.45E+03 1.45E+03 1.45E+03 1.45E+03 1.45E+03 1.45E+03 O.OOE+OO NA-24 8.14E+01 8.14E+01 8.14E+01 8.14E+01 8.14E+01 8.14E+01 8.14E+01 O.OOE+OO P-32 1.57E+04 9.76E+02 6.07E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.77E+03 O.OOE+OO CA-41 1.54E+04 O.OOE+OO 1.67E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.53E+01 O.OOE+OO SC-46 4.57E-01 8.88E-01 2.58E-01 O.OOE+OO 8.29E-01 O.OOE+OO 4.32E+03 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 2.19E-01 1.31 E-01 4.82E-02 2.91 E-01 5.51 E+01 O.OOE+OO MN-54 O.OOE+OO 3.80E+02 7.26E+01 O.OOE+OO 1.13E+02 O.OOE+OO 1.17E+03 O.OOE+OO MN-56 O.OOE+OO 3.81 E-01 6.75E-02 O.OOE+OO 4.83E-01 O.OOE+OO 1.21 E+01 O.OOE+OO FE-55 2.29E+02 1.58E+02 3.69E+01 O.OOE+OO O.OOE+OO 8.83E+01 9.08E+01 O.OOE+OO FE-59 3.59E+02 8.43E+02 3.23E+02 O.OOE+OO O.OOE+OO 2.36E+02 2.81 E+03 O.OOE+OO C0-57 O.OOE+OO 1.46E+01 2.42E+01 O.OOE+OO O.OOE+OO O.OOE+OO 3.70E+02 O.OOE+OO C0-58 O.OOE+OO 6.18E+01 1.38E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.25E+03 O.OOE+OO C0-60 O.OOE+OO 1.78E+02 3.93E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.35E+03 O.OOE+OO Nl-59 8.13E+02 2.79E+02 1.36E+02 O.OOE+OO O.OOE+OO O.OOE+OO 5.75E+01 O.OOE+OO Nl-63 1.08E+04 7.51E+02 3.63E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.57E+02 O.OOE+OO Nl-65 1.62E+OO 2.11 E-01 9.61 E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.34E+OO O.OOE+OO CU-64 O.OOE+OO 3.61 E+OO 1.69E+OO O.OOE+OO 9.09E+OO O.OOE+OO 3.07E+02 O.OOE+OO ZN-65 4.03E+02 1.28E+03 5.79E+02 O.OOE+OO 8.57E+02 O.OOE+OO 8.07E+02 O.OOE+OO ZN-69M 7.74E+OO 1.86E+01 1.70E+OO O.OOE+OO 1.12E+01 O.OOE+OO 1.13E+03 O.OOE+OO ZN-69 1.08E-04 2.08E-04 1.44E-05 O.OOE+OO 1.35E-04 O.OOE+OO 3.12E-05 O.OOE+OO SE-79 O.OOE+OO 2.19E+02 3.66E+01 O.OOE+OO 3. 79E+02 O.OOE+OO 4.48E+01 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.49E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1. 71 E+02 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.03E-01 O.OOE+OO O.OOE+OO O.OOE+OO 1.49E-01 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 6.64E-07 O.OOE+OO O.OOE+OO O.OOE+OO 5.21 E-12 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 4.40E-77 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.73E+03 8.04E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.40E+02 O.OOE+OO RB-87 O.OOE+OO 1.03E+03 3.57E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.80E+01 O.OOE+OO RB-88 O.OOE+OO 3.36E-12 1.78E-12 O.OOE+OO O.OOE+OO O.OOE+OO 4.64E-23 O.OOE+OO RB-89 O.OOE+OO 3.06E-14 2.15E-14 O.OOE+OO O.OOE+OO O.OOE+OO 1.78E-27 O.OOE+OO SR-89 2.55E+04 O.OOE+OO 7.32E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.09E+03 O.OOE+OO SR-90 7.26E+05 O.OOE+OO 1.46E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.82E+04 O.OOE+OO SR-91 1.97E+02 O.OOE+OO 7.95E+OO O.OOE+OO O.OOE+OO O.OOE+OO 9.37E+02 O.OOE+OO SR-92 8.32E+OO O.OOE+OO 3.60E-01 O.OOE+OO O.OOE+OO O.OOE+OO 1.65E+02 O.OOE+OO Y-90 7.04E-01 O.OOE+OO 1.89E-02 O.OOE+OO O.OOE+OO O.OOE+OO 7.47E+03 O.OOE+OO Y-91M 3.31 E-07 O.OOE+OO 1.28E-08 O.OOE+OO O.OOE+OO O.OOE+OO 9.71 E-07 O.OOE+OO Rev.29 Page 142 of 329 12/2016
CY-LG-170-301 TABLE 111-9 ADULT DRINKING WATER A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN Y-91 1.17E+01 O.OOE+OO 3.12E-01 O.OOE+OO O.OOE+OO O.OOE+OO 6.43E+03 O.OOE+OO Y-92 6.72E-03 O.OOE+OO 1.96E-04 O.OOE+OO O.OOE+OO O.OOE+OO 1.18E+02 O.OOE+OO Y-93 9.80E-02 O.OOE+OO 2.71E-03 O.OOE+OO O.OOE+OO O.OOE+OO 3.11 E+03 O.OOE+OO ZR-93 3.48E+OO 1.95E-01 9.08E-02 O.OOE+OO 7.39E-01 O.OOE+OO 2.03E+02 O.OOE+OO ZR-95 2.52E+OO 8.08E-01 5.47E-01 O.OOE+OO 1.27E+OO O.OOE+OO 2.56E+03 O.OOE+OO ZR-97 8.56E-02 1.73E-02 7.90E-03 O.OOE+OO 2.61 E-02 O.OOE+OO 5.35E+03 O.OOE+OO NB-93M 2.12E+OO 6.93E-01 1.71 E-01 O.OOE+OO 7.97E-01 O.OOE+OO 3.20E+02 O.OOE+OO NB-95 5.13E-01 2.85E-01 1.53E-01 O.OOE+OO 2.82E-01 O.OOE+OO 1.73E+03 O.OOE+OO NB-97 4.29E-06 1.08E-06 3.96E-07 O.OOE+OO 1.27E-06 O.OOE+OO 4.00E-03 O.OOE+OO M0-93 O.OOE+OO 6.26E+02 1.69E+01 O.OOE+OO 1. 78E+02 O.OOE+OO 1.02E+02 O.OOE+OO M0-99 O.OOE+OO 3.17E+02 6.02E+01 O.OOE+OO 7.17E+02 O.OOE+OO 7.34E+02 O.OOE+OO TC-99M 5.17E-03 1.46E-02 1.86E-01 O.OOE+OO 2.22E-01 7.16E-03 8.64E+OO O.OOE+OO TC-99 1.04E+01 1.55E+01 4.18E+OO O.OOE+OO 1.95E+02 1.32E+OO 5.07E+02 O.OOE+OO TC-101 1.15E-17 1.66E-17 1.63E-16 O.OOE+OO 2.99E-16 8.50E-18 5.00E-29 O.OOE+OO RU-103 1.53E+01 O.OOE+OO 6.58E+OO O.OOE+OO 5.83E+01 O.OOE+OO 1.78E+03 O.OOE+OO RU-105 1.97E-01 O.OOE+OO 7.78E-02 O.OOE+OO 2.55E+OO O.OOE+OO 1.21E+02 O.OOE+OO RU-106 2.29E+02 O.OOE+OO 2.90E+01 O.OOE+OO 4.42E+02 O.OOE+OO 1.48E+04 O.OOE+OO RH-105 7.97E+OO 5.83E+OO 3.84E+OO
- O.OOE+OO 2.48E+01 O.OOE+OO 9.29E+02 O.OOE+OO PD-107 O.OOE+OO 1.23E+01 7.83E-01 O.OOE+OO 1.10E+02 O.OOE+OO 7.59E+01 O.OOE+OO PD-109 O.OOE+OO 7.95E+OO 1.79E+OO O.OOE+OO 4.54E+01 O.OOE+OO 8.80E+02 O.OOE+OO AG-110M 1.33E+01 1.23E+01 7.31 E+OO O.OOE+OO 2.42E+01 O.OOE+OO 5.03E+03 0.00E+OO AG-111 4.62E+OO 1.93E+OO 9.63E-01 O.OOE+OO 6.24E+OO O.OOE+OO 3.55E+03 O.OOE+OO CD-113M O.OOE+OO 2.65E+02 8.50E+OO O.OOE+OO 2.92E+02 O.OOE+OO 2.13E+03 O.OOE+OO CD-115M O.OOE+OO 1.52E+02 4.85E+OO O.OOE+OO 1.21 E+02 O.OOE+OO 6.40E+03 O.OOE+OO SN-123 2.58E+03 4.28E+01 6.31 E+01 3.64E+01 O.OOE+OO O.OOE+OO 5.26E+03 O.OOE+OO SN-125 6.70E+02 1.35E+01 3.04E+01 1.12E+01 O.OOE+OO O.OOE+OO 8.36E+03 O.OOE+OO SN-126 7.04E+03 1.39E+02 2.00E+02 4.10E+01 O.OOE+OO O.OOE+OO 2.03E+03 O.OOE+OO SB-124 2.32E+02 4.38E+OO 9.20E+01 5.63E-01 O.OOE+OO 1.81 E+02 6.59E+03 O.OOE+OO SB-125 1.49E+02 1.67E+OO 3.55E+01 1.52E-01 O.OOE+OO 1.15E+02 1.64E+03 O.OOE+oo SB-126 9.32E+01 1.90E+OO 3.36E+01 5.70E-01 O.OOE+OO 5.71 E+01 7.62E+03 O.OOE+OO SB-127 1.96E+01 4.30E-01 7.54E+OO 2.36E-01 O.OOE+OO 1.17E+01 4.49E+03 O.OOE+OO TE-125M 2.22E+02 8.04E+01 2.97E+01 6.68E+01 9.03E+02 O.OOE+OO 8.86E+02 O.OOE+OO TE-127M 5.62E+02 2.01 E+02 6.85E+01 1.44E+02 2.28E+03 O.OOE+OO 1.89E+03 O.OOE+OO TE-127 3. 77E+OO 1.35E+OO 8.15E-01 2.79E+OO 1.53E+01 O.OOE+OO 2.97E+02 O.OOE+OO TE-129M 9.48E+02 3.54E+02 1.50E+02 3.26E+02 3.96E+03 O.OOE+OO 4.78E+03 O.OOE+OO TE-129 2.01 E-03 7.56E-04 4.90E-04 1.54E-03 8.46E-03 O.OOE+OO 1.52E-03 O.OOE+OO TE-131M 1.09E+02 5.34E+01 4.45E+01 8.46E+01 5.41 E+02 O.OOE+OO 5.31 E+03 O.OOE+OO TE-131 3.51 E-09 1.47E-09 1.11E-09 2.89E-09 1.54E-08 O.OOE+OO 4.97E-10 O.OOE+OO Rev.29 Page 143 of 329 12/2016
CY-LG-170-301 TABLE 111-9 ADULT DRINKING WATER A1rFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 1.89E+02 1.22E+02 1.15E+02 1.35E+02 1.18E+03 O.OOE+OO 5.78E+03 O.OOE+OO TE-133M 4.71E-04 2.75E-04 2.65E-04 3.99E-04 2.72E-03 O.OOE+OO 9.44E-05 O.OOE+OO TE-134 1.76E-05 1.15E-05 7.07E-06 1.54E-05 1.12E-04 O.OOE+OO 1.95E-08 O.OOE+OO 1-129 2.73E+02 2.34E+02 7.68E+02 6.03E+05 5.03E+02 O.OOE+OO 3.70E+01 O.OOE+OO 1-130 3.21E+01 9.48E+01 3.74E+01 8.04E+03 1.48E+02 O.OOE+OO 8.16E+01 O.OOE+OO 1-131 3.32E+02 4.75E+02 2.72E+02 1.56E+05 8.14E+02 O.OOE+OO 1.25E+02 O.OOE+OO 1-132 4.55E-01 1.22E+OO 4.26E-01 4.26E+01 1.94E+OO O.OOE+OO 2.28E-01 O.OOE+OO 1-133 7.93E+01 1.38E+02 4.21 E+01 2.03E+04 2.41 E+02 O.OOE+OO 1.24E+02 O.OOE+OO 1-134 6.69E-04 1.82E-03 6.50E-04 3.15E-02 2.89E-03 O.OOE+OO 1.58E-06 O.OOE+OO 1-135 1.05E+01 2.75E+01 1.01 E+01 1.81 E+03 4.40E+01 O.OOE+OO 3.1 OE+01 O.OOE+OO CS-134M 1.01E-01 2.12E-01 1.08E-01 O.OOE+OO 1.15E-01 1.81E-02 7.48E-02 O.OOE+OO CS-134 5.18E+03 1.23E+04 1.01 E+04 O.OOE+OO 3.99E+03 1.32E+03 2.16E+02 O.OOE+OO CS-135 1.63E+03 1.50E+03 6.66E+02 O.OOE+OO 5.68E+02 1.70E+02 3.51 E+01 O.OOE+OO CS-136 5.28E+02 2.09E+03 1.50E+03 O.OOE+OO 1.16E+03 1.59E+02 2.37E+02 O.OOE+OO CS-137 6.64E+03 9.08E+03 5.95E+03 O.OOE+OO 3.08E+03 1.02E+03 1.76E+02 O.OOE+OO CS-138 8.54E-07 1.69E-06 8.36E-07 O.OOE+OO 1.24E-06 1.22E-07 7.20E-12 O.OOE+OO CS-139 2.49E-23 3.71E-23 1.35E-23 O.OOE+OO 2.97E-23 2.70E-24 8.03E-46 O.OOE+OO BA-139 1.99E-02 1.42E-05 5.83E-04 O.OOE+OO 1.33E-05 8.05E-06 3.53E-02 O.OOE+OO BA-140 1.65E+03 2.07E+OO 1.08E+02 O.OOE+OO 7.03E-01 1.18E+OO 3.39E+03 O.OOE+OO BA-141 5.38E-12 4.06E-15 1.82E-13 O.OOE+OO 3.78E-15 2.31E-15 2.53E-21 O.OOE+OO BA-142 9.84E-21 1.01 E-23 6.19E-22 O.OOE+OO 8.55E-24 5. 73E-24 1.39E-38 O.OOE+OO LA-140 1.69E-01 8.54E-02 2.26E-02 O.OOE+OO O.OOE+OO O.OOE+OO 6.27E+03 O.OOE+OO LA-141 3.22E-03 9.99E-04 1.63E-04 O.OOE+OO O.OOE+OO O.OOE+OO 1.19E+02 O.OOE+OO LA-142 5.70E-05 2.59E-05 6.46E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.89E-01 O.OOE+OO CE-141 7.72E-01 5.22E-01 5.92E-02 O.OOE+OO 2.42E-01 O.OOE+OO 2.00E+03 O.OOE+OO CE-143 1.07E-01 7.90E+01 8.74E-03 O.OOE+OO 3.48E-02 O.OOE+OO 2.95E+03 O.OOE+OO CE-144 4.06E+01 1.70E+01 2.18E+OO O.OOE+OO 1.01E+01 O.OOE+OO 1.37E+04 O.OOE+OO PR-143 7.47E-01 3.00E-01 3.70E-02 O.OOE+OO 1.73E-01 O.OOE+OO 3.27E+03 O.OOE+OO PR-144 7.19E-16 2.98E-16 3.65E-17 O.OOE+OO 1.68E-16 O.OOE+OO 1.03E-22 O.OOE+OO ND-147 5.08E-01 5.87E-01 3.51 E-02 O.OOE+OO 3.43E-01 O.OOE+OO 2.82E+03 O.OOE+OO PM-147 6.28E+OO 5.91 E-01 2.39E-01 O.OOE+OO 1.12E+OO O.OOE+OO 7.44E+02 O.OOE+OO PM-148M 2.54E+OO 6.57E-01 5.02E-01 O.OOE+OO 9.92E-01 O.OOE+OO 5.57E+03 O.OOE+OO PM-148 5.60E-01 9.30E-02 4.68E-02 O.OOE+OO 1.76E-01 O.OOE+OO 7.30E+03 O.OOE+OO PM-149 1.08E-01 1.53E-02 6.26E-03 O.OOE+OO 2.89E-02 O.OOE+OO 2.87E+03 O.OOE+OO PM-151 4.33E-02 7.27E-03 3.67E-03 O.OOE+OO 1.30E-02 O.OOE+OO 2.00E+03 O.OOE+OO SM-151 5.75E+OO 9.92E-01 2.37E-01 O.OOE+OO 1.11 E+OO O.OOE+OO 4.37E+02 O.OOE+OO SM-153 5.98E-02 4.99E-02 3.64E-03 O.OOE+OO 1.61 E-02 O.OOE+OO 1.78E+03 O.OOE+OO EU-152 1.62E+01 3. 70E+OO 3.25E+OO O.OOE+OO 2.29E+01 O.OOE+OO 2.13E+03 O.OOE+OO Rev.29 Page 144 of 329 12/2016
CY-LG-170-301 TABLE 111-9 ADULT DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN EU-154 5.12E+01 6.30E+OO 4.48E+OO O.OOE+OO 3.02E+01 O.OOE+OO 4.57E+03 O.OOE+OO EU-155 7.17E+OO 1.02E+OO 6.56E-01 O.OOE+OO 4.69E+OO O.OOE+OO 8.00E+02 O.OOE+OO EU-156 1.12E+OO 8.63E-01 1.39E-01 O.OOE+OO 5.77E-01 O.OOE+OO 5.91 E+03 O.OOE+OO TB-160 3.90E+OO O.OOE+OO 4.86E-01 O.OOE+OO 1.61 E+OO O.OOE+OO 3.59E+03 O.OOE+OO H0-166M 2.25E+01 7.02E+OO 5.33E+OO O.OOE+OO 1.05E+01 O.OOE+OO 2.13E+03 O.OOE+OO W-181 8.23E-01 2.68E-01 2.88E-02 O.OOE+OO O.OOE+OO O.OOE+OO 3.06E+01 O.OOE+OO W-185 3.36E+01 1.12E+01 1.18E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.29E+03 O.OOE+OO W-187 6.05E+OO 5.06E+OO 1.77E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.66E+03 O.OOE+OO U-232 3.44E+05 O.OOE+OO 2.46E+04 O.OOE+OO 3.72E+04 O.OOE+OO 5.65E+03 O.OOE+OO U-233 7.26E+d4 O.OOE+OO 4.40E+03 O.OOE+OO 1.69E+04 O.OOE+OO 5.23E+03 O.OOE+OO U-234 6.97E+04 O.OOE+OO 4.31 E+03 O.OOE+OO 1.66E+04 O.OOE+OO 5.12E+03 O.OOE+OO U-235 6.68E+04 O.OOE+OO 4.05E+03 O.OOE+OO 1.56E+04 O.OOE+OO 6.51 E+03 O.OOE+OO U-236 6.68E+04 O.OOE+OO 4.13E+03 O.OOE+OO 1.59E+04 O.OOE+OO 4.80E+03 O.OOE+OO U-237 4.37E+OO O.OOE+OO 1.16E+OO O.OOE+OO 1.80E+01 O.OOE+OO 1.54E+03 O.OOE+OO U-238 6.39E+04 O.OOE+OO 3.78E+03 O.OOE+OO 1.46E+04 O.OOE+OO 4.58E+03 O.OOE+OO NP-237 1.05E+05 7.47E+03 4.62E+03 O.OOE+OO 3.43E+04 O.OOE+OO 6.62E+03 O.OOE+OO NP-238 9.69E-01 2.61 E-02 1.51 E-02 O.OOE+OO 8.84E-02 O.OOE+OO 2.43E+03 O.OOE+OO NP-239 8.56E-02 8.42E-03 4.64E-03 O.OOE+OO 2.63E-02 O.OOE+OO 1.73E+03 O.OOE+OO PU-238 5.25E+04 6.65E+03 1.42E+03 O.OOE+OO 6.10E+03 O.OOE+OO 6.08E+03 O.OOE+OO PU-239 6.04E+04 7.26E+03 1.59E+03 O.OOE+OO 6.76E+03 O.OOE+OO 5.55E+03 O.OOE+OO PU-240 6.03E+04 7.25E+03 1.59E+03 O.OOE+OO 6.75E+03 O.OOE+OO 5.65E+03 O.OOE+OO PU-241 1.31E+03 6.21E+01 2.77E+01 O.OOE+OO 1.27E+02 O.OOE+OO 1.17E+02 O.OOE+OO PU-242 5.60E+04 6.99E+03 1.53E+03 O.OOE+OO 6.51 E+03 O.OOE+OO 5.44E+03 O.OOE+OO PU-244 6.53E+04 8.01 E+03 1.76E+03 O.OOE+OO 7.46E+03 O.OOE+OO 8.11 E+03 O.OOE+OO AM-241 6.29E+04 5.87E+04 4.51E+03 O.OOE+OO 3.39E+04 O.OOE+OO 6.18E+03 O.OOE+OO AM-242M 6.34E+04 5.52E+04 4.52E+03 O.OOE+OO 3.37E+04 O.OOE+OO 7.78E+03 O.OOE+OO AM-243 6.28E+04 5.75E+04 4.42E+03 O.OOE+OO 3.33E+04 O.OOE+OO 7.25E+03 O.OOE+OO CM-242 1.71E+03 1.82E+03 1.14E+02 O.OOE+OO 5.17E+02 O.OOE+OO 6.59E+03 O.OOE+OO CM-243 4.99E+04 4.57E+04 3.12E+03 O.OOE+OO 1.46E+04 O.OOE+OO 6.51 E+03 O.OOE+OO CM-244 3.80E+04 3.56E+04 2.39E+03 O.OOE+OO 1.12E+04 O.OOE+OO 6.29E+03 O.OOE+OO CM-245 7.82E+04 6.81 E+04 4.80E+03 O.OOE+OO 2.24E+04 O.OOE+OO 5.87E+03 O.OOE+OO CM-246 7.75E+04 6.80E+04 4.79E+03 O.OOE+OO 2.23E+04 O.OOE+OO 5.76E+03 O.OOE+OO CM-247 7.56E+04 6.70E+04 4.73E+03 O.OOE+OO 2.20E+04 O.OOE+OO 7.58E+03 O.OOE+OO CM-248 6.28E+05 5.53E+05 3.89E+04 O.OOE+OO 1.82E+05 O.OOE+OO 1.23E+05 O.OOE+OO CF-252 2.17E+04 O.OOE+OO 5.24E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.40E+04 O.OOE+OO Rev.29 Page 145 of 329 12/2016
CY-LG-170-301
- TABLE 111-10 ADULT FRESHWATER FISH Air FACTORS mrem-ml peruCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.29E-01 1.29E-01 1.29E-01 1.29E-01 1.29E-01 1.29E-01 O.OOE+OO C-14 3.13E+04 6.26E+03 6.26E+03 6.26E+03 6.26E+03 6.26E+03 6.26E+03 O.OOE+OO NA-22 4.17E+03 4.17E+03 4.17E+03 4.17E+03 4.17E+03 4.17E+03 4.17E+03 O.OOE+OO NA-24 1.34E+02 1.34E+02 1.34E+02 1.34E+02 1.34E+02 1.34E+02 1.34E+02 O.OOE+OO P-32 1.32E+06 8.22E+04 5.11 E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.49E+05 O.OOE+OO CA-41 1.77E+04 O.OOE+OO 1.92E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.76E+01 O.OOE+OO SC-46 2.62E-02 5.09E-02 1.48E-02 O.OOE+OO 4.75E-02 O.OOE+OO 2.48E+02 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.24E+OO 7.43E-01 2.74E-01 1.65E+OO 3.13E+02 O.OOE+OO MN-54 O.OOE+OO 4.37E+03 8.34E+02 O.OOE+OO 1.30E+03 O.OOE+OO 1.34E+04 O.OOE+OO MN-56 O.OOE+OO 1.74E-01 3.09E-02 O.OOE+OO 2.21E-01 O.OOE+OO 5.55E+OO O.OOE+OO FE-55 6.59E+02 4.55E+02 1.06E+02 O.OOE+OO O.OOE+OO 2.54E+02 2.61E+02 O.OOE+OO FE-59 1.02E+03 2.41E+03 9.23E+02 O.OOE+OO O.OOE+OO 6.73E+02 8.03E+03 O.OOE+OO C0-57 O.OOE+OO 2.09E+01 3.48E+01 O.OOE+OO O.OOE+OO O.OOE+OO 5.31E+02 O.OOE+OO C0-58 O.OOE+OO 8.84E+01 1.98E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.79E+03 O.OOE+OO C0-60 O.OOE+OO 2.56E+02 5.66E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.82E+03 O.OOE+OO Nl-59 2.34E+03 8.03E+02 3.91E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.65E+02 O.OOE+OO Nl-63 3.12E+04 2.16E+03 1.05E+03 O.OOE+OO O.OOE+OO O.OOE+OO 4.51E+02 O.OOE+OO Nl-65 1.72E-01 2.23E-02 1.02E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.67E-01 O.OOE+OO CU-64 O.OOE+OO 2.69E+OO 1.26E+OO O.OOE+OO 6.79E+OO O.OOE+OO 2.30E+02 O.OOE+OO ZN-65 2.31E+04 7.36E+04 3.33E+04 O.OOE+OO 4.92E+04 O.OOE+OO 4.64E+04 O.OOE+OO ZN-69M 2.43E+02 5.84E+02 5.34E+01 O.OOE+OO 3.53E+02 O.OOE+OO 3.56E+04 O.OOE+OO ZN-69 7.89E-07 1.51E-06 1.05E-07 O.OOE+OO 9.81E-07 O.OOE+OO 2.27E-07 O.OOE+OO SE-79 O.OOE+OO 1.07E+03 1.79E+02 O.OOE+OO 1.85E+03 O.OOE+OO 2.19E+02 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.42E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.63E+03 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.84E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.53E-02 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.23E-12 O.OOE+OO O.OOE+OO O.OOE+OO 9.62E-18 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.31E-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 9.75E+04 4.54E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.92E+04 O.OOE+OO RB-87 O.OOE+OO 5.90E+04 2.05E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.76E+03 O.OOE+OO RB-88 O.OOE+OO 1.29E-22 6.83E-23 O.OOE+OO O.OOE+OO O.OOE+OO 1.78E-33 O.OOE+OO RB-89 O.OOE+OO 1.62E-26 1.14E-26 O.OOE+OO O.OOE+OO O.OOE+OO 9.39E-40 O.OOE+OO SR-89 2.18E+04 O.OOE+OO 6.27E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.50E+03 O.OOE+OO SR-90 6.26E+05 O.OOE+OO 1.26E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.57E+04 O.OOE+OO SR-91 7.08E+01 O.OOE+OO 2.86E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.37E+02 O.OOE+OO SR-92 3.34E-01 O.OOE+OO 1.44E-02 O.OOE+OO O.OOE+OO O.OOE+OO 6.61E+OO O.OOE+OO Y-90 4.45E-01 O.OOE+OO 1.19E-02 O.OOE+OO O.OOE+OO O.OOE+OO 4.72E+03 O.OOE+OO Y-91M 1.04E-11 O.OOE+OO 4.02E-13 O.OOE+OO O.OOE+OO O.OOE+OO 3.05E-11 O.OOE+OO Rev.29 Page 146 of 329 12/2016
CY-LG-170-301 TABLE 111-10 ADULT FRESHWATER FISH A1TFACTORS mrem-ml peruCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 8.35E+OO O.OOE+OO 2.23E-01 O.OOE+OO O.OOE+OO O.OOE+OO 4.60E+03 O.OOE+OO Y-92 4.61 E-04 O.OOE+OO 1.35E-05 O.OOE+OO O.OOE+OO O.OOE+OO 8.07E+OO O.OOE+OO Y-93 3.09E-02 O.OOE+OO 8.54E-04 O.OOE+OO O.OOE+OO O.OOE+OO 9.81 E+02 O.OOE+OO ZR-93 3.31 E-01 1.85E-02 8.62E-03 O.OOE+OO 7.02E-02 O.OOE+OO 1.92E+01 O.OOE+OO ZR-95 2.38E-01 7.63E-02 5.17E-02 O.OOE+OO 1.20E-01 O.OOE+OO 2.42E+02 O.OOE+OO ZR-97 4.97E-03 1.00E-03 4.58E-04 O.OOE+OO 1.51 E-03 O.OOE+OO 3.1 OE+02 O.OOE+OO NB-93M 1.83E+03 5.98E+02 1.47E+02 O.OOE+OO 6.88E+02 O.OOE+OO 2.76E+05 O.OOE+OO NB-95 4.39E+02 2.44E+02 1.31E+02 O.OOE+OO 2.41E+02 O.OOE+OO 1.48E+06 O.OOE+OO NB-97 3.65E-06 9.23E-07 3.37E-07 O.OOE+OO 1.08E-06 O.OOE+OO 3.40E-03 O.OOE+OO M0-93 O.OOE+OO 1.80E+02 4.87E+OO O.OOE+OO 5.11 E+01 O.OOE+OO 2.92E+01 O.OOE+OO M0-99 . O.OOE+OO 8.03E+01 1.53E+01 O.OOE+OO 1.82E+02 O.OOE+OO 1.86E+02 O.OOE+OO TC-99M 5.60E-04 1.58E-03 2.02E-02 O.OOE+OO 2.40E-02 7.76E-04 9.37E-01 O.OOE+OO TC-99 4.49E+OO 6.69E+OO 1.81E+OO O.OOE+OO 8.41 E+01 5.68E-01 2.19E+02 O.OOE+OO TC-101 2.71 E-33 3.91 E-33 3.84E-32 O.OOE+OO 7.04E-32 2.00E-33 1.18E-44 O.OOE+OO RU-103 4.36E+OO O.OOE+OO 1.88E+OO O.OOE+OO 1.66E+01 O.OOE+OO 5.09E+02 O.OOE+OO RU-105 8.71E-03 O.OOE+OO 3.44E-03 O.OOE+OO 1.13E-01 O.OOE+OO 5.33E+OO O.OOE+OO RU-106 6.58E+01 O.OOE+OO 8.33E+OO O.OOE+OO 1.27E+02 O.OOE+OO 4.26E+03 O.OOE+OO RH-105 1.81 E+OO 1.33E+OO 8.73E-01 O.OOE+OO 5.63E+OO O.OOE+OO 2.11 E+02 O.OOE+OO PD-107 O.OOE+OO 3.52E+OO 2.25E-01 O.OOE+OO 3.16E+01 O.OOE+OO 2.18E+01 O.OOE+OO PD-109 O.OOE+OO 1.23E+OO 2.78E-01 O.OOE+OO 7.03E+OO O.OOE+OO 1.36E+02 O.OOE+OO AG-110M 8.80E-01 8.14E-01 4.83E-01 O.OOE+OO 1.60E+OO O.OOE+OO 3.32E+02 O.OOE+OO AG-111 2.92E-01 1.22E-01 6.08E-02 O.OOE+OO 3.94E-01 O.OOE+OO 2.24E+02 O.OOE+OO CD-113M O.OOE+OO 1.52E+03 4.89E+01 O.OOE+OO 1.68E+03 O.OOE+OO 1.23E+04 O.OOE+OO CD-115M O.OOE+OO 8.69E+02 2.77E+01 O.OOE+OO 6.89E+02 O.OOE+OO 3.65E+04 O.OOE+OO SN-123 2.22E+05 3.68E+03 5.43E+03 3.13E+03 O.OOE+OO O.OOE+OO 4.53E+05 O.OOE+OO SN-125 5.58E+04 1.12E+03 2.53E+03 9.30E+02 O.OOE+OO O.OOE+OO 6.96E+05 O.OOE+OO SN-126 6.08E+05 1.20E+04 1.73E+04 3.54E+03 O.OOE+OO O.OOE+OO 1.75E+05 O.OOE+OO SB-124 6.64E+OO 1.25E-01 2.63E+OO 1.61 E-02 O.OOE+OO 5.17E+OO 1.88E+02 O.OOE+OO SB-125 4.29E+OO 4.79E-02 1.02E+OO 4.36E-03 O.OOE+OO 3.31 E+OO 4.72E+01 O.OOE+OO SB-126 2.61E+OO 5.30E-02 9.41 E-01 1.60E-02 O.OOE+OO 1.60E+OO 2.13E+02 O.OOE+OO SB-127 5.17E-01 1.13E-02 1.98E-01 6.21 E-03 O.OOE+OO 3.06E-01 1.18E+02 O.OOE+OO TE-125M 2.54E+03 9.20E+02 3.40E+02 7.64E+02 1.03E+04 O.OOE+OO 1.01 E+04 O.OOE+OO TE-127M 6.45E+03 2.31 E+03 7.86E+02 1.65E+Q3 2.62E+04 O.OOE+OO 2.16E+04 O.OOE+OO TE-127 1.78E+01 6.39E+OO 3.85E+OO 1.32E+01 7.25E+01 O.OOE+OO 1.40E+03 O.OOE+OO TE-129M 1.08E+04 4.03E+03 f71E+03 3.71 E+03 4.51 E+04 O.OOE+OO 5.44E+04 O.OOE+OO TE-129 1.78E-05 6.69E-06 4.34E-06 1.37E-05 7.48E-05 O.OOE+OO 1.34E-05 O.OOE+OO TE-131M 9.53E+02 4.66E+02 3.88E+02 7.38E+02 4.72E+03 O.OOE+OO 4.63E+04 O.OOE+OO TE-131 8.65E-17 3.61E-17 2.73E-17 7.11E-17 3.79E-16 O.OOE+OO 1.22E-17 O.OOE+OO Rev. 29 Page 147 of 329 12/2016
CY-LG-170-301 TABLE 111-10 ADULT FRESHWATER FISH A1rFACTORS mrem-ml peruCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 1.95E+03 1.26E+03 1.19E+03
- 1.40E+03 1.22E+04 O.OOE+OO 5.98E+04 O.OOE+OO TE-133M 6.63E-07 3.88E-07 3. 73E-07 5.61 E-07 3.83E-06 O.OOE+OO 1.33E-07 O.OOE+OO TE-134 1.32E-09 8.66E-10 5.31 E-10 1.16E-09 8.38E-09 O.OOE+OO 1.47E-12 O.OOE+OO 1-129 1.18E+02 1.01E+02 3.31E+02 2.60E+05 2.17E+02 O.OOE+OO 1.60E+01 O.OOE+OO 1-130 7.08E+OO 2.09E+01 8.24E+OO 1.77E+03 3.26E+01 O.OOE+OO 1.80E+01 O.OOE+OO 1-131 1.37E+02 1.96E+02 1.12E+02 6.43E+04 3.36E+02 O.OOE+OO 5.18E+01 O.OOE+OO 1-132 5.27E-03 1.41 E-02 4.94E-03 4.94E-01 2.25E-02 O.OOE+OO 2.65E-03 O.OOE+OO 1-133 2.29E+01 3.99E+01 1.22E+01 5.87E+03 6.97E+01 O.OOE+OO 3.59E+01 O.OOE+OO 1-134 2.19E-08 5.94E-08 2.13E-08 1.03E-06 9.45E-08 O.OOE+OO 5.18E-11 O.OOE+OO 1-135 1.29E+OO 3.37E+OO 1.24E+OO 2.22E+02 5.40E+OO O.OOE+OO ~.80E+OO O.OOE+OO CS-134M 3.29E-01 6.93E-01 3.54E-01 O.OOE+OO 3.76E-01 5.92E-02 2.44E-01 O.OOE+OO CS-134 2.98E+05 7.09E+05 5.80E+05 O.OOE+OO 2.29E+05 7.62E+04 1.24E+04 O.OOE+OO CS-135 9.35E+04 8.63E+04 3.83E+04 O.OOE+OO 3.27E+04 9.78E+03 2.02E+03 O.OOE+OO CS-136 2.96E+04 1.17E+05 8.41 E+04 O.OOE+OO 6.50E+04 8.92E+03 1.33E+04 O.OOE+OO CS-137 3.82E+05 5.23E+05 3.42E+05 O.OOE+OO 1.77E+05 5.90E+04 1.01 E+04 O.OOE+OO CS-138 9.13E-12 1.80E-11 8.93E-12 O.OOE+OO 1.32E-11 1.31E-12 7.69E-17 O.OOE+OO CS-139 1.25E-44 1.87E-44 6.80E-45 O.OOE+OO 1.50E-44 1.36E-45 4.04E-67 O.OOE+OO BA-139 5.65E-06 4.03E-09 1.65E-07 O.OOE+OO 3.76E-09 2.28E-09 1.00E-05 O.OOE+OO BA-140 1.84E+02 2.32E-01 1.21E+01 O.OOE+OO 7.88E-02 1.33E-01 3.80E+02 O.OOE+OO BA-141 8.48E-25 6.41E-28 2.86E-26 O.OOE+OO 5.96E-28 3.64E-28 4.00E-34 O.OOE+OO BA-142 6.28E-42 6.45E-45 3.95E-43 O.OOE+OO 5.45E-45 3.65E-45 8.84E-60 O.OOE+OO LA-140 9.91E-02 4.99E-02 1.32E-02 O.OOE+OO O.OQE+OO O.OOE+OO 3.67E+03 O.OOE+OO LA-141 2.80E-04 8.70E-05 1.42E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.04E+01 O.OOE+OO LA-142 2.19E-07 9.97E-08 2.48E-08 O.OOE+OO O.OOE+OO O.OOE+OO 7.28E-04 O.OOE+OO CE-141 2.20E-02 1.49E-02 1.68E-03 O.OOE+OO 6.90E-03 O.OOE+OO 5.68E+01 O.OOE+OO CE-143 2.39E-03 1.77E+OO 1.95E-04 O.OOE+OO 7.78E-04 O.OOE+OO 6.60E+01 O.OOE+OO CE-144 1.17E+OO 4.88E-01 6.27E-02 O.OOE+OO 2.89E-01 O.OOE+OO 3.95E+02 O.OOE+OO PR-143 5.24E-01 2.10E-01 2.60E-02 O.OOE+OO 1.21 E-01 O.OOE+OO 2.29E+03 O.OOE+OO PR-144 1.48E-28 6.15E-29 7.53E-30 O.OOE+OO 3.47E-29 O.OOE+OO 2.13E-35 O.OOE+OO ND-147 3.54E-01 4.09E-01 2.45E-02 O.OOE+OO 2.39E-01 O.OOE+OO 1.96E+03 O.OOE+OO PM-147 4.52E+OO 4.25E-01 1.72E-01 O.OOE+OO 8.03E-01 O.OOE+OO 5.35E+02 O.OOE+OO PM-148M 1.81E+OO 4.69E-01 3.58E-01 O.OOE+OO 7.07E-01 O.OOE+OO 3.97E+03 O.OOE+OO PM-148 3.78E-01 6.27E-02 3.16E-02 O.OOE+OO 1.19E-01 O.OOE+OO 4.93E+03 O.OOE+OO PM-149 6.66E-02 9.42E-03 3.85E-03 O.OOE+OO 1.78E-02 O.OOE+OO 1.77E+03 O.OOE+OO PM-151 2.33E-02 3.90E-03 1.97E-03 O.OOE+OO 6.97E-03 O.OOE+OO 1.07E+03 O.OOE+OO SM-151 4.14E+OO 7.13E-01 1.71E-01 O.OOE+OO 7.97E-01 O.OOE+OO 3.15E+02 O.OOE+OO SM-153 3.60E-02 3.00E-02 2.19E-03 O.OOE+OO 9.70E-03 O.OOE+OO 1.07E+03 O.OOE+OO EU-152 1.17E+01 2.66E+OO 2.34E+OO O.OOE+OO 1.65E+01 O.OOE+OO 1.53E+03 O.OOE+OO Rev.29 Page 148 of 329 12/2016
- - _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _L _ _ _ J
CY-LG-170-301 TABLE 111-10 ADULT FRESHWATER FISH Air FACTORS mrem-ml peruCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 3.68E+01 4.53E+OO 3.22E+OO O.OOE+OO 2.17E+01 O.OOE+OO 3.28E+03 O.OOE+OO EU-155 5.15E+OO 7.31E-01 4.71 E-01 O.OOE+OO 3.37E+OO O.OOE+OO 5.75E+02 O.OOE+OO EU-156 7.84E-01 6.07E-01 9.79E-02 O.OOE+OO 4.0SE-01 O.OOE+OO 4.16E+03 O.OOE+OO TB-160 2.79E+OO O.OOE+OO 3.48E-01 O.OOE+OO 1.1 SE+OO O.OOE+OO 2.57E+03 O.OOE+OO H0-166M 1.62E+01 5.05E+OO 3.84E+OO O.OOE+OO 7.55E+OO O.OOE+OO 1.53E+03 O.OOE+OO W-181 2.83E+01 9.24E+OO 9.90E-01 O.OOE+OO O.OOE+OO O.OOE+OO 1.05E+03 O.OOE+OO W-185 1.15E+03 3.85E+02 4.05E+01 O.OOE+OO O.OOE+OO O.OOE+OO 4.45E+04 O.OOE+OO W-187 1.47E+02 1.23E+02 4.31E+01 O.OOE+OO O.OOE+OO O.OOE+OO 4.04E+04 O.OOE+OO U-232 1.98E+04 O.OOE+OO 1.41E+03 O.OOE+OO 2.14E+03 O.OOE+OO 3.25E+02 O.OOE+OO U-233 4.18E+03 O.OOE+OO 2.53E+02 O.OOE+OO 9.73E+02 O.OOE+OO 3.01E+02 O.OOE+OO U-234 4.01 E+03 O.OOE+OO 2.48E+02 O.OOE+OO 9.54E+02 O.OOE+OO 2.94E+02 O.OOE+OO U-235 3.84E+03 . O.OOE+OO 2.33E+02 O.OOE+OO 8.97E+02 O.OOE+OO 3.74E+02 O.OOE+OO U-236 3.84E+03 O.OOE+OO 2.38E+02 O.OOE+OO 9.16E+02 O.OOE+OO 2. 76E+02 O.OOE+OO U-237 2.39E-01 O.OOE+OO 6.36E-02 O.OOE+OO 9.82E-01 O.OOE+OO 8.39E+01 O.OOE+OO U-238 3.68E+03 O.OOE+OO 2.18E+02 O.OOE+OO 8.39E+02 O.OOE+OO 2.64E+02 O.OOE+OO NP-237 3.02E+04 2.15E+03 1.33E+03 O.OOE+OO 9.88E+03 O.OOE+OO 1.90E+03 O.OOE+OO NP-238 2.37E-01 6.38E-03 3.68E-03 O.OOE+OO 2.16E-02 O.OOE+OO 5.93E+02 O.OOE+OO NP-239 2.13E-02 2.09E-03 1.15E-03 O.OOE+OO 6.52E-03 O.OOE+OO 4.29E+02 O.OOE+OO PU-238 5.29E+03 6.70E+02 1.43E+02 O.OOE+OO 6.14E+02 O.OOE+OO 6.12E+02 O.OOE+OO PU-239 6.08E+03 7.31 E+02 1.60E+02 O.OOE+OO 6.80E+02 O.OOE+OO 5.59E+02 O.OOE+OO PU-240 6.07E+03 7.30E+02 1.60E+02 O.OOE+OO 6.80E+02 O.OOE+OO 5.69E+02 O.OOE+OO PU-241 1.32E+02 6.25E+OO 2.79E+OO O.OOE+OO 1.28E+01 O.OOE+OO 1.17E+01 O.OOE+OO PU-242 5.64E+03 7.04E+02 1.54E+02 O.OOE+OO 6.55E+02 O.OOE+OO 5.48E+02 O.OOE+OO PU-244 6.58E+03 8.06E+02 1.77E+02 O.OOE+OO 7.51 E+02 O.OOE+OO 8.16E+02 O.OOE+OO AM-241 4.52E+04 4.23E+04 3.24E+03 O.OOE+OO 2.44E+04 O.OOE+OO 4.45E+03 O.OOE+OO AM-242M 4.56E+04 3.97E+04 3.25E+03 O.OOE+OO 2.43E+04 O.OOE+OO 5.60E+03 O.OOE+OO AM-243 4.52E+04 4.14E+04 3.18E+03 O.OOE+OO 2.39E+04 O.OOE+OO 5.21 E+03 O.OOE+OO CM-242 1.23E+03 1.31 E+03 8.18E+01 O.OOE+OO 3.71E+02 O.OOE+OO 4.73E+03 O.OOE+OO CM-243 3.59E+04 3.29E+04 2.25E+03 O.OOE+OO 1.05E+04 O.OOE+OO 4.68E+03 O.OOE+OO CM-244 2.73E+04 2.56E+04 1.72E+03 O.OOE+OO 8.03E+03 O.OOE+OO 4.52E+03 O.OOE+OO CM-245 5.62E+04 4.90E+04 3.45E+03 O.OOE+OO 1.61 E+04 O.OOE+OO 4.22E+03 O.OOE+OO CM-246 5.57E+04 4.89E+04 3.45E+03 O.OOE+OO 1.61 E+04 O.OOE+OO 4.14E+03 O.OOE+OO CM-247 5.44E+04 4.82E+04 3.40E+03 O.OOE+OO 1.58E+04 O.OOE+OO 5.45E+03 O.OOE+OO CM-248 4.52E+05 3.97E+05 2.80E+04 O.OOE+OO 1.31 E+05 O.OOE+OO 8.81 E+04 O.OOE+OO CF-252 1.56E+04 O.OOE+OO 3.77E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+04 O.OOE+OO Rev.29 Page 149 of 329 12/2016
CY-LG-170-301 TABLE 111-11 ADULT SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG. Gl-LLI SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.34E+04 NA-24 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.48E+01 P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 3.48E+04 SC-46 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1. 72E+03 CR-51 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 9.87E+OO MN-54 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.91 E+03 MN-56 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.91 E+OO FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 4.89E+02 4.89E+02 4.89E+02 4.89E+02 4.89E+02 4.89E+02 4.89E+02 5.75E+02 C0-57 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.71 E+02 C0-58 6. 79E+02 6. 79E+02 6. 79E+02 6.79E+02 6.79E+02 6.79E+02 6.79E+02 7.95E+02 C0-60 4.32E+04 4.32E+04 4.32E.f.04 4.32E+04 4.32E+04 4.32E+04 4.32E+04 5.08E+04 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO . Nl-65 5.32E-01 5.32E-01 5.32E-01 5.32E-01 5.32E-01 5.32E-01 5.32E-01 6.19E-01 CU-64 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.23E+OO ZN-65 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.54E+03 ZN-69M 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.67E+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 3.83E+01 3.83E+01 3.83E+01 3.83E+01 3.83E+01 3.83E+01 3.83E+01 4.43E+01 BR-83 8.73E-03 8.73E-03 8.73E-03 8.73E-03 8.73E-03 8.73E-03 8.73E-03 1.27E-02 BR-84 3.63E-01 3.63E-01 3.63E-01 3.63E-01 3.63E-01 3.63E-01 3.63E-01 4.24E-01 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 1.61E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.84E+01 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 5.93E-02 5.93E-02 5.93E-02 5.93E-02 5.93E-02 5.93E-02 5.93E-02 6.77E-02 RB-89 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.64E-01 SR-89 3.88E-02 3.88E-02 3.88E-02 3.88E-02 3.88E-02 3.88E-02 3.88E-02 4.50E-02 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 4.50E+OO SR-92 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.55E+OO Y-90 8.05E-03 8.05E-03 8.05E-03 8.05E-03 8.05E-03 8.05E-03 8.05E-03 9.51E-03 Y-91M 1.80E-01 1.80E-01 1.80E-01 1.80E-01 1.80E-01 1.80E-01 1.80E-01 2.08E-01 Rev.29 Page 150 of 329 12/2016
CY-LG-170-301 TABLE 111-11 ADULT SHORELINE A17FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 2.16E+OO Y-92 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.84E-01 Y-93 3.29E-01 3.29E-01 3.29E-01 3.29E-01 3.29E-01 3.29E-01 3.29E-01 4.50E-01 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 4.39E+02 4.39E+02 4.39E+02 4.39E+02 4.39E+02 4.39E+02 4.39E+02 5.09E+02 ZR-97 5.31E+OO 5.31E+OO 5.31E+OO 5.31E+OO 5.31E+OO 5.31E+OO 5.31E+OO 6.17E+OO NB-93M 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO . 5.08E+02 NB-95 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.88E+02* NB-97 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.70E-01 M0-93 1.98E+02 1.98E+02 1.98E+02 1.98E+02 1.98E+02 1.98E+02 1.98E+02 8.06E+03 M0-99 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 8.29E+OO TC-99M 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.78E-01 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 3.65E-02 3.65E-02 3.65E-02 3.65E-02 3.65E-02 3.65E-02 3.65E-02 4.05E-02 RU-103 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 2.26E+02 RU-105 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.29E+OO RU-106 7.57E+02 7.57E+02 7.57E+02 7.57E+02 7.57E+02 7.57E+02 7.57E+02 9.08E+02 RH-105 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.55E+OO PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 2.69E-02 2.69E-02 2.69E-02 2.69E-02 2.69E-02 2.69E-02 2.69E-02 3.07E-02 AG-110M 6.16E+03 6.16E+03 6.16E+03 6.16E+03 6.16E+03 6.16E+03 6.16E+03 7.19E+03 AG-111 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 2.15E+OO CD-113M 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.28E+01 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.14E+04 SN-125 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 8.72E+OO SN-126 7.80E+04 7.80E+04 7.80E+04 7.80E+04 7.80E+04 7.80E+04 7.80E+04 8.67E+04 SB-124 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.24E+03 SB-125 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.84E+03 SB-126 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51 E+02 1.51E+02 1.70E+02 I SB-127 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.48E+01 TE-125M 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 3.81E+OO TE-127M 1.64E-01 1.64E-01 1.64E-01 1.64E-01 1.64E-01 1.64E-01 1.64E-01 1.94E-01 TE-127 5.34E-03 5.34E-03 5.34E-03 5.34E-03 5.34E-03 5.34E-03 5.34E-03 5.87E-03 TE-129M 3.54E+01 3.54E+01 3.54E+01 3.54E+01 3.54E+01 3.54E+01 3.54E+01 4.14E+01 TE-129 4.70E-02 4.70E-02 4.70E-02 4.70E-02 4.70E-02 4.70E-02 4.70E-02 5.56E-02 TE-131M 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.70E+01 TE-131 5.23E-02 5.23E-02 5.23E-02 5.23E-02 5.23E-02 5.23E-02 *'5.23E-02 6.18E+01 Rev,29 Page 151 of 329 12/2016
CY-LG-170-301 TABLE 111-11 ADULT SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 8.93E+OO TE-133M 7.91E-01 7.91E-01 7.91E-01 7.91 E-01 7.91 E-01 7.91 E-01 7.91E-01 8.96E-01 TE-134 3.98E-02 3.98E-02 3.98E-02 3.98E-02 3.98E-02 3.98E-02 3.98E-02 4.77E-02 1-129 3.90E+03 3.90E+03 3.90E+03 3.90E+03 3.90E+03 3.90E+03 3.90E+03 6.50E+03 1-130 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 1.20E+01 1-131 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.74E+01 1-132 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.63E+OO 1-133 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 5.34E+OO 1-134 8.01E-01 8.01E-01 8.01E-01 8.01 E-01 8.01E-01 8.01E-01 8.01 E-01 9.51 E-01 1-135 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 5.28E+OO CS-134M 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.21 E-01 CS-134 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.44E+04 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 2.70E+02 2.70E+02 2.70E+02 2.70E+02 2.70E+02 2.70E+02 2.70E+02 3.06E+02 CS-137 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 3.23E+04 CS~138 6.43E-01 6.43E-01 6.43E-01 6.43E-01 6.43E-01 6.43E-01 6.43E-01 7.35E-01 CS-139 5.63E-02 5.63E-02 *s.63E-02 5.63E-02 5.63E-02 5.63E-02 5.63E-02 6.44E-02 BA-139 1.90E-01 1.90E-01 1.90E-01 1.90E-01 1.90E-01 1.90E-01 1.90E-01 2.13E-01 BA-140 3.68E+01 3.68E+01 3.68E+01 3.68E+01 3.68E+01 3.68E+01 3.68E+01 4.20E+01 BA-141 7.47E-02 7.47E-02 7.47E-02 7.47E-02 7.47E-02 7.47E-02 7.47E-02 8.52E-02 BA-142 8.04E-02 8.04E-02 8.04E-02 8.04E-02 8.04E-02 8.04E-02 8.04E-02 9.16E-02 LA-140 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.90E+01 LA-141 5.62E-02 5.62E-02 5.62E-02 5.62E-02 5.62E-02 5.62E-02 5.62E-02 6.30E-02 LA-142 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.63E+OO CE-141 2.45E+01 2.45E+01 2.45E+01 2.45E+01 2.45E+01 2.45E+01 2.45E+01 2.76E+01 CE-143 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.71E+OO CE-144 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.44E+02 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.78E-03 ND-147 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.81E+01 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 7.98E+02 7.98E+02 7.98E+02 7.98E+02 7.98E+02 7.98E+02 7.98E+02 4.62E+03 PM-148 3.38E+01 3.38E+01 3.38E+01 3.38E+01 3.38E+01 3.38E+01 3.38E+01 3.90E+01 PM-149 7.57E-02 7.57E-02 7.57E-02 7.57E-02 7.57E-02 7.57E-02 7.57E-02
- 8.79E-02 PM-151 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.73E+OO SM-151 3.79E+02 3.79E+02 3.79E+02 3.79E+02 3.79E+02 3.79E+02 3.79E+02 1.66E+03 SM-153 7.20E-01 7.20E-01 7.20E-01 7.20E-01 7.20E-01 7.20E-01 7.20E-01 8.00E-01 EU-152 3.61E+04 3.61E+04 3.61E+04 3.61E+04 3.61E+04 3.61E+04 3.61E+04 4.18E+04 Rev.29 Page 152 of 329 12/2016
CY-LG-170-301 TABLE 111-11 ADULT SHORELINE A1rFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 3.41 E+04 EU-155 9.17E+02 9.17E+02 9.17E+02 9.17E+02 9.17E+02 9.17E+02 9.17E+02 1.04E+03 EU-156 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.81 E+02 TB-160 8.52E+02 8.52E+02 8.52E+02 8.52E+02 8.52E+02 8.52E+02 8.52E+02 9.90E+02 H0-166M 7.66E+04 7.66E+04 7.66E+04 7.66E+04 7.66E+04 7.66E+04 7.66E+04 8.61 E+04 W-181 3.48E-01 3.48E-01 3.48E-01 3.48E-01 3.48E-01 3.48E-01 3.48E-01 4.64E-01 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.90E+OO U-232 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.07E+02 U-233 1.99E+04 1.99E+04 1.99E+04 1.99E+04 1.99E+04 1.99E+04 1.99E+04 2.43E+04 U-234 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 1.38E+03 U-235 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 3.47E+04 U-236 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.56E+02 U-237 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 1.20E+01 U-238 9.54E+02 9.54E+02 9.54E+02 9.54E+02 9.54E+02 9.54E+02 9.54E+02 1.30E+03 NP-237 1.21E+04 1.21E+04 1.21E+04 1.21 E+04 1.21 E+04 1.21 E+04 1.21 E+04 1.39E+04 NP-238 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 9.28E+OO NP-239 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.55E+OO PU-238. 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.42E+02 PU-239 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.67E+01 PU-240 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.56E+02 PU-241 2.32E+01 2.32E+01 2.32E+01 2.32E+01 2.32E+01 2.32E+01 2.32E+01 3.43E+01 PU-242 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 1.39E+02 PU-244 7.76E+03 7.76E+03 7.76E+03 7.76E+03 7.76E+03 7.76E+03 7.76E+03 8.34E+03 AM-241 1.53E+03 1.53E+03 1.53E+03 1.53E+03 1.53E+03 1.53E+03 1.53E+03 2.21 E+03 AM-242M 2.13E+02 2.13E+02 2.13E+02 2.13E+02 2.13E+02 2.13E+02 2.13E+02 1.48E+03 AM-243 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.30E+04 CM-242 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 5.14E+OO CM-243 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.88E+04 CM-244 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.00E+02 CM-245 8.23E+03 8.23E+03 8.23E+03 8.23E+03 8.23E+03 8.23E+03 8.23E+03 1.04E+04 CM-246 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 1.30E+02 CM-247 1.91E+04 1.91E+04 1.91E+04 1.91 E+04 1.91 E+04 1.91 E+04 1.91 E+04 2.25E+04 CM-248 4.53E+04 4.53E+04 4.53E+04 4.53E+04 4.53E+04 4.53E+04 4.53E+04 5.90E+04 CF-252 8.70E+04 8.70E+04 8.70E+04 8.70E+04 8.70E+04 8.70E+04 8.70E+04 9.49E+04 Rev.29 Page 153 of 329 12/2016
CY-LG-170-301 TABLE 111-12 TEEN DRINKING WATER Air FACTORS mrem-r:nl per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 3.52E+OO 3.52E+OO 3.52E+OO 3.52E+OO 3.52E+OO 3.52E+OO O.OOE+OO C-14 2.36E+02 4.73E+01 4.73E+01 4.73E+01 4.73E+01 4.73E+01 4.73E+01 O.OOE+OO NA-22 1.36E+03 1.36E+03 1.36E+03 1.36E+03 1.36E+03 1.36E+03 1.36E+03 O.OOE+OO NA-24 7.69E+01 7.69E+01 7.69E+01 7.69E+01 7.69E+01 7.69E+01 7.69E+01 O.OOE+OO P-32 1.57E+04 9.72E+02 6.08E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.32E+03 O.OOE+OO CA-41 1.15E+04 O.OOE+OO 1.24E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.14E+01 O.OOE+OO SC-46 4.20E-01 8.18E-01 2.42E-01 O.OOE+OO 7.83E-01 O.OOE+OO 2.78E+03 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 2.07E-01 1.15E-01 4.54E-02 2.96E-01 3.48E+01 O.OOE+OO MN-54 O.OOE+OO 3.43E+02 6.80E+01 O.OOE+OO 1.02E+02 O.OOE+OO 7.04E+02 O.OOE+OO MN-56 O.OOE+OO 3.65E-01 6.50E-02 O.OOE+OO 4.63E-01 O.OOE+OO 2.41 E+01 O.OOE+OO FE-55 2.20E+02 1.56E+02 3.64E+01 O.OOE+OO O.OOE+OO 9.89E+01 6.75E+01 O.OOE+OO FE-59 3.39E+02 7.91 E+02 3.06E+02 O.OOE+OO O.OOE+OO 2.50E+02 1.87E+03 O.OOE+OO C0-57 O.OOE+OO 1.38E+01 2.32E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.58E+02 O.OOE+OO C0-58 O.OOE+OO 5.63E+01 1.30E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.76E+02 O.OOE+OO C0-60 O.OOE+OO 1.64E+02 3.68E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.13E+03 O.OOE+OO Nl-59 7.68E+02 2.71E+02 1.30E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.26E+01 O.OOE+OO Nl-63 1.03E+04 7.28E+02 3.49E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.16E+02 O.OOE+OO Nl-65 1.61 E+OO 2.05E-01 9.36E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.11 E+01 O.OOE+OO CU-64 O.OOE+OO 3.48E+OO 1.64E+OO O.OOE+OO 8.80E+OO O.OOE+OO 2.70E+02 O.OOE+OO ZN-65 3.35E+02 1.16E+03 5.42E+02 O.OOE+OO 7.44E+02 O.OOE+OO 4.92E+02 O.OOE+OO ZN-69M 7.63E+OO 1.80E+01 1.65E+OO O.OOE+OO 1.09E+01 O.OOE+OO 9.89E+02 O.OOE+OO ZN-69 1.08E-04 2.06E-04 1.44E-05 O.OOE+OO 1.35E-04 O.OOE+OO 3.80E-04 O.OOE+OO SE-79 O.OOE+OO 2.17E+02 3.65E+01 O.OOE+OO 3.78E+02 O.OOE+OO 3.32E+01 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.40E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.03E-01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 6.42E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 4.38E-77 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.70E+03 8.00E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.52E+02 O.OOE+OO RB-87 O.OOE+OO 1.02E+03 3.56E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.56E+01 O.OOE+OO RB-88 O.OOE+OO 3.30E-12 1.76E-12 O.OOE+OO O.OOE+OO O.OOE+OO 2.83E-19 O.OOE+OO RB-89 O.OOE+OO 2.94E-14 2.08E-14 O.OOE+OO O.OOE+OO O.OOE+OO 4.50E-23 O.OOE+OO SR-89 2.54E+04 O.OOE+OO 7.29E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.03E+03 O.OOE+OO SR-90 5. 94E+05 O.OOE+OO 1.19E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.36E+04 O.OOE+OO SR-91 1.96E+02 O.OOE+OO 7.79E+OO O.OOE+OO O.OOE+OO O.OOE+OO 8.88E+02 O.OOE+OO SR-92 8.25E+OO O.OOE+OO 3.52E-01 O.OOE+OO O.OOE+OO O.OOE+OO 2.1 OE+02 O.OOE+OO Y-90 7.01 E-01 O.OOE+OO 1.89E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.78E+03 O.OOE+OO Y-91M 3.28E-07 O.OOE+OO 1.25E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.55E-05 O.OOE+OO Rev.29 Page 154 of 329 12/2016
CY-LG-170-301 TABLE 111-12 TEEN DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 1.16E+01 O.OOE+OO 3.12E-01 O.OOE+OO O.OOE+OO O.OOE+OO 4.77E+03 O.OOE+OO Y-92 6.72E-03 O.OOE+OO 1.94E-04 O.OOE+OO O.OOE+OO O.OOE+OO 1.84E+02 O.OOE+OO Y-93 9.79E-02 O.OOE+OO 2.68E-03 O.OOE+OO O.OOE+OO O.OOE+OO 2.99E+03 O.OOE+OO ZR-93 3.22E+OO 1.59E-01 8.67E-02 O.OOE+OO 5.62E-01 O.OOE+OO 1.50E+02 O.OOE+OO ZR-95 2.39E+OO 7.53E-01 5.1 BE-01 O.OOE+OO 1.11E+OO O.OOE+OO 1.74E+03 O.OOE+OO ZR-97 8.43E-02 1.67E-02 7 .69E-03 O.OOE+OO 2.53E-02 O.OOE+OO 4.52E+03 O.OOE+OO NB-93M 2.00E+OO 6.58E-01 1.65E-01 O.OOE+OO 7.68E-01 O.OOE+OO 2.37E+02 O.OOE+OO NB-95 4.74E-01 2.63E-01 1.45E-01 O.OOE+OO 2.55E-01 O.OOE+OO 1.12E+03 O.OOE+OO NB-97 4.23E-06 1.05E-06 3.83E-07 O.OOE+OO 1.23E-06 O.OOE+OO 2.51 E-02 O.OOE+OO M0-93 O.OOE+OO 6.17E+02 1.69E+01 O.ObE+OO 1.77E+02 O.OOE+OO 7.51 E+01 O.OOE+OO M0-99 O.OOE+OO 3.1 OE+02 5.90E+01 O.OOE+OO 7.08E+02 O.OOE+OO 5.54E+02 O.OOE+OO TC-99M 4.85E-03 1.35E-02 1.75E-01 O.OOE+OO 2.02E-01 7.52E-03 8.89E+OO O.OOE+OO TC-99 1.04E+01 1.53E+01 4.17E+OO O.OOE+OO 1.94E+02 1.58E+OO 3.75E+02 O.OOE+OO TC-101 1.14E-17 1.62E-17 1.60E-16 O.OOE+OO 2.94E-16 9.90E-18 2.78E-24 O.OOE+OO RU-103 1.47E+01 O.OOE+OO 6.29E+OO O.OOE+OO 5.19E+01 O.OOE+OO 1.23E+03 O.OOE+OO RU-105 1.95E-01 O.OOE+OO 7.57E-02 O.OOE+OO 2.46E+OO O.OOE+OO 1.57E+02 O.OOE+OO RU-106 2.28E+02 O.OOE+OO 2.87E+01 O.OOE+OO 4.40E+02 O.OOE+OO 1.09E+04 O.OOE+OO RH-105 7.96E+OO 5.75E+OO 3.77E+OO O.OOE+OO 2.44E+01 O.OOE+OO 7.32E+02 O.OOE+OO PD-107 O.OOE+OO 1.21E+01 7.BOE-01 O.OOE+OO 1.09E+02 O.OOE+OO 5.62E+01 O.OOE+OO PD-109 O.OOE+OO 7.87E+OO 1.79E+OO O.OOE+OO 4.55E+01 O.OOE+OO 7.94E+02 O.OOE+OO AG-110M 1.19E+01 1.13E+01 6.86E+OO O.OOE+OO 2.15E+01 O.OOE+OO 3.17E+03 O.OOE+OO AG-111 4.61E+OO 1.91E+OO 9.61 E-01 O.OOE+OO 6.22E+OO O.OOE+OO 2.67E+03 O.OOE+OO CD-113M O.OOE+OO 2.63E+02 8.44E+OO O.OOE+OO 2.90E+02 O.OOE+OO 1.58E+03 O.OOE+OO CD-115M O.OOE+OO 1.50E+02 4.85E+OO O.OOE+OO 1.20E+02 O.OOE+OO 4.75E+03 O.OOE+OO SN-123 2.58E+03 4.23E+01 6.27E+01 3.39E+01 O.OOE+OO O.OOE+OO 3.90E+03 O.OOE+OO SN-125 6.68E+02 1.33E+01 3.02E+01 1.04E+01 O.OOE+OO O.OOE+OO 6.29E+03 O.OOE+OO SN-126 6.75E+03 1.26E+02 1.92E+02 3.31E+01 O.OOE+OO O.OOE+OO 1.50E+03 O.OOE+OO SB-124 2.24E+02 4.13E+OO 8.74E+01 5.0BE-01 O.OOE+OO 1.96E+02 4.52E+03 O.OOE+OO SB-125 1.44E+02 1.58E+OO 3.38E+01 1.38E-01 O.OOE+OO 1.27E+02
- 1.12E+03 O.OOE+OO SB-126 9.00E+01 1.84E+OO 3.23E+01 5.09E-01 O.OOE+OO 6.45E+01 5.33E+03 O;OOE+OO SB-127 1.93E+01 4.13E-01 7.29E+OO 2.17E-01 O.OOE+OO 1.31 E+01 3.28E+03 O.OOE+OO TE-125M 2.22E+02 7.99E+01 2.96E+01 6.19E+01 O.OOE+OO O.OOE+OO 6.54E+02 O.OOE+OO TE-127M 5.61 E+02 1.99E+02 6.67E+01 1.33E+02 2.27E+03 O.OOE+OO 1.40E+03 O.OOE+OO TE-127 3. 78E+OO 1.34E+OO 8.1.3E-01 2.61 E+OO 1.53E+01 O.OOE+OO 2.92E+02 O.OOE+OO TE-129M 9.39E+02 3.49E+02 1.49E+02 3.03E+02 3.93E+03 O.OOE+OO 3.53E+03 O.OOE+OO TE-129 2.01E-03 7.48E-04 4.88E-04 1.43E-03 8.42E-03 O.OOE+OO 1.1 OE-02 O.OOE+OO TE-131M 1.08E+02 5.16E+01 4.31E+01 7.77E+01 5.38E+02 O.OOE+OO 4.14E+03 O.OOE+OO TE-131 3.48E-09 1.43E-09 1.09E-09 2.68E-09 1.52E-08 O.OOE+OO 2.85E-10 O.OOE+OO Rev.29 Page 155 of 329 12/2016
CY-LG-170-301 TABLE 111-12 TEEN DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 1.83E+02 1.16E+02 1.09E+02 1.22E+02 1.11 E+03 O.OOE+OO 3.66E+03 O.OOE+OO TE-133M 4.59E-04 2.61E-04 2.54E-04 3.64E-04 2.58E-03 O.OOE+OO 1.05E-03 O.OOE+OO TE-134 1.70E-05 1.09E-05 1.14E-05 1.39E-05 1.04E-04 O.OOE+OO 6.31 E-07 O.OOE+OO 1-129 2. 71 E+02 2.28E+02 3.81 E+02 2.78E+05 4.08E+02 O.OOE+OO 2.66E+01 O.OOE+OO 1-130 3.06E+01 8.85E+01 3.53E+01 7.22E+03 1.36E+02 O.OOE+OO 6.80E+01 O.OOE+OO 1-131 3.26E+02 4.57E+02 2.45E+02 1.33E+05 7.86E+02 O.OOE+OO 9.03E+01 O.OOE+OO 1-132 4.37E-01 1.14E+00' 4.1 OE-01 3.85E+01 1.80E+OO O.OOE+OO 4.98E-01 O.OOE+OO 1-133 7.84E+01 1.33E+02 4.06E+01 1.86E+04 2.33E+02 O.OOE+OO 1.01 E+02 O.OOE+OO 1-134 6.44E-04 1.71E-03 6.13E-04 2.84E-02 2.69E-03 O.OOE+OO 2.25E-05 O.OOE+OO 1-135 1.01E+01 2.60E+01 9.63E+OO 1.67E+03 4.1 OE+01 O.OOE+OO 2.88E+01 O.OOE+OO CS-134M 9.72E-02 2.01 E-01 1.04E-01 O.OOE+OO 1.12E-01 1.97E-02 1.34E-01 O.OOE+OO CS-134 4.87E+03 1.15E+04 5.32E+03 O.OOE+OO 3.64E+03 1.39E+03 1.43E+02 O.OOE+OO CS-135 1.62E+03 1.48E+03 3.4 7E+02 O.OOE+OO 5.66E+02 2.05E+02 2.60E-+'01 O.OOE+OO CS-136 4.87E+02 1.92E+03 1.29E+03 O.OOE+OO 1.04E+03 1.64E+02 1.54E+02 O.OOE+OO CS-137 6.52E+03 8.67E+03 3.02E+03 O.OOE+OO 2.95E+03 1.15E+03 1.23E+02 O.OOE+OO CS-138 8.39E-07 1.61E-06 8.06E-07 O.OOE+OO 1.19E-06 1.38E-07 7.31E-10 O.OOE+OO CS-139 2.48E-23 3.66E-23 1.34E-23 O.OOE+OO 2.95E-23 3.23E-24 1.70E-38 O.OOE+OO BA-139 1.99E-02 1.40E-05 5.81E-04 O.OOE+OO 1.32E-05 9.67E-06 1.78E-01 O.OOE+OO BA-140 1.61E+03 1.97E+OO 1.04E+02 O.OOE+OO 6.69E-01 1.33E+OO 2.48E+03 O.OOE+OO BA-141 5.35E-12 4.00E-15 1.79E-13 O.OOE+OO 3.71E-15 2.74E-15 1.14E-17 O.OOE+OO BA-142 9.65E-21 9.65E-24 5.94E-22 O.OOE+OO 8.17E-24 6.42E-24 2.96E-32 O.OOE+OO LA-140 1.65E-01 8.1 OE-02 2.15E-02 O.OOE+OO O.OOE+OO O.OOE+OO 4.65E+03 O.OOE+OO LA-141 3.21 E-03 9.87E-04 1.63E-04 O.OOE+OO O.OOE+OO O.OOE+OO 1.75E+02 O.OOE+OO LA-142 5.57E-05 2.47E-05 6.16E-06 O.OOE+OO O.OOE+OO O.OOE+OO 7.53E-01 O.OOE+OO CE-141 7.66E-01 5.12E-01 5.88E-02 O.OOE+OO 2.41E-01 O.OOE+OO 1.46E+03 O.OOE+OO CE-143 1.06E-01 7.74E+01 8.64E-03 O.OOE+OO 3.47E-02 O.OOE+OO 2.33E+03 O.OOE+OO CE-144 4.05E+01 1.67E+01 2.17E+OO O.OOE+OO 1.00E+01 O.OOE+OO 1.02E+04 O.OOE+OO PR-143 7.43E-01 2.97E-01 3.70E-02 O.OOE+OO 1.73E-01 O.OOE+OO 2.45E+03 O.OOE+OO PR-144 7.17E-16 2.94E-16 3.64E-17 O.OOE+OO 1.68E-16 O.OOE+OO 7.91E-19 O.OOE+OO ND-147 5.29E-01 5.75E-01 3.45E-02 O.OOE+OO 3.38E-01 O.OOE+OO 2.08E+03 O.OOE+OO PM-147 6.11E+OO 5.80E-01 2.36E-01 O.OOE+OO 1.11E+OO O.OOE+OO 5.51 E+02 O.OOE+OO PM-148M 2.39E+OO 6.06E-01 4.74E-01 O.OOE+OO 9.18E-01 O.OOE+OO 3.82E+03 O.OOE+OO PM-148 5.57E-01 9.06E-02 4.56E-02 O.OOE+OO 1.64E-01 O.OOE+OO 5.40E+03 O.OOE+OO PM-149 1.08E-01 1.52E-02 6.22E-03 O.OOE+OO 2.89E-02 O.OOE+OO 2.23E+03 O.OOE+OO PM-151 4.29E-02 7.08E-03 3.58E-03 O.OOE+OO 1.27E-02 O.OOE+OO 1.59E+03 O.OOE+OO SM-151 5.08E+OO 9.78E-01 2.29E-01 O.OOE+OO 1.07E+OO O.OOE+OO 3.32E+02 O.OOE+OO SM-153 5.94E-02 4.92E-02 3.62E-03 O.OOE+OO 1.61 E-02 O.OOE+OO 1.39E+03 O.OOE+OO EU-152 1.43E+01 3.43E+OO 3.03E+OO O.OOE+OO 1.60E+01 O.OOE+OO 1.26E+03 O.OOE+OO Rev.29 Page 156 of 329 12/2016
CY-LG-170-301 TABLE 111-12 TEEN DRINKING WATER A17FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN EU-154 4.60E+01 5.94E+OO 4.19E+OO O.OOE+OO 2.65E+01 O.OOE+OO 3.14E+03 O.OOE+OO EU-155 1.01 E+01 9.78E-01 6.05E-01 O.OOE+OO 3.82E+OO O.OOE+OO 5.61 E+03 O.OOE+OO EU-156 1.09E+OO 8.19E-01 1.34E-01 O.OOE+OO 5.51 E-01 O.OOE+OO 4.19E+03 O.OOE+OO TB-160 3.75E+OO O.OOE+OO 4.68E-01 O.OOE+OO 1.48E+OO O.OOE+OO 2.43E+03 O.OOE+OO H0-166M 2.08E+01 6.40E+OO 4.63E+OO O.OOE+OO 9.37E+OO O.OOE+OO 1.58E+03 O.OOE+OO W-181 8.24E-01 2.66E-01 2.78E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.26E+01 O.OOE+OO W-185 3.36E+01 1.11 E+01 1.17E+OO O.OOE+OO O.OOE+OO O.OOE+OO 9.56E+02 O.OOE+OO W-187 6.00E+OO 4.89E+OO 1.71 E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.32E+03 O.OOE+OO U-232 3.43E+05 O.OOE+OO 2.45E+04 O.OOE+OO 3.71E+04 O.OOE+OO 4.19E+03 O.OOE+OO U-233 7.22E+04 O.OOE+OO 4.39E+03 O.OOE+OO 1.69E+04 O.OOE+OO 3.87E+03 O.OOE+OO U-234 6.93E+04 O.OOE+OO 4.30E+03 O.OOE+OO 1.66E+04 O.OOE+OO 3.79E+03 O.OOE+OO U-235 6.64E+04 O.OOE+OO 4.04E+03 O.OOE+OO 1.55E+04 O.OOE+OO 4.82E+03 O.OOE+OO U-236 6.64E+04 O.OOE+OO 4.13E+03 O.OOE+OO 1.59E+04 O.OOE+OO 3.56E+03 O.OOE+OO U-237 4.36E+OO O.OOE+OO 1.16E+OO O.OOE+OO 1. 79E+01 O.OOE+OO 1.16E+03 O.OOE+OO U-238 6.35E+04 O.OOE+OO 3.78E+03 O.OOE+OO 1.46E+04 O.OOE+OO 3.39E+03 O.OOE+OO NP-237 7.74E+04 5.56E+03 3.41E+03 O.OOE+OO 2.52E+04 O.OOE+OO 4.90E+03 O.OOE+OO NP-238 9.64E-01 2.58E-02 1.50E-02 O.OOE+OO 8.85E-02 O.OOE+OO 1.89E+03 O.OOE+OO NP-239 8.84E-02 8.34E-03 4.63E-03 O.OOE+OO 2.62E-02 O.OOE+OO 1.34E+03 O.OOE+OO PU-238 3.90E+04 5.00E+03 1.06E+03 O.OOE+OO 4.54E+03 O.OOE+OO 4.50E+03 O.OOE+OO PU-239 4.45E+04 5.41E+03 1.17E+03 O.OOE+OO 4.99E+03 O.OOE+OO 4.11 E+03 O.OOE+OO PU-240 4.45E+04 5.40E+03 1.17E+03 O.OOE+OO 4.98E+03 O.OOE+OO 4.19E+03 O.OOE+OO PU-241 1.02E+03 4.89E+01 2.15E+01 O.OOE+OO 9.95E+01 O.OOE+OO 8.62E+01 O.OOE+OO PU-242 4.13E+04 5.20E+03 1.13E+03 O.OOE+OO 4.80E+03 O.OOE+OO 4.03E+03 O.OOE+OO PU-244 4.82E+04 5.94E+03 1.29E+03 O.OOE+OO 5.50E+03 O.OOE+OO 6.00E+03 O.OOE+OO AM-241 4.65E+04 4.38E+04 3.35E+03 O.OOE+OO 2.51 E+04 O.OOE+OO 4.58E+03 O.OOE+OO AM-242M 4.70E+04 4.14E+04 3.38E+03 O.OOE+OO 2.50E+04 O.OOE+OO 5.76E+03 O.OOE+OO AM-243 4.63E+04 4.28E+04 3.27E+03 O.OOE+OO 2.46E+04 O.OOE+OO 5.37E+03 O.OOE+OO CM-242 1. 71 E+03 1.80E+03 1.13E+02 O.OOE+OO 5.16E+02 O.OOE+OO 4.88E+03 O.OOE+OO CM-243 3.78E+04 3.51E+04 2.38E+03 O.OOE+OO 1.11 E+04 O.OOE+OO 4.82E+03 O.OOE+OO CM-244 2.93E+04 2.78E+04 1.86E+03 O.OOE+OO 8.67E+03 O.OOE+OO 4.66E+03 O.OOE+OO CM-245 5.76E+04 5.07E+04 3.55E+03 O.OOE+OO 1.66E+04 O.OOE+OO 4.34E+03 O.OOE+OO CM-246 5.72E+04 5.07E+04 3.55E+03 O.OOE+OO 1.65E+04 O.OOE+OO 4.27E+03 O.OOE+OO CM-247 5.57E+04 4.99E+04 3.49E+03 O.OOE+OO 1.63E+04 O.OOE+OO 5.61 E+03 O.OOE+OO CM-248 4.63E+05 4.11 E+05 2.88E+04 O.OOE+OO 1.34E+05 O.OOE+OO 9.02E+04 O.OOE+OO CF-252 2.02E+04 O.OOE+OO 4.87E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.78E+04 O.OOE+OO Rev.29 Page 157 of 329 12/2016
CY-LG-170-301 TABLE 111-13 TEEN FRESHWATER FISH Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 9.93E-02 9.93E-02 9.93E-02 9.93E-02 9.93E-02 9.93E-02 O.OOE+OO C-14 3.41 E+04 6.82E+03 6.82E+03 6.82E+03 6.82E+03 6.82E+03 6.82E+03 O.OOE+OO NA-22 4.27E+03 4.27E+03 4.27E+03 4.27E+03 4.27E+03 4.27E+03 4.27E+03 O.OOE+OO NA-24 1.39E+02 1.39E+02 1.39E+02 1.39E+02 1.39E+02 1.39E+02 1.39E+02 O.OOE+OO P-32 1.44E+06 8.93E+04 5.59E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.21 E+05 O.OOE+OO CA-41 1.44E+04 O.OOE+OO 1.56E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.42E+01 O.OOE+OO SC-46 2.62E-02 5.11 E-02 1.51 E-02 O.OOE+OO 4.89E-02 O.OOE+OO 1.74E+02 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.28E+OO 7.13E-01 2.81 E-01 1.83E+OO 2.16E+02 O.OOE+OO MN-54 O.OOE+OO 4.30E+03 8.53E+02 O.OOE+OO 1.28E+03 O.OOE+OO 8.82E+03 O.OOE+OO MN-56 O.OOE+OO 1.82E-01 3.24E-02 O.OOE+OO 2.31 E-01 O.OOE+OO 1.20E+01 O.OOE+OO FE-55 6.90E+02 4.89E+02 1.14E+02 O.OOE+OO O.OOE+OO 3.10E+02 2.12E+02 O.OOE+OO FE-59 1.06E+03 2.46E+03 9.51E+02 O.OOE+OO O.OOE+OO 7.77E+02 5.83E+03 O.OOE+OO C0-57 O.OOE+OO 2.17E+01 3.63E+01 O.OOE+OO O.OOE+OO O.OOE+OO 4.04E+02 O.OOE+OO C0-58 O.OOE+OO 8.79E+01 2.03E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.21 E+03 O.OOE+OO C0-60 O.OOE+OO 2.57E+02 5.78E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.34E+03 O.OOE+OO Nl-59 2.41E+03 8.51E+02 4.09E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.34E+02 O.OOE+OO Nl-63 3.23E+04 2.28E+03 1.10E+03 O.OOE+OO O.OOE+OO O.OOE+OO 3.63E+02 O.OOE+OO Nl-65 1.86E-01 2.37E-02 1.08E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.29E+OO O.OOE+OO CU-64 O.OOE+OO 2.83E+OO 1.33E+OO O.OOE+OO 7.17E+OO O.OOE+OO 2.20E+02 O.OOE+OO ZN-65 2.1 OE+04 7.29E+04 3.40E+04 O.OOE+OO 4.66E+04 O.OOE+OO 3.09E+04 O.OOE+OO ZN-69M 2.62E+02 6.17E+02 5.66E+01 O.OOE+OO 3.75E+02 O.OOE+OO 3.39E+04 O.OOE+OO ZN-69 8.58E-07 1.63E-06 1.14E-07 O.OOE+OO 1.07E-06 O.OOE+OO 3.01 E-06 O.OOE+OO SE-79 O.OOE+OO 1.16E+03 1.95E+02 O.OOE+OO 2.02E+03 O.OOE+OO 1.77E+02 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.46E+03 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 4.18E-02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.29E-12 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.43E-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.05E+05 4.93E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.55E+04 O.OOE+OO RB-87 O.OOE+OO 6.39E+04 2.23E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.23E+03 O.OOE+OO RB-88 O.OOE+OO 1.38E-22 7.36E-23 O.OOE+OO O.OOE+OO O.OOE+OO 1.18E-29 O.OOE+OO RB-89 O.OOE+OO 1.69E-26 1.19E-26 O.OOE+OO O.OOE+OO O.OOE+OO 2.59E-35 O.OOE+OO SR-89 2.38E+04 O.OOE+OO 6.81E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.83E+03 O.OOE+OO SR-90 5.59E+05 O.OOE+OO 1.12E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.28E+04 O.OOE+OO SR-91 7.68E+01 O.OOE+OO 3.05E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.48E+02 O.OOE+OO SR-92 3.61E-01 O.OOE+OO 1.54E-02 O.OOE+OO O.OOE+OO O.OOE+OO 9.19E+OO O.OOE+OO Y-90 4.83E-01 O.OOE+OO 1.30E-02 O.OOE+OO O.OOE+OO O.OOE+OO 3.98E+03 O.OOE+OO Y-91M 1.12E-11 O.OOE+OO 4.29E-13 O.OOE+OO O.OOE+OO O.OOE+OO 5.30E-10 O.OOE+OO Rev.29 Page 158 of 329 12/2016
CY-LG-170-301 TABLE 111-13 TEEN FRESHWATER FISH A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 9.07E+OO O.OOE+OO 2.43E-01 O.OOE+OO O.OOE+OO O.OOE+OO 3.72E+03 O.OOE+OO Y-92 5.03E-04 O.OOE+OO 1.45E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.38E+01 O.OOE+OO Y-93 3.37E-02 O.OOE+OO 9.23E-04 O.OOE+OO O.OOE+OO O.OOE+OO 1.03E+03 O.OOE+OO ZR-93 3.33E-01 1.65E-02 8.98E-03 O.OOE+OO 5.82E-02 O.OOE+OO 1.56E+01 O.OOE+OO ZR-95 2.46E-01 7.75E-02 5.33E-02 O.OOE+OO 1.14E-01 O.OOE+OO 1.79E+02 O.OOE+OO ZR-97 5.34E-03 1.06E-03 4.87E-04 O.OOE+OO 1.60E-03 O.OOE+OO 2.86E+02 O.OOE+OO NB-93M 1.88E+03 6.19E+02 1.55E+02 O.OOE+OO 7.23E+02 O.OOE+OO 2.23E+05 O.OOE+OO NB-95 4.42E+02 2.45E+02 1.35E+02 O.OOE+OO 2.37E+02 O.OOE+OO 1.05E+06 O.OOE+OO NB-97 3.93E-06 9.75E-07 3.56E-07 O.OOE+OO 1.14E-06 O.OOE+OO 2.33E-02 O.OOE+OO M0-93 O.OOE+OO 1.94E+02 5.30E+OO O.OOE+OO 5.55E+01 O.OOE+OO 2.36E+01 O.OOE+OO M0-99 O.OOE+OO 8.56E+01 1.63E+01 O.OOE+OO 1.96E+02 O.OOE+OO 1.53E+02 O..OOE+OO TC-99M 5.74E-04 1.60E-03 2.07E-02 O.OOE+OO 2.38E-02 8.88E-04 1.05E+OO O.OOE+OO TC-99 4.90E+OO 7.21 E+OO 1.96E+OO O.OOE+OO 9.15E+01 7.45E-01 1.76E+02 O.OOE+OO TC-101 2.93E-33 4.17E-33 4.10E-32 O.OOE+OO 7.54E-32 2.54E-33 7.12E-40 O.OOE+OO RU-103 4.58E+OO O.OOE+OO 1.96E+OO O.OOE+OO 1.61 E+01 O.OOE+OO 3.82E+02 O.OOE+OO RU-105 9.39E-03 O.OOE+OO 3.65E-03 O.OOE+OO 1.19E-01 O.OOE+OO 7.58E+OO O.OOE+OO RU-106 7.15E+01 O.OOE+OO 9.01 E+OO O.OOE+OO 1.38E+02 O.OOE+OO 3.43E+03 O.OOE+OO RH-105 1.97E+OO 1.43E+OO 9.36E-01 O.OOE+OO 6.06E+OO O.OOE+OO 1.81 E:t-02 O.OOE+OO PD-107 O.OOE+OO 3.BOE+OO 2.45E-01 O.OOE+OO 3.43E+01 O.OOE+OO 1.76E+01 O.OOE+OO PD-109 O.OOE+OO 1.33E+OO 3.02E-01 O.OOE+OO 7.69E+OO O.OOE+OO 1.34E+02 O.OOE+OO AG-110M 8.59E-01 8.13E-01 4.94E-01 O.OOE+OO 1.55E+OO O.OOE+OO 2.28E+02 O.OOE+OO AG-111 3.17E-01 1.32E-01 6.62E-02 O.OOE+OO 4.29E-01 O.OOE+OO 1.84E+02 O.OOE+OO CD-113M O.OOE+OO 1.65E+03 5.30E+01 O.OOE+OO 1.82E+03 O.OOE+OO 9.90E+03 O.OOE+OO CD-115M O.OOE+OO 9.35E+02 3.02E+01 O.OOE+OO 7.48E+02 O.OOE+OO 2.96E+04 O.OOE+OO SN-123 2.42E+05 3.97E+03 5.89E+03 3.18E+03 O.OOE+OO O.OOE+OO 3.66E+05 O.OOE+OO SN-125 6.07E+04 1.21E+03 2.74E+03 9.48E+02 O.OOE+OO O.OOE+OO 5. 71 E+05 O.OOE+OO SN-126 6.36E+05 1.18E+04 1.81E+04 3.12E+03 O.OOE+OO O.OOE+OO 1.41E+05 O.OOE+OO SB-124 6.99E+OO 1.29E-01 2.73E+OO 1.59E-02 O.OOE+OO 6.1 OE+OO 1.41 E+02 O.OOE+OO SB-125 4.53E+OO 4.95E-02 1.06E+OO 4.33E-03 O.OOE+OO 3.98E+OO . 3.52E+01 O.OOE+OO SB-126 2.75E+OO 5.61 E-02 9.86E-01 1.55E-02 O.OOE+OO 1.97E+OO 1.63E+02 O.OOE+OO SB-127 5.54E-01 1.18E-02 2.09E-01 6.22E-03 O.OOE+OO 3.77E-01 9.40E+01 O.OOE+OO TE-125M 2.76E+03 9.96E+02 3.70E+02 7.72E+02 O.OOE+OO O.OOE+OO 8.16E+03 O.OOE+OO TE-127M 7.02E+03 2.49E+03 8.35E+02 1.67E+03 2.85E+04 O.OOE+OO 1.75E+04 O.OOE+OO TE-127 1.95E+01 6.91 E+OO 4.19E+OO 1.34E+01 7.89E+01 O.OOE+OO 1.50E+03 O.OOE+OO TE-129M 1.17E+04 4.33E+03 1.85E+03 3.76E+03 4.88E+04 O.OOE+OO 4.38E+04 O.OOE+OO TE-129 1.94E-05 7.21 E-06 4.71E-06 1.38E-05 8.12E-05 O.OOE+OO 1.06E-04 O.OOE+OO TE-131M 1.02E+03 4.91 E+02 4.10E+02 7.39E+02 5.12E+03 O.OOE+OO 3.94E+04 O.OOE+OO TE-131 9.33E-17 3.85E-17 2.92E-17 7.19E-17 4.08E-16 O.OOE+OO 7.66E-18 O.OOE+OO Rev.29 Page 159 of 329 12/2016
CY-LG-170-301 TABLE 111-13 TEEN FRESHWATER FISH Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 2.06E+03 1.31E+03 1.23E+03 1.38E+03 1.25E+04 O.OOE+OO 4.13E+04 O.OOE+OO TE-133M 7.05E-07 4.00E-07 3.90E-07 5.59E-07 3.96E-06 O.OOE+OO 1.62E-06 O.OOE+OO TE-134 1.39E-09 8.94E-10 9.34E-10 1.14E-09 8.53E-09 O.OOE+OO 5.17E-11 O.OOE+OO 1-129 1.28E+02 1.07E+02 1.79E+02 1.31 E+05 1.92E+02 O.OOE+OO 1.25E+01 O.OOE+OO 1-130 7 .35E+OO 2.13E+01 8.49E+OO 1.73E+03 3.27E+01 O.OOE+OO 1.63E+01 O.OOE+OO 1-131 1.47E+02 2.06E+02 1.11 E+02 6.01 E+04 3.54E+02 O.OOE+OO 4.07E+01 O.OOE+OO 1-132 5.52E-03 1.44E-02 5.19E-03 4.87E-01 2 . 28E-02 O.OOE+OO 6.29E-03 O.OOE+OO 1-133 2.47E+01 4.20E+01 1.28E+01 5.86E+03 7.36E+01 O.OOE+OO 3.18E+01 O.OOE+OO 1-134 2.30E-08 6.09E-08 2.19E-08 . 1.01E-06 9.59E-08 O.OOE+OO 8.02E-10 O.OOE+OO 1-135 1.35E+OO 3.47E+OO 1.29E+OO 2.23E+02 5.48E+OO O.OOE+OO 3.85E+OO O.OOE+OO CS-134M 3.47E-01 7.18E-01 3.69E-01 O.OOE+OO 4.00E-01 7.01 E-02 4.77E-01 O.OOE+OO CS-134 3.05E+05 7.19E+05 3.34E+05 O.OOE+OO 2.28E+05 8.72E+04 8.94E+03 O.OOE+OO CS-135 1.02E+05 9.32E+04 2.18E+04 O.OOE+OO 3.55E+04 1.29E+04 1.63E+03 O.OOE+OO CS-136 2.98E+04 1.17E+05 7.87E+04 O.OOE+OO 6.38E+04 1.01 E+04 9.43E+03 O.OOE+OO CS-137 4.09E+05 5.44E+05 1.90E+05 O.OOE+OO 1.85E+05 7.20E+04 7.74E+03 O.OOE+OO CS-138 9.78E-12 1.88E-11 9.39E-12 O.OOE+OO 1.39E-11 1.61E-12 8.52E-15 O.OOE+OO CS-139 1.36E-44 2.01 E-44 7.37E-45 O.OOE+OO 1.62E-44 1.78E-45 9.33E-60 O.OOE+OO BA-139 6.17E-06 4.34E-09 1.80E-07 O.OOE+OO 4.09E-09 2.99E-09 5.50E-05 O.OOE+OO BA-140 1.97E+02 2.41E-01 1.27E+01 O.OOE+OO 8.17E-02 1.62E-01 3.03E+02 O.OOE+OO BA-141 9.20E-25 6.87E-28 3.07E-26 O.OOE+OO 6.38E-28 4.70E-28 1.96E-30 O.OOE+OO BA-142 6.71E-42 6.71E-45 4.13E-43 O.OOE+OO 5.68E-45 4.47E-45 2.06E-53 O.OOE+OO LA-140 1.05E-01 5.16E-02 1.37E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.97E+03 O.OOE+OO LA-141 3.05E-04 9.38E-05 1.55E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.66E+01 O.OOE+OO LA-142 2.34E-07 1.04E-07 2.58E-08 O.OOE+OO O.OOE+OO O.OOE+OO 3.16E-03 O.OOE+OO CE-141 2.38E-02 1.59E-02 1.82E-03 O.OOE+OO 7.47E-03 O.OOE+OO 4.54E+01 O.OOE+OO CE-143 2.59E-03 1.89E+OO 2.11E-04 O.OOE+OO 8.46E-04 O.OOE+OO 5.67E+01 O.OOE+OO CE-144 1.27E+OO 5.25E-01 6.81E-02 O.OOE+OO 3.13E-01 O.OOE+OO 3.19E+02 O.OOE+OO PR-143 5.68E-01 2.27E-01 2.83E-02 O.OOE+OO 1.32E-01 O.OOE+OO 1.87E+03 O.OOE+OO PR-144 1.61 E-28 6.60E-29 8.17E-30 O.OOE+OO 3.78E~29 O.OOE+OO 1.78E-31 O.OOE+OO ND-147 4.02E-01 4.37E-01 2.62E-02 O.OOE+OO 2.57E-01 O.OOE+OO 1.58E+03 O.OOE+OO PM-147 4.79E+OO 4.54E-01 1.85E-01 O.OOE+OO 8.67E-01 O.OOE+OO 4.32E+02 O.OOE+OO PM-148M 1.86E+OO 4.71E-01 3.69E-01 O.OOE+OO 7.14E-01 O.OOE+OO 2.97E+03 O.OOE+OO PM-148 4.09E-01 6.66E-02 3.36E-02 O.OOE+OO 1.20E-01 O.OOE+OO 3.97E+03 O.OOE+OO . PM-149 7.24E-02 1.02E-02 4.17E-03 O.OOE+OO 1.94E-02 O.OOE+OO 1.50E+03 O.OOE+OO PM-151 2.51 E-02 4.14E-03 2.10E-03 O.OOE+OO 7.45E-03 O.OOE+OO 9.30E+02 O.OOE+OO SM-151 3.99E+OO 7.67E-01 1.80E-01 O.OOE+OO 8.40E-01 O.OOE+OO 2.60E+02 O.OOE+OO SM-153 3.90E-02 3.23E-02 2.38E-03 O.OOE+OO 1.06E-02 O.OOE+OO 9.11 E+02 O.OOE+OO EU-152 1.12E+01 2.69E+OO 2.37E+OO O.OOE+OO 1.25E+01 O.OOE+OO 9.91 E+02 O.OOE+OO Rev.29 Page 160 of 329 12/2016
CY-LG-170-301 TABLE 111-13 TEEN FRESHWATER FISH Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN EU-154 3.61E+01 4.66E+OO 3.28E+OO O.OOE+OO 2.08E+01 O.OOE+OO 2.46E+03 O.OOE+OO EU-155 7.94E+OO 7.67E-01 4.75E-01 O.OOE+OO 3.00E+OO O.OOE+OO 4.40E+03 O.OOE+OO EU-156 8.38E-01 6.28E-01 1.03E-01 O.OOE+OO 4.23E-01 O.OOE+OO 3.21 E+03 O.OOE+OO TB-160 2.93E+OO O.OOE+OO 3.65E-01 O.OOE+OO 1.16E+OO O.OOE+OO 1.89E+03 O.OOE+OO H0-166M 1.63E+01 5.02E+OO 3.63E+OO O.OOE+OO 7.35E+OO O.OOE+OO 1.24E+03 O.OOE+OO W-181 3.09E+01 9.98E+OO 1.04E+OO O.OOE+OO O.OOE+OO O.OOE+OO 8.50E+02 O.OOE+OO W-185 1.26E+03 4.15E+02 4.39E+01 O.OOE+OO O.OOE+OO O.OOE+OO 3.58E+04 O.OOE+OO W-187 1.59E+02 1.30E+02 4.55E+01 O.OOE+OO O.OOE+OO O.OOE+OO 3.51 E+04 O.OOE+OO U-232 2.15E+04 O.OOE+OO 1.54E+03 O.OOE+OO 2.33E+03 O.OOE+OO 2.63E+02 O.OOE+OO U-233 4.53E+03 O.OOE+OO 2.75E+02 O.OOE+OO 1.06E+03 O.OOE+OO 2.43E+02 O.OOE+OO U-234 4.35E+03 O.OOE+OO 2.70E+02 O.OOE+OO 1.04E+03 O.OOE+OO 2.38E+02 O.OOE+OO U-235 4.16E+03 O.OOE+OO 2.54E+02 O.OOE+OO 9.75E+02 O.OOE+OO 3.02E+02 O.OOE+OO U-236 4.16E+03 O.OOE+OO 2.59E+02 O.OOE+OO 9.97E+02 O.OOE+OO 2.23E+02 O.OOE+OO U-237 2.60E-01 O.OOE+OO 6.92E-02 O.OOE+OO 1.07E+OO O.OOE+OO 6.89E+01 O.OOE+OO U-238 3.98E+03 O.OOE+OO 2.37E+02 O.OOE+OO 9.13E+02 O.OOE+OO 2.13E+02 O.OOE+OO NP-237 2.43E+04 1.74E+03 1.07E+03 O.OOE+OO 7.91 E+03 O.OOE+OO 1.54E+03 O.OOE+OO NP-238 2.57E-01 6.87E-03 4.00E-03 O.OOE+OO 2.36E-02 O.OOE+OO 5.04E+02 O.OOE+OO NP-239 2.39E-02 2.26E-03 1.25E-03 O.OOE+OO 7.09E-03 O.OOE+OO 3.63E+02 O.OOE+OO PU-238 4.28E+03 5.48E+02 1.16E+02 O.OOE+OO 4.99E+02 O.OOE+OO 4.94E+02 O.OOE+OO PU-239 4.89E+03 5.94E+02 1.28E+02 O.OOE+OO 5.48E+02 O.OOE+OO 4.51 E+02 O.OOE+OO PU-240 4.88E+03 5.93E+02 1.28E+02 O.OOE+OO 5.47E+02 O.OOE+OO 4.60E+02 O.OOE+OO PU-241 1.12E+02 5.37E+OO 2.36E+OO O.OOE+OO 1.09E+01 O.OOE+OO 9.46E+OO O.OOE+OO PU-242 4.53E+03 5.72E+02 1.24E+02 O.OOE+OO 5.27E+02 O.OOE+OO 4.42E+02 O.OOE+OO PU-244 5.29E+03 6.52E+02 1.42E+02 O.OOE+OO 6.04E+02 O.OOE+OO 6.58E+02 O.OOE+OO AM-241 3.64E+04 3.44E+04 2.63E+03 O.OOE+OO 1.97E+04 O.OOE+OO 3.59E+03 O.OOE+OO AM-242M 3.68E+04 3.25E+04 2.65E+03 O.OOE+OO 1.96E+04 O.OOE+OO 4.52E+03 O.OOE+OO AM-243 3.63E+04 3.36E+04 2.57E+03 O.OOE+OO 1.93E+04 O.OOE+OO 4.21 E+03 O.OOE+OO CM-242 1.34E+03 1.41 E+03 8.87E+01 O.OOE+OO 4.04E+02 O.OOE+OO 3.82E+03 O.OOE+OO CM-243 2.97E+04 2.75E+04 1.87E+03 O.OOE+OO 8.72E+03 O.OOE+OO 3.78E+03 O.OOE+OO CM~244 2.30E+04 2.18E+04 1.46E+03 O.OOE+OO 6.80E+03 O.OOE+OO 3.65E+03 O.OOE+OO CM-245 4.52E+04 3.98E+04 2.79E+03 O.OOE+OO 1.30E+04 O.OOE+OO 3.41 E+03 O.OOE+OO CM-246 4.48E+04 3.97E+04 2.78E+03 O.OOE+OO 1.30E+04 O.OOE+OO 3.35E+03 O.OOE+OO CM-247 4.37E+04 3.91 E+04 2.74E+03 O.OOE+OO 1.28E+04 O.OOE+OO 4.40E+03 O.OOE+OO CM-248 3.63E+05 3.22E+05 2.26E+04 O.OOE+OO 1.05E+05 O.OOE+OO 7.08E+04 O.OOE+OO CF-252 1.58E+04 O.OOE+OO 3.82E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.39E+04 O.OOE+OO Rev.29 Page 161 of 329 12/2016
CY-LG-170-301 TABLE 111-14 TEEN SHORELINE Air FACTORS
- mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.08E+04 2.34E+04 NA-24 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.14E+01 2.48E+01 P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 3.48E+04 SC-46 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1.49E+03 1. 72E+03 CR-51 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 8.35E+OO 9.87E+OO MN-54 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.48E+03 2.91 E+03 MN-56 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.62E+OO 1.91 E+OO FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 4.89E+02 4.89E+02 4.89E+02 4.89E+02 4.89E+02 4.89E+02 4.89E+02 5.75E+02 C0-57 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.38E+02 3.71E+02 C0-58 6.79E+02 6.79E+02 6.79E+02 6.79E+02 6.79E+02 6.79E+02 6.79E+02 7.95E+02 C0-60 4.32E+04 4.32E+04 4.32E+04 4.32E+04 4.32E+04 4.32E+04 4.32E+04 5.08E+04 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 5.32E-01 5.32E-01 5.32E-01 5.32E-01 5.32E-01 5.32E-01 5.32E-01 6.19E-01 CU-64 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.09E+OO 1.23E+OO ZN-65 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.34E+03 1.54E+03 ZN-69M 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.28E+OO 2.67E+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO o:ooE+oo O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 3.83E+01 3.83E+01 3.83E+01 3.83E+01 3.83E+01 3.83E+01 3.83E+01 4.43E+01 BR-83 8.73E-03 8.73E-03 8.73E-03 8.73E-03 8.73E-03 8.73E-03 8.73E-03 1.27E-02 BR-84 3.63E-01 3.63E-01 3.63E-01 3.63E-01 3.63E-01 3.63E-01 3.63E-01 4.24E-01 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.61 E+01 1.84E+01 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 5.93E-02 5.93E-02 5.93E-02 5.93E-02 5.93E-02 5.93E-02 5.93E-02 6.77E-02 RB-89 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.20E-01 2.64E-01 SR-89 3.88.E-02 3.88E-02 3.88E-02 3.88E-02 3.88E-02 3.88E-02 3.88E-02 4.50E-02 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 3.85E+OO 4.50E+OO SR-92 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.55E+OO Y-90 8.05E-03 8.05E-03 8.05E-03 8.05E-03 8.05E-03 8.05E-03 8.05E-03 9.51 E-03 Y-91 M 1.80E-01 1.80E-01 1.80E-01 1.80E-01 1.80E-01 1.80E-01 1.80E-01 2.08E-01 Rev.29 Page 162 of 329 12/2016
CY-LG-170-301 TABLE 111-14 TEEN SHORELINE A1T FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLk SKIN Y-91 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 1.92E+OO 2.16E+OO Y-92 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.23E-01 3.84E-01 Y-93 3.29E-01 3.29E-01 3.29E-01 3.29E-01 3.29E-01 3.29E-01 3.29E-01 4.50E-01 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 4.39E+02 4.39E+02 4.39E+02 4.39E+02 4.39E+02 4.39E+02 4.39E+02 5.09E+02 ZR-97 5.31E+OO 5.31E+OO 5.31 E+OO 5.31E+OO 5.31E+OO 5.31E+OO 5.31E+OO 6.17E+OO NB-93M 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 4.16E+OO 5.08E+02 NB-95 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.45E+02 2.88E+02 NB-97 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.16E-01 3.70E-01 M0-93 1.98E+02 1.98E+02 1.98E+02 1.98E+02 1.98E+02 1.98E+02 1.98E+02 8.06E+03 M0-99 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 7.16E+OO 8.29E+OO TC-99M 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.30E-01 3.78E-01 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 3.65E-02 3.65E-02 3.65E-02 3.65E-02 3.65E-02 3.65E-02 3.65E-02 4.05E-02 RU-103 1.94E+02
- 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 2.26E+02 RU-105 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.29E+OO RU-106 7.57E+02 7.57E+02 7.57E+02 7.57E+02 7.57E+02 7.57E+02 7.57E+02 9.08E+02 RH-105 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.33E+OO 1.55E+OO PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 2.69E-02 2.69E-02 2.69E-02 2.69E-02 2.69E-02 2.69E-02 2.69E-02 3.07E-02 AG-110M 6.16E+03 6.16E+03 6.16E+03 6.16E+03 6.16E+03 6.16E+03 6.16E+03 7.19E+03 AG-111 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 1.84E+OO 2.15E+OO CD-113M 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.28E+01 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.14E+04 SN-125 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 7.53E+OO 8.72E+OO SN-126 7.80E+04 7.80E+04 7.80E+04 7.80E+04 7.80E+04 7.80E+04 7.80E+04 8.67E+04 SB-124 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.07E+03 1.24E+03 SB-125 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.29E+03 4.84E+03 SB-126 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.70E+02 SB-127 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.01E+01 3.48E+01 TE-125M 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 2.78E+OO 3.81E+OO TE-127M 1.64E-01 1-64E-01 1.64E-01 I
1.64E-01 1.64E-01 1.64E-01 1.64E-01 1.94E-01 TE-127 5.34E-03 5.34E-03 5'.34E-03 5.34E-03 5.34E-03 5.34E-03 5.34E-03 5.87E-03 TE-129M 3.54E+01 3.54E+01 3.54E+01 3.54E+01 3.54E+01 3.54E+01 3.54E+01 4.14E+01 TE-129 4.70E+02 4.70E+02 4.70E+02 4.70E+02 4.70E+02 4.70E+02 4.70E+02 5.56E+02 TE-131M 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.44E+01 1.70E+01 TE-131 5.23E-02 5.23E-02 5.23E-02 5.23E-02 5.23E-02 5.23E-02 5.23E-02 6.18E+01 Rev.29 Page 163 of 329 12/2016
CY-LG-170-301 TABLE 111-14 TEEN SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 7.59E+OO 8.93E+OO TE-133M 7.91 E-01 7.91E-01 7.91 E-01 7.91 E-01 7.91E-01 7.91 E-01 7.91E-01 8.96E-01 TE-134 3.98E-02 3.98E-02 3.98E-02 3.98E-02 3.98E-02 3.98E-02 3.98E-02 4.77E-02 1-129 3.90E+03 3.90E+03 3.90E+03 3.90E+03 3.90E+03 3.90E+03 3.90E+03 6.50E+03 1-130 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 9.88E+OO 1.20E+01 1-131 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.08E+01 3.74E+01 1-132 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.23E+OO 2.63E+OO 1-133 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 4.39E+OO 5.34E+OO 1-134 8.01 E-01 8.01E-01 8.01 E-01 8.01 E-01 8.01 E-01 8.01E-01 8.01E-01 9.51 E-01 1-135 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 4.53E+OO 5.28E+OO CS-134M 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.03E-01 1.21 E-01 CS-134 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.24E+04 1.44E+04 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS~136 2.70E+02 2.70E+02 2.70E+02 2.70E+02 2.70E+02 2.70E+02 2.70E+02 3.06E+02 CS-137 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 .3.23E+04 CS-138 6.43E-01 6.43E-01 6.43E-01 6.43E-01 6.43E-01 6.43E-01 6.43E-01 7.35E-01 CS-139 5.63E-02 5.63E-02 5.63E-02 5.63E-02 5.63E-02 5.63E-02 5.63E-02 6.44E-02 BA-139 1.90E-01 1.90E-01 1.90E-01 1.90E-01 1.90E-01 1.90E-01 1.90E-01 2.13E-01 BA-140 3.68E+01 3.68E+01 3.68E+01 3.68E+01 3.68E+01 3.68E+01 3.68E+01 4.20E+01 BA-141 7.47E-02 7.47E-02 7.47E-02 7.47E-02 7.47E-02 7.47E-02 7.47E-02 8.52E-02 BA-142 8.04E-02 8.04E-02 8.04E-02 8.04E-02 8.04E-02 8.04E-02 8.04E-02 9.16E-02 LA-140 3.44E+01
- 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.44E+01 3.90E+01 LA-141 5.62E-02 5.62E-02 5.62E-02 5.62E-02 5.62E-02 5.62E-02 5.62E-02 6.30E-02 LA-142 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.36E+OO 1.63E+OO CE-141 2.45E+01 2.45E+01 2.45E+01 2.45E+01 2.45E+Q1 . 2.45E+01 2.45E+01 2.76E+01 CE-143 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.14E+OO 4.71E+OO CE-144 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.25E+02 1.44E+02 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.29E-03 3.78E-03 ND-147 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.50E+01 1.81E+01 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 7.98E+02 7.98E+02 7.98E+02 7.98E+02 7.98E+02 7.98E+02 7.98E+02 4.62E+03 PM-148 3.38E+01 3.38E+01 3.38E+01 3.38E+01 3.38E+01. 3.38E+01 3.38E+01 3.90E+01 PM-149 7.57E-02 7.57E-02 7.57E-02 7.57E-02 7.57E-02 7.57E-02 7.57E-02 8.79E-02 PM-151 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.57E+OO 3.73E+OO SM-151 3.79E+02 3.79E+02 3.79E+02 3.79E+02 3.79E+02 3.79E+02 3.79E+02 1.66E+03 SM-153 7.20E-01 7.20E-01 7.20E-01 7.20E-01 7.20E-01 7.20E-01 7.20E-01 8.00E-01 EU-152 3.61E+04 3.61E+04 3.61E+04 3.61E+04 3.61E+04 3.61E+04 3.61E+04 4.18E+04 Rev.29 Page 164 of 329 12/2016 l_____ - - - - - -
CY-LG-170-301 TABLE 111-14 TEEN SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN EU-154 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 2.96E+04 3.41E+04 EU-155 9.17E+02 9.17E+02 9.17E+02 9.17E+02 9.17E+02 9.17E+02 9.17E+02 1.04E+03 EU-156 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.58E+02 1.81 E+02 TB-160 8.52E+02 8.52E+02 8.52E+02 8.52E+02 8.52E+02 8.52E+02 8.52E+02 9.90E+02 H0-166M 7.66E+04 7.66E+04 7.66E+04 7.66E+04 7.66E+04 7.66E+04 7.66E+04 8.61 E+04 W-181 3.48E-01 3.48E-01 3.48E-01 3.48E-01 3.48E-01 3.48E-01 3.48E-01 4.64E-01 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.22E+OO 4.90E+OO U-232 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.00E+01 2.07E+02 U-233 1.99E+04 1.99E+04 1.99E+04 1.99E+04 1.99E+04 1.99E+04 1.99E+04 2.43E+04 U-234 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 5.48E+OO 1.38E+03 U-235 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 2.77E+04 3.47E+04 U-236 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.82E-01 1.56E+02 U-237 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 9.25E+OO 1.20E+01 U-238 9.54E+02 9.54E+02 9.54E+02 9.54E+02 9.54E+02 9.54E+02 9.54E+02 1.30E+03 NP-237 1.21 E+04 1.21 E+04 1.21 E+04 1.21 E+04 1.21 E+04 1.21 E+04 1.21 E+04 1.39E+04 NP-238 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 8.12E+OO 9.28E+OO NP-239 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.06E+OO 3.55E+OO PU-238 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.02E+01 1.42E+02 PU-239 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.85E+OO 6.67E+01 PU-240 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.13E+01 1.56E+02 PU-241 2.32E+01 2.32E+01 2.32E+01 2.32E+01 2.32E+01 2.32E+01 2.32E+01 3.43E+01 PU-242 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 9.54E+OO 1.39E+02 PU-244 7.76E+03 7.76E+03 7.76E+03 7.76E+03 7.76E+03 7.76E+03 7.76E+03 8.34E+03 AM-241 1.53E+03 1.53E+03 1.53E+03 1.53E+03 1.53E+03 1.53E+03 1.53E+03 2.21 E+03 AM-242M 2.13E+02 2.13E+02 2.13E+02 2.13E+02 2.13E+02 2.13E+02 2.13E+02 1.48E+03 AM-243 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.13E+04 1.30E+04 CM-242. 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 1.23E+OO 5.14E+OO CM-243 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.49E+04 1.88E+04 CM-244 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.62E+01 1.00E+02 CM-245 8.23E+03 8.23E+03 8.23E+03 8.23E+03 8.23E+03 8.23E+03 8.23E+03 1.04E+04 CM-246 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 8.65E+OO 1.30E+02 CM-247 1.91 E+04 1.91 E+04 1.91 E+04 1.91 E+04 1.91 E+04 1.91 E+04 1.91 E+04 2.25E+04 CM-248 4.53E+04 4.53E+04 4.53E+04 4.53E+04 4.53E+04 4.53E+04 4.53E+04 5.90E+04 CF-252 8.70E+04 8.70E+04 8.70E+04 8.70E+04 8.70E+04 8.70E+04 8.70E+04 9.49E+04 Rev.29 Page 165 of 329 12/2016
CY-LG-170-301 TABLE 111-15 CHILD DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 6.75E+OO 6.75E+OO 6.75E+OO 6.75E+OO 6.75E+OO 6.75E+OO O.OOE+OO C-14 7.04E+02 1.41E+02 1.41E+02 1.41E+02 1.41E+02 1.41E+02 1.41E+02 O.OOE+OO NA-22 3.42E+03 3.42E+03 3.42E+03 3.42E+03 3.42E+03 3.42E+03 3.42E+03 O.OOE+OO NA-24 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 O.OOE+OO P-32 4.69E+04 2.19E+03 1.81 E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.30E+03 O.OOE+OO CA-41 2.02E+04 O.OOE+OO 2.21 E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.11 E+01 O.OOE+OO SC-46 1.14E+OO 1.57E+OO 6.03E-01 O.OOE+OO 1.39E+OO O.OOE+OO 2.29E+03 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 5.12E-01 2.84E-01 7.76E-02 5.19E-01 2.71 E+01 O.OOE+OO MN-54 O.OOE+OO 6.22E+02 1.66E+02 O.OOE+OO 1.74E+02 O.dOE+OO 5.22E+02 O.OOE+OO MN-56 O.OOE+OO 7.72E-01 1.74E-01 O.OOE+OO 9.34E-01 O.OOE+OO 1.12E+02 O.OOE+OO FE-55 6.69E+02 3.55E+02 1.1 OE+02 O.OOE+OO O.OOE+OO 2.01 E+02 6.58E+01 O.OOE+OO FE-59 9.53E+02 1.54E+03 7.68E+02 O.OOE+OO O.OOE+OO 4.47E+02 1.61 E+03 O.OOE+OO C0-57 O.OOE+OO 2.87E+01 5.80E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.35E+02 O.OOE+OO C0-58 O.OOE+OO 1.04E+02 3.19E+02 O.OOE+OO O.OOE+OO O.OOE+OO 6.08E+02 O.OOE+OO C0-60 O.OOE+OO 3.08E+02 9.08E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.71E+03 O.OOE+OO Nl-59 2.34E+03 6.23E+02 3.97E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.13E+01 O.OOE+OO Nl-63 3.13E+04 1.68E+03 1.07E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.13E+02 O.OOE+OO Nl-65 4.76E+OO 4.48E-01 2.62E-01 O.OOE+OO O.OOE+OO O.OOE+OO 5.49E+01 O.OOE+OO CU-64 O.OOE+OO 7.41 E+OO 4.48E+OO O.OOE+OO 1.79E+01 O.OOE+OO 3.48E+02 O.OOE+OO ZN-65 7.96E+02 2.12E+03 1.32E+03 O.OOE+OO 1.34E+03 O.OOE+OO 3.73E+02 O.OOE+OO ZN-69M 2.26E+01 3.85E+01 4.55E+OO O.OOE+OO 2.24E+01 O.OOE+OO 1.25E+03 O.OOE+OO ZN-69 3.22E-04 4.66E-04 4.31E-05 O.OOE+OO 2.83E-04 O.OOE+OO 2.94E-02 O.OOE+OO SE-79 O.OOE+OO 4.91 E+02 1.09E+02 O.OOE+OO 7.98E+02 O.OOE+OO 3.22E+01 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 3.47E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.07E-01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1. 76E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.31 E-76 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 3.83E+03 2.35E+03 O.OOE+OO O.OOE+OO O.OOE+OO 2.46E+02 O.OOE+OO RB-87 O.OOE+OO 2.30E+03 1.07E+03 O.OOE+OO O.OOE+OO O.OOE+OO 3.45E+01 O.OOE+OO RB-88 O.OOE+OO 7.37E-12 5.12E-12 O.OOE+OO O.OOE+OO O.OOE+OO 3.61 E-13 O.OOE+OO RB-89 O.OOE+OO 6.25E-14 5.55E-14 O.OOE+OO O.OOE+OO O.OOE+OO 5.45E-16 O.OOE+OO SR-89 7.63E+04 O.OOE+OO 2.18E+03 O.OOE+OO O.OOE+OO O.OOE+OO 2.95E+03 O.OOE+OO SR-90 1.49E+06 O.OOE+OO 3.00E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.33E+04 O.OOE+OO SR-91 5.82E+02 O.OOE+OO 2.20E+01 O.OOE+OO O.OOE+OO O.OOE+OO 1.29E+03 O.OOE+OO SR-92 2.44E+01 O.OOE+OO 9.79E-01 O.OOE+OO O.OOE+OO O.OOE+OO 4.62E+02 O.OOE+OO Y-90 2.1 OE+OO O.OOE+OO 5.62E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.98E+03 O.OOE+OO Y-91M 9.71E-07 O.OOE+OO 3.53E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.90E-03 O.OOE+OO Rev.29 Page 166 of 329 12/2016
CY-LG-170-301 TABLE 111-15 CHILD DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 3.48E+01 O.OOE+OO 9.32E-01 O.OOE+OO O.OOE+OO O.OOE+OO 4.64E+03 O.OOE+OO Y-92 2.00E-02 O.OOE+OO 5.72E-04 O.OOE+OO O.OOE+OO O.OOE+OO 5.78E+02 O.OOE+OO Y-93 2.91E-01 O.OOE+OO 8.00E-03 O.OOE+OO O.OOE+OO O.OOE+OO 4.34E+03 O.OOE+OO ZR-93 9.72E+OO 3.64E-01 2.59E-01 O.OOE+OO 1.41 E+OO O.OOE+OO 1.38E+02 O.OOE+OO ZR-95 6.72E+OO 1.48E+OO 1.31 E+OO O.OOE+OO 2.11 E+OO O.OOE+OO 1.54E+03 O.OOE+OO ZR-97 2.49E-01 3.59E-02 2.12E-02 O.OOE+OO 5.16E-02 O.OOE+OO 5.45E+03 O.OOE+OO NB-93M 6.11 E+OO 1.53E+OO 5.01 E-01 O.OOE+OQ 1.65E+OO O.OOE+OO 2.30E+02 O.OOE+OO NB-95 1.30E+OO 5.05E-01 3.61E-01 O.OOE+OO 4.74E-01 O.OOE+OO 9.34E+02 O.OOE+OO NB-97 1.25E-05 2.25E-06 1.05E-06 O.OOE+OO 2.50E-06 O.OOE+OO 6.95E-01 O.OOE+OO M0-93 O.OOE+OO 1.40E+03 5.04E+01 O.OOE+OO 3.70E+02 O.OOE+OO 7.1 OE+01 O.OOE+OO M0-99 O.OOE+OO 6.83E+02 1.69E+02 O.OOE+OO 1.46E+03 O.OOE+OO 5.65E+02 O.OOE+OO TC-99M 1.35E-02 2.65E-02 4.39E-01 O.OOE+OO
- 3.85E-01 1.34E-02 1.51 E+01 O.OOE+OO TC-99 3.11E+01 3.47E+01 1.25E+01 O.OOE+OO 4.09E+02 3.07E+OO 3.64E+02 O.OOE+OO TC-101 3.40E-17 3.55E-17 4.51E-16 O.OOE+OO 6.06E-16 1.88E-17 1.13E-16 O.OOE+OO RU-103 4.22E+01 O.OOE+OO 1.62E+01 O.OOE+OO 1.06E+02 O.OOE+OO 1.09E+03 O.OOE+OO RU-105 5.77E-01 O.OOE+OO 2.09E-01 O.OOE+OO 5.07E+OO O.OOE+OO 3.76E+02 O.OOE+OO RU-106 6.81 E+02 O.OOE+OO 8.49E+01 O.OOE+OO 9.19E+02 O.OOE+OO 1.06E+04 O.OOE+OO RH-105 2.37E+01 1.27E+01 1.09E+01 O.OOE+OO 5.06E+01 O.OOE+OO 7.87E+02 O.OOE+OO PD-107 O.OOE+OO 2.75E+01 2.33E+OO O.OOE+OO 2.30E+02 O.OOE+OO 5.46E+01 O.OOE+OO PD-109 O.OOE+OO 1.78E+01 5.33E+OO O.OOE+OO 9.54E+01 O.OOE+OO 1.05E+03 O.OOE+OO AG-110M 3.13E+01 2.12E+01 1.69E+01 O.OOE+OO 3.94E+01 O.OOE+OO 2.52E+03 O.OOE+OO AG-111 1.38E+01 4.31 E+OO 2.85E+OO O.OOE+OO 1.30E+01 O.OOE+OO 2.64E+03 O.OOE+OO CD-113M O.OOE+OO 5.94E+02 2.53E+01 O.OOE+OO 6.11 E+02 O.OOE+OO 1.53E+03 O.OOE+OO CD-115M O.OOE+OO 3.40E+02 1.45E+01 O.OOE+OO 2.53E+02 O.OOE+OO 4.63E+03 O.OOE+OO SN-123 7.72E+03 9.58E+01 1.88E+02 1.02E+02 O.OOE+OO O.OOE+OO 3.79E+03 O.OOE+OO SN-125 1.99E+03 3.00E+01 8.93E+01 3.12E+01 O.OOE+OO O.OOE+OO 6.18E+03 O.OOE+OO SN-126 1.94E.+04 2.42E+02 5.51 E+02 6.64E+01 O.OOE+OO O.OOE+OO 1.46E+03 O.OOE+OO SB-124 6.43E+02 8.34E+OO 2.25E+02 1.42E+OO O.OOE+OO 3.57E+02 4.02E+03 O.OOE+OO SB-125 4.17E+02 3.21E+OO 8.73E+01 3.866-01 O.OOE+OO 2.32E+02 9.95E+02 O.OOE+OO SB-126 2.49E+02 3.81E+OO 8.95E+01 1.46E+OO O.OOE+OO 1.19E+02 5.02E+03 O.OOE+OO SB-127 5.64E+01 8.73E-01 1.96E+01 6.28E-01 O.OOE+OO 2.45E+01 3.18E+03 O.OOE+OO TE-125M 6.60E+02 1.79E+02 8.80E+01 1.85E+02 O.OOE+OO O.OOE+OO 6.37E+02 O.OOE+OO TE-127M 1.68E+03 4.52E+02 1.99E+02 4.01 E+02 4. 78E+03 O.OOE+OO 1.36E+03 O.OOE+OO TE-127 1.13E+01 3.04E+OO 2.42E+OO 7.80E+OO 3.20E+01 O.OOE+OO 4.40E+02 O.OOE+OO TE-129M 2.81E+03 7.84E+02 4.36E+02 9.05E+02 8.24E+03 O.OOE+OO 3.42E+03 O.OOE+OO TE-129 6.00E-03 1.67E-03 1.42E-03 4.28E-03 1.75E-02 O.OOE+OO 3.73E-01 O.OOE+OO TE-131M 3.18E+02 1.10E+02 1.17E+02 2.26E+02 1.06E+03 O.OOE+OO 4.46E+03 O.OOE+OO TE-131 1.03E-08 3.15E-09 3.08E-09 7.91E-09 3.13E-08 O.OOE+OO 5.43E-08 O.OOE+OO Rev.29 Page 167 of 329 12/2016
CY-LG-170-301 TABLE 111-15 CHILD DRINKING WATER A1T FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 5.29E+02 2.34E+02 2.83E+02 3.41E+02 2.17E+03 O.OOE+OO 2.36E+03 O.OOE+OO
- TE-133M 1.33E-03 5.39E-04 6.68E-04 1.03E-03 5.12E-03 O.OOE+OO 4.11 E-02 O.OOE+OO TE-134 4.90E-05 2.20E-05 2.94E-05 3.88E-05 2.04E-04 O.OOE+OO 2.24E-04 O.OOE+OO 1-129 8.09E+02 4.97E+02 4.44E+02 3.25E+05 8.38E+02 O.OOE+OO 2.50E+01 O.OOE+OO 1-130 8.67E+01 1.75E+02 9.03E+01 1.93E+04 2.62E+02 O.OOE+OO 8.20E+01 O.OOE+OO 1-131 9.59E+02 9.65E+02 5.48E+02 3.19E+05 1.58E+03 O.OOE+OO 8.59E+01 O.OOE+OO 1-132 1.25E+OO 2.30E+OO 1.06E+OO 1.07E+02 3.52E+OO O.OOE+OO 2. 71 E+OO O.OOE+OO 1-133 2.31 E+02 2.86E+02 1.08E+02 5.31 E+04 4.76E+02 O.OOE+OO 1.15E+02 O.OOE+OO 1-134 1.85E-03 3.43E-03 1.58E-03 '7.90E-02 5.25E-03 O.OOE+OO 2.28E-03 O.OOE+OO 1-135 2.89E+01 5.21E+01 2.46E+01 4.61E+03 7.99E+01 O.OOE+OO
- 3.97E+01 O.OOE+OO CS-134M 2.79E-01 4.13E-01 2.70E-01 O.OOE+OO 2.18E-01 3.60E-02 5.22E-01 O.OOE+OO CS-134 1.36E+04 2.23E+04 4.71 E+03 O.OOE+OO 6.92E+03 2.48E+03 1.20E+02 O.OOE+OO
- CS-135 4.83E+03 3.37E+03 3.45E+02 O.OOE+OO 1.19E+03 3.96E+02 2.52E+01 O.OOE+OO CS-136 1.33E+03 3.66E+03 2.37E+03 O.OOE+OO 1.95E+03 2.91 E+02 1.29E+02 O.OOE+OO CS-137 1.90E+04 1.82E+04 2.69E+03 O.OOE+OO 5.94E+03 2.14E+03 1.14E+02 O.OOE+OO CS-138 2.47E-06 3.43E-06 2.17E-06 O.OOE+OO 2.41E-06 2.60E-07 1.58E-06 O.OOE+OO CS-139 7.39E-23 8.21E-23 3.95E-23 O.OOE+OO 6.17E-23 6.22E-24 7,39E-27 O.OOE+OO BA-139 5.94E-02 3.17E-05 1.72E-03 O.OOE+OO 2.77E-05 1.87E-05 3.43E+OO O.OOE+OO BA-140 4.71E+03 4.13E+OO 2.75E+02 O.OOE+OO 1.34E+OO 2.46E+OO 2.39E+03 O.OOE+OO BA-141 1.60E-11 8.93E-15 5.19E-13 O.OOE+OO 7.73E-15 5.25E-14 9.09E-12 O.OOE+OO BA-142 2.82E-20 2.03E-23 1.57E-21 O.OOE+OO 1.64E-23 1.19E-23 3.68E-22 O.OOE+OO LA-140 4.78E-01 1.67E-01 5.63E-02 O.OOE+OO O.OOE+OO O.OOE+OO 4.66E+03 O.OOE+OO LA-141 9.59E-03 2.24E-03 4.85E-04 O.OOE+OO O.OOE+OO O.OOE+OO 4.97E+02 O.OOE+OO LA-142 1.63E-04 5.20E-05 1.63E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.03E+01 O.OOE+OO CE-141 2.29E+OO 1.14E+OO 1.69E-01
- O.OOE+OO 5.00E-01 O.OOE+OO 1.42E+03 O.OOE+OO CE-143 3.16E-01 1.71 E+02 2.48E-02 O.OOE+OO 7.19E-02 O.OOE+OO 2.51 E+03 O.OOE+OO CE-144 1.21E+02 3.79E+01 6.45E+OO O.OOE+OO 2.10E+01 O.OOE+OO 9.89E+03 O.OOE+OO PR-143 2.23E+OO 6.70E-01 1.11 E-01 O.OOE+OO 3.63E-01 O.OOE+OO 2.41 E+03 O.OOE+OO PR-144 2.15E-15 6.65E-16 1.08E-16 O.OOE+OO 3.52E-16 O.OOE+OO 1.43E-12 O.OOE+OO ND-147 1.57E+OO 1.27E+OO 9.87E-02 O.OOE+OO 6.99E-01 O.OOE+OO 2.02E+03 O.OOE+OO PM-147 1.85E+01 1.32E+OO 7.10E-01 O.OOE+OO 2.33E+OO O.OOE+OO 5.35E+02 O.OOE+OO PM-148M 5.95E+OO 1.18E+OO 1.18E+OO O.OOE+OO 1.76E+OO O.OOE+OO 3.34E+03 O.OOE+OO PM-148 1.65E+OO 1.98E-01 1.28E-01 O.OOE+OO 3.37E-01 O.OOE+OO 5.29E+03 O.OOE+OO PM-149 3.23E-01 3.43E-02 1.86E-02 O.OOE+OO 6.07E-02 O.OOE+OO 2.34E+03 O.OOE+OO PM-151 1.27E-01 1.54E-02 1.00E-02 O.OOE+OO 2.61 E-02 O.OOE+OO 1.75E+03 O.OOE+OO SM-151 1.49E+01 2.22E+OO 6.99E-01 O.OOE+OO 2.29E+OO O.OOE+OO 3.22E+02 O.OOE+OO SM-153 1.78E-01 1.11E-01 1.07E-02 O.OOE+OO 3.37E-02 O.OOE+OO 1.47E+03 O.OOE+OO EU-152 3.58E+01 6.52E+OO 7.74E+OO O.OOE+OO 2.75E+01 O.OOE+OO 1.07E+03 O.OOE+OO Rev.29 Page 168 of 329 12/2016
CY-LG-170-301 TABLE 111-15 CHILD DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 1.34E+02 1.21 E+01 1.10E+01 O.OOE+OO 5.29E+01 O.OOE+OO 2.80E+03 O.OOE+OO EU-155 2.81 E+01 2.02E+OQ 1.58E+OO O.OOE+OO 7.57E+OO O.OOE+OO 5.06E+03 O.OOE+OO EU-156 3.20E+OO 1. 71 E+OO 3.55E-01 O.OOE+OO 1.1 OE+OO O.OOE+OO 3.89E+03 O.OOE+OO TB-160 9.62E+OO O.OOE+OO 1.19E+OO O.OOE+OO 2.86E+OO O.OOE+OO 2.13E+03 O.OOE+OO H0-166M 6.29E+01 1.32E+01 1.11E+01 O.OOE+OO 1.87E+01 O.OOE+OO 1.53E+03 O.OOE+OO W-181 2.46E+OO 6.04E-01 8.30E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.20E+01 O.OOE+OO W-185 1.00E+02 2.50E+01 3.51 E+OO O.OOE+OO O.OOE+OO O.OOE+OO 9.33E+02 O.OOE+OO W-187 1.76E+01 1.04E+01 4.68E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.47E+03 O.OOE+OO U-232 1.02E+06 O.OOE+OO 7.34E+04 O.OOE+OO 7.80E+04 O.OOE+OO 4.06E+03 O.OOE+OO U-233 2.17E+05 O.OOE+OO 1.31E+04 O.OOE+OO 3.55E+04 O.OOE+OO 3.76E+03 O.OOE+OO U-234 2.08E+05 O.OOE+OO 1.29E+04 O.OOE+OO 3.48E+04 O.OOE+OO 3.68E+03 O.OOE+OO U-235 1.99E+05 O.OOE+OO 1.21E+04 O.OOE+OO 3.27E+04 O.OOE+OO 4.68E+03 O.OOE+OO U-236 1.99E+05 O.OOE+OO 1.23E+04 O.OOE+OO 3.34E+04 O.OOE+OO 3.45E+03 O.OOE+OO U-237 1.31 E+01 O.OOE+OO 3.47E+OO O.OOE+OO 3.77E+01 O.OOE+OO 1.15E+03 O.OOE+OO U-238 1.90E+05 O.OOE+OO 1.13E+04 O.OOE+OO 3.05E+04 O.OOE+OO 3.30E+03 O.OOE+OO NP-237 1.30E+05 8.56E+03 5.70E+03 O.OOE+OO 3.52E+04 O.OOE+OO 4.75E+03 O.OOE+OO NP-238 2.88E+OO 5.83E-02 4.49E-02 O.OOE+OO 1.86E-01 O.OOE+OO 2.00E+03 O.OOE+OO NP-239 2.64E-01 1.89E-02 1.33E-02 O.OOE+OO 5.48E-02 O.OOE+OO 1.40E+03 O.OOE+OO PU-238 6.93E+04 8.03E+03 1.84E+03 O.OOE+OO 6.70E+03 O.OOE+OO 4.37E+03 O.OOE+OO PU-239 7.51E+04 8.03E+03 1.93E+03 O.OOE+OO 7.10E+03 O.OOE+OO 3.99E+03 O.OOE+OO PU-240 7.45E+04 8.33E+03 1.93E+03 O.OOE+OO 7.1 OE+03 O.OOE+OO 4.06E+03 O.OOE+OO* PU-241 2.25E+03 9.20E+01 4.68E+01 O.OOE+OO 1.72E+02 O.OOE+OO 8.38E+01 O.OOE+OO PU-242 6.93E+04 8.03E+03 1.86E+03 O.OOE+OO 6.81 E+03 O.OOE+OO 3.91 E+03 O.OOE+OO PU-244 8.09E+04 9.20E+04 2.13E+03 O.OOE+OO 7.86E+03 O.OOE+OO 5.82E+03 O.OOE+OO AM-241 7.92E+04 6.81 E+04 5.94E+03 O.OOE+OO 3.63E+04 O.OOE+OO 4.45E+03 O.OOE+OO AM-242M 8.15E+04 6.52E+04 6.05E+03 O.OOE+OO 3.67E+04 O.OOE+OO 5.59E+03 O.OOE+OO AM-243 7.80E+04 6.58E+04 5.72E+03 O.OOE+OO 3.53E+04 O.OOE+OO 5.21 E+03 O.OOE+OO CM-242 5.10E+03 4.07E+03 3.39E+02 O.OOE+OO 1.09E+03 O.OOE+OO 4.74E+03 O.OOE+OO CM-243 7.45E+04 6.05E+04 4.80E+03 O.OOE+OO 1.79E+04 O.OOE+OO 4.67E+03 O.OOE+OO CM-244 6.29E+04 5.09E+04 4.03E+03 O.OOE+OO 1.48E+04 O.OOE+OO 4.52E+03 O.OOE+OO CM-245 9.72E+04 7.80E+04 6.11E+03 O.OOE+OO 2.39E+04 O.OOE+OO 4.22E+03 O.OOE+OO CM-246 9.61 E+04 7.80E+04 6.11 E+03 O.OOE+OO 2.39E+04 O.OOE+OO 4.14E+03 O.OOE+OO CM-247 9.37E+04 7.68E+04 6.00E+03 O.OOE+OO 2.35E+04 O.OOE+OO 5.44E+03 O.OOE+OO CM-248 7.80E+05 6.35E+05 4.96E+04 O.OOE+OO 1.94E+05 O.OOE+OO 8.79E+04 O.OOE+OO CF-252 6.11 E+04 O.OOE+OO 1.48E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+04 O.OOE+OO Rev.29 Page 169 of 329 12/2016
CY-LG-170-301 TABLE 111-16 CHILD FRESHWATER FISH A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 8.22E-02 8.22E-02 8.22E-02 8.22E-02 8.22E-02 8.22E-02 O.OOE+OO C-14 4.38E+04 8.77E+03 8.77E+03 8.77E+03 8.77E+03 8.77E+03 8.77E+03 O.OOE+OO NA-22 4.63E+03 4.63E+03 4.63E+03 4.63E+03 4.63E+03 4.63E+03 4.63E+03 O.OOE+OO NA-24 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 1.51E+02 O.OOE+OO P-32 1.86E+06 8.69E+04 7.16E+04 O.OOE+OO O.OOE+OO O.OOE+OO 5.13E+04 O.OOE+OO CA-41 1.09E+04 O.OOE+OO 1.19E+03 O.OOE+OO O.OOE+OO O.OOE+OO 5.99E+OO O.OOE+OO SC-46 3.08E-02 4.22E-02 1.62E~02 O.OOE+OO 3.73E-02 O.OOE+OO 6.17E+01 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.37E+OO 7.59E-01 2.07E-01 1.39E+OO 7.25E+01 O.OOE+OO MN-54 O.OOE+OO 3.36E+03 8.96E+02 O.OOE+OO 9.43E+02 O.OOE+OO 2.82E+03 O.OOE+OO MN-56 O.OOE+OO 1.66E-01 3.75E-02 O.OOE+OO 2.01 E-01 O.OOE+OO 2.41 E+01 O.OOE+OO FE-55 9.05E+02 4.80E+02 1.49E+02 O.OOE+OO O.OOE+OO 2.72E+02 8.89E+01 O.OOE+OO FE-59 1.28E+03 2.07E+03 1.03E+03 O.OOE+OO O.OOE+OO 6.00E+02 2.16E+03 O.OOE+OO C0-57 O.OOE+OO 1.94E+01 3.92E+01 O.OOE+OO O.OOE+OO O.OOE+OO 1.59E+02 O.OOE+OO C0-58 O.OOE+OO 7.02E+01 2.15E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.09E+02 O.OOE+OO C0-60 O.OOE+OO 2.08E+02 6.14E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.15E+03 O.OOE+OO Nl-59 3.17E+03 8.43E+02 5.37E+02 O.OOE+OO O.OOE+OO O.OOE+OO 5.59E+01 O.OOE+OO Nl-63 4.24E+04 2.27E+03 1.44E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.53E+02 O.OOE+OO Nl-65 2.38E-01 2.24E-02 1.31 E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.74E+OO O.OOE+OO CU-64 O.OOE+OO 2.60E+OO 1.57E+OO O.OOE+OO 6.29E+OO O.OOE+OO . 1,22E+02 O.OOE+OO ZN-65 2.15E+04 5. 73E+04 3.57E+04 O.OOE+OO 3.61 E+04 O.OOE+OO 1.01E+04 O.OOE+OO ZN-69M 3.34E+02 5.69E+02 6.72E+01 O.OOE+OO 3.30E+02 O.OOE+OO 1.85E+04 O.OOE+OO ZN-69 1.1 OE-06 1.59E-06 1.47E-07 O.OOE+OO 9.67E-07 O.OOE+OO 1.00E-04 O.OOE+OO SE-79 O.OOE+OO 1.13E+03 2.50E+02 O.OOE+OO 1.83E+03 O.OOE+OO 7.40E+01 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.56E+03 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 5.37E-02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.53E-12 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.84E-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.02E+05 6.25E+04 O.OOE+OO O.OOE+OO O.OOE+OO 6.54E+03 O.OOE+OO RB-87 O.OOE+OO 6.22E+04 2.88E+04 O.OOE+OO O.OOE+OO O.OOE+OO 9.33E+02 O.OOE+OO RB-88 O.OOE+OO 1.33E-22 9.22E-23 O.OOE+OO O.OOE+OO O.OOE+OO 6.51 E-24 O.OOE+OO RB-89 O.OOE+OO 1.55E-26 1.38E-26 O.OOE+OO O.OOE+OO O.OOE+OO 1.35E-28 O.OOE+OO SR-89 3.08E+04 O.OOE+OO 8.79E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.19E+03 O.OOE+OO SR-90 6.05E+05 O.OOE+OO 1.22E+04 O.OOE+OO O.OOE+OO O.OOE+OO 5.41 E+03 O.OOE+OO SR-91 9.84E+01 O.OOE+OO 3.72E+OO O.OOE+OO O.OOE+OO O.OOE+OO 2.17E+02 O.OOE+OO SR-92 4.60E-01 O.OOE+OO 1.85E-02 O.OOE+OO O.OOE+OO O.OOE+OO 8.72E+OO O.OOE+OO Y-90 6.24E-01 O.OOE+OO 1.67E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.78E+03 O.OOE+OO Y-91M 1.43E-11 O.OOE+OO 5.21E-13 O.OOE+OO O.OOE+OO O.OOE+OO 2.81 E-08 O.OOE+OO Rev.29 Page 170 of 329 12/2016
CY-LG-170-301 TABLE 111-16 CHILD.FRESHWATER FISH A1rFACTORS mrem-ml per uCi-h~ NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 1.17E+01 O.OOE+OO 3.13E-01 O.OOE+OO O.OOE+OO O.OOE+OO 1.56E+03 O.OOE+OO Y-92 6.45E-04 O.OOE+OO 1.85E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.86E+01 O.OOE+OO Y-93 4.32E-02 O.OOE+OO 1.19E-03 O.OOE+OO O.OOE+OO O.OOE+OO 6.45E+02 O.OOE+OO ZR-93 4.34E-01 1.62E-02 1.16E-02 O.OOE+OO 6.29E-02 O.OOE+OO 6.16E+OO O.OOE+OO ZR-95 2.98E-01 6.56E-02 5.84E-02 O.OOE+OO 9.39E-02 O.OOE+OO 6.84E+01 O.OOE+OO ZR-97 6.79E-03 9.81E-04 5.79E-04 O.OOE+OO 1.41E-03 O.OOE+OO 1.49E+02 O.OOE+OO NB~93M 2.48E+03 6.19E+02 2.03E+02 O.OOE+OO 6.69E+02 O.OOE+OO 9.33E+04 O.OOE+OO NB-95 5.21 E+02 2.03E+02 1.45E+02 O.OOE+OO 1.91 E+02 O.OOE+OO 3.75E+05 O.OOE+OO NB-97 4.99E-06 9.01 E-07 4.20E-07 O.OOE+OO 9.99E-07 O.OOE+OO 2.78E-01 O.OOE+OO M0-93 O.OOE+OO 1.90E+02 6.81E+OO O.OOE+OO 5.00E+01 O.OOE+OO 9.61 E+OO O.OOE+OO M0-99 O.OOE+OO 8.14E+01 2.01E+01 O.OOE+OO 1.74E+02 O.OOE+OO 6.73E+01 O.OOE+OO TC-99M 6.BBE-04 1.35E-03 2.24E-02 O.OOE+OO 1.96E-02 . 6.85E-04 7.68E-01 O.OOE+OO TC-99 6.32E+OO 7.04E+OO 2.53E+OO O.OOE+OO 8.29E+01 6.23E-01 7.38E+01 O.OOE+OO TC-101 3.76E-33 3.93E-33 4.99E-32 O.OOE+OO 6.71 E-32 2.0BE-33 1.25E-32 O.OOE+OO RU~103 5.66E+OO O.OOE+OO 2.17E+OO O.OOE+OO 1.42E+01 O.OOE+OO 1.46E+02
- O.OOE+OO RU-105 1.20E-02 O.OOE+OO 4.35E-03 O.OOE+OO 1.05E-01 O.OOE+OO 7.82E+OO O.OOE+OO RU-106 9.20E+01 O.OOE+OO 1.15E+01 O.OOE+OO 1.24E+02 O.OOE+OO 1.43E+03 O.OOE+OO RH-105 2.53E+OO 1.36E+OO 1.16E+OO O.OOE+OO 5.41 E+OO O.OOE+OO 8.41 E+01 O.OOE+OO PD-107 O.OOE+OO 3.72E+OO 3.16E-01 O.OOE+OO 3.11 E+01 O.OOE+OO 7.38E+OO O.OOE+OO PD-109 O.OOE+OO 1.30E+OO 3.89E-01 O.OOE+OO 6.95E+OO O.OOE+OO 7.66E+01 O.OOE+OO AG-110M 9.74E-01 6.58E-01 5.26E-01 O.OOE+OO 1.22E+OO O.OOE+OO 7.82E+01 O.OOE+OO AG-111 4.09E-01 1.28E-01 8.45E-02 O.OOE+OO 3.86E-01 O.OOE+OO 7.84E+01 O.OOE+OO CD-113M O.OOE+OO 1.61 E+03 6.84E+01 O.OOE+OO 1.65E+03 O.OOE+OO 4.14E+03 O.OOE+OO CD-115M O.OOE+OO 9.14E+02 3.89E+01 O.OOE+OO 6.79E+02 O.OOE+OO 1.24E+04 O.OOE+OO SN-123 3.13E+05 3.88E+03 7.62E+03 4.11 E+03 O.OOE+OO O.OOE+OO 1.53E+05 O.OOE+OO SN-125 7.81E+04 1.18E+03 3.50E+03 1.22E+03 O.OOE+OO O.OOE+OO 2.42E+05 O.OOE+OO SN-126 7.87E+05 9.81 E+03 2.24E+04 2.69E+03 O.OOE+OO O.OOE+OO 5.91 E+04 O.OOE+OO SB-124 8.64E+OO 1.12E-01 3.03E+OO 1.91 E-02 O.OOE+OO 4.BOE+OO 5.40E+01 O.OOE+OO SB-125 5.64E+OO 4.34E-02 1.18E+OO 5.22E-03 O.OOE+OO 3.14E+OO 1.35E+01 O.OOE+OO SB-126 3.28E+OO 5.01E-02 1.18E+OO 1.92E-02 O.OOE+OO 1.56E+OO 6.61 E+01 O.OOE+OO SB-127 6.97E-01 1.0BE-02 2.42E-01 7.76E-03 O.OOE+OO 3.03E-01 3.93E+01 O.OOE+OO TE-125M 3.55E+03 9.62E+02 4.73E+02 9.96E+02 O.OOE+OO O.OOE+OO 3.42E+03 O.OOE+OO TE-127M 9.05E+03 2.44E+03 1.07E+03 2.16E+03 2.58E+04 O.OOE+OO 7.33E+03 O.OOE+OO TE-127 2.50E+01 6.75E+OO 5.37E+OO 1.73E+01 7.13E+01 O.OOE+OO 9.78E+02 O.OOE+OO TE-129M 1.50E+04 4.20E+03 2.33E+03 4.85E+03 4.41 E+04 O.OOE+OO 1.83E+04 O.OOE+OO TE-129 2.50E-05 6.97E-06 5.92E-06 1.78E-05 7.30E-05 O.OOE+OO 1.55E-03 O.OOE+OO TE-131M 1.30E+03 4.51 E+02 4.80E+02 9.27E+02 4.36E+03 O.OOE+OO 1.83E+04 O.OOE+OO TE-131 1.20E-16 3.65E-17 3.56E-17 9.16E-17 3.62E-16 O.OOE+OO 6.29E-16 O.OOE+OO Rev.29 Page 171 of 329 12/2016
CY-LG-170-301 TABLE 111-16 CHILD FRESHWATER FISH A1rFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 2.57E+03 1.14E+03 1.38E+03 1.66E+03 1.06E+04 O.OOE+OO 1.15E+04 O.OOE+OO TE-133M 8.82E-07 3.57E-07 4.42E-07 6.84E-07 3.39E-06 O.OOE+OO 2.72E-05 O.OOE+OO TE-134 1.73E-09 7.79E-10 1.04E-09 1.37E-09 7.21 E-09 O.OOE+OO 7.91 E-09 O.OOE+OO 1-129 1.64E+02 1.01 E+02 9.00E+01 6.59E+04 1.70E+02 O.OOE+OO 5.07E+OO O.OOE+OO 1-130 8.98E+OO 1.81E+01 9.35E+OO 2.00Ef.03 2.71 E+01 O.OOE+OO 8.49E+OO O.OOE+OO 1-131 1.86E+02 1.88E+02 1.07E+02 6.20E+04 3.08E+02 O.OOE+OO 1.67E+01 O.OOE+OO 1-132 6.83E-03 1.25E-02 5.77E-03 5.82E-01 1.92E-02 O.OOE+OO 1.48E-02 O.OOE+OO 1-133 3.14E+01 3.89E+01 1.47E+01 7.22E+03 6.48E+01 O.OOE+OO 1.57E+01 O.OOE+OO 1-134 2.84E-08 5.28E-08 2.43E-08 1.21 E-06 8.07E-08 O.OOE+OO 3.50E-08 O.OOE+OO 1-135 1.67E+OO 3.00E+OO 1.42E+OO 2.66E+02 4.61 E+OO O.OOE+OO 2.29E+OO O.OOE+OO CS-134M 4.29E-01 6.35E-01 4.15E-01 O.OOE+OO 3.35E-01 5.54E-02 8.03E-01 O.OOE+OO CS-134 3.68E+05 6.04E+05 1.27E+05 O.OOE+OO 1.87E+05 6.72E+04 3.26E+03 O.OOE+OO CS-135 1.31E+05 9.11E+04 9.34E+03 O.OOE+OO 3.21 E+04 1.07E+04 6.82E+02 O.OOE+OO CS-136 3.51 E+04 9.65E+04 6.25E+04 O.OOE+OO 5.14E+04 7.67E+03 3.39E+03 O.OOE+OO CS-137 5.15E+05 4.93E+05 7.28E+04 O.OOE+OO 1.61 E+05 5.78E+04 3.09E+03 O.OOE+OO CS-138 1.24E-11 1.72E-11 1.09E-11 O.OOE+OO 1.21E-11 1.30E-12 7.93E-12 O.OOE+OO CS-139 1.75E-44 1.95E-44 9.35E-45 O.OOE+OO 1.46E-44 1.47E-45 1.75E-48 O.OOE+OO BA-139 7.93E-06 4.23E-09 2.30E-07 O.OOE+OO 3.69E-09 2.49E-09 4.58E-04 O.OOE+OO BA-140 2.48E+02 2.17E-01 1.45E+01 O.OOE+OO 7.07E-02 1.30E-01 1.26E+02 O.OOE+OO BA-141 1.18E-24 6.62E-28 3.85E-26 O.OOE+OO 5.73E-28 3.89E-27 6.74E-25 O.OOE+OO BA-142 8.46E-42 6.09E-45 4.72E-43 O.OOE+OO 4.93E-45 3.58E-45 1.10E-43 O.OOE+OO LA-140 1.32E-01 4.60E-02 1.55E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.28E+03 O.OOE+oo LA-141 3.93E-04 9.16E-05 1.99E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.04E+01 O.OOE+OO LA-142 2.95E-07 9.40E-08 2.94E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.86E-02 O.OOE+OO CE-141 3.06E-02 1.53E-02 2.27E-03 O.OOE+OO 6.69E-03 O.OOE+OO 1.90E+01 O.OOE+OO CE-143 3.33E-03 1.80E+OO 2.61E-04 O.OOE+OO 7.57E-04 O.OOE+OO 2.64E+01 O.OOE+OO CE-144 1.63E+OO 5.12E-01 8.72E-02 O.OOE+OO 2.84E-01 O.OOE+OO 1.34E+02 O.OOE+OO PR-143 7.35E-01 2.21 E-01 3.65E-02 O.OOE+OO 1.20E-01 O.OOE+OO 7.93E+02 O.OOE+OO PR-144 2.08E-28 6.45E-29 1.05E-29 O.OOE+OO 3.41 E-29 O.OOE+OO 1.39E-25 O.OOE+OO ND-147 5.16E-01 4.18E-01 3.24E-02 O.OOE+OO 2.29E-01 O.OOE+OO 6.62E+02 O.OOE+OO PM-147 6.26E+OO 4.47E-01 2.40E-01 O.OOE+OO 7.89E-01 O.OOE+OO 1.81E+02 O.OOE+OO PM-148M 1.99E+OO 3.97E-01 3.97E-01 O.OOE+OO 5.89E-01 O.OOE+OO 1.12E+03 O.OOE+OO PM-148 5.23E-01 6.28E-02 4.07E-02 O.OOE+OO 1.07E-01 O.OOE+OO 1.68E+03 O.OOE+OO PM-149 9.34E-02 9.93E-03 5.38E-03 O.OOE+OO 1.76E-02 O.OOE+OO 6.78E+02 O.OOE+OO PM-151 3.20E-02 3.89E-03 2.53E-03 O.OOE+OO 6.90E-03 O.OOE+OO 4.42E+02 O.OOE+OO SM-151 5.04E+OO 7.50E-01 2.36E-01 O.OOE+OO 7.76E-01 O.OOE+OO 1.09E+02 O.OOE+OO SM-153 5.03E-02 3.13E-02 3.02E-03 O.OOE+OO 9.53E-03 O.OOE+OO 4.16E+02 O.OOE+OO EU-152. 1.21E+01 2.21E+OO 2.62E+OO O.OOE+OO 9.31 E+OO O.OOE+OO 3.62E+02 O.OOE+OO Rev.29 Page 172 of 329 12/2016
CY-LG-170-301 TABLE 111-16 CHILD FRESHWATER FISH A1rFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 4.53E+01 4.08E+OO 3.72E+OO O.OOE+OO 1.79E+01 O.OOE+OO 9.47E+02 O.OOE+OO EU-155 9.49E+OO 6.83E-01 5.35E-01 O.OOE+OO 2.56E+OO O.OOE+OO 1.71E+03 O.OOE+OO EU-156 1.06E+OO 5.66E-01 1.17E-01 O.OOE+OO 3.65E-01 O.OOE+OO 1.28E+03 O.OOE+OO TB-160 3.24E+OO O.OOE+OO 4.02E-01 O.OOE+OO 9.63E-01 O.OOE+OO 7.18E+02 O.OOE+OO H0-166M 2.13E+01 4.45E+OO 3.76E+OO O.OOE+OO 6.34E+OO O.OOE+OO 5.18E+02 O.OOE+OO W-181 3.98E+01 9.77E+OO 1.34E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.56E+02 O.OOE+OO W-185 1.62E+03 4.05E+02 5.67E+01 O.OOE+OO O.OOE+OO O.OOE+OO 1.51 E+04 O.OOE+OO W-187 2.02E+02 1.19E+02 5.36E+01 O.OOE+OO O.OOE+OO O.OOE+OO 1.68E+04 O.OOE+OO U-232 2.77E+04 O.OOE+OO 1.98E+03 O.OOE+OO 2.11 E+03 O.OOE+OO 1.1 OE+02 O.OOE+OO U-233 5.86E+03 O.OOE+OO 3.54E+02 O.OOE+OO 9.61 E+02 O.OOE+OO 1.02E+02 O.OOE+OO U-234 5.62E+03 O.OOE+OO 3.48E+02 O.OOE+OO 9.42E+02 O.OOE+OO 9.96E+01 O.OOE+OO U-235 5.39E+03 O.OOE+OO 3.26E+02 O.OOE+OO 8.84E+02 O.OOE+OO 1.27E+02 O.OOE+OO U-236 5.39E+03 O.OOE+OO 3.34E+02 O.OOE+OO 9.03E+02 O.OOE+OO 9.33E+01 O.OOE+OO U-237 3.35E-01 O.OOE+OO 8.91E-02 O.OOE+OO 9.68E-01 O.OOE+OO 2.96E+01 O.OOE+OO U-238 5.15E+03 O.OOE+OO 3.06E+02 O.OOE+OO 8.25E+02 O.OOE+OO 8.92E+01 O.OOE+OO NP-237 1.76E+04 1.16E+03 7.71E+02 O.OOE+OO 4.77E+03 O.OOE+OO 6.43E+02 O.OOE+OO NP-238 3.31 E-01 6.70E-03 5.16E-03 O.OOE+OO 2.13E-02 O.OOE+OO 2.29E+02 O.OOE+OO NP-239 3.08E-02 2.21 E-03 1.56E-03 O.OOE+OO 6.40E-03 O.OOE+OO 1.64E+02 O.OOE+OO PU-238 3.28E+03 3.80E+02 8.71 E+01 O.OOE+OO 3.17E+02 O.OOE+OO 2.07E+02 O.OOE+OO PU-239 3.56E+03 3.80E+02 9.13E+01 O.OOE+OO 3.36E+02 O.OOE+OO 1.89E+02 ,O.OOE+OO PU-240 3.53E+03 3.94E+02 9.13E+01 O.OOE+OO 3.36E+02 O.OOE+OO 1.92E+02 O.OOE+OO PU-241 1.07E+02 4.36E+OO 2.22E+OO O.OOE+OO 8.16E+OO O.OOE+OO 3.97E+OO O.OOE+OO PU-242 3.28E+03 3.80E+02 8.79E+01 O.OOE+OO 3.23E+02 O.OOE+OO 1.85E+02 O.OOE+OO PU-244 3.83E+03 4.36E+03 1.01E+02 O.OOE+OO 3.72E+02 O.OOE+OO 2.76E+02 O.OOE+OO AM-241 2.68E+04 2.30E+04 2.01E+03 O.OOE+OO 1.23E+04 O.OOE+OO 1.50E+03 O.OOE+OO AM-242M 2.76E+04 2.21 E+04 2.05E+03 O.OOE+OO 1.24E+04 O.OOE+OO 1.89E+03 O.OOE+OO AM-243 2.64E+04 2.23E+04 1.94E+03 O.OOE+OO 1.19E+04 O.OOE+OO 1. 76E+03 O.OOE+OO CM-242 1. 72E+03 1.37E+03 1.15E+02 O.OOE+OO 3.67E+02 O.OOE+OO 1.60E+03 O.OOE+OO CM-243 2.52E+04 2.05E+04 1.62E+03 O.OOE+OO 6.06E+03 O.OOE+OO 1.58E+03 O.OOE+OO CM-244 2.13E+04 1.72E+04 1.36E+03 O.OOE+OO 5.00E-i-03 O.OOE+OO 1.53E+03 O.OOE+OO CM-245 3.29E+04 2.64E+04 2.07E+03 O.OOE+OO 8.09E+03 O.OOE+OO 1.43E+03 O.OOE+OO CM-246- 3.25E+04 2.64E+04 2.07E+03 O.OOE+OO 8.07E+03 O.OOE+OO - 1.40E+03 O.OOE+OO CM-247 3.17E+04 2.60E+04 2.03E+03 O.OOE+OO 7.96E+03 O.OOE+OO 1.84E+03 O.OOE+OO CM-248 2.64E+05 2.15E+05 1.68E+04 O.OOE+OO 6.56E+04 O.OOE+OO 2.97E+04 O.OOE+OO CF-252 2.07E+04 O.OOE+OO 5.00E+02 O.OOE+OO O.OOE+OO O.OOE+OO 5.82E+03 O.OOE+OO Rev.29 Page 173 of 329 12/2016
CY-LG-170-301 TABLE 111-17 CHILD SHORELINE A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI . SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 3.12E+03 3.12E+03 3.12E+03 3.12E+03 3.12E+03 3.12E+03 3.12E+03 3.51E+03 NA-24 3.21E+OO 3.21E+OO 3.21E+OO 3.21E+OO 3.21E+OO 3.21 E+OO 3.21E+OO 3.72E+OO P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 4.43E+03 4.43E+03 4.43E+03 4.43E+03 4.43E+03 4.43E+03 4.43E+03 5.21E+03 SC-46 2.24E+02 2.24E+02 2.24E+02 2.24E+02 2.24E+02 2.24E+02 2,24E+02 2.58E+02 CR-51 1.25E+OO 1.25E+OO 1.25E+OO 1.25E+OO 1.25E+OO 1.25E+OO 1.25E+OO 1.48E+OO MN-54 3.73E+02 3.73E+02 3.73E+02 3.73E+02 3.73E+02 3.73E+02 3.73E+02 4.37E+02 MN-56 2.43E-01 2.43E-01 2.43E-01 2.43E-01 2.43E-01 2.43E-01 2.43E-01 2.87E-01 FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 7.34E+01 7.34E+01 7.34E+01 7.34E+01 7.34E+01 7.34E+01 7.34E+01 8.62E+01 C0-57 5.07E+01 5.07E+01 5.07E+01 5.07E+01 5.07E+01 5.07E+01 5.07E+01 5.57E+01 C0-58 1.02E+02 1.02E+02 1.02Ei-02 1.02E+02 1.02E+02 1.02E+02 1.02E+02 1.19E+02 C0-60 6.47E+03 6.47E+03 6.47E+03 6.47E+03 6.47E+03 6.47E+03 6.47E+03 7.62E+03 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 7.98E-02 7.98E-02 7.98E-02 7.98E-02 7.98E-02 7.98E-02 7.98E-02 9.28E-02 CU-64 1.63E-01 1.63E-01 1.63E-01 1.63E-01 1.63E-01 1.63E-01 1.63E-01 1.85E-01 ZN-65 2.01E+02 2.01E+02 2.01E+02 2.01E+02 2.01E+02 2.01E+02 2.01E+02 2.31E+02 ZN-69M 3.42E-01 3.42E-01 3.42E-01 3.42E-01 3.42E-01 3.42E-01 3.42E-01 4.00E-01 ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 5.74E+OO 5.74E+OO 5.74E+OO 5.74E+OO 5.74E+OO 5.74E+OO 5.74E+OO 6.65E+OO BR-83 1.31 E-03 1.31 E-03 1.31E-03 1.31E-03 1.31 E-03 1.31E-03 1.31 E-03 1.90E-03 BR-84 5.45E-02 5.45E-02 5.45E-02 5.45E-02 5.45E-02 5.45E-02 5.45E-02 6.35E-02 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 2.42E+OO 2.42E+OO 2.42E+OO 2.42E+OO 2.42E+OO 2.42E+OO 2.42E+OO 2.76E+OO RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 8.89E-03 8.89E-03 8.89E-03 8.89E-03 8.89E-03 8.89E-03 8.89E-03 1.02E-02 RB-89 3.30E-02 3.30E-02 3.30E-02 3.30E-02 3.30E-02 3.30E-02 3.30E-02 3.97E-02 SR-89 5.82E-03 5.82E-03 5.82E-03 5.82E-03 5.82E-03 5.82E-03 5.82E-03 6.75E-03 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 5.78E-01 5.78E-01 5.78E-01 5.78E-01 5.78E-01 5.78E-01 5.78E-01 6.75E-01 SR-92 2.09E-01 2.09E-01 2.09E-01 2.09E-01 2.09E-01 2.09E-01 2.09E-01 2.32E-01 Y-90 1.21 E-03 1.21 E-03 1.21 E-03 1.21 E-03 1.21E-03 1.21 E-03 1.21E-03 1.43E-03 Y-91M 2.70E-02 2.70E-02 2.70E-02 2.70E-02 2.70E-02 2.70E-02 2.70E-02 3.12E-02 Rev.29 Page 174 of 329 12/2016
CY-LG-170-301 TABLE 111-17 CHILD SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 2.89E-01 2.89E-01 2.89E-01 2.89E-01 2.89E-01 2.89E-01 2.89E-01 3.25E-01 Y-92 4.85E-02 4.85E-02 4.85E-02 4.85E-02 4.85E-02 4.85E-02 4.85E-02 5.76E-02 Y-93 4.93E-02 4.93E-02 4.93E-02 4.93E-02 4.93E-02 4.93E-02 4.93E-02 6.75E-02 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+Op ZR-95 6.58E+01 6.58E+01 6.58E+01 6.58E+01 6.58E+01 6.58E+01 6.58E+01 7.63E+01 ZR-97 7.96E-01 7.96E-01 7.96E-01 7.96E-01 7.96E-01 7.96E-01 7.96E-01 9.26E-01 NB-93M 6.24E-01 6.24E-01 6.24E-01 6.24E-01 6.24E-01 6.24E-01 6.24E-01 7.61E+01 NB-95 3.67E+01 3.67E+01 3.67E+01 3.67E+01 3.67E+01 3.67E+01 3.67E+01 4.32E+01 NB~97 4.73E-02 4.73E-02 4.73E-02 4.73E-02 4.73E-02 4.73E-02 4.73E-02 5.56E-02 M0-93 2.97E+01 2.97E+01 2.97E+01 2.97E+01 2.97E+01 2.97E+01 2.97E+01 1.21E+03 M0-99 1.07E+OO 1.07E+OO 1.07E+OO 1.07E+OO 1.07E+OO 1.07E+OO 1.07E+OO 1.24E+OO TC-99M 4.95E-02 4.95E-02 4.95E-02 4.95E-02 4.95E-02 4.95E-02 4.95E-02 5.67E-02 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 5.47E-03 5.47E-03 5.47E-03 5.47E-03 5.47E-03 5.47E-03 5.47E-03 6.08E-03 RU-103 2.91E+01 2.91E+01 2.91E+01 2.91E+01 2.91E+01 2.91 E+01 2.91E+01 3.40E+01 RU-105 1.71E-01 1.71 E-01 1.71E-01 1.71E-01 1.71 E-01 1.71 E-01 1.71 E-01 1.94E-01 RU-106 1.13E+02 1.13E+02 1.13E+02 1.13E+02 1.13E+02 1.13E+02 1.13E+02 1.36E+02 RH-105 2.00E-01 2.00E-01 2.00E-01 2.00E-01 2.00E-01 2.00E-01 2.00E-01 2.33E-01 PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 4.03E-03 4.03E-03 4.03E-03 4.03E-03 4.03E-03 4.03E-03 4.03E-03 4.61E-03 AG-110M 9.24E+02 9.24E+02 9.24E+02 9.24E+02 9.24E+02 9.24E+02 9.24E+02 1.08E+03 AG-111 2.76E-01 2.76E-01 2.76E-01 2.76E-01 2.76E-01 2.76E-01 2.76E-01 3.22E-01 CD-113M 1.70E+OO 1.70E+OO 1.70E+OO 1.70E+OO 1.70E+OO 1.70E+OO 1.70E+OO 1.92E+OO CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+03 SN-125 1.13E+OO 1.13E+OO 1.13E+OO 1.13E+OO 1.13E+OO 1.13E+OO 1.13E+OO 1.31E+OO SN-126 1.17E+04 1.17E+04 1.17E+04 1.17E+04 1.17E+04 1.17E+04 1.17E+04 1.30E+04 SB-124 1.61E+02 1.61E+02 1.61E+02 1.61E+02 1.61E+02 1.61E+02 1.61E+02 1.86E+02 SB-125 6.43E+02 6.43E+02 6.43E+02 6.43E+02 6.43E+02 6.43E+02 6.43E+02 7.26E+02 SB-126 2.27E+01 2:27E+01 2.27E+01 2.27E+01 2.27E+01 2.27E+01 2.27E+01 2.55E+01 SB-127 4.51E+OO 4.51E+OO 4.51E+OO 4.51E+OO 4.51E+OO 4.51E+OO 4.51E+OO 5.22E+OO TE-125M 4.17E-01 4.17E-01 4.17E-01 4.17E-01 4.17E-01 4.17E-01 4.17E-01 5.72E-01 TE-127M 2.46E-02 2.46E-02 2.46E-02 2.46E-02 2.46E-02 2.46E-02 2.46E-02 2.91E-02 TE-127 8.01 E-04 8.01E-04 8.01E-04 8.01E-04 8.01 E-04 8.01E-04 8.01E-04 8.81E-04 TE-129M 5.32E+OO 5.32E+OO 5.32E+OO 5.32E+OO 5.32E+OO 5.32E+OO 5.32E+OO 6.21E+OO TE-129 7.05E-03 7.05E-03 7.05E-03 7.05E-03 7.05E~03 7.05E-0;3 7.05E-03 8.34E-03 TE-131M 2.16E+OO 2.16E+OO 2.16E+OO 2.16E+OO 2.16E+OO 2.16E+OO 2.16E+OO 2.54E+OO TE-131 7.85E-03 7.85E-03 7.85E-03 7.85E-03 7.85E-03 7.85E-03 7.85E-03 9.28E+OO Rev.29 Page 175 of 329 12/2016
CY-LG-170-301 TABLE 111-17 CHILD SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN TE-132 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.14E+OO 1.34E+OO TE-133M 1.19E-01 1.19E-01 1.19E-01 1.19E-01 1.19E-01 1.19E-01 1.19E-01 1.34E-01 TE-134 5.96E-03 5.96E-03 5.96E-03 5.96E-03 5.96E-03 5.96E-03 5.96E-03 7.16E-03 1-129 5.85E+02 5.85E+02 5.85E+02 5.85E+02 5.85E+02 5.85E+02 5.85E+02 9.75E+02 1-130 1.48E+OO 1.48E+OO 1.48E+OO 1.48E+OO 1.48E+OO 1.48E+OO 1.48E+OO 1.80E+OO 1-131 4.63E+OO 4.63E+OO 4.63E+OO 4.63E+OO 4.63E+OO 4.63E+OO 4.63E+OO 5.62E+OO 1-132 3.35E-01 3.35E-01 3.35E-01 3.35E-01 3.35E-01 3.35E-01 3.35E-01 3.94E-01 1-133 6.59E-01 6.59E-01 6.59E-01 6.59E-01 6.59E-01 6.59E-01 6.59E-01 8.01 E-01 1-134 1.20E-01 1.20E-01 1.20E-01 1.20E-01 1.20E-01 1.20E-01 1.20E-01 1.43E-01 1-135 6.79E-01 6.79E-01 6.79E-01 6.79E-01 6.79E-01 6.79E-01 6.79E-01 7.92E-01 CS-134M 1.54E-02 1.54E-02 1.54E-02 1.54E-02 1.54E-02 1.54E-02 1.54E-02 1.81 E-02 CS-134 1.86E+03 1.86E+03 1.86E+03 1.86E+03 1.86E+03 1.86E+03 1.86E+03 2.17E+03 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 4.06E+01 4.06E+01 4.06E+01 4.06E+01 4.06E+01 4.06E+01 4.06E+01 4.60E+01 CS-137 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.85E+03 CS-138 9.65E-02 9.65E-02 9.65E-02 9.65E-02 9.65E-02 9.65E-02 9.65E-02 1.10E-01 CS-139 8.45E-03 8.45E-03 8.45E-03 8.45E-03 8.45E-03 8.45E-03 8.45E-03 9.66E-03 BA-139 2.85E-02 2.85E-02 2.85E-02 2.85E-02 2.85E-02 2.85E-02 2.85E-02 3.20E-02 BA-140 5.52E+OO 5.52E+OO 5.52E+OO 5.52E+OO 5.52E+OO 5.52E+OO 5.52E+OO 6.31E+OO BA-141 1.12E-02 1.12E-02 1.12E-02 1.12E-02 1.12E-02 1.12E-02 1.12E-02 1.28E-02 BA-142 1.21 E-02 1.21E-02 1.21 E-02 1.21 E-02 1.21E-02 1.21E-02 1.21 E-02 1.37E-02 LA-140 5.17E+OO 5.17E+OO 5.17E+OO 5.17E+OO 5.17E+OO 5.17E+OO 5.17E+OO 5.85E+OO LA-141 8.43E-03 8.43E-03 8.43E-03 8.43E-03 8.43E-03 8.43E-03 8.43E-03 9.45E-03 LA-142 2.04E-01 2.04E-01 2.04E-01 2.04E-01 2.04E-01 2.04E-01 2.04E-01 2.45E-01 CE-141 3.67E+OO 3.67E+OO 3.67E+OO 3.67E+OO 3.67E+OO 3.67E+OO 3.67E+OO 4.14E+OO CE-143 6.22E-01 6.22E-01 6.22E-01 6.22E-01 6.22E-01 6.22E-b1 6.22E-01 7.06E-01 CE-144 1.87E+01 1.87E+01 1.87E+01 1.87E+01 1.87E+01 1.87E+01 1.87E+01 2.16E+01 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 4.93E-04 4.93E-04 4.93E-04 4.93E-04 4.93E-04 4.93E-04 4.93E-04 5.67E-04 ND-147 2.26E+OO 2.26E+OO 2.26E+OO 2.26E+OO 2.26E+OO 2.26E+OO 2.26E+OO 2.71E+OO PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 1.20E+02 1.20E+02 1.20E+02 1.20E+02 1.20E+02 1.20E+02 1.20E+02 6.93E+02 PM-148 5.08E+OO 5.08E+OO 5.08E+OO 5.08E+OO 5.08E+OO 5.08E+OO 5.08E+OO 5.85E+OO PM-149 1.14E-02 1.14E-02 1.14E-02 1.14E-02 1.14E-02 1.14E-02 1.14E-02 1.32E-02 PM-151 5.35E-01 5.35E-01 5.35E-01 5.35E-01 5.35E-01 5.35E-01 5.35E-01 5.59E-01 SM-151 5.68E+01 5.68E+01 5.68E+01 5.68E+01 5.68E+01 -5.68E+01 5.68E+01 2.48E+02 SM-153 1.08E-01 1.08E-01 1.08E-01 1.08E-01 1.08E-01 1.08E-01 1.08E-01 1.20E-01 EU-152 5.42E+03 5.42E+03 5.42E+03 5.42E+03 5.42E+03 5.42E+03 5.42E+03 6.27E+03 Rev.29 Page 176 of 329 12/2016
CY-LG-170-301 TABLE 111-17 CHILD SHORELINE A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 4.43E+03 A.43E+03 4.43E+03 4.43E+03 4.43E+03 4.43E+03 4.43E+03 5.11 E+03 EU-155 1.38E+02 1.38E+02 1.38E+02 1.38E+02 1.38E+02 1.38E+02 1.38E+02 1.56E+02 EU-156 2.37E+01 2.37E+01 2.37E+01 2.37E+01 2.37E+01 2.37E+01 2.37E+01 2.72E+01 TB-160 1.28E+02 1.28E+02 1.28E+02 1.28E+02 1.28E+02 1.28E+02 1.28E+02 1.49E+02 H0-166M 1.15E+04 1.15E+04 1.15E+04 1.15E+04 1.15E+04 1.15E+04 1.15E+04 1.29E+04 W-181 5.22E-02 5.22E-02 5.22E-02 5.22E-02 5.22E-02 5.22E-02 5.22E-02 6.96E-02 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 6.33E-01 6.33E-01 6.33E-01 6.33E-01 6.33E-01 6.33E-01 6.33E-01 7.35E-01 U-232 2.99E+OO 2.99E+OO 2.99E+OO 2.99E+OO 2.99E+OO 2.99E+OO 2.99E+OO 3.11E+01 U-233 2.99E+03 2.99E+03 2.99E+03 2.99E+03 2.99E+03 2.99E+03 2.99E+03 3.64E+03 U-234 8.22E-01 8.22E-01 8.22E-01 8.22E-01 8.22E-01 8.22E-01 8.22E-01 2.07E+02 U-235 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.16E+03 4.16E+03 5.20E+03 U-236 2.73E-02 2.73E-02 2.73E-02 2.73E-02 2.73E-02 2.73E-02 2.73E-02 2.34E+01 U-237 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.39E+OO 1.80E+OO U-238 1.43E+02 1.43E+02 1.43E+02 1.43E+02 1.43E+02 1.43E+02 1.43E+02 1.95E+02 NP-237 1.82E+03 1.82E+03 1.82E+03 1.82E+03 1.82E+03 1.82E+03 1.82E+03 2.08E+03 NP-238 1.22E+OO 1.22E+OO 1.22E+OO 1.22E+OO 1.22E+OO 1.22E+OO 1.22E+OO 1.39E+OO NP-239 4.60E-01 4.60E-01 4.60E-01 4.60E-01 4.60E-01 4.60E-01 4.60E-01 5.32E-01 PU-238 1.53E+OO 1.53E+OO 1.53E+OO 1.53E+OO 1.53E+OO 1.53E+OO 1.53E+OO 2.12E+01 PU-239 1.03E+OO 1.03E+OO 1.03E+OO 1.03E+OO 1.03E+OO 1.03E+OO 1.03E+OO 1.00E+01 PU-240 1.69E+OO 1.69E+OO 1.69E+OO 1.69E+OO 1.69E+OO 1.69E+OO 1.69E+OO 2.34E+01 PU-241 3.48E+OO 3.48E+OO 3.48E+OO 3.48E+OO 3.48E+OO 3.48E+OO 3.48E+OO 5.14E+OO PU-242 1.43E+OO 1.43E+OO 1.43E+OO 1.43E+OO 1.43E+OO 1.43E+OO 1.43E+OO 2.08E+01 PU-244 1.16E+03 1.16E+03 1.16E+03 1.16E+03 1.16E+03 1.16E+03 1.16E+03 1.25E+03 AM-241 2.29E+02 2.29E+02 2.29E+02 2.29E+02 2.29E+02 2.29E+02 2.29E+02 3.31E+02 AM-242M 3.20E+01 3.20E+01 3.20E+01 3.20E+01 3.20E+01 3.20E+01 3.20E+01 2.21E+02 AM-243 1.69E+03 1.69E+03 1.69E+03 1.69E+03 1.69E+03 1.69E+03 1.69E+03 1.95E+03 CM-242 1.84E-01 1.84E-01 1.84E-01 1.84E-01 1.84E-01 1.84E-01 1.84E-01 7.71E-01 CM-243 2.24E+03 2.24E+03 2.24E+03 2.24E+03 2.24E+03 2.24E+03 2.24E+03 2.83E+03 CM-244 2.43E+OO 2.43E+OO 2.43E+OO 2.43E+OO 2.43E+OO 2.43E+OO 2.43E+OO 1.51E+01 CM-245 1.23E+03 1.23E+03 1.23E+03 1.23E+03 1.23E+03 1.23E+03 1.23E+03 1.56E+03 CM-246 1.30E+OO 1.30E+OO 1.30E+OO 1.30E+OO 1.30E+OO 1.30E+OO 1.30E+OO 1.95E+01 CM-247 2.86E+03 2.86E+03 2.86E+03 2.86E+03 2.86E+03 2.86E+03 2.86E+03 3.38E+03 .CM-248 6.80E+03 6.80E+03 6.80E+03 6.80E+03 6.80E+03 6.80E+03 6.80E+03 8.86E+03 CF-252 1.31E+04 1.31E+04 1.31E+04 1.31E+04 1.31 E+04 1.31 E+04 1.31 E+04 1.42E+04 Rev.29 Page 177 of 329 12/2016
CY-LG-170-301 TABLE 111-18 INFANT DRINKING WATER A17FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 6.63E+OO 6.63E+OO 6.63E+OO 6.63E+OO 6.63E+OO 6.63E+OO O.OOE+OO C-14 8.93E+02 1.91E+02 1.91E+02 1.91 E+02 1.91 E+02 1.91 E+02 1.91 E+02 O.OOE+OO NA-22 3.70E+03 3.70E+03 3.70E+03 3.70E+03 3.70E+03 3.70E+03 3.70E+03 O.OOE+OO NA-24 2.19E+02 2.19E+02 2.19E+02 2.19E+02 2.19E+02 2.19E+02 2.19E+02 O.OOE+OO P-32 6.25E+04 3.68E+03 2.42E+03 O.OOE+OO O.OOE+OO . O.OOE+OO 8.46E+02 O.OOE+OO CA-41 1.41 E+04 O.OOE+OO 1.54E+03 O.OOE+OO O.OOE+OO O.OOE+OO 7.20E+OO O.OOE+OO SC-46 1.41 E+OO 2.03E+OO 6.34E-01 O.OOE+OO 1.34E+OO O.OOE+OO 1.32E+03 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 5.25E-01 3.42E-01 7.48E-02 6.66E-01 1.53E+01 O.OOE+OO MN-54 O.OOE+OO 7.49E+02 1.70E+02 O.OOE+OO 1.66E+02 O.OOE+OO 2.75E+02 O.OOE+OO MN-56 O.OOE+OO 1.22E+OO 2.11 E-01 O.OOE+OO 1.05E+OO O.OOE+OO 1.11 E+02 O.OOE+OO FE-55 5.23E+02 3.38E+02 9.04E+01 O.OOE+OO O.OOE+OO 1.65E+02 4.29E+01 O.OOE+OO FE-59 1.15E+03 2.01 E+03 7.92E+02 O.OOE+OO O.OOE+OO 5.94E+02 9.61 E+02 O.OOE+OO C0-57 O.OOE+OO 4.33E+01 7.04E+01 O.OOE+OO O.OOE+OO O.OOE+OO 1.47E+02 O.OOE+OO C0-58 O.OOE+OO 1.35E+02 3.37E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.36E+02 O.OOE+OO C0-60 O.OOE+OO 4.07E+02 9.60E+02 O.OOE+OO O.OOE+OO O.OOE+OO 9.68E+02 O.OOE+OO Nl-59 1.78E+03 5.46E+02 3.08E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.70E+01 O.OOE+OO Nl-63 2.39E+04 1.48E+03 8.29E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.35E+01 O.OOE+OO Nl-65 6.53E+OO 7.39E-01 3.36E-01 O.OOE+OO O.OOE+OO O.OOE+OO 5.62E+01 O.OOE+OO CU-64 O.OOE+OO 1.19E+01 5.52E+OO O.OOE+OO 2.02E+01 O.OOE+OO 2.45E+02 O.OOE+OO ZN-65 6.92E+02 2.37E+03 1.09E+03 O.OOE+OO 1.15E+03 O.OOE+OO 2.01 E+03 O.OOE+OO ZN-69M 3.09E+01 6.30E+01 5.74E+OO O.OOE+OO 2.55E+01 O.OOE+OO 8.73E+02 O.OOE+OO ZN-69 4.44E-04 8.00E-04 5.95E-05 O.OOE+OO 3.32E-04 O.OOE+OO 6.52E-02 O.OOE+OO SE-79 O.OOE+OO 7.91 E+02 1.47E+02 O.OOE+OO 9.15E+02 O.OOE+OO 2.1 OE+01 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 3.78E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 4.21 E-01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 2.20E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.80E-76 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 6.29E+03 3.11 E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.61 E+02 O.OOE+OO RB-87 O.OOE+OO 3.35E+03 1.33E+03 O.OOE+OO O.OOE+OO O.OOE+OO 2.25E+01 O.OOE+OO RB-88 O.OOE+OO 1.25E-11 6.85E-12 O.OOE+OO O.OOE+OO O.OOE+OO 1.22E-1.1 O.OOE+OO RB-89 O.OOE+OO 9.88E-14 6.80E-14 O.OOE+OO O.OOE+OO O.OOE+OO 3.36E-14 O.OOE+OO SR-89 9.39E+04 O.OOE+OO 2.69E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.93E+03 O.OOE+OO SR-90 1.07E+06 O.OOE+OO 2.16E+04 O.OOE+OO O.OOE+OO O.OOE+OO 8.70E+03 O.OOE+OO SR-91 7.85E+02 O.OOE+OO 2.84E+01 O.OOE+OO O.OOE+OO O.OOE+OO 9.29E+02 O.OOE+OO SR-92 3.36E+01 O.OOE+OO 1.25E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.62E+02 O.OOE+OO Y-90 2.88E+OO O.OOE+OO 7.71 E-02 O.OOE+OO O.OOE+OO O.OOE+OO 3.97E+03 O.OOE+OO Y-91M 1.33E-06 O.OOE+OO 4.54E-08 O.OOE+OO O.OOE+OO O.OOE+OO 4.44E-03 O.OOE+OO Rev.29 Page 178 of 329 12/2016
CY-LG-170-301 TABLE 111-18 INFANT DRINKING WATER Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN Y-91 4.23E+01 O.OOE+OO 1.13E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.03E+03 O.OOE+OO Y-92 2.75E-02 O.OOE+OO 7.73E-04 O.OOE+OO O.OOE+OO O.OOE+OO 5.25E+02 O.OOE+OO Y-93 4.02E-01 O.OOE+OO 1.09E-02 O.OOE+OO O.OOE+OO O.OOE+OO 3.17E+03 O.OOE+OO ZR-93 7.27E+OO 3.46E-01 2.09E-01 O.OOE+OO 1.02E+OO O.OOE+OO 9.00E+01 O.OOE+OO ZR-95 7.72E+OO 1.88E+OO 1.33E+OO O.OOE+OO 2.03E+OO O.OOE+OO 9.37E+02 O.OOE+oo ZR-97 3.41 E-01 5.85E-02 2.67E-02 O.OOE+OO 5.90E-02 O.OOE+OO 3.73E+03 O.OOE+OO NB-93M 4.63E+OO 1.25E+OO 3.92E-01 O.OOE+OO 1.22E+OO O.OOE+OO 1.50E+02 O.OOE+OO NB-95 1.57E+OO 6.45E-01 3. 73E-01 O.OOE+OO 4.63E-01 O.OOE+OO 5.45E+02 O.OOE+OO NB-97 1.70E-05 3.64E-06 1.31 E-06 O.OOE+OO 2.84E-06 O.OOE+OO 1.15E+OO O.OOE+OO M0-93 O.OOE+OO 2.13E+03 6.86E+01 O.OOE+OO 4.26E+02 O.OOE+OO 4.56E+01 O.OOE+OO M0-99 O.OOE+OO 1.13E+03 2.20E+02 O.OOE+OO 1.69E+03 O.OOE+OO 3.72E+02 O.OOE+OO TC-99M 1.82E-02 3.75E-02 4.83E-01 O.OOE+OO 4.03E-01 1.96E-02 1.09E+01 O.OOE+OO TC-99 4.07E+01 5.50E+01 1.71E+01 O.OOE+OO 4.63E+02 5.35E+OO 2.38E+02 O.OOE+OO TC-101 4.66E-17 5.87E-17 5.81E-16 O.OOE+OO 6.98E-16 3.20E-17 9.98E-15 O.OOE+OO RU-103 5.53E+01 O.OOE+OO 1.85E+01 O.OOE+OO 1.15E+02 O.OOE+OO 6.72E+02 O.OOE+OO RU-105 7.87E-01 O.OOE+OO 2.65E-01 O.OOE+OO 5. 79E+OO O.OOE+OO 3.13E+02 O.OOE+OO RU-106 9.07E+02 O.OOE+OO 1.13E+02 O.OOE+OO 1.07E+03 O.OOE+OO 6.89E+03 O.OOE+OO RH-105 3.25E+01 2.12E+01 1.43E+01 O.OOE+OO 5.90E+01 O.OOE+OO 5.27E+02 O.OOE+OO PD-107 O.OOE+OO 4.48E+01 3.18E+OO O.OOE+OO 2.56E+02 O.OOE+OO 3.56E+01 O.OOE+OO PD-109 O.OOE+OO 3.04E+01 7.35E+OO O.OOE+OO 1.12E+02 O.OOE+OO 7.47E+02 O.OOE+OO . AG-110M 3.75E+01 2.73E+01 1.81E+01 O:OOE+OO 3.91 E+01 O.OOE+OO 1.42E+03 O.OOE+OO AG-111 1.87E+01 7.26E+OO 3.85E+OO O.OOE+OO 1.52E+01 O.OOE+OO 1.73E+03 O.OOE+OO CD-113M O.OOE+OO 6.67E+02 2.46E+01 O.OOE+OO 5.05E+02 O.OOE+OO 1.00E+03 O.OOE+OO CD-115M O.OOE+OO 5.31 E+02 1.84E+01 O.OOE+OO 2.77E+02 O.OOE+OO 3.02E+03 O.OOE+OO SN-123 9.36E+03 1.46E+02 2.44E+02 1.47E+02 O.OOE+OO O.OOE+OO 2.47E+03 O.OOE+OO SN-125 2.69E+03 5.02E+01 1.20E+02 4.94E+01 O.OOE+OO O.OOE+OO 4.03E+03 O.OOE+OO SN-126 2.08E+04 2.73E+02 6.78E+02 7.20E+01 O.OOE+OO O.OOE+OO 9.49E+02 O.OOE+OO SB-124 8.02E+02 1.18E+01 2.48E+02 2.13E+OO O.OOE+OO 5.02E+02 2.47E+03 O.OOE+OO SB-125 4.63E+02 4.48E+OO 9.53E+01 5.80E-01 O.OOE+OO 2.68E+02 6.18E+02 O.OOE+OO SB-126 2.95E+02 5.79E+OO 1.07E+02 2.27E+OO O.OOE+OO 1.86E+02 3.06E+03 O.OOE+OO SB-127 7.68E+01 1.37E+OO 2.38E+01 9.78E-01 O.OOE+OO 3.96E+01 2.03E+03 O.OOE+OO TE-125M 8.73E+02 2.92E+02 1.18E+02 2.94E+02 O.OOE+OO O.OOE+OO 4.16E+02 O.OOE+OO TE-127M 2.20E+03 7.29E+02 2.66E+02 6.35E+02 5.41 E+03 O.OOE+OO 8.86E+02 O.OOE+OO TE-127 1.55E+01 5.18E+OO 3.33E+OO 1.26E+01 3.78E+01 O.OOE+OO 3.25E+02 O.OOE+OO TE-129M 3.73E+03 1.28E+03 5.74E+02 1.43E+03 9.32E+03 O.OOE+OO 2.23E+03 O.OOE+OO TE-129 8.23E-03 2.84E-03 1.92E-03 6.89E-03 2.05E-02 O.OOE+OO 6.58E-01 O.OOE+OO TE-131M 4.34E+02 1.75E+02 1.44E+02 3.54E+02 1.20E+03 O.OOE+OO 2.94E+03 O.OOE+OO TE-131 1.42E-08 5.24E-09 3.98E-09 1.27E-08 3.63E-08 O.OOE+OO 5.73E-07 O.OOE+OO Rev.29 Page 179 of 329 12/2016
CY-LG-170-301 TABLE 111-18 INFANT DRINKING WATER A1TFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN TE-132 7.04E+02 3.49E+02 3.25E+02 5.15E+02 2.18E+03 O.OOE+OO 1.29E+03 O.OOE+OO TE-133M 1.80E-03 8.25E-04 7.88E-04 1.59E-03 5.62E-03 O.OOE+OO 8.90E-02 O.OOE+OO TE-134 6.57E-05 3.30E-05 3.39E-05 5.88E-05 2.22E-04 O.OOE+OO 7.53E-04 O.OOE+OO 1-129 1.08E+03 7.99E+02 5.84E+02 5.12E+05 9.46E+02 O.OOE+OO 1.60E+01 O.OOE+OO 1-130 1.15E+02 2.54E+02 1.02E+02 2.84E+04 2.79E+02 O.OOE+OO 5.44E+01 O.OOE+OO 1-131 1.30E+03 1.53E+03 6. 71 E+02 5.02E+05 1. 78E+03 O.OOE+OO 5.45E+01 O.OOE+OO 1-132 1.68E+OO 3.41 E+OO 1.22E+OO 1.60E+02 3.81E+OO O.OOE+OO 2.76E+OO O.OOE+OO 1-133 3.16E+02 4.60E+02 1.35E+02 8.36E+04 5.40E+02 O.OOE+OO 7.78E+01 O.OOE+OO 1-134 2.48E-03 5.08E-03 1.81 E-03 1.18E-01 5.68E-03 O.OOE+OO 5.25E-03 O.OOE+OO 1-135 3.90E+01 7.75E+01 2.83E+01 6.95E+03 8.64E+01 O.OOE+OO 2.80E+01 O.OOE+OO CS-134M 3.77E-01 6.27E-01 3.17E-01 O.OOE+OO 2.42E-01 5.56E-02 4.96E-01 O.OOE+OO CS-134 1.42E+04 2.65E+04 2.67E+03 O.OOE+OO 6.82E+03 2. 79E+03 7.19E+01 O.OOE+OO CS-135 5.01 E+03 4.56E+03 2.37E+02 O.OOE+OO 1.30E+03 4.93E+02 1.65E+01 O.OOE+OO CS-136 1.68E+03 4.95E+03 1.85E+03 O.OOE+OO 1.97E+03 4.04E+02 7.52E+01 O.OOE+OO CS-137 1.97E+04 2.30E+04 1.63E+03 O.OOE+OO 6.18E+03 2.50E+03 7.19E+01 O.OOE+OO CS-138 3.37E-06 5.47E-06 2.65E-06 O.OOE+OO 2.73E-06 4.26E-07 8.75E-06 O.OOE+OO CS-139 1.02E-22 1.40E-22 5.34E-23 O.OOE+OO 7.22E-23 1.09E-23 8.78E-24 O.OOE+OO BA-139 8.18E-02 5.42E-05 2.37E-03 O.OOE+OO 3.26E-OS 3.29E-05 5.18E+OO O.OOE+OO BA-140 6.27E+03 6.27E+OO 3.23E+02 O.OOE+OO 1.49E+OO . 3.85E+OO 1.54E+03 O.OOE+OO BA-141 2.19E-11 1.50E-14 6.92E-13 O.OOE+OO 9,03E-15 9.14E-15 2.68E-10 O.OOE+OO BA-142 3.84E-20 3.20E-23 1.89E-21 O.OOE+OO 1.84E-23 1.93E-23 1.58E-19 O.OOE+OO LA-140 6.46E-01 2.55E-01 6.56E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.99E+03 O.OOE+OO LA-141 1.32E-02 3.82E-03 6.66E-04 O.OOE+OO O.OOE+OO O.OOE+OO 4.38E+02 O.OOE+OO LA-142 2.22E-04 8.14E-05 1.95E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.38E+01 O.OOE+OO CE-141 2.93E+OO 1.79E+OO 2.11 E-01 O.OOE+OO 5.52E-01 O.OOE+OO 9.24E+02 O.OOE+OO CE-143 4.33E-01 2.88E+02 3.28E-02 O.OOE+OO 8.37E-02 O.OOE+OO 1.68E+03 O.OOE+OO CE-144 1.12E+02 4.59E+01 6.28E+OO O.OOE+OO 1.85E+01 O.OOE+OO 6.43E+03 O.OOE+OO PR-143 2.99E+OO 1.12E+OO 1.48E-01 O.OOE+OO 4.15E-01 O.OOE+OO 1.58E+03 O.OOE+OO PR-144 2.96E-15 1.14E-15 1.49E-16 O.OOE+OO 4.14E-16 O.OOE+OO 5.32E-11 O.OOE+OO ND-147 2.02E+OO 2.07E+OO 1.27E-01 O.OOE+OO 7.99E-01 O.OOE+OO 1.31 E+03 O.OOE+OO PM-147 1.46E+01 1.23E+OO 5.99E-01 O.OOE+OO 1.84E+OO O.OOE+OO 3.49E+02 O.OOE+OO PM-148M 6.16E+OO 1.56E+OO 1.23E+OO O.OOE+OO 1.79E+OO O.OOE+OO 2.03E+03 O.OOE+OO PM-148 2.23E+OO 3.22E-01 1.62E-01 O.OOE+OO 3.85E-01 O.OOE+OO 3.44E+03 O.OOE+OO PM-149 4.44E-01 5.83E-02 2.54E-02 O.OOE+OO 7.09E-02 O.OOE+OO 1.57E+03 O.OOE+OO PM-151 1.74E-01 2.53E-02 1.28E-02 O.OOE+OO 3.01 E-02 O.OOE+OO 1.17E+03 O.OOE+OO SM-151 1.09E+01 2.51E+OO 5.42E-01 O.OOE+OO 1.71E+OO O.OOE+OO 2.10E+02 O.OOE+OO SM-153 2.43E-01 1.88E-01 1.44E-02 O.OOE+OO 3.94E-02 O.OOE+OO . 9.84E+02 O.OOE+OO EU-152 2.54E+01 6.74E+OO 5.69E+OO O.OOE+OO 1.89E+01 O.OOE+OO 5.99E+02 O.OOE+OO Rev. 29 Page 180 of 329 12/2016
CY-LG-170-301 TABLE 111-18 INFANT DRINKING WATER A1rFACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 9.94E+01 1.38E+01 8.29E+OO O.OOE+OO 3.75E+01 O.OOE+OO 1.73E+03 O.OOE+OO EU-155 2.04E+01 2.35E+OO 1.22E+OO O.OOE+OO 5.27E+OO O.OOE+OO 3.15E+03 O.OOE+OO EU-156 4.20E+OO 2.60E+OO 4.12E-01 O.OOE+OO 1.20E+OO O.OOE+OO 2.46E+03 O.OOE+OO TB-160 9.71E+OO O.OOE+OO 1.21 E+OO O.OOE+OO 2.76E+OO O.OOE+OO 1.29E+03 O.OOE+OO HP-166M 4.71 E+01 1.01 E+01 8.02E+OO O.OOE+OO 1.34E+01 O.OOE+OO 1.00E+03 O.OOE+OO W-181 3.32E+OO 1.02E+OO 1.14E-01 O.OOE+OO O.OOE+OO O.OOE+OO 1.43E+01 O.OOE+OO W-185 1.36E+02 4.24E+01 4.84E+OO O.OOE+OO O.OOE+OO O.OOE+OO 6.07E+02 O.OOE+OO W-187 2.40E+01 1.67E+01 5.77E+OO O.OOE+OO O.OOE+OO O.OOE+OO 9.81 E+02 O.OOE+OO U-232 9.12E+05 O.OOE+OO 8.14E+04 O.OOE+OO 8.93E+04 O.OOE+OO 2.65E+03 O.OOE+OO U-233 1.91 E+05 O.OOE+OO 1.46E+04 O.OOE+OO 4.07E+04 O.OOE+OO 2.45E+03 O.OOE+OO U-234 1.84E+05 O.OOE+OO 1.43E+04 O.OOE+OO 3.99E+04 O.OOE+OO 2.40E+03 O.OOE+OO U-235 1.76E+05 O.OOE+OO 1.34E+04 O.OOE+OO 3.74E+04 O.OOE+OO 3.05E+03 O.OOE+OO U-236 1.76E+05 O.OOE+OO 1.37E+04 O.OOE+OO 3.80E+04 O.OOE+OO 2.25E+03 O.OOE+OO U-237 1.77E+01 O.OOE+OO 4.72E+OO O.OOE+OO 4.40E+01 O.OOE+OO 7.55E+02 O.OOE+OO U-238 1.68E+05 O.OOE+OO 1.25E+04 O.OOE+OO 3.50E+04 O.OOE+OO 2.15E+03 O.OOE+OO NP-237 9.04E+04 5.99E+03 3.96E+03 O.OOE+OO 2.39E+04 O.OOE+OO 3.1 OE+03 O.OOE+OO NP-238 3.97E+OO 9.98E-02 6.14E-02 O.OOE+OO 2.18E-01 O.OOE+OO 1.33E+03 O.OOE+OO NP-239 3.61E-01 3.23E-02 1.82E-02 O.OOE+OO 6.44E-02 O.OOE+OO 9.33E+02 O.OOE+OO PU-238 4.82E+04 5.65E+03 1.28E+03 O.OOE+OO 4.56E+03 O.OOE+OO 2.85E+03 O.OOE+OO PU-239 5.20E+04 5.84E+03 1.33E+03 O.OOE+OO 4.82E+03 O.OOE+OO 2.60E+03 O.OOE+OO PU-240 5.20E+04 5.84E+03 1.33E+03 O.OOE+OO 4.82E+03 O.OOE+OO 2.65E+03 O.OOE+OO PU-241 1.60E+03 6.63E+01 3.32E+01 O.OOE+OO 1.19E+02 O.OOE+OO 5.46E+01 O.OOE+OO PU-242 4.82E+04 5.61 E+03 1.28E+03 O.OOE+OO 4.63E+03 O.OOE+OO 2.55E+03 O.OOE+OO PU-244 5.61E+04 6.44E+03 1.47E+03 O.OOE+OO 5.31 E+03 O.OOE+OO 3.80E+03 O.OOE+OO AM-241 5.50E+04 4.78E+04 4.11 E+03 O.OOE+OO 2.47E+04 O.OOE+OO 2.90E+03 O.OOE+OO AM-242M 5.69E+04 4.60E+04 4.26E+03 O.OOE+OO 2.50E+04 O.OOE+OO 3.65E+03 O.OOE+OO AM-243 5.42E+04 4.63E+04 3.99E+03 O.OOE+OO 2.40E+04 O.OOE+OO 3.40E+03 O.OOE+OO CM-242 5.15E+03 4.77E+03 3.42E+02 O.OOE+OO 9.85E+02 O.OOE+OO 3.09E+03 . O.OOE+OO CM-243 5.27E+04 4.33E+04 3.38E+03 O.OOE+OO 1.23E+04 O.OOE+OO 3.05E+03 O.OOE+OO CM-244 4.44E+04 3.65E+04 2.86E+03 O.OOE+OO 1.02E+04 O.OOE+OO 2.95E+03 O.OOE+OO CM-245 6.74E+04 5.46E+04 4.26E+03 O.OOE+OO 1.63E+04 O.OOE+OO 2.75E+03 O.OOE+OO CM-246 6.67E+04 5.46E+04 4.26E+03 O.OOE+OO 1.62E+04 O.OOE+OO 2.70E+03 O.OOE+OO CM-247 6.52E+04 5.39E+04 4.18E+03 O.OOE+OO 1.60E+04 O.OOE+OO 3.55E+03 O.OOE+OO CM-248 5.39E+05 4.45E+05 3.45E+04 O.OOE+OO 1.32E+05 O.OOE+OO 5.73E+04 O.OOE+OO CF-252 4.59E+04 O.OOE+OO 1.11 E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.13E+04 O.OOE+OO Rev.29 Page 181 of 329 12/2016
CY-LG-170-301 TABLE 111-19 INFANT FRESHWATER FISH A1T FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SC-46 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CR-51 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-54 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-56 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-:59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-57 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-58 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-60 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CU-64 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO O.OOE+OO O.OOE+OO . O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 182 of 329 12/2016
CY-LG-170-301 TABLE 111-19 INFANT FRESHWATER FISH A 17 FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-93M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-99 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-106 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RH-105 O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-110M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-111 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-113M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-124 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-125 O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-125M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 183 of 329 12/2016
CY-LG-170-301 TABLE 111-19 INFANT FRESHWATER FISH Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Q;OOE+OO O.OOE+OO O.OOE+OO TE-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 'O.OOE+OO O.OOE+OO 1-130 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-133 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-137 O.OOE+OO . O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-149 O.OOE+OO O.OOE+OO O.OOE+OO . O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-153 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-152 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 184 of 329 12/2016
CY-LG-170-301 TABLE 111-19 INFANT FRESHWATER FISH Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN EU-154 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-155 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-156 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TB-160 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO H0-166M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-181 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-232 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+oo O.OOE+OO U-233 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-234 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-235 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-236 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-237 O.OOE+OO O.OOE+OO O.OOE+OO
- O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO. O.OOE+OO NP-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-240 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-242M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-245 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-246 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-247 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-248 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+Od O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CF-252 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 185 of 329 12/2016
CY-LG-170-301 TABLE 111-20 INFANT SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU. SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SC-46 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CR-51 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-54 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-56 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-57 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO
- O.OOE+OO O.OOE+OO O.OOE+OO C0-58 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-60 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CU-64 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO
. SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 186 of 329 12/2016
CY-LG-170-301 TABLE 111-20
- INFANT SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN Y-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-93M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-106 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RH-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-107 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-110M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-111 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-113M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-124 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-125M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 187 of 329 12/2016
CY-LG-170-301 TABLE 111-20 INFANT SHORELINE A1T FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-130 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-133 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-137 O.OOE+OO O.OOE+OO O.OOE;+-00 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-149 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-153 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-152 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-154 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 188 of 329 12/2016
CY-LG-170-301 TABLE 111-20 INFANT SHORELINE Air FACTORS mrem-ml per uCi-hr NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN EU-155 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-156 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TB-160 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO H0-166M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-181 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-232 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-233 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-234 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-235 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-236 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-240 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-242M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-245 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-246 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-247 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-248 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CF-252 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 189 of 329 12/2016
CY-LG-170-301 TABLE 111-21 ASSUMPTIONS USED IN LIMERICK LIQUID EFFLUENT DOSE EVALUATION Symbol Description Value Reference( 1) Tb Period of buildup of activity in sediment(hr) 2.192E+05 RG 1.109 Appendix A Equation A-4 adjusted for license renewal (25 riears) tD Envtl transit time for water ingestion (hr) 1.200E+01 A-2< J PF tp Envtl transit time for fish ingestion (hr) 2.400E+01 A-3<2> tps Envtl transit time for shore exposure (hr) O.OOOE+OO Site Specific Uap Water ingestion (1/yr) adult 7.300E+02 E-5 Uap Water ingestion (1/yr) teen 5.100E+02 E-5 Uap Water ingestion (1/yr) child 5.100E+02 E-5 Uap Water ingestion (1/yr) infant 3.300E+02 E-5 Uap Shore exposure (hr/yr) adult 6.000E+02 Site Specific Uap Shore exposure (hr/yr) teen 6.000E+02 Site Specific Uap Shore exposure (hr/yr) child 9.000E+01 Site Specific Uap Shore exposure (hr/yr) infant O.OOOE+OO Site Specific Uap Fresh water fish ingestion (kg/yr) adult 2.100E+01 E-5 Uap Fresh water fish ingestion (kg/yr) teen 1.600E+01 E-5 Uap Fresh water fish ingestion (kg/yr) child 6.900E+OO E-5 Uap Fresh water fish ingestion (kg/yr) infant O.OOOE+OO E-5 RC Reconcentration Factor 1.000E+OO Site Specific w Shoreline Width Factor (dimensionless) 2.000E-01 A-2<3 >
- 1) The References refer to tables contained in Regulatory Guide 1.109 unless otherwise specified.
- 2) Equation A-2 and A-3 from Reg. Guide 1.109, Appendix A.
- 3) Table A-2 from Reg. Guide 1.109, Appendix A.
Rev.29 Page 190 of 329 12/2016
CY-LG-170-301 TABLE 112-1 DOSE FACTORS FOR NOBLE GAS From Table B-1 of Reg._ Guide 1.109 RADIONUCLIDE TOTAL BODY BETA SKIN GAMMA AIR BETA AIR DOSE DOSE FACTOR DOSE FACTOR DOSE FACTOR FACTOR NI Kl (MREMNR LI (MREMNR Ml (MRADNR (MRADNR PER PER PCl/M 3} PER PCl/M 3} PER PCl/M 3} PCl/M 3} AR-41 8.84E-03 2.69E-03 9.30E-03 3.28E-03 KR-83M 7.56E-08 1.93E-05 2.88E-04 KR-85M 1.17E-03 1.46E-03 1.23E-03 1.97E-03 KR-85 1.61 E-05 1.34E-03 1.72E-05 1.95E-03 KR-87 5.92E-03 9.73E-03 6.17E-03 1.03E-02 KR-88 1.47E-02 2.37E-03 1.52E-02 2.93E-03 KR-89 1.66E-02 1.01E-02 1.73E-02 1.06E-02 KR-90 1.56E-02 7.29E-03 1.63E-02 7.83E-03 XE-131M 9.15E-05 4.76E-04 1.56E-04 1.11E-03 XE-133M 2.51E-04 9.94E-04 3.27E-04 1.48E-03 XE-133 .. 2.94E-04 3.06E-04 3.53E-04 1.05E-03 XE-135M 3.12E-03 7.11E-04 3.36E-03 7.39E-04 XE-135 1.81E-03 1.86E-03 1.92E-03 2.46E-03 XE-137 1.42E-03 1.22E-02 1.51 E-03 1.27E-02 XE-138 8.83E-03 4.13E-03 9.21E-03 4.75E-03 Rev. 29 I* Page 191 of 329 12/2016
CY-LG-170-301 TABLE 112-2 R 1 I P1 DOSE FACTORS AGE: ADULT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO 7.18E+02 7.18E+02 7.18E+02 7.18E+02 7.18E+02 7.18E+02 O.OOE+OO C-14 1.82E+04 3.41 E+03 3.41 E+03 3.41 E+03 3.41 E+03 3.41 E+03 3.41 E+03 O.OOE+OO NA-22 1.04E+05 1.04E+05 1.04E+05 1.04E+05 1.04E+05 1.04E+05 1.04E+05 O.OOE+OO NA-24 1.02E+04 1.02E+04 1.02E+04 1.02E+04 1.02E+04 1.02E+04 1.02E+04 O.OOE+OO P-32 1.32E+06 7.71E+04 5.01E+04 O.OOE+OO O.OOE+OO O.OOE+OO 8.64E+04 O.OOE+OO CA-41 3.06E+05 O.OOE+OO 3.30E+04 O.OOE+OO O.OOE+OO 3.06E+04 2.29E+03 O.OOE+OO SC-46 4.41E+05 8.56E+05 2.49E+05 O.OOE+OO 7.99E+05 O.OOE+OO 2.58E+05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.00E+02 5.95E+01 2.28E+01 1.44E+04 3.32E+03 O.OOE+OO MN-54 O.OOE+OO 3.96E+04 6.30E+03 O.OOE+OO 9.84E+03 1.40E+06 7.74E+04 O.OOE+OO MN-56 O.OOE+OO 1.24E+OO 1.83E-01 O.OOE+OO 1.30E+OO 9.44E+03 2.02E+04 O.OOE+OO FE-55 2.46E+04 1. 70E+04 3.94E+03 O.OOE+OO O.OOE+OO 7.21 E+04 6.03E+03 O.OOE+OO FE-59 1.18E+04 2. 78E+04 1.06E+04 O.OOE+OO O.OOE+OO 1.02E+06 1.88E+05 O.OOE+OO C0-57 O.OOE+OO 6.92E+02 6.71 E+02 O.OOE+OO O.OOE+OO 3.70E+05 3.14E+04 O.OOE+OO C0-58 O.OOE+OO 1.58E+03 2.07E+03 O.OOE+OO O.OOE+OO 9.28E+05 1.06E+05 O.OOE+OO C0-60 O.OOE+OO 1.15E+04 1.48E+04 O.OOE+OO O.OOE+OO 5.97E+06 2.85E+05 O.OOE+OO Nl-59 3.25E+04 1.17E+04 5.42E+03 O.OOE+OO O.OOE+OO 6.56E+04 4.89E+03 O.OOE+OO Nl-63 4.32E+05 3.14E+04 1.45E+04 O.OOE+OO O.OOE+OO 1.78E+05 1.34E+04 O.OOE+OO Nl-65 1.54E+OO 2.1 OE-01 9.12E-02 O.OOE+OO O.OOE+OO 5.60E+03 1.23E+04 O.OOE+OO CU-64 O.OOE+OO 1.46E+OO 6.15E-01 O.OOE+OO 4.62E+OO 6.78E+03 4.90E+04 O.OOE+OO ZN-65 3.24E+04 1.03E+05 4.66E+04 O.OOE+OO 6.90E+04 8.64E+05 5.34E+04 O.OOE+OO ZN-69M 8.16E+OO 1.96E+01 1.79E+OO O.OOE+OO 1.18E+01 1.90E+04 1.37E+05 O.OOE+OO ZN-69 3.38E-02 6.51 E-02 4.52E-03 O.OOE+OO 4.22E-02 9.20E+02 1.63E+01 O.OOE+OO SE-79 O.OOE+OO 3.06E+03 4.87E+02 O.OOE+OO 4.55E+03 3.58E+05 2.66E+04 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.35E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.04E+04 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 2.41E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.32E+02 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 3.13E+02
- O.OOE+OO 0.00~+00 O.OOE+OO 1.64E-03 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.28E+01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.35E+05 5.90E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.66E+04 O.OOE+OO RB-87 O.OOE+OO 7.89E+04 2.57E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.30E+03 O.OOE+OO RB-88 O.OOE+OO 3.87E+02 1.93E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.34E-09 O.OOE+OO RB-89 O.OOE+OO 2.56E+02 1.70E+02 O.OOE+OO O.OOE+OO O.OOE+OO 9.28E-12 O.OOE+OO SR-89 3.04E+05 O.OOE+OO 8.72E+03 O.OOE+OO O.OOE+OO 1.40E+06 3.50E+05 O.OOE+OO SR-90 2.87E+07 O.OOE+OO 5.77E+05 O.OOE+OO O.OOE+OO 9.60E+06 7.22E+05 O.OOE+OO SR-91 6.19E+01 O.OOE+OO 2.50E+OO O.OOE+OO O.OOE+OO 3.65E+04 1.91E+05 O.OOE+OO SR-92 6.74E+OO O.OOE+OO 2.91 E-01 O.OOE+OO O.OOE+OO 1.65E+04 4.30E+04 O.OOE+OO Y-90 2.09E+03 O.OOE+OO 5.61 E+01 O.OOE+OO O.OOE+OO 1.70E+05 5.06E+05 O.OOE+OO Y-91 M 2.61 E-01 O.OOE+OO 1.02E-02 O.OOE+OO O.OOE+OO 1.92E+03 1.33E+OO O.OOE+OO Y-91 4.62E+05 O.OOE+OO 1.24E+04 O.OOE+OO O.OOE+OO 1.70E+06 3.85E+05 O.OOE+OO Y-92 1.03E+01 O.OOE+OO 3.02E-01 O.OOE+OO O.OOE+OO 1.57E+04 7.35E+04 O.OOE+OO Rev.29 Page 192 of 329 12/2016
CY-LG-170-301 TABLE 112-2 R1 I P1 DOSE FACTORS AGE: ADULT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-93 9.44E+01 O.OOE+OO 2.61 E+OO O.OOE+OO O.OOE+OO 4.85E+04 4.22E+05 O.OOE+OO ZR-93 4.18E+05 2.34E+04 1.10E+04 O.OOE+OO 8.88E+04 1.70E+05 1.21E+04 O.OOE+OO ZR-95 1.07E+05 3.44E+04 2.33E+04 O.OOE+OO 5.42E+04 1.77E+06 1.50E+05 O.OOE+OO ZR-97 9.68E+01 1.96E+01 9.04E+OO O.OOE+OO 2.97E+01 7.87E+04 5.23E+05 O.OOE+OO NB-93M 2.48E+05 8.08E+04 1.99E+04 O.OOE+OO 9.28E+04 2.49E+05 1.90E+04 O.OOE+OO NB-95 1.41E+04 7.82E+03 4.21E+03 O.OOE+OO 7.74E+03 5.05E+05 1.04E+05 O.OOE+OO NB-97 2.22E-01 5.62E-02 2.05E-02 O.OOE+OO 6.54E-02 2.40E+03 2.42E+02 O.OOE+OO M0-93 O.OOE+OO 9.36E+03 2.54E+02 O.OOE+OO 2.84E+03 4.09E+05 3.03E+04 O.OOE+OO M0-99 O.OOE+OO 1.21 E+02 2.30E+01 O.OOE+OO 2.91 E+02 9.12E+04 2.48E+05 O.OOE+OO TC-99M 1.03E-03 2.91 E-03 3.70E-02 O.OOE+OO 4.42E-02 7.64E+02 4.16E+03 O.OOE+OO TC-99 2.50E+02 3. 71 E+02 1.00E+02 O.OOE+OO 4.68E+03 8.08E+05 6.03E+04 O.OOE+OO TC-101 4.1 BE-05 6.02E-05 5.90E-04 O.OOE+OO 1.0BE-03 3.99E+02 1.09E-11 O.OOE+OO RU-103 1.53E+03 O.OOE+OO 6.58E+02 O.OOE+OO 5.83E+03 5.05E+05 1.10E+05 O.OOE+OO RU-105 7.90E-01 O.OOE+OO 3.11 E-01 O.OOE+OO 1.02E+OO 1.1 OE+04 4.82E+04 O.OOE+OO RU-106 6.91 E+04 O.OOE+OO 8.72E+03 O.OOE+OO 1.34E+05 9.36E+06 9.12E+05 O.OOE+OO RH-105 7.39E+OO 5.38E+OO 3.54E+OO O.OOE+OO 2.29E+01 1.93E+04 8.72E+04 O.OOE+OO PD-107 O.OOE+OO 6.62E+02 4.70E+01 O.OOE+OO 5.26E+03 7.58E+04 5.65E+03 O.OOE+OO PD-109 O.OOE+OO 3. 70E+OO 9.28E-01 O.OOE+OO 1.88E+01 1.48E+04 1.22E+05 O.OOE+OO AG-110M 1.08E+04 1.00E+04 5.94E+03 O.OOE+OO 1.97E+04 4.63E+06 3.02E+05 O.OOE+OO AG-111 3.40E+02 1.42E+02 7.1 OE+01 O.OOE+OO 4.59E+02 1.86E+05 2.23E+05 O.OOE+OO CD-113M O.OOE+OO 1.23E+06 3.98E+04 O.OOE+OO 1.37E+06 1.66E+06 1.27E+05 O.OOE+OO CD-115M O.OOE+OO 1.97E+05 6.36E+03 O.OOE+OO 1.58E+05 1.41 E+06 3.84E+05 O.OOE+OO SN-123 2.42E+05 5.34E+03 7.86E+03 4.54E+03 O.OOE+OO 2.30E+06 3.14E+05 O.OOE+OO SN-125 9.28E+03 2.50E+02 5.62E+02 2.07E+02 O.OOE+OO 5.90E+05 5.45E+05 O.OOE+OO SN-126 1.26E+06 3.34E+04 4.80E+04 9.84E+03 O.OOE+OO 9.36E+06 1.27E+05 O.OOE+OO
'
SB-124 3.12E+04 5.89E+02 1.24E+04 7.55E+01 O.OOE+OO 2.48E+06 4.06E+05 O.OOE+OO SB-125 5.34E+04 5.95E+02 1.26E+04 5.40E+01 O.OOE+OO 1.74E+06 1.01 E+05 O.OOE+OO SB-126 3.60E+03 7.30E+01 1.30E+03 2.20E+01 O.OOE+OO 7.66E+05 4.81 E+05 O.OOE+OO SB-127 2.64E+02 5. 78E+OO 1.02E+02 3.1 BE+OO O.OOE+OO 1.64E+05 3.02E+05 O.OOE+OO TE-125M 3.42E+03 1.58E+03 4.67E+02 1.05E+03 1.24E+04 3.14E+05 7.06E+04 O.OOE+OO TE-127M 1.26E+04 5.77E+03 1.57E+03 3.29E+03 4.58E+04 9.60E+05 1.50E+05 O.OOE+OO TE-127 1.40E+OO 6.42E-01 3.10E-01 1.06E+OO 5.10E+OO 6.51E+03 5.74E+04 O.OOE+OO TE-129M 9.76E+03 4.67E+03 1.58E+03 3.44E+03 3.66E+04 1.16E+06 3.83E+05 O.OOE+OO TE-129 4.98E-02 2.39E-02 1.24E-02 3.90E-02 1.87E-01 1.94E+03 1.57E+02 O.OOE+OO TE-131M 6.99E+01 4.36E+01 2.90E+01 5.50E+01 3.09E+02 1.46E+05 5.56E+05 O.OOE+OO TE-131 1.11 E-02 5.95E-03 3.59E-03 9.36E-03 4.37E-02 1.39E+03 1.84E+01 O.OOE+OO TE-132 2.60E+02 2.15E+02 1.62E+02 1.90E+02 1.46E+03 2.88E+05 5.1 OE+05 O.OOE+OO TE-133M 5.79E-02 4.32E-02 3.34E-02 5.02E-02 2.99E-01 4.41 E+03 6.12E+01 O.OOE+OO TE-134 3.07E-02 2.58E-02 1.26E-02 2.75E-02 1.74E-01 3.47E+03 2.38E-01 O.OOE+OO Rev. 29 Page 193 of 329 12/2016
CY-LG-170-301 TABLE 112-2 R1I P1 DOSE FACTORS AGE: ADULT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-129 1.98E+04 1.69E+04 5.53E+04 4.43E+07 3.62E+04 O.OOE+OO 1. 78E+03 O.OOE+OO 1-130 4.58E+03 1.34E+04 5.28E+03 1.14E+06 2.09E+04 O.OOE+OO 7.69E+03 O.OOE+OO 1-131 2.52E+04 3.58E+04 2.05E+04 1.19E+07 6.13E+04 O.OOE+OO 6.28E+03 O.OOE+OO 1-132 1.16E+03 3.26E+03 1.16E+03 1.14E+05 5.18E+03 O.OOE+OO 4.06E+02 O.OOE+OO 1-133 8.64E+03 1.48E+04 4.52E+03 2.15E+06 2.58E+04 O.OOE+OO 8.88E+03 O.OOE+OO 1-134 6.44E+02 1.73E+03 6.15E+02 2.98E+04 2.75E+03 O.OOE+OO 1.01 E+OO O.OOE+OO 1-135 2.68E+03 6.98E+03 2.57E+03 4.48E+05 1.11 E+04 O.OOE+OO 5.25E+03 O.OOE+OO CS-134M 1.27E+02 2.56E+02 1.38E+02 O.OOE+OO 1.46E+02 2.34E+01 6.34E+01 O.OOE+OO CS-134 3.73E+05 8.48E+05 7.28E+05 O.OOE+OO 2.87E+05 9.76E+04 1.04E+04 O.OOE+OO CS-135 1.17E+05 1.03E+05 4.79E+04 O.OOE+OO 4.09E+04 1.26E+04 1.69E+03 O.OOE+OO CS-136 3.90E+04 1.46E+05 1.1 OE+05 O.OOE+OO 8.56E+04 1.20E+04 1.17E+04 O.OOE+OO CS-137 4.78E+05 6.21E+05 4.28E+05 O.OOE+OO 2.22E+05 7.52E+04 8.40E+03 O.OOE+OO CS-138 3.31 E+02 6.21 E+02 3.24E+02 O.OOE+OO 4.80E+02 4.86E+01 1.86E-03 O.OOE+OO CS-139 2.05E+02 2.90E+02 1.11 E+02 O.OOE+OO 2.44E+02 2.27E+01 4.39E-21 O.OOE+OO BA-139 9.36E-01 6.66E-04 2.74E-02 O.OOE+OO 6.22E-04 3.76E+03 8.96E+02 O.OOE+OO BA-140 3.90E+04 4.90E+01 2.57E+03 O.OOE+OO 1.67E+01 1.27E+06 2.18E+05 O.OOE+OO BA-141 1.00E-01 7.53E-05 3.36E-03 O.OOE+OO 7.00E-05 1.94E+03 1.16E-07 O.OOE+OO BA-142 2.63E-02 2.70E-05 1.66E-03 O.OOE+OO 2.29E-05 1.19E+03 1.57E-16 O.OOE+OO LA-140 3.44E+02 1.74E+02 4.58E+01 O.OOE+OO O.OOE+OO 1.36E+05 4.58E+05 O.OOE+OO LA-141 4.27E+OO 1.33E+OO 2.17E-01 O.OOE+OO O.OOE+OO 1.08E+04 5.85E+04 O.OOE+OO LA-142 6.83E-01 3.1 OE-01 7.72E-02 O.OOE+OO O.OOE+OO 6.33E+03 2.11 E+03 O.OOE+OO CE-141 1.99E+04 1.35E+04 1.53E+03 O.OOE+OO 6.26E+03 3.62E+05 1.20E+05 O.OOE+OO CE-143 1.86E+02 1.38E+02 1.53E+01 O.OOE+OO 6.08E+01 7.98E+04 2.26E+05 O.OOE+OO CE-144 3.43E+06 1.43E+06 1.84E+05 O.OOE+OO 8.48E+05 7.78E+06 8.16E+05 O.OOE+OO PR-143 9.36E+03 3.75E+03 4.64E+02 O.OOE+OO 2.16E+03 2.81 E+05 2.00E+05 O.OOE+OO PR-144 3.01 E-02 1.25E-02 1.53E-03 O.OOE+OO 7.05E-03 1.02E+03 2.15E-08 O.OOE+OO ND-147 5.27E+03 6.10E+03 3.65E+02 O.OOE+OO 3.56E+03 2.21E+05 1.73E+05 O.OOE+OO PM-147 6. 70E+05 6.30E+04 2.55E+04 O.OOE+OO 1.19E+05 5.28E+05 4.43E+04 O,OOE+OO PM-148M 7.86E+04 2.03E+04 1.55E+04 O.OOE+OO 3.08E+04 1.71 E+06 3.34E+05 O.OOE+OO PM-148 3.07E+03 5.1 OE+02 2.56E+02 O.OOE+OO 9.60E+02 3.13E+05 4.64E+05 O.OOE+OO PM-149 2.75E+02 3.90E+01 1.59E+01 O.OOE+OO 7.35E+01 5.77E+04 2.00E+05 O.OOE+OO PM-151 6.80E+01 1.14E+01 5.77E+OO O.OOE+OO 2.04E+01 3.15E+04 1.60E+05 O.OOE+OO SM-151 6.87E+05 1.18E+05 2.84E+04 O.OOE+OO 1.33E+05 3.56E+05 2.60E+04 O.OOE+OO SM-153 1.36E+02 1.14E+02 8.32E+OO O.OOE+OO 3.67E+01 3.31 E+04 1.26E+05 O.OOE+OO EU-152 1.90E+06 4.33E+05 3.81 E+05 O.OOE+OO 2.68E+06 2*.74E+06 1.27E+05 O.OOE+OO EU-154 5.92E+06 7.28E+05 5.18E+05 O.OOE+OO 3.49E+06 4.67E+06 2.72E+05 O.OOE+OO EU-155 8.08E+05 1.14E+05 7.37E+04 O.OOE+OO 5.27E+05 7.57E+05 4.76E+04 O.OOE+OO EU-156 1.54E+04 1.18E+04 1.92E+03 O.OOE+OO 7.96E+03 6.85E+05 3.60E+05 O.OOE+OO TB-160 1.77E+05 O.OOE+OO 2.20E+04 O.OOE+OO 7.28E+04 1.54E+06 2.14E+05 O.OOE+OO Rev.29 Page 194 of 329 12/2016
CY-LG-170-301 TABLE 112-2 R1 I P1 DOSE FACTORS AGE: ADULT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H0-166M 2.70E+06 8.40E+05 6.40E+05 O.OOE+OO 1.26E+06 3.15E+06 1.27E+05 O.OOE+OO W-181 4.98E+01 1.62E+01 1.74E+OO O.OOE+OO O.OOE+OO 1.37E+04 2.02E+03 O.OOE+OO W-185 1.56E+03 5.18E+02 5.45E+01 O.OOE+OO O.OOE+OO 4.46E+05 8.56E+04 O.OOE+OO W-187 8.48E+OO 7.08E+OO 2.48E+OO O.OOE+OO O.OOE+OO 2.90E+04 1.55E+05 O.OOE+OO U-232 4.11 E+08 O.OOE+OO 2.93E+07 O.OOE+OO 4.45E+07 1.78E+09 3.37E+05 O.OOE+OO U-233 8.72E+07 O.OOE+OO 5.28E+06 O.OOE+OO 2.03E+07 4.26E+08 3.11 E+05 O.OOE+OO U-234 8.32E+07 O.OOE+OO 5.17E+06 O.OOE+OO 1.99E+07 4.18E+08 3.05E+05 O.OOE+OO U-235 8.00E+07 O.OOE+OO 4.86E+06 O.OOE+OO 1.87E+07 3.92E+08 3.87E+05 O.OOE+OO U-236 8.00E+07 O.OOE+OO 4.96E+06 O.OOE+OO 1.91 E+07 4.00E+08 2.86E+05 O.OOE+OO U-237 2.94E+02 O.OOE+OO 7.82E+01 O.OOE+OO 1.21E+03 8.16E+04 9.60E+04 O.OOE+OO U-238 7.66E+07 O.OOE+OO 4.54E+06 O.OOE+OO 1.74E+07 3.66E+08 2.73E+05 O.OOE+OO NP-237 1.25E+10 8.00E+09 5.50E+08 O.OOE+OO 4.08E+09 4.18E+08 3.94E+05 O.OOE+OO NP-238 2.37E+03 5.76E+02 3.69E+01 O.OOE+OO 2.18E+02 8.16E+04 1.70E+05 O.OOE+OO NP-239 2.30E+02 2.03E+02 1.24E+01 O.OOE+OO 7.00E+01 3.76E+04 1.19E+05 O.OOE+OO PU-238 1.14E+10 7.77E+09 5.52E+08 O.OOE+OO 2.37E+09 1.46E+09 3.62E+05 O.OOE+OO PU-239 1.33E+10 8.56E+09 6.20E+08 O.OOE+OO 2.6'4E+09 1.38E+09 3.30E+05 O.OOE+OO PU-240 1.32E+10 8.56E+09 6.18E+o8 O.OOE+OO 2.63E+09 1.38E+09 3.37E+05 O.OOE+OO PU-241 2.74E+08 6.95E+07 1.03E+07 O.OOE+OO 4.74E+07 1.22E+06 6.92E+03 O.OOE+OO PU-242 1.22E+10 8.24E+09 5.97E+08 O.OOE+OO 2.54E+09 1.32E+09 3.24E+05 O.OOE+OO PU-244 1.43E+10 9.44E+09 6.83E+08 O.OOE+OO 2.91E+09 1.51E+09 4.82E+05 O.OOE+OO AM-241 1.34E+10 9.04E+09 5.37E+08. O.OOE+OO 4.03E+09 4.85E+08 3.68E+05 O.OOE+OO AM-242M 1.36E+10 8.48E+09 5.38E+08 O.OOE+OO 4.01E+09 1.95E+08 4.63E+05 O.OOE+OO AM-243 1.34E+10 8.80E+09 5.26E+08 O.OOE+OO 3.96E+09 4.60E+08 4.32E+05 O.OOE+OO CM-242 1.78E+08 1.42E+08 7.87E+06 O.OOE+OO 3.58E+07 3.14E+08 3.93E+05 O.OOE+OO CM-243 8.80E+09 6.09E+09 3.69E+08 O.OOE+OO 1.72E+09 5.05E+08 3.87E+05 O.OOE+OO CM-244 6.70E+09 4.70E+09 2.81E+08 O.OOE+OO 1.31E+09 4.85E+08 3.74E+05 O.OOE+OO CM-245 1.39E+10 9.12E+09 5.71E+08 O.OOE+OO 2.66E+09 4.68E+08 3.49E+05 O.OOE+OO CM-246 1.38E+10 9.12E+09 5.70E+08 O.OOE+OO 2.66E+09 4.77E+08 3.43E+05 O.OOE+OO CM-247 1.34E+10 8;96E+09 5.62E+08 O.OOE+OO 2.62E+09 4.68E+08 4.50E+05 O.OOE+OO CM-248 1.12E+09 7.41E+10 4.63E+09 O.OOE+OO 2.16E+10 3.86E+09 7.27E+06 O.OOE+OO CF-252 4.34E+09 O.OOE+OO 1.86E+08 O.OOE+OO O.OOE+OO 1.59E+09 1.42E+06 O.OOE+OO Rev. 29 Page 195 of 329 12/2016
CY-LG-170-301 TABLE 112-3 R 1 I P1 DOSE FACTORS AGE: TEEN PATHWAY: INHALATION mrem/yr per µCi/m3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 7.25E+02 7.25E+02 7.25E+02 7.25E+02 7.25E+02 7.25E+02 O.OOE+OO C-14 2.60E+04 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 O.OOE+OO NA-22 1.41 E+05 1.41 E+05 1.41 E+05 1.41 E+05 1.41 E+05 1.41 E+05 1.41 E+05 O.OOE+OO NA-24 1.38E+04 1.38E+04 1.38E+04 1.38E+04 1.38E+04 1.38E+04 1.38E+04 O.OOE+OO P-32 1.89E+06 1.10E+05 7.16E+04 O.OOE+OO O.OOE+OO O.OOE+OO 9.28E+04 O.OOE+OO CA-41 3.24E+05 O.OOE+OO 3.50E+04 O.OOE+OO O.OOE+OO 8.08E+08 2.42E+03 O.OOE+OO SC-46 5.79E+05 1.13E+06 3.34E+05 O.OOE+OO 1.08E+06 O.OOE+OO, 2.38E+05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.35E+02 7.50E+01 3.07E+01 2.1 OE+04 3.00E+03 O.OOE+OO MN-54 O.OOE+OO 5.11 E+04 8.40E+03 O.OOE+OO 1.27E+04 1.98E+06 6.68E+04 O.OOE+OO MN-56 O.OOE+OO 1.70E+OO 2.52E-01 O.OOE+OO 1.79E+OO 1.52E+04 5.74E+04 O.OOE+OO FE-55 3.34E+04 2.38E+04 5.54E+03 O.OOE+OO O.OOE+OO 1.24E+05 6.39E+03 O.OOE+OO FE-59 1.59E+04 3.70E+04 1.43E+04 O.OOE+OO O.OOE+OO 1.53E+06 1.78E+05 O.OOE+OO C0-57 O.OOE+OO 9.44E+02 9.20E+02 O.OOE+OO O.OOE+OO 5.86E+05 3.14E+04 O.OOE+OO C0-58 O.OOE+OO 2.07E+03 2.78E+03 O.OOE+OO O.OOE+OO 1.34E+06 9.52E+04 O.OOE+OO . C0-60 O.OOE+OO 1.51 E+04 1.98E+04 O.OOE+OO O.OOE+OO 8.72E+06 2.59E+05 O.OOE+OO Nl-59 4.35E+04 1.62E+04 7.39E+03 O.OOE+OO O.OOE+OO 1.13E+05 5.18E+03 O.OOE+OO Nl-63 5.80E+05 4.34E+04 1.98E+04 O.OOE+OO O.OOE+OO 3.07E+05 1.42E+04 O.OOE+OO Nl-65 2.18E+OO 2.93E-01 1.27E-01 O.OOE+OO O.OOE+OO 9.36E+03 3.67E+04 O.OOE+OO CU-64 O.OOE+OO 2.03E+OO 8.48E-01 O.OOE+OO 6.41 E+OO 1.11 E+04 6.14E+04 O.OOE+OO ZN-65 3.86E+04 1.34E+05 6.24E+04 O.OOE+OO 8.64E+04 1.24E+06 4.66E+04 O.OOE+OO ZN-69M 1.15E+01 2. 71 E+01 2.49E+OO O.OOE+OO 1.65E+01 3.14E+04 1.71 E+05 O.OOE+OO ZN-69 4.83E-02 9.20E-02 6.46E-03 O.OOE+OO 6.02E-02 1.58E+03 2.85E+02 O.OOE+OO SE-79 O.OOE+OO 4.34E+03 6.97E+02 O.OOE+OO 6.50E+03 6.17E+05 2.82E+04 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.82E+04 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.44E+02 O.OOE+OO O.OOE+OO O.OOE+OQ O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 4.33E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.83E+01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.90E+05 8.40E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.77E+04 O.OOE+OO RB-87 O.OOE+OO 1.12E+05 3.66E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.44E+03 O.OOE+OO RB-88 O.OOE+OO 5.46E+02 2.72E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.92E-05 O.OOE+OO RB-89 O.OOE+OO 3.52E+02 2.33E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.38E-07 O.OOE+OO SR-89 4.34E+05 O.OOE+OO 1.25E+04 O.OOE+OO O.OOE+OO 2.42E+06 3.71 E+05 O.OOE+OO SR-90 3.31 E+07 O.OOE+OO 6.66E+05 O.OOE+OO O.OOE+OO 1.65E+07 7.65E+05 O.OOE+OO SR-91 8.80E+01 O.OOE+OO 3.51 E+OO O.OOE+QO O.OOE+OO 6.07E+04 2.59E+05 O.OOE+OO SR-92 9.52E+OO O.OOE+OO 4.06E-01 O.OOE+OO O.OOE+OO 2.74E+04 1.19E+05 O.OOE+OO Y-90 2.98E+03 O.OOE+OO 8.00E+01 O.OOE+OO O.OOE+OO 2.93E+05 5.59E+05 O.OOE+OO Y-91M 3. 70E-01 O.OOE+OO 1.42E-02 O.OOE+OO O.OOE+OO 3.20E+03 3.02E+01 O.OOE+OO Rev.29 Page 196 of 329 12/2016
CY-LG-170-301 TABLEll2-3 R1 I P1 DOSE FACTORS AGE: TEEN PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-91 6.61 E+05 O.OOE+OO 1.77E+04 O.OOE+OO O.OOE+OO 2.94E+06 4.09E+05 O.OOE+OO Y-92 1.47E+01 O.OOE+OO 4.29E-01 O.OOE+OO O.OOE+OO 2.68E+04 1.65E+05 O.OOE+OO Y-93 1.35E+02 O.OOE+OO 3.72E+OO O.OOE+OO O.OOE+OO 8.32E+04 5.79E+05 O.OOE+OO ZR-93 5.46E+05 2. 70E+04 1.47E+04 O.OOE+OO 9.28E+04 2.94E+05 1.28E+04 O.OOE+OO ZR-95 1.46E+05 4.58E+04 3.15E+04 O.OOE+OO 6.74E+04 2.69E+06 1.49E+05 O.OOE+OO ZR-97 1.38E+02 2. 72E+01 1.26E+01 O.OOE+OO 4.12E+01 1.30E+05 6.30E+05 O.OOE+OO NB-93M 3.31 E+05 1.09E+05 2.73E+04 O.OOE+OO 1.27E+05 4.29E+05 2.02E+04 O.OOE+OO NB-95 1.86E+04 1.03E+04 5.66E+03 O.OOE+OO 1.00E+04 7.51 E+05 9.68E+04 O.OOE+OO NB-97 3.14E-01 7.78E-02 2.84E-02 O.OOE+OO 9.12E-02 3.93E+03 2.17E+03 O.OOE+OO M0-93 O.OOE+OO 1.33E+04 3.62E+02 O.OOE+OO 4.05E+03 7.05E+05 3.19E+04 O.OOE+OO M0-99 O.OOE+OO 1.69E+02 3.22E+01 O.OOE+OO 4.11 E+02 1.54E+05 2.69E+05 O.OOE+OO TC-99M 1.38E-03 3.86E-03 4.99E-02 O.OOE+OO 5. 76E-02 1.15E+03 6.13E+03 O.OOE+OO TC-99 3.58E+02 5.26E+02 1.43E+02 O.OOE+OO 6.68E+03 1.39E+06 6.39E+04 O.OOE+OO TC-101 5.92E-05 8.40E-05 . 8.24E-04 O.OOE+OO 1.52E-03 6.67E+02 8.72E-07 O.OOE+OO RU-103 2.1 OE+03 O.OOE+OO 8.96E+02 O.OOE+OO 7.43E+03 7.83E+05 1.09E+05 O.OOE+OO RU-105 1.12E+OO O.OOE+OO 4.34E-01 O.OOE+OO 1.41 E+OO 1.82E+04 9.04E+04 O.OOE+OO RU-106 9.84E+04 O.OOE+OO 1.24E+04 O.OOE+OO 1.90E+05 1.61 E+07 9.60E+05 O.OOE+OO RH-105 1.06E+01 7.58E+OO 4.99E+OO . O.OOE+OO 3.23E+01 3.27E+04 9.84E+04 O.OOE+OO PD-107 O.OOE+OO 9.36E+02 6.71 E+01 O.OOE+OO 7.51 E+03 1.30E+05 5.99E+03 O.OOE+OO PD-109 O.OOE+OO 5.25E+OO 1.33E+OO O.OOE+OO 2.69E+01 2.55E+04 1.57E+05 O.OOE+OO AG-110M 1.38E+04 1.31 E+04 7.99E+03 O.OOE+OO 2.50E+04 6.75E+06 2.73E+05 O.OOE+OO AG-111 4.86E+02 2.02E+02 1.01 E+02 O.OOE+OO 6.54E+02 3.20E+05 2.40E+05 O.OOE+OO CD-113M O.OOE+OO 1.74E+06 5.68E+04 O.OOE+OO 1.94E+06 2.87E+06 1.34E+05 O.OOE+OO CD-115M O.OOE+OO 2.78E+05 9.12E+03 O.OOE+OO 2.26E+05 2.42E+06 4.08E+05 O.OOE+OO SN-123 3.45E+05 7.55E+03 1.12E+04 6.04E+03 O.OOE+OO 3.97E+06 3.33E+05 O.OOE+OO SN-125 1.33E+04 3.54E+02 7.99E+02 2.76E+02 O.OOE+OO 1.01 E+06 5.83E+05 O.OOE+OO SN-126 1.74E+06 4.31 E+04 6.59E+04 1.14E+04 O.OOE+OO 1.38E+07 1.34E+05 O.OOE+OO SB-124 4.30E+04 7.94E+02 1.68E+04 9.76E+01 O.OOE+OO 3.85E+06 3.98E+05 O.OOE+OO SB-125 7.38E+04 8.08E+02 1.72E+04 7.04E+01 O.OOE+OO 2.74E+06 9.92E+04 O.OOE+OO SB-126 4.95E+03 1.02E+02 1.78E+03 2.80E+01 O.OOE+OO 1.24E+06 4.81 E+05 O.OOE+OO SB-127 3.71 E+02 7.94E+OO 1.40E+02 4.17E+OO O.OOE+OO 2.65E+05 3.15E+05 O.OOE+OO TE-125M 4.88E+03 2.24E+03 6.67E+02 1.40E+03 O.OOE+OO 5.36E+05 7.50E+04 O.OOE+OO TE-127M 1.80E+04 8.16E+03 2.18E+03 4.38E+03 6.54E+04 1.66E+06 1.59E+05 O.OOE+OO TE-127 2.01 E+OO 9.12E-01 4.42E-01 1.42E+OO 7.28E+OO 1.12E+04 8.08E+04 O.OOE+OO TE-129M 1.39E+04 6.58E+03. 2.25E+03 4.58E+03 5.19E+04 1.98E+06 4.05E+05 O.OOE+OO TE-129 7.10E-02 3.38E-02 1.76E-02 5.1 BE-02 2.66E-01 3.30E+03 1.62E+03 O.OOE+OO TE-131M 9.84E+01 6.01 E+01 4.02E+01 7.25E+01 4.39E+02 2.38E+05 6.21 E+05 O.OOE+OO Rev.29 Page 197 of 329 12/2016
CY-LG-170-301 TABLE 112-3 R1 I P1 DOSE FACTORS AGE: TEEN PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN TE-131 1.58E-02 8.32E-03 5.04E-03 1.24E-02 6.18E-02 2.34E+03 1.51 E+01 O.OOE+OO TE-132 3.60E+02 2.90E+02 2.19E+02 2.46E+02 1.95E+03 4.49E+05 4.63E+05 O.OOE+OO TE-133M 8.08E-02 5.86E-02 4.57E-02 6.54E-02 4.06E-01 6.97E+03 9.84E+02 O.OOE+OO TE-134 4.25E-02 3.48E-02 2.91 E-02 3.57E-02 2.33E-01 5.40E+03 1.1 OE+01 O.OOE+OO 1-129 2.82E+04 2.35E+04 3.92E+04 2.93E+07 4.21 E+04 O.OOE+OO 1.83E+03 O.OOE+OO 1-130 6.24E+03 1. 7SE+04 7.17E+03 1.49E+06 2.75E+04 O.OOE+OO 9.12E+03 O.OOE+OO 1-131 3.54E+04 4.91 E+04 . 2.64E+04 1.46E+07 8.40E+04 O.OOE+OO 6.49E+03 O.OOE+OO 1-132 1.59E+03 4.38E+03 1.58E+03 1.51 E+05 6.92E+03 O.OOE+OO 1.27E+03 O.OOE+OO 1-133 1.22E+04 2.05E+04 6.22E+03 2.92E+06 3.59E+04 O.OOE+OO 1.03E+04 O.OOE+OO 1-134 8.88E+02 2.32E+03 8.40E+02 3.95E+04 3.66E+03 O.OOE+OO 2.04E+01 O.OOE+OO 1-135 3. 70E+03 9.44E+03 3.49E+03 6.21 E+05 1.49E+04 O.OOE+OO 6.95E+03 O.OOE+OO CS-134M 1. 76E+02 3.48E+02 1.88E+02 O.OOE+OO 2.03E+02 3.65E+01 1.62E+02 O.OOE+OO CS-134 5.02E+05 1.13E+06 5.49E+05 O.OOE+OO 3.75E+05 1.46E+05 9.76E+03 O.OOE+OO CS-135 1.66E+05 1.46E+05 3.58E+04 O.OOE+OO 5.84E+04 2.16E+04 1.78E+03 O.OOE+OO CS-136 5.15E+04 1.94E+05 1.37E+05 O.OOE+OO 1.10E+05 1.78E+04 1.09E+04 O.OOE+OO CS-137 6.70E+05 8.48E+05 3.11 E+05 O.OOE+OO 3.04E+05 1.21 E+05 8.48E+03 O.OOE+OO CS-138 4.66E+02 8.56E+02 4.46E+02 O.OOE+OO 6.62E+02 7.87E+01 2.70E-01 O.OOE+OO CS-139 2.92E+02 4.1 OE+02 1.58E+02 O.OOE+OO 3.47E+02 3.89E+01 1.33E-13 O.OOE+OO BA-139 1.34E+OO 9.44E-04 3.90E-02 O.OOE+OO 8.88E-04 6.46E+03 6.45E+03 O.OOE+OO BA-140 5.47E+04 6.70E+01 3.52E+03 O.OOE+OO 2.28E+01 2.03E+06 2.29E+05 O.OOE+OO BA-141 1.42E-01 1.06E-04 4.74E-03 O.OOE+OO 9.84E-05 3.29E+03 7.46E-04 O.OOE+OO BA-142 3.70E-02 3.70E-05 2.27E-03 O.OOE+OO 3.14E-05 1.91E+03 4.79E-10 O.OOE+OO LA-140 4.79E+02 2.36E+02 6.26E+01 O.OOE+OO O.OOE+OO 2.14E+05 4.87E+05 O.OOE+OO LA-141 6.1 OE+OO 1.88E+OO 3.1 OE-01 O.OOE+OO O.OOE+OO 1.85E+04 1.23E+05 O.OOE+OO LA-142 9.60E-01 4.25E-01 1.06E-01 O.OOE+OO O.OOE+OO 1.02E+04 1.20E+04 O.OOE+OO CE-141 2.84E+04 1.90E+04 2.17E+03 O.OOE+OO 8.88E+03 6.14E+05 1.26E+05 O.OOE+OO CE-143 2.66E+02 1.94E+02 2.16E+01 O.OOE+OO 8.64E+01 1.30E+05 2.55E+05 O.OOE+OO CE-144 4.89E+06 2.02E+06 2.62E+05 O.OOE+OO 1.21 E+06 1.34E+07 8.64E+05 O.OOE+OO PR-143 1.34E+04 5.31 E+03 6.62E+02 O.OOE+OO 3.09E+03 4.83E+05 2.14E+05 O.OOE+OO PR-144 4.30E-02 1. 76E-02 2.18E-03 O.OOE+OO 1.01 E-02 1.75E+03 2.35E-04 O.OOE+OO ND-147 7.86E+03 8.56E+03 5.13E+02 O.OOE+OO 5.02E+03 3.72E+05 1.82E+05 O.OOE+OO PM-147 9.20E+05 8.80E+04 3.60E+04 O.OOE+OO 1.68E+05 9.12E+05 4.70E+04 O.OOE+OO PM-148M 1.06E+05 2.68E+04 2.1 OE+04 O.OOE+OO 4.06E+04 2.56E+06 3.28E+05 O.OOE+OO PM-148 4.35E+03 7.1 OE+02 3.58E+02 O.OOE+OO 1.28E+03 5.22E+05 4.91 E+05 O.OOE+OO PM-149 3.93E+02 5.51 E+01 2.27E+01 O.OOE+OO 1.05E+02 9.92E+04 2.23E+05 O.OOE+OO PM-151 9.60E+01 1.59E+01 8.08E+OO O.OOE+OO 2.86E+01 5.25E+04 1.82E+05 O.OOE+OO SM-151 8.56E+05 1.68E+05 3.89E+04 O.OOE+OO 1.82E+05 6.14E+05 2.82E+04 O.OOE+OO Rev.29 Page 198 of 329 12/2016
CY-LG-170-301 TABLE 112-3 R1 I P1 DOSE FACTORS AGE: TEEN PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID
- KIDNEY LUNG Gl-LLI SKIN SM-153 1.94E+02 1.61 E+02 1.18E+01 O.OOE+OO 5.25E+01 5.69E+04 1.42E+05 O.OOE+OO EU-152 2.37E+06 5.75E+05 5.04E+05 O.OOE+OO 2.67E+06 4.01 E+06 1.08E+05 O.OOE+OO EU-154 7.54E+06 9.84E+05 6.88E+05 O.OOE+OO 4.35E+06 7.30E+06 2.67E+05 O.OOE+OO EU-155 1.60E+06 1.57E+05 9.68E+04 O.OOE+OO 6.12E+05 1.21 E+07 4.78E+05 O.OOE+OO EU-156 2.16E+04 1.62E+04 2.64E+03 O.OOE+OO 1.09E+04 1.1 OE+06 3.65E+05 O.OOE+OO TB-160 2.43E+05 O.OOE+OO 3.03E+04 O.OOE+OO 9.60E+04 2.38E+06 2.08E+05 O.OOE+OO H0-166M 3.52E+06 1.09E+06 7.90E+05 O.OOE+OO 1.60E+06 4.99E+06 1.34E+05 O.OOE+OO W-181 7.12E+01 2.30E+01 2.41E+OO O.OOE+OO O.OOE+OO 2.36E+04 2.15E+03 O.OOE+OO W-185 2.22E+03 7.34E+02 7.78E+01 O.OOE+OO O.OOE+OO 7.68E+05 9.12E+04 O.OOE+OO W-187 1.20E+01 9.76E+OO 3.43E+OO O.OOE+OO O.OOE+OO 4.74E+04 1.77E+05 O.OOE+OO U-232 5.85E+08 O.OOE+OO 4.18E+07 O.OOE+OO 6.35E+07 3.07E+09 3.57E+05 O.OOE+OO U-233 1.24E+08 O.OOE+OO 7.54E+06 O.OOE+OO 2.90E+07 7.34E+08 3.30E+05 O.OOE+OO U-234 1.18E+08 O.OOE+OO 7.38E+06 O.OOE+OO 2.84E+07 7.19E+08 3.23E+05 O.OOE+OO U-235 1.14E+08 O.OOE+OO 6.94E+06 O.OOE+OO 2.67E+07 6.75E+08 4.10E+05 O.OOE+OO U-236 1.14E+08 O.OOE+OO 7.09E+06 O.OOE+OO 2.73E.t07 6.90E+08 3.03E+05 O.OOE+OO U-237 4.20E+02 O.OOE+OO 1.12E+02 O.OOE+OO 1.73E+03 1.41E+05 1.03E+05 O.OOE+QO U-238 1.09E+08 O.OOE+OO 6.48E+06 O.OOE+OO 2.50E+07 6.31 E+08 2.90E+05 O.OOE+OO NP-237 1.31E+10 8.48E+09 5. 77E+08 O.OOE+OO 4.28E+09 7.19E+08 4.18E+05 O.OOE+OO NP-238 3.38E+03 8.16E+02 5.27E+01 O.OOE+OO 3.1 OE+02 1.40E+05 1.90E+05 O.OOE+OO NP-239 3.38E+02 2.88E+02 1.77E+01 O.OOE+OO 1.00E+02 6.49E+04 1.32E+05 O.OOE+OO
- PU-238 1.20E+10 8.24E+09 5.78E+08 O.OOE+OO 2.48E+09 2.50E+09 3.83E+05 O.OOE+OO PU-239 1.38E+10 8.96E+09 6.44E+08 O.OOE+OO 2.75E+09 2.34E+09 3.50E+05 O.OOE+OO PU-240 1.38E+10 8.96E+09 6.43E+08 O.OOE+OO 2.74E+09 2.34E+09 3.57E+05 O.OOE+OO PU-241 2.99E+08 7.65E+07 1.12E+07 O.OOE+OO 5.18E+07 2.08E+06 7.34E+03 O.OOE+OO PU-242 1.28E+10 8.64E+09 6.20E+08 O.OOE+OO 2.65E+09 2.26E+09 3.43E+05 O.OOE+OO PU-244 1.50E+10 9.92E+09 7.1 OE+08 O.OOE+OO 3.03E+09 2.58E+09 5.11 E+05 O.OOE+OO AM-241 1.42E+10 9.60E+09 5.68E+08 O.OOE+OO 4.26E+09 8.40E+08 3.90E+05 O.OOE+OO AM-242M 1.43E+10 9.04E+09 5.72E+08 O.OOE+OO 4.24E+09 3.37E+08 4.91 E+05 O.OOE+OO AM-243 1.42E+10 9.36E+09 5.56E+08 O.OOE+OO 4.17E+09 7.93E+08 4.58E+05 O.OOE+OO CM-242 2.54E+08 2.01 E+08 1.13E+07 O.OOE+OO 5.12E+07 5.41E+08 4.17E+05 O.OOE+OO CM-243 9.52E+09 6.64E+09 4.00E+08 O.OOE+OO 1.87E+09 8.72E+08 4.1 OE+05 O.OOE+OO CM-244 7.35E+09 5.22E+09 3.1 OE+08 O.OOE+OO 1.45E+09 8.40E+08 3.97E+05 O.OOE+OO CM-245 1.46E+10 9. 76E+09 6.02E+08 O.OOE+OO 2.82E+09 8.08E+08 3.70E+05 O.OOE+OO CM-246 1.45E+10 9.76E+09 6.02E+08 O.OOE+OO 2.81 E+09 8.24E+08 3.63E+05 O.OOE+OO CM-247 1.42E+10 9.52E+09 5.93E+08 - O.OOE+OO 2.77E+09 8.08E+08 4.78E+05 O.OOE+OO CM-248 1.18E+09 7.86E+10 4.89E+09 O.OOE+OO 2.28E+10 6.66E+09 7,70E+06 O.OOE+OO CF-252 5.73E+09 O.OOE+OO 2.46E+08 O.OOE+OO O.OOE+OO 2.74E+09 1.51 E+06 O.OOE+OO Rev.29 Page 199 of 329 12/2016
CY-LG-170-301 TABLE 112-4 R1 I P1 DOSE FACTORS AGE: CHILD PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 6.40E+02 6.40E+02 6.40E+02 6.40E+02 6.40E+02 6.40E+02 O.OOE+OO C-14 3.59E+04 6.73E+03 6.73E+03 6.73E+03 6.73E+03 6.73E+03 6.73E+03 O.OOE+OO NA-22 1.63E+05 1.63E+05 1.63E+05 1.63E+05 1.63E+05 1.63E+05 1.63E+05 O.OOE+OO NA-24 1.61 E+04 1.61 E+04 1.61 E+04. 1.61 E+04 1.61 E+04 1.61 E+04 1.61 E+04 O.OOE+OO P-32 2.60E+06 1.14E+05 9.88E+04 O.OOE+OO O.OOE+OO O.OOE+OO 4.22E+04 O.OOE+oo* CA-41 2.61 E+05 O.OOE+OO 2.85E+04 O.OOE+OO O.OOE+OO 2.67E+08 1.09E+03 O.OOE+OO SC-46 7.29E+05 9.99E+05 3.85E+05 O.OOE+OO 8.84E+05 O.OOE+OO 9.07E+04 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.54E+02 8.55E+01 2.43E+01 1.70E+04 1.08E+03 O.OOE+OO MN-54 O.OOE+OO 4.29E+04 9.51 E+03 O.OOE+OO 1.00E+04 1.58E+06 2.29E+04 O.OOE+OO MN-56 O.OOE+OO 1.66E+OO 3.12E-01 O.OOE+OO 1.67E+OO 1.31 E+04 1.23E+05 O.OOE+OO FE-55 4.74E+04 2.52E+04 7.77E+03 O.OOE+OO O.OOE+OO 1.11 E+05 2.87E+03 O.OOE+OO FE-59 2.07E+04 3.34E+04 1.67E+04 O.OOE+OO O.OOE+OO 1.27E+06 7.07E+04 O.OOE+OO C0-57 O.OOE+OO 9.03E+02 1.07E+03 O.OOE+OO O.OOE+OO 5.07E+05 1.32E+04 O.OOE+OO C0-58 O.OOE+OO 1.77E+03 3.16E+03 O.OOE+OO O.OOE+OO 1.11E+06 3.44E+04 O.OOE+OO C0-60 O.OOE+OO 1.31 E+04 2.26E+04 O.OOE+OO O.OOE+OO 7.07E+06 9.62E+04 O.OOE+OO Nl-59 6.14E+04 1.73E+04 1.05E+04 O.OOE+OO O.OOE+OO 1.01 E+05 2.33E+03 O.OOE+OO Nl-63 8.21E+05 4.63E+04 2.80E+04 O.OOE+OO O.OOE+OO 2.75E+05 6.33E+03 O.OOE+OO Nl-65 2.99E+OO 2.96E-01 1.64E-01 O.OOE+OO O.OOE+OO 8.18E+03 8.40E+04 O.OOE+OO CU-64 O.OOE+OO 1.99E+OO 1.07E+OO O.OOE+OO 6.03E+OO 9.58E+03 3.67E+04 O.OOE+OO ZN-65 4.26E+04 1.13E+05 7.03E+04 O.OOE+OO 7.14E+04 9.95E+05 1.63E+04 O.OOE+OO ZN-69M 1.58E+01 2.69E+01 3.18E+OO O.OOE+OO 1.56E+01 2.72E+04 1.00E+05 O.OOE+OO ZN-69 6.70E-02 9.66E-02 8.92E-03 O.OOE+OO 5.85E-02 1.42E+03 1.02E+04 O.OOE+OO SE-79 O.OOE+OO 4.55E+03 9.62E+02 O.OOE+OO 6.33E+03 5.51 E+05 1.27E+04 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 2.09E+04 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 4.74E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 5.48E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 2.53E+01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.98E+05 1.14E+05 O.OOE+OO O.OOE+OO O.OOE+OO 7.99E+03 O.OOE+OO RB-87 O.OOE+OO 1.17E+05 5.07E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.1 OE+03 O.OOE+OO RB-88 O.OOE+OO 5.62E+02 3.66E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+01 O.OOE+OO RB-89 O.OOE+OO 3.45E+02 2.90E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.89E+OO O.OOE+OO SR-89 5.99E+05 O.OOE+OO 1.72E+04 O.OOE+OO O.OOE+OO 2.16E+06 1.67E+05 O.OOE+OO SR-90 3.85E+07 O.OOE+OO 7.66E+05 O.OOE+OO O.OOE+OO 1.48E+07 3.43E+05 O.OOE+OO SR-91 1.21 E+02 O.OOE+OO 4.59E+OO O.OOE+OO O.OOE+OO 5.33E+04 1.74E+05 O.OOE+OO SR-92 1.31 E+01 O.OOE+OO 5.25E-01 O.OOE+OO O.OOE+OO 2.40E+04 2.42E+05 O.OOE+OO Y-90 4.11 E+03 O.OOE+OO 1.11 E+02 O.OOE+OO O.OOE+OO 2.62E+05 2:68E+05 O.OOE+OO Y-91M 5.07E-01 O.OOE+OO 1.84E-02 O.OOE+OO O.OOE+OO 2.81E+03 1.72E+03 O.OOE+OO Y-91 9.14E+05 O.OOE+OO 2.44E+04 O.OOE+OO O.OOE+OO 2.63E+06 1.84E+05 O.OOE+OO Y-92 2.04E+01 O.OOE+OO 5.81 E-01 O.OOE+OO O.OOE+OO 2.39E+04 2.39E+05 O.OOE+OO Rev.29 Page 200 of 329 12/2016
CY-LG-170-301 TABLE 112-4 R1 I P1 DOSE FACTORS AGE: CHILD PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-93 1.86E+02 O.OOE+OO 5.11 E+OO O.OOE+OO O.OOE+OO 7.44E+04 3.89E+05 O.OOE+OO ZR-93 7.66E+05 2.89E+04 2.05E+04 O.OOE+OO 1.11 E+05 2.63E+05 5.44E+03 O.OOE+OO ZR-95 1.90E+05 4.18E+04 3.70E+04 O.OOE+OO 5.96E+04 2.23E+06 6.11 E+04 O.OOE+OO ZR-97 1.88E+02 2.72E+01 1.60E+01 O.OOE+OO 3.89E+01 1.13E+05 3.51E+05 O.OOE+OO NB-93M 4. 70E+05 1.17E+05 3.85E+04 O.OOE+OO 1.27E+05 3.85E+05 9.07E+03 O.OOE+OO NB-95 2.35E+04 9.18E+03 6.55E+03 O.OOE+OO 8.62E+03 6.14E+05 3.70E+04 O.OOE+OO NB-97 4.29E-01 7.70E-02 3.60E-02 O.OOE+OO 8.55E-02 3.42E+03 2.78E+04 O.OOE+OO M0-93 O.OOE+OO 1.39E+04 5.00E+02 O.OOE+OO 3.92E+03 6.29E+05 1.40E+04 O.OOE+OO M0-99 O.OOE+OO 1.72E+02 4.26E+01 O.OOE+OO 3.92E+02 1.35E+05 1.27E+05 O.OOE+OO TC-99M 1.78E-03 3.48E-03 5.77E-02 O.OOE+OO 5.07E-02 9.51E+02 4.81E+03 O.OOE+OO TC-99 4.96E+02 5.51 E+02 1.98E+02 O.OOE+OO 6.48E+03 1.25E+06 2.87E+04 O.OOE+OO TC-101 8.1 OE-05 8.51 E-05 1.08E-03 O.OOE+OO 1.45E-03 5.85E+02 1.63E+01 O.OOE+OO RU-103 2.79E+03 O.OOE+OO 1.07E+03 O.OOE+OO 7.03E+03 6.62E+05 4.48E+04 O.OOE+OO RU-105 1.53E+OO O.OOE+OO 5.55E-01 O.OOE+OO 1.34E+OO 1.59E+04 9.95E+04 O.OOE+OO RU-106 1.36E+05 O.OOE+OO 1.69E+04 O.OOE+OO 1.84E+05 1.43E+07 4.29E+05 O.OOE+OO RH-105 1.45E+01 7. 77E+OO 6.62E+OO O.OOE+OO 3.1 OE+01 2.89E+04 4.92E+04 O.OOE+OO PD-107 O.OOE+OO 9.81 E+02 9.29E+01 O.OOE+OO 7.29E+03 1.17E+05 2.69E+03 O.OOE+OO PD-109 O.OOE+OO 5.48E+OO 1.83E+OO O.OOE+OO *2.61 E+01 2.28E+04 9.58E+04 O.OOE+OO AG-110M 1.69E+04 1.14E+04 9.14E+03 O.OOE+OO 2.12E+04 5.48E+06 1.00E+05 O.OOE+OO AG-111 6. 70E+02 2.10E+02 1.39E+02 O.OOE+OO 6.33E+02 2.86E+05 1.1 OE+05 O.OOE+OO CD-113M O.OOE+OO 1.82E+06 7.84E+04 O.OOE+OO 1.90E+06 2.57E+06 6.03E+04 O.OOE+OO CD-115M O.OOE+OO 2.92E+05 1.25E+04 O.OOE+OO 2.19E+05 2.17E+06 1.84E+05 O.OOE+OO SN-123 4.77E+05 7.92E+03 1.55E+04 8.40E+03 O.OOE+OO 3.55E+06 1.50E+05 O.OOE+OO SN-125 1.83E+04 3.68E+02 1.09E+03 3.81 E+02 O.OOE+OO 8.99E+05 2.65E+05 O.OOE+OO SN-126 2.31 E+06 3.85E+04 8.73E+04 1.05E+04 O.OOE+OO 1.12E+07 6.03E+04 O.OOE+OO SB-124 5.74E+04 7.40E+02 2.00E+04 1.26E+02 O.OOE+OO 3.24E+06 1.64E+05 O.OOE+OO SB-125 9.84E+04 7.59E+02 2.07E+04 9.10E+01 O.OOE+OO 2.32E+06 4.03E+04 O.OOE+OO SB-126 6.36E+03 9.69E+01 2.28E+03 3.70E+01 O.OOE+OO 1.06E+06 2.10E+05 O.OOE+OO SB-127 5.03E+02 7.73E+OO 1.74E+02 5.59E+OO O.OOE+OO 2.28E+05 1.41 E+05 O.OOE+OO TE-125M 6.73E+03 2.33E+03 9.14E+02 1.92E+03 O.OOE+OO 4.77E+05 3.38E+04 O.OOE+OO TE-127M 2.49E+04 8.55E+03 3.02E+03 6.07E+03 6.36E+04 1.48E+06 7.14E+04 O.OOE+OO TE-127 2.77E+OO 9.51 E-01 6.11 E-01 1.96E+OO 7.07E+OO 1.00E+04 5.62E+04 O.OOE+OO TE-129M 1.92E+04 6.85E+03 3.04E+03 6.33E+03 5.03E+04 1.76E+06 1.82E+05 O.OOE+OO TE-129 9.77E-02 3.50E-02 2.38E-02 7.14E-02 2.57E-01 2.93E+03 2.55E+04 O.OOE+OO TE-131M 1.34E+02 5.92E+01 5.07E+01 9.77E+01 4.00E+02 2.06E+05 3.08E+05 O.OOE+OO TE-131 2.17E-02 8.44E-03 6.59E-03 1.70E-02 5.88E-02 2.05E+03 1.33E+03 O.OOE+OO TE-132 4.81E+02 2.72E+02 2.63E+02 3.17E+02 1.77E+03 3.77E+05 1.38E+05 O.OOE+OO TE-133M 1.08E-01 5.59E-02 5.55E-02 8.58E-02 3.74E-01 5.92E+03 1.76E+04 O.OOE+OO TE-134 5.66E-02 3.26E-02 3.48E-02 4.59E-02 2.11 E-01 4.55E+03 1.80E+03 O.OOE+OO Rev.29 Page 201 of 329 12/2016
CY-LG-170-301 TABLE 112-4 R1I P1 DOSE FACTORS AGE: CHILD PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-129 3.89E+04 2.37E+04 2.11 E+04 1.58E+07 4.00E+04 O.OOE+OO 7.96E+02 O.OOE+OO 1-130 8.18E+03 1.64E+04 8.44E+03 1.85E+06 2.45E+04 O.OOE+OO 5.11 E+03 O.OOE+OO 1-131 4.81 E+04 4.81 E+04 2.73E+04 1.62E+07 7.88E+04 O.OOE+OO 2.84E+03 O.OOE+OO 1-132 2.12E+03 4.07E+03 1.88E+03 1.94E+05 6.25E+03 O.OOE+OO 3.20E+03 O.OOE+OO 1-133 1.66E+04 2.03E+04 7.70E+03 3.85E+06 3.38E+04 O.OOE+OO 5.48E+03 O.OOE+OO 1-134 1.17E+03 2.16E+03 9.95E+02 5.07E+04 3.30E+03 O.OOE+OO 9.55E+02 O.OOE+OO 1-135 4.92E+03 8.73E+03 4.14E+03 7.92E+05 1.34E+04 O.OOE+OO 4.44E+03 O.OOE+OO CS-134M 2.34E+02 3.30E+02 2.26E+02 O.OOE+OO 1.83E+02 3.09E+01 2.93E+02 O.OOE+OO CS-134 6.51 E+05 1.01 E+06 2.25E+05 O.OOE+OO 3.30E+05 1.21 E+05 3.85E+03 O.OOE+OO CS-135 2.31 E+05 1.53E+05 1.65E+04 O.OOE+OO 5.66E+04 1.93E+04 8.03E+02 O.OOE+OO CS-136 6.51E+04 1.71E+05 1.16E+05 O.OOE+OO 9.55E+04 1.45E+04 4.18E+03 O.OOE+OO CS-137 9.07E+05 8.25E+05 1.28E+05 O.OOE+OO 2.82E+05 1.04E+05 3.62E+03 O.OOE+OO CS-138 6.33E+02 8.40E+02 5.55E+02 O.OOE+OO 6.22E+02 6.81 E+01 2.70E+02 O.OOE+OO CS-139 4.03E+02 4.26E+02 2.15E+02 O.OOE+OO 3.36E+02 3.46E+01 2.68E-02 O.OOE+OO BA-139 1.84E+OO 9.84E-04 5.37E-02 O.OOE+OO 8.62E-04 5.77E+03 5.77E+04 O.OOE+OO BA-140 7.40E+04 6.48E+01 4.33E+03 O.OOE+OO 2.11 E+01 1.74E+06 1.02E+05 O.OOE+OO BA-141 1.96E-01 1.09E-04 6.36E-03 O.OOE+OO 9.47E-05 2.92E+03 2.75E+02 O.OOE+OO BA-142 5.00E-02 3.60E-05 2.79E-03 O.OOE+OO 2.91 E-05 1.64E+03 2.74E+OO O.OOE+OO LA-140 6.44E+02 2.25E+02 7.55E+01 O.OOE+OO O.OOE+OO 1.83E+05 2.26E+05 O.OOE+OO LA-141 8.44E+OO 1.96E+OO 4.26E-01 O.OOE+OO O.OOE+OO 1.66E+04 1.62E+05 O.OOE+OO LA-142 1.30E+OO 4.11 E-01 1.29E-01 O.OOE+OO O.OOE+OO 8.70E+03 7.59E+04 O.OOE+OO CE-141 3.92E+04 1.95E+04 2.90E+03 O.OOE+OO 8.55E+03 5.44E+05 5.66E+04 O.OOE+OO CE-143 3.66E+02 1.99E+02 2.87E+01 O.OOE+OO 8.36E+01 1.15E+05 1.27E+05 O.OOE+OO CE-144 6.77E+06 2.12E+06 3.61E+05 O.OOE+OO 1.17E+06 1.20E+07 3.89E+05 O.OOE+OO PR-143 1.85E+04 5.55E+03 9.14E+02 O.OOE+OO 3.00E+03 4.33E+05 9.73E+04 O.OOE+OO PR-144 5.96E-02 1.85E-02 3.00E-03 O.OOE+OO 9.77E-03 1.57E+03 1.97E+02 O.OOE+OO ND-147 1.08E+04 8.73E+03 6.81 E+02 O.OOE+OO 4.81 E+03 3.28E+05 8.21 E+04 O.OOE+OO PM-147 1.30E+06 9.32E+04 5.03E+04 O.OOE+OO 1.65E+05 8.14E+05 2.11 E+04 O.OOE+OO PM-148M 1.22E+05 2.42E+04 2.42E+04 O.OOE+OO 3.60E+04 2.12E+06 1.32E+05 O.OOE+OO PM-148 5.96E+03 7.18E+02 4.63E+02 O.OOE+OO 1.22E+03 4.59E+05 2.22E+05 O.OOE+OO PM-149 5.44E+02 5.77E+01 3.13E+01 O.OOE+OO 1.02E+02 8.88E+04 1.08E+05 O.OOE+OO PM-151 1.32E+02 1.60E+01 1.04E+01 O.OOE+OO 2.72E+01 4.59E+04 9.25E+04 O.OOE+OO SM-151 1.16E+06 1:76E+05 5.51 E+04 O.OOE+OO 1".81 E+05 5.48E+05 1.27E+04 O.OOE+OO SM-153 2.68E+02 1.67E+02 1.61 E+01 O.OOE+OO 5.07E+01 5.07E+04 6.92E+04 O.OOE+OO EU-152 2.75E+06 5.07E+05 5.96E+05 O.OOE+OO 2.12E+06 3.33E+06 4.22E+04 O.OOE+OO EU-154 1.01E+07 9.21E+05 8.40E+05 O.OOE+OO 4.03E+06 6.14E+06 1.10E+05 O.OOE+OO EU-155 2.07E+06 1.50E+05 1.18E+05 O.OOE+OO 5.59E+05 1.03E+06 1.99E+05 O.OOE+OO EU-156 2.92E+04 1.57E+04 3.24E+03 O.OOE+OO 1.01 E+04 9.40E+05 1.57E+05 O.OOE+OO TB-160 2.88E+05 O.OOE+OO 3.58E+04 O.OOE+OO 8.58E+04 1.98E+06 8.44E+04 O.OOE+OO Rev.29 Page 202 of 329 12/2016
CY-LG-170-301 TABLE 112-4 R1 I P1 DOSE FACTORS AGE: CHILD PATHWAY: INHALATION mrem/yr per µCi/m3
- NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H0-166M 4.96E+06 1.04E+06 8.77E+05 O.OOE+OO 1.48E+06 4.18E+06 6.03E+04 O.OOE+OO W-181 9.84E+01 2.41E+01 3.33E+OO O.OOE+OO O.OOE+OO 2.11E+04 9.66E+02 O.OOE+OO W-185 3.07E+03 7.70E+02 1.08E+02 O.OOE+OO O.OOE+OO 6.88E+05 4.11E+04 O.OOE+OO W-187 1.63E+01 9.66E+OO 4.33E+OO O.OOE+OO O.OOE+OO 4.11 E+04 9.10E+04 O.OOE+OO U-232 8.10E+08 O.OOE+OO 5.77E+07 O.OOE+OO 6.18E+07 2.75E+09 1.60E+05 O.OOE+OO U-233 1.72E+08 O.OOE+OO 1.04E+07 O.OOE+OO 2.82E+07 6.55E+08 1.48E+05 O.OOE+OO U-234 1.65E+08 O.OOE+OO 1.02E+07 O.OOE+OO 2.76E+07 6.44E+08 1.45E+05 O.OOE+OO U-235 1.58E+08 O.OOE+OO 9.58E+06 O.OOE+OO 2.59E+07 6.03E+08 1.84E+05 O.OOE+OO U-236 1.58E+08 O.OOE+OO 9.81E+06 O.OOE+OO 2.65E+07 6.18E+08 1.36E+05 O.OOE+OO U-237 5.81E+02 O.OOE+OO 1.54E+02 O.OOE+OO 1.68E+03 1.26E+05 4.77E+04 O.OOE+OO U-238 1.51E+08 O.OOE+OO 8.95E+06 O.OOE+OO 2.42E+07 5.66E+08 1.30E+05 O.OOE+OO NP-237 1.01E+10 5.99E+09 4.40E+08 O.OOE+OO 2.74E+09 6.44E+08 1.87E+05 O.OOE+OO NP-238 4.66E+03 8.51E+02 7.29E+01 O.OOE+OO 3.02E+02 1.25E+05 9.25E+04 O.OOE+OO NP-239 4.66E+02 3.01E+02 2.35E+01 O.OOE+OO 9.73E+01 5.81E+04 6.40E+04 O.OOE+OO PU-238 9.44E+09 5.92E+09 4.48E+08 O.OOE+OO 1.65E+09 2.25E+09 1.72E+05 O.OOE+OO PU-239 1.03E+10 6.22E+09 4.74E+08 O.OOE+OO 1.77E+09 2.12E+09 1.57E+05 O.OOE+OO PU-240 1.03E+10 6.22E+09 4.70E+08 O.OOE+OO 1.76E+09 2.11 E+09 1.60E+05 O.OOE+OO PU-241 2.94E+08 6.48E+07 1.08E+07 O.OOE+OO
- 4.07E+07 1.87E+06 3.29E+03 O.OOE+OO PU-242 9.58E+09 5.99E+09 4.55E+08 O.OOE+OO 1.70E+09 2.04E+09 1.54E+05 O.OOE+OO PU-244 1.12E+10 6.85E+09 5.22E+08 O.OOE+OO 1.95E+09 2.33E+09 2.29E+05 O.OOE+OO AM-241 1.10E+10 6.81E+09 4.59E+08 O.OOE+OO 2.82E+09 7.47E+08 1.75E+05 O.OOE+OO AM-242M 1.14E+10 6.51E+09 4.70E+08 O.OOE+OO 2.85E+09 3.01E+08 2.21E+05 O.OOE+OO AM-243 1.09E+10 6.59E+09 4.44E+08 O.OOE+OO 2.75E+09 7.10E+08 2.05E+05 O.OOE+OO CM-242 3.51E+08 2.10E+08 1.55E+07 O.OOE+OO 4.96E+07 4.85E+08 1.87E+05 O.OOE+OO CM-243 8.58E+09 5.25E+09 3.68E+08 O.OOE+OO 1.38E+09 7.77E+08 1.84E+05 O.OOE+OO CM-244 7.18E+09 4.37E+09 3.07E+08 O.OOE+OO 1.13E+09 7.47E+08 1.78E+05 O.OOE+OO CM-245 1.13E+10 6.81E+09 4.74E+08 O.OOE+OO 1.86E+09 7.22E+08 1.66E+05 O.OOE+OO CM-246 1.12E+10 6.81E+09 4.74E+08 O.OOE+OO 1.86E+09 7.36E+08 1.63E+05 O.OOE+OO CM-247
- 1.09E+10 6.73E+09 4.66E+08 O.OOE+OO 1.83E+09 7.22E+08 2.15E+05 O.OOE+OO CM-248 9.07E+08 5.55E+08 3.85E+09 O.OOE+OO 1.51E+10 5.96E+09 3.46E+06 O.OOE+OO CF-252 8.07E+09 O.OOE+OO 3.45E+08 O.OOE+OO O.OOE+OO 2.45E+09 6.81E+05 O.OOE+OO Rev.29 Page 203 of 329 12/2016
CY-LG-170-301 TABLE 112-5 R1 I P1 DOSE FACTORS AGE: INFANT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 3.68E+02 3.68E+02 3.68E+02 3.68E+02 3.68E+02 3.68E+02 O.OOE+OO C-14 2.65E+04 5.31E+03 5.31E+03 5.31E+03 5.31E+03 5.31E+03 5.31E+03 O.OOE+OO NA-22 1.03E+05 1.03E+05 1.03E+05 1.03E+05 1.03E+05 1.03E+05 1.03E+05 O.OOE+OO NA-24 1.06E+04 1.06E+04 1.06E+04 1.06E+04 1.06E+04 1.06E+04 1.06E+04 O.OOE+OO P-32 2.03E+06 1.12E+05 7.74E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.61E+04 O.OOE+OO CA-41 1.05E+05 O.OOE+OO 1.14E+04 O.OOE+OO O.OOE+OO 9.72E+07 4.14E+02 O.OOE+OO SC-46 5.25E+05 7.57E+05 2.37E+05 O.OOE+OO 4.98E+05 O.OOE+OO 3.07E+04 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 8.95E+01 5.75E+01 1.32E+01 1.28E+04 3.57E+02 O.OOE+OO MN-54 O.OOE+OO 2.53E+04 4.98E+03 O.OOE+OO 4.98E+03 1.00E+06 7.06E+03 O.OOE+OO MN-56 O.OOE+OO 1.54E+OO 2.21E-01 O.OOE+OO 1.10E+OO 1.25E+04 7.17E+04 O.OOE+OO FE-55 1.97E+04 1.17E+04 3.33E+03 O.OOE+OO O.OOE+OO 8.69E+04 1.09E+03 O.OOE+OO FE-59 1.36E+04 2.35E+04 9.48E+03 O.OOE+OO O.OOE+OO 1.02E+06 2.48E+04 O.OOE+OO C0-57 O.OOE+OO 6.51E+02 6.41E+02 O.OOE+OO O.OOE+OO 3.79E+05 4.86E+03 O.OOE+OO C0-58 O.OOE+OO 1.22E+03 1.82E+03 O.OOE+OO O.OOE+OO 7.77E+05 1.11E+04 O.OOE+OO C0-60 O.OOE+OO 8.02E+03 1.18E+04 O.OOE+OO O.OOE+OO 4.51E+06 3.19E+04 O.OOE+OO Nl-59 2.53E+04 7.62E+03 4.34E+03 O.OOE+OO O.OOE+OO 7.67E+04 8.88E+02 O.OOE+OO Nl-63 3.39E+05 2.04E+04 1.16E+04 O.OOE+OO O.OOE+OO 2.09E+05 2.42E+03 O.OOE+OO Nl-65 2.39E+OO 2.84E-01 1.23E-01 O.OOE+OO O.OOE+OO 8.12E+03 5.01E+04 O.OOE+OO CU-64 O.OOE+OO 1.88E+OO 7.74E-01 O.OOE+OO 3.98E+OO 9.30E+03 1.50E+04 O.OOE+OO ZN-65 1.93E+04 6.26E+04 3.11E+04 O.OOE+OO 3.25E+04 6.47E+05 5.14E+04 O.OOE+OO ZN-69M 1.26E+01 2.58E+01 2.34E+OO O.OOE+OO 1.04E+01 2.67E+04 4.09E+04 O.OOE+OO ZN-69 5.39E-02 9.67E-02 7.18E-03 O.OOE+OO 4.02E-02 1.47E+03 1.32E+04 O.OOE+OO SE-79 O.OOE+OO 3.15E+03 5.88E+02 O.OOE+OO 3.46E+03 4.19E+05 4.84E+03 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.33E+04 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.81E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 4.00E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 2.04E+01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.90E+05 8.82E+04 O.OOE+OO O.OOE+OO O.OOE+OO 3.04E+03 O.OOE+OO RB-87 O.OOE+OO 9.95E+04 3.70E+04 O.OOE+OO O.OOE+OO O.OOE+OO 4.19E+02 O.OOE+OO RB-88 O.OOE+OO 5.57E+02 2.87E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.39E+02 O.OOE+OO RB-89 O.OOE+OO 3.21E+02 2.06E+02 O.OOE+OO O.OOE+OO O.OOE+OO 6.82E+01 O.OOE+OO SR-89 3.98E+05 O.OOE+OO 1.14E+04 O.OOE+OO O.OOE+OO 2.03E+06 6.40E+04 O.OOE+OO SR-90 1.55E+07 O.OOE+OO 3.12E+05 O.OOE+OO. O.OOE+OO 1.12E+07 1.31E+05 O.OOE+OO SR-91 9.56E+01 O.OOE+OO 3.46E+OO O.OOE+OO O.OOE+OO 5.26E+04 7.34E+04 O.OOE+OO SR-92 1.05E+01 O.OOE+OO 3.91 E-01 O.OOE+OO O.OOE+OO 2.38E+04 1.40E+05 O.OOE+OO Y-90 3.29E+03 O.OOE+OO 8.82E+01 O.OOE+OO O.OOE+OO 2.69E+05 1.04E+05 O.OOE+OO Y-91M 4.07E-01 O.OOE+OO 1.39E-02 O.OOE+OO O.OOE+OO 2.79E+03 2.35E+03 O.OOE+OO Y-91 5.88E+05 O.OOE+OO 1.57E+04 O.OOE+OO O.OOE+OO 2.45E+06 7.03E+04 O.OOE+OO Y-92 1.64E+01 O.OOE+OO 4.61E-01 O.OOE+OO O.OOE+OO 2.45E+04 1.27E+05 O.OOE+OO Y-93 1.50E+02 O.OOE+OO 4.07E+OO O.OOE+OO O.OOE+OO . 7.64E+04 1.67E+05 O.OOE+OO Rev.29 Page 204 of 329 12/2016
CY-LG-170-301 TABLE 112-5 R1 I P1 DOSE FACTORS AGE: INFANT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN ZR-93 3.14E+05 1.33E+04 8.65E+03 O.OOE+OO 4.47E+04 1.92E+05 2.07E+03 O.OOE+OO ZR-95 1.15E+05 2.79E+04 2.03E+04 O.OOE+OO 3.11 E+04 1.75E+06 2.17E+04 O.OOE+OO ZR-97 1.50E+02 2.56E+01 1.17E+01 O.OOE+OO 2.59E+01 1.10E+05 1.40E+05 O.OOE+OO NB-93M 1.93E+05 5.03E+04 1.61E+04 O.OOE+OO 5.15E+04 2.93E+05 3.46E+03 O.OOE+OO NB-95 1.57E+04 6.43E+03 3.78E+03 O.OOE+OO 4.72E+03 4.79E+05 1.27E+04 O.OOE+OO NB-97 3.42E-01 7.29E-02 2.63E-02 O.OOE+OO 5.70E-02 3.32E+03 2.69E+04 O.OOE+OO M0-93 O.OOE+OO 9.04E+03 3.11E+02 O.OOE+OO 2.16E+03 4.76E+05 5.26E+03 O.OOE+OO M0-99 O.OOE+OO 1.65E+02 3.23E+01 O.OOE+OO 2.65E+02 1.35E+05 4.87E+04 O.OOE+OO TC-99M 1.40E-03 2.88E-03 3.72E-02 O.OOE+OO 3.11 E-02 8.11 E+02 2.03E+03 O.OOE+OO TC-99 2.93E+02 3.75E+02 1.24E+02 O.OOE+OO 3.49E+03 9.48E+05 1.09E+04 O.OOE+OO TC-101 6.51E-05 8.23E-05 8.12E-04 O.OOE+OO 9.79E-04 5.84E+02 8.44E+02 O.OOE+OO RU-103 2.02E+03 O.OOE+OO 6.79E+02 O.OOE+OO 4.24E+03 5.52E+05 1.61E+04 O.OOE+OO RU-105 1.22E+OO O.OOE+OO 4.10E-01 O.OOE+OO 8.99E-01 1.57E+04 4.84E+04 O.OOE+OO RU-106 8.68E+04 O.OOE+OO 1.09E+04 O.OOE+OO 1.07E+05 1.16E+07 1.64E+05 O.OOE+OO RH-105 1.16E+01 7.57E+OO 5.08E+OO O.OOE+OO 2.10E+01 2.91E+04 1.92E+04 O.OOE+OO PD-107 O.OOE+OO 6.89E+02 5.75E+01 O.OOE+OO 3.85E+03 8.88E+04 1.03E+03 O.OOE+OO PD-109 O.OOE+OO 5.49E+OO 1.47E+OO O.OOE+OO 1.79E+01 2.35E+04 3.99E+04 O.OOE+OO AG-110M 9.98E+03 7.22E+03 5.00E+03 O.OOE+OO 1.09E+04 3.67E+06 3.30E+04 O.OOE+OO AG-111 5.25E+02 2.03E+02 1.09E+02 O.OOE+OO 4.27E+02 2.88E+05 4.23E+04 O.OOE+OO CD-113M O.OOE+OO 9.34E+05 3.70E+04 O.OOE+OO 8.12E+05 1.96E+06 2.31E+04 O.OOE+OO CD-115M O.OOE+OO 2.42E+05 8.67E+03 O.OOE+OO 1.32E+05 2.06E+06 7.03E+04 O.OOE+OO SN-123 2.93E+05 5.89E+03 1.02E+04 5.98E+03 O.OOE+OO
- 3.11E+06 5.71E+04 O.OOE+OO SN-125 1.41 E+04 3.51E+02 8.40E+02 3.46E+02 O.OOE+OO 9.00E+05 1.02E+05 O.OOE+OO SN-126 1.16E+06 2.02E+04 4.93E+04 5.38E+03 O.OOE+OO 6.90E+06 2.31E+04 O.OOE+OO SB-124 3.79E+04 5.56E+02 1.20E+04 1.01 E+02 O.OOE+OO 2.65E+06 5.91E+04 O.OOE+OO
- SB-125 5.17E+04 4.77E+02 1.09E+04 6.23E+01 O.OOE+OO 1.64E+06 1.47E+04 O.OOE+OO SB-126 4.31E+03 8.41 E+01 1.55E+03 3.29E+01 O.OOE+OO 9.63E+05 7.46E+04 O.OOE+OO SB-127 3.95E+02 7.06E+OO 1.23E+02 5.04E+OO O.OOE+OO 2.16E+05 5.29E+04 O.OOE+OO TE-125M 4.76E+03 1.99E+03 6.58E+02 1.62E+03 O.OOE+OO 4.47E+05 1.29E+04 O.OOE+OO TE-127M 1.67E+04 6.90E+03 2.07E+03 4.87E+03 3.75E+04 1.31E+06 2.73E+04 O.OOE+OO TE-127 2.23E+OO 9.53E-01 4.89E-01 1.85E+OO 4.86E+OO 1.03E+04 2.44E+04 O.OOE+OO TE-129M 1.41 E+04 6.09E+03 2.23E+03 5.47E+03 3.18E+04 1.68E+06 6.90E+04 O.OOE+OO TE-129 7.88E-02 3.47E-02 1.88E-02 6.75E-02 1.75E-01 3.00E+03 2.63E+04 O.OOE+OO TE-131M 1.07E+02 5.50E+01 3.63E+01 8.93E+01 2.65E+02 1.99E+05
- 1.19E+05 O.OOE+OO TE-131 1.74E-02 8.22E-03 5.00E-03 1.58E-02 3.99E-02 2.06E+03 8.22E+03 O.OOE+OO TE-132 3.72E+02 2.37E+02 1.76E+02 2.79E+02 1.03E+03 3.40E+05 4.41E+04 O.OOE+OO TE-133M 8.58E-02 5.03E-02 3.84E-02 7.73E-02 2.41 E-01 5.49E+03 2.23E+04 O.OOE+OO TE-134 4.45E-02 2.86E-02 2.35E-02 4.07E-02 1.34E-01 4.10E+03 3.54E+03 O.OOE+OO 1-129 3.02E+04 2.23E+04 1.62E+04 1.46E+07 2.63E+04 O.OOE+OO 2.97E+02 O.OOE+OO 1-130 6.36E+03 1.39E+04 5.57E+03 1.60E+06 1.53E+04 O.OOE+OO 1.99E+03 O.OOE+OO 1-131 3.79E+04 4.44E+04 1.96E+04 1.48E+07 5.18E+04 O.OOE+OO 1.06E+03 O.OOE+OO 1-132 1.69E+03 3.54E+03 1.26E+03 1.69E+05 3.95E+03 O.OOE+OO 1.90E+03 O.OOE+OO Rev.29 Page 205 of 329 12/2016
CY-LG-170-301 TABLE 112-5 R1 I P1 DOSE FACTORS AGE: INFANT PATHWAY: INHALATION mrem/yr per µCi/m3 NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-133 1.32E+04 1.92E+04 5.60E+03 3.56E+06 2.24E+04 O.OOE+OO 2.16E+03 O.OOE+OO 1-134 9.21E+02 1.88E+03 6.65E+02 4.45E+04 2.09E+03 O.OOE+OO 1.29E+03 O.OOE+OO 1-135 3.86E+03 7.60E+03 2.77E+03 6.96E+05 8.47E+03 O.OOE+OO 1.83E+03 O.OOE+OO CS-134M 1.85E+02 2.94E+02 1.55E+02 O.OOE+OO 1.19E+02 2.80E+01 1.62E+02 O.OOE+OO CS-134 3.96E+05 7.03E+05 7.45E+04 O.OOE+OO 1.90E+05 7.97E+04 1.33E+03 O.OOE+OO CS-135 1.40E+05 1.21 E+05 6.62E+03 O.OOE+OO 3.61E+04 1.41 E+04 3.05E+02 O.OOE+OO CS-136 4.83E+04 1.35E+05 5.29E+04 O.OOE+OO 5.64E+04 1.18E+04 1.43E+03 O.OOE+OO CS-137 5.49E+05 6.12E+05 4.55E+04 O.OOE+OO 1.72E+05 7.13E+04 1.33E+03 O.OOE+OO CS-138 5.05E+02 7.81E+02 3.98E+02 O.OOE+OO 4.10E+02 6.54E+01 8.76E+02 O.OOE+OO CS-139 3.25E+02 4.24E+02 1.71E+02 O.OOE+OO 2.31E+02 3.54E+01 1.86E+01 O.OOE+OO BA-139 1.48E+OO 9.84E-04 4.30E-02 O.OOE+OO 5.92E-04 5.95E+03 5.10E+04 O.OOE+OO BA-140 5.60E+04 5.60E+01 2.90E+03 O.OOE+OO 1.34E+01 1.60E+06 3.84E+04 O.OOE+OO BA-141 1.57E-01 1.08E-04 4.97E-03 O.OOE+OO 6.50E-05 2.97E+03 4.75E+03 O.OOE+OO BA-142 3.98E-02 3.30E-05 1.96E-03 O.OOE+OO 1.90E-05 1.55E+03 6.93E+02 O.OOE+OO LA-140 5.05E+02 2.00E+02 5.15E+01 O.OOE+OO O.OOE+OO 1.68E+05 8.48E+04 O.OOE+OO LA-141 6.79E+OO 1.96E+OO 3.43E-01 O.OOE+OO O.OOE+OO 1.71 E+04 8.34E+04 O.OOE+OO LA-142 1.03E+OO 3.77E-01 9.04E-02 O.OOE+OO O.OOE+OO 8.22E+03 5.95E+04 O.OOE+OO CE-141 . 2.77E+04 1.67E+04 1.99E+03 O.OOE+OO 5.25E+03 5.17E+05 2.16E+04 O.OOE+OO CE-143 2.93E+02 1.93E+02 2.21E+01 O.OOE+OO 5.64E+01 1.16E+05 4.97E+04 O.OOE+OO CE-144 3.19E+06 1.21E+06 1.76E+05 O.OOE+OO 5.38E+05 9.84E+06 1.48E+05 O.OOE+OO PR-143 1.40E+04 5.24E+03 6.99E+02 O.OOE+OO 1.97E+03 4.33E+05 3.72E+04 O.OOE+OO PR-144 4.79E-02 1.85E-02 2.41E-03 O.OOE+OO 6.72E-03 1.61E+03 4.28E+03 O.OOE+OO ND-147 7.94E+03 8.13E+03 5.00E+02 O.OOE+OO 3.15E+03 3.22E+05 3.12E+04 ' O.OOE+OO PM-147 5.47E+05 4.30E+04 2.18E+04 O.OOE+OO 6.90E+04 6.37E+05 8.05E+03 O.OOE+OO PM-148M 7.00E+04 1.74E+04 1.39E+04 O.OOE+OO 2.03E+04 1.71 E+06 4.72E+04 O.OOE+OO PM-148 4.68E+03 6.75E+02 3.42E+02 O.OOE+OO 8.06E+02. 4.48E+05 8.46E+04 O.OOE+OO PM-149 4.34E+02 5.71E+01 2.49E+01 O.OOE+OO 6.94E+01 9.10E+04 4.21E+04 O.OOE+OO PM-151 1.05E+02 1.54E+01 7.77E+OO O.OOE+OO 1.82E+01 4.55E+04 3.61E+04 O.OOE+OO SM-151 4.73E+05 9.03E+04 2.28E+04 O.OOE+OO 7.34E+04 4.17E+05 4.84E+03 O.OOE+OO SM-153 2.14E+02 1.65E+02 1.27E+01 O.OOE+OO 3.46E+01 5.18E+04 2.70E+04 O.OOE+OO EU-152 1.10E+06 2.48E+05 2.41E+05 O.OOE+OO 8.32E+05 2.07E+06 1.38E+04 O.OOE+OO EU-154 4.14E+06 4.84E+05 3.43E+05 O.OOE+OO 1.60E+06 4.27E+06 3.98E+04 O.OOE+OO EU-155 8.36E+05 8.01E+04 4.84E+04 O.OOE+OO 2.21E+05 7.28E+05 7.27E+04 O.OOE+OO EU-156 2.18E+04 1.34E+04 2.16E+03 O.OOE+OO 6.27E+03 8.57E+05 5.80E+04 O.OOE+OO TB-160 1.57E+05 O.OOE+OO 1.96E+04 O.OOE+OO 4.48E+04 1.55E+06 3.00E+04 O.OOE+OO H0-166M 2.03E+06 4.30E+05 3.51E+05 O.OOE+OO 5.91E+05 2.87E+06 2.31E+04 O.OOE+OO W-181 6.80E+01 2.04E+01 2.34E+OO O.OOE+OO O.OOE+OO 1.86E+04 3.68E+02 O.OOE+OO W-185 2.20E+03 6.76E+02 7.81E+01 O.OOE+OO O.OOE+OO 6.27E+05 1.57E+04 O.OOE+OO W-187 1.30E+01 9.02E+OO 3.12E+OO O.OOE+OO O.OOE+OO 3.96E+04 3.56E+04 O.OOE+OO U-232 3.60E+08 O.OOE+OO 2.98E+07 O.OOE+OO 3.36E+07 2.09E+09 6.10E+04 O.OOE+OO U-233 7.62E+07 O.OOE+OO 5.36E+06 O.OOE+OO 1.53E+07 4.98E+08 5.64E+04 O.OOE+OO U-234 7.31E+07 O.OOE+OO 5.25E+06 O.OOE+OO 1.50E+07 4.89E+08 5.53E+04 O.OOE+OO Rev.29 Page 206 of 329 12/2016
CY-LG-170-301 TABLE 112-5 R1 I P1 DOSE FACTORS AGE: INFANT PATHWAY: INHALATION mrem/yr per µCi/m 3 NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-235 7.01E+07 O.OOE+OO 4.93E+06 O.OOE+OO 1.41 E+07 4.59E+08 7.03E+04 O.OOE+OO U-236 7.01E+07 O.OOE+OO 5.04E+06 O.OOE+OO 1.44E+07 4.69E+08 5.19E+04 O.OOE+OO U-237 4.55E+02 O.OOE+OO 1.21 E+02 O.OOE+OO 1.13E+03 1.28E+05 1.83E+04 O.OOE+OO U-238 6.71E+07 O.OOE+OO 4.61E+06 O.OOE+OO 1.32E+07 4.28E+08 4.96E+04 O.OOE+OO NP-237 4.03E+09 2.39E+09 1.76E+08 O.OOE+OO 1.08E+09 4.89E+08 7.14E+04 O.OOE+OO NP-238 3.74E+03 8.47E+02 5.82E+01 O.OOE+OO 2.06E+02 1.29E+05 3.61E+04 O.OOE+OO NP-239 3.71E+02 2.98E+02 1.88E+01 O.OOE+OO 6.62E+01 5.95E+04 2.49E+04 O.OOE+OO PU-238 3.77E+09 2.35E+09 1.78E+08 O.OOE+OO 6.50E+08 1.26E+09 6.57E+04 O.OOE+OO PU-239 4.10E+09 2.46E+09 1.88E+08 O.OOE+OO 6.93E+08 1.19E+09 5.99E+04 O.OOE+OO PU-240 4.10E+09 2.45E+09 1.88E+08 O.OOE+OO 6.92E+08 1.19E+09 6.10E+04 O.OOE+OO PU-241 1.18E+08 2.59E+07 4.35E+06 O.OOE+OO 1.61E+07 1.07E+06 1.26E+03 O.OOE+OO PU-242 3.81E+09 2.37E+09 1.81E+08 O.OOE+OO 6.68E+08 1.14E+09 5.88E+04 O.OOE+OO PU-244 4.44E+09 2.72E+09 2.07E+08 O.OOE+OO 7.64E+08 1.31E+09 8.76E+04 O.OOE+OO AM-241 4.41E+09 2.73E+09 1.83E+08 O.OOE+OO 1.11E+09 5.68E+08 6.69E+04 O.OOE+OO AM-242M 4.55E+09 2.60E+09 1.89E+08 O.OOE+OO 1.12E+09 2.30E+08 8.41E+04 O.OOE+OO AM-243 4.34E+09 2.63E+09 1.78E+08 O.OOE+OO 1.08E+09 5.39E+08 7.84E+04 O.OOE+OO CM-242 1.79E+08 1.21 E+08 7.98E+06 O.OOE+OO 2.37E+07 4.16E+08 7.14E+04 O.OOE+OO CM-243 3.46E+09 2.13E+09 1.48E+08 O.OOE+OO 5.47E+08 5.94E+08 7.03E+04 O.OOE+OO CM-244 2.90E+09 1.78E+09 1.24E+08 O.OOE+OO 4.49E+08 5.71E+08 6.80E+04 O.OOE+OO CM-245 4.51E+09 2.74E+09 1.90E+08 O.OOE+OO 7.32E+08 5.49E+08 6.34E+04 O.OOE+OO CM-246 4.48E+09 2.74E+09 1.90E+08 O.OOE+OO 7.32E+08 5.59E+08 6.23E+04 O.OOE+OO CM-247 4.35E+09 2.70E+09 1.86E+08 O.OOE+OO 7.21E+08 5.49E+08 8.19E+04 O.OOE+OO CM-248 3.61E+08 2.23E+08 1.54E+09 O.OOE+OO 5.94E+09 4.52E+09 1.32E+06 O.OOE+OO CF-252 3.32E+09 O.OOE+OO 1.41E+08 O.OOE+OO O.OOE+OO 1.92E+09 2.59E+05 O.OOE+OO Rev.29 Page 207 of 329 12/2016 i
CY-LG-170-301 TABLE 112-6 R1 DOSE FACTORS AGE: ADULT PATHWAY: GROUND PLANE m 2-mrem/yr per µCi/sec NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.94E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61 E+08 CR-51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51 E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 2. 73E+08 2. 73E+08 2. 73E+08 2. 73E+08 2. 73E+08 2. 73E+08 2. 73E+08 3.21 E+08 C0-57 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 2.07E+08 C0-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 C0-60 . 2.41E+10 2.41E+10 2.41E+10 2.41 E+10 2.41E+10 2.41E+10 2.41E+10 2.83E+10 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 CU-64 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69M 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 3.31 E+04 3.31 E+04 3.31 E+04 3.31 E+04 3.31 E+04 3.31 E+04 3.31 E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05. SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51 E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31 E+03 Y-91M 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21 E+06 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 2.14E+05 Rev. 29 Page 208 of 329 12/2016
CY-LG-170-301 TABLE 112-6 R1 DOSE FACTORS AGE: ADULT PATHWAY: GROUND PLANE m 2-mrem/yr per µCi/sec NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG Gl-LLI SKIN Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51 E+05 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 NB-93M 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.83E+08 NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61 E+08 NB-97 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 2.07E+05 M0-93 1.11 E+08 1.11 E+08 1.11 E+08 1.11 E+08 1.11 E+08 1.11 E+08 1.11 E+08 4.50E+09 M0-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99M 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11 E+05 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21 E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 8.67E+05 PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71 E+04 AG-110M 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 4.01 E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113M 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 7.14E+06 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.84E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+0.8 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.70E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125M 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127M 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129M 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31 E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.1 OE+04 TE-131M 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 TE-133M 4.41 E+05 4.41 E+05 4.41 E+05 4.41 E+05 4.41 E+05 4.41 E+05 4.41 E+05 5.00E+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 3.63E+09 Rev.29 Page 209 of 329 12/2016
CY-LG-170-301 TABLE 112-6 R1 DOSE FACTORS AGE: ADULT PATHWAY: GROUND PLANE m 2-mrem/yr per µCi/sec NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LU SKIN 1-130 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-134M 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 6.74E+04 CS-134 6.91 E+09 6.91 E+09 6.91 E+09 6.91 E+09 6.91 E+09 6.91 E+09 6.91 E+09 8.06E+09 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71E+08 CS-137 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.80E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.10E+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4. 75E+04 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11 E+04 LA-140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 . 9.11E+05 CE-141 1.37E+07 1~37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 CE-143 2.31 E+06 2.31 E+06 2.31 E+06 2.31 E+06 2.31 E+06 2.31 E+06 2.31 E+06 2.63E+06 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11 E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01 E+07 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 2.18E+07 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 2.11 E+08 2.11 E+08 2.11 E+08 2.11 E+08 2.11 E+08 2.11 E+08 2.11 E+08 9.24E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.33E+10 EU-154 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.90E+10 EU-155 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.81E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01 E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 H0-166M 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.80E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.59E+05 Rev.29 Page 210 of 329 12/2016
CY-LG-170-301 TABLE 112-6 R1 DOSE FACTORS AGE: ADULT PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 U-232 1.11E+07 1.11E+°07 1.11E+07 1.11 E+07 1.11E+07 1.11E+07 1.11E+07 1.16E+08 U-233 1.11E+10 1.11E+10 1.11E+10 1.11 E+10 1.11E+10 1.11E+10 1.11E+10 1.35E+10 U-234 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 7.69E+08 U-235 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.94E+10 U-236 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 S.71E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71E+06 U-238 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 7.26E+08 NP-237 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 7.74E+09 NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 NP-239 1.71E+06 1.71 E+06 1.71E+06 1.71E+06 1.71 E+06 1.71 E+06 1.71E+06 1.98E+06 PU-238 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 7.90E+07 PU-239 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.72E+07 PU-240 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 8.70E+07 PU-241 1.29E+07 1;.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.91E+07 PU-242 5.32E+06 5.32E+06
- 5.32E+06 5.32E+06 5,.32E+06 5.32E+06 5.32E+06 7.74E+07 PU-244 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.65E+09 AM-241 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 1.23E+09 AM-242M 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 8.23E+08 AM-243 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 7.25E+09 CM-242 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 1.05E+10 CM-244 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 5.61E+07 CM-245 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 5.80E+09 CM-246 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 7.24E+07 CM-247 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.26E+10 CM-248 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 3.29E+10 CF-252 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 5.30E+10 Gross Alpha 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 O.OOE+OO Rev.29 Page 211 of 329 12/2016
CY-LG-170-301 TABLE 112-7 R1 DOSE FACTORS AGE: TEEN PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.94E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21E+08 C0-57 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 2.07E+08 C0-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 C0-60 2.41E+10 2.41E+10 2.41E+10 2.41 E+10 2.41E+10 2.41E+10 2.41E+10 2.83E+10 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO. O.OOE+OO O.OOE+OO Nl-65 2.97E+0.5 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 CU-64 6.07E+05 6.07E+05 *6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69M 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05. 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31E+03 Y-91M 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21 E+06 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 212 of 329 12/2016
CY-LG-170-301 TABLE 112-7 R1 DOSE FACTORS AGE: TEEN PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 NB-93M 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.83E+08 NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 2.07E+05 M0-93 1.11 E+08 1.11 E+08 1.11E+08 1.11E+08 1.11 E+08 1.11 E+08 1.11 E+08 4.50E+09 M0-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99M 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11E+05 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 8.67E+05 PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71E+04 AG-110M 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 4.01E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113M 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 7.14E+06 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.84E+10 SB-124 5.98E+08 5.98E+08 . 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.70E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125M 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127M 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129M 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.10E+04 TE-131M 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 TE-133M 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 5.00E+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 3.63E+09 1-130 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06
- 2.45E+06 2.45E+06 2.45E+06 2.98E+06 Rev.29 Page 213 of 329 12/2016
CY-LG-170-301 TABLE 112-7 R1 DOSE FACTORS AGE: TEEN PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-134M 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 6.74E+04 CS-134 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 8.06E+09 CS-135 O.OOE+OO O.OOE+OO . O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71 E+08 CS-137 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.80E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.10E+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11 E+04 LA-140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11 E+05 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 2.18E+07 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 2.11E+08 2.11E+08 2.11E+08 2.11E+08 2.11 E+08 2.11E+08 2.11E+08 9.24E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.33E+10 EU-154 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.90E+10 EU-155 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.81E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 H0-166M 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.80E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.59E+05 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 U-232 1.11 E+07 1.11 E+07 1.11E+07 1.11 E+07 1.11E+07 1.11 E+07 1.11E+07 1.16E+08 U-233 1.11E+10 1.11E+10 1.11E+10 1.11E+10 1.11E+10 1.11 E+10 1.11E+10 1.35E+10 U-234 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 7.69E+08 U-235 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.94E+10 Rev.29 Page 214 of 329 12/2016
CY-LG-170-301 TABLE 112-7 R1 DOSE FACTORS AGE: TEEN PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN U-236 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 8.71 E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71 E+06 U-238 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 7.26E+08 NP-237 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 7.74E+09 NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 NP-239 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.98E+06 PU-238 5.71 E+06 5.71E+06 5.71E+06 5.71 E+06 5.71E+06 5.71E+06 5.71E+06 7.90E+07 PU-239 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.72E+07 PU-240 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 8.70E+07 PU-241 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.91E+07 PU-242 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 7.74E+07 PU-244 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.65E+09 AM-241 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 1.23E+09 AM-242M 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 8.23E+08 AM-243 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 7.25E+09 CM-242 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 1.05E+10 CM-244 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 5.61E+07 CM-245 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E:+-09 5.80E+09 CM-246 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 7.24E+07 CM-247 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.26E+10 CM-248 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 3.29E+10 CF-252 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 5.30E+10 Gross Alpha 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 O.OOE+OO Rev.29 Page 215 of 329 12/2016
CY-LG-170-301 TABLE 112-8 R1 DOSE FACTORS AGE: CHILD PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 p..:32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.94E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21E+08 C0-57 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 2.07E+08 C0-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 C0-60 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.83E+10 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 CU-64 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69M 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.1'6E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31E+03 Y-91M 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21E+06 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05, 1.80E+05 1.80E+05 2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 NB-93M 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.83E+08 Rev.29 Page 216 of 329 12/2016
CY-LG-170-301 TABLE 112-8 R1 DOSE FACTORS AGE: CHILD PATHWAY: GROUND PLANE m2 -mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 2.07E+05 M0-93 1.11E+08 1.11 E+08 1.11E+08 1.11 E+08 1.11 E+08 1.11 E+08 1.11E+08 4.50E+09 M0-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99M 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11E+05 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21 E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 8.67E+05 PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71E+04 AG-110M 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 4.01E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113M 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 7.1.4E+06 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.84E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.70E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125M 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127M 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129M 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.10E+04 TE-131M 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 TE-133M 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 5.00E+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 3.63E+09 1-130 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-134M 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 6.74E+04 CS-134 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 8.06E+09 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51 E+08 1.71E+08 Rev.29 Page 217 of 329 12/2016
CY-LG-170-301 TABLE 112-8 R1 DOSE FACTORS AGE: CHILD PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN CS-137 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.80E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.10E+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11E+04 LA-140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11E+05 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 2.18E+07 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1:99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 2.11E+08 2.11 E+08 2.11E+08 2.11E+08 2.11 E+08 2.11E+08 2.11E+08 9.24E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.33E+10 EU-154 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.90E+10 EU-155 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.81E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+Q8 4.75E+08 5.53E+08 H0-166M 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.80E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.59E+05 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 U-232 1.11E+07 1.11E+07 1.11E+07 1.11E+07 1.11 E+07 1.11 E+07 1.11E+07 1.16E+08 U-233 1.11E+10 1.11E+10 1.11E+10 1.11E+10 1.11E+10 1.11E+10 1.11E+10 1.35E+10 U-234 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 7.69E+08 U-235 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.94E+10 U-236 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 8.71E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5 ..16E+06 6.71E+06 U-238 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 7.26E+08 NP-237 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 7.74E+09 NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 NP-239 1.71 E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.98E+06 PU-238 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 7.90E+07 PU-239 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.72E+07 PU-240 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 8.70E+07 Rev.29 Page 218 of 329 12/2016 _I
CY-LG-170-301 TABLE 112-8 R1 DOSE FACTORS AGE: CHILD PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-241 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.91E+07 PU-242 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 7.74E+07 PU-244 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.65E+09 AM-241 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 1.23E+09 AM-242M 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 8.23E+08 AM-243 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 6.28E+09 7.25E+09 CM-242 5.71E+06 5.71E+06 5.71 E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 7.90E+07 CM-243 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 1.05E+10 CM-244 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 5.61E+07 CM-245 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 5.80E+09 CM-246 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 7.24E+07 CM-247 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.26E+10 CM-248 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 3.29E+10 CF-252 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 5.30E+10 Gross Alpha 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 O.OOE+OO Rev.29 Page 219 of 329 12/2016 L __
CY-LG-170-301 TABLE 112-9 R1 DOSE FACTORS AGE: INFANT PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.94E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21E+08 C0-57 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 1.88E+08 2.07E+08 C0-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 C0-60 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.41E+10 2.83E+10 Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 CU-64 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69M 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31E+03 Y-91M 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.00E+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21 E+06 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 NB-93M 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.32E+06 2.83E+08 Rev.29 Page 220 of 329 12/2016
CY-LG-170-301 TABLE 112-9 R1 DOSE FACTORS AGE: INFANT PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 1.76E+05 1.76E+05
- 1.76E+05 1.76E+05 1.76E+05 1.76E+05 1.76E+05 2.07E+05 M0-93 1.11E+08 1.11E+08 1.11E+08 1.11 E+08 1.11E+08 1.11 E+08 1.11 E+08 4.50E+09 M0-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99M 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11E+05 TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 7.43E+05 8.67E+05 PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71E+04 AG-110M 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 3.44E+09 4.01E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113M 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 6.31E+06 7.14E+06 CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.35E+10 4.84E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08.
SB-125 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.39E+09 2.70E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125M 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127M 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129M 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.10E+04 TE-131M 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 TE-133M 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05. 4.41E+05 4.41E+05 5.00E+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 2.18E+09 3.63E+09 1-130 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-134M 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 5.73E+04 6.74E+04 CS-134 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 6.91E+09 8.06E+09 CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71E+08 Rev.29 Page 221 of 329 12/2016 L
CY-LG-170-301 TABLE 112-9 R1 DOSE FACTORS AGE: INFANT PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-137 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.80E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.10E+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11E+04 LA-140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11E+05 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11 E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 1.89E+07 2.18E+07 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 2.11E+08 2.11E+08 2.11E+08 2.11E+08 2.11 E+08 2.11E+08 2.11E+08 9.24E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.02E+10 2.33E+10 EU-154 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.65E+10 1.90E+10 EU-155 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.12E+08 5.81E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 H0-166M 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.27E+10 4.80E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.59E+05 W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 U-232 1.11E+07 1.11E+07 1.11E+07 1.11E+07 1.11E+07 1.11E+07 1.11E+07 1.16E+08 U-233 1.11E+10 1.11E+10 1.11E+10 1.11 E+10 1.11E+10 1.11E+10 1.11E+10 1.35E+10 U-234 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 7.69E+08 U-235 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.55E+10 1.94E+10 U-236 1.02E+05 *1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 1.02E+05 8.71E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71E+06 U-238 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 5.32E+08 7.26E+08 NP-237 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 6.77E+09 7.74E+09 NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 NP-239 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71 E+06 1.98E+06 PU-238 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 5.71E+06 7.90E+07 PU-239 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.82E+06 3.72E+07 PU-240 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 6.28E+06 8.70E+07 Rev.29 Page 222 of 329 12/2016
CY-LG-170-301 TABLE 112-9 R1 DOSE FACTORS AGE: INFANT PATHWAY: GROUND PLANE m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-241 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.29E+07 1.91E+07 PU-242 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 5.32E+06 7.74E+07 PU-244 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.33E+09 4.65E+09 AM-241 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 8.54E+08 1.23E+09 AM-242M 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 1.19E+08 8.23E+08 AM-243 6.28E+09 6.28E+09 6.28E+09 s:2sE+09 6.28E+09 6.28E+09 6.28E+09 7.25E+09 CM-242 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 8.34E+09 1.05E+10 CM-244 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 9.03E+06 5.61E+07 CM-245 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 4.59E+09 5.80E+09 CM-246 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 4.83E+06 7.24E+07 CM-247 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.06E+10 1.26E+10 CM-248 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 2.53E+10 3.29E+10 CF-252 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 4.86E+10 5.30E+10 Gross Alpha 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 O.OOE+OO Rev.29 Page 223 of 329 12/2016
CY-LG-170-301 TABLE 112-10 R1 DOSE FACTORS AGE: ADULT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.19E+03 1.19E+03 1.19E+03 1.19E+03 1.19E+03 1.19E+03 O.OOE+OO C-14 8.24E+05 1.65E+05 1.65E+05 1.65E+05
- 1.65E+05 1.65E+05 1.65E+05 O.OOE+OO NA-22 1.21E+09 1.21E+09 1.21 E+09 1.21E+09 1.21 E+09 1.21E+09 1.21 E+09 O.OOE+OO NA-24 1.12E+05 1.12E+05 1.12E+05 1.12E+05 1.12E+05 1.12E+05 1.12E+05 O.OOE+OO P-32 8.03E+08 4.99E+07 . 3.10E+07 O.OOE+OO O.OOE+OO O.OOE+OO 9.02E+07 O.OOE+OO CA-41 1.36E+10 O.OOE+OO 1.47E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.36E+07 O.OOE+OO SC-46 2.20E+05 4.28E+05 1.24E+05 O.OOE+OO 3.99E+05 O.OOE+OO 2.08E+09 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 3.53E+04 2.11E+04 7.77E+03 4.68E+04 8.87E+06 O.OOE+OO MN-54 O.OOE+OO 2.85E+08 5.43E+07 O.OOE+OO 8.47E+07 O.OOE+OO 8.72E+08 O.OOE+OO MN-56 O.OOE+OO 6.48E+OO 1.15E+OO O.OOE+OO 8.23E+OO O.OOE+OO 2.07E+02 O.OOE+OO FE-55 1.92E+08 1.33E+08 3.09E+07 O.OOE+OO O.OOE+OO 7.40E+07 7.61E+07 O.OOE+OO FE-59 1.05E+08 2.47E+08 9.46E+07 O.OOE+OO O.OOE+OO 6.90E+07 8.23E+08 O.OOE+OO C0-57 O.OOE+OO 1.06E+07 1.77E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.70E+08 O.OOE+OO C0-58 O.OOE+OO 2.67E+07 5.99E+07 O.OOE+OO O.OOE+OO O.OOE+OO 5.42E+08 O.OOE+OO C0-60 O.OOE+OO 1.53E+08 3.38E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.88E+09 O.OOE+OO Nl-59 7.19E+08 2.47E+08 1.20E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.08E+07 O.OOE+OO Nl-63 9.56E+09 6.63E+08 3.21E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.38E+08 O.OOE+OO Nl-65 2.50E+01 3.25E+OO 1.48E+OO O.OOE+OO O.OOE+OO O.OOE+OO 8.25E+01 O.OOE+OO CU-64 O.OOE+OO 3.84E+03 1.80E+03 O.OOE+OO 9.68E+03 O.OOE+OO 3.27E+05 O.OOE+OO ZN-65 2.88E+08 9.16E+08 4.14E+08 O.OOE+OO 6.12E+08 O.OOE+OO 5.77E+08 O.OOE+OO ZN-69M 9.36E+03
- 2.25E+04 2.05E+03 O.OOE+OO 1.36E+04 O.OOE+OO 1.37E+06 O.OOE+OO ZN-69 2.12E-06 4.06E-06 2.82E-07 O.OOE+OO 2.64E-06 O.OOE+OO 6.10E-07 O.OOE+OO SE-79 O.OOE+OO 1.94E+08 3.23E+07 O.OOE+OO 3.35E+08 O.OOE+OO 3.96E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 6.29E+05 O.OOE+OO O.OOE+OO O.OOE+OO 7.21E+05 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.26E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.82E+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 8.99E-12 O.OOE+OO O.OOE+OO O.OOE+OO 7.06E-17 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.44E+08 6.72E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.84E+07 O.OOE+OO RB-87 O.OOE+OO 9.06E+08 3.15E+08 O.OOE+OO O.OOE+OO O.OOE+OO 4.24E+07 O.OOE+OO RB-88 O.OOE+OO 1.11E-22 5.89E-23 O.OOE+OO O.OOE+OO O.OOE+OO 1.53E-33 O.OOE+OO RB-89 O.OOE+OO 1.21E-26 8.51E-27 O.OOE+OO O.OOE+OO O.OOE+OO 7.03E-40 O.OOE+OO SR-89 8.43E+09 O.OOE+OO 2.42E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.35E+09 O.OOE+OO SR-90 6.38E+11 O.OOE+OO 1.28E+10 O.OOE+OO O.OOE+OO O.OOE+OO 1.61E+10 O.OOE+OO SR-91 1.27E+05 O.OOE+OO 5.13E+03 O.OOE+OO O.OOE+OO O.OOE+OO 6.04E+05 O.OOE+OO SR-92 1.74E+02 O.OOE+OO 7.53E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.45E+03 O.OOE+OO Y-90 5.58E+03 O.OOE+OO 1.50E+02 O.OOE+OO O.OOE+OO O.OOE+OO 5.91E+07 O.OOE+OO Y-91M 2.00E-09 O.OOE+OO 7.73E-11 O.OOE+OO O.OOE+OO O.OOE+OO 5.87E-09 O.OOE+OO Y-91 4.38E+06 O.OOE+OO 1.17E+05 O.OOE+OO O.OOE+OO O.OOE+OO 2.41E+09 O.OOE+OO Y-92 3.76E-01 O.OOE+OO 1.10E-02 O.OOE+OO O.OOE+OO O.OOE+OO 6.59E+03 O.OOE+OO Y-93 7.07E+01 O.OOE+OO 1.95E+OO O.OOE+OO O.OOE+OO O.OOE+OO 2.24E+06 O.OOE+OO ZR-93 3.08E+06 1.72E+05 8.03E+04 O.OOE+OO 6.53E+05 O.OOE+OO 1.79E+08 O.OOE+OO ZR-95 1.01E+06 3.25E+05 2.20E+05 O.OOE+OO 5.11 E+05 O.OOE+OO 1.03E+09 O.OOE+OO Rev.29 Page 224 of 329 12/2016 I
CY-LG-170-301 TABLE 112-10 R1 DOSE FACTORS AGE: ADULT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN ZR-97 1.41E+02 2.85E+01 1.30E+01 O.OOE+OO 4.30E+01 O.OOE+OO 8.81E+06 O.OOE+OO NB-93M 1.86E+06 6.07E+05 1.50E+05 O.OOE+OO 6.98E+05 O.OOE+OO 2.80E+08 O.OOE+OO NB-95 1.14E+05 6.35E+04 3.41E+04 O.OOE+OO 6.28E+04 O.OOE+OO 3.85E+08 O.OOE+OO NB-97 8.48E-07 2.15E-07 7.83E-08 O.OOE+OO 2.50E-07 O.OOE+OO 7.91E-04 O.OOE+OO M0-93 O.OOE+OO 5.53E+08 1.50E+07 O.OOE+OO 1.57E+08 O.OOE+OO 8.99E+07 O.OOE+OO M0-99 O.OOE+OO 2.58E+06 4.91E+05 O.OOE+OO 5.84E+06 O.OOE+OO 5.98E+06 O.OOE+OO TC-99M 1.29E+OO 3.64E+OO 4.63E+01 O.OOE+OO 5.52E+01 1.78E+OO 2.15E+03 O.OOE+OO TC-99 9.21E+06 1.37E+07 3.70E+06 O.OOE+OO 1.72E+08 1.16E+06 4.48E+08 O.OOE+OO TC-101 2.49E-31 3.59E-31 3.52E-30 O.OOE+OO 6.47E-30 1.83E-31 1.0SE-42 O.OOE+OO RU-103 3.90E+06 O.OOE+OO 1.68E+06 O.OOE+OO 1.49E+07 O.OOE+OO 4.56E+08 O.OOE+OO RU-105 2.22E+01 O.OOE+OO 8.78E+OO O.OOE+OO 2.87E+02 O.OOE+OO 1.36E+04 O.OOE+OO RU-106 1.76E+08 O.OOE+OO 2.22E+07 O.OOE+OO 3.39E+08 O.OOE+OO 1.14E+10 o:ooE+oo RH-105 3.38E+04 2.47E+04 1.63E+04 O.OOE+OO 1.05E+05 O.OOE+OO 3.93E+06 O.OOE+OO PD-107 O.OOE+OO 1.08E+07 6.92E+05 O.OOE+OO 9.72E+07 O.OOE+OO 6.71E+07 O.OOE+OO PD-109 O.OOE+OO 9.28E+03 2.09E+03 O.OOE+OO 5.30E+04 O.OOE+OO 1.03E+06 O.OOE+OO AG-110M 9.56E+06 8.84E+06 5.25E+06 O.OOE+OO 1.74E+07 O.OOE+OO 3.61E+09 O.OOE+OO AG-111 9.16E+04 3.83E+04 1.91E+04 O.OOE+OO 1.24E+05 O.OOE+OO 7.03E+07 O.OOE+OO CD-113M O.OOE+OO 2.32E+08 7.43E+06 O.OOE+OO 2.55E+08 O.OOE+OO 1.87E+09 O.OOE+OO CD-115M O.OOE+OO 4.45E+07 1.42E+06 O.OOE+OO .3.53E+07 O.OOE+OO 1.87E+09 O.OOE+OO SN-123 1.53E+09 2.54E+07 3.74E+07 2.16E+07 O~OOE+OO O.OOE+OO 3.12E+09 O.OOE+OO SN-125 1.80E+07 3.62E+05 8.16E+05 3.00E+05 O.OOE+OO O.OOE+OO 2.24E+08 O.OOE+OO SN-126 6.22E+09 1.23E+08 1.77E+08 3.62E+07 O.OOE+OO O.OOE+OO 1.79E+09 O.OOE+OO SB-124 8.91E+07 1.68E+06 3.53E+07 2.16E+05 O.OOE+OO 6.94E+07 2.53E+09 O.OOE+OO SB-125 1.25E+08 1.40E+06 2.98E+07 1.27E+05 O.OOE+OO 9.65E+07 1.38E+09 O.OOE+OO SB-126 3.70E+06 7.53E+04 1.34E+06 2.27E+04 O.OOE+OO 2.27E+06 3.03E+08 O.OOE+OO SB-127 2.18E+05 4.78E+03 8.37E+04 2.62E+03 O.OOE+OO 1.29E+05 4.99E+07 O.OOE+OO TE-125M 8.27E+07 3.00E+07 1.11E+07 2.49E+07 3.37E+08 O.OOE+OO 3.30E+08 O.OOE+OO TE-127M 3.11 E+08 1.11E+08 3.78E+07 7.94E+07 1.26E+09 O.OOE+OO 1.04E+09 O.OOE+OO TE-127 2.36E+03 8.47E+02 5.10E+02 1.75E+03 9.60E+03 O.OOE+OO 1.86E+05 O.OOE+OO TE-129M 2.00E+08 7.45E+07 3.16E+07 6.86E+07 8.34E+08 O.OOE+OO 1.01E+09 O.OOE+OO TE-129 3.00E-04 1.13E-04 7.30E-05 2.30E-04 1.26E-03 O.OOE+OO 2.26E-04 O.OOE+OO TE-131M 3.82E+05 1.87E+05 1.56E+05 2.96E+05 1.89E+06 O.OOE+OO 1,85E+07 O.OOE+OO TE-131 5.24E-16 2.19E-16 1.65E-16 4.31E-16 2.30E-15 O.OOE+OO 7.42E-17 O.OOE+OO TE-132 1.80E+06 1.17E+06 1.10E+06 1.29E+06 1.12E+07 O.OOE+OO 5.52E+07 O.OOE+OO TE-133M 8.89E-06 5.20E-06 5.01E-06 7.53E-06 5.14E-05 O.OOE+OO 1.78E-06 O.OOE+OO TE-134 1.34E-08 8.77E-09 5.38E-09 1.17E-08 8.48E-08 O.OOE+OO 1.48E-11 O.OOE+OO 1-129 1.20E+09 1.03E+09 3.39E+09 2.66E+12 2.22E+09 O.OOE+OO 1.64E+08 O.OOE+OO 1-130 1.64E+05 4.83E+05 1.91E+05 4.09E+07 7.54E+05 O.OOE+OO 4.16E+05 O.OOE+OO 1-131 3.56E+07 5.10E+07 2.92E+07 1.67E+10 8.74E+07 O.OOE+OO 1.34E+07 O.OOE+OO 1-132 2.34E+01 6.26E+01 2.19E+01 2.19E+03 9.96E+01 O.OOE+OO 1.18E+01 O.OOE+OO 1-133 8.73E+05 1.52E+06 4.63E+05 2.23E+08 2.65E+06 O.OOE+OO 1.36E+06 O.OOE+OO 1-134 3.71E-05 1.01E-04 3.61E-05 1.75E-03 1.60E-04 O.OOE+OO 8.79E-08 O.OOE+OO Rev. 29 Page 225 of 329 12/2016
CY-LG-170-301
- I TABLE 112-10 R1 DOSE FACTORS AGE: ADULT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE . BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-135 1.62E+04 4.24E+04 1.56E+04 2.79E+06 6.79E+04 O.OOE+OO 4.79E+04 O.OOE+OO CS-134M 2.76E+OO 5.80E+OO 2.97E+OO O.OOE+OO 3.15E+OO 4.96E-01 2.05E+OO O.OOE+OO CS-134 4.27E+09 1.02E+10 8.31E+09 O.OOE+OO 3.29E+09 1.09E+09 1.78E+08 O.OOE+OO CS-135 1.44E+09 1.33E+09 5.89E+08 O.OOE+OO 5.02E+08 1.50E+08 3.10E+07 O.OOE+OO CS-136 2.33E+07 9.19E+07 6.62E+07 O.OOE+OO 5.12E+07 7.01E+06 1.04E+07 O.OOE+OO CS-137 5.84E+09 7.99E+09 5.23E+09 O.OOE+OO 2.71E+09 9.02E+08 1.55E+08 O.OOE+OO CS-138 1.42E-11 2.81 E-11 1.39E-11 O.OOE+OO 2.07E-11 2.04E-12 1.20E-16 O.OOE+OO CS-139 5.72E-45 8.52E-45 3.10E-45 O.OOE+OO 6.82E-45 6.20E-46 1.84E-67 O.OOE+OO BA-139 1.13E-02 8.08E-06 3.32E-04 O.OOE+OO 7.56E-06 4.59E-06 2.01E-02 O.OOE+OO BA-140 6.90E+07 8.67E+04 4.52E+06 O.OOE+OO 2.95E+04 4.96E+04 1.42E+08 O.OOE+OO BA-141 3.76E-22 2.84E-25 1.27E-23 O.OOE+OO 2.64E-25 1.61E-25 1.77E-31 O.OOE+OO BA-142 1.63E-39 1.67E-42 1.02E-40 O.OOE+OO 1.41 E-42 9.48E-43 2.29E-57 O.OOE+OO LA-140 8.29E+02 4.18E+02 1.10E+02 O.OOE+OO O.OOE+OO O.OOE+OO 3.07E+07 O.OOE+OO LA-141 2.54E-01 7.89E-02 1.29E-02 O.OOE+OO O.OOE+OO O.OOE+OO 9.41 E+03 O.OOE+OO LA-142 8.08E-05 3.68E-05 9.16E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.68E-01 O.OOE+OO CE-141 1.56E+05 1.05E+05 1.19E+04 O.OOE+OO 4.89E+04 O.OOE+OO 4.02E+08 O.OOE+OO CE-143 4.18E+02 3.09E+05 3.42E+01 O.OOE+OO 1.36E+02 O.OOE+OO 1.16E+07 O.OOE+OO CE-144 2.99E+07 1.25E+07 1.60E+06 O.OOE+OO 7.41 E+06 O.OOE+OO 1.01E+10 O.OOE+OO PR-143 3.47E+04 1.39E+04 1.72E+03 O.OOE+OO 8.04E+03 O.OOE+OO 1.52E+08 O.OOE+OO PR-144 9.92E-27 4.12E-27 5.04E-28 O.OOE+OO 2.32E-27 O.OOE+OO 1.43E-33 O.OOE+OO ND-147 1.65E+04 1.91E+04 1.14E+03 O.OOE+OO 1.12E+04 O.OOE+OO 9.16E+07 O.OOE+OO PM-147 5.26E+06 4.94E+05 2.00E+05 O.OOE+OO 9.34E+05 O.OOE+OO 6.23E+08 O.OOE+OO PM-148M 6.84E+05 1.77E+05 1.35E+05 O.OOE+OO 2.67E+05 O.OOE+OO 1.50E+09 O.OOE+OO PM-148 8.25E+03 1.37E+03 6.90E+02 O.OOE+OO 2.59E+03 O.OOE+OO 1.08E+08 O.OOE+OO PM-149 7.11 E+02 1.01E+02 4.11E+01 O.OOE+OO 1.90E+02 O.OOE+OO 1.89E+07 O.OOE+OO PM-151 1.42E+02 2.38E+01 1.20E+01 O.OOE+OO 4.25E+01 O.OOE+OO 6.55E+06 O.OOE+OO SM-151 5.07E+06 8.75E+05 2.10E+05 O.OOE+OO 9.78E+05 O.OOE+OO 3.86E+08 O.OOE+OO SM-153 3.44E+02 2.87E+02 2.09E+01 O.OOE+OO 9.26E+01 O.OOE+OO 1.02E+07 O.OOE+OO EU-152 1.42E+07 3.24E+06 2.84E+06 O.OOE+OO 2.00E+07 O.OOE+OO 1.87E+09 O.OOE+OO EU-154 4.46E+07 5.48E+06 3.90E+06 O.OOE+OO 2.62E+07 O.OOE+OO 3.97E+09 O.OOE+OO EU-155 6.15E+06 8.73E+05 5.63E+05 O.OOE+OO 4.03E+06 O.OOE+OO 6.87E+08 O.OOE+OO EU-156 6.38E+04 4.94E+04 7.97E+03 O.OOE+OO 3.30E+04 O.OOE+OO 3.38E+08 O.OOE+OO TB-160 1.71 E+06 O.OOE+OO 2.13E+05 O.OOE+OO 7.06E+05 O.OOE+OO 1.58E+09 O.OOE+OO H0-166M 1.99E+07 6.21E+06 4.71E+06 O.OOE+OO 9.28E+06 O.OOE+OO 1.89E+09 O.OOE+OO W-181 4.76E+05 1.55E+05 1.66E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.77E+07 O.OOE+OO W-185 1.51E+07 5.04E+06 5.30E+05 O.OOE+OO O.OOE+OO O.OOE+OO 5.83E+08 O.OOE+OO W-187 1.59E+04 1.33E+04 4.65E+03 O.OOE+OO O.OOE+OO O.QOE+OO 4.36E+06 O.OOE+OO U-232 3.04E+11 O.OOE+OO 2.17E+10 O.OOE+OO 3.29E+10 O.OOE+OO 4.98E+09 O.OOE+OO U-233 6.42E+10 O.OOE+OO 3.89E+09 O.OOE+OO 1.50E+10 O.OOE+OO 4.62E+09 O.OOE+OO U-234 6.16E+10 O.OOE+OO 3.81E+09 O.OOE+OO 1.47E+10 O.OOE+OO 4.52E+09 O.OOE+OO U-235 5.90E+10 O.OOE+OO 3.58E+09 O.OOE+OO 1.38E+10 O.OOE+OO 5.75E+09 O.OOE+OO U-236 5.90E+10 O.OOE+OO 3.65E+09 O.OOE+OO 1.41E+10 O.OOE+OO 4.24E+09 O.OOE+OO Rev.29 Page 226 of 329 12/2016
- CY-LG-170-301 TABLE 112-10 R1 DOSE FACTORS AGE: ADULT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-237 7.86E+04 O.OOE+OO 2.09E+04 O.OOE+OO 3.23E+05 O.OOE+OO 2.76E+07 O.OOE+OO U-238 5.65E+10 O.OOE+OO 3.34E+09 O.OOE+OO 1.29E+10 O.OOE+OO 4.05E+09 O.OOE+OO NP-237 9.28E+10 6.60E+09 4.08E+09 O.OOE+OO 3.03E+10 O.OOE+OO 5.85E+09 O.OOE+OO NP-238 6.08E+03 1.64E+02 9.46E+01 O.OOE+OO 5.55E+02 O.OOE+OO 1.52E+07 O.OOE+OO NP-239 5.99E+02 5.89E+01 3.25E+01 O.OOE+OO 1.84E+02 O.OOE+OO 1.21E+07 O.OOE+OO PU-238 4.63E+10 5.87E+09 1.26E+09 O.OOE+OO 5.38E+09 O.OOE+OO 5.37E+09 O.OOE+OO PU-239 5.34E+10 6.42E+09 1.41E+09 O.OOE+OO 5.97E+09 O.OOE+OO 4.91E+09 O.OOE+OO PU-240 5.33E+10 6.41E+09 1.41E+09 O.OOE+OO 5.97E+09 O.OOE+OO 4.99E+09 O.OOE+OO PU-241 1.14E+09 5.43E+07 2.42E+07 O.OOE+OO 1.12E+08 O.OOE+OO 1.02E+08 O.OOE+OO PU-242 4.95E+10 6.18E+09 1.36E+09 O.OOE+OO 5.75E+09 O.OOE+OO 4.81E+09 O.OOE+OO PU-244 5.78E+10 7.08E+09 1.55E+09 O.OOE+OO 6.59E+09 O.OOE+OO 7.17E+09 O.OOE+OO AM-241 5.56E+10 5.19E+10 3.98E+09 O.OOE+OO 3.00E+10 O.OOE+OO 5.46E+09 O.OOE+OO AM-242M 5.60E+10 4.88E+10 4.00E+09 O.OOE+OO 2.98E+10 O.OOE+OO 6.87E+09 O.OOE+OO AM-243 5.55E+10 5.08E+10 3.90E+09 O.OOE+OO 2.94E+10 O.OOE+OO 6.41E+09 O.OOE+OO CM-242 1.10E+09 1.17E+09 7.34E+07 O.OOE+OO 3.33E+08 O.OOE+OO 4.24E+09 O.OOE+OO CM-243 4.39E+10 4.02E+10 2.75E+09 O.OOE+OO 1.28E+10 O.OOE+OO 5.72E+09 O.OOE+OO CM-244 3.33E+10 3.12E+10 2.10E+09 O.OOE+OO 9.79E+09 O.OOE+OO 5.52E+09 O.OOE+OO CM-245 6.91E+10 6.02E+10 4.24E+09 O.OOE+OO 1.98E+10 O.OOE+OO 5.19E+09 O.OOE+OO CM-246 6.85E+10 6.01E+10 4.24E+09 O.OOE+OO 1.97E+10 O.OOE+OO 5.09E+09 O.OOE+OO CM-247 6.68E+10 5.92E+10 4.18E+09 O.OOE+OO 1.94E+10 O.OOE+OO 6.70E+09 O.OOE+OO CM-248 5.55E+11 4.88E+11 3.44E+10 O.OOE+OO 1.61 E+11 O.OOE+OO 1.08E+11 O.OOE+OO CF-252 1.82E+10 O.OOE+OO 4.39E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.01E+10 O.OOE+OO I Rev. 29 F?age 227 of 329 I 12/2016
CY-LG-170-301 TABLE 112-11 R1 DOSE FACTORS AGE: TEEN PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.41E+03 1.41 E+03 1.41E+03 1.41E+03 1.41E+03 1.41E+03 O.OOE+OO C-14 1.39E+06 2.77E+05 2.77E+05 2.77E+05 2.77E+05 2.77E+05 2.77E+05 O.OOE+OO NA-22 1.92E+09 1.92E+09 1.92E+09 1.92E+09 1.92E+09 1.92E+09 1.92E+09 O.OOE+OO NA-24 9.98E+04 9.98E+04 9.98E+04 9.98E+04 9.98E+04 9.98E+04 9.98E+04 O.OOE+OO P-32 1.04E+09 6.47E+07 4.05E+07 O.OOE+OO O.OOE+OO O.OOE+OO 8.78E+07 O.OOE+OO CA-41 1.71E+10 O.OOE+OO 1.85E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.69E+07 O.OOE+OO SC-46 3.35E+05 6.52E+05 1.93E+05 O.OOE+OO 6.24E+05 O.OOE+OO 2.22E+09 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 5.18E+04 2.88E+04 1.13E+04 7.39E+04 8.70E+06 O.OOE+OO MN-54 O.OOE+OO 4.31E+08 8.54E+07 O.OOE+OO 1.28E+08 O.OOE+OO 8.83E+08 O.OOE+OO MN-56 O.OOE+OO 5.84E+OO 1.04E+OO O.OOE+OO 7.40E+OO O.OOE+OO 3.85E+02 O.OOE+OO FE-55 3.10E+08 2.20E+08 5.13E+07 O.OOE+OO O.OOE+OO 1.39E+08 9.51E+07 O.OOE+OO FE-59 1.61E+08 3.75E+08 1.45E+08 O.OOE+OO O.OOE+OO 1.18E+08 8.87E+08 O.OOE+OO C0-57 O.OOE+OO 1.69E+07 2.84E+07 O.OOE+OO O.OOE+OO O.OOE+OO 3.16E+08 O.OOE+OO C0-58 O.OOE+OO 4.02E+07 9.26E+07 O.OOE+OO O.OOE+OO O.OOE+OO 5.54E+08 O.OOE+OO C0-60 O.OOE+OO 2.37E+08 5.33E+08 O.OOE+OO O.OOE+OO O.OOE+OO 3.08E+09 O.OOE+OO Nl-59 1.14E+09 4.04E+08 1.94E+08 O.OOE+OO O.OOE+OO O.OOE+OO 6.33E+07 O.OOE+OO Nl-63 1.53E+10 1.08E+09 5.19E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+08 O.OOE+OO Nl-65 2.33E+01 2.98E+OO 1.36E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.62E+02 O.OOE+OO CU-64 O.OOE+OO 3.48E+03 1.64E+03 O.OOE+OO 8.81E+03 O.OOE+OO 2.70E+05 O.OOE+OO ZN-65 4.01E+08 1.39E+09 6.49E+08 O.OOE+OO 8.91E+08 O.OOE+OO 5.89E+08 O.OOE+OO ZN-69M 8.67E+03 2.04E+04 1.88E+03 O.OOE+OO 1.24E+04 O.OOE+OO 1.12E+06 O.OOE+OO ZN-69 1.99E-06 3.79E-06 2.65E-07 O.OOE+OO 2.48E-06 O.OOE+OO 6.98E-06 O.OOE+OO SE-79 O.OOE+OO 3.23E+08 5.43E+07 O.OOE+OO 5.63E+08 O.OOE+OO 4.94E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 5.55E+05 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.18E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 8.18E-12 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO j RB-86 O.OOE+OO 2.04E+08 9.58E+07 O.OOE+OO O.OOE+OO O.OOE+OO 3.02E+07 O.OOE+OO RB-87 O.OOE+OO 1.52E+09 5.29E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.29E+07 O.OOE+OO RB-88 O.OOE+OO 1.03E-22 5.47E-23 O.OOE+OO O.OOE+OO O.OOE+OO 8.79E-30 O.OOE+OO RB-89 O.OOE+OO 1.09E-26 7.70E-27 O.OOE+OO O.OOE+OO O.OOE+OO 1.67E-35 O.OOE+OO SR-89 1.37E+10 O.OOE+OO
- 3.92E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.63E+09 O.OOE+OO SR-90 8.79E+11 O.OOE+OO 1.76E+10 O.OOE+OO O.OOE+OO O.OOE+OO 2.01E+10 O.OOE+OO SR-91 1.19E+05 O.OOE+OO 4.72E+03 O.OOE+OO O.OOE+OO O.OOE+OO 5.38E+05 O.OOE+OO SR-92 1.62E+02 O.OOE+OO 6.91E+OO O.OOE+OO O.OOE+OO O.OOE+OO 4.13E+03 O.OOE+OO Y-90 5.21E+03 O.OOE+OO 1.40E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.30E+07 O.OOE+OO Y-91M 1.86E-09 O.OOE+OO 7.11E-11 O.OOE+OO O.OOE+OO O.OOE+OO 8.78E-08 O.OOE+OO Y-91 7.15E+06 O.OOE+OO 1.92E+05 O.OOE+OO O.OOE+OO O.OOE+OO 2.93E+09 O.OOE+OO Y-92 3.53E-01 O.OOE+OO 1.02E-02 O.OOE+OO O.OOE+OO O.OOE+OO 9.70E+03 O.OOE+OO Y-93 6.63E+01 O.OOE+OO 1.82E+OO O.OOE+OO O.OOE+OO O.OOE+OO 2.02E+06 O.OOE+OO ZR-93 4.79E+06 2.37E+05 1.29E+05 O.OOE+OO *8.36E+05 O.OOE+OO 2.24E+08 O.OOE+OO ZR-95 1.58E+06 4.98E+05 3.43E+05 O.OOE+OO 7.32E+05 O.OOE+OO 1.15E+09 O.OOE+OO Rev.29 Page 228 of 329 12/2016
CY-LG-170-301 TABLE 112-11 R1 DOSE FACTORS AGE: TEEN PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN ZR-97 1.31E+02 2.58E+01 1.19E+01 O.OOE+OO 3.92E+01 O.OOE+OO 7.00E+06 O.OOE+OO NB-93M 2.95E+06 9.69E+05 2.43E+05 O.OOE+OO 1.13E+06 O.OOE+OO 3.49E+08 O.OOE+OO NB-95 1.68E+05 9.31E+04 5.12E+04 O.OOE+OO 9.02E+04 O.OOE+OO 3.98E+08 O.OOE+OO NB-97 7.86E-07 1.95E-07 7.12E-08 O.OOE+OO 2.28E-07 O.OOE+OO 4.66E-03 O.OOE+OO M0-93 O.OOE+OO 9.18E+08 2.51E+07 O.OOE+OO 2.63E+08 O.OOE+OO 1.12E+08 O.OOE+OO M0-99 O.OOE+OO 2.37E+06 4.52E+05 O.OOE+OO 5.42E+06 O.OOE+OO 4.24E+06 O.OOE+OO TC-99M 1.13E+OO 3.16E+OO 4.10E+01 O.OOE+OO 4.72E+01 1.76E+OO 2.08E+03 O.OOE+OO TC-99 1.55E+07 2.28E+07 6.21E+06 O.OOE+OO 2.89E+08 2.36E+06 5.58E+08 O.OOE+OO TC-101 2.32E-31 3.30E-31 3.24E-30 O.OOE+OO 5.96E-30 2.01 E-31 5.63E-38 O.OOE+OO RU-103 6.04E+06 O.OOE+OO 2.58E+06 O.OOE+OO 2.13E+07 O.OOE+OO 5.04E+08 O.OOE+OO RU-105 2.07E+01 O.OOE+OO 8.01E+OO O.OOE+OO 2.60E+02 O.OOE+OO 1.67E+04 O.OOE+OO RU-106 2.93E+08 O.OOE+OO 3.70E+07 O.OOE+OO 5.66E+08 O.OOE+OO 1.41E+10 O.OOE+OO RH-105 3.17E+04 2.29E+04 1.50E+04 O.OOE+OO 9.72E+04 O.OOE+OO 2.91E+06 O.OOE+OO PD-107 O.OOE+OO 1.80E+07 1.16E+06 O.OOE+OO 1.63E+08 O.OOE+OO 8.37E+07 O.OOE+OO PD-109 O.OOE+OO 8.64E+03 1.96E+03 O.OOE+OO 4.99E+04 O.OOE+OO 8.71E+05 O.OOE+OO AG-110M 1.43E+07 1.36E+07 8.25E+06 O.OOE+OO 2.59E+07 O.OOE+OO 3.81E+09 O.OOE+OO AG-111 9.00E+04 3.74E+04 1.88E+04 O.OOE+OO 1.22E+05 O.OOE+OO 5.21E+07 O.OOE+OO CD-113M O.OOE+OO 3.87E+08 1.24E+07 O.OOE+OO 4.28E+08 O.OOE+OO 2.32E+09 O.OOE+OO CD-115M O.OOE+OO 7.11E+07 2.30E+06 O.OOE+OO 5.69E+07 O.OOE+OO 2.25E+09 O.OOE+OO SN-123 2.55E+09 4.19E+07 6.20E+07 3.35E+07 O.OOE+OO O.OOE+OO 3.85E+09 O.OOE+OO SN-125 1.93E+07 3.85E+05 8.73E+05 3.02E+05 O.OOE+OO O.OOE+OO 1.82E+08 O.OOE+OO SN-126 1.01E+10 1.87E+08 2.86E+08 4.93E+07 O.OOE+OO O.OOE+OO 2.24E+09 O.OOE+OO SB-124 1.41E+08 2.60E+06 5.51E+07 3.20E+05 O.OOE+OO 1.23E+08 2.84E+09 O.OOE+OO SB-125 2.04E+08 2.23E+06 4.76E+07 1.95E+05 O.OOE+OO 1.79E+08 1.59E+09 O.OOE+OO SB-126 4.36E+06 8.91E+04 1.57E+06 2.47E+04 O.OOE+OO 3.13E+06 2.58E+08 O.OOE+OO SB-127 2.01E+05 4.31E+03 7.60E+04 2.26E+03 O.OOE+OO 1.37E+05 3.42E+07 O.OOE+OO TE-125M 1.35E+08 4.88E+07 1.81 E+07 3.78E+07 O.OOE+OO O.OOE+OO 3.99E+08 O.OOE+OO TE-127M 5.15E+08 1.83E+08 6.13E+07 1.23E+08 2.09E+09 O.OOE+OO 1.28E+09 O.OOE+OO TE-127 2.22E+03 7.88E+02 4.78E+02 1.53E+03 9.00E+03 O.OOE+OO 1.72E+05 O.OOE+OO TE-129M 3.14E+08 1.16E+08 4.97E+07 1.01E+08 1.31E+09 O.OOE+OO 1.18E+09 O.OOE+OO TE-129 2.81E-04 1.05E-04 6.83E-05 2.00E-04 1.18E-03 O.OOE+OO 1.53E-03 O.OOE+OO TE-131M 3.54E+05 1.70E+05 1.41 E+05 2.55E+05 1.77E+06 O.OOE+OO 1.36E+07 O.OOE+OO TE-131 4.87E-16 2.01E-16 1.52E-16 3.75E-16 2.13E-15 O.OOE+OO 4.00E-17 O.OOE+OO TE-132 1.64E+06 1.04E+06 9.77E+05 1.09E+06 9.96E+06 O.OOE+OO 3.29E+07 O.OOE+OO TE-133M 8.14E-06 4.62E-06 4.50E-06 6.46E-06 4.57E-05 O.OOE+OO 1.87E-05 O.OOE+OO TE-134 1.21E-08 7.79E-09 8.14E-09 9.96E-09 7.44E-08 O.OOE+OO 4.51E-10 O.OOE+OO 1-129 2.02E+09 1.70E+09 2.83E+09 2.07E+12 3.04E+09 O.OOE+OO 1.98E+08 O.OOE+OO 1-130 1.46E+05 4.24E+05 1.69E+05 3.45E+07 6.52E+05 O.OOE+OO 3.26E+05 O.OOE+OO 1-131 3.52E+07 4.93E+07 2.65E+07 1.44E+10 8.49E+07 O.OOE+OO 9.75E+06 O.OOE+OO 1-132 2.11E+01 5.52E+01 1.98E+01 1.86E+03 8.69E+01 O.OOE+OO 2.40E+01 O.OOE+OO 1-133 8.11E+05 1.38E+06 4.19E+05 1.92E+08 2.41E+06 O.OOE+OO 1.04E+06 O.OOE+OO 1-134 3.36E-05 8.90E-05 3.20E-05 1.48E-03 1.40E-04 O.OOE+OO 1.17E-06 O.OOE+OO Rev.29 Page 229 of 329 12/2016
CY-LG-170-301 TABLE 112-11 R1 DOSE FACTORS AGE: TEEN PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-135 1.46E+04 3.76E+04 1.40E+04 2.42E+06 5.94E+04 O.OOE+OO 4.17E+04 O.OOE+OO CS-134M 2.50E+OO 5.18E+OO 2.66E+OO O.OOE+OO 2.88E+OO 5.06E-01 3.44E+OO O.OOE+OO CS-134 6.75E+09 1.59E+10 7.37E+09 O.OOE+OO 5.05E+09 1.93E+09 1.98E+08 O.OOE+OO CS-135 2.41E+09 2.21E+09 5.16E+08 O.OOE+OO 8.43E+08 3.05E+08 3.86E+07 O.OOE+OO CS-136 2.69E+07 1.06E+08 7.12E+07 O.OOE+OO 5.77E+07 9.10E+06 8.53E+06 O.OOE+OO CS-137 9.66E+09 1.28E+10 4.47E+09 O.OOE+OO 4.37E+09 1.70E+09 1.83E+08 O.OOE+OO CS-138 1.31E-11 2.52E-11 1.26E-11 O.OOE+OO 1.86E-11 2.17E-12 1.14E-14 O.OOE+OO CS-139 5.36E-45 7.89E-45 2.89E-45 O.OOE+OO 6.37E-45 6.98E-46 3.66E-60 O.OOE+OO BA-139 1.07E-02 7.51E-06 3.11E-04 O.OOE+OO 7.08E-06 5.17E-06 9.52E-02 O.OOE+OO BA-140 8.35E+07 1.02E+05 5.38E+06 O.OOE+OO 3.47E+04 6.88E+04 1.29E+08 O.OOE+OO BA-141 3.51E-22 2.62E-25 1.17E-23 O.OOE+OO 2.43E-25 1.79E-25 7.48E-28 O.OOE+OO BA-142 1.50E-39 1.50E-42 9.23E-41 O.OOE+OO 1.27E-42 9.99E-43 4.61E-51 O.OOE+OO LA-140 7.57E+02 3.72E+02 9.90E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.14E+07 O.OOE+OO LA-141 2.38E-01 7 ..33E-02 1.21E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.30E+04 O.OOE+OO LA-142 7.42E-05 3.29E-05 8.21E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.00E+OO O.OOE+OO CE-141 2.44E+05 1.63E+05 1.87E+04 O.OOE+OO 7.68E+04 O.OOE+OO 4.66E+08 O.OOE+OO CE-143 3.91E+02 2.84E+05 3.18E+01 O.OOE+OO 1.28E+02 O.OOE+OO 8.55E+06 O.OOE+OO CE-144 4.99E+07 2.07E+07 2.68E+06 O.OOE+OO 1.23E+07 O.OOE+OO 1.26E+10 O.OOE+OO PR-143 4.40E+04 1.76E+04 2.19E+03 O.OOE+OO 1.02E+04 O.OOE+OO 1.45E+08 O.OOE+OO PR-144 9.30E-27 3.81E-27 4.72E-28 O.OOE+OO 2.19E-27 O.OOE+OO 1.03E-29 O.OOE+OO ND-147 1.97E+04 2.15E+04 1.29E+03 O.OOE+OO 1.26E+04 O.OOE+OO 7.74E+07 O.OOE+OO PM-147 8.60E+06 8.16E+05 3.32E+05 O.OOE+OO 1.56E+06 O.OOE+OO 7.76E+08 O.OOE+OO PM-148M 1.04E+06 2.63E+05 2.06E+05 O.OOE+OO 3.99E+05 O.OOE+OO 1.66E+09 O.OOE+OO PM-148 7.75E+03 1.26E+03 6.36E+02 O.OOE+OO 2.28E+03 O.OOE+OO 7.53E+07 O.OOE+OO PM-149 6.66E+02 9.36E+01 3.84E+01 O.OOE+OO 1.78E+02 O.OOE+OO 1.38E+07 O.OOE+OO PM-151 1.32E+02 2.18E+01 1.10E+01 O.OOE+OO 3.91E+01 O.OOE+OO 4.89E+06 O.OOE+OO SM-151 7.55E+06 1.45E+06 3.41 E+05 O.OOE+OO 1.59E+06 O.OOE+OO 4.93E+08 O.OOE+OO SM-153 3.21E+02 2.66E+02 1.95E+01 O.OOE+OO 8.68E+01 O.OOE+OO 7.50E+06 O.OOE+OO EU-152 2.10E+07 5.06E+06 4.46E+06 O.OOE+OO 2.35E+07 O.OOE+OO 1.86E+09 O.OOE+OO EU-154 6.74E+07 8.69E+06 6.13E+06 O.OOE+OO 3.88E+07 O.OOE+OO 4.59E+09 O.OOE+OO EU-155 1.46E+07 1.41E+06 8.75E+05 O.OOE+OO 5.52E+06 O.OOE+OO 8.10E+09 O.OOE+OO EU-156 8.35E+04 6.26E+04 1.02E+04 O.OOE+OO 4.22E+04 O.OOE+OO 3.20E+08 O.OOE+OO TB-160 2.71E+06 O.OOE+OO 3.39E+05 O.OOE+OO 1.07E+06 O.OOE+OO 1.76E+09 O.OOE+OO H0-166M 3.09E+07 9.53E+06 6.90E+06 O.OOE+OO 1.39E+07 O.OOE+OO 2.35E+09 O.OOE+OO W-181 7.93E+05 2.56E+05 2.68E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.18E+07 O.OOE+OO W-185 2.49E+07 8.23E+06 8.70E+05 O.OOE+OO O.OOE+OO O.OOE+OO 7.11E+08 O.OOE+OO W-187 1.48E+04 1.21E+04 4.23E+03 O.OOE+OO O.OOE+OO O.OOE+OO 3.27E+06 O.OOE+OO U-232 5.09E+11 O.OOE+OO 3.64E+10 O.OOE+OO 5.52E+10 O.OOE+OO 6.22E+09 O.OOE+OO U-233 1.07E+11 O.OOE+OO 6.53E+09 O.OOE+OO 2.51E+10 O.OOE+OO 5.76E+09 O.OOE+OO U-234 1.03E+11 O.OOE+OO 6.40E+09 O.OOE+OO 2.47E+10 O.OOE+OO 5.64E+09
- O.OOE+OO U-235 9.88E+10 O.OOE+OO 6.01E+09 O.OOE+OO 2.31E+10 O.OOE+OO 7.17E+09 O.OOE+OO U-236 9.88E+10 O.OOE+OO 6.14E+09 O.OOE+OO 2.37E+10 O.OOE+OO 5.29E+09 O.OOE+OO Rev.29 Page 230 of 329 12/2016
CY-LG-170-301 TABLE 112-11 R1 DOSE FACTORS AGE: TEEN PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-237 7.58E+04 O.OOE+OO 2.02E+04 O.OOE+OO 3.11 E+05 O.OOE+OO 2.01E+07 O.OOE+OO U-238 9.44E+10 O.OOE+OO 5.62E+09 O.OOE+OO 2.17E+10 O.OOE+OO 5.05E+09 O.OOE+OO NP-237 1.15E+11 8.27E+09 5.07E+09 O.OOE+OO 3.75E+10 O.OOE+OO 7.29E+09 O.OOE+OO NP-238 5.68E+03 1.52E+02 8.86E+01 O.OOE+OO 5.22E+02 O.OOE+OO 1.12E+07 O.OOE+OO NP-239 5.81E+02 5.48E+01 3.04E+01 O.OOE+OO 1.72E+02 O.OOE+OO 8.82E+06 O.OOE+OO PU-238 5.80E+10 7.42E+09 1.57E+09 O.OOE+OO 6.75E+09 O.OOE+OO 6.69E+09 O.OOE+OO PU-239 6.63E+10 8.05E+09 1.74E+09 O.OOE+OO 7.42E+09 O.OOE+OO 6.12E+09 O.OOE+OO PU-240 6.62E+10 8.03E+09 1.74E+09 O.OOE+OO 7.42E+09 O.OOE+OO 6.23E+09 O.OOE+OO PU-241 1.50E+09 7.20E+07 3.16E+07 O.OOE+OO 1.47E+08 O.OOE+OO 1.27E+08 O.OOE+OO PU-242 6.14E+10 7.75E+09 1.68E+09 O.OOE+OO 7.15E+09 O.OOE+OO 6.00E+09 O.OOE+OO PU-244 7.17E+10 8.84E+09 1.92E+09 O.OOE+OO 8.19E+09 O.OOE+OO 8.92E+09 O.OOE+OO AM-241 6.91E+10 6.52E+10 4.98E+09 O.OOE+OO 3.73E+10 O.OOE+OO 6.82E+09 O.OOE+OO AM-242M 6.98E+10 6.15E+10 5.02E+09 O.OOE+OO 3.72E+10 O.OOE+OO 8.57E+09 O.OOE+OO AM-243 6.90E+10 6.37E+10 4.87E+09 O.OOE+OO 3.66E+10 O.OOE+OO 8.00E+09 O.OOE+OO CM-242 1.84E+09 1.94E+09 1.22E+08 O.OOE+OO 5.55E+08 O.OOE+OO 5.25E+09 O.OOE+OO CM-243 5.60E+10 5.20E+10 3.53E+09 O.OOE+OO 1.65E+10 O.OOE+OO 7.14E+09 O.OOE+OO CM-244 4.33E+10 4.10E+10 2.74E+09 O.OOE+OO 1.28E+10 O.OOE+OO 6.87E+09 O.OOE+OO CM-245 8.58E+10 7.55E+10 5.28E+09 O.OOE+OO 2.47E+10 O.OOE+OO 6.46E+09 O.OOE+OO CM-246 8.51E+10 7.54E+10 5.28E+09 O.OOE+OO 2.46E+10 O.OOE+OO 6.35E+09 O.OOE+OO CM-247 8.29E+10 7.42E+10 5.20E+09 O.OOE+OO 2.43E+10 O.OOE+OO 8.34E+09 O.OOE+OO CM-248 6.89E+11 6.12E+11 4.29E+10 O.OOE+OO 2.00E+11 O.OOE+OO 1.34E+11 O.OOE+OO CF-252 2.84E+10 O.OOE+OO 6.86E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.50E+10 O.OOE+OO Rev.29 Page 231 of 329 12/2016
CY-LG-170-301 TABLE 112-12 R1 DOSE FACTORS AGE: CHILD PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec* NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 2.21E+03 2.21E+03 2.21E+03 2.21E+03 2.21E+03 2.21E+03 O.OOE+OO C-14 3.38E+06 6.76E+05 6.76E+05 6.76E+05 6.76E+05 6.76E+05 6.76E+05 O.OOE+OO NA-22 3.94E+09 3.94E+09 3.94E+09 3.94E+09 3.94E+09 3.94E+09 3.94E+09 O.OOE+OO NA-24 1.56E+05 1.56E+05 1.56E+05 1.56E+05 1.56E+05 1.56E+05 1.56E+05 O.OOE+OO P-32 2.33E+09 1.09E+08 8.96E+07 O.OOE+OO O.OOE+OO O.OOE+OO 6.43E+07 O.OOE+OO CA-41 2.46E+10 O.OOE+OO 2.69E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.35E+07 O.OOE+OO SC-46 7.41E+05 1.02E+06 3.91E+05 O.OOE+OO 8.99E+05 O.OOE+OO 1.49E+09 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.02E+05 5.66E+04 1.55E+04 1.03E+05 5.41E+06 O.OOE+OO MN-54 O.OOE+OO 6.38E+08 1.70E+08 O.OOE+OO 1.79E+08 O.OOE+OO 5.35E+08 O.OOE+OO MN-56 O.OOE+OO 7.65E+OO 1.73E+OO O.OOE+OO 9.25E+OO O.OOE+OO 1.11E+03 O.OOE+OO FE-55 7.71E+08 4.09E+08 1.27E+08 O.OOE+OO O.OOE+OO 2.31E+08 7.58E+07 O.OOE+OO FE-59 3.65E+08 5.91E+08 2.94E+08 O.OOE+OO O.OOE+OO 1.71E+08 6.15E+08 O.OOE+OO C0-57 O.OOE+OO 2.86E+07 5.79E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.35E+08 O.OOE+OO C0-58 O.OOE+OO 6.05E+07 1.85E+08 O.OOE+OO O.OOE+OO O.OOE+OO 3.53E+08 O.OOE+OO C0-60 O.OOE+OO 3.64E+08 1.07E+09 O.OOE+OO O.OOE+OO O.OOE+OO 2.02E+09 O.OOE+OO Nl-59 2.85E+09 7.58E+08 4.83E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.03E+07 O.OOE+OO Nl-63 3.81E+10 2.04E+09 1.30E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.37E+08 O.OOE+OO Nl-65 4.28E+01 4.03E+OO 2.35E+OO O.OOE+OO O.OOE+OO O.OOE+OO 4.93E+02 O.OOE+OO CU-64 O.OOE+OO 4.59E+03 2.77E+03 O.OOE+OO 1.11E+04 O.OOE+OO 2.15E+05 O.OOE+OO ZN-65 7.79E+08 2.07E+09 1.29E+09 O.OOE+OO 1.31E+09 O.OOE+OO 3.64E+08 O.OOE+OO ZN-69M 1.59E+04 2.71E+04 3.20E+03 O.OOE+OO 1.57E+04 O.OOE+OO 8.81E+05 O.OOE+OO ZN-69 3.67E-06 5.30E-06 4.90E-07 O.OOE+OO 3.22E-06 O.OOE+OO 3.34E-04 O.OOE+OO SE-79 O.OOE+OO 5.97E+08 1.33E+08 O.OOE+OO 9.71E+08 O.OOE+OO 3.92E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 8.54E+05 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 2.18E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.39E-11 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 3.55E+08 2.18E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.28E+07 O.OOE+OO RB-87 O.OOE+OO 2.80E+09 1.30E+09 O.OOE+OO O.OOE+OO O.OOE+OO 4.20E+07 O.OOE+OO RB-88 O.OOE+OO 1.42E-22 9.84E-23 O.OOE+OO O.OOE+OO O.OOE+OO 6.95E-24 O.OOE+OO RB-89 O.OOE+OO 1.43E-26 1.28E-26 O.OOE+OO O.OOE+OO O.OOE+OO 1.25E-28 O.OOE+OO SR-89 3.33E+10 O.OOE+OO 9.50E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.29E+09 O.OOE+OO SR-90 1.80E+12 O.OOE+OO 3.63E+10 O.OOE+OO O.OOE+OO O.OOE~OO 1.61 E+10 O.OOE+OO SR-91 2.18E+05 O.OOE+OO 8.24E+03 O.OOE+OO O.OOE+OO O.OOE+OO 4.82E+05 O.OOE+OO SR-92 2.97E+02 O.OOE+OO 1.19E+01 O.OOE+OO O.OOE+OO O.OOE+OO 5.63E+03 O.OOE+OO Y-90 9.68E+03 O.OOE+OO 2.59E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.76E+07 O.OOE+OO Y-91M 3.41 E-09 O.OOE+OO 1.24E-10 O.OOE+OO O.OOE+OO O.OOE+OO 6.68E-06 O.OOE+OO Y-91 1.74E+07 O.OOE+OO 4.65E+05 O.OOE+OO O.OOE+OO O.OOE+OO 2.32E+09 O.OOE+OO Y-92 6.51E-01 O.OOE+OO 1.86E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.88E+04 O.OOE+OO ZR-93 1.18E+07 4.43E+05 3.15E+05 O.OOE+OO 1.72E+06 O.OOE+OO 1.68E+08 O.OOE+OO ZR-95 3.61E+06 7.93E+05 7.06E+05 O.OOE+OO 1.14E+06 O.OOE+OO 8.28E+08 O.OOE+OO ZR-97 2.38E+02 3.44E+01 2.03E+01 O.OOE+OO 4.94E+01 O.OOE+OO 5.22E+06 O.OOE+OO Y-93 1.22E+02 O.OOE+OO 3.35E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.82E+06 O.OOE+OO NB-93M 7.37E+06 1.84E+06 6.04E+05 O.OOE+OO 1.99E+06 O.OOE+OO 2.77E+08 O.OOE+OO NB-95 3.69E+05 1.44E+05 1.03E+05 O.OOE+OO 1.35E+05 O.OOE+OO 2.66E+08 O.OOE+OO Rev.29 Page 232 of 329 12/2016
CY-LG-170-301 TABLE 112-12 R1 DOSE FACTORS AGE: CHILD PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 1.43E-06 2.59E-07 1.21 E-07 O.OOE+OO 2.87E-07 O.OOE+OO 7.99E-02 O.OOE+OO M0-93 O.OOE+OO 1.71E+09 6.13E+07 O.OOE+OO 4.50E+08 O.OOE+OO 8.65E+07 O.OOE+OO M0-99 O.OOE+OO 3.24E+06 8.00E+05 O.OOE+OO 6.91E+06 O.OOE+OO 2.68E+06 O.OOE+OO TC-99 3.79E+07 4.22E+07 1.52E+07 O.OOE+OO 4.98E+08 3.74E+06 4.43E+08 O.OOE+OO TC-99M 1.95E+OO 3.83E+OO 6.35E+01 O.OOE+OO 5.56E+01 1.94E+OO 2.18E+03 O.OOE+OO TC-101 4.27E-31 4.46E-31 5.66E-30 O.OOE+OO 7.61E-30 2.36E-31 1.42E-30 O.OOE+OO RU-103 1.39E+07 O.OOE+OO 5.36E+06 O.OOE+OO 3.51E+07 O.OOE+OO 3.61E+08 O.OOE+OO RU-105 3.78E+01 O.OOE+OO 1.37E+01 O.OOE+OO 3.32E+02 O.OOE+OO 2.47E+04 O.OOE+OO RU-106 7.16E+08 O.OOE+OO 8.93E+07 O.OOE+OO' 9.67E+08 O.OOE+OO 1.11E+10 O.OOE+OO RH-105 5.83E+04 3.13E+04 2.68E+04 O.OOE+OO 1.25E+05 O.OOE+OO 1.94E+06 O.OOE+OO PD-107 O.OOE+OO 3.35E+07 2.84E+06 O.OOE+OO 2.80E+08 O.OOE+OO 6.64E+07 O.OOE+OO PD-109 O.OOE+OO 1.21E+04 3.62E+03 O.OOE+OO 6.48E+04 O.OOE+OO 7.14E+05 O.OOE+OO AG-110M 3.08E+07 2.08E+07 1.66E+07 O.OOE+OO 3.87E+07 O.OOE+OO 2.47E+09 O.OOE+OO AG-111 1.72E+05 5.39E+04 3.56E+04 O.OOE+OO 1.63E+05 O.OOE+OO 3.30E+07 O.OOE+OO CD-113M O.OOE+OO 7.15E+08 3.04E+07 O.OOE+OO 7.36E+08 O.OOE+OO 1.84E+09 O.OOE+OO CD-115M O.OOE+OO 1.30E+08 5.55E+06 O.OOE+OO 9.68E+07 O.OOE+OO 1.77E+09 O.OOE+OO SN-123 6.23E+09 7.73E+07 1.52E+08 8.19E+07 O.OOE+OO O.OOE+OO 3.05E+09 O.OOE+OO SN-125 3.91E+07 5.89E+05 1.75E+06 6.11E+05 O.OOE+OO O.OOE+OO 1.21E+08 O.OOE+OO SN-126 2.36E+10 2.94E+08 6.70E+08 8.08E+07 O.OOE+OO O.OOE+OO 1.77E+09 O.OOE+OO SB-124 3.28E+08 4.26E+06 1.15E+08 7.25E+05 O.OOE+OO 1.82E+08 2.05E+09 O.OOE+OO SB-125 4.81E+08 3.71E+06 1.01E+08 4.45E+05 O.OOE+OO 2.68E+08 1.15E+09 O.OOE+OO SB-126 8.72E+06 1.33E+05 3.13E+06 5.11 E+04 O.OOE+OO 4.16E+06 1.76E+08 O.OOE+OO SB-127 3.64E+05 5.64E+03 1.26E+05 4.05E+03 O.OOE+OO 1.58E+05 2.05E+07 O.OOE+OO TE-125M 3.27E+08 8.85E+07 4.36E+07 9.17E+07 O.OOE+OO O.OOE+OO 3.15E+08 O.OOE+OO TE-127M 1.25E+09 3.38E+08 1.49E+08 3.00E+08 3.58E+09 O.OOE+OO 1.02E+09 O.OOE+OO TE-127 4.10E+03 1.11 E+03 8.79E+02 2.84E+03 1.17E+04 O.OOE+OO 1.60E+05 O.OOE+OO TE-129M 7.52E+08 2.10E+08 1.17E+08 2.43E+08 2.21E+09 O.OOE+OO 9.18E+08 O.OOE+OO TE-129 5.19E-04 1.45E-04 1.23E-04 3.71E-04 1.52E-03 O.OOE+OO 3.23E-02 O.OOE+OO TE-131M 6.46E+05 2.23E+05 2.38E+05 4.59E+05 2.16E+06 O.OOE+OO 9.06E+06 O.OOE+OO TE-131 8.97E-16 2.73E-16 2.67E-16 6.86E-16 2.71E-15 O.OOE+OO 4.71E-15 O.OOE+OO TE-132 2.94E+06 1.30E+06 1.57E+06 1.89E+06 1.21 E+07 O.OOE+OO 1.31E+07 O.OOE+OO TE-133M 1.46E-05 5.91E-06 7.33E-06 1.13E-05 5.62E-05 O.OOE+OO 4.51E-04 O.OOE+OO TE-134 2.17E-08 9.75E-09 1.30E-08 1.71E-08 9.02E-08 O.OOE+OO 9.90E-08 O.OOE+OO 1-129 4.93E+09 3.02E+09 2.70E+09 1.98E+12 5.10E+09 O.OOE+OO 1.52E+08 O.OOE+OO 1-130 2.57E+05 5.19E+05 2.68E+05 5.72E+07 7.76E+05 O.OOE+OO 2.43E+05 O.OOE+OO 1-131 6.72E+07 6.76E+07 3.84E+07 2.23E+10 1.11E+08 O.OOE+OO 6.01E+06 O.OOE+OO 1-132 3.74E+01 6.88E+01 3.16E+01 3.19E+03 1.05E+02 O.OOE+OO 8.10E+01 O.OOE+OO 1-133 1.48E+06 1.83E+06 6.91E+05 3.40E+08 3.05E+06 O.OOE+OO 7.36E+05 O.OOE+OO 1-134 5.96E-05 1.11 E-04 5.09E-05 2.55E-03 1.69E-04 O.OOE+OO 7.34E-05 O.OOE+OO 1-135 2.60E+04 4.67E+04 2.21E+04 4.14E+06 7.17E+04 O.OOE+OO 3.56E+04 O.OOE+OO CS-134M 4.44E+OO 6.58E+OO 4.29E+OO O.OOE+OO 3.47E+OO 5.73E-01 8.31E+OO O.OOE+OO CS-134 1.54E+10 2.53E+10 5.34E+09 O.OOE+OO 7.85E+09 2.82E+09 1.37E+08 O.OOE+OO CS-135 5.88E+09 4.10E+09 4.20E+08 O.OOE+OO 1.45E+09 4.83E+08 3.07E+07 O.OOE+OO CS-136 5.40E+07 1.48E+08 9.60E+07 O.OOE+OO 7.90E+07 1.18E+07 5.21E+06 O.OOE+OO CS-137 2.31E+10 2.21E+10 3.26E+09 O.OOE+OO 7.19E+09 2.59E+09 1.38E+08 O.OOE+OO Rev.29 Page 233 of 329 12/2016
CY-LG-170-301 TABLE 112-12 R1 DOSE FACTORS AGE: CHILD PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-138 2.39E-11 3.32E-11 2.11 E-11 O.OOE+OO 2.34E-11 2.52E-12 1.53E-11 O.OOE+OO CS-139 9.88E-45 1.10E-44 5.27E-45 O.OOE+OO 8.24E-45 8.31E-46 9.88E-49 O.OOE+OO BA-139 1.97E-02 1.05E-05 5.70E-04 O.OOE+OO 9.17E-06 6.18E-06 1.14E+OO O.OOE+OO BA-140 1.78E+08 1.56E+05 1.04E+07 O.OOE+OO 5.07E+04 9.28E+04 9.01E+07 O.OOE+OO BA-141 6.48E-22 3.63E-25 2.11E-23 O.OOE+OO 3.14E-25 2.13E-24 3.69E-22 O.OOE+OO BA-142 2.71 E-39 1.95E-42 1.52E-40 O.OOE+OO 1.58E-42 1.15E-42 3.54E-41 O.OOE+OO LA-140 1.36E+03 4.76E+02 1.60E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.33E+07 O.OOE+OO LA-141 4.41 E-01 1.03E-01 2.23E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.28E+04 O.OOE+OO LA-142 1.34E-04 4.28E-05 1.34E-05 O.OOE+OO O.OOE+OO O.OOE+OO 8.49E+OO O.OOE+OO CE-141 5.85E+05 2.92E+05 4.33E+04 O.OOE+OO 1.28E+05 O.OOE+OO 3.64E+08 O.OOE+OO CE-143 7.20E+02 3.90E+05 5.65E+01 O.OOE+OO 1.64E+02 O.OOE+OO 5.71E+06 O.OOE+OO CE-144 1.22E+08 3.82E+07 6.51E+06 O.OOE+OO 2.12E+07 O.OOE+OO 9.96E+09 O.OOE+OO PR-143 9.73E+04 2.92E+04 4.83E+03 O.OOE+OO 1.58E+04 O.OOE+OO 1.05E+08 O.OOE+OO PR-144 1.73E-26 5.34E-27 8.69E-28 O.OOE+OO 2.83E-27 O.OOE+OO 1.15E-23 O.OOE+OO ND-147 4.12E+04 3.33E+04 2.58E+03 O.OOE+OO 1.83E+04 O.OOE+OO 5.28E+07 O.OOE+OO PM-147 2.13E+07 1.52E+06 8.17E+05 O.OOE+OO 2.69E+06 O.OOE+OO 6.15E+08 O.OOE+OO PM-148M 2.08E+06 4.15E+05 4.15E+05 O.OOE+OO 6.15E+05 O.OOE+OO 1.17E+09 O.OOE+OO PM-148 1.43E+04 1.72E+03 1.11E+03 O.OOE+OO 2.92E+03 O.OOE+OO 4.58E+07 O.OOE+OO PM-149 1.23E+03 1.31E+02 7.11E+01 O.OOE+OO 2.32E+02 O.OOE+OO 8.95E+06 O.OOE+OO PM-151 2.41E+02 2.94E+01 1.91E+01 O.OOE+OO 4.98E+01 O.OOE+OO 3.33E+06 O.OOE+OO SM-151 1.81E+07 2.70E+06 8.49E+05 O.OOE+OO 2.79E+06 O.OOE+OO 3.91E+08 O.OOE+OO SM-153 5.94E+02 3.70E+02 3.57E+01 O.OOE+OO 1.13E+02 O.OOE+OO 4.92E+06 O.OOE+OO EU-152 4.31E+07 7.85E+06 9.32E+06 O.OOE+OO 3.32E+07 O.OOE+OO 1.29E+09 O.OOE+OO EU-154 1.60E+08 1.44E+07 1.32E,+07 O.OOE+OO 6.33E+07 O.OOE+OO 3.35E+09 O.OOE+OO EU-155 3.32E+07 2.39E+06 1.87E+06 O.OOE+OO 8.94E+06 O.OOE+OO 5.98E+09 O.OOE+OO EU-156 1.84E+05 9.86E+04 2.04E+04 O.OOE+OO 6.35E+04 O.OOE+OO 2.24E+08 O.OOE+OO TB-160 5.66E+06 O.OOE+OO 7.03E+05 O.OOE+OO 1.68E+06 O.OOE+OO 1.25E+09 O.OOE+OO H0-166M 7.65E+07 1.60E+07 1.35E+07 O.OOE+OO 2.28E+07 O.OOE+OO 1.86E+09 O.OOE+OO W-181 1.93E+06 4.74E+05 6.51E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.73E+07 O.OOE+OO W-185 6.06E+07 1.51E+07 2.12E+06 O.OOE+OO O.OOE+OO O.OOE+OO 5.64E+08 O.OOE+OO W-187 2.69E+04 1.59E+04 7.16E+03 O.OOE+OO O.OOE+OO O.OOE+OO 2.24E+06 O.OOE+OO U-232 1.24E+12 O.OOE+OO 8.91E+10 O.OOE+OO 9.48E+10 O.OOE+OO 4.94E+09 O.OOE+OO U-233 2.64E+11 O.OOE+OO 1.59E+10 O.OOE+OO 4.32E+10 O.OOE+OO 4.57E+09 O.OOE+OO U-234 2.53E+11 O.OOE+OO 1.57E+10 O.OOE+OO 4.24E+10 O.OOE+OO 4.48E+09 O.OOE+OO U-235 2.42E+11 O.OOE+OO 1.47E+10 O.OOE+OO 3.98E+10 O.OOE+OO 5.69E+09 O.OOE+OO U-236 2.42E+11 O.OOE+OO 1.50E+10 O.OOE+OO 4.06E+10 O.OOE+OO 4.20E+09 O.OOE+OO U-237 1.43E+05 O.OOE+OO 3.81E+04 O.OOE+OO 4.13E+05 O.OOE+OO 1.26E+07 O.OOE+OO U-238 2.32E+11 O.OOE+OO 1.37E+10 O.OOE+OO 3.71E+10 O.OOE+OO 4.01E+09 O.OOE+OO NP-237 1.58E+11 1.04E+10 6.94E+09 O.OOE+OO 4.29E+10 O.OOE+OO 5.78E+09 O.OOE+OO NP-238 1.05E+04 2.13E+02 1.64E+02 O.OOE+OO 6.78E+02 O.OOE+OO 7.29E+06 O.OOE+OO NP-239 1.07E+03 7.71 E+01 5.42E+01 O.OOE+OO 2.23E+02 O.OOE+OO 5.70E+06 O.OOE+OO PU-238 8.42E+10 9.76E+09 2.24E+09 O.OOE+OO 8.14E+09 O.OOE+OO 5.31E+09 O.OOE+OO PU-239 9.14E+10 9.78E+09 2.35E+09 O.OOE+OO 8.65E+09 O.OOE+OO 4.85E+09 O.OOE+OO PU-240 9.07E+10 1.01E+10 2.35E+09 O.OOE+OO 8.65E+09 O.OOE+OO 4.95E+09 O.OOE+OO PU-241 2.71E+09 1.11E+08 5.64E+07 O.OOE+OO 2.08E+08 O.OOE+OO 1.01E+08 O.OOE+OO Rev.29 Page 234 of 329 12/2016
CY-LG-170-301 TABLE 112-12 R1 DOSE FACTORS AGE: CHILD PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 8.43E+10 9.78E+09 2.26E+09 O.OOE+OO 8.29E+09 O.OOE+OO 4.76E+09 O.OOE+OO PU-244 9.85E+10 1.12E+11 2.59E+09 O.OOE+OO 9.57E+09 O.OOE+OO 7.09E+09 O.OOE+OO AM-241 9.64E+10 8.29E+10 7.23E+09 O.OOE+OO 4.41E+10 O.OOE+OO 5.41 E+09 O.OOE+OO AM-242M 9.91E+10 7.93E+10 7.36E+09 O.OOE+OO 4.46E+10 O.OOE+OO 6.80E+09 O.OOE+OO AM-243 9.50E+10 8.01 E+10 6.97E+09 O.OOE+OO 4.30E+10 O.OOE+OO 6.34E+09 O.OOE+OO CM-242 4.48E+09 3.57E+09 2.98E+08 O.OOE+OO 9.53E+08 O.OOE+OO 4.16E+09 O.OOE+OO CM-243 9.02E+10 7.33E+10 5.81E+09 O.OOE+OO 2.17E+10 O.OOE+OO 5.66E+09 O.OOE+OO CM-244 7.59E+10 6.14E+10 4.87E+09 O.OOE+OO 1.79E+10 O.OOE+OO 5.46E+09 O.OOE+OO CM-245 1.18E+11 9.50E+10 7.44E+09 O.OOE+OO 2.91E+10 O.OOE+OO 5:13E+09 O.OOE+OO CM-246 1.17E+11 9.50E+10 7.44E+09 O.OOE+OO 2.91E+10 O.OOE+OO 5.04E+09 O.OOE+OO CM-247 1.14E+11 9.36E+10 7.30E+09 O.OOE+OO 2.86E+10 O.OOE+OO 6.63E+09 O.OOE+OO CM-248 9.50E+11 7.73E+11 6.04E+10 O.OOE+OO 2.36E+11 O.OOE+OO 1.07E+11 O.OOE+OO CF-252 7.03E+10 O.OOE+OO 1.70E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.98E+10 O.OOE+OO Rev. 29 Page 235 of 329 12/2016
CY-LG-170-301 TABLE 112-13 R1 DOSE FACTORS AGE: INFANT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SC-46 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CR-51 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-54 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-56 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-57 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-58 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-60 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CU-64 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-93M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 236 of 329 12/2016
CY-LG-170-301
- TABLE 112-13 R1 DOSE FACTORS AGE: INFANT PATHWAY: GREEN LEAFY VEGETATION m2 -mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-106 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RH-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-110M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-111 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+Ob O.OOE+OO O.OOE+OO CD-113M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-124 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-125M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-134 . O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-130 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-133 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-137 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 237 of 329 12/2016
CY-LG-170-301 TABLE 112-13 R1 DOSE FACTORS AGE: INFANT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-147 O.OOE+OO O.O'OE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-149 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-153 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-152 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-154 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-155 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-156 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TB-160 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO H0-166M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-181 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-232 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-233 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-234 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-235 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-236 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-240 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev. 29 Page 238 of 329 12/2016 I.
CY-LG-170-301 TABLE 112-13 R1 DOSE FACTORS AGE: INFANT PATHWAY: GREEN LEAFY VEGETATION m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-242M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-245 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-246 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-247 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-248 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CF-252 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 239 of 329 12/2016
CY-LG-170-301 TABLE 112-14 R1 DOSE FACTORS AGE: ADULT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.85E+02 1.85E+02 1.85E+02 1.85E+02 1.85E+02 1.85E+02 O.OOE+OO C-14 3.33E+05 6.66E+04 6.66E+04 6.66E+04 6.66E+04 6.66E+04 6.66E+04 O.OOE+OO NA-22 7.29E+08 7.29E+08 7.29E+08 7.29E+08 7.29E+08 7.29E+08 7.29E+08 O.OOE+OO NA-24 3.97E-04 3.97E-04 3.97E-04 3.97E-04 3.97E-04 3.97E-04 3.97E-04 O.OOE+OO P-32 1.38E+09 8.56E+07 5.32E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.55E+08 O.OOE+OO CA-41 1.10E+09 O.OOE+OO 1.19E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.09E+06 O.OOE+OO SC-46 7.20E+04 1.40E+05 4.06E+04 O.OOE+OO 1.31E+05 O.OOE+OO 6.81E+08 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 2.24E+03 1.34E+03 4.95E+02 2.98E+03 5.65E+05 O.OOE+OO MN-54 O.OOE+OO 4.55E+06 8.68E+05 O.OOE+OO 1.35E+06 O.OOE+OO 1.39E+07 O.OOE+OO MN-56 O.OOE+OO 4.43E-54 7.86E-55 O.OOE+OO 5.63E-54 O.OOE+OO 1.41 E-52 O.OOE+OO FE-55' 1.54E+08 1.06E+08 2.48E+07 O.OOE+OO O.OOE+OO 5.93E+07 6.10E+07 O.OOE+OO FE-59 9.39E+07 2.21E+08 8.46E+07 O.OOE+OO O.OOE+OO 6.17E+07 7.36E+08 O.OOE+OO C0-57 O.OOE+OO 2.76E+06 4.58E+06 O.OOE+OO O.OOE+OO O.OOE+OO 7.00E+07 O.OOE+OO C0-58 O.OOE+OO 7.20E+06 1.61E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.46E+08 O.OOE+OO C0-60 O.OOE+OO 4.00E+07 8.83E+07 O.OOE+OO O.OOE+OO O.OOE+OO 7.52E+08 O.OOE+OO Nl-59 7.66E+07 2.63E+07 1.28E+07 O.OOE+OO O.OOE+OO O.OOE+OO 5.42E+06 O.OOE+OO Nl-63 1.02E+09 7.06E+07 3.42E+b7 O.OOE+OO O.OOE+OO O.OOE+OO 1.47E+07 O.OOE+OO Nl-65 6.57E-54 8.54E-55 3.89E-55 O.OOE+OO O.OOE+OO O.OOE+OO 2.17E-53 O.OOE+OO CU-64 O.OOE+OO 7.94E-08 3.72E-08 O.OOE+OO 2.00E-07 O.OOE+OO 6.76E-06 O.OOE+OO ZN-65 1.72E+08 5.48E+08 2.48E+08 O.OOE+OO 3.67E+08 O.OOE+OO 3.45E+08 O.OOE+OO ZN-69M 4.90E-06 1.18E-05 1.08E-06 O.OOE+OO 7.12E-06 O.OOE+OO 7.18E-04 O.OOE+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO 5.84E+07 9.75E+06 O.OOE+OO 1.01E+08 O.OOE+OO 1.20E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 3.58E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.10E+02 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.76E-57 O.OOE+OO O.OOE+OO O.OOE+OO 2.53E-57 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.47E+08 6.84E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.89E+07 O.OOE+OO RB-87 O.OOE+OO 5.65E+08 1.97E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.64E+07 O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 1.10E+08 O.OOE+OO 3.16E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.76E+07 O.OOE+OO SR-90 7.70E+09 O.OOE+OO 1.55E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.94E+08 O.OOE+OO SR-91 4.44E-11 O.OOE+OO 1.79E-12 O.OOE+OO O.OOE+OO O.OOE+OO 2.12E-10 O.OOE+OO SR-92 3.45E-50 O.OOE+OO 1.49E-51 O.OOE+OO O.OOE+OO O.OOE+OO 6.83E-49 O.OOE+OO Y-90 3.15E+01 O.OOE+OO 8.44E-01 O.OOE+OO O.OOE+OO O.OOE+OO 3.34E+05 O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91 4.28E+05 O.OOE+OO 1.14E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.35E+08 O.OOE+OO Y-92 4.44E-40 O.OOE+OO 1.30E-41 O.OOE+OO O.OOE+OO O.OOE+OO 7.77E-36 O.OOE+OO Y-93 1.37E-12 O.OOE+OO 3.79E-14 O.OOE+OO O.OOE+OO O.OOE+OO 4.35E-08 O.OOE+OO ZR-93 2.11E+06 1.18E+05 5.49E+04 O.OOE+OO 4.47E+05 O.OOE+OO 1.22E+08 O.OOE+OO ZR-95 7.23E+05 2.32E+05 1.57E+05 O.OOE+OO 3.64E+05 O.OOE+OO 7.35E+08 O.OOE+OO Rev.29 Page 240 of 329 12/2016
CY-LG-170-301 TABLE 112-14 R1 DOSE FACTORS AGE: ADULT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN ZR-97 6.05E-06 1.22E-06 5.58E-07 O.OOE+OO 1.84E-06 O.OOE+OO 3.78E-01 O.OOE+OO NB-93M 1.05E+07 3.41E+06 8.41E+05 O.OOE+OO 3.93E+06 O.OOE+OO 1.58E+09 O.OOE+OO NB-95 7.68E+05 4.27E+05 2.30E+05 O.OOE+OO 4.22E+05 O.OOE+OO 2.59E+09 O.OOE+OO NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO 8.90E+07 2.41E+06 O.OOE+OO 2.52E+07 O.OOE+OO 1.45E+07 O.OOE+OO M0-99 O.OOE+OO 2.92E+04 5.56E+03 O.OOE+OO 6.62E+04 O.OOE+OO 6.78E+04 O.OOE+OO TC-99M 1.30E-21 3.68E-21 4.68E-20 O.OOE+OO 5.58E-20 1.80E-21 2.18E-18 O.OOE+OO TC-99 7.41E+07 1.10E+08 2.97E+07 O.OOE+OO 1.39E+09 9.36E+06 3.60E+09 O.OOE+OO TC-101 O.OOE+OO . O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 3.61E+07 O.OOE+OO 1.56E+07 O.OOE+OO 1.38E+08 O.OOE+OO 4.22E+09 O.OOE+OO RU-105 1.69E-28 O.OOE+OO 6.67E-29 O.OOE+OO 2.18E-27 O.OOE+OO 1.03E-25 O.OOE+OO RU-106 1.40E+09 O.OOE+OO 1.78E+08 O.OOE+OO 2.71E+09 O.OOE+OO 9.08E+10 O.OOE+OO RH-105 1.12E+OO 8.22E-01 5.42E-01 O.OOE+OO 3.49E+OO O.OOE+OO 1.31E+02 O.OOE+OO PD-107 O.OOE+OO 8.71E+05 5.57E+04 O.OOE+OO 7.82E+06 O.OOE+OO 5.40E+06 O.OOE+OO PD-109 O.OOE+OO 3.86E-07 8.70E-08 O.OOE+OO 2.20E-06 O.OOE+OO 4.27E-05 O.OOE+OO AG-110M 3.24E+06 3.00E+06 1.78E+06 O.OOE+OO 5.90E+06 O.OOE+OO 1.22E+09 O.OOE+OO AG-111 4.29E+04 1.79E+04 8.93E+03 O.OOE+OO 5.78E+04 O.OOE+OO 3.29E+07 O.OOE+OO CD-113M O.OOE+OO 2.47E+06 7.92E+04 O.OOE+OO 2.72E+06 O.OOE+OO 1.99E+07 O.OOE+OO CD-115M O.OOE+OO 5.27E+05 1.68E+04 O.OOE+OO 4.18E+05 O.OOE+OO 2.22E+07 O.OOE+OO SN-123 2.46E+09 4.08E+07 6.01E+07 3.47E+07 O.OOE+OO O.OOE+OO 5.01E+09 O.OOE+OO SN-125 5.17E+07 1.04E+06 2.35E+06 8.63E+05 O.OOE+OO O.OOE+OO 6.46E+08 O.OOE+OO SN-126 1.00E+10 1.98E+08 2.84E+08 5.83E+07 O.OOE+OO O.OOE+OO 2.88E+09 O.OOE+OO SB-124 7.53E+06 1.42E+05 2.98E+06 1.83E+04 O.OOE+OO 5.86E+06 2.14E+08 O.OOE+OO SB-125 1.00E+07 1.12E+05 2.39E+06 1.02E+04 O.OOE+OO 7.74E+06 1.10E+08 O.OOE+OO SB-126 5.69E+05 1.16E+04 2.05E+05 3.48E+03 O.OOE+OO 3.49E+05 4.65E+07 O.OOE+OO SB-127 4.85E+03 1.06E+02 1.86E+03 5.83E+01 O.OOE+OO 2.88E+03 1.11 E+06 O.OOE+OO TE-125M 1.35E+08 4.90E+07 1.81E+07 4.07E+07 5.50E+08 O.OOE+OO 5.40E+08 O.OOE+OO TE-127M 4.82E+08 1.72E+08 5.87E+07 1.23E+08 1.96E+09 O.OOE+OO 1.62E+09 O.OOE+OO TE-127 6.21 E-11 2.23E-11 1.34E-11 4.60E-11 2.53E-10 O.OOE+OO 4.90E-09 O.OOE+OO TE-129M 3.76E+08 1.40E+08 5.94E+07 1.29E+08 1.57E+09 O.OOE+OO 1.89E+09 O.OOE+OO TE-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M 1.32E+02 6.45E+01 5.38E+01 1.02E+02 6.54E+02 O.OOE+OO 6.41E+03 O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-132 4.15E+05 2.69E+05 2.52E+05 2.97E+05 2.59E+06 O.OOE+OO 1.27E+07 O.OOE+OO TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 7.02E+07 6.04E+07 1.98E+08 1.55E+11 1.30E+08 O.OOE+OO 9.54E+06 O.OOE+OO 1-130 6.17E-07 1.82E-06 7.18E-07 1.54E~04 2.84E-06 O.OOE+OO 1.57E-06 O.OOE+OO 1-131 3.14E+06 4.49E+06 2.58E+06 1.47E+09 7.70E+06 O.OOE+OO 1.19E+06 O.OOE+OO 1-132 2.04E-59 5.45E-59 1.91E-59 1.91 E-57 8.68E-59 O.OOE+OO 1.02E-59 O.OOE+OO 1-133 1.07E-01 1.86E-01 5.66E-02 2.73E+01 3.24E-01 O.OOE+OO 1.67E-01 O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 241 of 329 12/2016
CY-LG-170-301 TABLE 112-14 R1 DOSE FACTORS AGE: ADULT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-135 1.29E-17 3.39E-17 1.25E-17 2.24E-15 5.44E-17 O.OOE+OO 3.83E-17 O.OOE+OO CS-134M 7.65E-48 1.61E-47 8.23E-48 O.OOE+OO 8.73E-48 1.38E-48 5.67E-48 O.OOE+OO CS-134 3.42E+08 8.14E+08 6.66E+08 O.OOE+OO 2.64E+08 8.75E+07 1.43E+07 O.OOE+OO CS-135 1.16E+08 1.07E+08 4.73E+07 O.OOE+OO 4.03E+07 1.21 E+07 2.49E+06 O.OOE+OO CS-136 3.55E+06 1.40E+07 1.01E+07 O.OOE+OO 7.80E+06 1.07E+06 1.59E+06 O.OOE+OO CS-137 4.70E+08 6.43E+08 4.21E+08 O.OOE+OO 2.18E+08 7.25E+07 1.24E+07 O.OOE+OO CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 3.64E-102 2.59E-105 1.06E-103 O.OOE+OO 2.42E-105 1.47E-105 6.45E-102 O.OOE+OO BA-140 8.46E+06 1.06E+04 5.54E+05 O.OOE+OO 3.61E+03 6.08E+03 1.74E+07 O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140 1.09E-02 5.47E-03 1.45E-03 O.OOE+OO O.OOE+OO O.OOE+OO 4.01E+02 O.OOE+OO LA-141 1.14E-37 3.54E-38 5.79E-39 O.OOE+OO O.OOE+OO O.OOE+OO 4.22E-33 O.OOE+OO LA-142 1.01E-92 4.58E-93 1.14E-93 O.OOE+OO O.OOE+OO O.OOE+OO 3.35E-89 O.OOE+OO CE-141 4.62E+03 3.12E+03 3.54E+02 O.OOE+OO 1.45E+03 O.OOE+OO 1.19E+07 O.OOE+OO CE-143 5.87E-03 4.34E+OO 4.80E-04 O.OOE+OO 1.91 E-03 O.OOE+OO 1.62E+02 O.OOE+OO CE-144 7.16E+05 2.99E+05 3.85E+04 O.OOE+OO 1.78E+05 O.OOE+OO 2.42E+08 O.OOE+OO PR-143 6.18E+03 2.48E+03 3.07E+02 O.OOE+OO 1.43E+03 O.OOE+OO 2.71E+07 O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 2.07E+03 2.40E+03 1.43E+02 O.OOE+OO 1.40E+03 O.OOE+OO 1.15E+07 O.OOE+OO PM-147 5.06E+05 4.76E+04 1.92E+04 O.OOE+OO 8.99E+04 O.OOE+OO 5.99E+07 O.OOE+OO PM-148M 7.49E+04 1.94E+04 1.48E+04 O.OOE+OO 2.93E+04 O.OOE+OO 1.64E+08 O.OOE+OO PM-148 5.77E+02 9.58E+01 4.82E+01 O.OOE+OO 1.81 E+02 O.OOE+OO 7.53E+06 O.OOE+OO PM-149 1.50E+OO 2.13E-01 8.68E-02 O.OOE+OO 4.01E-01 O.OOE+OO 3.98E+04 O.OOE+OO PM-151 1.69E-03 2.83E-04 1.43E-04 O.OOE+OO 5.05E-04 O.OOE+OO 7.79E+01 O.OOE+OO SM-151 5.10E+05 8.80E+04 2.11 E+04 O.OOE+OO 9.83E+04 O.OOE+OO 3.88E+07 O.OOE+OO SM-153 3.35E-01 2.79E-01 2.04E-02 O.OOE+OO 9.03E-02 O.OOE+OO 9.97E+03 O.OOE+OO EU-152 1.37E+06 3.12E+05 2.74E+05 O.OOE+OO 1.93E+06 O.OOE+OO 1.80E+08 O.OOE+OO EU-154 4.30E+06 5.28E+05 3.76E+05 O.OOE+OO 2.53E+06 O.OOE+OO 3.83E+08 O.OOE+OO EU-155 5.93E+05 8.41E+04 5.42E+04 O.OOE+OO 3.88E+05 O.OOE+OO 6.62E+07 O.OOE+OO EU-156 1.12E+04 8.64E+03 1.39E+03 O.OOE+OO 5.77E+03 O.OOE+OO 5.91E+07 O.OOE+OO TB-160 1.56E+05 O.OOE+OO 1.94E+04 O.OOE+OO 6.43E+04 O.OOE+OO 1.43E+08 O.OOE+OO H0-166M 1.76E+06 5.49E+05 4.17E+05 O.OOE+OO 8.21 E+05 O.OOE+OO 1.67E+08 O.OOE+OO W-181 1.24E+04 4.05E+03 4.34E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.62E+05 O.OOE+OO W-185 4.05E+05 1.35E+05 1.42E+04 O.OOE+OO O.OOE+OO O.OOE+OO 1.56E+07 O.OOE+OO W-187 6.05E-03 5.05E-03 1.77E-03 O.OOE+OO O.OOE+OO O.OOE+OO 1.66E+OO O.OOE+OO U-232 2.08E+09 O.OOE+OO 1.48E+08 O.OOE+OO 2.25E+08 O.OOE+OO 3.41E+07 O.OOE+OO U-233 4.39E+08 O.OOE+OO 2.66E+07 O.OOE+OO 1.02E+08 O.OOE+OO 3.16E+07 O.OOE+OO U-234 4.21E+08 O.OOE+OO 2.60E+07 O.OOE+OO 1.00E+08 O.OOE+OO 3.09E+07 O.OOE+OO U-235 4.03E+08 O.OOE+OO 2.45E+07 O.OOE+OO 9.42E+07 O.OOE+OO 3.93E+07 O.OOE+OO U-236 4.03E+08 O.OOE+OO 2.50E+07 O.OOE+OO 9.62E+07 O.OOE+OO 2.90E+07 O.OOE+OO Rev.29 Page 242 of 329 12/2016
CY-LG-170-301 TABLE 112-14 R1 DOSE FACTORS AGE: ADULT PATHWAY: MEAT m2 -mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-237 6.27E+02 O.OOE+OO 1.67E+02 O.OOE+OO 2.58E+03 O.OOE+OO 2.20E+05 O.OOE+OO U-238 3.86E+08 O.OOE+OO 2.29E+07 O.OOE+OO 8.81E+07 O.OOE+OO 2.77E+07 O.OOE+OO NP-237 3.73E+08 2.65E+07 1.64E+07 O.OOE+OO 1.22E+08 O.OOE+OO 2.35E+07 O.OOE+OO NP-238 4.10E-01 1.11 E-02 6.38E-03 O.OOE+OO 3.74E-02 O.OOE+OO 1.03E+03 O.OOE+OO NP-239 7.58E-02 7.45E-03 4.11 E-03 O.OOE+OO 2.33E-02 O.OOE+OO 1.53E+03 O.OOE+OO PU-238 1.30E+07 1.65E+06 3.54E+05 O.OOE+OO 1.52E+06 O.OOE+OO 1.51E+06 O.OOE+OO PU-239 1.50E+07 1.81E+06 3.96E+05 O.OOE+OO 1.68E+06 O.OOE+OO 1.38E+06 O.OOE+OO PU-240 1.50E+07 1.80E+06 3.96E+05 O.OOE+OO 1.68E+06 O.OOE+OO 1.41E+06 O.OOE+OO PU-241 3.22E+05 1.53E+04 6.81E+03 O.OOE+OO 3.14E+04 O.OOE+OO 2.87E+04 O.OOE+OO PU-242 1.39E+07 1.74E+06 3.82E+05 O.OOE+OO 1.62E+06 O.OOE+OO 1.35E+06 O.OOE+OO PU-244 1.63E+07 1.99E+06 4.38E+05 O.OOE+OO 1.86E+06 O.OOE+OO 2.02E+06 O.OOE+OO AM-241 2.24E+08 2.09E+08 1.60E+07 O.OOE+OO 1.21E+08 O.OOE+OO 2.20E+07 O.OOE+OO AM-242M 2.25E+08 1.96E+08 1.61E+07 O.OOE+OO 1.20E+08 O.OOE+OO 2.76E+07 O.OOE+OO AM-243 2.23E+08 2.04E+08 1.57E+07 O.OOE+OO 1.18E+08 O.OOE+OO 2.58E+07 O.OOE+OO CM-242 4.41E+06 4.69E+06 2.93E+05 O.OOE+OO 1.33E+06 O.OOE+OO 1.70E+07 O.OOE+OO CM-243 1.76E+08 1.62E+08 1.10E+07 O.OOE+OO 5.16E+07 O.OOE+OO 2.30E+07 O.OOE+OO CM-244 1.34E+08 1.25E+08 8.43E+06 O.OOE+OO 3.94E+07 O.OOE+OO 2.22E+07 O.OOE+OO CM-245 2.78E+08 2.42E+08 1.71 E+07 O.OOE+OO 7.97E+07 O.OOE+OO 2.09E+07 O.OOE+OO CM-246 2.76E+08 2.42E+08 1.70E+07 O.OOE+OO 7.94E+07 O.OOE+OO 2.05E+07 O.OOE+OO CM-247 2.69E+08 2.38E+08 1.68E+07 O.OOE+OO 7.82E+07 O.OOE+OO 2.69E+07 O.OOE+OO CM-248 2.23E+09 1.96E+09 1.38E+08 O.OOE+OO 6.46E+08 O.OOE+OO 4.35E+08 O.OOE+OO CF-252 7.30E+07 O.OOE+OO 1.76E+06 O.OOE+OO O.OOE+OO O.OOE+OO 8.05E+07 O.OOE+OO Rev.29 Page 243 of 329 12/2016
CY-LG-170-301 TABLE 112-15 R1 DOSE FACTORS AGE: TEEN PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.10E+02 1.10E+02 1.10E+02 1.10E+02 1.10E+02 1.10E+02 O.OOE+OO C-14 2.81E+05 5.62E+04 5.62E+04 5.62E+04 5.62E+04 5.62E+04 5.62E+04 O.OOE+OO NA-22 5.79E+08 5.79E+08 5.79E+08 5.79E+08 5.79E+08. 5.79E+08 5.79E+08 O.OOE+OO NA-24 3.17E-04 3.17E-04 3.17E-04 3.17E-04 3.17E-04 3.17E-04 3.17E-04 O.OOE+OO P-32 1.16E+09 7.21E+07 4.51E+07 O.OOE+OO O.OOE+OO O.OOE+OO 9.78E+07 O.OOE+OO CA-41 6.90E+08 O.OOE+OO 7.46E+07 O.OOE+OO O.OOE+OO O.OOE+OO 6.83E+05 O.OOE+OO SC-46 5.59E+04 1.09E+05 3.23E+04 O.OOE+OO 1.04E+05 O.OOE+OO 3.71E+08 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.80E+03 9.97E+02 3.93E+02 2.56E+03 3.02E+05 O.OOE+OO MN-54 O.OOE+OO 3.47E+06 6.88E+05 O.OOE+OO 1.03E+06 O.OOE+OO 7.11 E+06 O.OOE+OO MN-56 O.OOE+OO 3.60E-54 6.40E-55 O.OOE+OO 4.56E-54 O.OOE+OO 2.37E-52 O.OOE+OO FE-55 1.25E+08 8.87E+07 2.07E+07 O.OOE+OO O.OOE+OO 5.62E+07 3.84E+07 O.OOE+OO FE-59 7.51E+07 1.75E+08 6.76E+07 O.OOE+OO O.OOE+OO 5.52E+07 4.14E+08 O.OOE+OO C0-57 O.OOE+OO 2.22E+06 3.71E+06 O.OOE+OO O.OOE+OO O.OOE+OO 4.13E+07 O.OOE+OO C0-58 O.OOE+OO 5.55E+06 1.28E+07 O.OOE+OO O.OOE+OO O.OOE+OO 7.65E+07 O.OOE+OO C0-60 O.OOE+OO 3.11E+07 7.00E+07 O.OOE+OO O.OOE+OO O.OOE+OO 4.04E+08 O.OOE+OO Nl-59 6.12E+07 2.16E+07 1.04E+07 O.OOE+OO O.OOE+OO O.OOE+OO 3.39E+06 O.OOE+OO Nl-63 8.20E+08 5.79E+07 2.78E+07 O.OOE+OO O.OOE+OO O.OOE+OO 9.22E+06 O.OOE+OO Nl-65 5.51E-54 7.04E-55 3.21E-55 O.OOE+OO O.OOE+OO O.OOE+OO 3.82E-53 O.OOE+OO CU-64 O.OOE+OO 6.47E-08 3.05E-08 O.OOE+OO 1.64E-07 O.OOE+OO 5.02E-06 O.OOE+OO ZN-65 1.21 E+08 4.21E+08 1.96E+08 O.OOE+OO 2.69E+08 O.OOE+OO 1.78E+08 O.OOE+OO ZN-69M 4.09E-06 9.64E-06 8.84E-07 O.OOE+OO 5.86E-06 O.OOE+OO 5.30E-04 O.OOE+OO ZN-69 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO 4.90E+07 8.23E+06 O.OOE+OO 8.53E+07 O.OOE+OO 7.48E+06 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 2.84E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.48E-57 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.22E+08 5.75E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.81E+07 O.OOE+OO RB-87 O.OOE+OO 4.75E+08 1.66E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.66E+07 O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 9.28E+07 O.OOE+OO 2.66E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.11 E+07 O.OOE+OO SR-90 5.33E+09 O.OOE+OO 1.07E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.22E+08 O.OOE+OO SR-91 3.74E-11 O.OOE+OO 1.49E-12 O.OOE+OO O.OOE+OO O.OOE+OO 1.69E-10 O.OOE+OO SR-92 2.89E-50 O.OOE+OO 1.23E-51 O.OOE+OO O.OOE+OO O.OOE+OO 7.36E-49 O.OOE+OO Y-90 2.65E+01 O.OOE+OO 7.14E-01 O.OOE+OO O.OOE+OO O.OOE+OO 2.19E+05 O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91 3.60E+05 O.OOE+OO 9.66E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.48E+08 O.OOE+OO Y-92 3.75E-40 O.OOE+OO 1.09E-41 O.OOE+OO O.OOE+OO O.OOE+OO 1.03E-35 O.OOE+OO Y-93 1.16E-12 O.OOE+OO 3.18E-14 O.OOE+OO O.OOE+OO O.OOE+OO 3.54E-08 O.OOE+OO ZR-93 1.65E+06 8.12E+04 4.43E+04 O.OOE+OO 2.87E+05 O.OOE+OO 7.68E+07 O.OOE+OO ZR-95 5.79E+05 1.83E+05 1.26E+05 O.OOE+OO 2.68E+05 O.OOE+OO 4.21E+08 O.OOE+OO ZR-97 5.04E-06 9.97E-07 4.59E-07 O.OOE+OO 1.51 E-06 O.OOE+OO 2.70E-01 O.OOE+OO NB-93M 8.34E+06 2.74E+06 6.86E+05 O.OOE+OO 3.20E+06 O.OOE+OO 9.87E+08 O.OOE+OO NB-95 6.00E+05 3.33E+05 1.83E+05 O.OOE+OO 3.22E+05 O.OOE+OO 1.42E+09 O.OOE+OO Rev.29 Page 244 of 329 12/2016
- --------- -----------------------------------------~ CY-LG-170-301 TABLE 112-15 R1 DOSE FACTORS AGE: TEEN PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO 7.42E+07 2.03E+06 O.OOE+OO 2.13E+07 O.OOE+OO 9.03E+06 O.OOE+OO M0-99 O.OOE+OO 2.42E+04 4.61E+03 O.OOE+OO 5.53E+04 O.OOE+OO 4.33E+04 O.OOE+OO TC-99M 1.03E-21 2.88E-21 3.74E-20 O.OOE+OO 4.30E-20 1.60E-21 1.89E-18 O.OOE+OO TC-99 6.27E+07 9.21E+07 2.51E+07 O.OOE+OO 1.17E+09 9.52E+06 2.25E+09 O.OOE+OO TC-101 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 2.94E+07 O.OOE+OO 1.26E+07 O.OOE+OO 1.04E+08 O.OOE+OO 2.46E+09 O.OOE+OO RU-105 1.41 E-28 O.OOE+OO 5.48E-29 O.OOE+OO 1.78E-27 O.OOE+OO 1.14E-25 O.OOE+OO RU-106 1.18E+09 O.OOE+OO 1.49E+08 O.OOE+OO 2.28E+09 O.OOE+OO 5.67E+10 O.OOE+OO RH-105 9.50E-01 6.86E-01 4.50E-01 O.OOE+OO 2.91E+OO O.OOE+OO 8.73E+01 O.OOE+OO PD-107 O.OOE+OO 7.28E+05 4.69E+04 O.OOE+OO 6.58E+06 O.OOE+OO 3.38E+06 O.OOE+OO PD-109 O.OOE+OO 3.23E-07 7.35E-08 O.OOE+OO 1.87E-06 O.OOE+OO 3.26E-05 O.OOE+OO AG-110M 2.46E+06 2.32E+06 1.41E+06 O.OOE+OO 4.43E+06 O.OOE+OO 6.53E+08 O.OOE+OO AG-111 3.61E+04 1.50E+04 7.54E+03 O.OOE+OO 4.88E+04 O.OOE+OO 2.09E+07 O.OOE+OO CD-113M O.OOE+OO 2.07E+06 6.65E+04 O.OOE+OO 2.29E+06 O.OOE+OO 1.24E+07 O.OOE+OO CD-115M O.OOE+OO 4.40E+05 1.42E+04 O.OOE+OO 3.52E+05 O.OOE+OO 1.39E+07 O.OOE+OO SN-123 2.08E+09 3.41E+07 5.05E+07 2.73E+07 O.OOE+OO O.OOE+OO 3.14E+09 O.OOE+OO SN-125 4.37E+07 8.70E+05 1.97E+06 6.82E+05 O.OOE+OO O.OOE+OO 4.11E+08 O.OOE+OO SN-126 8.12E+09 1.51E+08 2.31E+08 3.98E+07 O.OOE+OO O.OOE+OO 1.81E+09 O.OOE+OO SB-124 6.15E+06 1.13E+05 2.40E+06 1.39E+04 O.OOE+OO 5.37E+06 1.24E+08 O.OOE+OO SB-125 8.22E+06 8.98E+04 1.92E+06 7.85E+03 O.OOE+OO 7.22E+06 6.39E+07 O.OOE+OO SB-126 4.65E+05 9.50E+03 1.67E+05 2.63E+03 O.OOE+OO 3.33E+05 2.75E+07 O.OOE+OO SB-127 4.04E+03 8.63E+01 1.52E+03 4.54E+01 O.OOE+OO 2.75E+03 6.85E+05 O.OOE+OO TE-125M 1.14E+08 4.12E+07 1.53E+07 3.19E+07 O.OOE+OO O.OOE+OO 3.37E+08 O.OOE+OO TE-127M 4.07E+08 1.44E+08 4.84E+07 9.68E+07 1.65E+09 O.OOE+OO 1.01E+09 O.OOE+OO TE-127 5.27E-11 1.87E-11 1.13E-11 3.63E-11 2.13E-10 O.OOE+OO 4.07E-09 O.OOE+OO TE-129M 3.15E+08 1.17E+08 4.98E+07 1.02E+08 1.32E+09 O.OOE+OO 1.18E+09 O.OOE+OO TE..:129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M 1.10E+02 5.27E+01 4.40E+01 7.93E+01 5.50E+02 O.OOE+OO 4.23E+03 O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-132 3.40E+05 2.15E+05 2.02E+05 2.27E+05 2.06E+06 O.OOE+OO 6.81E+06 O.OOE+OO TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 5.91E+07 4.98E+07 8.30E+07 6.05E+10 8.90E+07 O.OOE+OO 5.80E+06 O.OOE+OO 1-130 4.97E-07 1.44E-06 5.74E-07 1.17E-04 2.21 E-06 O.OOE+OO 1.10E-06 O.OOE+OO 1-131 2.61E+06 3.66E+06 1.96E+06 1.07E+09 6.29E+06 O.OOE+OO 7.23E+05 O.OOE+OO 1-132 1.65E-59 4.33E-59 1.55E-59 1.46E-57 6.82E-59 O.OOE+OO 1.89E-59 O.OOE+OO 1-133 8.93E-02 1.52E-01 4.62E-02 2.12E+01 2.66E-01 O.OOE+OO 1.15E-01 O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-135 1.05E-17 2.71E-17 1.01E-17 1.74E-15 4.28E-17 O.OOE+OO 3.00E-17 O.OOE+OO CS-134M 6.24E-48 1.29E-47 6.64E-48 O.OOE+OO 7.19E-48 1.26E-48 8.60E-48 O.OOE+OO CS-134 2.72E+08 6.41E+08 2.97E+08 O.OOE+OO 2.04E+08 7.77E+07 7.97E+06 O.OOE+OO CS-135 9.73E+07 8.93E+07 2.09E+07 O.OOE+OO 3.41E+07 1.23E+07 1.56E+06 O.OOE+OO CS-136 2.77E+06 1.09E+07 7.32E+06 O.OOE+OO 5.93E+06 9.35E+05 8.77E+05 O.OOE+OO CS-137 3.90E+08 5.19E+08 1.81E+08 O.OOE+OO 1.77E+08 6.86E+07 7.38E+06 O.OOE+OO Rev.29 Page 245 of 329 12/2016
CY-LG-170-301 TABLE 112-15 R1 DOSE FACTORS AGE: TEEN PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 3.08E-102 2.17E-105 8.97E-104 O.OOE+OO 2.04E-105 1.49E-105 2.75E-101 O.OOE+OO BA-140 6.99E+06 8.57E+03 4.51E+05 O.OOE+OO 2.91E+03 5.76E+03 1.08E+07 O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140 8.93E-03 4.39E-03 1.17E-03 O.OOE+OO O.OOE+OO O.OOE+OO 2.52E+02 O.OOE+OO LA-141 9.61E-38 2.96E-38 4.88E-39 O.OOE+OO O.OOE+OO O.OOE+OO 5.24E-33 O.OOE+OO LA-142 8.33E-93 3.70E-93 9.21E-94 O.OOE+OO O.OOE+OO O.OOE+OO 1.13E-88 O.OOE+OO CE-141 3.88E+03 2.59E+03 2.97E+02 O.OOE+OO 1.22E+03 O.OOE+OO 7.41 E+06 O.OOE+OO CE-143 4.94E-03 3.60E+OO 4.02E-04 O.OOE+OO 1.61E-03 O.OOE+OO 1.08E+02 O.OOE+OO CE-144 6.04E+05 2.50E+05 3.24E+04 O.OOE+OO 1.49E+05 O.OOE+OO 1.52E+08 O.OOE+OO PR-143 5.20E+03 2.08E+03 2.59E+02 O.OOE+OO 1.21 E+03 O.OOE+OO 1.71E+07 O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 1.83E+03 1.99E+03 1.19E+02 O.OOE+OO 1.17E+03 O.OOE+OO 7.17E+06 O.OOE+OO PM-147 4.16E+05 3.95E+04 1.61E+04 O.OOE+OO 7.53E+04 O.OOE+OO 3.75E+07 O.OOE+OO PM-148M 5.97E+04 1.51E+04 1.18E+04 O.OOE+OO 2.29E+04 O.OOE+OO 9.53E+07 O.OOE+OO PM-148 4.85E+02 7.90E+01 3.98E+01 O.OOE+OO 1.43E+02 O.OOE+OO 4.71E+06 O.OOE+OO PM-149 1.27E+OO 1.78E-01 7.30E'-02 O.OOE+OO 3.39E-01 O.OOE+OO 2.62E+04 O.OOE+OO PM-151 1.41 E-03 2.33E-04 1.18E-04 O.OOE+OO 4.19E-04 O.OOE+OO 5.23E+01 O.OOE+OO SM-151 3.81E+05 7.34E+04 1.72E+04 O.OOE+OO 8.04E+04 O.OOE+OO 2.49E+07 O.OOE+OO SM-153 2.82E-01 2.33E-01 1.72E-02 O.OOE+OO 7.62E-02 O.OOE+OO 6.58E+03 O:OOE+OO EU-152 1.02E+06 2.45E+05 2.16E+05 O.OOE+OO 1.14E+06 O.OOE+OO 9.01E+07 O.OOE+OO EU-154 3.27E+.06 4.21E+05 2.97E+05 O.OOE+OO 1.88E+06 O.OOE+OO 2.23E+08 O.OQE+OO EU-155 7.09E+05 6.84E+04 4.24E+04 O.OOE+OO 2.68E+05 O.OOE+OO 3.92E+08 O.OOE+OO EU-156 9.24E+03 6.93E+03 1.13E+03 O.OOE+OO 4.66E+03 O.OOE+OO 3.54E+07 O.OOE+OO TB-160 1.27E+05 O.OOE+OO 1.58E+04 O.OOE+OO 5.01E+04 O.OOE+OO 8.20E+07 O.OOE+OO H0-166M 1.37E+06 4.24E+05 3.07E+05 O.OOE+OO 6.20E+05 O.OOE+OO 1.04E+08 O.OOE+OO W-181 1.05E+04 3.39E+03 3.55E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.89E+05 O.OOE+OO W-185 3.42E+05 1.13E+05 1.19E+04 O.OOE+OO O.OOE+OO O.OOE+OO 9.75E+06 O.OOE+OO W-187 5.06E-03 4.13E-03 1.45E-03 O.OOE+OO O.OOE+OO O.OOE+OO 1.12E+OO O.OOE+OO U-232 1.75E+09 O.OOE+OO 1.25E+08 O.OOE+OO 1.89E+08 O.OOE+OO 2.14E+07 O.OOE+OO U-233 3.69E+08 O.OOE+OO 2.24E+07 O.OOE+OO 8.63E+07 O.OOE+OO 1.98E+07 O.OOE+OO U-234 3.54E+08 O.OOE+OO 2.20E+07 O.OOE+OO 8.48E+07 O.OOE+OO 1.94E+07 O.OOE+OO U-235 3.39E+08 O.OOE+OO 2.07E+07 O.OOE+OO 7.95E+07 O.OOE+OO 2.46E+07 O.OOE+OO U-236 3.39E+08 O.OOE+OO 2.11 E+07 O.OOE+OO 8.12E+07 O.OOE+OO 1.82E+07 O.OOE+OO. NP-239 6.62E-02 6.25E-03 3.47E-03 O.OOE+OO 1.96E-02 O.OOE+OO 1.01E+03 O.OOE+OO U-237 5.29E+02 O.OOE+OO 1.41E+02 O.OOE+OO 2.17E+03 O.OOE+OO 1.40E+05 O.OOE+OO U-238 3.24E+08 O.OOE+OO 1.93E+07 O.OOE+OO 7.44E+07 O.OOE+OO 1.74E+07 O.OOE+OO NP-237 2.33E+08 1.67E+07 1.02E+07 O.OOE+OO 7.58E+07 O.OOE+OO 1.47E+07 O.OOE+OO NP-238 3.45E-01 9.24E-03 5.38E-03 O.OOE+OO 3.17E-02 O.OOE+OO 6.78E+02 O.OOE+OO PU-238 8.20E+06 1.05E+06 2.23E+05 O.OOE+OO 9.54E+05 O.OOE+OO 9.46E+05 O.OOE+OO PU-239 9.37E+06 1.14E+06 2.46E+05 O.OOE+OO 1.05E+06 O.OOE+OO 8.65E+05 O.OOE+OO PU-240 9.36E+06 1.14E+06 2.46E+05 O.OOE+OO 1.05E+06 O.OOE+OO 8.81E+05 O.OOE+OO PU-241 2.12E+05 1.02E+04 4.47E+03 O.OOE+OO 2.07E+04 O.OOE+OO 1.79E+04 O.OOE+OO Rev.29 Page 246 of 329
.12/2016
CY-LG-170-301 TABLE 112-15 R1 DOSE FACTORS AGE: TEEN PATHWAY: MEAT m2-mrem/yr per µCi/~ec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 8.69E+06 1.10E+06 2.38E+05 O.OOE+OO 1.01 E+06 O.OOE+OO 8.48E+05 O.OOE+OO PU-244 1.01E+07 1.25E+06 2.72E+05 O.OOE+OO 1.16E+06 O.OOE+OO 1.26E+06 O.OOE+OO AM-241 1.40E+08 1.32E+08 1.01 E+07 O.OOE+OO 7.54E+07 O.OOE+OO 1.38E+07 O.OOE+OO AM-242M 1.41 E+08 1.24E+08 1.01E+07 O.OOE+OO 7.52E+07 O.OOE+OO 1.73E+07 O.OOE+OO AM-243 1.39E+08 1.29E+08 9.84E+06 O.OOE+OO 7.39E+07 O.OOE+OO 1.62E+07 O.OOE+OO CM-242 3.72E+06 3.92E+06 2.47E+05 O.OOE+OO 1.12E+06 O.OOE+OO 1.06E+07 O.OOE+OO CM-243 1.13E+08 1.05E+08 7.12E+06 O.OOE+OO 3.33E+07 O.OOE+OO 1.44E+07 O.OOE+OO CM-244 8.75E+07 8.28E+07 5.54E+06 O.OOE+OO 2.59E+07 O.OOE+OO 1.39E+07 O.OOE+OO CM-245 1.73E+08 1.52E+08 1.07E+07 O.OOE+OO 4.99E+07 O.OOE+OO 1.31E+07 O.OOE+OO CM-246 1.72E+08 1.52E+08 1.07E+07 O.OOE+OO 4.97E+07 O.OOE+OO 1.28E+07 O.OOE+OO CM-247 1.68E+08 1.50E+08 1.05E+07 O.OOE+OO 4.90E+07 O.OOE+OO 1.69E+07 O.OOE+OO CM-248 1.39E+09 1.24E+09 8.67E+07 O.OOE+OO 4.04E+08 O.OOE+OO 2.71E+08 O.OOE+OO CF-252 5.73E+07 O.OOE+OO 1.38E+06 O.OOE+OO O.OOE+OO O.OOE+OO 5.04E+07 O.OOE+OO Rev.29 Page 24 7 of 329 12/2016
CY-LG-170-301 TABLE 112-16 R1 DOSE FACTORS AGE: CHILD PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.34E+02 1.34E+02 1.34E+02 1.34E+02 1.34E+02 1.34E+02 O.OOE+OO C-14 5.29E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 O.OOE+OO NA-22 9.18E+08 9.18E+08 9.18E+08 9.18E+08 9.18E+08 9.18E+08 9.18E+08 O.OOE+OO NA-24 5.04E-04 5.04E-04 5.04E-04 5.04E-04 5.04E-04 5.04E-04 5.04E-04 O.OOE+OO P-32 2.19E+09 1.03E+08 8.45E+07 O.OOE+OO O.OOE+OO O.OOE+OO 6.06E+07 O.OOE+OO CA-41 7.66E+08 O.OOE+OO 8.37E+07 O.OOE+OO O.OOE+OO O.OOE+OO 4.20E+05 O.OOE+OO SC-46 9.59E+04 1.32E+05 5.07E+04 O.OOE+OO 1.16E+05 O.OOE+OO 1.92E+08 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 2.80E+03 1.55E+03 4.25E+02 2.84E+03 1.48E+05 O.OOE+OO MN-54 O.OOE+OO 3.97E+06 1.06E+06 O.OOE+OO 1.11E+06 O.OOE+OO 3.33E+06 O.OOE+OO MN-56 O.OOE+OO 4.80E-54 1.08E-54 O.OOE+OO 5.80E-54 O.OOE+OO 6.95E-52 O.OOE+OO FE-55 2.40E+08 1.27E+08 3.94E+07 O.OOE+OO O.OOE+OO 7.20E+07 2.36E+07 O.OOE+OO FE-59 1.33E+08 2.15E+08 1.07E+08 O.OOE+OO O.OOE+OO 6.24E+07 2.24E+08 O.OOE+OO C0-57 O.OOE+OO 2.89E+06 5.86E+06 O.OOE+OO O.OOE+OO O.OOE+OO 2.37E+07 O.OOE+OO C0-58 O.OOE+OO 6.48E+06 1.99E+07 O.OOE+OO O.OOE+OO O.OOE+OO 3.78E+07 O.OOE+OO C0-60 O.OOE+OO 3.69E+07 1.09E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.04E+08 O.OOE+OO Nl-59 1.18E+08 3.13E+07 2.00E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.08E+06 O.OOE+OO Nl-63 1.57E+09 8.41E+07 5.35E+07 O.OOE+OO O.OOE+OO O.OOE+OO 5.67E+06 O.OOE+OO Nl-65 *1.03E-53 9.69E-55 5.66E-55 O.OOE+OO O.OOE+OO O.OOE+OO 1.19E-52 O.OOE+OO CU-64 O.OOE+OO 8.70E-08 5.26E-08 O.OOE+OO 2.10E-07 O.OOE+OO 4.08E-06 O.OOE+OO ZN-65 1.82E+08 4.84E+08 3.01E+08 O.OOE+OO 3.05E+08 O.OOE+OO 8.51E+07 O.OOE+OO ZN-69M 7.63E-06 1.30E-05 1.54E-06 O.OOE+OO 7.55E-06 O.OOE+OO 4.23E-04 O.OOE+OO ZN-6,9 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO 6.98E+07 1.55E+07 O.OOE+OO 1.13E+08 O.OOE+OO 4.58E+06 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 4.45E+02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 2.78E-57 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.74E+08 1.07E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.12E+07 O.OOE+OO RB-87 O.OOE+OO 6.76E+08 3.13E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.01E+07 O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 1.76E+08 O.OOE+OO 5.02E+06 O.OOE+OO O.OOE+OO O.OOE+OO 6.80E+06 O.OOE+OO SR-90 8.43E+09 O.OOE+OO 1.70E+08 O.OOE+OO O.OOE+OO O.OOE+OO 7.55E+07 O.OOE+OO SR-91 7.01 E-11 . O.OOE+OO 2.65E-12 O.OOE+OO O.OOE+OO O.OOE+OO 1.55E-10 O.OOE+OO SR-92 5.39E-50 O.OOE+OO 2.16E-51 O.OOE+OO O.OOE+OO O.OOE+OO 1.02E-48 O.OOE+OO Y-90 5.01E+01 O.OOE+OO 1.34E+OO O.OOE+OO O.OOE+OO O.OOE+OO 1.43E+05 O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91 6.81E+05 O.OOE+OO 1.82E+04 O.OOE+OO O.OOE+OO O.OOE+OO 9.07E+07 O.OOE+OO Y-92 7.05E-40 O.OOE+OO 2.02E-41 O.OOE+OO O.OOE+OO O.OOE+OO 2.04E-35 O.OOE+OO Y-93 2.18E-12 O.OOE+OO 5.97E-14 O.OOE+OO O.OOE+OO O.OOE+OO 3.24E-08 O.OOE+OO ZR-93 3.13E+06 1.17E+05 8.35E+04 O.OOE+OO 4.54E+05 O.OOE+OO 4.45E+07 O.OOE+OO ZR-95 1.03E+06 2.26E+05 2.01E+05 O.OOE+OO 3.23E+05 O.OOE+OO 2.36E+08 O.OOE+OO Rev.29 Page 248 of 329 12/2016
CY-LG-170-301 TABLE 112-16 R1 DOSE FACTORS AGE: CHILD PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN ZR-97 9.37E-06 1.35E-06 7.99E-07 O.OOE+OO 1.94E-06 O.OOE+OO 2.05E-01 O.OOE+OO NB-93M 1.61E+07 4.01E+06 1.32E+06 O.OOE+OO 4.33E+06 O.OOE+OO 6.04E+08 O.OOE+OO NB-95 1.04E+06 4.03E+05 2.88E+05 O.OOE+OO 3.79E+05 O.OOE+OO 7.45E+08 O.OOE+OO NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO 1.06E+08 3.82E+06 O.OOE+OO 2.80E+07 O.OOE+OO 5.39E+06 O.OOE+OO M0-99 O.OOE+OO 3.36E+04 8.32E+03 O.OOE+OO 7.18E+04 O.OOE+OO 2.78E+04 O.OOE+OO TC-99M 1.81E-21 3.55E-21 5.89E-20 O.OOE+OO 5.16E-20 1.80E-21 2.02E-18 O.OOE+OO TC-99 1.18E+08 1.32E+08 4.73E+07 O.OOE+OO 1.55E+09 1.16E+07 1.38E+09 O.OOE+OO TC-101 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 5.32E+07 O.OOE+OO 2.04E+07. O.OOE+OO 1.34E+08 O.OOE+OO 1.37E+09 O.OOE+OO RU-105 2.64E-28 O.OOE+OO 9.57E-29 O.OOE+OO 2.32E-27 O.OOE+OO 1.72E-25 O.OOE+OO RU-106 2.23E+09 O.OOE+OO 2.78E+08 O.OOE+OO 3.01E+09 O.OOE+OO 3.46E+10 O.OOE+OO RH-105 1.78E+OO 9.56E-01 8.17E-01 O.OOE+OO 3.81E+OO O.OOE+OO 5.92E+01 O.OOE+OO PD-107 O.OOE+OO 1.04E+06 8.86E+04 O.OOE+OO 8.72E+06 O.OOE+OO 2.07E+06 O.OOE+OO PD-109 O.OOE+OO 4.61 E-07 1.38E-07 O.OOE+OO 2.47E-06 O.OOE+OO 2.72E-05 O.OOE+OO AG-110M 4.07E+06 2.75E+06 2.20E+06 O.OOE+OO 5.12E+06 O.OOE+OO 3.27E+08 O.OOE+OO AG-111 6.82E+04 2.13E+04 1.41E+04 O.OOE+OO 6.43E+04 O.OOE+OO 1.31E+07 O.OOE+OO CD-113M O.OOE+OO 2.95E+06 1.26E+05 O.OOE+OO 3.04E+06 O.OOE+OO 7.61E+06 O.OOE+OO CD-115M O.OOE+OO 6.29E+05 2.68E+04 O.OOE+OO 4.68E+05 O.OOE+OO 8.56E+06 O.OOE+OO SN-123 3.92E+09 4.87E+07 9.56E+07 5.16E+07 O.OOE+OO O.OOE+OO 1.92E+09 O.OOE+OO SN-125 8.22E+07 1.24E+06 3.68E+06 1.28E+06 O.OOE+OO O.OOE+OO 2.55E+08 O.OOE+OO SN-126 1.47E+10 1.83E+08 4.18E+08 5.04E+07 O.OOE+OO O.OOE+OO 1.10E+09 O.OOE+OO SB-124 1.11 E+07 1.44E+05 3.90E+06 2.45E+04 O.OOE+OO 6.17E+06 6.95E+07 O.OOE+OO SB-125 1.50E+07 1.15E+05 3.13E+06 1.39E+04 O.OOE+OO 8.34E+06 3.57E+07 O.OOE+OO SB-126 8.11E+05 1.24E+04 2.91E+05 4.76E+03 O.OOE+OO 3.87E+05 1.64E+07 O.OOE+OO SB-127 7.43E+03 1.15E+02 2.58E+03 8.28E+01 O.OOE+OO 3.23E+03 4.19E+05 O.OOE+OO TE-125M 2.14E+08 5.81E+07 2.86E+07 6.02E+07 O.OOE+OO O.OOE+OO 2.07E+08 O.OOE+OO TE-127M 7.67E+08 2.06E+08 9.10E+07 1.83E+08 2.19E+09 O.OOE+OO 6.21E+08 O.OOE+OO TE-127 9.91E-11 2.67E-11 2.12E-11 6.86E-11 2.82E-10 O.OOE+OO 3.87E-09 O.OOE+OO TE-129M 5.93E+08 1.66E+08 9.20E+07 1.91E+08 1.74E+09 O.OOE+OO 7.23E+08 O.OOE+OO TE-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M 2.05E+02 7.08E+01 7.53E+01 1.46E+02 6.85E+02 O.OOE+OO 2.87E+03 O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO . O.OOE+OO O.OOE+OO O.OOE+OO TE-132 6.20E+05 2.74E+05 3.32E+05 4.00E+05 2.55E+06 O.OOE+OO 2.76E+06 O.OOE+OO TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 1.11 E+08 6.83E+07 6.10E+07 4.47E+10 1.15E+08 O.OOE+OO 3.43E+06 O.OOE+OO 1-130 8.88E-07 1.79E-06 9.24E-07 1.98E-04 2.68E-06 O.OOE+OO 8.39E-07 O.OOE+OO 1-131 4.84E+06 4.87E+06 2.77E+06 1.61E+09 8.00E+06 O.OOE+OO 4.34E+05 O.OOE+OO 1-132 2.99E-59 5.50E-59 2.53E-59 2.55E-57 8.42E-59 O.OOE+OO 6.47E-59 O.OOE+OO 1-133 1.66E-01 2.05E-01 7.77E-02 3.81E+01 3.42E-01 O.OOE+OO 8.27E-02 O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev. 29 Page 249 of 329 12/2016
CY-LG-170-301 TABLE 112-16 R1 DOSE FACTORS AGE: CHILD PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN 1-135 1.91E-17 3.43E-17 1.62E-17 3.04E-15 5.26E-17 O.OOE+OO 2.61E-17 O.OOE+OO CS-134M 1.13E-47 1.67E-47 1.09E-47 O.OOE+OO 8.82E-48 1.46E-48 2.12E-47 O.OOE+OO CS-134 4.80E+08 7.88E+08 1.66E+08 O.OOE+OO 2.44E+08 8.76E+07 4.25E+06 O.OOE+OO CS-135 1.83E+08 1.28E+08 1.31 E+07 O.OOE+OO 4.51E+07 1.50E+07 9.56E+05 O.OOE+OO CS-136 4.7BE+06 1.31E+07 8.50E+06 O.OOE+OO 6.99E+06 1.04E+06 4.62E+05 O.OOE+OO CS-137 7.18E+08 6.88E+08 1.02E+08 O.OOE+OO 2.24E+08 8.06E+07 4.31E+06 O.OOE+OO CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 5.78E-102 3.09E-105 1.68E-103 O.OOE+OO 2.70E-105 1.82E-105 3.34E-100 O.OOE+OO BA-140 1.29E+07 1.13E+04 7.53E+05 O.OOE+OO 3.68E+03 6.74E+03 6.54E+06 O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140 1.63E-02 5.71E-03 1.93E-03 O.OOE+OO O.OOE+OO O.OOE+OO 1.59E+02 O.OOE+OO LA-141 1.81E-37 4.22E-38 9.17E-39 O.OOE+OO O.OOE+OO O.OOE+OO 9.39E-33 O.OOE+OO LA-142 1.54E-92 4.90E-93 1.53E-93 O.OOE+OO O.OOE+OO O.OOE+OO 9.71E-88 O.OOE+OO CE-141 7.30E+03 3.64E+03 5.41 E+02 O.OOE+OO 1.60E+03 O.OOE+OO 4.54E+06 O.OOE+OO CE-143 9.27E-03 5.03E+OO 7.28E-04 O.OOE+OO 2.11E-03 O.OOE+OO 7.36E+01 O.OOE+OO CE-144 1.14E+06 3.57E+05 6.07E+04 O.OOE+OO 1.97E+05 O.OOE+OO 9.30E+07 O.OOE+OO PR-143 9.85E+03 2.96E+03 4.89E+02 O.OOE+OO 1.60E+03 O.OOE+OO 1.06E+07 O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 3.43E+03 2.78E+03 2.15E+02 O.OOE+OO 1.52E+03 O.OOE+OO 4.40E+06 O.OOE+OO PM-147 7.95E+05 5.67E+04 3.05E+04 O.OOE+OO 1.00E+05 O.OOE+OO 2.30E+07 O.OOE+OO PM-148M 9.36E+04 1.86E+04 1.86E+04 O.OOE+OO 2.76E+04 O.OOE+OO 5.25E+07 O.OOE+OO PM-148 9.06E+02 1.09E+02 7.05E+01 O.OOE+OO 1.85E+02 O.OOE+OO 2.91E+06 O.OOE+OO PM-149 2.39E+OO 2.54E-01 1.38E-01 O.OOE+OO 4.50E-01 O.OOE+OO 1.74E+04 O.OOE+OO PM-151 2.63E-03 3.20E-04 2.08E-04 O.OOE+OO 5.43E-04 O.OOE+OO 3.63E+01 O.OOE+OO SM-151 7.05E+05 1.05E+05 3.31E+04 O.OOE+OO 1.09E+05 O.OOE+OO 1.52E+07 O.OOE+OO SM-153 5.32E-01 3.31E-01 3.19E-02 O.OOE+OO 1.01 E-01 O.OOE+OO 4.40E+03 O.OOE+OO EU-152 1.61E+06 2.93E+05 3.48E+05 O.OOE+OO 1.24E+06 O.OOE+OO 4.82E+07 O.OOE+OO EU-154 5.99E+06 5.39E+05 4.92E+05 O.OOE+OO 2.37E+06 O.OOE+OO 1.25E+08 O.OOE+OO EU-155 1.24E+06 8.92E+04 6.99E+04 O.OOE+OO 3.34E+05 O.OOE+OO 2.23E+08 O.OOE+OO EU-156 1.71E+04 9.14E+03 1.89E+03 O.OOE+OO 5.89E+03 O.OOE+OO 2.07E+07 O.OOE+OO TB-160 2.05E+05 O.OOE+OO 2.54E+04 O.OOE+OO 6.10E+04 O.OOE+OO 4.54E+07 O.OOE+OO H0-166M
- 2.62E+06 5.49E+05 4.64E+05 O.OOE+OO 7.82E+05 O.OOE+OO 6.39E+07 O.OOE+OO W-181 1.98E+04 4.86E+03 6.69E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.77E+05 O.OOE+OO W-185 6.45E+05 1.61E+05 2.26E+04 O.OOE+OO O.OOE+OO O.OOE+OO 6.00E+06 O.OOE+OO W-187 9.39E-03 5.56E-03 2.49E-03 O.OOE+OO O.OOE+OO O.OOE+OO 7.81 E-01 O.OOE+OO U-232 3.30E+09 O.OOE+OO 2.36E+08 O.OOE+OO 2.51E+08 O.OOE+OO 1.31 E+07 O.OOE+OO U-233 6.98E+08 O.OOE+OO 4.22E+07 O.OOE+OO 1.15E+08 O.OOE+OO 1.21E+07 O.OOE+OO U-234 6.70E+08 O.OOE+OO 4.15E+07 O.OOE+OO 1.12E+08 O.OOE+OO 1.19E+07 O.OOE+OO U-235 6.42E+08 O.OOE+OO 3.89E+07 O.OOE+OO 1.05E+08 O.OOE+OO 1.51E+07 O.OOE+OO U-236 6.42E+08 O.OOE+OO 3.98E+07 O.OOE+OO 1.08E+08 O.OOE+OO 1.11 E+07 O.OOE+OO Rev.29 Page 250 of 329 12/2016
CY-LG-170-301 TABLE 112-16 R1 DOSE FACTORS AGE: CHILD PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-237 9.99E+02 O.OOE+OO 2.65E+02 O.OOE+OO 2.88E+03 O.OOE+OO 8.80E+04 O.OOE+OO U-238 6.14E+08 O.OOE+OO 3.64E+07 O.OOE+OO 9.84E+07 O.OOE+OO 1.06E+07 . O.OOE+OO NP-237 2.46E+08 1.62E+07 1.08E+07 O.OOE+OO 6.68E+07 O.OOE+OO 9.01E+06 O.OOE+OO NP-238 6.51E-01 1.32E-02 1.01 E-02 O.OOE+OO 4.20E-02 O.OOE+OO 4.51E+02 O.OOE+OO NP-239 1.25E-01 8.95E-03 6.29E-03 O.OOE+OO 2.59E-02 O.OOE+OO 6.62E+02 O.OOE+OO PU-238 9.18E+06 1.06E+06 2.44E+05 O.OOE+OO 8.87E+05 O.OOE+OO 5.79E+05 O.OOE+OO PU-239 9.97E+06 1.07E+06 2.56E+05 O.OOE+OO 9.43E+05 O.OOE+OO 5.29E+05 O.OOE+OO PU-240 9.89E+06 1.11E+06 2.56E+05 O.OOE+OO 9.43E+05 O.OOE+OO 5.40E+05 O.OOE+OO PU-241 2.96E+05 1.21E+04 6.15E+03 O.OOE+OO 2.26E+04 O.OOE+OO 1.10E+04 O.OOE+OO PU-242 9.20E+06 1.07E+06 2.47E+05 O.OOE+OO 9.04E+05 O.OOE+OO 5.19E+05 O.OOE+OO PU-244 1.07E+07 1.22E+07 2.82E+05 O.OOE+OO 1.04E+06 O.OOE+OO 7.73E+05 O.OOE+OO AM-241 1.50E+08 1.29E+08 1.13E+07 O.OOE+OO 6.88E+07 O.OOE+OO 8.43E+06 O.OOE+OO AM-242M 1.54E+08 1.24E+08 1.15E+07 O.OOE+OO 6.95E+07 O.OOE+OO 1.06E+07 O.OOE+OO AM-243 1.48E+08 1.25E+08 1.09E+07 O.OOE+OO 6.69E+07 O.OOE+OO 9.88E+06 O.OOE+OO CM-242 7.01E+06 5.59E+06 4.66E+05 O.OOE+OO 1.49E+06 O.OOE+OO 6.51E+06 O.OOE+OO CM-243 1.41 E+08 1.14E+08 9.05E+06 O.OOE+OO 3.38E+07 O.OOE+OO 8.82E+06 O.OOE+OO CM-244 1.18E+08 9.57E+07 7.59E+06 O.OOE+OO 2.78E+07 O.OOE+OO 8.51E+06 O.OOE+OO CM-245 1.84E+08 1.48E+08 1.16E+07 O.OOE+OO 4.54E+07 O.OOE+OO 7.99E+06 O.OOE+OO CM-246 1.82E+08 1.48E+08 1.16E+07 O.OOE+OO 4.53E+07 O.OOE+OO 7.85E+06 O.OOE+OO CM-247 1.78E+08 1.46E+08 1.14E+07 O.OOE+OO 4.46E+07 O.OOE+OO 1.03E+07 O.OOE+OO CM-248 1.48E+09 1.20E+09 9.41E+07 O.OOE+OO 3.68E+08 O.OOE+OO 1.67E+08 O.OOE+OO CF-252 1.09E+08 O.OOE+OO 2.65E+06 O.OOE+OO O.OOE+OO O.OOE+OO 3.08E+07 O.OOE+OO Rev.29 Page 251 of 329 12/2016
CY-LG-170-301 TABLE 112-17 R1 DOSE FACTORS AGE: INFANT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C-14 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-22 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NA-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO P-32 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CA-41 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SC-46 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CR-51 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-54 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO MN-56 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-55 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO FE-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-57 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-58 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO C0-60 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-59 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-63 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Nl-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO
- CU-64 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-65 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZN-69 0.00.E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SE-79 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-82 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE:+-00 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-87 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-88 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-89 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-90 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SR-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-90 O.OOE+OO
- O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-91 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-92 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Y-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-93 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ZR-97 O.OOE+OO O.OOE+OO
- O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-93M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NB-95 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 252 of 329 12/2016
CY-LG-170-301 TABLE 112-17 R1 DOSE FACTORS AGE: INFANT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO M0-93 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO
- O.OOE+OO O.OOE+OO M0-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-99 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TC-101 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-103 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RU-106 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RH-105 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-107 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PD-109 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-110M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AG-111 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-113M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CD-115M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-123 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SN-126 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-124 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-125 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-126 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SB-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-125M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-127 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-131 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-133M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TE-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-129 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-130 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-131 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-132 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-133 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 1-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-134 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-135 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-136 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-137 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 253 of ~29 12/2016
CY-LG-170-301 TABLE 112-17 R1 DOSE FACTORS AGE: INFANT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN CS-138 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CS-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-139 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-140 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-140- O.OOE+Oci O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO LA-142 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-141 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-143 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CE-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PR-144 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO ND-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-147 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-148 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-149 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-151 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO SM-153 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-152 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-154 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-155 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO EU-156 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO TB-160 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO 0.00.E+OO H0-166M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-181 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-185 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO W-187 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-232 O.OOE+OO O.OOE+OO. O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-233 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-234 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-235 O.OOE+OO O.OOE+OO 0.00E+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-236 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO U-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-237 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO NP-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-238 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-239 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-240 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 254 of 329 12/2016
CY-LG-170-301 TABLE 112-17 R1 DOSE FACTORS AGE: INFANT PATHWAY: MEAT m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO PU-244 O.OOE+OO O.OOE+OO
- O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-241 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-242M O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO AM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-242 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-243 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-244 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-245 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-246 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-247 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Cl.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CM-248 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO CF-252 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Rev.29 Page 255 of 329 121201a I
CY-LG-170-301 TABLE 112-18 R1 DOSE FACTORS AGE: ADULT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 p.OOE+OO 4.35E+02 4.35E+02 4.35E+02 4.35E+02 4.35E+02 4.35E+02 O.OOE+OO C-14 3.63E+05 7.26E+04 7.26E+04 7.26E+04 7.26E+04 7.26E+04 7.26E+04 O.OOE+OO NA-22 2.78E+09 2.78E+09 2.78E+09 2.78E+09 2.78E+09 2.78E+09 2.78E+09 O.OOE+OO NA-24 7.13E+05 7.13E+05 7.13E+05 7.13E+05 7.13E+05 7.13E+05 7.13E+05 O.OOE+OO P-32 5.05E+09 3.14E+08 1.95E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.68E+08 O.OOE+OO CA-41 6.18E+09 O.OOE+OO 6.68E+08 O.OOE+OO O.OOE+OO O.OOE+OO. 6.14E+06 O.OOE+OO SC-46 7.36E+01 1.43E+02 4.15E+01 O.OOE+OO 1.33E+02 O.OOE+OO 6.96E+05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 9.10E+03 5.44E+03 2.01E+03 1.21E+04 2.29E+06 O.OOE+OO MN-54 O.OOE+OO 4.17E+06 7.95E+05 O.OOE+OO 1.24E+06 O.OOE+OO 1.28E+07 O.OOE+OO MN-56 O.OOE+OO 1.21E-03 2.15E-04. O.OOE+OO 1.54E-03 O.OOE+OO 3.87E-02 O.OOE+OO FE-55 1.32E+07 9.11 E+06 2.12E+06 O.OOE+OO O.OOE+OO 5.08E+06 5.23E+06 O.OOE+OO FE-59 1.05E+07 2.47E+07 9.46E+06 O.OOE+OO O.OOE+OO 6.90E+06 8.23E+07 O.OOE+OO C0-57 O.OOE+OO 6.26E+05 1.04E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.59E+07 O.OOE+OO C0-58 O.OOE+OO 1.86E+06 4.17E+06 O.OOE+OO O.OOE+OO O.OOE+OO 3.77E+07 O.OOE+OO C0-60 O.OOE+OO 8.73E+06 1.93E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.64E+08 O.OOE+OO Nl-59 2.73E+08 9.37E+07 4.56E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.93E+07 O.OOE+OO Nl-63 3.63E+09 2.52E+08 1.22E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.25E+07 O.OOE+OO Nl-65 1.08E-01 1.41E-02 6.41E-03 O.OOE+OO O.OOE+OO O.OOE+OO 3.57E-01 O.OOE+OO CU-64 O.OOE+OO 6.97E+03 3.27E+03 O.OOE+OO 1.76E+04 O.OOE+OO 5.94E+05 O.OOE+OO ZN-65 6.64E+08 2.11E+09 9.56E+08 O.OOE+OO 1.41 E+09 O.OOE+OO 1.33E+09 O.OOE+OO ZN-69M 5.23E+04 1.26E+05 1.15E+04 O.OOE+OO 7.60E+04 O.OOE+OO 7.67E+06 O.OOE+OO ZN-69 6.12E-13 1.17E-12 8.14E-14 O.OOE+OO 7.60E-13 O.OOE+OO 1.76E-13 O.OOE+OO SE-79 O.OOE+OO 4.94E+08 8.25E+07 O.OOE+OO 8.55E+08 O.OOE+OO 1.01E+08 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 9.45E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.08E+07 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 2.84E-02 O.OOE+OO O.OOE+OO O.OOE+OO 4.09E-02 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 4.71 E-24 O.OOE+OO O.OOE+OO O.OOE+OO 3.69E-29 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 7.82E+08 3.64E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.54E+08 O.OOE+OO RB-87 O.OOE+OO 1.54E+09 5.36E+08 O.OOE+OO O.OOE+OO O.OOE+OO 7.21E+07 O.OOE+OO RB-88 O.OOE+OO 6.26E-46 3.32E-46 O.OOE+OO O.OOE+OO O.OOE+OO 8.64E-57 O.OOE+OO RB-89 O.OOE+OO 1.27E-53 8.91E-54 O.OOE+OO O.OOE+OO O.OOE+OO 7.36E-67 O.OOE+OO SR-89 5.29E+08 O.OOE+OO 1.52E+07 O.OOE+OO O.OOE+OO O.OOE+OO 8.48E+07 O.OOE+OO SR-90 2.90E+10 O.OOE+OO 5.82E+08 O.OOE+OO O.OOE+OO O.OOE+OO 7.28E+08 O.OOE+OO SR-91 8.46E+03 O.OOE+OO 3.42E+02 O.OOE+OO O.OOE+OO O.OOE+OO 4.03E+04 O.OOE+OO SR-92 1.43E-01 O.OOE+OO 6.18E-03 O.OOE+OO O.OOE+OO O.OOE+OO 2.83E+OO O.OOE+OO Y-90 2.07E+01 O.OOE+OO 5.56E-01 O.OOE+OO O.OOE+OO O.OOE+OO 2.20E+05 O.OOE+OO Y-91M 1.75E-20 O.OOE+OO 6.78E-22 O.OOE+OO O.OOE+OO O.OOE+OO 5.14E-20 O.OOE+OO Y-91 3.24E+03 O.OOE+OO 8.67E+01 O.OOE+OO O.OOE+OO O.OOE+OO 1.79E+06 O.OOE+OO Y-92 1.63E-05 O.OOE+OO 4.77E-07 O.OOE+OO O.OOE+OO
- O.OOE+OO 2.86E-01 O.OOE+OO Y-93 6.53E-02 O.OOE+OO 1.80E-03 O.OOE+OO O.OOE+OO O.OOE+OO 2.07E+03 O.OOE+OO ZR-93 8.72E+02 4.88E+01 2.28E+01 O.OOE+OO 1.85E+02 O.OOE+OO 5.07E+04 O.OOE+OO ZR-95 3.64E+02 1.17E+02 7.90E+01 O.OOE+OO 1.83E+02 O.OOE+OO 3.70E+05 O.OOE+OO Rev.29 Page 256 of 329 12/2016
r CY-LG-170-301 TABLE 112-18 R1 DOSE FACTORS AGE: ADULT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN ZR-97 1.27E-01 2.56E-02 1.17E-02 O.OOE+OO 3.86E-02 O.OOE+OO 7.92E+03 O.OOE+OO NB-93M 2.64E+05 8.61E+04 2.12E+04 O.OOE+OO 9.91E+04 O.OOE+OO 3.97E+07 O.OOE+OO NB-95 2.76E+04 1.53E+04 8.25E+03 o*.ooE+oo 1.52E+04 O.OOE+OO 9.32E+07 O.OOE+OO NB-97 9.62E-13 2.43E-13 8.89E-14 O.OOE+OO 2.84E-13 O.OOE+OO 8.98E-10 O.OOE+OO M0-93 O.OOE+OO 2.35E+08 6.36E+06 O.OOE+OO 6.67E+07 O.OOE+OO 3.82E+07 O.OOE+OO M0-99 O.OOE+OO 7.25E+06 1.38E+06 O.OOE+OO 1.64E+07 O.OOE+OO 1.68E+07 O.OOE+OO TC-99M 9.71 E-01 2.74E+OO 3.50E+01 O.OOE+OO 4.17E+01 1.34E+OO 1.62E+03 O.OOE+OO TC-99 1.30E+07 1.94E+07 5.24E+06 O.OOE+OO 2.44E+08 1.65E+06 6.35E+08 O.OOE+OO TC-101 7.58E-61 1.09E-60 1.07E-59 O.OOE+OO 1.97E-59 5.58E-61 3.28E-72 O.OOE+OO RU-103 3.49E+02 O.OOE+OO 1.51E+02 O.OOE+OO 1.33E+03 O.OOE+OO 4.08E+04 O.OOE+OO RU-105 2.51E-04 O.OOE+OO 9.89E-05 O.OOE+OO 3.24E-03 O.OOE+OO 1.53E-01 O.OOE+OO RU-106 1.02E+04 O.OOE+OO 1.29E+03 O.OOE+OO 1.98E+04 O.OOE+OO 6.62E+05 O.OOE+OO RH-105 1.02E+05 7.43E+04 4.89E+04 O.OOE+OO 3.16E+05 O.OOE+OO 1.18E+07 O.OOE+OO PD-107 O.OOE+OO 6.14E+06 3.92E+05 O.OOE+OO 5.51E+07 O.OOE+OO 3.80E+07 O.OOE+OO PD-109 O.OOE+OO 1.30E+04 2.92E+03 O.OOE+OO 7.39E+04 O.OOE+OO 1.43E+06 O.OOE+OO AG-110M 2.83E+07 2.61E+07 1.55E+07 O.OOE+OO 5.14E+07 O.OOE+OO 1.07E+10 O.OOE+OO AG-111 1.90E+06 7.93E+05 3.95E+05 O.OOE+OO 2.56E+06 O.OOE+OO 1.46E+09 O.OOE+OO CD-113M O.OOE+OO 1.58E+06 5.06E+04 O.OOE+OO 1.74E+06 O.OOE+OO 1.27E+07 O.OOE+OO CD-115M O.OOE+OO 4.45E+05 1.42E+04 O.OOE+OO 3.53E+05 O.OOE+OO 1.87E+07 O.OOE+OO SN-123 2.39E+08 3.95E+06 5.83E+06 3.36E+06 O.OOE+OO O.OOE+OO 4.86E+08 O.OOE+OO SN-125 1.66E+07 3.36E+05 7.55E+05 2.78E+05 O.OOE+OO O.OOE+OO 2.0BE+OB O.OOE+OO SN-126 8.82E+08 1.74E+07 2.50E+07 5.13E+06 O.OOE+OO O.OOE+OO 2.54E+08 O.OOE+OO SB-124 9.79E+06 1.85E+05 3.88E+06 2.37E+04 O.OOE+OO 7.62E+06 2.78E+08 O.OOE+OO SB-125 1.07E+07 1.20E+05 2.56E+06 1.09E+04 O.OOE+OO 8.28E+06 1.18E+08 O.OOE+OO SB-126 1.65E+06 3.35E+04 5.94E+05 1.01E+04 O.OOE+OO 1.01E+06 1.35E+08 O.OOE+OO SB-127 1.32E+05 2.88E+03 5.05E+04 1.58E+03 O.OOE+OO 7.80E+04 3.01E+07 O.OOE+OO TE-125M 6.14E+06 2.22E+06 8.23E+05 1.85E+06 2.50E+07 O.OOE+OO 2.45E+07 O.OOE+OO TE-127M 1.98E+07 7.07E+06 2.41E+06 5.06E+06 8.04E+07 O.OOE+OO 6.63E+07 O.OOE+OO TE-127 1.91 E+02 6.86E+01 4.13E+01 1.41E+02 7.78E+02 O.OOE+OO 1.51E+04 O.OOE+OO TE-129M 1.99E+07 7.44E+06 3.15E+06 6.85E+06 8.32E+07 O.OOE+OO 1.00E+OB O.OOE+OO TE-129 8.26E-11 3.10E-11 2.01 E-11 6.34E-11 3.47E-10 O.OOE+OO 6.23E-11 O.OOE+OO TE-131M 1.06E+05 5.16E+04 4.30E+04 8.18E+04 5.23E+05 O.OOE+OO 5.13E+06 O.OOE+OO TE-131 1.0SE-33 4.40E-34 3.33E-34 8.67E-34 4.62E-33 O.OOE+OO 1.49E-34 O.OOE+OO TE-132 7.02E+05 4.54E+05 4.26E+05 5.02E+05 4.38E+06 O.OOE+OO 2.15E+07 O.OOE+OO TE-133M 6.16E-14 3.60E-14 3.46E-14 5.21 E-14 3.56E-13 O.OOE+OO 1.23E-14 O.OOE+OO TE-134 2.60E-19 1.70E-19 1.04E-19 2.27E-19 1.65E-18 O.OOE+OO 2.89E-22 O.OOE+OO 1-129 4.10E+08 3.52E+08 1.15E+09 9.05E+11 7.56E+08 O.OOE+OO 5.56E+07 O.OOE+OO 1-130 1.23E+05 3.62E+05 1.43E+05 3.07E+07 5.66E+05 O.OOE+OO . 3.12E+05 O.OOE+OO 1-131 8.66E+07 1.24E+08 7.10E+07 4.06E+10 2.12E+08 O.OOE+OO 3.27E+07 O.OOE+OO 1-132 4.BOE-02 1.29E-01 4.SOE-02 4.50E+OO 2.0SE-01 O.OOE+OO 2.41E-02 O.OOE+OO 1-133 1.13E+06 1.97E+06 6.00E+05 2.89E+08 3.44E+06 O.OOE+OO 1.77E+06 O.OOE+OO 1-134 5.90E-13 1.60E-12 5.73E-13 2.78E-11 2.55E-12 O.OOE+OO 1.40E-15 O.OOE+OO Rev.29 Page 257 of 329 12/2016
CY-LG-170-301 TABLE 112-18 R1 DOSE FACTORS AGE: ADULT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN 1-135 3.75E+03 9.83E+03 3.63E+03 6.48E+05 1.58E+04 O.OOE+OO 1.11E+04 O.OOE+OO CS-134M 5.08E-02 1.07E-01 5.46E-02 O.OOE+OO 5.79E-02 9.13E-03 3.77E-02 O.OOE+OO CS-134 2.94E+09 7.00E+09 5.72E+09 O.OOE+OO 2.27E+09 7.52E+08 1.23E+08 O.OOE+OO CS-135 9.77E+08 9.02E+08 4.00E+08 O.OOE+OO 3.41E+08 1.02E+08 2.11E+07 O.OOE+OO CS-136 7.76E+07 3.06E+08 2.20E+08 O.OOE+OO 1.70E+08 2.34E+07 3.48E+07 O.OOE+OO CS-137 3.98E+09 5.44E+09 3.56E+09 O.OOE+OO 1.85E+09 6.14E+08 1.05E+08 O.OOE+OO CS-138 2.64E-24 5.22E-24 2.59E-24 O.OOE+OO 3.84E-24 3.79E-25 2.23E-29 O.OOE+OO CS-139 1.98E-90 2.95E-90 1.08E-90 O.OOE+OO 2.37E-90 2.15E-91 6.40E-113 O.OOE+OO BA-139 1.29E-08 . 9.21E-12 3.78E-10 O.OOE+OO 8.61E-12 5.22E-12 2.29E-08 O.OOE+OO BA-140 7.91E+06 9.94E+03 5.18E+05 O.OOE+OO 3.38E+03 5.69E+03 1.63E+07 O.OOE+OO BA-141 1.20E-46 9.05E-50 4.04E-48 O.OOE+OO 8.41E-50 5.14E-50 5.64E-56 O.OOE+OO BA-142 7.77E-81 7.99E-84 4.89E-82 O.OOE+OO 6.75E-84 4.53E-84 1.09E-98 O.OOE+OO LA-140 1.32E+OO 6.65E-01 1.76E-01 O.OOE+OO O.OOE+OO O.OOE+OO 4.88E+04 O.OOE+OO LA-141 8.90E-06 2.76E-06 4.52E-07 O.OOE+OO O.OOE+OO O.OOE+OO 3.29E-01 O.OOE+OO LA-142 5.43E-12 2.47E-12 6.16E-13 O.OOE+OO O.OOE+OO O.OOE+OO 1.80E-08 O.OOE+OO CE-141 1.59E+03 1.08E+03 1.22E+02 O.OOE+OO 5.00E+02 O.OOE+OO 4.12E+06 O.OOE+OO CE-143 1.22E+01 8.99E+03 9.95E-01 O.OOE+OO 3.96E+OO O.OOE+OO 3.36E+05 O.OOE+OO CE-144 1.76E+05 7.35E+04 9.44E+03 O.OOE+OO 4.36E+04 O.OOE+OO 5.94E+07 O.OOE+OO PR-143 4.66E+01 1.87E+01 2.31E+OO O.OOE+OO 1.08E+01 O.OOE+OO 2.04E+05 O.OOE+OO PR-144 1.72E-54 7.13E-55 8.73E-56 O.OOE+OO 4.02E-55 O.OOE+OO 2.47E-61 O.OOE+OO ND-147 2.76E+01 3.19E+01 1.91E+OO O.OOE+OO 1.87E+01 O.OOE+OO 1.53E+05 O.OOE+oo* PM-147 1.50E+03 1.41 E+02 5.73E+01 O.OOE+OO 2.67E+02 O.OOE+OO 1.78E+05 O.OOE+OO PM-148M 2.97E+02 7.70E+01 5.89E+01 O.OOE+OO 1.16E+02 O.OOE+OO 6.53E+05 O.OOE+OO PM-148 1.74E+01 2.88E+OO 1.45E+OO O.OOE+OO 5.44E+OO O.OOE+OO 2.26E+05 O.OOE+OO PM-149 1.25E+OO 1.77E-01 7.23E-02 O.OOE+OO 3.34E-01 O.OOE+OO 3.32E+04 O.OOE+OO PM-151 1.90E-01 3.19E-02 1.61E-02 O.OOE+OO 5.70E-02 O.OOE+OO 8.78E+03 O.OOE+OO SM-151 1.44E+03 2.48E+02 5.94E+01 O.OOE+OO 2.77E+02 O.OOE+OO 1.09E+05 O.OOE+OO SM-153 5.79E-01 4.83E-01 3.53E-02 O.OOE+OO 1.56E-01 O.OOE+OO 1.72E+04 O.OOE+OO EU-152 4.03E+03 9:19E+02 8.07E+02 O.OOE+OO 5.69E+03 O.OOE+OO 5.30E+05 O.OOE+OO EU-154 1.27E+04 1.56E+03 1.11E+03 O.OOE+OO 7.45E+03 O.OOE+OO 1.13E+06 O.OOE+OO EU-155 1.75E+03 2.49E+02 1.60E+02 O.OOE+OO 1.15E+03 O.OOE+OO 1.96E+05 O.OOE+OO EU-156 7.46E+01 5.77E+01 9.31E+OO O.OOE+OO 3.85E+01 O.OOE+OO 3.95E+05 O.OOE+OO TB-160 5.93E+02 O.OOE+OO 7.39E+01 O.OOE+OO 2.45E+02 O.OOE+OO 5.46E+05 O.OOE+OO H0-166M 5.63E+03 1.76E+03 1.34E+03 O.OOE+OO 2.63E+03 O.OOE+OO 5.34E+05 O.OOE+OO W-181 1.49E+04 4.87E+03 5.22E+02 O.OOE+OO O.OOE+OO O.OOE+OO
- 5.55E+05 O.OOE+OO W-185 5.18E+05 1.73E+05 1.82E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.00E+07 O.OOE+OO W-187 1.91E+03 1.59E+03 5.57E+02 O.OOE+OO O.OOE+OO O.OOE+OO 5.22E+05 O.OOE+OO U-232 8.61E+09 O.OOE+OO 6.15E+08 O.OOE+OO 9.31E+08 O.OOE+OO 1.41E+08 O.OOE+OO U-233 1.82E+09 O.OOE+OO 1.10E+08 O.OOE+OO 4.24E+08 O.OOE+OO 1.31E+08 O.OOE+OO U-234 1.74E+09 O.OOE+OO 1.08E+08 O.OOE+OO 4.15E+08 O.OOE+OO 1.28E+08 O.OOE+OO U-235 1.67E+09 O.OOE+OO 1.01E+08 O.OOE+OO 3.90E+08 O.OOE+OO 1.63E+08 O.OOE+OO U-236 1.67E+09 O.OOE+OO 1.04E+08 O.OOE+OO 3.99E+08 O.OOE+OO 1.20E+08 O.OOE+OO Rev.29 Page 258 of 329 12/2016
CY-LG-170-301 TABLE 112-18 R1 DOSE FACTORS AGE: ADULT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-237 1.65E+04 O.OOE+OO 4.40E+03 O.OOE+OO 6.80E+04 O.OOE+OO 5.81E+06 O.OOE+OO U-238 1.60E+09 O.OOE+OO 9.48E+07 O.OOE+OO 3.65E+08 O.OOE+OO 1.15E+08 O.OOE+OO NP-237 2.63E+07 1.87E+06 1.16E+06 O.OOE+OO 8.60E+06 O.OOE+OO 1.66E+06 O.OOE+OO NP-238 1.06E+01 2.84E-01 1.64E-01 O.OOE+OO 9.63E-01 O.OOE+OO 2.64E+04 O.OOE+OO NP-239 1.07E+OO 1.06E-01 5.82E-02 O.OOE+OO 3.30E-01 O.OOE+OO 2.17E+04 O.OOE+OO PU-238 5.25E+06 6.65E+05 1.43E+05 O.OOE+OO 6.10E+05 O.OOE+OO 6.09E+05 O.OOE+OO PU-239 6.05E+06 7.27E+05 1.59E+05 O.OOE+OO 6.77E+05 O.OOE+OO 5.56E+05 O.OOE+OO PU-240 6.04E+06
- 7.26E+05 1.59E+05 O.OOE+OO 6.76E+05 O.OOE+OO 5.66E+05 O.OOE+OO PU-241 1.30E+05 6.17E+03 2.75E+03 O.OOE+OO 1.27E+04 O.OOE+OO 1.16E+04 O.OOE+OO PU-242 5.61E+06 7.00E+05 1.54E+05 O.OOE+OO 6.52E+05 O.OOE+OO 5.45E+05 O.OOE+OO PU-244 6.55E+06 8.02E+05 1.76E+05 O.OOE+OO 7.47E+05 O.OOE+OO 8.12E+05 O.OOE+OO AM-241 1.58E+07 1.47E+07 1.13E+06 O.OOE+OO 8.49E+06 O.OOE+OO 1.55E+06 O.OOE+OO AM-242M 1.59E+07 1.38E+07 1.13E+06 O.OOE+OO 8.45E+06 O.OOE+OO 1.95E+06 O.OOE+OO AM-243 1.57E+07 1.44E+07 1.11E+06 O.OOE+OO 8.33E+06 O.OOE+OO 1.82E+06 O.OOE+OO CM-242 3.35E+05 3.57E+05 2.23E+04 O.OOE+OO 1.01E+05 O.OOE+OO 1.29E+06 O.OOE+OO CM-243 1.24E+07 1.14E+07 7.79E+05 O.OOE+OO 3.64E+06 O.OOE+OO 1.62E+06 O.OOE+OO CM-244 9.45E+06 8.85E+06 5.95E+05 O.OOE+OO 2.78E+06 O.OOE+OO 1.57E+06 O.OOE+OO CM-245 1.96E+07 1.71E+07 1.20E+06 O.OOE+OO 5.61E+06 O.OOE+OO 1.47E+06 O.OOE+OO CM-246 1.94E+07 1.70E+07 1.20E+06 O.OOE+OO 5.59E+06 O.OOE+OO 1.44E+06 O.OOE+OO CM-247 1.89E+07 1.68E+07 1.18E+06 O.OOE+OO 5.51E+06 O.OOE+OO 1.90E+06 O.OOE+OO CM-248 1.57E+08 1.38E+08 9.75E+06 O.OOE+OO 4.55E+07 O.OOE+OO 3.07E+07 O.OOE+OO CF-252 5.21E+06 O.OOE+OO 1.26E+05 O.OOE+OO O.OOE+OO O.OOE+OO 5.75E+06 O.OOE+OO Rev.29 Page 259 of 329 12/2016
CY-LG-170-301 TABLE 112-19 R1 DOSE FACTORS AGE: TEEN PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 5.66E+02 5.66E+02 5.66E+02 5.66E+02 5.66E+02 5.66E+02 O.OOE+OO C-14 6.70E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 O.OOE+OO NA-22 4.82E+09 4.82E+09 4.82E+09 4.82E+09 4.82E+09 4.82E+09 4.82E+09 O.OOE+OO NA-24 1.24E+06 1.24E+06 1.24E+06 1.24E+06 1.24E+06 1.24E+06 1.24E+06 O.OOE+OO P-32 9.32E+09 5.78E+08 3.61E+08 O.OOE+OO O.OOE+OO O.OOE+OO 7.84E+08 O.OOE+OO CA-41 8.49E+09 O.OOE+OO 9.18E+08 O.OOE+OO O.OOE+OO O.OOE+OO 8.40E+06 O.OOE+OO SC-46 1.25E+02 2.43E+02 7.20E+01 O.OOE+OO 2.33E+02 O.OOE+OO 8.27E+05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.59E+04 8.83E+03 3.48E+03 2.27E+04 2.67E+06 O.OOE+OO MN-54 O.OOE+OO 6.94E+06 1.38E+06 O.OOE+OO 2.07E+06 O.OOE+OO 1.42E+07 O.OOE+OO MN-56 O.OOE+OO 2.15E-03 3.83E-04 O.OOE+OO 2.72E-03 O.OOE+OO 1.42E-01 O.OOE+OO FE-55 2.34E+07 1.66E+07 3.87E+06 O.OOE+OO O.OOE+OO 1.05E+07 7.17E+06 O.OOE+OO FE-59 1.83E+07 4.28E+07 1.65E+07 O.OOE+OO O.OOE+OO 1.35E+07 1.01 E+08 O.OOE+OO C0-57 O.OOE+OO 1.10E+06 1.84E+06 O.OOE+OO O.OOE+OO O.OOE+OO 2.05E+07 O.OOE+OO C0-58 O.OOE+OO 3.14E+06 7.22E+06 O.OOE+OO O.OOE+OO O.OOE+OO 4.32E+07 O.OOE+OO C0-60 O.OOE+OO 1.48E+07 3.33E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.93E+08 O.OOE+OO Nl-59 4.76E+08 1.68E+08 8.08E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.64E+07 O.OOE+OO Nl-63 6.38E+09 4.51E+08 2.16E+08 O.OOE+OO O.OOE+OO O.OOE+OO 7.17E+07 O.OOE+OO Nl-65 1.98E-01 2.53E-02 1.15E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.37E+OO O.OOE+OO CU-64 O.OOE+OO 1.24E+04 5.84E+03 O.OOE+OO 3.14E+04 O.OOE+OO 9.63E+05 O.OOE+OO ZN~65 1.02E+09 3.54E+09 1.65E+09 O.OOE+OO 2.27E+09 O.OOE+OO 1.50E+09 O.OOE+OO ZN-69M 9.53E+04 2.25E+05 2.06E+04 O.OOE+OO 1.37E+05 O.OOE+OO 1.24E+07 O.OOE+OO ZN-69 1.13E-12 2.15E-12 1.50E-13 O.OOE+OO 1.40E-12 O.OOE+OO 3.95E-12 O.OOE+OO SE-79 O.OOE+OO 9.04E+08 1.52E+08 O.OOE+OO 1.58E+09 O.OOE+OO 1.38E+08 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.64E+07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO
- 5.24E-02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 8.41E-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.42E+09 6.69E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.11E+08 O.OOE+OO RB-87 O.OOE+OO 2.83E+09 9.87E+08 O.OOE+OO O.OOE+OO O.OOE+OO 9.87E+07 O.OOE+OO RB-88 O.OOE+OO 1.14E-45 6.06E-46 O.OOE+OO O.OOE+OO O.OOE+OO 9.74E-53 O.OOE+OO RB-89 O.OOE+OO 2.24E-53 1.59E-53 O.OOE+OO O.OOE+OO O.OOE+OO 3.44E-62 O.OOE+OO SR-89 9.75E+08 O.OOE+OO 2.79E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.16E+08 O.OOE+OO SR-90 4.38E+10 O.OOE+OO 8.75E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.00E+09 O.OOE+OO SR-91 1.55E+04 O.OOE+OO 6.18E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.05E+04 O.OOE+OO SR-92 2.61E-01 O.OOE+OO 1.11 E-02 O.OOE+OO O.OOE+OO O.OOE+OO 6.66E+OO O.OOE+OO Y-90 3.81E+01 O.OOE+OO 1.03E+OO O.OOE+OO O.OOE+OO O.OOE+OO 3.14E+05 O.OOE+OO Y-91M 3.20E-20 O.OOE+OO 1.22E-21 O.OOE+OO O.OOE+OO O.OOE+OO 1.51E-18 O.OOE+OO Y-91 5.97E+03 O.OOE+OO 1.60E+02 O.OOE+OO O.OOE+OO O.OOE+OO 2.45E+06 O.OOE+OO Y-92 3.02E-05 O.OOE+OO 8.72E-07 O.OOE+OO O.OOE+OO O.OOE+OO 8.27E-01 O.OOE+OO Y-93 1.20E-01 O.OOE+OO 3.30E-03 O.OOE+OO O.OOE+OO O.OOE+OO 3.68E+03 O.OOE+OO ZR-93 1.49E+03 7.35E+01 4.01E+01 O.OOE+OO 2.60E+02 O.OOE+OO 6.95E+04 O.OOE+OO ZR-95 6.37E+02 2.01E+02 1.38E+02 O.OOE+OO 2.95E+02 O.OOE+OO 4.64E+05 O.OOE+OO ZR-97 2.31 E-01 4.56E-02 2.10E-02 O.OOE+OO 6.92E-02 O.OOE+OO 1.24E+04 O.OOE+OO NB-93M 4.59E+05 1.51E+05 3.78E+04 O.OOE+OO 1.76E+05 O.OOE+OO 5.44E+07 O.OOE+OO NB-95 4.71E+04 2.61E+04 1.44E+04 O.OOE+OO 2.53E+04 O.OOE+OO 1.12E+08 O.OOE+OO Rev.29 Page 260 of 329 12/2016
CY-LG-170-301 TABLE 112-19 R1 DOSE FACTORS AGE: TEEN PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN NB-97 1.75E-12 4.35E-13 1.59E-13 O.OOE+OO 5.09E-13 O.OOE+OO 1.04E-08 O.OOE+OO M0-93 O.OOE+OO 4.28E+08 1.17E+07 O.OOE+OO 1.23E+08 O.OOE+OO 5.21E+07 O.OOE+OO M0-99 O.OOE+OO 1.31E+07 2.49E+06 O.OOE+OO 2.99E+07 O.OOE+OO 2.34E+07 O.OOE+OO TC-99M 1.68E+OO 4.70E+OO 6.09E+01 O.OOE+OO 7.00E+01 2.61E+OO 3.09E+03 O.OOE+OO TC-99 2.41E+07 3.54E+07 9.66E+06 O.OOE+OO 4.50E+08 3.66E+06 8.67E+08 O.OOE+OO TC-101 1.39E-60 1.97E-60 1.94E-59 O.OOE+OO 3.57E-59 1.20E-60 3.37E-67 O.OOE+OO RU-103 6.21E+02 O.OOE+OO 2.66E+02 O.OOE+OO 2.19E+03 O.OOE+OO 5.19E+04 O.OOE+OO RU-105 4.58E-04 O.OOE+OO 1.78E-04 O.OOE+OO 5.77E-03 O.OOE+OO 3.70E-01 O.OOE+OO RU-106 1.88E+04 O.OOE+OO 2.37E+03 O.OOE+OO 3.63E+04 O.OOE+OO 9.02E+05 O.OOE+OO RH-105 1.87E+05 1.35E+05 8.88E+04 O.OOE+OO 5.75E+05 O.OOE+OO 1.72E+07 O.OOE+OO PD-107 O.OOE+OO 1.12E+07 7.22E+05 O.OOE+OO 1.01E+08 O.OOE+OO 5.20E+07 O.OOE+OO PD-109 O.OOE+OO 2.37E+04 5.38E+03 O.OOE+OO 1.37E+05 O.OOE+OO 2.39E+06 O.OOE+OO AG-110M 4.67E+07 4.42E+07 2.69E+07 O.OOE+OO 8.43E+07 O.OOE+OO 1.24E+10 O.OOE+OO AG-111 3.49E+06 1.45E+06 7.28E+05 O.OOE+OO 4.72E+06 O.OOE+OO 2.02E+09 O.OOE+OO CD-113M O.OOE+OO 2.89E+06 9.29E+04 O.OOE+OO 3.20E+06 O.OOE+OO 1.74E+07 O.OOE+OO CD-115M O.OOE+OO 8.12E+05 2.62E+04 O.OOE+OO 6.49E+05 O.OOE+OO 2.57E+07 O.OOE+OO SN-123 4.40E+08 7.22E+06 1.07E+07 5.79E+06 O.OOE+OO O.OOE+OO 6.65E+08 O.OOE+OO SN-125 3.07E+07 6.11 E+05 1.38E+06 4.80E+05 O.OOE+OO O.OOE+OO 2.89E+08 O.OOE+OO SN-126 1.56E+09 2.91E+07 4.44E+07 7.66E+06 O.OOE+OO O.OOE+OO 3.47E+08 O.OOE+OO SB-124 1.75E+07 3.22E+05 6.81E+06 3.96E+04 O.OOE+OO 1.52E+07 3.52E+08 O.OOE+OO SB-125 1.92E+07 2.10E+05 4.49E+06 1.83E+04 O.OOE+OO 1.69E+07 1.49E+08 O.OOE+OO SB-126 2.94E+06 6.00E+04 1.05E+06 1.66E+04 O.OOE+OO 2.11E+06 1.74E+08 O.OOE+OO SB-127 2.39E+05 5.11 E+03 9.02E+04 2.68E+03 O.OOE+OO 1.63E+05 4.05E+07 O.OOE+OO TE-125M 1.13E+07 4.08E+06 1.51E+06 3.16E+06 O.OOE+OO O.OOE+OO 3.34E+07 O.OOE+OO TE-127M 3.65E+07 1.29E+07 4.34E+06 8.67E+06 1.48E+08 O.OOE+OO 9.09E+07 O.OOE+OO TE-127 3.54E+02 1.25E+02 7.62E+01 2.44E+02 1.43E+03 O.OOE+OO 2.73E+04 O.OOE+OO TE-129M 3.65E+07 1.35E+07 5.77E+06 1.18E+07 1.53E+08 O.OOE+OO 1.37E+08 O.OOE+OO TE-129 1.52E-10 5.67E-11 3.70E-11 1.09E-10 6.38E-10 O.OOE+OO 8.31 E-10 O.OOE+OO TE-131M 1.92E+05 9.22E+04 7.69E+04 1.39E+05 9.61E+05 O.OOE+OO 7.40E+06 O.OOE+OO TE-131 1.93E-33 7.94E-34 6.02E-34 1.48E-33 8.42E-33 O.OOE+OO 1.58E-34 O.OOE+OO TE-132 1.26E+06 7.95E+05 7.48E+05 8.38E+05 7.63E+06 O.OOE+OO 2.52E+07 O.OOE+OO TE-133M 1.11 E-13 6.29E-14 6.12E-14 8.79E-14 6.22E-13 O.OOE+OO 2.54E-13 O.OOE+OO TE-134 4.64E-19 2.98E-19 3.11 E-19 3.81E-19 2.84E-18 O.OOE+OO 1.72E-20 O.OOE+OO 1-129 7.53E+08 6.33E+08 1.06E+09 7.71E+11 1.13E+09 O.OOE+OO 7.38E+07 O.OOE+OO 1-130 2.16E+05 6:25E+05 2.50E+05 5.10E+07 9.63E+05 O.OOE+OO 4.80E+05 O.OOE+OO 1-131 1.57E+08 2.20E+08 1.18E+08 6.42E+10 3.79E+08 O.OOE+OO 4.35E+07 O.OOE+OO 1-132 8.52E-02 2.23E-01 8.00E-02 7.51E+OO 3.51 E-01 O.OOE+OO 9.71 E-02 O.OOE+OO 1-133 2.07E+06 3.51E+06 1.07E+06 4.90E+08 6.15E+06 O.OOE+OO 2.65E+06 O.OOE+OO 1-134 1.05E-12 2.78E-12 9.98E-13 4.63E-11 4.38E-12 O.OOE+OO 3.66E-14 O.OOE+OO 1-135 6.67E+03 1.72E+04 6.37E+03 1.10E+06 2.71E+04 O.OOE+OO 1.90E+04 O.OOE+OO CS-134M 9.05E-02 1.87E-01 9.63E-02 O.OOE+OO 1.04E-01 1.83E-02 1.25E-01 O.OOE+OO CS-134 5.11E+09 1.20E+10 5.58E+09 O.OOE+OO 3.82E+09 1.46E+09 1.50E+08 O.OOE+OO CS-135 1.80E+09 1.65E+09 3.85E+08 O.OOE+OO 6.29E+08 2.28E+08 2.88E+07 O.OOE+OO CS-136 1.32E+08 5.20E+08 3.49E+08 O.OOE+OO 2.83E+08 4.46E+07 4.18E+07 O.OOE+OO CS-137 7.21E+09 9.59E+09 3.34E+09 O.OOE+OO 3.26E+09 1.27E+09 1.36E+08 O.OOE+OO Rev.29 Page 261 of 329 12/2016
CY-LG-170-301 TABLE 112-19 R1 DOSE FACTORS AGE: TEEN PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-138 4.80E-24 9.21 E-24 4.61 E-24 O.OOE+OO 6.80E-24 7.91E-25 4.18E-27 O.OOE+OO CS-139 3.65E-90 5.38E-90 1.97E-90 O.OOE+OO 4.34E-90 4.76E-91 2.50E-105 O.OOE+OO BA-139 2.39E-08 1.68E-11 6.96E-10 O.OOE+OO 1.59E-11 1.16E-11 2.13E-07 O.OOE+OO BA-140 1.43E+07 1.75E+04 9.20E+05 O.OOE+OO 5.93E+03 1.18E+04 2.20E+07 O.OOE+OO BA-141 2.20E-46 1.64E-49 7.35E-48 O.OOE+OO 1.53E-49 1.13E-49 4.69E-52 O.OOE+OO BA-142 1.41 E-80 1.41 E-83 8.67E-82 O.OOE+OO 1.19E-83 9.37E-84 4.32E-92 O.OOE+OO LA-140 2.37E+OO 1.16E+OO 3.10E-01 O.OOE+OO O.OOE+OO O.OOE+OO 6.69E+04 O.OOE+OO LA-141 1.64E-05 5.04E-06 8.32E-07 O.OOE+OO O.OOE+OO O.OOE+OO 8.93E-01 O.OOE+OO LA-142 9.81E-12 4.36E-12 1.08E-12 O.OOE+OO O.OOE+OO O.OOE+OO 1.33E-07 O.OOE+OO CE-141 2.92E+03 1.95E+03 2.24E+02 O.OOE+OO 9.18E+02 O.OOE+OO 5.58E+06 O.OOE+OO CE-143 2.23E+01 1.63E+04 1.82E+OO O.OOE+OO 7.29E+OO O.OOE+OO 4.89E+05 O.OOE+OO CE-144 3.23E+05 1.34E+05 1.74E+04 O.OOE+OO 7.99E+04 O.OOE+OO 8.13E+07 O.OOE+OO PR-143 8.56E+01 3.42E+01 4.26E+OO O.OOE+OO 1.99E+01 O.OOE+OO 2.82E+05 O.OOE+OO PR-144 3.16E-54 1.30E-54 1.60E-55 O.OOE+OO 7.43E-55 O.OOE+OO 3.49E-57 O.OOE+OO ND-147 5.31E+01 5.78E+01
- 3.46E+OO O.OOE+OO 3.39E+01 O.OOE+OO 2.08E+05 O.OOE+OO PM-147 2.70E+03 2.56E+02 1.05E+02 O.OOE+OO 4.89E+02 O.OOE+OO 2.44E+05 O.OOE+OO PM-148M 5.17E+02 1.31E+02 1.03E+02 O.OOE+OO 1.99E+02 O.OOE+OO 8.26E+05 O.OOE+OO PM-148 3.18E+01 5.18E+OO 2.61E+OO O.OOE+OO 9.37E+OO O.OOE+OO 3.09E+05 O.OOE+OO PM-149 2.31E+OO 3.24E-01 1.33E-01 O.OOE+OO 6.17E-01 O.OOE+OO 4.77E+04 O.OOE+OO PM-151 3.47E-01 5.73E-02 2.90E-02 O.OOE+OO 1.03E-01 O.OOE+OO 1.29E+04 O.OOE+OO SM-151 2.35E+03 4.52E+02 1.06E+02 O.OOE+OO 4.95E+02 O.OOE+OO 1.53E+05 O.OOE+OO SM-153 1.06E+OO 8.81 E-01 6.48E-02 O.OOE+OO 2.88E-01 O.OOE+OO 2.49E+04 O.OOE+OO EU-152 6.54E+03 1.58E+03 1.39E+03 O.OOE+OO 7.31E+03 O.OOE+OO 5.79E+05 O.OOE+OO EU-154 2.10E+04 2.71E+03 .1.91E+03 O.OOE+OO 1.21E+04 O.OOE+OO 1.43E+06 O.OOE+OO EU-155 4.57E+03 4.42E+02 2.73E+02 O.OOE+OO 1.73E+03 O.OOE+OO 2.53E+06 O.OOE+OO EU-156 1.35E+02 1.01 E+02 1.65E+01 O.OOE+OO 6.81E+01 O.OOE+OO 5.17E+05 O.OOE+OO TB-160 1.05E+03 O.OOE+OO 1.31 E+02 O.OOE+OO 4.16E+02 O.OOE+OO 6.82E+05 O.OOE+OO H0-166M 9.61E+03 2.96E+03 2.14E+03 O.OOE+OO 4.34E+03 O.OOE+OO 7.30E+05 O.OOE+OO W-181 2.76E+04 8.91E+03 9.32E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.59E+05 O.OOE+OO W-185 9.56E+05 3.15E+05 3.34E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.73E+07 O.OOE+OO W-187 3.48E+03 2.84E+03 9.95E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.69E+05 O.OOE+OO U-232 1.58E+10 O.OOE+OO 1.13E+09 O.OOE+OO 1.72E+09 O.OOE+OO 1.93E+08 O.OOE+OO U-233 3.34E+09 O.OOE+OO 2.03E+08 O.OOE+OO 7.81E+08 O.OOE+OO 1.79E+08 O.OOE+OO U-234 3.20E+09 O.OOE+OO 1.99E+08 O.OOE+OO 7.68E+08 O.OOE+OO 1.75E+08 O.OOE+OO U-235 3.07E+09 O.OOE+OO 1.87E+08 O.OOE+OO 7.19E+08 O.OOE+OO 2.23E+08 O.OOE+OO U-236 3.07E+09 O.OOE+OO 1.91E+08 O.OOE+OO 7.35E+08 O.OOE+OO 1.65E+08 O.OOE+OO U-237 3.05E+04 O.OOE+OO 8.11E+03 O.OOE+OO 1.25E+05 O.OOE+OO 8.07E+06 O.OOE+OO U-238 2.94E+09 O.OOE+OO 1.75E+08 O.OOE+OO 6.73E+08 O.OOE+OO 1.57E+08 O.OOE+OO NP-237 3.58E+07 2.57E+06 1.58E+06 O.OOE+OO 1.17E+07 O.OOE+OO 2.26E+06 O.OOE+OO NP-238 1.94E+01 5.19E-01 3.02E-01 O.OOE+OO 1.78E+OO O.OOE+OO 3.81E+04 O.OOE+OO NP-239 2.05E+OO 1.93E-01 1.07E-01 O.OOE+OO 6.07E-01 O.OOE+OO 3.11E+04 O.OOE+OO PU-238 7.21E+06 9.23E+05 1.96E+05 O.OOE+OO 8.39E+05 O.OOE+OO 8.32E+05 O.OOE+OO PU-239 8.24E+06 1.00E+06 2.17E+05 O.OOE+OO 9.23E+05 O.OOE+OO 7.61E+05 O.OOE+OO PU-240 8.23E+06 9.99E+05 2.17E+05 O.OOE+OO 9.22E+05 O.OOE+OO 7.75E+05 O.OOE+OO
- PU-241 1.87E+05 8.97E+03 3.94E+03 O.OOE+OO 1.83E+04 O.OOE+OO 1.58E+04 O.OOE+OO Rev.29 Page 262 of 329 12/2016
CY-LG-170-301 TABLE 112-19 R1 DOSE FACTORS AGE: TEEN PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 7.64E+06 9.63E+05 2.09E+05 O.OOE+OO 8.89E+05 O.OOE+OO 7.45E+05 O.OOE+OO PU-244 8.92E+06 1.10E+06 2.39E+05 O.OOE+OO 1.02E+06 O.OOE+OO 1.11 E+06 O.OOE+OO AM-241 2.15E+07 2.03E+07 1.55E+06 O.OOE+OO 1.16E+07 O.OOE+OO 2.12E+06 O.OOE+OO AM-242M 2.17E+07 1.91E+07 1.56E+06 O.OOE+OO 1.16E+07 O.OOE+OO 2.66E+06 O.OOE+OO AM-243 2.14E+07 1.98E+07 1.51E+06 O.OOE+OO 1.14E+07 O.OOE+OO 2.49E+06 O.OOE+OO CM-242 6.18E+05 6.51E+05 4.10E+04 O.OOE+OO 1.87E+05 O.OOE+OO 1.76E+06 O.OOE+OO CM-243 1.74E+07 1.62E+07 1.10E+06 O.OOE+OO 5.12E+06 O.OOE+OO 2.22E+06 O.OOE+OO CM-244 1.35E+07 1.28E+07 8.53E+05 O.OOE+OO 3.99E+06 O.OOE+OO 2.14E+06 O.OOE+OO CM-245 2.67E+07 2.35E+07 1.64E+06 O.OOE+OO 7.68E+06 O.OOE+OO 2.01E+06 O.OOE+OO CM-246 2.64E+07 2.34E+07 1.64E+06 O.OOE+OO 7.65E+06 O.OOE+OO 1.97E+06 O.OOE+OO CM-247 2.58E+07 2.31E+07 1.62E+06 O.OOE+OO 7.54E+06 O.OOE+OO 2.59E+06 O.OOE+OO CM-248 2.14E+08 1.90E+08 1.33E+07 O.OOE+OO 6.22E+07 O.OOE+OO 4.17E+07 O.OOE+OO CF-252 8.93E+06 O.OOE+OO 2.15E+05 O.OOE+OO O.OOE+OO O.OOE+OO 7.85E+06 O.OOE+OO Rev.29 Page 263 of 329 12/2016
CY-LG-170-301 TABLE 112-20 Ri DOSE FACTORS AGE: CHILD PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 8.97E+02 8.97E+02 8.97E+02 8.97E+02 8.97E+02 8.97E+02 O.OOE+OO C-14 1.65E+06 3.29E+05 3.29E+05 3.29E+05 3.29E+05 3.29E+05 3.29E+05 O.OOE+OO NA-22 9.99E+09 9.99E+09 9.99E+09 9.99E+09 9.99E+09 9.99E+09 9.99E+09 O.OOE+OO NA-24 2.59E+06 2.59E+06 2.59E+06 2.59E+06 2.59E+06 2.59E+06 2.59E+06 O.OOE+OO P-32 2.30E+10 1.08E+09 8.86E+08 O.OOE+OO O.OOE+OO O.OOE+OO 6.35E+08 O.OOE+OO CA-41 1.23E+10 O.OOE+OO 1.35E+09 O.OOE+OO O.OOE+OO O.OOE+OO 6.75E+06 O.OOE+OO SC-46 2.80E+02 3.84E+02 1.48E+02 O.OOE+OO 3.40E+02 O.OOE+OO 5.62E+05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 3.24E+04 1.80E+04 4.92E+03 3.29E+04 1.72E+06 O.OOE+OO MN-54 O.OOE+OO 1.04E+07 2.77E+06 O.OOE+OO 2.91E+06 O.OOE+OO 8.72E+06 O.OOE+OO MN-56 O.OOE+OO 3.75E-03 8.47E-04 O.OOE+OO 4.54E-03 O.OOE+OO 5.44E-01 O.OOE+OO FE-55 5.87E+07 3.11E+07 9.64E+06 O.OOE+OO O.OOE+OO 1.76E+07 5.77E+06 O.OOE+OO FE-59 4.25E+07 6.88E+07 3.43E+07 O.OOE+OO O.OOE+OO 1.99E+07 7.16E+07 O.OOE+OO C0-57 O.OOE+OO 1.88E+06 3.80E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.54E+07 O.OOE+OO C0-58 O.OOE+OO 4.79E+06 1.47E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.79E+07 O.OOE+OO C0-60 O.OOE+OO 2.30E+07 6.78E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.27E+08 O.OOE+OO Nl-59 1.20E+09 3.19E+08 2.03E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.11E+07 O.OOE+OO Nl-63 1.60E+10 8.56E+08 5.44E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.77E+07 O.OOE+OO Nl-65 4.84E-01 4.56E-02 2.66E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.58E+OO O.OOE+OO CU-64 O.OOE+OO 2.18E+04 1.32E+04 O.OOE+OO 5.27E+04 O.OOE+OO 1.02E+06 O.OOE+OO ZN-65 2.00E+09 5.33E+09 3.32E+09 O.OOE+OO 3.36E+09 O.OOE+OO 9.37E+08 O.OOE+OO ZN-69M 2.33E+05 3.97E+05 4.69E+04 O.OOE+OO 2.30E+05 O.OOE+OO 1.29E+07 O.OOE+OO ZN-69 2.77E-12 4.00E-12 3.70E-13 O.OOE+OO 2.43E-12 O.OOE+OO 2.52E-10 O.OOE+OO SE-79 O.OOE+OO 1.69E+09 3.74E+08 O.OOE+OO 2.74E+09 O.OOE+OO 1.11E+08 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 3.36E+07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.29E-01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.90E-23 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 2.64E+09 1.62E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.70E+08 O.OOE+OO RB-87 O.OOE+OO 5.27E+09 2.44E+09 O.OOE+OO O.OOE+OO O.OOE+OO 7.89E+07 O.OOE+OO RB-88 O.OOE+OO 2.09E-45 1.45E-45 O.OOE+OO O.OOE+OO O.OOE+OO 1.03E-46 O.OOE+OO RB-89 O.OOE+OO 3.93E-53 3.50E-53 O.OOE+OO O.OOE+OO O.OOE+OO 3.43E-55 O.OOE+OO SR-89 2.41E+09 O.OOE+OO 6.89E+07 O.OOE+OO O.OOE+OO O.OOE+OO 9.34E+07 O.OOE+OO SR-90 9.06E+10 O.OOE+OO 1.82E+09 O.OOE+OO O.OOE+OO O.OOE+OO 8.11E+08 O.OOE+OO SR-91 3.81E+04 O.OOE+OO 1.44E+03 O.OOE+OO O.OOE+OO O.OOE+OO 8.42E+04 O.OOE+OO SR-92 6.39E-01 O.OOE+OO 2.56E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.21E+01 O.OOE+OO Y-90 9.42E+01 O.OOE+OO 2.52E+OO O.OOE+OO O.OOE+OO O.OOE+OO 2.68E+05 O.OOE+OO Y-91M 7.83E-20 O.OOE+OO 2.85E-21 O.OOE+OO O.OOE+OO O.OOE+OO 1.53E-16 O.OOE+OO Y-91 1.47E+04 O.OOE+OO 3.94E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.96E+06 O.OOE+OO Y-92 7.40E-05 O.OOE+OO 2.12E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.14E+OO O.OOE+OO Y-93 2.96E-01 O.OOE+OO 8.12E-03 O.OOE+OO O.OOE+OO O.OOE+OO 4.41E+03 O.OOE+OO ZR-93 3.71E+03 1.39E+02 9.89E+01 O.OOE+OO 5.38E+02 O.OOE+OO 5.27E+04 O.OOE+OO ZR-95 1.48E+03 3.25E+02 2.89E+02 O.OOE+OO 4.65E+02 O.OOE+OO 3.39E+05 O.OOE+OO Rev.29 Page 264 of 329 12/2016
CY-LG-170-301 TABLE 112-20 Ri DOSE FACTORS AGE: CHILD PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN ZR-97 5.61 E-01 8.11 E-02 4.78E-02 O.OOE+OO 1.16E-01 O.OOE+OO 1.23E+04 O.OOE+OO NB-93M 1.16E+06 2.89E+05 9.49E+04 O.OOE+OO 3.12E+05 O.OOE+OO 4.35E+07 O.OOE+OO NB-95 1.06E+05 4.14E+04 2.96E+04 O.OOE+OO 3.89E+04 O.OOE+OO 7.65E+07 O.OOE+OO NB-97 4.26E-12 7.69E-13 3.59E-13 O.OOE+OO 8.54E-13 O.OOE+OO 2.37E-07 O.OOE+OO M0-93 O.OOE+OO 8.03E+08 2.88E+07 O.OOE+OO 2.12E+08 O.OOE+OO 4.07E+07 O.OOE+OO M0-99 O.OOE+OO 2.38E+07 5.89E+06 O.OOE+OO 5.08E+07 O.OOE+OO 1.97E+07 O.OOE+OO TC-99M 3.86E+OO 7.58E+OO 1.26E+02 O.OOE+OO 1.10E+02 3.85E+OO 4.31E+03 O.OOE+OO TC-99 5.94E+07 6.62E+07 2.38E+07 O.OOE+OO 7.BOE+OB 5.85E+06 6.94E+08 O.OOE+OO TC-101 3.40E-60 3.56E-60 4.51E-59 O.OOE+OO 6.07E-59 1.BBE-60 1.13E-59 O.OOE+OO RU-103 1.47E+03 O.OOE+OO 5.65E+02 O.OOE+OO 3.70E+03 O.OOE+OO 3.80E+04 O.OOE+OO RU-105 1.12E-03 O.OOE+OO 4.05E-04 O.OOE+OO 9.82E-03 O.OOE+OO 7.29E-01 O.OOE+OO RU-106 4.63E+04 O.OOE+OO 5.78E+03 O.OOE+OO 6.26E+04 O.OOE+OO 7.21E+05 O.OOE+OO RH-105 4.59E+05 2.47E+05 2.11 E+05 O.OOE+OO 9.83E+05 O.OOE+OO 1.53E+07 O.OOE+OO PD-107 O.OOE+OO 2.10E+07 1.78E+06 O.OOE+OO 1.76E+08 O.OOE+OO 4.16E+07 O.OOE+OO PD-109 O.OOE+OO 4.42E+04 1.32E+04 O.OOE+OO 2.37E+05 O.OOE+OO 2.61E+06 O.OOE+OO AG-110M 1.01E+08 6.84E+07 5.47E+07 O.OOE+OO 1.27E+08 O.OOE+OO 8.14E+09 O.OOE+OO AG-111 8.61E+06 2.70E+06 1.78E+06 O.OOE+OO 8.13E+06 O.OOE+OO 1.65E+09 O.OOE+OO CD-113M O.OOE+OO 5.39E+06 2.29E+05 O.OOE+OO 5.55E+06 O.OOE+OO 1.39E+07 O.OOE+OO CD-115M O.OOE+OO 1.52E+06 6.46E+04 O.OOE+OO 1.13E+06 O.OOE+OO 2.06E+07 O.OOE+OO SN-123 1.09E+09 1.35E+07 2.65E+07 1.43E+07 O.OOE+OO O.OOE+OO 5.33E+08 O.OOE+OO SN-125 7.55E+07 1.14E+06 3.38E+06 1.18E+06 O.OOE+OO O.OOE+OO 2.34E+08 O.OOE+OO SN-126 3.70E+09 4.61E+07 1.05E+08 1.27E+07 O.OOE+OO O.OOE+OO 2.78E+08 O.OOE+OO SB-124 4.13E+07 5.36E+05 1.45E+07 9.12E+04 O.OOE+OO 2.29E+07 2.58E+08 O.OOE+OO SB-125 4.57E+07 3.52E+05 9.58E+06 4.23E+04 O.OOE+OO 2.55E+07 1.09E+08 O.OOE+OO SB-126 6.71E+06 1.03E+05 2.41E+06 3.93E+04 O.OOE+OO 3.20E+06 1.35E+08 O.OOE+OO SB-127 5.75E+05 8.90E+03 2.00E+05 6.41E+03 O.OOE+OO 2.50E+05 3.24E+07 O.OOE+OO TE-125M 2.78E+07 7.54E+06 3.71E+06 7.80E+06 O.OOE+OO O.OOE+OO 2.68E+07 O.OOE+OO TE-127M 8.99E+07 2.42E+07 1.07E+07 2.15E+07 2.56E+08 O.OOE+OO 7.28E+07 O.OOE+OO TE-127 8.70E+02 2.35E+02 1.87E+02 6.02E+02 2.48E+03 O.OOE+OO 3.40E+04 O.OOE+OO TE-129M 8.99E+07 2.51E+07 1.40E+07 2.90E+07 2.64E+08 O.OOE+OO 1.10E+08 O.OOE+OO TE-129 3.75E-10 1.05E-10 8.90E-11 2.68E-10 1.10E-09 O.OOE+OO 2.34E-08 O.OOE+OO TE-131M 4.68E+05 1.62E+05 1.72E+05 3.33E+05 1.57E+06 O.OOE+OO 6.56E+06 O.OOE+OO TE-131 4.73E-33 1.44E-33 1.41 E-33 3.62E-33 1.43E-32 O.OOE+OO 2.48E-32 O.OOE+OO TE-132 3.00E+06 1.33E+06 1.60E+06 1.93E+06 1.23E+07 O.OOE+OO 1.34E+07 O.OOE+OO TE-133M 2.65E-13 1.07E-13 1.33E-13 2.06E-13 1.02E-12 O.OOE+OO 8.19E-12 O.OOE+OO TE-134 1.10E-18 4.96E-19 6.62E-19 8.73E-19 4.60E-18 O.OOE+OO 5.04E-18 O.OOE+OO 1-129 1.85E+09 1.14E+09 1.02E+09 7.44E+11 1.92E+09 O.OOE+OO 5.72E+07 O.OOE+OO 1-130 5.05E+05 1.02E+06 5.26E+05 1.12E+08 1.53E+06 O.OOE+OO 4.78E+05 O.OOE+OO 1-131 3.81E+08 3.84E+08 2.18E+08 1.27E+11 6.30E+08 O.OOE+OO 3.41E+07 O.OOE+OO 1-132 2.02E-01 3.70E-01 1.70E-01 1.72E+01 5.67E-01 O.OOE+OO 4.36E-01 O.OOE+OO 1-133 5.02E+06 6.21E+06 2.35E+06 1.15E+09 1.04E+07 O.OOE+OO 2.50E+06 O.OOE+OO 1-134 2.48E-12 4.61 E-12 2.12E-12 1.06E-10 7.05E-12 O.OOE+OO 3.06E-12 O.OOE+OO Rev.29 Page 265 of 329 12/2016
CY-LG-170-301 TABLE 112-20 Ri DOSE FAC"fORS AGE: CHILD PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN 1-135 1.58E+04 2.84E+04 1.34E+04 2.52E+06 4.36E+04 O.OOE+OO 2.17E+04 O.OOE+OO CS-134M 2.14E-01 3.17E-01 2.07E-01 O.OOE+OO 1.67E-01 2.77E-02 4.01E-01 O.OOE+OO CS-134 1.18E+10 1.93E+10 4.08E+09 O.OOE+OO 5.99E+09 2.15E+09 1.04E+08 O.OOE+OO CS-135 4.43E+09 3.08E+09 3.16E+08 O.OOE+OO 1.09E+09 3.63E+08 2.31E+07 O.OOE+OO CS-136 2.98E+08 8.19E+08 5.30E+08 O.OOE+OO 4.36E+08 6.51E+07 2.88E+07 O.OOE+OO CS-137 1.74E+10 1.66E+10 2.45E+09 O.OOE+OO 5.42E+09 1.95E+09 1.04E+08 O.OOE+OO CS-138 1.16E-23 1.62E-23 1.03E-23 O.OOE+OO 1.14E-23 1.22E-24 7.45E-24 O.OOE+OO CS-139 8.98E-90 9.97E-90 4.79E-90 O.OOE+OO 7.49E-90 7.55E-91 8.98E-94 O.OOE+OO BA-139 5.87E-08 3.14E-11 1.70E-09 O.OOE+OO 2.74E-11 1.84E-11 3.39E-06 O.OOE+OO BA-140 3.45E+07 3.02E+04 2.01E+06 O.OOE+OO 9.83E+03 1.80E+04 1.75E+07 O.OOE+OO BA-141 5.41E-46 3.03E-49 1.76E-47 O.OOE+OO 2.62E-49 1.78E-48 3.0BE-46 O.OOE+OO BA-142 3.40E-80 2.44E-83 1.90E-81 O.OOE+OO 1.98E-83 1.44E-83 4.43E-82 O.OOE+OO LA-140 5.68E+OO 1.98E+OO 6.69E-01 O.OOE+OO O.OOE+OO O.OOE+OO 5.53E+04 O.OOE+OO LA-141 4.04E-05 9.42E-06 2.04E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.09E+OO O.OOE+OO LA-142 2.37E-11 7.55E-12 2.36E-12 O.OOE+OO O.OOE+OO O.OOE+OO 1.50E-06 O.OOE+OO CE-141 7.19E+03 3.59E+03 5.33E+02 O.OOE+OO 1.57E+03 O.OOE+OO 4.47E+06 O.OOE+OO CE-143 5.48E+01 2.97E+04 4.31E+OO O.OOE+OO 1.25E+01 O.OOE+OO 4.35E+05 O.OOE+OO CE-144 7.97E+05 2.50E+05 4.26E+04 O.OOE+OO 1.38E+05 O.OOE+OO 6.52E+07 O.OOE+OO PR-143 2.12E+02 6.36E+01 1.05E+01 O.OOE+OO 3.44E+01 O.OOE+OO 2.29E+05 O.OOE+OO PR-144 7.83E-54 2.42E-54 3.94E-55 O.OOE+OO 1.28E-54 O.OOE+OO 5.22E-51 O.OOE+OO ND-147 1.30E+02 1.06E+02 8.18E+OO O.OOE+OO 5.80E+01 O.OOE+OO 1.67E+05 O.OOE+OO PM-147 6.75E+03 4.82E+02 2.59E+02 O.OOE+OO 8.52E+02 O.OOE+OO 1.95E+05 O.OOE+OO PM-148M 1.06E+03 2.11E+02 2.11 E+02 O.OOE+OO 3.13E+02 O.OOE+OO 5.96E+05 O.OOE+OO PM-148 7.78E+01 9.35E+OO 6.05E+OO O.OOE+OO 1.59E+01 O.OOE+OO 2.50E+05 O.OOE+OO PM-149 5.69E+OO 6.05E-01 3.28E-01 O.OOE+OO 1.07E+OO O.OOE+OO 4.13E+04 O.OOE+OO PM-151 8.47E-01 1.03E-01 6.70E-02 O.OOE+OO 1.75E-01 O.OOE+OO 1.17E+04 O.OOE+OO SM-151 5.68E+03 8.45E+02 2.66E+02 O.OOE+OO 8.74E+02 O.OOE+OO 1.23E+05 O.OOE+OO SM-153 2.63E+OO 1.63E+OO 1.58E-01 O.OOE+OO 4.97E-01 O.OOE+OO 2.17E+04 O.OOE+OO EU-152 1.35E+04 2.47E+03 2.93E+03 O.OOE+OO 1.04E+04 O.OOE+OO 4.05E+05 O.OOE+OO EU-154 5.04E+04 4.54E+03 4.14E+03 O.OOE+OO 1.99E+04 O.OOE+OO 1.05E+06 O.OOE+OO EU-155 1.05E+04 7.53E+02 5.90E+02 O.OOE+OO 2.82E+03 O.OOE+OO 1.88E+06 O.OOE+OO EU-156 3.26E+02 1.74E+02 3.61E+01 O.OOE+OO 1.12E+02 O.OOE+OO 3.96E+05 O.OOE+OO TB-160 2.23E+03 O.OOE+OO 2.76E+02 O.OOE+OO 6.63E+02 O.OOE+OO 4.94E+05 O.OOE+OO H0-166M 2.40E+04 5.02E+03 4.24E+03 O.OOE+OO 7.15E+03 O.OOE+OO 5.84E+05 O.OOE+OO W-181 6.79E+04 1.67E+04 2.29E+03 O.OOE+OO O.OOE+OO O.OOE+OO 6.08E+05 O.OOE+OO W-185 2.36E+06 5.89E+05 8.24E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.19E+07 O.OOE+OO W-187 8.45E+03 5.00E+03 2.24E+03 O.OOE+OO O.OOE+OO O.OOE+OO 7.03E+05 O.OOE+OO U-232 3.90E+10 O.OOE+OO 2.79E+09 O.OOE+OO 2.97E+09 O.OOE+OO 1.55E+08 O.OOE+OO U-233 8.27E+09 O.OOE+OO 5.00E+08 O.OOE+OO 1.36E+09 O.OOE+OO 1.43E+08 O.OOE+OO U-234 7.93E+09 O.OOE+OO 4.91E+08 O.OOE+OO 1.33E+09 O.OOE+OO 1.40E+08 O.OOE+OO U-235 7.60E+09 O.OOE+OO 4.60E+08 O.OOE+OO 1.25E+09 O.OOE+OO 1.78E+08 O.OOE+OO U-236 7.60E+09 O.OOE+OO 4.71E+08 O.OOE+OO 1.27E+09 O.OOE+OO 1.32E+08 O.OOE+OO Rev.29 Page 266 of 329 12/2016
CY-LG-170-301 TABLE 112-20 Ri DOSE FACTORS AGE: CHILD PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-237 7.52E+04 O.OOE+OO 2.00E+04 O.OOE+OO 2.17E+05 O.OOE+OO 6.63E+06 O.OOE+OO U-238 7.27E+09 O.OOE+OO 4.31E+08 O.OOE+OO 1.16E+09 O.OOE+OO 1.26E+08 O.OOE+OO NP-237 4.95E+07 3.27E+06 2.18E+06 O.OOE+OO 1.34E+07 O.OOE+OO 1.81E+06 O.OOE+OO NP-238 4.78E+01 9.68E-01 7.45E-01 O.OOE+OO 3.08E+OO O.OOE+OO 3.31E+04 O.OOE+OO NP-239 5.05E+OO 3.62E-01 2.55E-01 O.OOE+OO 1.05E+OO O.OOE+OO 2.68E+04 O.OOE+OO PU-238 1.06E+07 1.22E+06 2.80E+05
- O.OOE+OO 1.02E+06 O.OOE+OO 6.66E+05 O.OOE+OO PU-239 1.15E+07 1.23E+06 2.94E+05 O.OOE+OO 1.08E+06 O.OOE+OO 6.09E+05 O.OOE+OO PU-240 1.14E+07 1.27E+06 2.94E+05 O.OOE+OO 1.08E+06 O.OOE+OO 6.20E+05 O.OOE+OO PU-241 3.41E+05 1.39E+04 7.09E+03 O.OOE+OO 2.61E+04 O.OOE+OO 1.27E+04 O.OOE+OO PU-242 1.06E+07 1.23E+06 2.84E+05 O.OOE+OO 1.04E+06 O.OOE+OO 5.96E+05 O.OOE+OO PU-244 1.24E+07 1.40E+07 3.24E+05 O.OOE+OO 1.20E+06 O.OOE+OO
- 8.89E+05 O.OOE+OO AM-241 3.02E+07 2.60E+07 2.27E+06 O.OOE+OO 1.38E+07 O.OOE+OO 1.70E+06 O.OOE+OO AM-242M 3.11E+07 2.49E+07 2.31E+06 O.OOE+OO 1.40E+07 O.OOE+OO 2.13E+06 O.OOE+OO AM-243 2.98E+07 2.51E+07 2.18E+06 O.OOE+OO 1.35E+07 O.OOE+OO 1.99E+06 O.OOE+OO CM-242 1.52E+06 1.22E+06 1.01 E+05 O.OOE+OO 3.24E+05 O.OOE+OO 1.41E+06 O.OOE+OO CM-243 2.83E+07 2.30E+07 1.82E+06 O.OOE+OO 6.81E+06 O.OOE+OO 1.78E+06 O.OOE+OO CM-244 2.38E+07 1.93E+07 1.53E+06 O.OOE+OO 5.61E+06 O.OOE+OO 1.71E+06 O.OOE+OO CM-245 3.71E+07 2.98E+07 2.33E+06 O.OOE+OO 9.13E+06 O.OOE+OO 1.61E+06 O.OOE+OO CM-246 3.67E+07 2.98E+07 2.33E+06 O.OOE+OO 9.11 E+06 O.OOE+OO 1.58E+06 O.OOE+OO CM-247 3.58E+07 2.93E+07 2.29E+06 O.OOE+OO 8.98E+06 O.OOE+OO 2.08E+06 O.OOE+OO CM-248 2.98E+08 2.42E+08 1.89E+07 O.OOE+OO 7.40E+07 O.OOE+OO 3.36E+07 O.OOE+OO CF-252 2.23E+07 O.OOE+OO 5.40E+05 O.OOE+OO O.OOE+OO O.OOE+OO 6.29E+06 O.OOE+OO Rev. 29 Page 267 of 329 12/2016
CY-LG-170-301 TABLE 112-21 R1 DOSE FACTORS AGE: INFANT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO 1.36E+03 1.36E+03 1.36E+03 1.36E+03 1.36E+03 1.36E+03 O.OOE+OO C-14 3.23E+06 6.89E+05 6.89E+05 6.89E+05 6.89E+05 6.89E+05 6.89E+05 O.OOE+OO NA-22 1.67E+10 1.67E+10 1.67E+10 1.67E+10 1.67E+10 1.67E+10 1.67E+10 O.OOE+OO NA-24 4.51E+06 4.51E+06 4.51E+06 4.51E+06 4.51E+06 4.51E+06 4.51E+06 O.OOE+OO P-32 4.74E+10 2.79E+09 1.84E+09 O.OOE+OO O.OOE+OO O.OOE+OO 6.41E+08 O.OOE+OO CA-41 1.33E+10 O.OOE+OO 1.45E+09 O.OOE+OO O.OOE+OO O.OOE+OO 6.79E+06 O.OOE+OO SC-46 5.33E+02 7.69E+02 2.40E+02 O.OOE+OO 5.06E+02 O.OOE+OO 5.02E+05 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 5.14E+04 3.35E+04 7.32E+03 6.52E+04 1.50E+06 O.OOE+OO MN-54 O.OOE+OO 1.93E+07 4.38E+06 O.OOE+OO 4.28E+06 O.OOE+OO 7.10E+06 O.OOE+OO MN-56 O.OOE+OO 9.19E-03 1.58E-03 O.OOE+OO 7.90E-03 O.OOE+OO 8.35E-01 O.OOE+OO FE-55 7.09E+07 4.58E+07 1.22E+07 O.OOE+OO O.OOE+OO 2.24E+07 5.82E+06 O.OOE+OO FE-59 7.94E+07 1.39E+08 5.46E+07 O.OOE+OO O.OOE+OO 4.10E+07 6.62E+07 O.OOE+OO C0-57 O.OOE+OO 4.38E+06 7.12E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.49E+07 O.OOE+OO C0-58 O.OOE+OO 9.58E+06 2.39E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.39E+07 O.OOE+OO C0-60 O.OOE+OO 4.69E+07 1.11 E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.12E+08 O.OOE+OO Nl-59 1.41 E+09 4.32E+08 2.43E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.13E+07 O.OOE+OO Nl-63 1.89E+10 1.17E+09 6.54E+08 O.OOE+OO O.OOE+OO O.OOE+OO 5.80E+07 O.OOE+OO Nl-65 1.03E+OO 1.16E-01 5.28E-02 O.OOE+OO O.OOE+OO O.OOE+OO 8.83E+OO O.OOE+OO CU-64 O.OOE+OO 5.43E+04 2.51E+04 O.OOE+OO 9.18E+04 O.OOE+OO 1.11E+06 O.OOE+OO ZN-65 2.69E+09 9.22E+09 4.25E+09 O.OOE+OO 4.47E+09 O.OOE+OO 7.79E+09 O.OOE+OO ZN-69M 4.92E+05 1.00E+06 9.14E+04 O.OOE+OO 4.06E+05 O.OOE+OO 1.39E+07 O.OOE+OO ZN-69 5.90E-12 1.06E-11 7.90E-13 O.OOE+OO 4.41 E-12 O.OOE+OO 8.66E-10 O.OOE+OO SE-79 O.OOE+OO 4.20E+09 7.80E+08 O.OOE+OO 4.86E+09 O.OOE+OO 1.12E+08 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 5.65E+07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO' O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 2.73E-01 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 3.67E-23 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 6.70E+09 3.31E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+08 O.OOE+OO RB-87 O.OOE+OO 1.18E+10 4.69E+09 O.OOE+OO O.OOE+OO O.OOE+OO 7.97E+07 O.OOE+OO RB-88 O.OOE+OO 5.48E-45 3.00E-45 O.OOE+OO O.OOE+OO O.OOE+OO 5.34E-45 O.OOE+OO RB-89 O.OOE+OO 9.62E-53 6.62E-53 O.OOE+OO O.OOE+OO O.OOE+OO 3.27E-53 O.OOE+OO SR-89 4.59E+09 O.OOE+OO 1.32E+08 O.OOE+OO O.OOE+OO O.OOE+OO 9.43E+07 O.OOE+OO SR-90 1.00E+11 O.OOE+OO 2.03E+09 O.OOE+OO O.OOE+OO O.OOE+OO 8.18E+08 O.OOE+OO SR-91 7.94E+04 O.OOE+OO 2.88E+03 O.OOE+OO O.OOE+OO O.OOE+OO 9.40E+04 O.OOE+OO SR-92 1.36E+OO O.OOE+OO 5.04E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.46E+01 O.OOE+OO Y-90 1.99E+02 O.OOE+OO 5.34E+OO O.OOE+OO O.OOE+OO O.OOE+OO 2.75E+05 O.OOE+OO Y-91M 1.66E-19 O.OOE+OO 5.66E-21 O.OOE+OO O.OOE+OO O.OOE+OO 5.53E-16 O.OOE+OO Y-91 2.77E+04 O.OOE+OO 7.37E+02 O.OOE+OO O.OOE+OO O.OOE+OO 1.98E+06 O.OOE+OO Y-92 1.57E-04 O.OOE+OO 4.42E-06 O.OOE+OO O.OOE+OO O.OOE+OO 3.00E+OO O.OOE+OO Y-93 6.31E-01 O.OOE+OO 1.72E-02 O.OOE+OO O.OOE+OO O.OOE+OO 4.98E+03 O.OOE+OO ZR-93 4.29E+03 2.04E+02 1.23E+02 O.OOE+OO 6.02E+02 O.OOE+OO 5.31E+04 O.OOE+OO ZR-95 2.63E+03 6.40E+02 4.54E+02 O.OOE+OO 6.90E+02 O.OOE+OO 3.19E+05 O.OOE+OO ZR-97 1.19E+OO 2.04E-01 9.31E-02 O.OOE+OO 2.06E-01 O.OOE+OO 1.30E+04 O.OOE+OO NB-93M 1.36E+06 3.67E+05 1.15E+05 O.OOE+OO 3.58E+05 O.OOE+OO 4.39E+07 O.OOE+OO NB-95 1.98E+05 8.17E+04 4.72E+04 O.OOE+OO 5.86E+04 O.OOE+OO 6.89E+07 O.OOE+OO Rev.29 Page 268 of 329 12/2016
CY-LG-170-301 TABLE 112-21 R1 DOSE FACTORS AGE: INFANT PATHWAY: COW MILK m2:.mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 9.01 E-12 1.92E-12 6.93E-13 O.OOE+OO 1.50E-12 O.OOE+OO 6.06E-07 O.OOE+OO M0-93 O.OOE+OO 1.88E+09 6.07E+07 O.OOE+OO 3.77E+08 O.OOE+OO 4.03E+07 O.OOE+OO M0-99 O.OOE+OO 6.08E+07 1.19E+07 O.OOE+OO 9.09E+07 O.OOE+OO 2.00E+07 O.OOE+OO TC-99M 8.04E+OO 1:66E+01 2.13E+02 O.OOE+OO 1.78E+02 8.67E+OO 4.81E+03 O.OOE+OO TC-99 1.20E+08 1.62E+08 5.05E+07 O.OOE+OO 1.37E+09 1.58E+07 7.01E+08 O.OOE+OO TC-101 7.21E-60 9.09E-60 8.99E-59 O.OOE+OO 1.0BE-58 4.96E-60 1.54E-57 O.OOE+OO RU-103 2.98E+03 O.OOE+OO 9.95E+02 O.OOE+OO 6.19E+03 O.OOE+OO 3.62E+04 O.OOE+OO RU-105 2.36E-03 O.OOE+OO 7.93E-04 O.OOE+OO 1.73E-02. O.OOE+OO 9.37E-01 O.OOE+OO RU-106 9.54E+04 O.OOE+OO 1.19E+04 O.OOE+OO 1.13E+05 O.OOE+OO 7.25E+05 O.OOE+OO RH-105 9.74E+05 6.37E+05 4.28E+05 O.OOE+OO 1.77E+06 O.OOE+OO 1.q8E+07 O.OOE+OO PD-107 O.OOE+OO 5.29E+07 3.76E+06 O.OOE+OO 3.02E+08 O.OOE+OO 4.20E+07 O.OOE+OO PD-109 O.OOE+OO 1.17E+05 2.82E+04 O.OOE+OO 4.29E+05 O.OOE+OO 2.87E+06 O.OOE+OO AG-110M 1.87E+08 1.37E+08 9.04E+07 O.OOE+OO 1.96E+08 O.OOE+OO 7.09E+09 O.OOE+OO AG-111 1.81E+07 7.02E+06 3.72E+06 O.OOE+OO 1.47E+07 O.OOE+OO 1.67E+09 O.OOE+OO CD-113M O.OOE+OO 9.36E+06 3.45E+05 O.OOE+OO 7.08E+06 O.OOE+OO 1.41 E+07 O.OOE+OO CD-115M O.OOE+OO 3.66E+06 1.27E+05 O.OOE+OO 1.91E+06 O.OOE+OO 2.08E+07 O.OOE+OO SN-123 2.04E+09 3.18E+07 5.31E+07 3.20E+07 O.OOE+OO O.OOE+OO 5.38E+08 O.OOE+OO SN-125 1.58E+08 2.94E+06 7.00E+06 2.89E+06 O.OOE+OO O.OOE+OO 2.36E+08 O.OOE+OO SN-126 6.14E+09 8.07E+07 2.00E+OB 2.12E+07 O.OOE+OO O.OOE+OO 2.80E+08 O.OOE+OO SB-124 7.96E+07 1.17E+06 2.47E+07 2.11E+05 O.OOE+OO 4.99E+07 2.46E+08 O.OOE+OO SB-125 7.85E+07 7.60E+05 1.62E+07 9.83E+04 O.OOE+OO 4.55E+07 1.05E+08 O.OOE+OO SB-126 1.23E+07 2.41E+05 4.44E+06 9.44E+04 O.OOE+OO 7.73E+06 1.27E+08 O.OOE+OO SB-127 1.21E+06 2.16E+04 3.75E+05 1.54E+04 O.OOE+OO 6.24E+05 3.21E+07 O.OOE+OO TE-125M 5.68E+07 1.90E+07 7.68E+06 1.91E+07 O.OOE+OO O.OOE+OO 2.71E+07 O.OOE+OO TE-127M 1.82E+08 6.04E+07 2.20E+07 5.26E+07 4.48E+08 O.OOE+OO 7.34E+07 O.OOE+OO TE-127 1.85E+03 6.19E+02 3.97E+02 1.50E+03 4.51E+03 O.OOE+OO 3.88E+04 O.OOE+OO TE-129M 1.85E+08 6.33E+07 2.84E+07 7.09E+07 4.61E+08 O.OOE+OO 1.10E+08 O.OOE+OO TE-129 7.95E-10 2.74E-10 1.86E-10 6.66E-10 1.98E-09 O.OOE+OO 6.36E-08 O.OOE+OO TE-131M 9.88E+05 3.98E+05 3.28E+05 8.06E+05 2.74E+06 O.OOE+OO 6.69E+06 O.OOE+OO TE-131 1.00E-32 3.70E-33 2.81E-33 8.94E-33 2.56E-32 O.OOE+OO 4.05E-31 O.OOE+OO TE-132 6.17E+06 3.06E+06 2.85E+06 4.51E+06 1.91E+07 O.OOE+OO 1.13E+07 o:ooE+oo TE-133M 5.55E-13 2.54E-13 2.43E-13 4.89E-13 1.73E-12 O.OOE+OO 2.74E-11 O.OOE+OO TE-134 2.28E-18 1.15E-18 1.18E-18 2.05E-18 7.73E-18 O.OOE+OO 2.62E-17 O.OOE+OO 1-129 3.81E+09 2.83E+09 2.07E+09 1.81E+12 3.35E+09 O.OOE+OO 5.65E+07 O.OOE+OO 1-130 1.04E+06 2.28E+06 9.17E+05 2.56E+08 2.51E+06 O.OOE+OO 4.90E+05 O.OOE+OO 1-131 7.96E+08 9.38E+08 4.12E+08 3.08E+11 1.10E+09 O.OOE+OO 3.35E+07 O.OOE+OO 1-132 4.18E-01 8.49E-01 3.02E-01 3.98E+01 9.47E-01 O.OOE+OO 6.BBE-01 O.OOE+OO 1-133 1.06E+07 1.54E+07 4.52E+06 2.81E+09 1.82E+07 O.OOE+OO 2.61E+06 O.OOE+OO 1-134 5.15E-12 1.05E-11 3.75E-12 2.46E-10 1.18E-11 O.OOE+OO 1.09E-11 O.OOE+OO 1-135 3.28E+04 6.53E+04 2.38E+04 5.86E+06 7.28E+04 O.OOE+OO 2.36E+04 O.OOE+OO CS-134M 4.47E-01 7.44E-01 3.76E-01 O.OOE+OO 2.87E-01 6.60E-02 5.89E-01 O.OOE+OO CS-134 1.90E+10 3.54E+10 3.57E+09 O.OOE+OO 9.11 E+09 3.74E+09 9.62E+07 O.OOE+OO CS-135 7.09E+09 6.45E+09 3.36E+08 O.OOE+OO 1.83E+09 6.99E+08 2.33E+07 O.OOE+OO CS-136 5.82E+08 1.71E+09 6.39E+08 O.OOE+OO 6.82E+08 1.40E+08 2.60E+07 O.OOE+OO CS-137 2.77E+10 3.25E+10 2.30E+09 O.OOE+OO 8.71E+09 3.53E+09 1.01E+08 O.OOE+OO Rev.29 Page 269 of 329 12/2016
CY-LG-170-301 TABLE 112-21 R1 DOSE FACTORS AGE: INFANT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN CS-138 2.45E-23 3.99E-23 1.93E-23 O.OOE+OO 1.99E-23 3.11 E-24 6.38E-23 O.OOE+OO CS-139 1.92E-89 2.62E-89 1.00E-89 O.OOE+OO 1.36E-89 2.04E-90 1.65E-90 O.OOE+OO BA-139 1.25E-07 8.28E-11 3.62E-09 O.OOE+OO 4.98E-11 5.02E-11 7.92E-06 O.OOE+OO BA-140 7.10E+07 7.10E+04 3.66E+06 O.OOE+OO 1.68E+04 4.36E+04 1.74E+07 O.OOE+OO BA-141 1.15E-45 7.87E-49 3.63E-47 O.OOE+OO 4.74E-49 4.79E-49 1.40E-44 O.OOE+OO BA-142 7.15E-80 5.94E-83 3.52E-81 O.OOE+OO 3.42E-83 3.60E-83 2.95E-79 O.OOE+OO LA-140 1.19E+01 4.67E+OO 1.20E+OO O.OOE+OO O.OOE+OO O.OOE+OO 5.49E+04 O.OOE+OO LA-141 8.58E-05 2.49E-05 4.34E-06
- O.OOE+OO O.OOE+OO O.OOE+OO 2.85E+OO O.OOE+OO LA-142 4.97E-11 1.83E-11 4.37E-12 O.OOE+OO O.OOE+OO O.OOE+OO 3.10E-06 O.OOE+OO CE-141 1.43E+04 8.70E+03 1.02E+03 O.OOE+OO 2.68E+03 O.OOE+OO 4.49E+06 O.OOE+OO CE-143 1.16E+02 7.70E+04 8.78E+OO O.OOE+OO 2.24E+01 O.OOE+OO 4.49E+05 O.OOE+OO CE-144 1.14E+06 4.68E+05 6.40E+04 O.OOE+OO 1.89E+05 O.OOE+OO 6.56E+07 O.OOE+OO PR-143 4.38E+02 1.64E+02 2.17E+01 O.OOE+OO 6.09E+01 O.OOE+OO 2.31E+05 O.OOE+OO PR-144 1.66E-53 6.44E-54 8.38E-55 O.OOE+OO 2.33E-54 O.OOE+OO 2.99E-49 O.OOE+OO ND-147 2.58E+02 2.65E+02 1.63E+01 O.OOE+OO 1.02E+02 O.OOE+OO 1.68E+05 O.OOE+OO PM-147 8.24E+03 6.94E+02 3.38E+02 O.OOE+OO 1.04E+03 O.OOE+OO 1.97E+05 O.OOE+OO PM-148M 1.70E+03 4.31E+02 3.38E+02 O.OOE+OO 4.95E+02 O.OOE+OO 5.61E+05 O.OOE+OO PM-148 1.63E+02 2.35E+01 1.18E+01 O.OOE+OO 2.81E+01 O.OOE+OO 2.51E+05 O.OOE+OO PM-149 1.21E+01 1.59E+OO 6.92E-01 O.OOE+OO 1.93E+OO O.OOE+OO 4.26E+04 O.OOE+OO PM-151 1.79E+OO 2.61E-01 1.32E-01 O.OOE+OO 3.11 E-01 O.OOE+OO 1.21 E+04 O.OOE+OO SM-151 6.43E+03 1.48E+03 3.20E+02 O.OOE+OO 1.01E+03 O.OOE+OO 1.24E+05 O.OOE+OO SM-153 5.55E+OO 4.30E+OO 3.30E-01 O.OOE+OO 8.99E-01 O.OOE+OO 2.24E+04 O.OOE+OO EU-152 1.48E+04 3.94E+03 3.33E+03 O.OOE+OO 1.11E+04 O.OOE+OO 3.50E+05 O.OOE+OO EU-154 5.79E+04 8.04E+03 4.82E+03 O.OOE+OO 2.18E+04 O.OOE+OO 1.00E+06 O.OOE+OO EU-155 1.18E+04 1.36E+03 7.01E+02 O.OOE+OO 3.04E+03 O.OOE+OO 1.82E+06 O.OOE+OO EU-156 6.61E+02 4.09E+02 6.49E+01 O.OOE+OO 1.89E+02 O.OOE+OO 3.86E+05 O.OOE+OO TB-160 3.48E+03 O.OOE+OO 4.35E+02 O.OOE+OO 9.89E+02 O.OOE+OO 4.63E+05 O.OOE+OO H0-166M 2.78E+04 5.98E+03 4.73E+03 O.OOE+OO 7.93E+03 O.OOE+OO 5.91E+05 O.OOE+OO W-181 1.42E+05 4.37E+04 4.88E+03 O.OOE+OO O.OQE+OO O.OOE+OO 6.13E+05 O.OOE+OO W-185 4.93E+06 1.54E+06 1.76E+05 O.OOE+OO O.OOE+OO O.OOE+OO 2.21E+07 O.OOE+OO W-187 1.78E+04 1.24E+04 4.27E+03 O.OOE+OO O.OOE+OO O.OOE+OO 7.27E+05 O.OOE+OO U-232 5.37E+10 O.OOE+OO 4.79E+09 O.OOE+OO 5.26E+09 O.OOE+OO 1.56E+08 O.OOE+OO U-233 1.13E+10 O.OOE+OO 8.60E+08 O.OOE+OO 2.40E+09 O.OOE+OO 1.45E+08 O.OOE+OO U-234 1.08E+10 O.OOE+OO 8.44E+08 O.OOE+OO 2.36E+09 O.OOE+OO 1.42E+08 O.OOE+OO U-235 1.04E+10 O.OOE+OO 7.91E+08 O.OOE+OO 2.21E+09 O.OOE+OO 1.80E+08 O.OOE+OO U-236 1.04E+10 O.OOE+OO 8.09E+08 O.OOE+OO 2.24E+09 O.OOE+OO 1.33E+08 O.OOE+OO U-237 1.58E+05 O.OOE+OO 4.21E+04 O.OOE+OO 3.92E+05 O.OOE+OO 6.72E+06 . O.OOE+OO U-238 9.93E+09 O.OOE+OO 7.40E+08 O.OOE+OO 2.06E+09 O.OOE+OO 1.27E+08 O.OOE+OO NP-237 5.33E+07 3.53E+06 2.33E+06 O.OOE+OO 1.41E+07 O.OOE+OO 1.83E+06 O.OOE+OO NP-238 1.02E+02 2.56E+OO 1.58E+OO O.OOE+OO 5.59E+OO O.OOE+OO 3.42E+04 O.OOE+OO NP-239 1.07E+01 9.54E-01 5.39E-01 O.OOE+OO 1.90E+OO O.OOE+OO 2.76E+04 O.OOE+OO PU-238 1.14E+07 1.33E+06 3.02E+05 O.OOE+OO 1.07E+06 O.OOE+OO 6.72E+05 O.OOE+OO PU-239 1.23E+07 1.38E+06 3.15E+05 O.OOE+OO 1.14E+06 O.OOE+OO 6.14E+05 O.OOE+OO PU-240 1.23E+07 1.38E+06 3.15E+05 O.OOE+OO 1.14E+06 O.OOE+QO 6.26E+05 O.OOE+OO PU-241 3.75E+05 1.55E+04 7.77E+03 O.OOE+OO 2.79E+04 O.OOE+OO 1.28E+04 O,OOE+OO Rev.29 Page 270 of 329 12/2016
CY-LG-170-301 TABLE 112-21 R1 DOSE FACTORS AGE: INFANT PATHWAY: COW MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 1.14E+07 1.32E+06 3.03E+05 O.OOE+OO 1.09E+06 O.OOE+OO 6.02E+05 O.OOE+OO PU-244 1.32E+07 1.52E+06 3.48E+05 O.OOE+OO 1.25E+06 O.OOE+OO 8.98E+05 O.OOE+OO AM-241 3.24E+07 2.82E+07 2.42E+06 O.OOE+OO 1.45E+07 O.OOE+OO 1.71E+06 O.OOE+OO AM-242M 3.35E+07 2.71E+07 2.51E+06 O.OOE+OO 1.47E+07 O.OOE+OO 2.15E+06 O.OOE+OO AM-243 3.20E+07 2.73E+07 2.36E+06 O.OOE+OO 1.41 E+07 O.OOE+OO 2.01E+06 O.OOE+OO CM-242 2.37E+06 2.20E+06 1.58E+05 O.OOE+OO 4.54E+05 O.OOE+OO 1.43E+06 O.OOE+OO CM-243 3.10E+07 2.54E+07 1.99E+06 O.OOE+OO 7.24E+06 O.OOE+OO 1.79E+06 O.OOE+OO CM-244 2.60E+07 2.14E+07 1.68E+06 O.OOE+OO 5.98E+06 O.OOE+OO 1.73E+06 O.OOE+OO CM-245 3.98E+07 3.22E+07 2.51E+06 O.OOE+OO 9.60E+06 O.OOE+OO 1.62E+06 O.OOE+OO CM-246 3.93E+07 3.22E+07 2.51E+06 O.OOE+OO 9.58E+06 O.OOE+OO 1.59E+06 O.OOE+OO CM-247 3.84E+07 3.18E+07 2.47E+06 O.OOE+OO 9.42E+06 O.OOE+OO 2.10E+06 O.OOE+OO CM-248 3.18E+08 2.62E+08 2.04E+07 O.OOE+OO 7.78E+07 O.OOE+OO 3.38E+07 O.OOE+OO CF-252 2.59E+07 O.OOE+OO 6.27E+05 O.OOE+OO O.OOE+OO O.OOE+OO 6.35E+06 O.OOE+OO Rev.29 Page 271 of 329 12/2016
CY-LG-170-301 TABLE 112-22 R1 DOSE FACTORS AGE: ADULT PATHWAY: GOAT MILK m2 -mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 8.88E+02 8.88E+02 8.88E+02 8.88E+02 8.88E+02 8.88E+02 O.OOE+OO C-14 3.63E+05 7.26E+04 7.26E+04 7.26E+04 7.26E+04 7.26E+04 7.26E+04 O.OOE+OO NA-22 3.33E+08 3.33E+08 3.33E+08 3.33E+08 3.33E+08 3.33E+08 3.33E+08 O.OOE+OO NA-24 8.56E+04 8.56E+04 8.56E+04 8.56E+04 8.56E+04 8.56E+04 8.56E+04 O.OOE+OO P-32 6.06E+09 3.77E+08 2.34E+08 O.OOE+OO O.OOE+OO O.OOE+OO 6.82E+08 O.OOE+OO CA-41 4.356E+10 O.OOE+OO 4.71E+09 O.OOE+OO O.OOE+OO O.OOE+OO 4.33E+07 O.OOE+OO SC-46 8.83E+OO 1.72E+01 4.98E+OO O.OOE+OO 1.60E+01 O.OOE+OO 8.35E+04 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.09E+03 6.53E+02 2.41E+02 1.45E+03 2.75E+05 O.OOE+OO MN-54 O.OOE+OO 5.00E+05 9.54E+04 O.OOE+OO 1.49E+05 O.OOE+OO 1.53E+06 O.OOE+OO FE-55 1.714E+05 1.184E+05 2.761E+04 O.OOOE+OO O.OOOE+OO 6.606E+04 6.793E+04 O.OOOE+OO MN-56 O.OOE+OO 1.46E-04 2.58E-05 O.OOE+OO 1.85E-04 O.OOE+OO 4.65E-03 O.OOE+OO C0-57 O.OOE+OO 7.51E+04 1.25E+05 O.OOE+OO O.OOE+OO O.OOE+OO 1.91E+06 O.OOE+OO C0-58 O.OOE+OO 2.23E+05 5.01E+05 O.OOE+OO O.OOE+OO O.OOE+OO 4.53E+06 O.OOE+OO FE-59 1.366E+05 3.209E+05 1.230E+05 O.OOOE+OO O.OOOE+OO 8.967E+04 1.070E+06 O.OOOE+OO C0-60 O.OOE+OO 1.05E+06 2.31 E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.97E+07 O.OOE+OO Nl-59 3.28E+07 1.12E+07 5.47E+06 O.OOE+OO O.OOE+OO O.OOE+OO 2.32E+06 O.OOE+OO Nl-63 4.36E+08 3.02E+07 1.46E+07 O.OOE+OO O.OOE+OO O.OOE+OO 6.30E+06 O.OOE+OO CU-64 O.OOE+OO 7.77E+02 3.65E+02 O.OOE+OO 1.96E+03 O.OOE+OO 6.62E+04 O.OOE+OO Nl-65 1.30E-02 1.69E-03 7.70E-04 O.OOE+OO O.OOE+OO O.OOE+OO 4.28E-02 O.OOE+OO ZN-65 7.97E+07 2.54E+08 1.15E+08 O.OOE+OO 1.70E+08 O.OOE+OO 1.60E+08 O.OOE+OO ZN-69m 6.28E+03 1.51E+04 1.38E+03 O.OOE+OO 9.13E+03 O.OOE+OO 9.20E+05 O.OOE+OO ZN-69 7.34E-14 1.40E-13 9.76E-15 O.OOE+OO 9.12E-14 O.OOE+OO 2.11E-14 O.OOE+OO SE-79 O.OOE+OO 5.93E+07 9.90E+06 O.OOE+OO 1.03E+08 O.OOE+OO 1.21E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.13E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.30E+06 O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.41 E-03 O.OOE+OO O.OOE+OO O.OOE+OO 4.91 E-03 O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 5.65E-25 O.OOE+OO O.OOE+OO O.OOE+OO 4.43E-30 O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 9.38E+07 4.37E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.85E+07 O.OOE+OO RB-87 O.OOE+OO 1.85E+08 6.43E+07 O.OOE+OO O.OOE+OO O.OOE+OO 8.66E+06 O.OOE+OO RB-88 O.OOE+OO 7.51E-47 3.98E-47 O.OOE+OO O.OOE+OO O.OOE+OO 1.04E-57 O.OOE+OO RB-89 O.OOE+OO 1.52E-54 1.07E-54 O.OOE+OO O.OOE+OO O.OOE+OO 8.83E-68 O.OOE+OO SR-89 1.11 E+09 O.OOE+OO 3.19E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.78E+08 O.OOE+OO SR-90 6.08E+10 O.OOE+OO 1.22E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.53E+09 O.OOE+OO Y-90 2.49E+OO O.OOE+OO 6.67E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.64E+04 O.OOE+OO SR-91 1.78E+04 O.OOE+OO 7.18E+02 O.OOE+OO O.OOE+OO O.OOE+OO 8.46E+04 O.OOE+OO Y-91m 2.1 OE-21 O.OOE+OO 8.13E-23 O.OOE+OO O.OOE+OO O.OOE+OO 6.17E-21 O.OOE+OO Y-91 3.89E+02 O.OOE+OO 1.04E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.14E+05 O.OOE+OO SR-92 3.00E-01 O.OOE+OO 1.30E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.94E+OO O.OOE+OO Y-92 1.96E-06 O.OOE+OO 5.72E-08 O.OOE+OO O.OOE+OO O.OOE+OO 3.43E-02 O.OOE+OO Y-93 7.84E-03 O.OOE+OO 2.16E-04 O.OOE+OO O.OOE+OO O.OOE+OO 2.49E+02 O.OOE+OO NB-93m 3.17E+04 1.03E+04 2.55E+03 O.OOE+OO 1.19E+04 O.OOE+OO 4.77E+06 O.OOE+OO NB-95 3.31E+03 1.84E+03 9.90E+02 O.OOE+OO 1.82E+03 O.OOE+OO 1.12E+07 O.OOE+OO Rev.29 Page 272 of 329 12/2016
CY-LG-170-301 TABLE 112-22 R1 DOSE FACTORS AGE: ADULT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 1.15E-13 2.92E-14 1.07E-14 O.OOE+OO 3.41E-14 O.OOE+OO 1.0BE-10 O.OOE+OO ZR-93 1.05E+02 5.86E+OO 2.73E+OO O.OOE+OO 2.22E+01 O.OOE+OO 6.09E+03 O.OOE+OO ZR-95 4.37E+01 1.40E+01 9.48E+OO O.OOE+OO 2.20E+01 O.OOE+OO 4.44E+04 O.OOE+OO ZR-97 1.52E-02 3.07E-03 1.40E-03 O.OOE+OO 4.63E-03 O.OOE+OO 9.50E+02 O.OOE+OO M0-93 O.OOE+OO 2.82E+07 7.63E+05 O.OOE+OO 8.00E+06 O.OOE+OO 4.58E+06 O.OOE+OO M0-99 O.OOE+OO 8.69E+05 1.65E+05 O.OOE+OO 1.97E+06 O.OOE+OO 2.02E+06 O.OOE+OO TC-99 1.57E+06 2.33E+06 6.29E+05 O.OOE+OO 2.93E+07 1.98E+05 7.61E+07 O.OOE+OO TC-99m 1.17E-01 3.29E-01 4.20E+OO O.OOE+OO 5.00E+OO 1.61E-01 1.95E+02 O.OOE+OO TC-101 9.10E-62 1.31E-61 1.29E-60 O.OOE+OO 2.36E-60 6.70E-62 3.94E-73 O.OOE+OO RU-103 4.19E+01 O.OOE+OO 1.81 E+01 O.OOE+OO 1.60E+02 O.OOE+OO 4.90E+03 O.OOE+OO RU-105 3.01 E-05 O.OOE+OO 1.19E-05 O.OOE+OO 3.89E-04 O.OOE+OO 1.84E-02 O.OOE+OO RU-106 1.23E+03 O.OOE+OO 1.55E+02 O.OOE+OO 2.37E+03 O.OOE+OO 7.95E+04 O.OOE+OO RH-105 1.22E+04 8.91E+03 5.87E+03 O.OOE+OO 3.79E+04 O.OOE+OO 1.42E+06 O.OOE+OO PD-107 O.OOE+OO 7.36E+05 4.71E+04 O.OOE+OO 6.61E+06 O.OOE+OO 4.56E+06 O.OOE+OO PD-109 O.OOE+OO 1.55E+03 3.50E+02 O.OOE+OO 8.87E+03 O.OOE+OO 1.72E+05 O.OOE+OO AG-110m 3.39E+06 3.14E+06 1.86E+06 O.OOE+OO 6.17E+06 O.OOE+OO 1.28E+09 O.OOE+OO AG-111 2.27E+05 9.51E+04 4.74E+04 O.OOE+OO 3.07E+05 O.OOE+OO 1.75E+08 O.OOE+OO CD-113m O.OOE+OO 1.89E+05 6.08E+03 O.OOE+OO 2.09E+05 O.OOE+OO 1.53E+06 O.OOE+OO CD-115m O.OOE+OO 5.34E+04 1.70E+03 O.OOE+OO 4.24E+04 O.OOE+OO 2.25E+06 O.OOE+OO SN-123 2.87E+07 4.75E+05 6.99E+05 4.04E+05 O.OOE+OO O.OOE+OO 5.83E+07 O.OOE+OO SN-125 2.00E+06 4.03E+04 9.06E+04 3.33E+04 O.OOE+OO O.OOE+OO 2.49E+07 O.OOE+OO SN-126 1.06E+08 2.09E+06 3.01E+06 6.16E+05 O.OOE+OO O.OOE+OO 3.04E+07 O.OOE+OO SB-124 1.17E+06 2.22E+04 4.66E+05 2.85E+03 O.OOE+OO 9.14E+05 3.33E+07 O.OOE+OO SB-125 1.29E+06 1.44E+04 3.07E+05 1.31E+03 O.OOE+OO 9.93E+05 1.42E+07 O.OOE+OO SB-126 1.98E+05 4.02E+03 7.13E+04 1.21E+03 O.OOE+OO 1.21 E+05 1.62E+07 O.OOE+OO SB-127 1.58E+04 3.46E+02 6.06E+03 1.90E+02 O.OOE+OO 9.36E+03 3.61E+06 O.OOE+OO TE-125m 7.37E+05 2.67E+05 9.87E+04 2.22E+05 3.00E+06 O.OOE+OO 2.94E+06 O.OOE+OO TE-127m 2.37E+06 8.49E+05 2.89E+05 6.07E+05 9.64E+06 O.OOE+OO 7.96E+06 O.OOE+OO TE-127 2.29E+01 8.23E+OO 4.96E+OO 1.70E+01 9.33E+01 O.OOE+OO 1.81E+03 O.OOE+OO TE-129m 2.39E+06 8.92E+05 3.79E+05 8.22E+05 9.98E+06 O.OOE+OO 1.20E+07 O.OOE+OO TE-129 9.91 E-12 3.72E-12 2.41E-12 7.61E-12 4.17E-11 O.OOE+OO 7.48E-12 O.OOE+OO TE-133m 7.39E-15 4.32E-15 4.16E-15 6.25E-15 4.27E-14 O.OOE+OO 1.48E-15 O.OOE+OO
- TE-134 3.13E-20 2.04E-20 1.25E-20 2.73E-20 1.98E-19 O.OOE+OO 3.46E-23 O.OOE+OO 1-129 4.91E+08 4.22E+08 1.38E+09 1.09E+12 9.08E+08 O.OOE+OO 6.67E+07 O.OOE+OO 1-130 1.47E+05 4.35E+05 1.72E+05 3.69E+07 6.79E+05 O.OOE+OO 3.74E+05 O.OOE+OO 1-131 1.04E+08 1.49E+08 8.52E+07 4.87E+10 2.55E+08 O.OOE+OO 3.92E+07 O.OOE+OO TE-131m 1.27E+04 6.20E+03 5.16E+03 9.82E+03 6.28E+04 O.OOE+OO 6.15E+05 O.OOE+OO TE-131 1.26E-34 5.28E-35 3.99E-35 1.04E-34 5.54E-34 O.OOE+OO' 1.79E-35 O.OOE+OO 1-132 5.76E-02 1.54E-01 5.40E-02 5.40E+OO 2.46E-01 O.OOE+OO 2.90E-02 O.OOE+OO TE-132 8.43E+04 5.45E+04 5.12E+04 6.02E+04 5.25E+05 O.OOE+OO 2.58E+06 O.OOE+OO 1-133 1.36E+06 2.36E+06 7.20E+05 3.47E+08 4.12E+06 O.OOE+OO 2.12E+06 O.OOE+OO CS-134m 1.52E-01 3.20E-01 1.64E-01 O.OOE+OO 1.74E-01 2.74E-02 1.13E-01 O.OOE+OO Rev.29 Page 273 of 329 12/2016
CY-LG-170-301 TABLE 112-22 R1 DOSE FACTORS AGE: ADULT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN CS-134 8.83E+09 2.10E+10 1.72E+10 O.OOE+OO 6.80E+09 2.26E+09 3.68E+08 O.OOE+OO 1-134 7.08E-13 1.92E-12 6.88E-13 3.33E-11 3.06E-12 O.OOE+OO 1.68E-15 O.OOE+OO 1-135 4.51E+03 1.18E+04 4.35E+03 7.78E+05 1.89E+04 O.OOE+OO 1.33E+04 O.OOE+OO CS-135 2.93E+09 2.71E+09 1.20E+09 O.OOE+OO 1.02E+09 3.07E+08 6.33E+07 O.OOE+OO CS-136 2.33E+08 9.19E+08 6.61E+08 O.OOE+OO 5.11 E+08 7.01E+07 1.04E+08 O.OOE+OO CS-137 1.19E+10 1.63E+10 1.07E+10 O.OOE+OO 5.54E+09 1.84E+09 3.16E+08 O.OOE+OO CS-138 7.93E-24 1.57E-23 7.76E-24 O.OOE+OO 1.15E-23 1.14E-24 6.68E-29 O.OOE+OO CS-139 5.95E-90 8.86E-90 3.23E-90 O.OOE+OO 7.10E-90 6.46E-91 1.92E-112 O.OOE+OO BA-139 1.55E-09 1.11E-12 4.54E-11 O.OOE+OO 1.03E-12 6.27E-13 2.75E-09 O.OOE+OO BA-140 9.49E+05 1.19E+03 6.22E+04 O.OOE+OO 4.06E+02 6.83E+02 1.96E+06 O.OOE+OO LA-140 1.58E-01 7.98E-02 2.11E-02 O.OOE+OO O.OOE+OO O.OOE+OO 5.86E+03 O.OOE+OO BA-141 1.44E-47 1.09E-50 4.85E-49 O.OOE+OO 1.01E-50 6.16E-51 6.77E-57 O.OOE+OO LA-141 1.07E-06 3.31E-07 5.42E-08 O.OOE+OO O.OOE+OO O.OOE+OO 3.95E-02 O.OOE+OO CE-141 1.91E+02 1.29E+02 1.47E+01 O.OOE+OO 6.00E+01 O.OOE+OO 4.94E+05 O.OOE+OO BA-142 9.33E-82 9.59E-85 5.87E-83 O.OOE+OO 8.10E-85 5.43E-85 1.31 E-99 O.OOE+OO LA-142 6.52E-13 2.97E-13 7.39E-14 O.OOE+OO O.OOE+OO O.OOE+OO 2.17E-09 O.OOE+OO CE-143 1.46E+OO 1.08E+03 1.19E-01 O.OOE+OO 4.75E-01 O.OOE+OO 4.03E+04 O.OOE+OO PR-143 5.59E+OO 2.24E+OO 2.77E-01 O.OOE+OO 1.29E+OO O.OOE+OO 2.45E+04 O.OOE+OO CE-144 2.11E+04 8.82E+03 1.13E+03 O.OOE+OO 5.23E+03 O.OOE+OO 7.13E+06 O.OOE+OO PR-144 2.06E-55 8.55E-56 1.05E-56 O.OOE+OO 4.82E-56 O.OOE+OO 2.96E-62 O.OOE+OO ND-147 3.31E+OO 3.83E+OO 2.29E-01 O.OOE+OO 2.24E+OO O.OOE+OO 1.84E+04 O.OOE+OO PM-147 1.80E+02 1.70E+01 6.87E+OO O.OOE+OO 3.21E+01 O.OOE+OO 2.14E+04 O.OOE+OO PM-148m 3.57E+01 9.24E+OO 7.07E+OO O.OOE+OO 1.39E+01 O.OOE+OO 7.84E+04 O.OOE+OO PM-148 2.08E+OO 3.46E-01 1.74E-01 O.OOE+OO 6.53E-01 O.OOE+OO 2.72E+04 O.OOE+OO PM-149 1.50E-01 2.12E-02 8.67E-03 O.OOE+OO 4.01 E-02 O.OOE+OO 3.98E+03 O.OOE+OO PM-151 2.28E-02 3.83E-03 1.93E-03 O.OOE+OO 6.84E-03 O.OOE+OO 1.05E+03 O.OOE+OO SM-151 1.73E+02 2.98E+01 7.13E+OO O.OOE+OO 3.33E+01 O.OOE+OO 1.31E+04 O.OOE+OO SM-153 6.95E-02 5.80E-02 4.23E-03 O.OOE+OO 1.87E-02 O.OOE+OO 2.07E+03 O.OOE+OO EU-152 4.84E+02 1.10E+02 9.68E+01 O.OOE+OO 6.83E+02 O.OOE+OO 6.36E+04 O.OOE+OO EU-154 1.52E+03 1.87E+02 1.33E+02 O.OOE+OO 8.94E+02 O.OOE+OO 1.35E+05 O.OOE+OO EU-155 2.10E+02 2.98E+01 1.92E+01 O.OOE+OO 1.38E+02 O.OOE+OO 2.35E+04 O.OOE+OO EU-156 8.95E+OO 6.92E+OO 1.12E+OO O.OOE+OO 4.62E+OO O.OOE+OO 4.74E+04 O.OOE+OO TB-160 7.11 E+01 O.OOE+OO 8.86E+OO O.OOE+OO 2.93E+01 O.OOE+OO 6.55E+04 O.OOE+OO H0-166m 6.76E+02 2.11E+02 1.60E+02 O.OOE+OO 3.16E+02 O.OOE+OO 6.41E+04 O.OOE+OO W-181 1.79E+03 5.84E+02 6.26E+01 O.OOE+OO O.OOE+OO O.OOE+OO 6.66E+04 O.OOE+OO W-185 6.22E+04 2.07E+04 2.18E+03 O.OOE+OO O.OOE+OO O.OOE+OO 2.40E+06 O.OOE+OO W-187 2.29E+02 1.91 E+02 6.68E+01 O.OOE+OO O.OOE+OO O.OOE+OO 6.26E+04 O.OOE+OO NP-239 1.29E-01 1.27E-02 6.99E-03 O.OOE+OO 3.95E-02 O.OOE+OO 2.60E+03 O.OOE+OO U-232 1.03E+09 O.OOE+OO 7.38E+07 O.OOE+OO 1.12E+08 O.OOE+OO 1.70E+07 O.OOE+OO U-233 2.18E+08 O.OOE+OO 1.32E+07 O.OOE+OO 5.08E+07 O.OOE+OO 1.57E+07 O.OOE+OO U-234 2.09E+08 O.OOE+OO 1.29E+07 O.OOE+OO 4.98E+07 , O.OOE+OO 1.54E+07 O.OOE+OO U-235 2.01E+08 O.OOE+OO 1.22E+07 O.OOE+OO 4.68E+07 O.OOE+OO 1.96E+07 O.OOE+OO Rev.29 Page 274 of 329 12/2016
CY-LG-170-301 TABLE 112-22 R1 DOSE FACTORS AGE: ADULT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN U-236 2.01E+08 O.OOE+OO 1.24E+07 O.OOE+OO 4.78E+07 O.OOE+OO 1.44E+07 O.OOE+OO U-237 1.98E+03 O.OOE+OO 5.28E+02 O.OOE+OO 8.15E+03 O.OOE+OO 6.97E+05 O.OOE+OO U-238 1.92E+08 O.OOE+OO 1.14E+07 O.OOE+OO 4.38E+07 O.OOE+OO 1.38E+07 O.OOE+OO NP-237 3.16E+06 2.24E+05 1.39E+05 O.OOE+OO 1.03E+06 O.OOE+OO 1.99E+05 O.OOE+OO NP-238 1.27E+OO 3.41E-02 1.97E-02 O.OOE+OO 1.16E-01 O.OOE+OO 3.17E+03 O.OOE+OO PU-238 6.30E+05 7.98E+04 1.71E+04 O.OOE+OO 7.32E+04 O.OOE+OO 7.30E+04 O.OOE+OO PU-239 7.26E+05 8.73E+04 1.91E+04 O.OOE+OO 8.13E+04 O.OOE+OO 6.67E+04 O.OOE+OO PU-240 7.25E+05 8.72E+04 1.91 E+04 O.OOE+OO 8.12E+04 O.OOE+OO 6.79E+04 O.OOE+OO PU-241 1.56E+04 7.40E+02 3.30E+02 O.OOE+OO 1.52E+03 O.OOE+OO 1.39E+03 O.OOE+OO PU-242 6.73E+05 8.41E+04 1.84E+04 O.OOE+OO 7.82E+04 O.OOE+OO 6.54E+04 O.OOE+OO PU-244 7.85E+05 9.63E+04 2.11 E+04 O.OOE+OO 8.97E+04 O.OOE+OO 9.75E+04 O.OOE+OO AM-241 1.89E+06 1.77E+06 1.35E+05 O.OOE+OO 1.02E+06 O.OOE+OO 1.86E+05 O.OOE+OO AM-242m 1.90E+06 1.66E+06 1.36E+05 O.OOE+OO 1.01 E+06 O.OOE+OO 2.34E+05 O.OOE+OO AM-243 1.89E+06 1.73E+06 1.33E+05 O.OOE+OO 9.99E+05 O.OOE+OO 2.18E+05 O.OOE+OO CM-242 4.03E+04 4.28E+04 2.68E+03 O.OOE+OO 1.22E+04 O.OOE+OO 1.55E+05 O.OOE+OO CM-243 1.49E+06 1.37E+06 9.35E+04 O.OOE+OO 4.36E+05 O.OOE+OO 1.95E+05 O.OOE+OO . CM-244 1.13E+06 1.06E+06 7.14E+04 O.OOE+OO 3.33E+05 O.OOE+OO 1.88E+05 O.OOE+OO CM-245 2.35E+06 2.05E+06 1.44E+05 O.OOE+OO 6.74E+05 O.OOE+OO 1.76E+05 O.OOE+OO CM-246 2.33E+06 2.04E+06 1.44E+05 O.OOE+OO 6.71E+05 O.OOE+OO 1.73E+05 O.OOE+OO CM-247 2.27E+06 2.01E+06 1.42E+05 O.OOE+OO 6.61E+05 O.OOE+OO 2.28E+05 O.OOE+OO CM-248 1.89E+07 1.66E+07 1.17E+06 O.OOE+OO 5.46E+06 O.OOE+OO 3.68E+06 O.OOE+OO CF-252 6.25E+05 O.OOE+OO 1.51E+04 O.OOE+OO O.OOE+OO O.OOE+OO 6.90E+05 O.OOE+OO Rev.29 Page 275 of 329 12/2016
. CY-LG-170-301 TABLE 112-23 R1 DOSE FACTORS AGE: TEEN PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN H-3 O.OOE+OO 1.16E+03 1.16E+03 1.16E+03 1.16E+.03 1.16E+03 1.16E+03 O.OOE+OO C-14 6.70E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 O.OOE+OO NA-22 5.78E+08 5.78E+08 5.78E+08 5.78E+08 5.78E+08 5.78E+08 5.78E+08 O.OOE+OO NA-24 1.49E+05 1.49E+05 1.49E+05 1.49E+05 1.49E+05 1.49E+05 1.49E+05 O.OOE+OO P-32 1.12E+10 6.93E+08 4.34E+08 O.OOE+OO O.OOE+OO O.OOE+OO 9.41E+08 O.OOE+OO CA-41 5.98E+10 O.OOE+OO 6.47E+09 O.OOE+OO O.OOE+OO O.OOE+OO 5.92E+07 O.OOE+OO SC-46 1.50E+01 2.92E+01 8.65E+OO O.OOE+OO 2.79E+01 O.OOE+OO 9.93E+04 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 1.91 E+03 1.06E+03 4.18E+02 2.72E+03 3.21E+05 O.OOE+OO MN-54 O.OOE+OO 8.33E+05 1.65E+05 O.OOE+OO 2.49E+05 O.OOE+OO 1.71E+06 O.OOE+OO FE-55 3.039E+05 2.155E+05 5.026E+04 O.OOOE+OO O.OOOE+OO 1.367E+05 9.327E+04 O.OOOE+OO MN-56 O.OOE+OO 2.58E-04 4.59E-05 O.OOE+OO 3.27E-04 O.OOE+OO 1.70E-02 0.00E+OO C0-57 O.OOE+OO 1.32E+05 2.21E+05 O.OOE+OO O.OOE+OO O.OOE+OO 2.46E+06 O.OOE+OO C0-58 O.OOE+OO 3.76E+05 8.67E+05 O.OOE+OO O.OOE+OO O.OOE+OO 5.19E+06 O.OOE+OO FE-59 2.383E+05 5.562E+05 2.148E+05 O.OOOE+OO O.OOOE+OO 1.754E+05 1.315E+06 O.OOOE+OO C0-60 O.OOE+OO 1.78E+06 4.00E+06 O.OOE+OO O.OOE+OO O.OOE+OO 2.31E+07 O.OOE+OO Nl-59 5.72E+07 2.02E+07 9.70E+06 O.OOE+OO O.OOE+OO O.OOE+OO 3.17E+06 O.OOE+OO Nl-63 7.66E+08 5.41E+07 2.60E+07 O.OOE+OO O.OOE+OO O.OOE+OO 8.61E+06 O.OOE+OO CU-64 O.OOE+OO 1.38E+03 6.51E+02 O.OOE+OO 3.50E+03 O.OOE+OO 1.07E+05 O.OOE+OO Nl-65 2.38E-02 3.04E-03 1.38E-03 O.OOE+OO O.OOE+OO O.OOE+OO 1.65E-01 O.OOE+OO ZN-65 1.22E+08 4.25E+08 1.98E+08 O.OOE+OO 2.72E+08 O.OOE+OO 1.80E+08 O.OOE+OO ZN-69m 1.14E+04 2.70E+04 ' 2.47E+03 O.OOE+OO 1.64E+04 O.OOE+OO 1.48E+06 O.OOE+OO ZN-69 1.35E-13 2.57E-13 1.80E-14 O.OOE+OO 1.68E-13 O.OOE+OO 4.74E-13 O.OOE+OO SE-79 O.OOE+OO 1.08E+08 1.82E+07 O.OOE+OO 1.89E+08 O.OOE+OO 1.66E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 1.97E+06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 6.28E-03 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.01E-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.71E+08 8.03E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.53E+07 O.OOE+OO RB-87 O.OOE+OO 3.39E+08 1.18E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.18E+07 O.OOE+OO RB-88 O.OOE+OO 1.36E-46 7.27E-47 O.OOE+OO O.OOE+OO O.OOE+OO 1.17E-53 O.OOE+OO RB-89 O.OOE+OO 2.69E-54 1.90E-54 O.OOE+OO O.OOE+OO O.OOE+OO 4.12E-63 O.OOE+OO SR-89 2.05E+09 O.OOE+OO 5.86E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.44E+08 O.OOE+OO SR-90 9.19E+10 O.OOE+OO 1.84E+09 O.OOE+OO O.OOE+OO O.OOE+OO 2.10E+09 O.OOE+OO Y-90 4.57E+OO O.OOE+OO 1.23E-01 O.OOE+OO O.OOE+OO O.OOE+OO 3.77E+04 O.OOE+OO SR-91 3.26E+04 O.OOE+OO 1.30E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.48E+05 O.OOE+OO Y-91m 3.84E-21 O.OOE+OO 1.47E-22 O.OOE+OO O.OOE+OO O.OOE+OO 1.82E-19 O.OOE+OO Y-91 7.16E+02 O.OOE+OO 1.92E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.93E+05 O.OOE+OO SR-92 5.49E-01 O.OOE+OO 2.34E-02 O.OOE+OO O.OOE+OO O.OOE+OO 1.40E+01 O.OOE+OO Y-92 3.62E-06 O.OOE+OO 1.05E-07 O.OOE+OO O.OOE+OO O.OOE+OO 9.93E-02 O.OOE+OO Y-93 1.45E-02 O.OOE+OO 3.96E-04 O.OOE+OO O.OOE+OO O.OOE+OO 4.42E+02 O.OOE+OO NB-93m 5.51E+04 1.81E+04 4.54E+03 O.OOE+OO 2.12E+04 O.OOE+OO 6.52E+06 O.OOE+OO NB-95 5.65E+03 3.13E+03 1.72E+03 O.OOE+OO 3.04E+03 O.OOE+OO 1.34E+07 O.OOE+OO NB-97 2.10E-13 5.22E-14 1.91E-14 O.OOE+OO 6.11 E-14 O.OOE+OO 1.25E-09 O.OOE+OO ZR-93 1.79E+02 8.82E+OO 4.82E+OO O.OOE+OO 3.12E+01 O.OOE+OO 8.34E+03 O.OOE+OO ZR-95 7.64E+01 2.41E+01 1.66E+01 O.OOE+OO 3.54E+01 O.OOE+OO 5.56E+04 O.OOE+OO Rev.29 Page 276 of 329 12/2016
CY-LG-170-301 TABLE 112-23 R1 DOSE FACTORS AGE: TEEN PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN ZR-97 2.77E-02 5.48E-03 2.52E-03 O.OOE+OO 8.30E-03 O.OOE+OO 1.48E+03 O.OOE+OO M0-93 O.OOE+OO 5.14E+07 1.41E+06 O.OOE+OO 1.47E+07 O.OOE+OO 6.25E+06 O.OOE+OO M0-99 O.OOE+OO 1.57E+06 2.99E+05 O.OOE+OO 3.59E+06 O.OOE+OO 2.81E+06 O.OOE+OO TC-99 2.89E+06 4.25E+06 1.16E+06 O.OOE+OO 5.40E+07 4.40E+05 1.04E+08 O.OOE+OO TC-99m 2.02E-01 5.64E-01 7.31E+OO O.OOE+OO 8.40E+OO 3.13E-01 3.70E+02 O.OOE+OO TC-101 1.66E-61 2.37E-61 2.33E-60 O.OOE+OO 4.28E-60 1.44E-61 4.04E-68 O.OOE+OO RU-103 7.46E+01 O.OOE+OO 3.19E+01 O.OOE+OO 2.63E+02. O.OOE+OO 6.23E+03 O.OOE+OO RU-105 5.49E-05 O.OOE+OO 2.13E-05 O.OOE+OO 6.93E-04 O.OOE+OO 4.43E-02 O.OOE+OO RU-106 2.26E+03 O.OOE+OO 2.85E+02 O.OOE+OO 4.35E+03 O.OOE+OO 1.08E+05 O.OOE+OO RH-105 2.25E+04 1.62E+04 1.07E+04 O.OOE+OO 6.90E+04 O.OOE+OO 2.07E+06 O.OOE+OO PD-107 O.OOE+OO 1.34E+06 8.66E+04 O.OOE+OO 1.22E+07 O.OOE+OO 6.24E+06 O.OOE+OO PD-109 O.OOE+OO 2.84E+03 6.46E+02 O.OOE+OO 1.64E+04 O.OOE+OO 2.87E+05 O.OOE+OO AG-110m 5.61E+06 5.31E+06 3.23E+06 O.OOE+OO 1.01 E+07 O.OOE+OO 1.49E+09 O.OOE+OO AG-111 4.19E+05 1.74E+05 8.74E+04 O.OOE+OO 5.66E+05 O.OOE+OO 2.42E+08 O.OOE+OO CD-113m O.OOE+OO 3.47E+05 1.11 E+04 O.OOE+OO 3.84E+05 O.OOE+OO 2.08E+06 O.OOE+OO CD-115m O.OOE+OO 9.74E+04 3.14E+03 O.OOE+OO 7.79E+04 O.OOE+OO 3.08E+06 O.OOE+OO SN-123 5.28E+07 8.67E+05 1.28E+06 6.94E+05 O.OOE+OO O.OOE+OO 7.98E+07 O.OOE+OO SN-125 3.68E+06 7.33E+04 1.66E+05 *5.75E+04 O.OOE+OO O.OOE+OO 3.47E+07 O.OOE+OO SN-126 1.87E+08 3.49E+06 5.33E+06 9.19E+05 O.OOE+OO O.OOE+OO 4.17E+07 O.OOE+OO SB-124 2.09E+06 3.86E+04 8.17E+05 4.75E+03 O.OOE+OO 1.83E+06 4.22E+07 O.OOE+OO SB-125 2.30E+06 2.52E+04 5.39E+05 2.20E+03 O.OOE+OO 2.02E+06 1.79E+07 O.OOE+OO SB-126 3.53E+05 7.21E+03 1.27E+05 1.99E+03 O.OOE+OO 2.53E+05 2.09E+07 O.OOE+OO SB-127 2.87E+04 6.13E+02 1.08E+04 3.22E+02 O.OOE+OO 1.95E+04 4.86E+06 O.OOE+OO TE-125m 1.36E+06 4.90E+05 1.82E+05 3.80E+05 O.OOE+OO O.OOE+OO 4.01E+06 O.OOE+OO TE-127m 4.38E+06 1.55E+06 5.20E+05 1.04E+06 1.77E+07 O.OOE+OO 1.09E+07 O.OOE+OO TE-127 4.25E+01 1.51E+01 9.14E+OO 2.93E+01 1.72E+02 O.OOE+OO 3.28E+03 O.OOE+OO TE-129m 4.37E+06 1.62E+06 6.92E+05 1.41E+06 1.83E+07 O.OOE+OO 1.64E+07 O.OOE+OO TE-129 1.82E-11 6.BOE-12 4.44E-12 1.30E-11 7.66E-11 O.OOE+OO 9.98E-11 O.OOE+OO TE-133m 1.33E-14 7.55E-15 7.35E-15 1.05E-14 7.47E-14 O.OOE+OO 3.05E-14 O.OOE+OO TE-134 5.56E-20 3.57E-20 3.73E-20 4.57E~20 3.41E-19 O.OOE+OO 2.07E-21 O.OOE+OO 1-129 9.04E+08 7.60E+08 1.27E+09 9.25E+11 1.36E+09 O.OOE+OO 8.86E+07 O.OOE+OO 1-130 2.59E+05 7.50E+05 2.99E+05 6.12E+07 1.16E+06 O.OOE+OO 5.76E+05 O.OOE+OO 1-131 1.89E+08 2.64E+08 1.42E+08 7.71E+10 4.55E+08 O.OOE+OO 5.22E+07 O.OOE+OO TE-131m 2.31E+04 1.11 E+04 9.23E+03 1.66E+04 1.15E+05 O.OOE+OO 8.88E+05 O.OOE+OO TE-131 2.31E-34 9.53E-35 7.22E-35 1.78E-34 1.01E-33 O.OOE+OO 1.90E-35 O.OOE+OO 1-132 1.02E-01 2.67E-01 9.60E-02 9.01E+OO 4.21E-01 O.OOE+OO 1.17E-01 O.OOE+OO TE-132 1.51E+05 9.54E+04 8.98E+04 1.01E+05 9.15E+05 O.OOE+OO 3.02E+06 O.OOE+OO 1-133 2.48E+06 4.21 E+06 . 1.28E+06 5.87E+08 7.38E+06 O.OOE+OO 3.18E+06 O.OOE+OO CS-134m 2.71E-01 5.62E-01 2.89E-01 O.OOE+OO 3.13E-01 5.49E-02 3.74E-01 O.OOE+OO CS-134 1.53E+10 3.61E+10 1.67E+10 O.OOE+OO 1.15E+10 4.38E+09 4.49E+08 O.OOE+OO 1-134 1.26E~12 3.33E-12 1.20E-12 5.56E-11 5.26E-12 O.OOE+OO 4.39E-14 O.OOE+OO 1-135 8.01E+03 2.06E+04 7.64E+03 1.33E+06 3.25E+04 O.OOE+OO 2.28E+04 O.OOE+OO CS-135 5.39E+09 4.94E+09 1.16E+09 O.OOE+OO 1.89E+09 6.83E+08 8.65E+07 O.OOE+OO CS-136 3.96E+08 1.56E+09 1.05E+09 O.OOE+OO 8.49E+08 1.34E+08 1.25E+08 O.OOE+OO CS-137 2.16E+10 2.88E+10 1.00E+10 O.OOE+OO 9.79E+09 3.80E+09 4.09E+08 O.OOE+OO Rev.29 Page 277 of 329 12/2016
CY-LG-170-301 TABLE 112-23 Rr DOSE FACTORS AGE: TEEN PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-138 1.44E-23 2.76E-23 1.38E-23 O.OOE+OO 2.04E-23 2.37E-24 1.25E-26 O.OOE+OO CS-139 1.10E-89 1.61E-89 5.92E-90 O.OOE+OO 1.30E-89 1.43E-90 7.50E-105 O.OOE+OO BA-139 2.87E-09 2.02E-12 8.36E-11 O.OOE+OO 1.90E-12 1.39E-12 2.56E-08 O.OOE+OO BA-140 1.71E+06 2.10E+03 1.10E+05 O.OOE+OO 7.12E+02 1.41 E+03 2.64E+06 O.OOE+OO LA-140 2.84E-01 1.40E-01 3.72E-02 O.OOE+OO O.OOE+OO O.OOE+OO 8.03E+03 O.OOE+OO BA-141 2.64E-47 1.97E-50 8.82E-49 O.OOE+OO 1.83E-50 1.35E-50 5.63E-53 O.OOE+OO LA-141 1.97E-06 6.05E-07 9.98E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.07E-01 O.OOE+OO CE-141 3.50E+02 2.34E+02 2.69E+01 O.OOE+OO 1.10E+02 O.OOE+OO 6.69E+05 O.OOE+OO BA-142 1.69E-81 1.69E-84 1.04E-82 O.OOE+OO 1.43E-84 1.12E-84 5.19E-93 O.OOE+OO LA-142 1.18E-12 5.23E-13 1.30E-13 O.OOE+OO O.OOE+OO O.OOE+OO 1.59E-08 O.OOE+OO CE-143 2.68E+OO 1.95E+03 2.18E-01 O.OOE+OO 8.75E-01 O.OOE+OO 5.86E+04 O.OOE+OO PR-143 1.03E+01 4.10E+OO 5.11 E-01 O.OOE+OO 2.38E+OO O.OOE+OO 3.38E+04 O.OOE+OO CE-144 3.88E+04 1.61E+04 2.09E+03 O.OOE+OO 9.59E+03 O.OOE+OO 9.76E+06 O.OOE+OO PR-144 3.80E-55 1.55E-55 1.93E-56 O.OOE+OO 8.92E-56 O.OOE+OO 4.19E-58 O.OOE+OO ND-147 6.38E+OO 6.93E+OO 4.15E-01 O.OOE+OO 4.07E+OO O.OOE+OO 2.50E+04 O.OOE+OO PM-147 3.24E+02 3.08E+01 1.25E+01 O.OOE+OO 5.87E+01 O.OOE+OO 2.93E+04 O.OOE+OO PM-148m 6.21E+01 1.57E+01 1.23E+01 O.OOE+OO 2.38E+01 O.OOE+OO 9.91E+04 O.OOE+OO PM-148 3.82E+OO 6.22E-01 3.13E-01 O.OOE+OO 1.12E+OO O.OOE+OO 3.71E+04 O.OOE+OO PM-149 2.77E-01 3.89E-02 1.59E-02 O.OOE+OO 7.41E-02 O.OOE+OO 5.72E+03 O.OOE+OO PM-151 4.17E-02 6.88E-03 3.48E-03 O.OOE+OO 1.24E-02 O.OOE+OO 1.54E+03 O.OOE+OO SM-151 2.82E+02 5.42E+01 1.27E+01 O.OOE+OO 5.94E+01 O.OOE+OO 1.84E+04 O.OOE+OO SM-153 1.28E-01 1.06E-01 7.78E-03 O.OOE+OO 3.45E-02 O.OOE+OO 2.98E+03 O.OOE+OO EU-152 7.85E+02 1.89E+02 1.67E+02 O.OOE+OO 8.78E+02 O.OOE+OO 6.95E+04 O.OOE+OO EU-154 2.52E+03 3.25E+02 2.29E+02 O.OOE+OO 1.45E+03 O.OOE+OO 1.72E+05 O.OOE+OO EU-155 5.49E+02 5.30E+01 3.28E+01 O.OOE+OO 2.07E+02 O.OOE+OO 3.04E+05 O.OOE+OO EU-156 1.62E+01 1.21E+01 1.98E+OO O.OOE+OO 8.17E+OO O.OOE+OO 6.20E+04 O.OOE+OO TB-160 1.26E+02 O.OOE+OO 1.58E+01 O.OOE+OO 5.00E+01 O.OOE+OO 8.18E+04 O.OOE+OO H0-166m 1.15E+03 3.55E+02 2.57E+02 O.OOE+OO 5.20E+02 O.OOE+OO 8.76E+04 O.OOE+OO W-181 3.31E+03 1.07E+03 1.12E+02 O.OOE+OO O.OOE+OO O.OOE+OO 9.10E+04 O.OOE+OO W-185 1.15E+05 3.79E+04 4.00E+03 O.OOE+OO O.OOE+OO O.OOE+OO 3.27E+06 O.OOE+OO W-187 4.18E+02 3.41E+02 1.19E+02 O.OOE+OO O.OOE+OO O.OOE+OO 9.22E+04 O.OOE+OO NP-239 2.46E-01 2.32E-02 1.29E-02 O.OOE+OO 7.28E-02 O.OOE+OO 3.73E+03 O.OOE+OO U-232 1.90E+09 O.OOE+OO 1.36E+08 O.OOE+OO 2.06E+08 O.OOE+OO 2.32E+07 O.OOE+OO U-233 4.01E+08 O.OOE+OO 2.44E+07 O.OOE+OO 9.37E+07 O.OOE+OO 2.15E+07 O.OOE+OO U-234 3.85E+08 O.OOE+OO 2.39E+07 O.OOE+OO 9.21E+07 O.OOE+OO 2.10E+07 O.OOE+OO U-235 3.68E+08 O.OOE+OO 2.24E+07 O.OOE+OO 8.63E+07 O.OOE+OO 2.68E+07 O.OOE+OO U-236 3.68E+08 O.OOE+OO 2.29E+07 O.OOE+OO 8.82E+07 O.OOE+OO 1.97E+07 O.OOE+OO U-237 3.66E+03 O.OOE+OO 9.73E+02 O.OOE+OO 1.50E+04 O.OOE+OO 9.69E+05 O.OOE+OO U-238 3.52E+08 O.OOE+OO 2.10E+07 O.OOE+OO 8.08E+07 O.OOE+OO 1.88E+07 O.OOE+OO NP-237 4.30E+06 3.09E+05 1.89E+05 O.OOE+OO 1.40E+06 O.OOE+OO 2.72E+05 O.OOE+OO NP-238 2.33E+OO 6.23E-02 3.63E-02 O.OOE+OO 2.14E-01 O.OOE+OO 4.57E+03 O.OOE+OO PU-238 8.65E+05 1.11E+05 2.35E+04 O.OOE+OO 1.01E+05 O.OOE+OO 9.98E+04 O.OOE+OO PU-239 9.89E+05 1.20E+05 2.60E+04 O.OOE+OO 1.11E+05 O.OOE+OO 9.13E+04 O.OOE+OO PU-240 9.88E+05 1.20E+05 2.60E+04 O.OOE+OO 1.11E+05 O.OOE+OO 9.29E+04 O.OOE+OO PU-241 2.24E+04 1.08E+03 4.73E+02 O.OOE+OO 2.19E+03 O.OOE+OO 1.90E+03 O.OOE+OO Rev.29 Page 278 of 329 12/2016
CY-LG-170-301 TABLE 112-23 R1 DOSE FACTORS AGE: TEEN PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 9.17E+05 1.16E+05 2.51E+04 O.OOE+OO 1.07E+05 O.OOE+OO 8.95E+04 O.OOE+OO PU-244 1.07E+06 1.32E+05 2.87E+04 O.OOE+OO 1.22E+05 O.OOE+OO 1.33E+05 O.OOE+OO AM-241 2.58E+06 2.43E+06 1.86E+05 O.OOE+OO 1.39E+06 O.OOE+OO 2.54E+05 O.OOE+OO AM-242m 2.61E+06 2.30E+06 1.87E+05 O.OOE+OO 1.39E+06 O.OOE+OO 3.20E+05 O.OOE+OO AM-243 2.57E+06 2.38E+06 1.82E+05 O.OOE+OO 1.36E+06 O.OOE+OO 2.98E+05 O.OOE+OO CM-242 7.41E+04 7.82E+04 4.92E+03 O.OOE+OO 2.24E+04 O.OOE+OO 2.12E+05 O.OOE+OO CM-243 2.09E+06 1.94E+06 1.32E+05 O.OOE+OO 6.15E+05 O.OOE+OO 2.66E+05 O.OOE+OO CM-244 1.62E+06 1.53E+06 1.02E+05 O.OOE+OO 4.78E+05 O.OOE+OO 2.57E+05 O.OOE+OO CM-245 3.20E+06 2.81E+06 1.97E+05 O.OOE+OO 9.21E+05 O.OOE+OO 2.41E+05 O.OOE+OO CM-246 3.17E+06 2.81E+06 1.97E+05 O.OOE+OO 9.18E+05 O.OOE+OO 2.37E+05 O.OOE+OO CM-247 3.09E+06 2.77E+06 1.94E+05 O.OOE+OO 9.05E+05 O.OOE+OO 3.11 E+05 O.OOE+OO CM-248 2.57E+07 2.28E+07 1.60E+06 O.OOE+OO 7.47E+06 O.OOE+OO 5.01E+06 O.OOE+OO CF-252 1.07E+06 O.OOE+OO 2.59E+04 O.OOE+OO O.OOE+OO O.OOE+OO 9.42E+05 O.OOE+OO Rev.29 Page 279 of 329 12/2016
CY-LG-170-301 TABLE 112-24 R1 DOSE FACTORS AGE: CHILD PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 O.OOE+OO C-14 1.65E+06 3.29E+05 3.29E+05 3.29E+05 3.29E+05 3.29E+05 3.29E+05 O.OOE+OO NA-22 1.20E+09 1.20E+09 1.20E+09 1.20E+09 1.20E+09 1.20E+09 1.20E+09 O.OOE+OO NA-24 3.11E+05 3.11E+05 3.11 E+05 3.11 E+05 3.11E+05 3.11E+05 3.11 E+05 O.OOE+OO P-32 2.76E+10 1.29E+09 1.06E+09 O.OOE+OO O.OOE+OO O.OOE+OO 7.63E+08 O.OOE+OO CA-41 8.70E+10 O.OOE+OO 9.50E+09 O.OOE+OO O.OOE+OO O.OOE+OO 4.76E+07 O.OOE+OO SC-46 3.36E+01 4.61E+01 1.77E+01 O.OOE+OO 4.08E+01 O.OOE+OO 6.74E+04 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 3.89E+03 2.16E+03 5.90E+02 3.94E+03 2.06E+05 O.OOE+OO MN-54 O.OOE+OO 1.25E+06 3.32E+05 O.OOE+OO 3.49E+05 O.OOE+OO 1.05E+06 O.OOE+OO FE-55 7.629E+05 4.047E+05 1.254E+05 O.OOOE+OO O.OOOE+OO 2.289E+05 7.496E+04 O.OOOE+OO MN-56 O.OOE+OO 4.50E-04 1.02E-04 O.OOE+OO 5.45E-04 O.OOE+OO 6.53E-02 O.OOE+OO C0-57 O.OOE+OO 2.25E+05 4.56E+05 O.OOE+OO O.OOE+OO O.OOE+OO 1.85E+06 O.OOE+OO C0-58 O.OOE+OO 5.75E+05 1.76E+06 O.OOE+OO O.OOE+OO O.OOE+OO 3.35E+06 O.OOE+OO FE-59 5.526E+05 8.943E+05 4.455E+05 O.OOOE+OO O.OOOE+OO 2.592E+05 9.311 E+05 O.OOOE+OO C0-60 O.OOE+OO 2.76E+06 8.13E+06 O.OOE+OO O.OOE+OO O.OOE+OO 1.53E+07 O.OOE+OO Nl-59 1.44E+08 3.82E+07 2.44E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.54E+06 O.OOE+OO Nl-63 1.92E+09 1.03E+08 6.53E+07 O.OOE+OO O.OOE+OO O.OOE+OO 6.92E+06 O.OOE+OO CU-64 O.OOE+OO 2.43E+03 1.47E+03 O.OOE+OO 5.88E+03 O.OOE+OO 1.14E+05 O.OOE+OO Nl-65 5.81E-02 5.47E-03 3.19E-03 O.OOE+OO O.OOE+OO O.OOE+OO 6.70E-01 O.OOE+OO ZN-65 2.40E+08 6.40E+08 3.98E+08 O.OOE+OO 4.03E+08 O.OOE+OO 1.12E+08 O.OOE+OO ZN-69m 2.79E+04 4.76E+04 5.62E+03 O.OOE+OO 2.76E+04 O.OOE+OO 1.55E+06 O.OOE+OO ZN-69 3.32E-13 4.80E-13 4.44E-14 O.OOE+OO 2.91 E-13 O.OOE+OO 3.03E-11 O.OOE+OO SE-79 O.OOE+OO 2.02E+08 4.49E+07 O.OOE+OO 3.29E+08 O.OOE+OO 1.33E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 4.03E+06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.54E-02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 2.28E-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 3.17E+08 1.95E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.04E+07 O.OOE+OO RB-87 O.OOE+OO 6.32E+08 2.93E+08 O.OOE+OO O.OOE+OO O.OOE+OO 9.47E+06 O.OOE+OO RB-88 O.OOE+OO 2.51E-46 1.74E-46 O.OOE+OO O.OOE+OO O.OOE+OO 1.23E-47 O.OOE+OO RB-89 O.OOE+OO 4.72E-54 4.20E-54 O.OOE+OO O.OOE+OO O.OOE+OO 4.12E-56 O.OOE+OO SR-89 5.07E+09 O.OOE+OO 1.45E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.96E+08 O.OOE+OO SR-90 1.90E+11 O.OOE+OO 3.83E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.70E+09 O.OOE+OO Y-90 1.13E+01 O.OOE+OO 3.03E-01 O.OOE+OO O.OOE+OO O.OOE+OO 3.22E+04 O.OOE+OO SR-91 8.01E+04 O.OOE+OO 3.02E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.77E+05 O.OOE+OO Y-91m 9.39E-21 O.OOE+OO 3.42E-22 O.OOE+OO O.OOE+OO O.OOE+OO 1.84E-17 O.OOE+OO Y-91 1.77E+03 O.OOE+OO 4.73E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.36E+05 O.OOE+OO SR-92 1.34E+OO O.OOE+OO 5.38E-02 O.OOE+OO O.OOE+OO O.OOE+OO 2.54E+01 O.OOE+OO Y-92 8.88E-06 O.OOE+OO 2.54E-07 O.OOE+OO O.OOE+OO O.OOE+OO 2.57E-01 O.OOE+OO Y-93 3.55E-02 O.OOE+OO 9.75E-04 O.OOE+OO O.OOE+OO O.OOE+OO 5.29E+02 O.OOE+OO NB-93m 1.39E+05 3.46E+04 1.14E+04 O.OOE+OO 3.74E+04 O.OOE+OO 5.22E+06 O.OOE+OO NB-95 1.28E+04 4.96E+03 3.55E+03 O.OOE+OO 4.66E+03 O.OOE+OO 9.18E+06 O.OOE+OO Rev.29 Page 280 of 329 12/2016
CY-LG-170-301 TABLE 112-24 R1 DOSE FACTORS AGE: CHILD PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN NB-97 5.11E-13 9.23E-14 4.31E-14 O.OOE+OO 1.02E-13 O.OOE+OO 2.85E-08 O.OOE+OO ZR-93
- 4.45E+02 1.67E+01 1.19E+01 O.OOE+OO 6.45E+01 O.OOE+OO 6.32E+03 O.OOE+OO ZR-95 1.77E+02 3.90E+01 3.47E+01 O.OOE+OO 5.58E+01 O.OOE+OO 4.07E+04 O.OOE+OO ZR-97 6.73E-02 9.73E-03 5.74E-03 O.OOE+OO 1.40E-02 O.OOE+OO 1.47E+03 O.OOE+OO M0-93 O.OOE+OO 9.64E+07 3.46E+06 O.OOE+OO 2.54E+07 O.OOE+OO 4.88E+06 O.OOE+OO M0-99 O.OOE+OO 2.86E+06 7.06E+05 O.OOE+OO 6.10E+06 O.OOE+OO 2.36E+06 O.OOE+OO TC-99 7.13E+06 7.95E+06 2.85E+06 O.OOE+OO 9.36E+07 7.03E+05 8.33E+07 O.OOE+OO TC-99m 4.64E-01 9.09E-01 1.51 E+01 O.OOE+OO 1.32E+01 4.62E-01 5.17E+02 O.OOE+OO TC-101 4.0BE-61 4.27E-61 5.42E-60 O.OOE+OO 7.28E-60 2.26E-61 1.36E-60 O.OOE+OO RU-103 1.76E+02 O.OOE+OO 6.78E+01 O.OOE+OO 4.44E+02 O.OOE+OO 4.56E+03 O.OOE+OO RU-105 1.34E-04 O.OOE+OO 4.86E-05 O.OOE+OO 1.18E-03 O.OOE+OO 8.75E-02 O.OOE+OO RU-106 5.56E+03 O.OOE+OO 6.94E+02 O.OOE+OO 7.51E+03 O.OOE+OO 8.65E+04 O.OOE+OO RH-105 5.51E+04 2.96E+04 2.53E+04 O.OOE+OO 1.18E+05 O.OOE+OO 1.83E+06 O.OOE+OO PD-107 O.OOE+OO 2.52E+06 2.14E+05 O.OOE+OO 2.11E+07 O.OOE+OO 5.00E+06 O.OOE+OO PD-109 O.OOE+OO 5.30E+03 1.59E+03 O.OOE+OO 2.84E+04 O.OOE+OO 3.13E+05 O.OOE+OO AG-110m 1.22E+07 8.21E+06 6.57E+06 O.OOE+OO 1.53E+07 O.OOE+OO 9.77E+08 O.OOE+OO AG-111 1.03E+06 3.23E+05 2.13E+05 O.OOE+OO 9.75E+05 O.OOE+OO 1.98E+OB O.OOE+OO CD-113m O.OOE+OO 6.47E+05 2.75E+04 O.OOE+OO 6.66E+05 O.OOE+OO 1.67E+06 O.OOE+OO CD-115m O.OOE+OO 1.82E+05 7.76E+03 O.OOE+OO 1.35E+05 O.OOE+OO 2.48E+06 O.OOE+OO SN-123 1.30E+08 1.62E+06 3.18E+06 1.72E+06 O.OOE+OO O.OOE+OO 6.40E+07 O.OOE+OO SN-125 9.06E+06 1.37E+05 4.06E+05 1.42E+05 O.OOE+OO O.OOE+OO 2.81E+07 O.OOE+OO SN-126 4.44E+OB 5.53E+06 1.26E+07 1.52E+06 O.OOE+OO O.OOE+OO 3.33E+07 O.OOE+OO SB-124 4.96E+06 6.43E+04 1.74E+06 1.09E+04 O.OOE+OO 2.75E+06 3.10E+07 O.OOE+OO SB-125 5.49E+06 4.23E+04 1.15E+06 5.08E+03 O.OOE+OO 3.06E+06 1.31E+07 O.OOE+OO SB-126 8.05E+05 1.23E+04 2.89E+05 4.72E+03 O.OOE+OO 3.84E+05 1.62E+07 O.OOE+OO SB-127 6.91E+04 1.07E+03 2.40E+04 7.69E+02 O.OOE+OO 3.00E+04 3.89E+06 O.OOE+OO TE-125m 3.34E+06 9.04E+05 4.45E+05 9.37E+05 O.OOE+OO O.OOE+OO 3.22E+06 O.OOE+OO TE-127m 1.0BE+07 2.90E+06 1.28E+06 2.58E+06 3.0BE+07 O.OOE+OO 8.74E+06 O.OOE+OO TE-127 1.04E+02 2.82E+01 2.24E+01 7.23E+01 2.97E+02 O.OOE+OO 4.08E+03 O.OOE+OO TE-129m 1.08E+07 3.01E+06 1.67E+06 3.48E+06 3.17E+07 O.OOE+OO 1.32E+07 O.OOE+OO TE-129 4.SOE-11 1.26E-11 1.07E-11 3.21 E-11 1.32E-10
- O.OOE+OO 2.BOE-09 O.OOE+OO TE-133m 3.18E-14 1.29E-14 1.60E-14 2.47E-14 1.22E-13 O.OOE+OO 9.82E-13 O.OOE+OO TE-134 1.32E-19 5.96E-20 7.95E-20 1.0SE-19 5.51E-19 O.OOE+OO 6.05E-19 O.OOE+OO 1-129 2.22E+09 1.36E+09 1.22E+09 8.93E+11 2.30E+09 O.OOE+OO 6.86E+07 O.OOE+OO 1-130 6.06E+05 1.22E+06 6.31E+05 1.35E+08 1.83E+06 O.OOE+OO 5.73E+05 O.OOE+OO 1-131 4.58E+OB 4.60E+08 2.61E+OB 1.52E+11 7.55E+OB O.OOE+OO 4.10E+07 O.OOE+OO TE-131m 5.61E+04 1.94E+04 2.07E+04 3.99E+04 1.88E+05 O.OOE+OO 7.88E+05 O.OOE+OO TE-131 5.67E-34 1.73E-34 1.69E-34 4.34E-34 1.72E-33 O.OOE+OO 2.98E-33 O.OOE+OO 1-132 2.42E-01 4.44E-01 2.04E-01 2.06E+01 6.BOE-01 O.OOE+OO 5.23E-01 O.OOE+OO TE-132 3.60E+05 1.59E+05 1.92E+05 2.32E+05 1.48E+06 O.OOE+OO 1.60E+06 O.OOE+OO 1-133 6.03E+06 7.45E+06 2.82E+06 1.38E+09 1.24E+07 O.OOE+OO 3.00E+06 O.OOE+OO CS-134m 6.43E-01 9.52E-01 6.21 E-01 O.OOE+OO 5.02E-01 8.30E-02 1.20E+OO O.OOE+OO Rev.29 Page 281 of 329 12/2016
CY-LG-170-301 TABLE 112-24 R1 DOSE FACTORS AGE: CHILD PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-134 3.53E+10 5.80E+10 1.22E+10 O.OOE+OO 1.80E+10 6.45E+09 3.13E+08 O.OOE+OO 1-134 2.98E-12 5.53E-12 2.54E-12 1.27E-10 8.46E-12 O.OOE+OO 3.67E-12 O.OOE+OO 1-135 1.89E+04 3.41E+04 1.61 E+04 3.02E+06 5.23E+04 O.OOE+OO 2.60E+04 O.OOE+OO CS-135 1.33E+10 9.25E+09 9.49E+08 O.OOE+OO 3.26E+09 1.09E+09 6.93E+07 O.OOE+OO CS-136 8.94E+08 2.46E+09 1.59E+09 O.OOE+OO 1.31E+09 1.95E+08 8.64E+07 O.OOE+OO CS-137 5.21E+10 4.99E+10 7.36E+09 O.OOE+OO 1.63E+10 5.85E+09 3.12E+08 O.OOE+OO CS-138 3.49E-23 4.85E-23 3.08E-23 O.OOE+OO 3.41E-23 3.67E-24 2.23E-23 O.OOE+OO CS-139 2.69E-89 2.99E-89 1.44E-89 O.OOE+OO 2.25E-89 2.27E-90 2.69E-93 O.OOE+OO BA-139 7.05E-09 3.76E-12 2.04E-10 O.OOE+OO 3.29E-12 2.21E-12 4.07E-07 O.OOE+OO BA-140 4.14E+06 3.62E+03 2.41E+05 O.OOE+OO 1.18E+03 2.16E+03 2.10E+06 O.OOE+OO LA-140 6.81E-01 2.38E-01 8.02E-02 O.OOE+OO O.OOE+OO O.OOE+OO 6.63E+03 O.OOE+OO BA-141 6.49E-47 3.64E-50 2.11 E-48 O.OOE+OO 3.15E-50 2.14E-49 3.70E-47 O.OOE+OO LA-141 4.85E-06 1.13E-06 2.45E-07 O.OOE+OO O.OOE+OO O.OOE+OO 2.51 E-01 O.OOE+OO CE-141 8.63E+02 4.30E+02 6.39E+01 O.OOE+OO 1.89E+02 O.OOE+OO 5.37E+05 O.OOE+OO BA-142 4.07E-81 2.93E-84 2.28E-82 O.OOE+OO 2.37E-84 1.72E-84 5.31 E-83 O.OOE+OO LA-142 2.84E-12 9.06E-13 2.84E-13 O.OOE+OO O.OOE+OO O.OOE+OO 1.80E-07 O.OOE+OO CE-143 6.58E+OO 3.57E+03 5.17E-01 O.OOE+OO 1.50E+OO O.OOE+OO 5.22E+04 O.OOE+OO PR-143 2.54E+01 7.63E+OO 1.26E+OO O.OOE+OO 4.13E+OO O.OOE+OO 2.74E+04 O.OOE+OO CE-144 9.57E+04 3.00E+04 5.11 E+03 O.OOE+OO 1.66E+04 O.OOE+OO 7.82E+06 O.OOE+OO PR-144 9.40E-55 2.91E-55 4.73E-56 O.OOE+OO 1.54E-55 O.OOE+OO 6.26E-52 O.OOE+OO
- ND-147 1~56E+01 1.27E+01 . 9.82E-01 O.OOE+OO 6.96E+OO O.OOE+OO 2.01E+04 O.OOE+OO PM-147 8.10E+02 5.78E+01 3.11 E+01 O.OOE+OO 1.02E+02 O.OOE+OO 2.34E+04 O.OOE+OO PM-148m 1.27E+02 2.54E+01 2.54E+01 O.OOE+OO 3.76E+01 O.OOE+OO 7.15E+04 O.OOE+OO PM-148 9.34E+OO 1.12E+OO 7.26E-01 O.OOE+OO 1.91E+OO O.OOE+OO 3.00E+04 O.OOE+OO PM-149 6.83E-01 7.26E-02 3.93E-02 O.OOE+OO 1.28E-01 O.OOE+OO 4.95E+03 O.OOE+OO PM-151 1.02E-01 1.24E-02 8.04E-03 O.OOE+OO 2.10E-02 O.OOE+OO 1.40E+03 O.OOE+OO SM-151 6.82E+02 1.01E+02 3.20E+01 O.OOE+OO 1.05E+02 O.OOE+OO 1.47E+04 O.OOE+OO SM-153 3.15E-01 1.96E-01 1.89E-02 O.OOE+OO 5.97E-02 O.OOE+OO 2.61E+03 O.OOE+OO EU-152 1.63E+03 2.96E+02 3.51E+02 O.OOE+OO 1.25E+03 O.OOE+OO 4.86E+04 O.OOE+OO EU-154 6.05E+03 5.44E+02 4.97E+02 O.OOE+OO 2.39E+03 O.OOE+OO 1.27E+05 O.OOE+OO EU-155 1.25E+03 9.03E+01 7.08E+01 O.OOE+OO 3.38E+02 O.OOE+OO 2.26E+05 O.OOE+OO EU-156 3.91E+01 2.09E+01 4.33E+OO O.OOE+OO 1.35E+01 O.OOE+OO 4.75E+04 O.OOE+OO TB-160 2.67E+02 O.OOE+OO 3.32E+01 O.OOE+OO 7.96E+01 O.OOE+OO 5.93E+04 O.OOE+OO H0-166m 2.88E+03 6.03E+02 5.09E+02 O.OOE+OO 8.58E+02 O.OOE+OO 7.01E+04 O.OOE+OO W-181 8.15E+03 2.00E+03 2.75E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.30E+04 O.OOE+OO W-185 2.83E+05 7.06E+04 9.89E+03 O.OOE+OO O.OOE+OO O.OOE+OO 2.63E+06 O.OOE+OO W-187 1.01E+03 6.00E+02 2.69E+02 O.OOE+OO O.OOE+OO O.OOE+OO 8.44E+04 O.OOE+OO NP-239 6.05E-01 4.35E-02 3.06E-02 O.OOE+OO 1.26E-01 O.OOE+OO 3.22E+03 O.OOE+OO U-232 4.68E+09 O.OOE+OO 3.35E+08 O.OOE+OO 3.57E+08 O.OOE+OO 1.86E+07 O.OOE+OO U-233 9.92E+08 O.OOE+OO 6.00E+07 O.OOE+OO 1.q3E+08 O.OOE+OO 1.72E+07 O.OOE+OO U-234 9.52E+o8* O.OOE+OO 5.89E+07 O.OOE+OO 1.59E+08 O.OOE+OO 1.69E+07 O.OOE+OO U-235 9.12E+08 O.OOE+OO 5.52E+07 O.OOE+OO 1.50E+08 O.OOE+OO 2.14E+07 O.OOE+OO Rev.29 Page 282 of 329 12/2016
CY-LG-170-301 TABLE 112-24 R1 DOSE FACTORS AGE: CHILD PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN U-236 9.12E+08 O.OOE+OO 5.65E+07 O.OOE+OO 1.53E+08 O.OOE+OO 1.58E+07 O.OOE+OO U-237 9.03E+03 O.OOE+OO 2.40E+03 O.OOE+OO 2.60E+04 O.OOE+OO 7.95E+05 O.OOE+OO U-238 8.72E+08 O.OOE+OO 5.17E+07 O.OOE+OO 1.40E+08 O.OOE+OO 1.51E+07 O.OOE+OO NP-237 5.95E+06 3.92E+05 2.61E+05 O.OOE+OO 1.61E+06 O.OOE+OO 2.18E+05 O.OOE+OO NP-238 5.74E+OO 1.16E-01 8.94E-02 O.OOE+OO 3.70E-01 O.OOE+OO 3.98E+03 O.OOE+OO PU-238 1.27E+06 1.47E+05 3.37E+04 O.OOE+OO 1.22E+05 O.OOE+OO 7.99E+04 O.OOE+OO PU-239 1.38E+06 1.47E+05 3.53E+04 O.OOE+OO 1.30E+05 O.OOE+OO 7.31E+04 O.OOE+OO PU-240 1.37E+06 1.53E+05 3.53E+04 O.OOE+OO 1.30E+05 O.OOE+OO 7.44E+04 O.OOE+OO PU-241 4.09E+04 1.67E+03 8.50E+02 O.OOE+OO 3.13E+03 O.OOE+OO 1.52E+03 O.OOE+OO PU-242 1.27E+06 1.47E+05 3.40E+04 O.OOE+OO 1.25E+05 O.OOE+OO 7.16E+04 O.OOE+OO PU-244 1.48E+06 1.69E+06 3.89E+04 O.OOE+OO 1.44E+05 O.OOE+OO 1.07E+05 O.OOE+OO AM-241 3.63E+06 3.12E+06 2.72E+05 O.OOE+OO 1.66E+06 O.OOE+OO 2.04E+05 O.OOE+OO AM-242m 3.73E+06 2.98E+06 2.77E+05 O.OOE+OO 1.68E+06 O.OOE+OO 2.56E+05 O.OOE+OO AM-243 3.57E+06 3.01E+06 2.62E+05 O.OOE+OO 1.62E+06 O.OOE+OO 2.39E+05 O.OOE+OO CM-242 1.83E+05 1.46E+05 1.21E+04 O.OOE+OO 3.89E+04 O.OOE+OO 1.70E+05 . O.OOE+OO CM-243 3.40E+06 2.76E+06 2.19E+05 O.OOE+OO 8.18E+05 O.OOE+OO 2.13E+05 O.OOE+OO CM-244 2.86E+06 2.31E+06 1.84E+05 O.OOE+OO 6.73E+05 O.OOE+OO 2.06E+05 O.OOE+OO CM-245 4.45E+06 3.57E+06 2.80E+05 O.OOE+OO 1.10E+06 O.OOE+OO 1.93E+05 O.OOE+OO CM-246 4.40E+06 3.57E+06 2.80E+05 O.OOE+OO 1.09E+06 O.OOE+OO 1.90E+05 O.OOE+OO CM-247 4.29E+06 3.52E+06 2.75E+05 O.OOE+OO 1.08E+06 O.OOE+OO 2.49E+05 O.OOE+OO CM-248 3.57E+07 2.91E+07 2.27E+O<;l O.OOE+OO 8.88E+06 O.OOE+OO 4.03E+06 O.OOE+OO CF-252 2.68E+06 O.OOE+OO 6.47E+04 O.OOE+OO O.OOE+OO O.OOE+OO 7.54E+05 O.OOE+OO Rev.29 Page 283 of 329 12/2016
CY-LG-170-301 TABLE 112-25 R1 DOSE FACTORS AGE: INFANT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN H-3 O.OOE+OO 2.78E+03 2.78E+03 2.78E+03 2.78E+03 2.78E+03 2.78E+03 O.OOE+OO C-14 3.23E+06 6.89E+05 6.89E+05 6.89E+05 6.89E+05 6.89E+05 6.89E+05 O.OOE+OO NA-22 2.00E+09 2.00E+09 2.00E+09 2.00E+09 2.00E+09 2.00E+09 2.00E+09 O.OOE+OO NA-24 5.41E+05 5.41E+05 5.41E+05 5.41E+05 5.41 E+05 5.41E+05 5.41E+05 O.OOE+OO P-32 5.69E+10 3.34E+09 2.20E+09 O.OOE+OO O.OOE+OO O.OOE+OO 7.69E+08 O.OOE+OO CA-41 9.37E+10 O.OOE+OO 1.02E+10 O.OOE+OO O.OOE+OO O.OOE+OO 4.79E+07 O.OOE+OO SC-46 6.40E+01 9.23E+01 2.88E+01 O.OOE+OO 6.07E+01 O.OOE+OO 6.02E+04 O.OOE+OO CR-51 O.OOE+OO O.OOE+OO 6.16E+03 4.02E+03 8.79E+02 7.82E+03 1.80E+05 O.OOE+OO MN-54 O.OOE+OO 2.32E+06 5.25E+05 O.OOE+OO 5.14E+05 O.OOE+OO 8.52E+05 O.OOE+OO FE-55 9.221 E+05 5.957E+05 1.592E+05 O.OOOE+OO O.OOOE+OO 2.912E+05 7.563E+04 O.OOOE+OO MN-56 O.OOE+OO 1.10E-03 1.90E-04 O.OOE+OO 9.48E-04 O.OOE+OO 1.00E-01 O.OOE+OO C0-57 O.OOE+OO 5.25E+05 8.54E+05 O.OOE+OO O.OOE+OO O.OOE+OO 1.79E+06 O.OOE+OO C0-58 O.OOE+OO 1.15E+06 2.87E+06 O.OOE+OO O.OOE+OO O.OOE+OO 2.86E+06 O.OOE+OO FE-59 1.032E+06 1.802E+06 7.101E+05 O.OOOE+OO O.OOOE+OO 5.325E+05 8.608E+05 O.OOOE+OO C0-60 O.OOE+OO 5.63E+06 1.33E+07 O.OOE+OO O.OOE+OO O.OOE+OO 1.34E+07 O.OOE+OO Nl-59 1.69E+08 5.18E+07 2.92E+07 O.OOE+OO O.OOE+OO O.OOE+OO 2.56E+06 O.OOE+OO Nl-63 2.26E+09 1.40E+08 7.85E+07 O.OOE+OO O.OOE+OO O.OOE+OO 6.96E+06 O.OOE+OO CU-64 O.OOE+OO 6.05E+03 2.80E+03 O.OOE+OO 1.02E+04 O.OOE+OO 1.24E+05 O.OOE+OO Nl-65 1.23E-01 1.39~-02 6.33E-03 O.OOE+OO O.OOE+OO O.OOE+OO 1.06E+OO O.OOE+OO ZN-65 3.23E+08 1.11E+09 5.10E+08 O.OOE+OO 5.37E+08 O.OOE+OO 9.35E+08 O.OOE+OO ZN-69m 5.90E+04 1.20E+05 1.10E+04 O.OOE+OO 4.88E+04 . O.OOE+OO 1.67E+06 O.OOE+OO ZN-69 7.08E-13 1.27E-12 9.48E-14 O.OOE+OO 5.30E-13 O.OOE+OO 1.04E-10 O.OOE+OO SE-79 O.OOE+OO 5.04E+08 9.36E+07 O.OOE+OO 5.83E+08 O.OOE+OO 1.34E+07 O.OOE+OO BR-82 O.OOE+OO O.OOE+OO 6.79E+06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 3.28E-02 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 4.41E-24 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 8.04E+08 3.97E+08 O.OOE+OO O.OOE+OO O.OOE+OO 2.06E+07 O.OOE+OO RB-87 O.OOE+OO 1.42E+09 5.63E+08 O.OOE+OO O.OOE+OO O.OOE+OO 9.57E+06 O.OOE+OO RB-88 O.OOE+OO 6.58E-46 3.61E-46 O.OOE+OO O.OOE+OO O.OOE+OO 6.41E-46 O.OOE+OO RB-89 O.OOE+OO 1.15E-53 7.95E-54 O.OOE+OO O.OOE+OO O.OOE+OO 3.93E-54 O.OOE+OO SR-89 9.64E+09 O.OOE+OO 2.76E+08 O.OOE+OO O.OOE+OO O.OOE+OO 1.98E+08 O.OOE+OO SR-90 2.10E+11 O.OOE+OO 4.27E+09 O.OOE+OO O.OOE+OO O.OOE+OO 1.72E+09 O.OOE+OO Y-90 2.39E+01 O.OOE+OO 6.41E-01 O.OOE+OO O.OOE+OO O.OOE+OO 3.30E+04 O.OOE+OO SR-91 1.67E+05 O.OOE+OO 6.04E+03 O.OOE+OO O.OOE+OO O.OOE+OO 1.97E+05 O.OOE+OO Y-91m 1.99E-20 O.OOE+OO 6.79E-22 O.OOE+OO O.OOE+OO O.OOE+OO 6.64E-17 O.OOE+OO Y-91 3.32E+03 O.OOE+OO 8.84E+01 O.OOE+OO O.OOE+OO O.OOE+OO 2.38E+05 O.OOE+OO SR-92 2.85E+OO O.OOE+OO 1.06E-01 O.OOE+OO O.OOE+OO O.OOE+OO 3.07E+01 O.OOE+OO Y-92 1.89E-05 O.OOE+OO 5.30E-07 O.OOE+OO O.OOE+OO O.OOE+OO 3.60E-01 O.OOE+OO Y-93 7.57E-02 O.OOE+OO 2.06E-03 O.OOE+OO O.OOE+OO O.OOE+OO 5.98E+02 O.OOE+OO NB-93m 1.63E+05 4.40E+04 1.38E+04 O.OOE+OO 4.30E+04 O.OOE+OO 5.26E+06 O.OOE+OO NB-95 2.38E+04 9.80E+03 5.67E+03 O.OOE+OO 7.03E+03 O.OOE+OO 8.27E+06 O.OOE+OO NB-97 1.08E-12 2.31E-13 8.31E-14 O.OOE+OO 1.80E-13 O.OOE+OO 7.28E-08 O.OOE+OO ZR-93 5.15E+02 2.45E+01 1.48E+01 O.OOE+OO 7.23E+01 O.OOE+OO 6.37E+03 O.OOE+OO ZR-95 3.15E+02 7.68E+01 5.45E+01 O.OOE+OO 8.28E+01 O.OOE+OO 3.82E+04 O.OOE+OO Rev.29 Page 284 of 329 12/2016
CY-LG-170-301 TABLE 112-25 R1 DOSE FACTORS AGE: INFANT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU SKIN ZR-97 1.43E-01 2.45E-02 1.12E-02 O.OOE+OO 2.47E-02 O.OOE+OO 1.56E+03 O.OOE+OO M0-93 O.OOE+OO 2.26E+08 7.28E+06 O.OOE+OO 4.52E+07 O.OOE+OO 4.84E+06 O.OOE+OO M0-99 O.OOE+OO 7.30E+06 1.42E+06 O.OOE+OO 1.09E+07 O.OOE+OO 2:41E+06 O.OOE+OO TC-99 1.44E+07 1.95E+07 6.07E+06 O.OOE+OO 1.64E+08 1.89E+06 8.41E+07 O.OOE+OO TC-99m 9.65E-01 1.99E+OO 2.56E+01 O.OOE+OO 2.14E+01 1.04E+OO 5.78E+02 O.OOE+OO TC-101 8.66E-61 1.09E-60 1.0BE-59 O.OOE+OO 1.30E-59 5.95E-61 1.85E-58 O.OOE+OO RU-103 3.57E+02 O.OOE+OO 1.19E+02 O.OOE+OO 7.43E+02 O.OOE+OO 4.34E+03 O.OOE+OO RU-105 2.83E-04 O.OOE+OO 9.52E-05 O.OOE+OO 2.0BE-03 O.OOE+OO 1.12E-01 O.OOE+OO RU-106 1.15E+04 O.OOE+OO 1.43E+03 O.OOE+OO 1.35E+04 O.OOE+OO 8.70E+04 O.OOE+OO RH-105 1.17E+05 7.64E+04 5.13E+04 O.OOE+OO 2.12E+05 O.OOE+OO 1.90E+06 O.OOE+OO PD-107 O.OOE+OO 6.35E+06 4.51E+05 O.OOE+OO 3.62E+07 O.OOE+OO 5.04E+06 O.OOE+OO PD-109 O.OOE+OO 1.40E+04 3.38E+03 O.OOE+OO 5.15E+04 O.OOE+OO 3.44E+05 O.OOE+OO AG-110m 2.25E+07 1.64E+07 1.09E+07 O.OOE+OO 2.35E+07 O.OOE+OO 8.51E+08 O.OOE+OO AG-111 2.17E+06 8.42E+05 4.46E+05 O.OOE+OO 1.76E+06 O.OOE+OO 2.01E+08 O.OOE+OO CD-113m O.OOE+OO 1.12E+06 4.14E+04 O.OOE+OO 8.50E+05 O.OOE+OO 1.69E+06 O.OOE+OO CD-115m O.OOE+OO 4.39E+05 1.52E+04 O.OOE+OO 2.29E+05 O.OOE+OO 2.50E+06 O.OOE+OO SN-123 2.44E+08 3.82E+06 6.38E+06 3.84E+06 O.OOE+OO O.OOE+OO 6.45E+07 O.OOE+OO SN-125 1.89E+07 3.52E+05 8.40E+05 3.47E+05 O.OOE+OO O.OOE+OO 2.83E+07 O.OOE+OO SN-126 7.37E+08 9.68E+06 2.40E+07 2.55E+06 O.OOE+OO O.OOE+OO 3.36E+07 O.OOE+OO SB-124 9.56E+06 1.41E+05 2.96E+06 2.54E+04 O.OOE+OO 5.98E+06 2.95E+07 O.OOE+OO SB-125 9.43E+06 9.12E+04 1.94E+06 1.18E+04 O.OOE+OO 5.46E+06 1.26E+07 O.OOE+OO SB-126 1.47E+06 2.89E+04 5.32E+05 1.13E+04 O.OOE+OO
- 9.27E+05 1.53E+07 O.OOE+OO SB-127 1.45E+05 2.59E+03 4.50E+04 1.85E+03 O.OOE+OO 7.49E+04 3.85E+06 O.OOE+OO TE-125m 6.82E+06 2.28E+06 9.22E+05 2.29E+06 O.OOE+OO O.OOE+OO 3.25E+06 O.OOE+OO TE-127m 2.18E+07 7.24E+06 2.64E+06 6.31E+06 5.38E+07 O.OOE+OO 8.81E+06 O.OOE+OO TE-127 2.22E+02 7.43E+01 4.77E+01 1.81E+02 5.41E+02 O.OOE+OO 4.66E+03 O.OOE+OO TE-129m 2.21E+07 7.60E+06 3.41E+06 8.50E+06 5.54E+07 O.OOE+OO 1.32E+07 O.OOE+OO TE-129 9.54E-11 3.29E-11 2.23E-11 8.00E-11 2.38E-10 O.OOE+OO 7.63E-09 O.OOE+OO TE-133m 6.66E-14 3.05E-14 2.91 E-14 5.87E-14 2.0BE-13 O.OOE+OO 3.29E-12 O.OOE+OO TE-134 2.74E-19 1.38E-19 1.42E-19 2.45E-19 9.27E-19 O.OOE+OO 3.14E-18 O.OOE+OO 1-129 4.58E+09 3.39E+09 2.48E+09 2.18E+12 4.02E+09 O.OOE+OO 6.78E+01 O.OOE+OO 1-130 1.25E+06 2.74E+06 1.10E+06 3.07E+08 3.01 E+06 O.OOE+OO 5.88E+05 O.OOE+OO 1-131 9.55E+08 1.13E+09 4.95E+08 3.70E+11 1.31 E+09 O.OOE+OO 4.02E+07 O.OOE+OO TE-131m 1.19E+05 4.77E+04 3.94E+04 9.67E+04 3.28E+05 O.OOE+OO 8.03E+05 O.OOE+OO TE-131 1.20E-33 4.44E-34 3.38E-34 1.07E-33 3.0BE-33 O.OOE+OO 4.86E-32 O.OOE+OO 1-132 5.02E-01 1.02E+OO 3.63E-01 4.78E+01 1.14E+OO O.OOE+OO 8.25E-01 O.OOE+OO TE-132 7.41E+05 3.67E+05 3.42E+05 5.41E+05 2.29E+06 O.OOE+OO 1.36E+06 O.OOE+OO 1-133 1.27E+07 1.85E+07 5.43E+06 3.37E+09 2.18E+07 O.OOE+OO 3.14E+06 O.OOE+OO CS-134m 1.34E+OO 2.23E+OO 1.13E+OO O.OOE+OO 8.60E-01 1.98E-01 1.77E+OO O.OOE+OO CS-134 5.69E+10 1.06E+11 1.07E+10 O.OOE+OO 2.73E+10 1.12E+10 2.89E+08 O.OOE+OO 1-134 6.18E-12 1.27E-11 4.50E-12 2.95E-10 1.41E-11 O.OOE+OO 1.31E-11 O.OOE+OO 1-135 3.94E+04 7.84E+04 2.86E+04 7.03E+06 8.74E+04 O.OOE+OO 2.84E+04 O.OOE+OO CS-135 2.13E+10 1.94E+10 1.01E+09 O.OOE+OO 5.50E+09 2.10E+09 6.99E+07 O.OOE+OO CS-136 1.75E+09 5.14E+09 1.92E+09 O.OOE+OO 2.05E+09 4.19E+08 7.80E+07 O.OOE+OO CS-137 8.32E+10 9.74E+10 6.90E+09 O.OOE+OO 2.61E+10 1.06E+10 3.04E+08 O.OOE+OO Rev.29 Page 285 of 329 12/2016
CY-LG-170-301 TABLE 112-25 R1 DOSE FACTORS AGE: INFANT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN CS-138 7.36E-23 1.20E-22 5.80E-23 O.OOE+OO 5.97E-23 9.32E-24 1.91E-22 O.OOE+OO CS-139 5.76E-89 7.87E-89 3.01E-89 O.OOE+OO 4.07E-89 6.13E-90 4.94E-90 O.OOE+OO BA-139 1.50E-08 9.94E-12 4.34E-10 O.OOE+OO 5.98E-12 6.03E-12 9.50E-07 O.OOE+OO BA-140 8.51 E+06 8.51E+03 4.39E+05 O.OOE+OO 2.02E+03 5.23E+03 2.09E+06 O.OOE+OO LA-140 1.42E+OO 5.61E-01 1.44E-01 O.OOE+OO O.OOE+OO O.OOE+OO 6.59E+03 O.OOE+OO BA-141 1.38E-46 9.45E-50 4.35E-48 O.OOE+OO 5.68E-50 5.75E-50 1.69E-45 O.OOE+OO LA-141 1.03E-05 2.99E-06 5.20E-07 O.OOE+OO O.OOE+OO O.OOE+OO 3.43E-01 O.OOE+OO CE-141 1.71E+03 1.04E+03 1.23E+02 O.OOE+OO 3.22E+02 O.OOE+OO 5.39E+05 O.OOE+OO BA-142 8.58E-81 7.13E-84 4.22E-82 O.OOE+OO 4.11 E-84 4.32E-84 3.54E-80 O.OOE+OO LA-142 5.97E-12 2.19E-12 5.24E-13 O.OOE+OO O.OOE+OO O.OOE+.00 3.72E-07 O.OOE+OO CE-143 1.39E+01 9.24E+03 1.05E+OO O.OOE+OO 2.69E+OO O.OOE+OO 5.39E+04 O.OOE+OO PR-143 5.26E+01 1.97E+01 2.61E+OO O.OOE+OO 7.31E+OO O.OOE+OO 2.77E+04 O.OOE+OO CE-144 1.37E+05 5.61E+04 7.68E+03 O.OOE+QO 2.27E+04 O.OOE+OO 7.87E+06 O.OOE+OO PR-144 2.00E-54 7.72E-55 1.01E-55 O.OOE+OO 2.80E-55 O.OOE+OO 3.59E-50 O.OOE+OO ND-147 3.10E+01 3.19E+01 1.95E+OO O.OOE+OO 1.23E+01 O.OOE+OO 2.02E+04 O.OOE+OO PM-147 9.89E+02 8.33E+01 4.05E+01 O.OOE+OO 1.24E+02 O.OOE+OO 2.36E+04 O.OOE+OO PM-148m 2.04E+02 5.17E+01 4.06E+01 O.OOE+OO 5.94E+01 O.OOE+OO 6.73E+04 O.OOE+OO PM-148 1.95E+01 2.82E+OO 1.42E+OO O.OOE+OO 3.37E+OO O.OOE+OO 3.01E+04 O.OOE+OO PM-149 1.45E+OO 1.90E-01 8.31E-02 O.OOE+OO 2.31 E-01 O.OOE+OO 5.11 E+03 O.OOE+OO PM-151 2.15E-01 3.14E-02 1.59E-02 O.OOE+OO 3.73E-02 O.OOE+OO 1.45E+03 O.OOE+OO SM-151 7.72E+02 1.78E+02 3.83E+01 O.OOE+OO 1.21E+02 O.OOE+OO 1.49E+04 O.OOE+OO SM-153 6.67E-01 5.15E-01 3.95E-02 O.OOE+OO 1.08E-01 O.OOE+OO 2.69E+03 O.OOE+OO EU-152 1.78E+03 4.73E+02 3.99E+02 O.OOE+OO 1.33E+03 O.OOE+OO 4.20E+04 O.OOE+OO EU-154 6.94E+03 9.65E+02 5.79E+02 O.OOE+OO 2.62E+03 O.OOE+OO 1.20E+05 O.OOE+OO EU-155 1.41E+03 1.63E+02 8.41E+01 O.OOE+OO 3.64E+02 O.OOE+OO 2.18E+05 O.OOE+OO EU-156 7.93E+01 4.91 E+01 7.79E+OO O.OOE+OO 2.27E+01 O.OOE+OO 4.64E+04 O.OOE+OO TB-160 4.17E+02 O.OOE+OO 5.22E+01 O.OOE+OO 1.19E+02 O.OOE+OO 5.56E+04 O.OOE+OO H0-166m 3.33E+03 7.17E+02 5.68E+02 O.OOE+OO 9.52E+02 O.OOE+OO 7.09E+04 O.OOE+OO W-181 1.70E+04 5.24E+03 5.85E+02 O.OOE+OO O.OOE+OO O.OOE+OO 7.36E+04 O.OOE+OO W-185 5.92E+05 1.85E+05 2.11 E+04 O.OOE+OO O.OOE+OO O.OOE+OO 2.65E+06 O.OOE+OO W-187 2.13E+03 1.48E+03 5.13E+02 O.OOE+OO O.OOE+OO O.OOE+OO 8.72E+04 O.OOE+OO NP-239 1.28E+OO 1.15E-01 6.47E-02 O.OOE+OO 2.28E-01 O.OOE+OO 3.31E+03 O.OOE+OO U-232 6.44E+09 O.OOE+OO 5.75E+08 O.OOE+OO 6.31E+08 O.OOE+OO 1.87E+07 O.OOE+OO U-233 1.35E+09 O.OOE+OO 1.03E+08 O.OOE+OO 2.88E+08 O.OOE+OO 1.74E+07 O.OOE+OO U-234 1.30E+09 O.OOE+OO 1.01E+08 O.OOE+OO 2.83E+08 O.OOE+OO 1.70E+07 O.OOE+OO U-235 1.25E+09 O.OOE+OO 9.49E+07 O.OOE+OO 2.65E+08 O.OOE+OO 2.16E+07 O.OOE+OO U-236 1.25E+09 O.OOE+OO 9.71E+07 O.OOE+OO 2.69E+08 O.OOE+OO 1.59E+07 O.OOE+OO U-237 1.89E+04 O.OOE+OO 5.05E+03 O.OOE+OO 4.70E+04 O.OOE+OO 8.07E+05 O.OOE+OO U-238 1.19E+09 O.OOE+OO 8.88E+07 O.OOE+OO 2.47E+08 O.OOE+OO 1.52E+07 O.OOE+OO NP-237 6.40E+06 4.24E+05 2.80E+05 O.OOE+OO 1.69E+06 O.OOE+OO 2.19E+05 O.OOE+OO NP-238 1.22E+01 3.07E-01 1.89E-01 O.OOE+OO 6.70E-01 O.OOE+OO 4.11E+03 O.OOE+OO PU-238 1.36E+06 1.60E+05 3.62E+04 O.OOE+OO 1.29E+05 O.OOE+OO 8.06E+04 O.OOE+OO PU-239 1.47E+06 1.65E+05 3.78E+04 O.OOE+OO 1.37E+05 O.OOE+OO 7.37E+04 O.OOE+OO PU-240 1.47E+06 1.65E+05 3.78E+04 O.OOE+OO 1.37E+05 O.OOE+OO 7.51E+04 O.OOE+OO PU-241 4.50E+04 1.86E+03 9.33E+02 O.OOE+OO 3.35E+03 O.OOE+OO 1.53E+03 O.OOE+OO Rev.29 Page 286 of 329 12/2016
CY-LG-170-301 TABLE 112-25 R1 DOSE FACTORS AGE: INFANT PATHWAY: GOAT MILK m2-mrem/yr per µCi/sec NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI SKIN PU-242 1.37E+06 1.59E+05 3.64E+04 O.OOE+OO 1.31E+05 O.OOE+OO 7.22E+04 O.OOE+OO PU-244 1.59E+06 1.82E+05 4.17E+04 O.OOE+OO 1.50E+05 O.OOE+OO 1.08E+05 O.OOE+OO AM-241 3.89E+06 3.39E+06 2.91E+05 O.OOE+OO 1.75E+06 O.OOE+OO 2.05E+05 O.OOE+OO AM-242m 4.02E+06 3.25E+06 3.01E+05 O.OOE+OO 1.77E+06 O.OOE+OO 2.58E+05 O.OOE+OO AM-243 3.84E+06 3.28E+06 2.83E+05 O.OOE+OO 1.70E+06 O.OOE+OO 2.41E+05 O.OOE+OO CM-242 2.85E+05 2.64E+05 1.89E+04 O.OOE+OO 5.45E+04 O.OOE+OO 1.71E+05 O.OOE+OO CM-243 3.72E+06 3.05E+06 2.38E+05 O.OOE+OO 8.68E+05 O.OOE+OO 2.15E+05 O.OOE+OO CM-244 3.13E+06 2.57E+06 2.01E+05 O.OOE+OO 7.18E+05 O.OOE+OO 2.08E+05 O.OOE+OO CM-245 4.77E+06 3.87E+06 3.01E+05 O.OOE+OO 1.15E+06 O.OOE+OO 1.95E+05 O.OOE+OO CM-246 4.72E+06 3.87E+06 3.01 E+05 O.OOE+OO 1.15E+06 O.OOE+OO 1.91E+05 O.OOE+OO CM-247 4.61E+06 3.81E+06 2.96E+05 O.OOE+OO 1.13E+06 O.OOE+OO 2.51E+05 O.OOE+OO CM-248 3.81E+07 3.15E+07 2.44E+06 O.OOE+OO 9.33E+06 O.OOE+OO 4.05E+06 O.OOE+OO CF-252 3.11 E+06 O.OOE+OO 7.52E+04 O.OOE+OO O.OOE+OO O.OOE+OO 7.62E+05 O.OOE+OO Rev.29 Page 287 of 329 12/2016
CY-LG-170-301 Table 112-26 STABLE ELEMENT TRANSFER DATA NUCLIDE VEG/SOIL COW MILK (D/L} MEAT (D/KG) GOAT MILK (D/L) H-3 4.8E+OO 1.0E-02 1.2E-02 1.7E-01 C-14 5.5E+OO 1.2E-02 3.1E-02 1.0E-01 NA-22 5.2E-02 4.0E-02 3.0E-02 4.0E-02 NA-24 5.2E-02 4.0E-02 3.0E-02 4.0E-02 P-32 1.1E+OO 2.5E-02 4.6E-02 2.5E-01 CA-41 3.6E-02 8.0E-03 4.0E-03 8.0E-03 SC-46 1.1E-03 5.0E-06 1.6E-02 5.0E-06 CR-51 2.5E-04 2.2E-03 2.4E-03 2.2E-03 MN-54 2.9E-02 2.5E-04 8.0E-04 2.5E-04 MN-56 2.9E-02 2.5E-04 8.0E-04 2.5E-04 FE-55 6.6E-04 1.2E-03 4.0E-02 1.3E-04 FE-59 .6.6E-04 1.2E-03 4.0E-02 1.3E-04 C0-57 9.4E-03 1.0E-03 1.3E-02 1.0E-03 C0-58 9.4E-03 1.0E-03 1.3E-02 1.0E-03 C0-60 9.4E-03 1.0E-03 1.3E-02 1.0E-03 Nl-59 1.9E-02 6.7E-03 5.3E-03 6.7E-03 Nl-63 1.9E-02 6.7E-03 5.3E-03 6.7E-03 Nl-65 1.9E-02 6.7E-03 5.3E-03 6.7E-03 CU-64 1.2E-01 1.4E-02 8.0E-03 1.3E-02 ZN-65 4.0E-01 3.9E-02 3.0E-02 3.9E-02 ZN-69M 4.0E-01 3.9E-02 3.0E-02 3.9E-02 ZN-69 4.0E-01 3.9E-02 3.0E-02 3.9E-02 SE-79 1.3E+OO 4.5E-02 1.5E-02 4.5E-02 BR-82 7.6E-01 5.0E-02 2.6E-02 5.0E-02 BR-83 7.6E-01 5.0E-02 2.6E-02 5.0E-02 BR-84 7.6E-01 5.0E-02 2.6E-02 5.0E-02 BR-85 7.6E-01 5.0E-02 2.6E-02 5.0E-02 RB-86 1.3E-01 3.0E-02 3.1E-02
- 3.0E-02 RB-87 1.3E-01 3.0E-02 . 3.1E-02 3.0E-02 RB-88 1.3E-01 3.0E-02 3.1E-02 3.0E-02 RB-89 1.3E-01 3.0E-02 3.1E-02 3.0E-02 SR-89 1.7E-02 8.0E-04 6.0E-04 1.4E-02 SR-90 1.7E-02 8.0E-04 6.0E-04 1.4E-02 SR-91 1.7E-02 8.0E-04 6.0E-04 1.4E-02 SR-92 1.7E-02 8.0E-04 6.0E-04 1.4E-02 Y-90 2.6E-03 1.0E-05 4.6E-03 1.0E-05 Y-91M 2.6E-03 1.0E-05 4.6E-03* 1.0E-05 Y-91 2.6E-03 1.0E-05 4.6E-03 1.0E-05 Y-92 2.6E-03 1.0E-05 4.6E-03 1.0E-05 Y-93 2.6E-03 1.0E-05 4.6E-03 1.0E-05 ZR-93 1.7E-04 5.0E-06 3.4E-02 5.0E-06 ZR-95 1.7E-04 5.0E-06 3.4E-02 5.0E-06 ZR-97 1.7E-04 5.0E-06 3.4E-02 5.0E-06 NB-93M 9.4E-03 2.5E-03 2.8E-01 2.5E-03 Rev.29 Page 288 of 329 12/2016
CY-LG-170-301 Table 112-26 STABLE ELEMENT TRANSFER DATA NUCLIDE VEG/SOIL COW MILK (D/L} MEAT (D/KG} GOAT MILK (D/L} NB-95 9.4E-03 2.5E-03 2.8E-01 2.5E-03 NB-97 9.4E-03 2.5E-03 2.8E-01 2.5E-03 M0-93 1.2E-01 7.5E-03 8.0E-03 7.5E-03 M0-99 1.2E-01 7.5E-03 8.0E-03 7.5E-03 TC-99M 2.51=-01 2.5E-02 4.0E-01 2.5E-02 TC-99 2.5E-01 2.5E-02 4.0E-01 2.5E-02 TC-101 2.5E-01 2.5E-02 4.0E-01 2.5E-02 RU-103 5.0E-02 1.0E-06 4.0E-01 1.0E-06 RU-105 5.0E-02 1.0E-06 4.0E-01 1.0E-06 RU-106 5.0E-02 1.0E-06 4.0E-01 1.0E-06 RH-105 1.3E+01 1.0E-02 1.5E-03 1.0E-02 PD-107 5.0E+OO 1.0E-02 4.0E-03 1.0E-02 PD-109 5.0E+OO 1.0E-02 4.0E-03 1.0E-02 AG-110M 1.5E-01 5.0E-02 1.7E-02 5.0E-02 AG-111 1.5E-01 5.0E-02 1.7E-02 5.0E-02 CD-113M 3.0E-01 1.2E-04 5.3E-04 1.2E-04 CD-115M 3.0E-01 1.2E-04 5.3E-04 1.2E-04 SN-123 2.5E-03 2.5E-03 8.0E-02 2.5E-03 SN-125 2.5E-03 2.5E-03 8.0E-02 2.5E-03 SN-126 2.5E-03 2.5E-03 8.0E-02 2.5E-03 SB-124 1.1E-02 1.5E-03 4.0E-03 1.5E-03 SB-125 1.1E-02 1.5E-03 4.0E-03 1.5E-03 SB-126 1.1E-02 1.5E-03 4.0E-03 1.5E-03 SB-127 1.1E-02 1.5E-03 4.0E-03 1.5E-03 TE-125M 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-127M 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-127 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-129M 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-129 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-131M 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-131 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-132 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-133M 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 TE-134 1.3E+OO 1.0E-03 7.7E-02 1.0E-03 1-129 2.0E-02 6.0E-03 2.9E-03 6.0E-02 1-130 2.0E-02 6.0E-03 2.9E-03 6.0E-02 1-131 2.0E-02 6.0E-03 2.9E-03 6.0E-02 1-132 2.0E-02 6.0E-03 2.9E-03 6.0E-03 1-133 2.0E-02 6.0E-03 2.9E-03 6.0E-02 1-134 2.0E-02 6.0E-03 2.9E-03 6.0E-02 1-135 2.0E-02 6.0E-03 2.9E-03 6.0E-02 CS-134M 1.0E-02 1.2E-02 4.0E-03 3.0E-01 CS-134 1.0E-02 1.2E-02 4.0E-03 3.0E-01 CS-135 1.0E-02 1.2E-02 4.0E-03 3.0E-01 Rev.29 Page 289 of 329 12/2016
CY-LG-170-301 Table 112-26 STABLE ELEMENT TRANSFER DATA NUCLIDE VEG/SOIL COW MILK (D/L) MEAT (D/KG) GOAT MILK (D/L) CS-136 1.0E-02 1.2E-02 4.0E-03 3.0E-01 CS-137 1.0E-02 1.2E-02 4.0E-03 3.0E-01 CS-138 1.0E-02 1.2E-02 4.0E-03 3.0E-01 CS-139 1.0E-02 1.2E-02 4.0E-03 3.0E-01 BA-139 5.0E-03 4.0E-04 3.2E-03 4.0E-04 BA-140 5.0E-03 4.0E-04 3.2E-03 4.0E-04 BA-141 5.0E-03 4.0E-04 3.2E-03 4.0E-04 BA-142 5.0E-03 4.0E-04 3.2E-03 4.0E-04 LA-140 2.5E-03 5.0E-06 2.0E-04 5.0E-06 LA-141 2.5E-03 5.0E-06 2.0E-04 5.0E-06 LA-142 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CE-141 2.5E-03 1.0E-04 1.2E-03 1.0E-04 CE-143 2.5E-03 *1.0E-04 1.2E-03 1.0E-04 CE-144 2.5E-03 1.0E-04 1.2E-03 1.0E-04 PR-143 2.5E-03 5.0E-06 4.7E-03 5.0E-06 PR-144 2.5E-03 5.0E-06 4.7E-03 5.0E-06 ND-147 2.4E-03 5.0E-06 3.3E-03 5.0E-06 PM-147 2.5E-03 5.0E-06 4.8E-03 5.0E-06 PM-148M 2.5E-03 5.0E-06 4.8E-03 5:0E-06 PM-148 2.5E-03 5.0E-06 4.8E-03 5.0E-06 PM-149 2.5E-03 5.0E-06 4.8E-03 5.0E-06 PM-151 2.5E-03 5.0E-06 4.8E-03 5.0E-06 SM-151 2.5E-03 5.0E-06 5.0E-03 5.0E-06 SM-153 2.5E-03 5.0E-06 5.0E-03 5.0E-06 EU-152 2.5E-03 5.0E-06 4.8E-03 5.0E-06 EU~154 2.5E-03 5.0E-06 4.8E-03 5.0E-06 EU-155 2.5E-03 5.0E-06 4.8E-03 5.0E-06 EU-156 2.5E-03 5.0E-06 4.8E-03 5.0E-06 TB-160 2.6E-03 5.0E-06 4.4E-03 5.0E-06 H0-166M 2.6E-03 5.0E-06 4.4E-03 5.0E-06 W-181 1.8E-02 5.0E-04 1.3E-03 5.0E-04 W-185 1.8E-02 5.0E-04 1.3E-03 5.0E-04 W-187 1.8E-02 5.0E-04 1.3E-03 5.0E-04 U-232 2.5E-03 5.0E-04 3.4E-04 5.0E-04 U-233 2.5E-03 5.0E-04 3.4E-04 5.0E-04 U-234 2.5E-03 5.0E-04 3.4E-04 5.0E-04 U-235 2.5E-03 5.0E-04 3.4E-04 5.0E-04 U-236 2.5E-03 5.0E-04 3.4E-04 5.0E-04 U-237 2.5E-03 5.0E-04 3.4E-04 5.0E-04 U-238 2.5E-03 5.0E-04 3.4E-04 5.0E-04 NP-237 2.5E-03 5.0E-06 2.0E-04 5.0E-06 NP-238 2.5E-03 5.0E-06 2.0E-04 5.0E-06 NP-239 2.5E-03 5.0E-06 2.0E-04 5.0E-06 PU-238 2.5E-04 2.0E-06 1.4E-05 2.0E-06 Rev.29 Page 290 of 329 12/2016
CY-LG-170-301 Table 112-26 STABLE ELEMENT TRANSFER DATA NUCLIDE VEG/SOIL COW MILK (D/L) MEAT (D/KG) GOAT MILK (D/L) PU-239 2.5E-04 2.0E-06 1.4E-05 2.0E-06 PU-240 2.5E-04 2.0E-06 1.4E-05 2.0E-06 PU-241 2.5E-04 2.0E-06 1.4E-05 2.0E-06 PU-242 2.5E-04 2.0E-06 1.4E-05 2.0E-06 PU-244 2.5E-04 2.0E-06 1.4E-05 2.0E-06 AM-241 2.5E-04 5.0E-06 2.0E-04 5.0E-06 AM-242M 2.5E-04 5.0E-06 2.0E-04 5.0E-06 AM-243 2.5E-04 5.0E-06 2.0E-04 5.0E-06 CM-242 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CM-243 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CM-244 2.5E-03 5.0E-06 2.0E-04" 5.0E-06 CM-245 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CM-246 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CM-247 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CM-248 2.5E-03 5.0E-06 2.0E-04 5.0E-06 CF-252 2.5E-03 5.0E-06 2.0E-04 5.0E-06 NUREG/CR-4653 GASPAR II, Technical Reference and User Guide Rev.29 Page 291 of 329 12/2016
CY-LG-170-301 TABLE 112-27 INHALATION DOSE FACTORS FOR ADULT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI H-3 O.OOE+OO 8.98E-08 8.98E-08 8.98E-08 8.98E-08 8.98E-08 8.98E-08 C-14 2.27E-06 4.26E-07 4.26E-07 4.26E-07 4.26E-07 4.26E-07 4.26E-07 NA-22 1.30E-05 1.30E-05 1.30E-05 1.30E-05 1.30E-05 1.30E-05 1.30E-05 NA-24 1.28E-06 1.28E-06 1.28E-06 1.28E-06 1.28E-06 1.28E-06 1.28E-06 P-32 1.65E-04 9.64E-06 6.26E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.08E-05 CA-41 3.83E-05 O.OOE+OO 4.13E-06 O.OOE+OO O.OOE+OO 3.83E-06 2.86E-07 SC-46 5.51E-05 1.07E-04 3.11 E-05 O.OOE+OO 9.99E-05 O.OOE+OO 3.23E-05 CR-51 O.OOE+OO O.OOE+OO 1.25E-08 7.44E-09 2.85E-09 1.80E-06 4.15E-07 MN-54 O.OOE+OO 4.95E-06 7.87E-07 O.OOE+OO 1.23E-06 1.75E-04 9.67E-06 MN-56 O.OOE+OO 1.55E-10 2.29E-11 O.OOE+OO 1.63E-10 1.18E-06 2.53E-06 FE-55 3.07E-06 2.12E-06 4.93E-07 O.OOE+OO O.OOE+OO 9.01E-06 7.54E-07 FE-59 1.47E-06 3.47E-06 1.32E-06 O.OOE+OO O.OOE+OO 1.27E-04 2.35E-05 C0-57 O.OOE+OO 8.65E-08 8.39E-08 O.OOE+OO O.OOE+OO 4.62E-05 3.93E-06 C0-58 O.OOE+OO 1.98E-07 2.59E-07 O.OOE+OO O.OOE+OO 1.16E-04 1.33E-05 C0-60 O.OOE+OO 1.44E-06 1.85E-06 O.OOE+OO O.OOE+OO 7.46E-04 3.56E-05 Nl-59 4.06E-06 1.46E-06 6.77E-07 O.OOE+OO O.OOE+OO 8.20E-06 6.11 E-07 Nl-63 5.40E-05 3.93E-06 1.81.E-06 O.OOE+OO O.OOE+OO 2.23E-05 1.67E-06 Nl-65 1.92E-10 2.62E-11 1.14E-11 O.OOE+OO O.OOE+OO 7.00E-07 1.54E-06 CU-64 O.OOE+OO 1.83E-10 7.69E-11 O.OOE+OO 5.78E-10 8.48E-07 6.12E-06 ZN-65 4.05E-06 1.29E-05 5.82E-06 O.OOE+OO 8.62E-06 1.08E-04 6.68E-06 ZN-69M 1.02E-09 2.45E-09 2.24E-10 O.OOE+OO 1.48E-09 2.38E-06 1.71 E-05 ZN-69 4.23E-12 8.14E-12 5.65E-13 O.OOE+OO 5.27E-12 1.15E-07 2.04E-09 SE-79 O.OOE+OO 3.83E-07 6.09E-08 O.OOE+OO 5.69E-07 4.47E-05 3.33E-06 BR-82 O.OOE+OO O.OOE+OO 1.69E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.30E-06 BR-83 O.OOE+OO O.OOE+OO 3.01 E-08 O.OOE+OO O.OOE+OO O.OOE+OO 2.90E-08 BR-84 O.OOE+OO O.OOE+OO 3.91 E-08 O.OOE+OO O.OOE+OO O.OOE+OO 2.05E-13 BR-85 O.OOE+OO O.OOE+OO 1.60E-09 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 1.69E-05 7.37E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.08E-06 RB-87 O.OOE+OO 9.86E-06 3.21E-06 O.OOE+OO O.OOE+OO O.OOE+OO 2.88E-07 RB-88 O.OOE+OO 4.84E-08 2.41E-08 O.OOE+OO O.OOE+OO O.OOE+OO 4.18E-19 RB-89 O.OOE+OO 3.20E-08 2.12E-08 O.OOE+OO O.OOE+OO O.OOE+OO 1.16E-21 SR-89 3.80E-05 O.OOE+OO 1.09E-06 O.OOE+OO O.OOE+OO 1.75E-04 4.37E-05 SR-90 3.59E-03 O.OOE+OO 7.21E-05 O.OOE+OO O.OOE+OO 1.20E-03 9.02E-05 SR-91 7.74E-09 O.OOE+OO 3.13E-10 O.OOE+OO O.OOE+OO 4.56E-06 2.39E-05 SR-92 8.43E-10 O.OOE+OO 3.64E-11 O.OOE+OO O.OOE+OO 2.06E-06 5.38E-06 Y-90 2.61E-07 O.OOE+OO 7.01E-09 O.OOE+OO O.OOE+OO 2.12E-05 6.32E-05 Y-91M 3.26E-11 O.OOE+OO 1.27E-12 O.OOE+OO O.OOE+OO 2.40E-07 1.66E-10 Y-91 5.78E-05 O.OOE+OO 1.55E-06 O.OOE+OO O.OOE+OO 2.13E-04 4.81E-05 Y-92 1.29E-09 O.OOE+OO 3.77E-11 O.OOE+OO O.OOE+OO 1.96E-06 9.19E-06 Y-93 1.18E-08 O.OOE+OO 3.26E-10 O.OOE+OO O.OOE+OO 6.06E-06 5.27E-05 ZR-93 5.22E-05 2.92E-06 1.37E-06 O.OOE+OO 1.11 E-05 2.13E-05 1.51 E-06 ZR-95 1.34E-05 4.30E-06 2.91E-06 O.OOE+OO 6.77E-06 2.21E-04 1.88E-05 ZR-97 1.21E-08 2.45E-09 1.13E-09 O.OOE+OO 3.71E-09 9.84E-06 6.54E-05 NB-93M 3.10E-05 1.01 E-05 2.49E-06 O.OOE+OO 1.16E-05 3.11E-05 2.38E-06 NB-95 1.76E-06 9.77E-07 5.26E-07 O.OOE+OO 9.67E-07 6.31E-05 1.30E-05 Rev.29 Page 292 of 329 12/2016
CY-LG-170-301 TABLE 112-27 INHALATION DOSE FACTORS FOR ADULT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI NB-97 2.78E-11 7.03E-12 2.56E-12 O.OOE+OO 8.18E-12. 3.00E-07 3.02E-08 M0-93 O.OOE+OO 1.17E-06 3.17E-08 O.OOE+OO 3.55E-07 5.11 E-05 3.79E-06 M0-99 O.OOE+OO 1.51E-08 2.87E-09 O.OOE+OO 3.64E-08 1.14E-05 3.10E-05 TC-99M 1.29E-13 3.64E-13 4.63E-12 O.OOE+OO 5.52E-12 9.55E-08 5.20E-07 TC-99 3.13E-08 4.64E-08 1.25E-08 O.OOE+OO 5.85E-07 1.01E-04 7.54E-06 TC-101 5.22E-15 7.52E-15 7.38E-14 O.OOE+OO 1.35E-13 4.99E-08 1.36E-21 RU-103 1.91 E-07 O.OOE+OO 8.23E-08 O.OOE+OO 7.29E-07 6.31E-05 1.38E-05 RU-105 9.88E-11 O.OOE+OO 3.89E-11 O.OOE+OO 1.27E-10 1.37E-06 6.02E-06 RU-106 8.64E-06 O.OOE+OO 1.09E-06 O.OOE+OO 1.67E-05 1.17E-03 1.14E-04 RH-105 9.24E-10 6.73E-10 4.43E-10 O.OOE+OO 2.86E-09 2.41E-06 1.09E-05 PD-107 O.OOE+OO 8.27E-08 5.87E-09 O.OOE+OO 6.57E-07 9.47E-06 7.06E-07 PD-109 O.OOE+OO 4.63E-10 1.16E-10 O.OOE+OO 2.35E-09 1.85E-06 1.52E-05 AG-110M 1.35E-06 1.25E-06 7.43E-07 O.OOE+OO 2.46E-06 5.79E-04 3.78E-05 AG-111 4.25E-08 1.78E-08 8.87E-09 O.OOE+OO 5.74E-08 2.33E-05 2.79E-05 CD-113M O.OOE+OO 1.54E-04 4.97E-06 O.OOE+OO 1.71E-04 2.0SE-04 1.59E-05 CD-115M O.OOE+OO 2.46E-05 7.95E-07 O.OOE+OO 1.98E-05 1.76E-04 4.SOE-05 SN-123 3.02E-05 '6.67E-07 9.82E-07 5.67E-07 O.OOE+OO 2.88E-04 3.92E-05 SN-125 1.16E-06 3.12E-08 7.03E-08 2.59E-08 O.OOE+OO 7.37E-05 6.81E-05 SN-126 1.58E-04 4.18E-06 6.00E-06 1.23E-06 O.OOE+OO 1.17E-03 1.59E-05 SB-124 3.90E-06 7.36E-08 1.55E-06 9.44E-09 O.OOE+OO 3.10E-04 5.0SE-05 SB-125 6.67E-06 7.44E-08 1.58E-06 6.75E-09 O.OOE+OO 2.18E-04 1.26E-05 SB-126 4.50E-07 9.13E-09 1.62E-07 2.75E-09 O.OOE+OO 9.57E-05 6.01 E-05 SB-127 3.30E-08 7.22E-10 1.27E-08 3.97E-10 O.OOE+OO 2.05E-05 3.77E-05 TE-125M 4.27E-07 1.98E-07 5.84E-08 1.31E-07 1.55E-06 3.92E-05 8.83E-06 TE-127M 1.58E-06 7.21 E-07 1.96E-07 4.11E-07 5.72E-06 1.20E-04 1.87E-05 TE-127 1.75E-10 8.03E-11 3.87E-11 1.32E-10 6.37E-10 8.14E-07 7.17E-06 TE-129M 1.22E-06 5.84E-07 1.98E-07 4.30E-07 4.57E-06 1.45E-04 4.79E-05 TE-129 6.22E-12 2.99E-12 1.55E-12 4.87E-12 2.34E-11 2.42E-07 1.96E-08 TE-131M 8.74E-09 5.45E-09 3.63E-09 6.88E-09 3.86E-08 1.82E-05 6.95E-05 TE-131 1.39E-12 7.44E-13 4.49E-13 1.17E-12 5.46E-12 1.74E-07 2.30E-09 TE-132 3.25E-08 2.69E-08 2.02E-08 2.37E-08 1.82E-07 3.60E-05 6.37E-05 TE-133M 7.24E-12 5.40E-12 4.17E-12 6.27E-12 3.74E-11 5.51E-07 7.65E-09 TE-134 3.84E-12 3.22E-12 1.57E-12 3.44E-12 2.18E-11 4.34E-07 2.97E-11 1-129 2.48E-06 2.11 E-06 6.91E-06 5.54E-03 4.53E-06 O.OOE+OO 2.22E-07 1-130 5.72E-07 1.68E-06 6.60E-07 1.42E-04 2.61E-06 O.OOE+OO 9.61E-07 1-131 3.15E-06 4.47E-06 2.56E-06 1.49E-03 7.66E-06 O.OOE+OO 7.85E-07 1-132 1.45E-07 4.07E-07 1.45E-07 1.43E-05 6.48E-07 O.OOE+OO 5.0SE-08 1-133 1.0SE-06 1.85E-06 5.65E-07 2.69E-04 3.23E-06 O.OOE+OO 1.11 E-06 1-134 8.05E-08 2.16E-07 7.69E-08 3.73E-06 3.44E-07 O.OOE+OO 1.26E-10 1-135 3.35E-07 873E-07 3.21E-07 . 5.60E-05 1.39E-06 O.OOE+OO 6.56E-07 CS-134M 1.59E-08 3.20E-08 1.72E-08 O.OOE+OO 1.83E-08 2.93E-09 7.92E-09 CS-134 4.66E-05 1.06E-04 9.10E-05 O.OOE+OO 3.59E-05 1.22E-05 1.30E-06 CS-135 1.46E-05 1.29E-05 5.99E-06 O.OOE+OO 5.11 E-06 1.57E-06 2.11 E-07 CS-136 4.88E-06 1.83E-05 1.38E-05 O.OOE+OO 1.07E-05 1.50E-06 1.46E-06 CS-137 5.98E-05 7.76E-05 5.35E-05 O.OOE+OO 2.78E-05 9.40E-06 1.05E-06 Rev.29 Page 293 of 329 12/2016
CY-LG-170-301 TABLE 112-27 INHALATION DOSE FACTORS FOR ADULT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU CS-138 4.14E-08 7.76E-08 4.05E-08 O.OOE+OO 6.00E-08 6.07E-09 2.33E-13 CS-139 2.56E-08 3.63E-08 1.39E-08 O.OOE+OO 3.05E-08 2.84E-09 5.49E-31 BA-139 1.17E-10 8.32E-14 3.42E-12 O.OOE+OO 7.78E-14 4.70E-07 1.12E-07 BA-140 4.88E-06 6.13E-09 3.21E-07 O.OOE+OO 2.09E-09 1.59E-04 2.73E-05 BA-141 1.25E-11 9.41E-15 4.20E-13 O.OOE+OO 8.75E-15 2.42E-07 1.45E-17 BA-142 3.29E-12 3.38E-15 2.07E-13 O.OOE+OO 2.86E-15 1.49E-07 1.96E-26 LA-140 4.30E-08 2.17E-08 5.73E-09 O.OOE+OO O.OOE+OO 1.70E-05 5.73E-05 LA-141 5.34E-10 1.66E-10 2.71E-11 O.OOE+OO O.OOE+OO 1.35E-06 7.31E-06 LA-142 8.54E-11 3.88E-11 9.65E-12 O.OOE+OO O.OOE+OO 7.91E-07 2.64E-07 CE-141 2.49E-06 1.69E-06 1.91E-07 O.OOE+OO 7.83E-07 4.52E-05 1.50E-05 CE-143 2.33E-08 1.72E-08 1.91 E-09 O.OOE+OO 7.60E-09 9.97E-06 2.83E-05 CE-144 4.29E-04 1.79E-04 2.30E-05 O.OOE+OO 1.06E-04 9.72E-04 1.02E-04 PR-143 1.17E-06 4.69E-07 5.80E-08 O.OOE+OO 2.70E-07 3.51E-05 2.50E-05 PR-144 3.76E-12 1.56E-12 1.91E-13 O.OOE+OO 8.81 E-13 1.27E-07 2.69E-18 ND-147 6.59E-07 7.62E-07 4.56E-08 O.OOE+OO 4.45E-07 2.76E-05 2.16E-05 PM-147 8.37E-05 7.87E-06 3.19E-06 O.OOE+OO 1.49E-05 6.60E-05 5.54E-06 PM-148M 9.82E-06 2.54E-06 1.94E-06 O.OOE+OO 3.85E-06 2.14E-04 4.18E-05 PM-148 3.84E-07 6.37E-08 3.20E-08 O.OOE+OO 1.20E-07 3.91E-05 5.80E-05 PM-149 3.44E-08 4.87E-09 1.99E-09 O.OOE+OO 9.19E-09 7.21E-06 2.50E-05 PM-151 8.50E-09 1.42E-09 7.21E-10 O.OOE+OO 2.55E-09 3.94E-06 2.00E-05 SM-151 8.59E-05 1.48E-05 3.55E-06 O.OOE+OO 1.66E-05 4.45E-05 3.25E-06 SM-153 1.70E-08 1.42E-08 1.04E-09 O.OOE+OO 4.59E-09 4.14E-06 1.58E-05 EU-152 2.38E-04 5.41E-05 4.76E-05 O.OOE+OO 3.35E-04 3.43E-04 1.59E-05 EU-154 7.40E-04 9.10E-05 6.48E-05 O.OOE+OO 4.36E-04 5.84E-04 3.40E-05 EU-155 1.01E-04 1.43E-05 9.21 E-06 O.OOE+OO 6.59E-05 9.46E-05 5.95E-06 EU-156 1.93E-06 1.48E-06 2.40E-07 O.OOE+OO 9.95E-07 8.56E-05 4.50E-05 TB-160 2.21E-05 O.OOE+OO 2.75E-06 O.OOE+OO 9.10E-06 1.92E-04 2.68E-05 H0-166M 3.37E-04 1.05E-04 8.00E-05 O.OOE+OO 1.57E-04 3.94E-04 1.59E-05 W-181 6.23E-09 2.03E-09 2.17E-10 O.OOE+OO O.OOE+OO 1.71 E-06 2.53E-07 W-185 1.95E-07 6.47E-08 6.81 E-09 O.OOE+OO O.OOE+OO 5.57E-05 1.07E-05 W-187 1.06E-09 8.85E-10 3.1 OE-10 O.OOE+OO O.OOE+OO 3.63E-06 1.94E-05 U-232 5.14E-02 O.OOE+OO 3.66E-03 O.OOE+OO 5.56E-03 2.22E-01 4.21E-05 U-233 1.09E-02 O.OOE+OO 6.60E-04 O.OOE+OO 2.54E-03 5.32E-02 3.89E-05 U-234 1.04E-02 O.OOE+OO 6.46E-04 O.OOE+OO 2.49E-03 5.22E-02 3.81E-05 U-235 1.00E-02 O.OOE+OO 6.07E-04 O.OOE+OO 2.34E-03 4.90E-02 4.84E-05 U-236 1.00E-02 O.OOE+OO 6.20E-04 O.OOE+OO 2.39E-03 5.00E-02 3.57E-05 U-237 3.67E-08 O.OOE+OO 9.77E-09 O.OOE+OO 1.51E-07 1.02E-05 1.20E-05 U-238 9.58E-03 O.OOE+OO 5.67E-04 O.OOE+OO 2.18E-03 4.58E-02 3.41 E-05 NP-237 1.56E+OO 1.00E+OO 6.87E-02 O.OOE+OO 5.10E-01 5.22E-02 4.92E-05 NP-238 2.96E-07 7.20E-08 4.61E-09 O.OOE+OO 2.72E-08 1.02E-05 2.13E-05 NP-239 2.87E-08 2.54E-08 1.55E-09 O.OOE+OO 8.75E-09 4.70E-06 1.49E-05 PU-238 1.43E+OO 9.71 E-01 6.90E-02 O.OOE+OO 2.96E-01 1.82E-01 4.52E-05 PU-239 1.66E+OO 1.07E+OO 7.75E-02 O.OOE+OO 3.30E-01 1.72E-01 4.13E-05 PU-240 1.65E+OO 1.07E+OO 7.73E-02 O.OOE+OO 3.29E-01 1.72E-01 4.21 E-05 PU-241 3.42E-02 8.69E-03 1.29E-03 O.OOE+OO 5.93E-03 1.52E-04 8.65E-07 Rev.29 Page 294 of 329 12/2016
CY-LG-170-301 TABLE 112-27 INHALATION DOSE FACTORS FOR ADULT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU PU-242 1.53E+OO 1.03E+OO 7.46E-02 O.OOE+OO 3.17E-01 1.65E-01 4.05E-05 PU-244 1.79E+OO 1.18E+OO 8.54E-02 O.OOE+OO 3.64E-01 1.89E-01 6.03E-05 AM-241 1.68E+OO 1.13E+OO 6.71E-02 O.OOE+OO 5.04E-01 6.06E-02 4.60E-05 AM-242M 1.70E+OO 1.06E+OO 6.73E-02 O.OOE+OO 5.01 E-01 2.44E-02 5.79E-05 AM-243 1.68E+OO 1.10E+OO 6.57E-02 O.OOE+OO 4.95E-01 5.75E-02 5.40E-05 CM-242 2.22E-02 1.77E-02 9.84E-04 O.OOE+OO 4.48E-03 3.92E-02 4.91E-05 CM-243 1.10E+OO 7.61 E-01 4.61E-02 O.OOE+OO 2.15E-01 6.31E-02 4.84E-05 CM-244 8.37E-01 5.88E-01 3.51E-02 O.OOE+OO 1.64E-01 6.06E-02 4.68E-05 CM-245 1.74E+OO 1.14E+OO 7.14E-02 O.OOE+OO 3.33E-01 5.85E-02 4.36E-05 CM-246 1.73E+OO 1.14E+OO 7.13E-02 O.OOE+OO 3.33E-01 5.96E-02 4.29E-05 CM-247 1.68E+OO 1.12E+OO 7.03E-02 O.OOE+OO 3.28E-01 5.85E-02 5.63E-05 CM-248 1.40E-01 9.26E+OO 5.79E-01 O.OOE+OO 2.70E+OO 4.82E-01 9.09E-04 CF-252 5.43E-01 O.OOE+OO 2.33E-02 O.OOE+OO O.OOE+OO 1.99E-01 1.78E-04 NUREG/CR-4653 GASPAR II, Technical Reference and User Guide
- I
. i Rev.29 Page 295 of 329 12/2016
CY-LG-170-301 TABLE 112-28 INHALATION DOSE FACTORS FOR TEENAGER (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI H-3 O.OOE+OO 9.06E-08 9.06E-08 9.06E-08 9.06E-08 9.06E-08 9.06E-08 C-14 3.25E-06 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 NA-22 1.76E-05 1.76E-05 1.76E-05 1.76E-05 1.76E-05 1.76E-05 1.76E-05 NA-24 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 P-32 2.36E-04 1.37E-05 8.95E-06 O.OOE+OO O.OOE+OO O.OOE+OO 1.16E-05 CA-41 4.05E-05 O.OOE+OO 4.38E-06 O.OOE+OO O.OOE+OO 1.01 E-01 3.03E-07 SC-46 7.24E-05 1.41 E-04 4.18E-05 O.OOE+OO 1.35E-04 O.OOE+OO 2.98E-05 CR-51 O.OOE+OO O.OOE+OO 1.69E-08 9.37E-09 3.84E-09 2.62E-06 3.75E-07 MN-54 O.OOE+OO 6.39E-06 1.05E-06 O.OOE+OO 1.59E-06 2.48E-04 8.35E-06 MN-56 O.OOE+OO 2.12E-10 3.15E-11 O.OOE+OO 2.24E-10 1.90E-06 7.18E-06 FE-55 4.18E-06 2.98E-06 6.93E-07 O.OOE+OO O.OOE+OO 1.55E-05 7.99E-07 FE-59 1.99E-06 4.62E-06 1.79E-06 O.OOE+OO O.OOE+OO 1.91E-04 2.23E-05 C0-57 O.OOE+OO 1.18E-07 1.15E-07 O.OOE+OO O.OOE+OO 7.33E-05 3.93E-06 C0-58 O.OOE+OO 2.59E-07 3.47E-07 O.OOE+OO O.OOE+OO 1.68E-04 1.19E-05 C0-60 O.OOE+OO 1.89E-06 2.48E-06 O.QOE+OO O.OOE+OO 1.09E-03 3.24E-05 Nl-59 5.44E-06 2.02E-06 9.24E-07 O.OOE+OO O.OOE+OO 1.41 E-05 6.48E-07 Nl-63 7.25E-05 . 5.43E-06 2.47E-06 O.OOE+OO O.OOE+OO 3.84E-05 1.77E-06 Nl-65 2.73E-10 3.66E-11 1.59E-11 O.OOE+OO O.OOE+OO 1.17E-06 4.59E-06 CU-64 O.OOE+OO 2.54E-10 1.06E-10 O.OOE+OO 8.01E-10 1.39E-06 7.68E-06 ZN-65 4.82E-06 1.67E-05 7.80E-06 O.OOE+OO 1.08E-05 1.55E-04 5.83E-06 ZN-69M 1.44E-09 3.39E-09 . 3.11E-10 O.OOE+OO 2.06E-09 3.92E-06 2.14E-05 ZN-69 6.04E-12 1.15E-11 8.07E-13 O.OOE+OO 7.53E-12 1.98E-07 3.56E-08 SE-79 O.OOE+OO 5.43E-07 8.71E-08 O.OOE+OO 8.13E-07 7.71 E-05 3.53E-06 BR-82 O.OOE+OO O.OOE+OO 2.28E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 4.30E-08 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 5.41E-08 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 2.29E-09 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 2.38E-05 1.05E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.21E-06 RB-87 O.OOE+OO 1.40E-05 4.58E-06 O.OOE+OO O.OOE+OO O.OOE+OO 3.05E-07 RB-88 O.OOE+OO 6.82E-08 3.40E-08 O.OOE+OO O.OOE+OO O.OOE+OO 3.65E-15 RB-89 O.OOE+OO 4.40E-08 2.91E-08 O.OOE+OO O.OOE+OO O.OOE+OO 4.22E-17 SR-89 5.43E-05 O.OOE+OO 1.56E-06 O.OOE+OO O.OOE+OO 3.02E-04 4.64E-05 SR-90 4.14E-03 O.OOE+OO 8.33E-05 O.OOE+OO O.OOE+OO 2.06E-03 9.56E-05 SR-91 1.10E-08 O.OOE+OO 4.39E-10 O.OOE+OO O.OOE+OO 7.59E-06 3.24E-05 SR-92 1.19E-09 O.OOE+OO 5.08E-11 O.OOE+OO O.OOE+OO 3.43E-06 1.49E-05 Y-90 3.73E-07 O.OOE+OO 1.00E-08 O.OOE+OO O.OOE+OO 3.66E-05 6.99E-05 Y-91M 4.63E-11 O.OOE+OO 1.77E-12 O.OOE+OO O.OOE+OO 4.00E-07 3.77E-09 Y-91 8.26E-05 O.OOE+OO 2.21E-06 O.OOE+OO O.OOE+OO 3.67E-04 5.11 E-05 Y-92 1.84E-09 O.OOE+OO 5.36E-11 O.OOE+OO O.OOE+OO 3.35E-06 2.06E-05 Y-93 1.69E-08 O.OOE+OO 4.65E-10 O.OOE+OO O.OOE+OO 1.04E-05 7.24E-05 ZR-93 6.83E-05 3.38E-06 1.84E-06 O.OOE+OO 1.16E-05 3.67E-05 1.60E-06 ZR-95 1.82E-05 5.73E-06 3.94E-06 O.OOE+OO 8.42E-06 3.36E-04 1.86E-05 ZR-97 1.72E-08 3.40E-09 1.57E-09 O.OOE+OO 5.15E-09 1.62E-05 7.88E-05 NB-93M 4.14E-05 1.36E-05 3.41E-06 O.OOE+OO 1.59E-05 5.36E-05 2.52E-06 NB-95 2.32E-06 1.29E-06 7.08E-07 O.OOE+OO 1.25E-06 9.39E-05 1.21 E-05 Rev.29 Page 296 of 329 12/2016
CY-LG-170-301 TABLE 112-28 INHALATION DOSE FACTORS FOR TEENAGER (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI NB-97 3.92E-11 9.72E-12 3.55E-12 O.OOE+OO 1.14E-11 4.91 E-07 2.71E-07 M0-93 O.OOE+OO 1.66E-06 4.52E-08 O.OOE+OO 5.06E-07 8.81E-05 3.99E-06 M0-99 O.OOE+OO 2.11E-08 4.03E-09 O.OOE+OO 5.14E-08 1.92E-05 3.36E-05 TC-99M 1.73E-13 4.83E-13 6.24E-12 O.OOE+OO 7.20E-12 1.44E-07 7.66E-07 TC-99 4.48E-08 6.58E-08 1.79E-08 O.OOE+OO 8.35E-07 1.74E-04 7.99E-06 TC-101 7.40E-15 1.05E-14 1.03E-13 O.OOE+OO 1.90E-13 8.34E-08 1.09E-16 RU-103 2.63E-07 O.OOE+OO 1.12E-07 O.OOE+OO 9.29E-07 9.79E-05 1.36E-05 RU-105 1.40E-10 O.OOE+OO 5.42E-11 O.OOE+OO 1.76E-10 2.27E-06 1.13E-05 RU-106 1.23E-05 O.OOE+OO 1.55E-06 O.OOE+OO 2.38E-05 2.01E-03 1.20E-04 RH-105 1.32E-09 9.48E-10 6.24E-10 O.OOE+OO 4.04E-09 4.09E-06 1.23E-05 PD-107 O.OOE+OO 1.17E-07 8.39E-09 O.OOE+OO 9.39E-07 1.63E-05 7.49E-07 PD-109 . O.OOE+OO 6.56E-10 1.66E-10 O.OOE+OO 3.36E-09 3.19E-06 1.96E-05 AG-110M 1.73E-06 1.64E-06 9.99E-07 O.OOE+OO 3.13E-06 8.44E-04 3.41E-05 AG-111 6.07E-08 2.52E-08 1.26E-08 O.OOE+OO 8.17E-08 4.00E-05 3.00E-05 CD-113M O.OOE+OO 2.17E-04 7.10E-06 O.OOE+OO 2.43E-04 3.59E-04 1.68E-05 CD-115M O.OOE+OO 3.48E-05 1.14E-06 O.OOE+OO 2.82E-05 3.03E-04 5.10E-05 SN-123 4.31E-05 9.44E-07 1.40E-06 7.55E-07 O.OOE+OO 4.96E-04 4.16E-05 SN-125 1.66E-06 4.42E-08 9.99E-08 3.45E-08 O.OOE+OO 1.26E-04 7.29E-05 SN-126 2.18E-04 5.39E-06 8.24E-06 1.42E-06 O.OOE+OO 1.72E-03 1.68E-05 SB-124 5.38E-06 9.92E-08 2.10E-06 1.22E-08 O.OOE+OO 4.81 E-04 4.98E-05 SB-125 9.23E-06 1.01 E-07 2.15E-06 8.80E-09 O.OOE+OO 3.42E-04 1.24E-05 SB-126 6.19E-07 1.27E-08 2.23E-07 3.50E-09 O.OOE+OO 1.55E-04 6.01 E-05 SB-127 4.64E-08 9.92E-10 1.75E-08 5.21 E-10 O.OOE+OO 3.31E-05 3.94E-05 TE-125M 6.10E-07 2.80E-07 8.34E-08 1.75E-07 O.OOE+OO 6.70E-05 9.38E-06 TE-127M 2.25E-06 1.02E-06 2.73E-07 5.48E-07 8.17E-06 2.07E-04 1.99E-05 TE-127 2.51 E-10 1.14E-10 5.52E-11 1.77E-10 9.10E-10 1.40E-06 1.01 E-05 TE-129M 1.74E-06 8.23E-07 2.81E-07 5.72E-07 6.49E-06 2.47E-04 5.06E-05 TE-129 8.87E-12 4.22E-12 2.20E-12 6.48E-12 3.32E-11 4.12E-07 2.02E-07 TE-131M 1.23E-08 7.51E-09 5.03E-09 9.06E-09 5.49E-08 2.97E-05 7.76E-05 TE-131 1.97E-12 1.04E-12 6.30E-13 1.55E-12 7.72E-12 2.92E-07 1.89E-09 TE-132 4.50E-08 3.63E-08 2.74E-08 3.07E-08 2.44E-07 5.61E-05 5.79E-05 TE-133M 1.01E-11 7.33E-12 5.71E-12 8.18E-12 5.07E-11 8.71E-07 1.23E-07 TE-134 5.31E-12 4.35E-12 3.64E-12 4.46E-12 2.91 E-11 6.75E-07 1.37E-09 1-129 3.53E-06 2.94E-06 4.90E-06 3.66E-03 5.26E-06 O.OOE+OO 2.29E-07 1-130 7.80E-07 2.24E-06 8.96E-07 1.86E-04 3.44E-06 O.OOE+OO 1.14E-06 1-131 4.43E-06 6.14E-06 3.30E-06 1.83E-03 1.05E-05 O.OOE+OO 8.11 E-07 1-132 1.99E-07 5.47E-07 1.97E-07 1.89E-05 8.65E-07 O.OOE+OO 1.59E-07 1-133 1.52E-06 2.56E-06 7.78E-07 3.65E-04 4.49E-06 O.OOE+OO 1.29E-06 1-134 1.11 E-07 2.90E-07 1.05E-07 4.94E-06 4.58E-07 O.OOE+OO 2.55E-09 1-135 4.62E-07 1.18E-06 4.36E-07 7.76E-05 1.86E-06 O.OOE+OO 8.69E-07 CS-134M 2.20E-08 4.35E-08 2.35E-08 O.OOE+OO 2.54E-08 4.56E-09 2.02E-08 CS-134 6.28E-05 1.41 E-04 6.86E-05 O.OOE+OO 4.69E-05 1.83E-05 1.22E-06 CS-135 2.0BE-05 1.82E-05 4.47E-06 O.OOE+OO 7.30E-06 2.70E-06 2.23E-07 CS-136 6.44E-06 2.42E-05 1.71E-05 O.OOE+OO 1.38E-05 2.22E-06 1.36E-06 CS-137 8.38E-05 1.06E-04 3.89E-05 O.OOE+OO 3.BOE-05 1.51 E-05 1.06E-06 Rev.29 Page 297 of 329 12/2016
CY-LG-170-301 TABLE 112-28 INHALATION DOSE FACTORS FOR TEENAGER (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU CS-138 5.82E-08 1.07E-07 5.58E-08 O.OOE+OO 8.28E-08 9.84E-09 3.38E-11 CS-139 3.65E-08 5.12E-08 1.97E-08 O.OOE+OO 4.34E-08 4.86E-09 1.66E-23 BA-139 1.67E-10 1.18E-13 4.87E-12 O.OOE+OO 1.11E-13 8.08E-07 8.06E-07 BA-140 6.84E-06 8.38E-09 4.40E-07 O.OOE+OO 2.85E-09 2.54E-04 2.86E-05 BA-141 1.78E-11 1.32E-14 5.93E-13 O.OOE+OO 1.23E-14 4.11E-07 9.33E-14 BA-142 4.62E-12 4.63E-15 2.84E-13 O.OOE+OO 3.92E-15 2.39E-07 5.99E-20 LA-140 5.99E-08 2.95E-08 7.82E-09 O.OOE+OO O.OOE+OO 2.68E-05 6.09E-05 LA-141 7.63E-10 2.35E-10 3.87E-11 O.OOE+OO O.OOE+OO 2.31E-06 1.54E-05 LA-142 1.20E-10 5.31 E-11 1.32E-11 O.OOE+OO O.OOE+OO 1.27E-06 1.50E-06 CE-141 3.55E-06 2.37E-06 2.71E-07 O.OOE+OO 1.11E-06 7.67E-05 1.58E-05 CE-143 3.32E-08 2.42E-08 2.70E-09 O.OOE+OO 1.08E-08 1.63E-05 3.19E-05 CE-144 6.11 E-04 2.53E-04 3.28E-05 O.OOE+OO 1.51E-04 1.67E-03 1.08E-04 PR-143 1.67E-06 6.64E-07 8.28E-08 O.OOE+OO 3.86E-07 6.04E-05 2.67E-05 PR-144 5.37E-12 2.20E-12 2.72E-13 O.OOE+OO 1.26E-12 2.19E-07 2.94E-14 ND-147 9.83E-07 1.07E-06 6.41 E-08 O.OOE+OO 6.28E-07 4.65E-05 2.28E-05 PM-147 1.15E-04 1.10E-05 4.50E-06 O.OOE+OO 2.10E-05 1.14E-04 5.87E-06 PM-148M 1.32E-05 3.35E-06 2.62E-06 O.OOE+OO 5.07E-06 3.20E-04 4.10E-05 PM-148 5.44E-07 8.88E-08 4.48E-08 O.OOE+OO 1.60E-07 6.52E-05 6.14E-05 PM-149 4.91E-08 6.89E-09 2.84E-09 O.OOE+OO 1.31E-08 1.24E-05 2.79E-05 PM-151 1.20E-08 1.99E-09 1.01 E-09 O.OOE+OO 3.57E-09 6.56E-06 2.27E-05 SM-151 1.07E-04 2.10E-05 4.86E-06 O.OOE+OO 2.27E-05 7.68E-05 3.53E-06 SM-153 2.43E-08 2.01E-08 1.47E-09 O.OOE+OO 6.56E-09 7.11 E-06 1.77E-05 EU-152 2.96E-04 7.19E-05 6.30E-05 O.OOE+OO 3.34E-04 5.01E-04 1.35E-05 EU-154 9.43E-04 1.23E-04 8.60E-05 O.OOE+OO 5.44E-04 9.12E-04 3.34E-05 EU-155 2.00E-04 1.96E-05 1.21 E-05 O.OOE+OO 7.65E-05 1.51 E-03 5.97E-05 EU-156 2.70E-06 2.03E-06 3.30E-07 O.OOE+OO 1.36E-06 1.37E-04 4.56E-05 TB-160 3.04E-05 O.OOE+OO 3.79E-06 O.OOE+OO 1.20E-05 2.97E-04 2.60E-05 H0-166M 4.40E-04 1.36E-04 9.87E-05 O.OOE+OO 2.00E-04 6.24E-04 1.68E-05 W-181 8.90E-09 2.88E-09 3.01E-10 O.OOE+OO O.OOE+OO 2.95E-06 2.69E-07 W-185 2.78E-07 9.17E-08 9.73E-09 O.OOE+OO O.OOE+OO 9.60E-05 1.14E-05 W-187 1.50E-09 1.22E-09 4.29E-10 O.OOE+OO O.OOE+OO 5.92E-06 2.21E-05 U-232 7.31E-02 O.OOE+OO 5.23E-03 O.OOE+OO 7.94E-03 3.84E-01 4.46E-05 U-233 1.55E-02 O.OOE+OO 9.42E-04 O.OOE+OO 3.63E-03 9.18E-02 4.12E-05 U-234 1.48E-02 O.OOE+OO 9.23E-04 O.OOE+OO 3.55E-03 8.99E-02 4.04E-05 U-235 1.42E-02 O.OOE+OO 8.67E-04 O.OOE+OO 3.34E-03 8.44E-02 5.13E-05 U-236 1.42E-02 O.OOE+OO 8.86E-04 O.OOE+OO 3.41 E-03 8.62E-02 3.79E-05 U-237 5.25E-08 O.OOE+OO 1.40E-08 O.OOE+OO 2.16E-07 1.76E-05 1.29E-05 U-238 1.36E-02 O.OOE+OO 8.10E-04 O.OOE+OO 3.12E-03 7.89E-02 3.62E-05 NP-237 1.64E+OO 1.06E+OO 7.21E-02 O.OOE+OO 5.35E-01 8.99E-02 5.22E-05 NP-238 4.23E-07 1.02E-07 6.59E-09 O.OOE+OO 3.88E-08 1.75E-05 2.38E-05 NP-239 4.23E-08 3.60E-08 2.21E-09 O.OOE+OO 1.25E-08 8.11E-06 1.65E-05 PU-238 1.50E+OO 1.03E+OO 7.22E-02 O.OOE+OO 3.1 OE-01 3.12E-01 4.79E-05 PU-239 1.73E+OO 1.12E+OO 8.05E-02 O.OOE+OO 3.44E-01 2.93E-01 4.37E-05 PU-240 1.72E+OO 1.12E+OO 8.04E-02 O.OOE+OO 3.43E-01 2.93E-01 4.46E-05 PU-241 3.74E-02 9.56E-03 1.40E-03 O.OOE+OO 6.47E-03 2.60E-04 9.17E-07 Rev.29 Page 298 of 329 12/2016
CY-LG-170-301 TABLE 112-28 INHALATION DOSE FACTORS FOR TEENAGER (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU PU-242 1.60E+OO 1.08E+OO 7.75E-02 O.OOE+OO 3.31 E-01 2.82E-01 4.29E-05 PU-244 1.87E+OO 1.24E+OO 8.88E-02 O.OOE+OO 3.79E-01 3.23E-01 6.39E-05 AM-241 1.77E+OO 1.20E+OO 7.10E-02 O.OOE+OO 5.32E-01 1.05E-01 4.88E-05 AM-242M 1.79E+OO 1.13E+OO 7.15E-02 O.OOE+OO 5.30E-01 4.21E-02 6.14E-05 AM-243 1.77E+OO 1.17E+OO 6.95E-02 O.OOE+OO 5.21E-01 9.91E-02 5.72E-05 CM-242 3.17E-02 2.51E-02 1.41 E-03 O.OOE+OO 6.40E-03 6.76E-02 5.21E-05 CM-243 1.19E+OO 8.30E-01 5.00E-02 O.OOE+OO 2.34E-01 1.09E-01 5.13E-05 CM-244 9.19E-01 6.53E-01 3.88E-02 O.OOE+OO 1.81 E-01 1.05E-01 4.96E-05 CM-245 1.83E+OO 1.22E+OO 7.53E-02 O.OOE+OO 3.52E-01 1.01 E-01 4.63E-05 CM-246 1.81E+OO 1.22E+OO 7.52E-02 O.OOE+OO 3.51E-01 1.03E-01 4.54E-05 CM-247 1.77E+OO 1.19E+OO 7.41E-02 O.OOE+OO 3.46E-01 1.01E-01 5.97E-05 CM-248 1.47E-01 9.83E+OO 6.11E-01 O.OOE+OO 2.85E+OO 8.32E-01 9.63E-04 CF-252 7.16E-01 O.OOE+OO 3.0?E-02 O.OOE+OO O.OOE+oo 3.43E-01 1.89E-04 NUREG/CR-4653 GASPAR II, Technical Reference and User Guide Rev.29 Page 299 of 329 12/2016
CY-LG-170-301 TABLE 112-29 INHALATION DOSE FACTORS FOR CHILD (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI H-3 O.OOE+OO 1.73E-07 1.73E-07 1.73E-07 1.73E-07 1.73E-07 1.73E-07 C-14 9.70E-06 1.82E-06 1.82E-06 1.82E-06 1.82E-06 1.82E-06 1.82E-06 NA-22 4.41E-05 4.41E-05 4.41E-05 4.41E-05 4.41E-05 4.41E-05 4.41 E-05 NA-24 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 P-32 7.04E-04 3.09E-05 2.67E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.14E-05 CA-41 7.06E-05 O.OOE+OO 7.70E-06 O.OOE+OO O.OOE+OO 7.21E-02 2.94E-07 SC-46 1.97E-04 2.70E-04 1.04E-04 O.OOE+OO 2.39E-04 O.OOE+OO 2.45E-05 CR-51 O.OOE+OO O.OOE+OO 4.17E-08 2.31E-08 6.57E-09 4.59E-06 2.93E-07 MN-54 O.OOE+OO 1.16E-05 2.57E-06 O.OOE+OO 2.71E-06 4.26E-04 6.19E-06 MN-56 O.OOE+OO 4.48E-10 8.43E-11 O.OOE+OO 4.52E-10 3.55E-06 3.33E-05 FE-55 1.28E-05 6.80E-06 2.10E-06 O.OOE+OO O.OOE+OO 3.00E-05 7.75E-07 FE-59 5.59E-06 9.04E-06 4.51E~o6 O.OOE+OO O.OOE+OO 3.43E-04 1.91 E-05 C0-57 O.OOE+OO 2.44E-07 2.88E-07 O.OOE+OO O.OOE+OO 1.37E-04 3.58E-06 C0-58 O.OOE+OO 4.79E-07 8.55E-07 O.OOE+OO O.OOE+OO 2.99E-04 9.29E-06 C0-60 O.OOE+OO 3.55E-06 6.12E-06 O.OOE+OO O.OOE+OO 1.91 E-03 2.60E-05 Nl-59 1.66E-05 4.67E-06 2.83E-06 O.OOE+OO O.OOE+OO 2.73E-05 6.29E-07 Nl-63 2.22E-04 1.25E-05 7.56E-06 O.OOE+OO O.OOE+OO 7.43E-05 1.71E-06 Nl-65 8.08E-10 7.99E-11 4.44E-11 O.OOE+OO O.OOE+OO 2.21E-06 2.27E-05 CU-64 O.OOE+OO 5.39E-10 2.90E-10 O.OOE+OO 1.63E-09 2.59E-06 9.92E-06 ZN-65 1.15E-05 3.06E-05 1.90E-05 O.OOE+OO 1.93E-05 2.69E-04 4.41 E-06 ZN-69M 4.26E-09 7.28E-09 8.59E-10 O.OOE+OO 4.22E-09 7.36E-06 2.71E-05 ZN-69 1.81E-11 2.61E-11 2.41E-12 O.OOE+OO 1.58E-11 3.84E-07 2.75E-06 SE-79 O.OOE+OO 1.23E-06 2.60E-07 O.OOE+OO 1.71 E-06 1.49E-04 3.43E-06 BR-82 O.OOE+OO . O.OOE+OO 5.66E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 1.28E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 1.48E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 6.84E-09 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO RB-86 O.OOE+OO 5.36E-05 3.09E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.16E-06 RB-87 O.OOE+OO 3.16E-05 1.37E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.96E-07 RB-88 O.OOE+OO 1.52E-07 9.90E-08 O.OOE+OO O.OOE+OO O.OOE+OO 4.66E-09 RB-89 O.OOE+OO 9.33E-08 7.83E-08 O.OOE+OO O.OOE+OO O.OOE+OO 5.11E-10 SR-89 1.62E-04 O.OOE+OO 4.66E-06 O.OOE+OO O.OOE+OO 5.83E-04 4.52E-05 SR-90 1.04E-02 O.OOE+OO 2.07E-04 O.OOE+OO O.OOE+OO 3.99E-03* 9.28E-05 SR-91 3.28E-08 O.OOE+OO 1.24E-09 O.OOE+OO O.OOE+OO 1.44E-05 4.70E-05 SR-92 3.54E-09 O.OOE+OO 1.42E-10 O.OOE+OO O.OOE+OO 6.49E-06 6.55E-05 Y-90 1.11E-06 O.OOE+OO 2.99E-08 O.OOE+OO O.OOE+OO 7.07E-05 7.24E-05 Y-91M 1.37E-10 O.OOE+OO 4.98E-12 O.OOE+OO O.OOE+OO 7.60E-07 4.64E-07 Y-91 2.47E-04 O.OOE+OO 6.59E-06 O.OOE+OO O.OOE+OO 7.10E-04 4.97E-05 Y-92 5.50E-09 O.OOE+OO 1.57E-10 O.OOE+OO O.OOE+OO 6.46E-06 6.46E-05
- Y-93 5.04E-08 O.OOE+OO 1.38E-09 O.OOE+OO O.OOE+OO 2.01E-05 1.05E-04 ZR-93 2.07E-04 7.80E-06 5.55E-06 O.OOE+OO 3.00E-05 7.10E-05 1.47E-06 ZR-95 5.13E-05 1.13E-05 1.00E-05 O.OOE+OO 1.61 E-05 6.03E-04 1.65E-05 ZR-97 5.07E-08 7.34E-09 4.32E-09 O.OOE+OO 1.05E-08 3.06E-05 9.49E-05 NB-93M 1.27E-04 3.17E-05 1.04E-05 O.OOE+OO 3.44E-05 1.04E-04 2.45E-06 NB-95 6.35E-06 2.48E-06 1.77E-06 O.OOE+OO 2.33E-06 1.66E-04 1.00E-05 Rev.29 Page 300 of 329 12/2016
CY-LG-170-301 TABLE 112-29 INHALATION DOSE FACTORS FOR CHILD (Daipi) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU . NB-97 1.16E-10 2.08E-11 9.74E-12 O.OOE+OO 2.31E-11 9.23E-07 7.52E-06 M0-93 O.OOE+OO 3.76E-06 1.35E-07 O.OOE+OO 1.06E-06 1.70E-04 3.78E-06 M0-99 O.OOE+OO 4.66E-08 1.15E-08 O.OOE+OO 1.06E-07 3.66E-05 3.42E-05 TC-99M 4.81E-13 9.41E-13 1.56E-11 O.OOE+OO 1.37E-11 2.57E-07 1.30E-06 TC-99 1.34E-07 1.49E-07 5.35E-08 O.OOE+OO 1.75E-06 3.37E-04 7.75E-06 TC-101 2.19E-14 2.30E-14 2.91E-13 O.OOE+OO 3.92E-13 1.58E-07 4.41E-09 RU-103 7.55E-07 O.OOE+OO 2.90E-07 O.OOE+OO 1.90E-06 1.79E-04 1.21 E-05 RU-105 4.13E-10 O.OOE+OO 1.50E-10 O.OOE+OO 3.63E-10 4.30E-06 2.69E-05 RU-106 3.68E-05 O.OOE+OO 4.57E-06 O.OOE+OO 4.97E-05 3.87E-03 1.16E-04 RH-105 3.91E-09 2.10E-09 1.79E-09 O.OOE+OO 8.39E-09 7.82E-06 1.33E-05 PD-107 O.OOE+OO 2.65E-07 2.51E-08 O.OOE+OO 1.97E-06 3.16E-05 7.26E-07 PD-109 O.OOE+OO 1.48E-09 4.95E-10 O.OOE+OO 7.06E-09 6.16E-06 2.59E-05 AG-110M 4.56E-06 3.08E-06 2.47E-06 O.OOE+OO 5.74E-06 1.48E-03 2.71E-05 AG-111 1.81 E-07 5.68E-08 3.75E-08 O.OOE+OO 1.71E-07 7.73E-05 2.98E-05 CD-113M O.OOE+OO 4.93E-04 2.12E-05 O.OOE+OO 5.13E-04 6.94E-04 1.63E-05 CD-115M O.OOE+OO 7.88E-05 3.39E-06 O.OOE+OO 5.93E-05 5.86E-04 4.97E-05 SN-123 1.29E-04 2.14E-06 4.19E-06 2.27E-06 O.OOE+OO 9.59E-04 4.05E-05 SN-125 4.95E-06 9.94E-08 2.95E-07 1.03E-07 O.OOE+OO 2.43E-04 7.17E-05 SN-126 6.23E-04 1.04E-05 2.36E-05 2.84E-06 O.OOE+OO 3.02E-03 1.63E-05 SB-124 1.55E-05 2.00E-07 5.41 E-06 3.41 E-08 O.OOE+OO 8.76E-04 4.43E-05 SB-125 2.66E-05 2.05E-07 5.59E-06 2.46E-08 O.OOE+OO 6.27E-04 1.09E-05 SB-126 1.72E-06 2.62E-08 6.16E-07 1.00E-08 O.OOE+OO 2.86E-04 5.67E-05 SB-127 1.36E-07 2.09E-09 4.70E-08 1.51 E-09 O.OOE+OO 6.17E-05 3.82E-05 TE-125M 1.82E-06 6.29E-07 2.47E-07 5.20E-07 O.OOE+OO 1.29E-04 9.13E-06 TE-127M 6.72E-06 2.31E-06 8.16E-07 1.64E-06 1.72E-05 4.00E-04 1.93E-05 TE-127 7.49E-10 2.57E-10 1.65E-10 5.30E-10 1.91 E-09 2.71E-06 1.52E-05 TE-129M 5.19E-06 1.85E-06 8.22E-07 1.71 E-06 1.36E-05 4.76E-04 4.91E-05 TE-129 2.64E-11 9.45E-12 6.44E-12 1.93E-11 6.94E-11 7.93E-07 6.89E-06 TE-131M 3.63E-08 1.60E-08 1.37E-08 2.64E-08 1.0BE-07 5.56E-05 8.32E-05 TE-131 5.87E-12 2.28E-12 1.78E-12 4.59E-12 1.59E-11 5.55E-07 3.60E-07 TE-132 1.30E-07 7.36E-08 7.12E-08 8.58E-08 4.79E-07 1.02E-04 3.72E-05 TE-133M 2.93E-11 1.51E-11 1.50E-11 2.32E-11 1.01E-10 1.60E-06 4.77E-06 TE-134 1.53E-11 8.81E-12 9.40E-12 1.24E-11 5.71E-11 1.23E-06 4.87E-07 1-129 1.05E-05 6.40E-06 5.71E-06 4.28E-03 1.0BE-05 O.OOE+OO 2.15E-07 1-130 2.21E-06 4.43E-06 2.28E-06 4.99E-04 6.61 E-06 O.OOE+OO 1.38E-06 1-131 1.30E-05 1.30E-05 7.37E-06 4.39E-03 2.13E-05 O.OOE+OO 7.68E-07 1-132 5.72E-07 1.10E-06 5.07E-07 5.23E-05 1.69E-06 O.OOE+OO 8.65E-07 1-133 4.48E-06 5.49E-06 2.08E-06 1.04E-03 9.13E-06 O.OOE+OO 1.48E-06 1-134 3.17E-07 5.84E-07 2.69E-07 1.37E-05 8.92E-07 O.OOE+OO 2.58E-07 1-135 1.33E-06 2.36E-06 1.12E-06 2.14E-04 3.62E-06 O.OOE+OO 1.20E-06 CS-134M 6.33E-08 8.92E-08 6.12E-08 O.OOE+OO 4.94E-08 8.35E-09 7.92E-08 CS-134 1.76E-04 2.74E-04 6.07E-05 O.OOE+OO 8.93E-05 3.27E-05 1.04E-06 CS-135 6.23E-05 4.13E-05 4.45E-06 O.OOE+OO 1.53E-05 5.22E-06 2.17E-07 CS-136 1.76E-05 4.62E-05 3.14E-05 O.OOE+OO 2.58E-05 3.93E-06 1.13E-06 CS-137 2.45E-04 2.23E-04 3.47E-05 O.OOE+OO 7.63E-05 2.81E-05 9.78E-07 Rev.29 Page 301 of 329 12/2016
CY-LG-170-301 TABLE 112-29 INHALATION DOSE FACTORS FOR CHILD (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI CS-138 1.71E-07 2.27E-07 1.50E-07 O.OOE+OO 1.68E-07 1.84E-08 7.29E-08 CS-139 1.09E-07 1.15E-07 5.80E-08 O.OOE+OO 9.08E-08 9.36E-09 7.23E-12 BA-139 4.98E-10 2.66E-13 1.45E-11 O.OOE+OO 2.33E-13 1.56E-06 1.56E-05 BA-140 2.00E-05 1.75E-08 1.17E-06 O.OOE+OO 5.71E-09 4.71E-04 2.75E-05 BA-141 5.29E-11 2.95E-14 1.72E-12 O.OOE+OO 2.56E-14 7.89E-07 7.44E-08 BA-142 1.35E-11 9.73E-15 7.54E-13 O.OOE+OO 7.87E-15 4.44E-07 7.41E-10 LA-140 1.74E-07 6.08E-08 2.04E-08 O.OOE+OO O.OOE+OO 4.94E-05 6.10E-05 LA-141 2.28E-09 5.31E-10 1.15E-10 O.OOE+OO O.OOE+OO 4.48E-06 4.37E-05 LA-142 3.50E-10 1.11 E-10 3.49E-11 O.OOE+OO O.OOE+OO 2.35E-06 2.05E-05 CE-141 1.06E-05 5.28E-06 7.83E-07 O.OOE+OO 2.31E-06 1.47E-04 1.53E-05 CE-143 9.89E-08 5.37E-08 7.77E-09 O.OOE+OO 2.26E-08 3.12E-05 3.44E-05 CE-144 1.83E-03 5.72E-04 9.77E-05 O.OOE+OO 3.17E-04 3.23E-03 1.0SE-04 PR-143 4.99E-06 1.50E-06 2.47E-07 O.OOE+OO 8.11E-07 1.17E-04 2.63E-05 PR-144 1.61E-11 4.99E-12 8.10E-13 O.OOE+OO 2.64E-12 4.23E-07 5.32E-08 ND-147 2.92E-06 2.36E-06 1.84E-07 O.OOE+OO 1.30E-06 8.87E-05 2.22E-05 PM-147 3.52E-04 2.52E-05 1.36E-05 O.OOE+OO 4.45E-05 2.20E-04 5.70E-06 PM-148M 3.31E-05 6.55E-06 6.55E-06 O.OOE+OO 9.74E-06 5.72E-04 3.58E-05 PM-148 1.61E-06 1.94E-07 1.25E-07 O.OOE+OO 3.30E-07 1.24E-04 6.01E-05 PM-149 1.47E-07 1.56E-08 8.45E-09 O.OOE+OO 2.75E-08 2.40E-05 2.92E-05 PM-151 3.57E-08 4.33E-09 2.82E-09 O.OOE+OO 7.35E-09 1.24E-05 2.50E-05 SM-151 3.14E-04 4.75E-05 1.49E-05 O.OOE+OO 4.89E-05 1.48E-04 3.43E-06 SM-153 7.24E-08 4.51E-08 4.35E-09 O.OOE+OO 1.37E-08 1.37E-05 1.87E-05 EU-152 7.42E-04 1.37E-04 1.61E-04 O.OOE+OO 5.73E-04 9.00E-04 1.14E-05 EU-154 2.74E-03 2.49E-04 2.27E-04 O.OOE+OO 1.09E-03 1.66E-03 2.98E-05 EU-155 5.60E-04 4.05E-05 3.18E-05 O.OOE+OO 1.51E-04 2.79E-04 5.39E-05 EU-156 7.89E-06 4.23E-06 8.75E-07 O.OOE+OO 2.72E-06 2.54E-04 4.24E-05 TB-160 7.79E-05 O.OOE+OO 9.67E-06 O.OOE+OO 2.32E-05 5.34E-04 2.28E-05 H0-166M 1.34E-03 2.81E-04 2.37E-04 O.OOE+OO 4.01 E-04 1.13E-03 1.63E-05 W-181 2.66E-08 6.52E-09 8.99E-10 O.OOE+OO O.OOE+OO 5.71E-06 2.61E-07 W-185 8.31E-07 2.08E-07 2.91E-08 O.OOE+OO O.OOE+OO 1.86E-04 1.11E-05 W-187 4.41E-09 2.61E-09 1.17E-09 O.OOE+OO O.OOE+OO 1.11E-05 2.46E-05 U-232 2.19E-01 O.OOE+OO 1.56E-02 O.OOE+OO 1.67E-02 7.42E-01 4.33E-05 U-233 4.64E-02 O.OOE+OO 2.82E-03 O.OOE+OO 7.62E-03 1.77E-01 4.00E-05 U-234 4.46E-02 O.OOE+OO 2.76E-03 O.OOE+OO 7.47E-03 1.74E-01 3.92E-05 u:23s 4.27E-02 O.OOE+OO 2.59E-03 O.OOE+OO 7.01E-03 1.63E-01 4.98E-05 U-236 4.27E-02 O.OOE+OO 2.65E-03 O.OOE+OO 7.16E-03 1.67E-01 3.67E-05 U-237 1.57E-07 O.OOE+OO 4.17E-08 O.OOE+OO 4.53E-07 3.40E-05 1.29E-05 U-238 4.09E-02 O.OOE+OO 2.42E-03 O.OOE+OO 6.55E-03 1.53E-01 3.51E-05 NP-237 2.72E+OO 1.62E+OO 1.19E-01 O.OOE+OO 7.41E-01 1.74E-01 5.06E-05 NP-238 1.26E-06 2.30E-07 1.97E-08 O.OOE+OO 8.16E-08 3.39E-05 2.50E-05 NP-239 1.26E-07 8.14E-08 6.35E-09 O.OOE+OO 2.63E-08 1.57E-05 1.73E-05 PU-238 2.55E+OO 1.60E+OO 1.21 E-01 O.OOE+OO 4.47E-01 6.08E-01 4.65E-05 PU-239 2.79E+OO 1.68E+OO 1.28E-01 O.OOE+OO 4.78E-01 5.72E-01 4.24E-05 PU-240 2.79E+OO 1.68E+OO 1.27E-01 O.OOE+OO 4.77E-01 5.71E-01 4.33E-05 PU-241 7.94E-02 1.75E-02 2.93E-03 O.OOE+OO 1.10E-02 5.06E-04 8.90E-07 Rev.29 Page 302 of 329 12/2016
CY-LG-170-301 TABLE 112-29 INHALATION DOSE FACTORS FOR CHILD (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI PU-242 2.59E+OO 1.62E+OO 1.23E-01 O.OOE+OO 4.60E-01 5.50E-01 4.16E-05 PU-244 3.02E+OO 1.85E+OO 1.41E-01 O.OOE+OO 5.27E-01 6.30E-01 6.20E-05 AM-241 2.97E+OO 1.84E+OO 1.24E-01 O.OOE+OO 7.63E-01 2.02E-01 4.73E-05 AM-242M 3.07E+OO 1.76E+OO 1.27E-01 O.OOE+OO 7.71 E-01 8.14E-02 5.96E-05 AM-243 2.94E+OO 1.78E+OO 1.20E-01 O.OOE+OO 7.42E-01 1.92E-01 5.55E-05 CM-242 9.48E-02 5.68E-02 4.20E-03 O.OOE+OO 1.34E-02 1.31 E-01 5.06E-05 CM-243 2.32E+OO 1.42E+OO 9.95E-02 O.OOE+OO 3.74E-01 2.10E-01 4.98E-05 CM-244 1.94E+OO 1.18E+OO 8.31E-02 O.OOE+OO 3.06E-01 2.02E-01 4.82E-05 CM-245 3.05E+OO 1.84E+OO 1.28E-01 O.OOE+OO 5.03E-01 1.95E-01 4.49E-05 CM-246 3.02E+OO 1.84E+OO 1.28E-01 O.OOE+OO 5.03E-01 1.99E-01 4.41E-05 CM-247 2.94E+OO 1.82E+OO 1.26E-01 O.OOE+OO 4.95E-01 1.95E-01 5.80E-05 CM-248 2.45E-01 1.50E-01 1.04E+OO O.OOE+OO 4.08E+OO 1.61E+OO 9.35E-04 CF-252 2.18E+OO O.OOE+OO 9.33E-02 O.OOE+OO O.OOE+OO 6.62E-01 1.84E-04 NUREG/CR-4653 GASPAR II, Technical Reference and User Guide Rev.29 Page 303 of 329 12/2016
CY-LG-170-301 TABLE 112-30 INHALATION DOSE FACTORS FOR INFANT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI H-3 O.OOE+OO 2.63E-07 2.63E-07 2.63E-07 2.63E-07 2.63E-07 2.63E-07 C-14 1.89E-05 3.79E-06 3.79E-06 3.79E-06 3.79E-06 3.79E-06 3.79E-06 NA-22 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 NA-24 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 P-32 1.45E-03 8.03E-05 5.53E-05 O.OOE+OO O.OOE+OO O.OOE+OO 1.15E-05 CA-41 7.48E-05 O.OOE+OO 8.16E-06 O.OOE+OO O.OOE+OO 6.94E-02 2.96E-07 SC-46 3.75E-04 5.41E-04 1.69E-04 O.OOE+OO 3.56E-04 O.OOE+OO 2.19E-05 CR-51 O.OOE+OO O.OOE+OO 6.39E-08 4.11 E-08 9.45E-09 9.17E-06 2.55E-07 MN-54 O.OOE+OO 1.81E-05 3.56E-06 O.OOE+OO 3.56E-06 7.14E-04 5.04E-06 MN-56 O.OOE+OO 1.10E-09 1.58E-10 O.OOE+OO 7.86E-10 8.95E-06 5.12E-05 FE-55 1.41 E-05 8.39E-06 2.38E-06 O.OOE+OO O.OOE+OO 6.21E-05 7.82E-07 FE-59 9.69E-06 1.68E-05 6.77E-06 O.OOE+OO O.OOE+OO 7.25E-04 1.77E-05 C0-57 O.OOE+OO 4.65E-07 4.58E-07 O.OOE+OO O.OOE+OO 2.71E-04 3.47E-06 C0-58 O.OOE+OO 8.71E-07 1.30E-06 O.OOE+OO O.OOE+OO 5.55E-04 7.95E-06
- C0-60 O.OOE+OO 5.73E-06 8.41E-06 O.OOE+OO O.OOE+OO 3.22E-03 2.28E-05 Nl-59 1.81E-05 5.44E-06 3.10E-06 O.OOE+OO O.OOE+OO 5.48E-05 6.34E-07 Nl-63 2.42E-04 1.46E-05 8.29E-06 O.OOE+OO O.OOE+OO 1.49E-04 1.73E-06 Nl-65 1.71E-09 2.03E-10 8.79E-11 O.OOE+OO O.OOE+OO 5.80E-06 3.58E-05 CU-64 O.OOE+OO 1.34E-09 5.53E-10 O.OOE+OO 2.84E-09 6.64E-06 1.07E-05 ZN-65 1.38E-05 4.47E-05 2.22E-05 O.OOE+OO 2.32E-05 4.62E-04 3.67E-05 ZN-69M 8.98E-09 1.84E-08 1.67E-09 O.OOE+OO 7.45E-09 1.91 E-05 2.92E-05 ZN-69 3.85E-11 6.91 E-11 5.13E-12 O.OOE+OO 2.87E-11 1.05E-06 9.44E-06 SE-79 O.OOE+OO 2.25E-06 4.20E-07 O.OOE+OO 2.47E-06 2.99E-04 3.46E-06 BR-82 O.OOE+OO O.OOE+OO 9.49E-06 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-83 O.OOE+OO O.OOE+OO 2.72E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-84 O.OOE+OO O.OOE+OO 2.86E-07 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO BR-85 O.OOE+OO O.OOE+OO 1.46E-08 O.OOE+OO O.OOE+OO o:ooE+oo O.OOE+OO RB-86 O.OOE+OO 1.36E-04 6.30E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.17E-06 RB-87 O.OOE+OO 7.11 E-05 2.64E-05 O.OOE+OO O.OOE+OO O.OOE+OO 2.99E-07 RB-88 O.OOE+OO 3.98E-07 2.05E-07 O.OOE+OO O.OOE+OO O.OOE+OO 2.42E-07 RB-89 O.OOE+OO 2.29E-07 1.47E-07 O.OOE+OO O.OOE+OO O.OOE+OO 4.87E-08 SR-89 2.84E-04 O.OOE+OO 8.15E-06 O.OOE+OO O.OOE+OO 1.45E-03 4.57E-05 SR-90 1.11 E-02 O.OOE+OO 2.23E-04 O.OOE+OO O.OOE+OO 8.03E-03 9.36E-05 SR-91 6.83E-08 O.OOE+OO 2.47E-09 O.OOE+OO O.OOE+OO 3.76E-05 5.24E-05 SR-92 7.50E-09 O.OOE+OO 2.79E-10 O.OOE+OO O.OOE+OO 1.?0E-05 1.00E-04 Y-90 2.35E-06 O.OOE+OO 6.30E-08 O.OOE+OO O.OOE+OO 1.92E-04 7.43E-05 Y-91M 2.91E-10 O.OOE+OO 9.90E-12 O.OOE+OO. O.OOE+OO 1.99E-06 1.68E-06 Y-91 4.20E-04 O.OOE+OO 1.12E-05 O.OOE+OO O.OOE+OO 1.75E-03 5.02E-05 Y-92 1.17E-08 O.OOE+OO 3.29E-10 O.OOE+OO O.OOE+OO 1.75E-05 9.04E-05 Y-93 1.0?E-07 O.OOE+OO 2.91E-09 O.OOE+OO O.OOE+OO 5.46E-05 1.19E-04 ZR-93 2.24E-04 9.51E-06 6.18E-06 O.OOE+OO 3.19E-05 1.37E-04 1.48E-06 ZR-95 8.24E-05 1.99E-05 1.45E-05 O.OOE+OO 2.22E-05 1.25E-03 1.55E-05 ZR-97 1.07E-07 1.83E-08 8.36E-09 O.OOE+OO 1.85E-08 7.88E-05 1.00E-04 NB-93M 1.38E-04 3.59E-05 1.15E-05 O.OOE+OO 3.68E-05 2.09E-04 2.47E-06 NB-95 1.12E-05 4.59E-06 2.70E-06 O.OOE+OO 3.37E-06 3.42E-04 9.05E-06 Rev.29 Page 304 of 329 12/2016
CY-LG-170-301 TABLE 112-30 INHALATION DOSE FACTORS FOR INFANT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG Gl-LLI NB-97 2.44E-10 5.21 E-11 1.88E-11 O.OOE+OO 4.07E-11 2.37E-06 1.92E-05 M0-93 O.OOE+OO 6.46E-06 2.22E-07 O.OOE+OO 1.54E-06 3.40E-04 3.76E-06 M0-99 O.OOE+OO 1.18E-07 2.31E-08 O.OOE+OO 1.89E-07 9.63E-05 3.48E-05 TC-99M 9.98E-13 2.06E-12 2.66E-11 O.OOE+OO 2.22E-11 5.79E-07 1.45E-06 TC-99 2.09E-07 2.68E-07 8.85E-08 O.OOE+OO 2.49E-06 6.77E-04 7.82E-06 TC-101 4.65E-14 5.88E-14 5.80E-13 O.OOE+OO 6.99E-13 4.17E-07 6.03E-07 RU-103 1.44E-06 O.OOE+OO 4.85E-07 O.OOE+OO 3.03E-06 3.94E-04 1.15E-05 RU-105 8.74E-10 O.OOE+OO 2.93E-10 O.OOE+OO 6.42E-10 1.12E-05 3.46E-05 RU-106 6.20E-05 O.OOE+OO 7.77E-06 O.OOE+OO 7.61E-05 8.26E-03 1.17E-04 RH-105 8.26E-09 5.41E-09 3.63E-09 O.OOE+OO 1.50E-08 2.08E-05 1.37E-05 PD-107 O.OOE+OO 4.92E-07 4.11 E-08 O.OOE+OO 2.75E-06 6.34E-05 7.33E-07 PD-109 O.OOE+OO 3.92E-09 1.05E-09 O.OOE+OO 1.28E-08 1.68E-05 2.85E-05 AG-110M 7.13E-06 5.16E-06 3.57E-06 O.OOE+OO 7.80E-06 2.62E-03 2.36E-05 AG-111 3.75E-07 1.45E-07 7.75E-08 O.OOE+OO 3.05E-07 2.06E-04 3.02E-05 CD-113M O.OOE+OO 6.67E-04 2.64E-05 O.OOE+OO 5.80E-04 1.40E-03 1.65E-05 CD-115M O.OOE+OO 1.73E-04 6.19E-06 O.OOE+OO 9.41 E-05 1.47E-03 5.02E-05 SN-123 2.09E-04 4.21E-06 7.28E-06 4.27E-06 O.OOE+OO 2.22E-03 4.08E-05 SN-125 1.01 E-05 2.51E-07 6.00E-07 2.47E-07 O.OOE+OO 6.43E-04 7.26E-05 SN-126 8.30E-04 1.44E-05 3.52E-05 3.84E-06 O.OOE+OO 4.93E-03 1.65E-05 SB-124 2.71E-05 3.97E-07 8.56E-06 7.18E-08 O.OOE+OO 1.89E-03 4.22E-05 SB-125 3.69E-05 3.41E-07 7.78E-06 4.45E-08 O.OOE+OO 1.17E-03 1.05E-05 SB-126 3.08E-06 6.01E-08 1.11E-06 2.35E-08 O.OOE+OO 6.88E-04 5.33E-05 SB-127 2.82E-07 5.04E-09 8.76E-08 3.60E-09 O.OOE+OO 1.54E-04 3.78E-05 TE-125M 3.40E-06 1.42E-06 4.70E-07 1.16E-06 O.OOE+OO 3.19E-04 9.22E-06 TE-127M 1.19E-05 4.93E-06 1.48E-06 3.48E-06 2.68E-05 9.37E-04 1.95E-05 TE-127 1.59E-09 6.81E-10 3.49E-10 1.32E-09 3.47E-09 7.39E-06 1.74E-05 TE-129M 1.01E-05 4.35E-06 1.59E-06 3.91E-06 2.27E-05 1.20E-03 4.93E-05 TE-129 5.63E-11 2.48E-11 1.34E-11 4.82E-11 1.25E-10 2.14E-06 1.88E-05 TE-131M 7.62E-08 3.93E-08 2.59E-08 6.38E-08 1.89E-07 1.42E-04 8.51E-05 TE-131 1.24E-11 5.87E-12 3.57E-12 1.13E-11 2.85E-11 1.47E-06 5.87E-06 TE-132 2.66E-07 1.69E-07 1.26E-07 1.99E-07 7.39E-07 2.43E-04 3.15E-05 TE-133M 6.13E-11 3.59E-11 2.74E-11 5.52E-11 1.72E-10 3.92E-06 1.59E-05 TE-134 3.18E-11 2.04E-11 1.68E-11 2.91E-11 9.59E-11 2.93E-06 2.53E-06 1-129 2.16E-05 1.59E-05 1.16E-05 1.04E-02 1.88E-05 O.OOE+OO 2.12E-07 1-130 4.54E-06 9.91E-06 3.98E-06 1.14E-03 1.09E-05 O.OOE+OO 1.42E-06 1-131 2.71E-05 3.17E-05 1.40E-05 1.06E-02 3.70E-05 O.OOE+OO 7.56E-07 1-132 1.21E-06 2.53E-06 8.99E-07 1.21E-04 *2.82E-06 O.OOE+OO 1.36E-06 1-133 9.46E-06 1.37E-05 4.00E-06 2.54E-03 1.60E-05 O.OOE+OO 1.54E-06 1-134 6.58E-07 1.34E-06 4.75E-07 3.18E-05 1.49E-06 O.OOE+OO 9.21E-07 1-135 2.76E-06 5.43E-06 1.98E-06 4.97E-04 6.05E-06 O.OOE+OO 1.31E-06 CS-134M 1.32E-07 2.10E-07 1.11E-07 O.OOE+OO 8.50E-08 2.00E-08 1.16E-07 CS-134 2.83E-04 5.02E-04 5.32E-05 O.OOE+OO 1.36E-04 5.69E-05 9.53E-07 CS-135 1.00E-04 8.66E-05 4.73E-06 O.OOE+OO 2.58E-05 1.01 E-05 2.18E-07 CS-136 3.45E-05 9.61E-05 3.78E-05 O.OOE+OO 4.03E-05 8.40E-06 1.02E-06 CS-137 3.92E-04 4.37E-04 3.25E-05 O.OOE+OO 1.23E-04 5.09E-05 9.53E-07 Rev.29 Page 305 of 329 12/2016
CY-LG-170-301 TABLE 112-30 INHALATION DOSE FACTORS FOR INFANT (Daipj) (mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU CS-138 3.61E-07 5.58E-07 2.84E-07 O.OOE+OO 2.93E-07 . 4.67E-08 6.26E-07 CS-139 2.32E-07 3.03E-07 1.22E-07 O.OOE+OO 1.65E-07 2.53E-08 1.33E-08 BA-139 1.06E-09 7.03E-13 3.07E-11 O.OOE+OO 4.23E-13 4.25E-06 3.64E-05 BA-140 4.00E-05 4.00E-08 2.07E-06 O.OOE+OO 9.59E-09 1.14E-03 2.74E-05 BA-141 1.12E-10 7.70E-14 3.55E-12 O.OOE+OO 4.64E-14 2.12E-06 3.39E-06 BA-142 2.84E-11 2.36E-14 1.40E-12 O.OOE+OO 1.36E-14 1.11E-06 4.95E-07 LA-140 *3.61 E-07 1.43E-07 3.68E-08 O.OOE+OO O.OOE+OO 1.20E-04 6.06E-05 LA-141 4.85E-09 1.40E-09 2.45E-10 O.OOE+OO O.OOE+OO 1.22E-05 5.96E-05 LA-142 7.36E-10 2.69E-10 6.46E-11 O.OOE+OO O.OOE+OO 5.87E-06 4.25E-05 CE-141 1.98E-05 1.19E-05 1.42E-06 O.OOE+OO 3.75E-06 3.69E-04 1.54E-05 CE-143 2.09E-07 1.38E-07 1.58E-08 O.OOE+OO 4.03E-08 8.30E-05 3.55E-05 CE-144 2.28E-03 8.65E-04 1.26E-04 O.OOE+OO 3.84E-04 7.03E-O~ 1.06E-04 PR-143 1.00E-05 3.74E-06 4.99E-07 O.OOE+OO 1.41 E-06 3.09E-04 2.66E-05 PR-144 3.42E-11 1.32E-11 1.72E-12 O.OOE+OO 4.80E-12 1.15E-06 3.06E-06 ND-147 5.67E-06 5.81E-06 3.57E-07 O.OOE+OO 2.25E-06 2.30E-04 2.23E-05 PM-147 3.91E-04 3.07E-05 1.56E-05 O.OOE+OO 4.93E-05 4.55E-04 5.75E-06 PM-148M 5.00E-05 1.24E-05 9.94E-06 O.OOE+OO 1.45E-05 1.22E-03 3.37E-05 PM-148 3.34E-06 4.82E-07 2.44E-07 O.OOE+OO 5.76E-07 3.20E-04 6.04E-05 PM-149 3.10E-07 4.08E-08 1.78E-08 O.OOE+OO 4.96E-08 6.50E-05 3.01E-05 PM-151 7.52E-08 1.10E-08 5.55E-09 O.OOE+OO 1.30E-08 3.25E-05 2.58E-05 SM-151 3.38E-04 6.45E-05 1.63E-05 O.OOE+OO 5.24E-05 2.98E-04 3.46E-06 SM-153 1.53E-07 1.18E-07 9.06E-09 O.OOE+OO 2.47E-08 3.70E-05 1.93E-05 EU-152 7.83E-04 1.77E-04 1.72E-04 O.OOE+OO 5.94E-04 1.48E-03 9.88E-06 EU-154 2.96E-03 3.46E-04 2.45E-04 O.OOE+OO 1.14E-03 3.05E-03 2.84E-05* EU-155 5.97E-04 5.72E-05 3.46E-05 O.OOE+OO 1.58E-04 5.20E-04 5.19E-05 EU-156 1.56E-05 9.59E-06 1.54E-06 O.OOE+OO 4.48E-06 6.12E-04 4.14E-05 TB-160 1.12E-04 O.OOE+OO 1.40E-05 O.OOE+OO 3.20E-05 1.11 E-03 2.14E-05 H0-166M 1.45E-03 3.07E-04 2.51E-04 O.OOE+OO 4.22E-04 2.05E-03 1.65E-05 W-181 4.86E-08 1.46E-08 1.67E-09 O.OOE+OO O.OOE+OO 1.33E-05 2.63E-07 W-185 1.57E-06 4.83E-07 5.58E-08 O.OOE+OO O.OOE+OO 4.48E-04 1.12E-05 W-187 9.26E-09 6.44E-09 2.23E-09 O.OOE+OO O.OOE+OO 2.83E-05 2.54E-05 U-232 2.57E-01 O.OOE+OO 2.13E-02 O.OOE+OO 2.40E-02 1.49E+OO 4.36E-05 U-233 5.44E-02 O.OOE+OO 3.83E-03 O.OOE+OO 1.09E-02 3.56E-01 4.03E-05 U-234 5.22E-02 O.OOE+OO 3.75E-03 O.OOE+OO 1.07E-02 3.49E-01 3.95E-05 U-235 5.01E-02 O.OOE+OO 3.52E-03 O.OOE+OO 1.01E-02 3.28E-01 5.02E-05 U-236 5.01E-02 O.OOE+OO 3.60E-03 O.OOE+OO 1.03E-02 3.35E-01 3.71E-05 U-237 3.25E-07 O.OOE+OO 8.65E-08 O.OOE+OO 8.08E-07 9.13E-05 1.31 E-05 U-238 4.79E-02 O.OOE+OO 3.29E-03 O.OOE+OO 9.40E-03 3.06E-01 3.54E-05 NP-237 2.88E+OO 1.71E+OO 1.26E-01 O.OOE+OO 7.69E-01 3.49E-01 5.10E-05 NP-238 2.67E-06 6.05E-07 4.16E-08 O.OOE+OO 1.47E-07 9.19E-05 2.58E-05 NP-239 2.65E-07 2.13E-07 1.34E-08 O.OOE+OO 4.73E-08 4.25E-05 1.78E-05 PU-238 2.69E+OO 1.68E+OO 1.27E-01 O.OOE+OO 4.64E-01 9.03E-01 4.69E-05 PU-239 2.93E+OO 1.76E+OO 1.34E-01 O.OOE+OO 4.95E-01 8.47E-01 4.28E-05 PU-240 2.93E+OO 1.75E+OO 1.34E-01 O.OOE+OO 4.94E-01 8.47E-01 4.36E-05 PU-241 8.43E-02 1.85E-02 3.11 E-03 O.OOE+OO 1.15E-02 7.62E-04 8.97E-07 Rev.29 Page 306 of 329 12/2016
CY-LG-170-301 TABLE 112-30
- INHALATION DOSE FACTORS FOR INFANT (Daipj)
(mrem per pCi inhaled) NUCLIDE BONE LIVER TBODY THYROID KIDNEY LUNG GI-LU PU-242 2.72E+OO 1.69E+OO 1.29E-01 O.OOE+OO 4.77E-01 8.15E-01 4.20E-05 PU-244 3.17E+OO 1.94E+OO 1.48E-01 O.OOE+OO 5.46E-01 9.33E-01 6.26E-05 AM-241 3.15E+OO 1.95E+OO 1.31E-01 O.OOE+OO 7.94E-01 4.06E-01 4.78E-05 AM-242M 3.25E+OO 1.86E+OO 1.35E-01 O.OOE+OO 8.03E-01 1.64E-01 6.01E-05 AM-243 3.10E+OO 1.88E+OO 1.27E-01 O.OOE+OO 7.72E-01 3.85E-01 5.60E-05 CM-242 1.28E-01 8.65E-02 5.70E-03 O.OOE+OO 1.69E-02 2.97E-01 5.10E-05 CM-243 2.47E+OO 1.52E+OO 1.06E-01 O.OOE+OO 3.91 E-01 4.24E-01 5.02E-05 CM-244 2.07E+OO 1.27E+OO 8.89E-02 O.OOE+OO 3.21 E-01 4.0SE-01 4.86E-05 CM-245 3.22E+OO 1.96E+OO 1.36E-01 O.OOE+OO 5.23E-01 3.92E-01 4.53E-05 CM-246 3.20E+OO 1.96E+OO 1.36E-01 O.OOE+OO 5.23E-01 3.99E-01 4.45E-05 CM-247 3.11 E+OO 1.93E+OO 1.33E-01 O.OOE+OO 5.15E-01 3.92E-01 5.85E-05 CM-248 2.58E-01 1.59E-01 1.10E+OO O.OOE+OO 4.24E+OO 3.23E+OO 9.43E-04 CF-252 2.37E+OO O.OOE+OO 1.01E-01 O.OOE+OO O.OOE+OO 1.37E+OO 1.85E-04 NUREG/CR-4653 GASPAR II, Technical Reference and User Guide Rev.29 Page 307 of 329 12/2016
CY-LG-170-301 TABLE 112-31 1 ASSUMPTIONS USED IN LIMERICK GASEOUS EFFLUENT R1 CALCULATIONs< > S~mbol Descri~tion Value Reference<2> f, Fraction of annual intake of fresh, leafy vegetation grown 0.42 Site Spec. locally fg Fraction of annual intake of stored vegetation grown 0.76 E-15 locally 2 Yv Vegetation area density (kg/m ) 2.0 E-15 r Fraction of deposited particulates retained on vegetation 0.20 E-15 r Fraction of deposited iodines retained on vegetation 1.0 E-15 SF Shielding factor of residential structures 0.7 E-15 t Period of buildup of activity in soil (sec) 7.89E08 Site Spec. Based on Tb t1 Transport time milkman (sec) 1.73E05 E-15 th Delay time for ingestion of stored feed by animals (sec) 7.78E06 E-15 t, Delay time for ingestion of leafy vegetable by man (sec) 8.64E04 E-15 th Delay time for ingestion of other vegetable by man (sec) 5.18E06 E-15 ts Time between slaughter and consumption of meat animal 1.73E06 E-15 (sec) Tb Approximate midpoint of facility operating life (years) 25 Reg Guide 1.109, App C, Equation C-1 adjusted for license renewal Yp Grass yield (kg/m**2) 0.7 E-15 Ys Stored feed yield (kg/m**2) 2.0 E-15 1 Aw Weathering rate constant for activity on veg (sec- ) 5.73E-07 E-15 QF Milk cow feed consumption rate (kg/day wet) 50.0 E-3 QF Beef cattle consumption rate (kg/day wet) 50.0 E-3 QF Goat feed consumption rate (kg/day wet) 6.0 E-3 K" Ground exposure (all age groups) (hr/yr) 8760.0 C-2<3> BR Breathing Rate adult (m**3/yr) 8000.0 E-5 BR Breathing Rate teen (m**3/yr) 8000.0 E-5 BR Breathing Rate child (m**3/yr) 3700.0 E-5 BR Breathing Rate infant (m**3/yr) 1400.0 E-5 u~ Leafy veg consumption rate adult (kg/yr) 64.0 E-5 u~ Leafy veg consumption rate teen (kg/yr 42.0 E-5 u~ Leafy veg consumption rate child (kg/yr) 26.0 E-5 u~ Leafy veg consumption rate infant (kg/yr) 0.0 E-5 u~ Stored veg consumption rate adult (kg/yr) 520.0 E-5 u~ Stored veg consumption rate teen (kg/yr) 630.0 E-5 u~ Stored veg consumption rate child (kg/yr) 520.0 E-5 u~ Stored veg consumption rate infant (kg/yr) 0.0 E-5 Uap Cow milk consumption rate adult (I/yr) 310.0 E-5 Uap Cow milk consumption rate teen (I/yr) 400.0 E-5 Uap Cow milk consumption rate child (I/yr) 330.0 E-5 Uap Cow milk consumption rate infant (I/yr) 330.0 E-5 Uap Goat milk consumption rate adult (I/yr) 310.0 E-5 Uap Goat milk consumption rate teen (I/yr) 400.0 E-5 Uap Goat milk consumption rate child (I/yr) 330.0 E-5 Uap Goat milk consumption rate infant (I/yr) 330.0 E-5 Uap Meat consumption rate adult (kg/yr) 110.0 E-5 Uap Meat consumption rate teen (kg/yr) 65.0 E-5 Uap Meat consumption rate child (kg/yr) 41.0 E-5 Rev.29 Page 308 of 329 12/2016
CY-LG-170-301 TABLE 112-31 ASSUMPTIONS USED IN LIMERICK GASEOUS EFFLUENT R1 CALCULATIONs<1> Symbol Description Value Reference<2> Uap Meat consumption rate infant (kg/yr) 0.0 E-5 fp Fraction of year animals on pasture 0.75 Site Spec. fs Fraction of feed from pasture when on pasture 0.39 Site Spec. H Atmosphere absolute humidity (gm/m 3 ) 8.0 (4) xto Highest annual average relative concentration (NE 3 1.10E-05 (5) Sector) (sec/m ) used for setpoint determination. xto Highest annual average relative concentration (sec!m\ 9.97E-07 Site Spec. Site Boundary Dose Rate (SE Sector) (6) x/O Highest annual average relative concentration (sec!m\ 5.63E-07 Site Spec. Residence Pathway (SE Sector) (6) xto Highest annual average relative concentration (sec!m\ 3.45E-07 Site Spec. Garden Pathway (ESE Sector) (6) xto Highest annual average relative concentration (sec!m\ 2.42E-07 Site Spec. Meat Pathway (ESE Sector) (6) xto Highest annual average relative concentration (sec!m\ 8.80E-08 Site Spec. Milk Animal Pathway (SSW Sector) (6) D/Q Highest average annual deposition (1/m2), Residence 9.83E-09 Site Spec. Pathway (SE Sector) (6) 2 D/Q Highest average annual deposition (1/m ), Garden 4.87E-09 Site Spec. Pathway (ESE Sector) (6) D/Q Highest average annual deposition (1/m 2), Meat Pathway 1.14E-09 Site Spec. (ESE Sector) . (6) 2 D/Q Highest average annual deposition (1/m ), Milk Animal 3.14E-10 Site Spec. Pathway (SSW Sector) (6) NOTES:
- 1) Ri values are calculated in accordance with the methodologies given in NUREG-0133.
- 2) The References refer to tables contained in Regulatory Guide 1.109 unless otherwise specified.
- 3) From Reg. Guide 1.109, Appendix C, Equation C-2
- 4) From NUREG-0133, Section 5.3.1.3
- 5) Site specific value from the Limerick Generating Station Final Environmental Statement (NUREG-0974)
- 6) 2010 - 2014 Five year average of site meteorology data Rev. 29 Page 309 of 329 12/2016
CY-LG-170-301 TABLE 112-32 NEAREST GASEOUS EFFLUENT DOSE RECEPTOR DISTANCES (Meters) Plume Ground Inhalation Pathways Vegetation Meat Cow Goat Direction (Nearest Pathway(1> Pathway(1> Pathway<1> Pathway(1> Residence)< 1> N 948 1016 7551 7551 0 NNE 825 2929 8015 0 0 NE 1057 4358 4287 0 0 ENE 985 4331 2271 0 0 E 873 3573 0 0 0 ESE 1047 1371 (2) 3775 0 0 SE 1202 7113(2) 7695 0 0 SSE 1647 2107 0 0 0 s 1325 1860 3722 6740 0 SSW 1543 1622 2323 3167 0 SW 991 1389 7055 0 0 WSW 1158 1374 4321 4321 0 w 1105 1317 5223 0 0 WNW 1123 0 0 0 0 NW 1104 2499 0 0 0 NNW 1540 1703 6379 0 0 (1) Based upon Control 3.3.2, Land Use Census (2015) (2) REMP garden located in the ESE sector at 555 meters and in the SE sector at 390 meters. Rev.29 Page 310 of 329 12/2016
CY-LG-170-301 FIGURES Rev.29 Page 311 of 329 12/2016
CY-LG-170-301 100 --~--....,._--....,.. __ ~ __.....,..._...________,..____________...,....__
*-* -- - w - -*---
~~~~~----~--.....,..--
. I
;
! i 1 -~,~~--------.........--~;--~--~-------...._.........o...+-__~________........,_,_....._,
'LE+01 1 E+02 1.E+b4 FLOW (cfs)
Figure 111.3.1-1 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW STATION OUTFALL Rev.29 Page 312 of 329 12/2016
CY-LG-170-301 I* *. 100 1.E+02 1.Ei-03 1;E+04 FLOW(cfs)
- .*.** .. "
. " ~ . ,,
Figure 111.3.1-2 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PENNSYLVANIA AMERICA WATER Rev.29 Page 313 of 329 12/2016
CY-LG-170-301 I I
=. -~. I:.
..
I tI"-~*==-l-~l-£1~ 1
*****1 .11******
i i . . I
. ' 1 1 E+.01 1;E+04 1.E+03 1.E+04 FLOW (Cf$)
Figure 111.3.1-3 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PHOENIXVILLE Rev.29 Page 314 of 329 12/2016
CY-LG-170-301 1 **+-------~~-- 1.E+01
. . . . ----.. . . .
1.E+02 1:E+03 1.E+04 fLOW(cf~)
. .* '
Figure 111.3.1-4 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW AQUA AMERICA Rev.29 Page 315 of 329 12/2016
CY-LG-170-301 i - a:: 0 l-100 - - - - - - o <( u.. z 0 E
- J 10 5
---c-1********---*-*** -
-f-~l----+--+-+-+---.~*---~****-*********-*----...
I 1 1.E+01 1.E+02 1.E+03 1 E+Q4 FLOW (cfs) Figure 111.3.1-5 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW CREW COURSE Rev.29 Page 316 of 329 12/2016
CY-LG-170-301 Lauridrv ()l{klM fl.D)
- 8.Utiltf*lcm
----!
frillllt*Cflil!IR. w11*1! Y.iJ.nk FD S,t\MPl.E "fJU.n( M:.i * . * ** . . ' ... ~* Ta* C'ohdoiliac&I*
'"' w..,.,. @1aita9111 TanJt' .
> :3tu.dl~.,. T*n' Egulpmmt
.Orcll' Ulf>J
. e)~h,,:::..*:.::l*::::fll:...._--1 EO
,.~u1:;~1t.
Tl\J:fj<
~ FE-ll3.'..<<i3 'W..nt.rl6N G<<i.aii1!11lnQ '!l'l*lktn.
""~1stj~:,-0.1:i o~~o~ u.. 11.. *ti;.,{*
uqu1.:a *emumf . Fi~~?1*it.t""1. Figure 111-1 Rev.29 Page 317 of 329 12/2016
CY-LG-170-301 "No.rill *v*n*** 1t)fl4w* ~ .z, ~ Wfde
'!'*"";' **1 ii~~ ~ang~
Accident, Mi::i:ntt()r** IC~r,!4J1l'.D\t* e-.ul*1*. 1"41n* * 'A..,.... ~.,.
~c-111*' Daa N~r~~
fliilJQit *lh>11iro.11. twbrin. mnalD'Im* Equlj..' c6~.t,P ..1t E~~AllMI t , ~IH~ r.*c~~ t!~h,µJ*lli>' s* . .Qf\V *~LSr.a*
~t_z}_,,.~~---::---i-~+-~.......
+-*
O<Q*:i). iz! .
**
U1n*1d"'k.>O*n"""""!iJ' .tim1loi'O Unllll I &*':!" Ga11i.ou11 Emuontil
- froi-t or..11ram *
'Ui;ir1fr:S111ok *
*-,Uni~ _1-Ch*.rcanl *.ay..,ttuns
.. iint,iz.ci.1.Mt~i\A.e~t~m:
Figure 112-1 Rev.29 Page 318 of 329 12/2016
CY-LG-170-301
- Soult* Vant 1>0'.ulh \itiM S>anti:iuh~U*
P lillioul"1" UnH 1 'Ulitl :(:!'
.1odim*
,loolna t>i'l4 t-l<it>l* GAi)
Elc 411'
. C-i>nll;.~Y<)aJ ii-El; 4.11'
~ntinuo'llii
- ,,,.,t;;,,. mnd
~ ....
,.;.,.,,11.., cil Mor:iU~ ~:i!l
*~
2-lJ<l.ll!1>Q. CfllM'. Miint:
.~f1.ualln9 .fli::iw.
f\*1\urtUna fl<><11t El\ti ..Y*'
£)tlliau&l * ~~~~~~~~~~~~~-1-i il1!'ft&c;lqt . EMl'2ti.lfill
- R11~tor E.n.ito11w;~
1----4--*~ Slihau~ *~~~~~~~~~~~~~-+ii"* 45 1 64.000 E:1d1au*l
- CFM Min;*
. J&i:jfJfj:i!l'UU'll IEqulp~*nl c~~p.utm.an1. .~fl:fllP.**nttt*tt1 ERhl'IU'l.Ji . . ---""9k;>;: Ei,hllUlll
~::....C:;;;;...,;:;;:....J Umilllf!ck: °'"'""*h*ttnd SI.ll!IRm
*u"'**. i .111 ;i.
<)a11nrmua. emuenl Flow. Dlagnsm
- S-ciUitl~ ~l'i!!r/;k .
Figure 112-2 Rev.29 Page 319 of 329 12/2016
CY-LG-170-301 UNTT'2 * .*R$3Ctor: Bl~t Bi it E1f1au 1t
$fac~. a:4 i~ rt ; 7000 C1111 ParticulaWbdln$
Radlatq~ Mo.ri1tor
~. *. l.
., dJ
. . ..
.l,.lt>ll>r1,.;1t <l*n*r.atmg .m.. u.o:"
' "* lh.1 <* ' ' '
- EXHAU$A 'FAN. ~**FILTER Figure 112-3 Rev. 29 Page 320 of 329 12/2016
CY-LG-170-301 APPENDIX A RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM - SAMPLE TYPE, LOCATION, AND ANALYSIS Rev.29 Page 321 of 329 12/2016
CY-LG-170-301 TABLE A-1 Page 1of3 ODCM - Limerick Generating Station Radiological Environmental Monitoring Program Pathway Station Code Location Collection Method Analyses Direct 36S2 3, 183 feet N of site 1 set of four (4) dosimeters from Gamma dose quarterly (1) Inner Ring 3S1 2,301 feet NNE of site each location at least quarterly 5S1 2,350 feet NE of site 7S1 3,099 feet ENE of site 10S3 2,648 feet E of site 11S1 2,017 feet ESE of site 13S2 2, 149 feet SE of site 14S1 3,319 feet SSE of site 18S2 1,390 feet S of site 21S2 977 feet SSW of site 23S2 2,793 feet SW of site 25S2 2,445 feet WSW of site 26S3 2,088 feet W of site 29S1 2,886 feet WNW of site 31S1 1,395 feet NW of site 34S2 3,071 feet NNW of site (2) Outer Ring 3601 18,527 feet N of site 2E1 25,112 feet NNE of site 4E1 25,221 feet NE of site 7E1 22,489 feet ENE of site 10E1 20,826 feet E of site 10F3 29,442 feet ESE of site 13E1 22,772 feet SE of site 16F1 26,608 feet SSE of site 1901 18,439 feet S of site 20F1 27,648 feet SSW of site 2401 20,972 feet SW of site 2501 21,044 feet WSW of site 2802 20,231 feet W of site 29E1 26, 11 o feet WNW of site 3102 20,446 feet NW of site 34E1 24,243 feet NNW of site Rev.29 Page 322 of 329 12/2016
CY-LG-170-301 TABLE A-1 (Continued) Page 2 of 3 Pathway Station Code Location Collection Method Analyses Direct (Continued) 5H1 C 130,742 feet NE of site (3) Controls and 6C1 11,305 feet NE of site Special Interest 9C1 11,377 feet E of site 13C1 14,980 feet SE of site 1501 16,877 feet SE of site 1781 8,462 feet S of site 2001 16, 157 feet SSW of site 3101 15,853 feet WNW of site II. Airborne 10S3 2,648 feet E of site Approximately 1 cfm continuous flow Gross beta analysis on each weekly Particulates 11S1 2,017 feet ESE of site through glass fiber filter which is collected sample. Gamma spectrometry shall be 14S1 3,319 feet SSE of site weekly. done when gross beta exceeds ten times 13S4 1, 186 feet SE of site the yearly mean of control station value. 1501 16,877 feet SE of site 22G1 C 93,619 feet SW of site Gross beta analysis done 24 hr after sampling to allow for Radon and Thoran daughter decay. Gamma Spec on quarterly composite. Iodine 10S3 2,648 feet E of site A TEDA impregnated flow-through Iodine 131 analysis on each weekly 11S1 2,017 feet ESE of site cartridge is connected to air sampler and sample. 14S1 3,319 feet SSE of site is collected weekly at site filter change. 13S4 1, 186 feet SE of site 1501 16,877 feet SE of site 22G1 C 93,619 feet SW of site Ill. Water 24SI c 1,058 feet SW of site Sample collected from a continuous water Gamma isotopic analysis monthly.
- a. Surface 1381 9,225 feet SE of site sampler, monthly. In event sampler is inoperable, weekly grab samples will be H-3 on quarterly composite collected until sampler returned to service.
- b. Ground No Ground water is sampled and analyzed, because ground water flow is to the river per UFSAR Section 2.4.13
- c. Drinking 15F7 33,400 feet SSE of site Sample collected froru. a continuous water lodine-131 LL, Gross beta and 15F4 45,514 feet SE of site sampler monthly. In event sampler is gamma isotopic monthly, 16C2 14,034 feet SSE of site inoperable, weekly grab samples will be 28F3 C 30,811 feet WNW of site collected until sampler returned to service. H-3 on quarterly composite
- d. Sediment from 16C4 11,51 O feet SSE of site A sediment sample is taken down stream Gamma isotopic analysis each shoreline of discharge semi-annually sample Rev. 29 Page 323 of 329 12/2016
CY-LG-170-301 TABLE A-1 (Continued) Page 3 of 3 Pathway Station Code Location Collection Method Analyses IV. Ingestion 18E1 22,704 feet S of site Sample of fresh milk is collected from Gamma isotopic and 1-131 analyses a.Milk 1981 10,317 feet SSW of site each farm biweekly when cows are on on each sample 25C1 14,224 feet WSW of site pasture (April) through October), monthly 23F1 C 26,505 feet SW of site at other times.
- b. Fish and 16C5 9,251 feet SE of site Two species of recreationally Gamma isotopic analyses on edible Invertebrates 29C1 C 13, 725 feet WNW of site important fish (Predator and bottom portions.
feeder) sampled in season or semiannual! if not seasonal. Seasons are Spring and Fall There are no commercially or recreationally important species of invertebrates. Therefore no invertebrates are sampld.
- c. Food Products There are no downstream food products that are irrigated by water in which liquid plant wastes have been discharged.
No broad leaf vegetation sampling is performed, because milk sampling is performed. C = Control Location Rev.29 Page 324 of 329 12/2016
CY-LG-170-301 Environmental SaFigu.re A-1 Near the Lime~~~n~enerating LocationsStOn . s*t at1onI e or P Rev.29 age 325 of 329 1212016 I
CY-LG-170-301 E UJ
- re
.
~.
.. ~
Figure A-2 Environmental Sampling Locations at Distances Less Than Five Miles from the Limerick Generating Station. Rev.29 Page 326 of 329 12/2016
CY-LG-170-301
.- *22G1 Figure A-3 Environmental Sampling Locations at Distances Greater Than Five Miles from the Limerick Generating Station.
Rev. 29 Page 327 of 329 12/2016
CY-LG-170-301 REFERENCES
- 1. Regulatory Guide 1.109, "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of"Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C.
20555, October 1977.
- 2. Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, July 1977.
- 3. Regulatory Guide 1.112, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Light-Water-Cooled Power Reactors," U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1976.
- 4. Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1977.
- 5. U.S. Nuclear Regulatory Commission, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Boiling Water Reactors (BWR-GALE Code),"
USNRC Report NUREG-0016, Washington, D.C. 20555, April 1976.
- 6. U.S. Nuclear Regulatory Commission, "XOQDOQ, Program for the Methodological Evaluation of Routine Effluent Releases at Nuclear Power Stations," USNRC Report NUREG-0324, Washington, D.C. 20555, September, 1977.
- 7. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 20, Appendix B, U.S.
Government Printing Office, Washington, D.C. 20402, January 1, 1977.
- 8. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 100, U.S. Government Printing Office, Washington, D.C. 20404, January 1, 1977.
- 9. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 141, U.S. Government Printing Office, Washington, D.C. 20402, January 1, 1977.
- 10. Regulatory Guide 1.21, "Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, June 1974.
- 11. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 190, Federal Register, Vol. 42, No. 9, Washington, D.C. 20402, January 13, 1977.
- 12. U.S. Nuclear Regulatory Commission, "Short Term Diffusion Estimates," Section 2.3.4, Standard Review Plan for the Review of Safety Analysis Reports for Nuclear Power Plants - LWR Edition, USNRC Report NUREG-75/087, Washington, D.C. 20555, November 1975.
- 13. U.S. Nuclear Regulatory Commission, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants," USNRC Report NUREG-0133, Washington, D.C. 20555, October 1978.
Rev.29 Page 328 of 329 12/2016
CY-LG-170-301
- 14. Letter From Thomas E. Marley, Director Office of Nuclear Reactor Regulations, To Thomas E. Tipton Vice President and Director Operations, Nuclear Management and Resources Council, 6/30/93.
- 15. ANSI N42.14-1991 (Revision of ANSI N42.14-1978) "Calibration and Use of Germanium Spectrometers For the Measurement of Gamma-Ray Emission Rates of Radionuclides",
Sect. 6.2.2
- 16. EML Procedures Manual, H.L. Volchok and G. dePlangue, Editors, U.S. Dept. Of Energy (Revised Annually)
- 17. L.A. Currie, "Limits For Qualitative Detection and Quantitative Determination -
Application to Radiochemistry", Analytical Chemistry, Vol. 40, pp. 586-593 (TABLE II), 1968
- 18. NUREG/CR-4007, "Lower Limit of Detection: Definition and Elaboration of a Proposed Position for Radiological Effluent and Environmental Measurements", prepared by NRC by L.A. Currie (Chapter II, Sect. D.2; Chapter Ill, Sect. C.1 ), September 1984
- 19. Tech. Spec. Section 1.24 (Definitions)
- 20. USNRC Generic Letter, 89-01
- 21. Tech. Spec. Section 6.14.
- 22. Tech. Spec. Section 6.5.1.6m.
- 23. Tech. Spec. Section 6.5.3.
- 24. Tech. Spec. Section 6.8.4d, e and f.
- 25. Tech. Spec. Section 6.9.1.8/0DCM Control 1.3.6.
- 26. Tech. Spec. Section 6.10.3m and n.
- 27. UFSAR, Section 11.5.6.
- 28. Bechtel, Inc., "Dilution Studies for Routine and Accidental Releases from Limerick Nuclear Plant into the Schuylkill River", March, 1996.
- 29. ANSl/ANS-6.6.1-1979 "calculation and measurement of direct and scattered gamma radiation from LWR nuclear power plants, Section 7.
- 30. Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques," Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975).
- 31. NUREG/CR-4653 GASPAR II, Technical Reference and User Guide
- 32. NUREG/CR-4013, LADTAP II Technical Reference and User Guide.
- 33. Kocher, David C., "Radioactive Decay Data Tables," DOE/TIC-11026,138 (1981).
- 34. NUREG 1302, "Offsite Dose Calculation Manual Guidance: Standard Radiological Effluent Controls for Boiling Water Reactors."
- 35. NUREG-0974, Final Environmental Statement related to the operation of Limerick Generating Station, Units 1 and 2 (April 1984)
Rev.29 Page 329 of 329 12/2016}}